

Supporting Information:

Supporting Information Corrected January 8, 2015

“Proxy-Phenotype Method Identifies Common Genetic Variants Associated with Cognitive Performance”

This document provides further details about materials, methods and additional analyses to accompany the research report “Proxy-Phenotype Method Identifies Common Genetic Variants Associated with Cognitive Performance.”

Contents

| | |
|--|-----------|
| Materials and Methods..... | 3 |
| 1. META-ANALYSES AND SELECTION OF EDUCATION-ASSOCIATED CANDIDATE SNPs | 3 |
| 2. COGNITIVE PERFORMANCE SAMPLE | 3 |
| 3. COGNITIVE PERFORMANCE MEASURES | 4 |
| 4. GENOTYPING AND IMPUTATION | 6 |
| 5. QUALITY CONTROL | 7 |
| 6. ASSOCIATION ANALYSIS | 7 |
| 7. META-ANALYSIS | 7 |
| 8. CORRECTION OF EFFECT SIZES FOR WINNER’S CURSE | 7 |
| 9. BAYESIAN ANALYSIS OF THE CREDIBILITY OF THE SNP ASSOCIATIONS | 14 |
| 10. SELECTION OF THEORY-BASED CANDIDATE SNPs..... | 15 |
| 11. TESTING THE Q–Q PLOTS FOR THE EDUCATION-ASSOCIATED AND THE THEORY-BASED CANDIDATES..... | 16 |
| 12. BIOLOGICAL ANNOTATION | 16 |
| 13. POLYGENIC SCORE ANALYSES IN FAMILY SAMPLES..... | 23 |
| 14. POLYGENIC SCORE ANALYSES IN THE HEALTH AND RETIREMENT STUDY | 25 |
| 15. STATISTICAL FRAMEWORK FOR THE PROXY-PHENOTYPE METHOD AS APPLIED TO COGNITIVE PERFORMANCE..... | 27 |
| Supplementary Figures | 33 |
| Supplementary Tables | 37 |
| Additional Notes..... | 90 |
| 1. AUTHOR CONTRIBUTIONS | 90 |
| 2. COHORT-SPECIFIC CONTRIBUTIONS..... | 91 |
| 3. ADDITIONAL ACKNOWLEDGEMENTS | 93 |
| References | 96 |

Materials and Methods

1. Meta-analyses and selection of education-associated candidate SNPs

The first stage of our two-stage procedure consisted of conducting a GWAS meta-analysis on years of schooling, using the same analysis plan as Rietveld et al. (1) for the years-of-schooling variable (referred to in Rietveld et al. as “EduYears”) and the same cohorts, except omitting the individuals that we include in the Cognitive Performance Sample (all individuals in the cohorts ALSPAC, ERF, LBC1921, LBC1936, and MCTFR, and subsamples of the cohorts QIMR and STR) described in section “Cognitive Performance Sample” below. Thus, compared with the meta-analysis sample size of $N = 126,559$ in Rietveld et al., the sample size for our meta-analysis of years of schooling is $N = 106,736$. We obtained permission to use these data under the SSGAC data sharing policy (<http://ssgac.org/documents/DatasharingpolicySSGAC.pdf>). Our meta-analysis found 927 single-nucleotide polymorphisms (SNPs) meeting the inclusion threshold of p -value $< 10^{-5}$, which was chosen based on power calculations prior to conducting our study (see section 15.E of this SI Appendix). We pruned this set of SNPs for linkage disequilibrium using the clumping command in PLINK and the HapMap II CEU (r23) data. The physical threshold for clumping was 1000 kB, and the R^2 threshold for clumping was 0.01. This pruning procedure resulted in a set of 69 approximately independent SNPs, which is our set of “education-associated SNPs.” These are listed in Supplementary Table S4.

We note that the education-associated SNPs (Table S4) are independent from *APOE*, a gene that has previously been associated with cognitive decline in older individuals (2–6). The *APOE* gene is located on chromosome 19, while none of our education-associated SNPs are located on that chromosome; thus, *APOE* status is inherited independently from all of our education-associated SNPs.

For the polygenic-score analyses in the Health and Retirement Study (HRS) described in section 14 below, we conducted the same meta-analysis, except that we additionally exclude the HRS cohort. The sample size of this meta-analysis is $N = 98,110$.

2. Cognitive Performance Sample

The Cognitive Performance Sample that we use in the second stage of our two-stage procedure consists of CHIC (the Childhood Intelligence Consortium (7)) and five additionally recruited GWA samples. CHIC consists of six studies: the Avon Longitudinal Study of Parents and Children (ALSPAC, $N = 5,517$), the Lothian Birth Cohorts of 1921 and 1936 (LBC1921, $N = 464$; LBC1936, $N = 947$), the Brisbane Adolescent Twin Study subsample of Queensland Institute of Medical Research (QIMR, $N = 1,752$), the Western Australian Pregnancy Cohort Study (Raine, $N = 936$), and the Twins Early Development Study (TEDS, $N = 2,825$). The five additional samples are the Erasmus Rucphen Family Study (ERF, $N = 1,076$), the Generation R Study (GenR, $N = 3,701$), the Harvard/Union Study (HU, $N = 389$), the Minnesota Center for Twin and Family Research Study (MCTFR, $N = 3,367$) and the Swedish Twin Registry Study (STR, $N = 3,215$). This brings the total sample size to 24,189 individuals from 11 studies.

In most of these cohorts, cognitive performance was elicited before participants completed schooling (for details, see section 3). Exceptions are ERF and HU, which constitute $\approx 6\%$ of the Stage 2 sample. In STR, cognitive performance was measured among males during military conscription at the age of 18. Some of these individuals may have also already completed schooling. However, some of the individuals in ERF and HU may have still been in school when cognitive performance was measured.

Participating studies were recruited from January 2013 – March 2013, and summary results were uploaded before the end of April 2013. All participants provided written informed consent, and the studies were performed in accordance with the respective Local Research Ethics Committees or Institutional Review Boards. The descriptive statistics and study designs are provided in Table S1.

To provide additional data for examining the within-family explanatory power of the polygenic score (see section 13), an additional cohort was recruited: Generation Scotland (GS). The sample consists of 1,081 siblings.

3. Cognitive performance measures

Measures of cognitive performance for the studies that are part of CHIC, and the cognitive performance measures for the other five GWA studies, are as follows:

ALSPAC: Cognitive performance at the age of 8 years was measured with the Wechsler Intelligence Scale for Children (WISC-III). A short version of the test consisting of alternate items only (except the Coding task) was applied by trained psychologists. Verbal (information, similarities, arithmetic, vocabulary, comprehension) and performance (picture completion, coding, picture arrangement, block design, object assembly) subscales were administered. Each subtest was age-scaled according to population norms, and a summary score for total cognitive performance was derived. We calculated the first two principal components of the genome-wide data using Eigenstrat. As inputs to the analysis reported here, we generated sex- and principal-component-adjusted Z-standardized cognitive performance scores for unrelated ALSPAC children for whom total cognitive performance and genome-wide data were available. To do so, cognitive performance scores within a range of ± 4 SD relative to the total ALSPAC sample were regressed on sex and the principal components. The residuals were Z-transformed. Using the resulting data, genome-wide association analysis was conducted.

ERF: Scores on the following cognitive tests were used to create the fluid-type general cognitive ability factor: Stroop 3 (time needed to complete Stroop color-word card), TMT-B (time needed to complete Trailmaking Test part B), phonemic fluency (with D, A, T, number of words mentioned beginning with each letter, one minute each, sum of the three trials), 15-word Auditory Verbal Learning Test (AVLT-sum) (sum of immediate (5 iterations) and delayed recall (once)), WAIS block design test (n of correct answers, Wechsler scoring). The tests, the method of application, and key references are described in (8). Principal components analysis was applied to these 5 tests. The first unrotated principal component, which accounted for 50.1% of the total test variance, is the measure of g . The mean age at reporting is 33.2 (SD = 7.1).

GenR: The phenotype has been constructed using assessments of the Snijders-Oomen Non-Verbal Intelligence Test (SON-R 2.5–7). The overall cognitive performance score was calculated based on two subtests: Mosaics (performance) and Categories (reasoning). The mean age at reporting is 6.17 (SD = 0.50).

GS: Scores on the following cognitive ability tests were used to create the general cognitive ability factor: Wechsler Digit Symbol Substitution Task, Wechsler Logical Memory Test, Verbal Fluency (sum of letters C, F, and L), and the Mill Hill Vocabulary Scale. The tests, the method of application and key references have been described in detail elsewhere (9). The number of siblings used in the analysis was 1081 (mean age 41.1 (SD 11.0), range 18–77). The Pearson correlations (r_s) among the 4 tests ranged from 0.07 to 0.40 (mean 0.22). Principal components analysis was applied to these 4 tests. The first unrotated principal component (FUPC) accounted for 42% of the total test variance. Loadings on the FUPC were as follows:

Wechsler Digit Symbol Substitution Task = 0.56, Wechsler Logical Memory Test = 0.63, Verbal Fluency = 0.71, Mill Hill Vocabulary Scale = 0.68.

HU: A composite score of several cognitive performance subtests was generated in the following way. A shortened version of Raven's Advanced Progressive Matrices (RAPM) (10); a 10-item vocabulary test; the Vocabulary, Similarities, and Arithmetic subtests of the Multidimensional Aptitude Battery II; and the number correct in a speeded version of the Shepard-Metzler Mental Rotation (SMMR) task were administered. RAPM, Arithmetic, and SMMR were standardized to have mean zero and variance one in the sample. The Vocabulary, Similarities, and separate 10-item vocabulary test were factor analyzed, and Bartlett's method was used to calculate a verbal factor score on the basis of the three observed scores. This verbal score was then standardized. The standardized verbal, RAPM, Arithmetic, and SMMR scores were added to form a raw composite, which was itself standardized separately for each sex. The composite IQ formed in this way showed a correlation of ~0.70 with self-reported SAT scores, which is quite good considering the restriction of range in SAT scores (a standard deviation only two-thirds of that observed in the total population of European-descent SAT examinees). The mean age at reporting is 25.48 (SD = 6.63).

LBC1921 and LBC1936: The measure of cognitive performance was the Moray House Test (MHT) No. 12. This is one of a series of tests of cognitive performance devised by Godfrey Thomson at the Moray House College, University of Edinburgh, from the late 1920s onwards. The MHT is a group test of cognitive performance with a time limit of 45 minutes. The test has 71 items and a maximum possible score of 76. It was also known as the "Verbal Test" because the items have a predominance of verbal reasoning. The test has a variety of items, as follows: following directions (14 items), same-opposites (11), word classification (10), analogies (8), practical items (6), reasoning (5), proverbs (4), arithmetic (4), spatial items (4), mixed sentences (3), cypher decoding (2), and other items (4). Mean age at reporting is 10.9 years (SD = 0.28).

MCTFR: Measurement of general cognitive ability in the Minnesota sample was based on an abbreviated form of the Wechsler Intelligence Scale for Children-Revised (WISC-R) for those 16 years or younger or Wechsler Adult Intelligence Scale-Revised (WAIS-R) for those older than 16 years. The short forms consisted of two Performance subtests (Block Design and Picture Arrangement) and two Verbal subtests (Information and Vocabulary), the scaled scores on which were prorated to determine Full-Scale IQ (FSIQ). FSIQ estimates from this short form have been shown to correlate greater than 0.90 with FSIQ from the complete test. The mean age at reporting is 14.2 (SD = 2.7).

QIMR: Cognitive performance was measured using a shortened version of the computerized Multi-dimensional Aptitude Battery (MAB), a general intelligence test similar to Wechsler Adult Intelligence Scale-Revised. The shortened MAB includes three verbal subtests (information, arithmetic, vocabulary) and two performance subtests (spatial, object assembly). Scaled scores for cognitive performance were computed in accordance with the manual.

Raine: Cognitive performance was estimated based on four cognitive tests carried out at approximately 10 years of age (Peabody Picture Vocabulary Test, Raven's Colored Progressive Matrices, Symbol Digits Modalities Test (SDMT) written score and SDMT oral score. The first principal component from the four cognitive measures was used for analyses.

STR: Men in the sample were matched to conscription data provided by the Military Archives of Sweden. Data on cognitive ability are available for most men in the sample born in 1936 or later. These men were required by law to participate in military conscription around the age of 18. They enlisted at a point in time when exemptions from military duty were rare and typically

only granted to men who could document a serious handicap that would make it impossible to complete training. For the men born after 1950, the military data have been digitalized. For men born 1936-1950, we manually retrieved the information from the Military Archives. The first test of cognitive ability used by the Swedish Military was implemented in 1944, and it has subsequently been revised and improved on a few occasions. (11) discusses the history of psychometric testing in the Swedish military and provides evidence that the measure of cognitive ability is a good measure of *g*. For men in the sample who did the military conscription before 1959, the cognitive ability test consisted of 5 subtests: logical, verbal, mathematical, spatial, and technical. The first subtest about logical ability was called “Instructions” and measured the ability to understand complicated instructions. The second subtest about verbal ability was called “Selection,” and in these questions the subjects had to pick out one out of five words that differed from the four other words. The third subtest was called “Multiplication” and consisted of multiplying a two-digit number by a one-digit number. The fourth subtest was called “Levers.” With the guidance of a graph depicting a system of levers, the subjects answered questions about the effect of a force applied to a specific point in the system. The final test was called “Technical comprehension,” in which the subjects answered questions about technical problems with the guidance of graphs. In 1959 the cognitive ability test was revised, and men in the sample who did the military conscription in 1959 or later took this revised test. The logical and verbal ability subtests were kept. The mathematical subtest (“Multiplication”) was dropped from the test. The spatial ability test (“Levers”) was replaced by a test of spatial ability called “Composition,” in which the subjects had to indicate which pieces fit with a specific figure. The technical ability test (“Technical comprehension”) was revised (it was modernized). For both men who did the military conscription before and after 1959, we use data for the 4 subtests of logical, verbal, spatial, and technical ability (since subtests of these abilities were included at the military conscription both before and after 1959). We do not include the mathematical ability test since it was only given to subjects who did the military conscription in 1959 and later. At the military conscription, each subtest was given a raw score and a standardized 1-9 stanine score. The norm tables for the stanine scores were updated each year to ensure that there was no trend in the stanine scores over time. We use the stanine scores of the four subtests of logical, verbal, spatial and technical ability. We use the first principal component of these four stanine scores as the measure of cognitive performance.

TEDS: Individuals were tested at 12 years using two verbal and two nonverbal measures: WISC-III-PI Multiple Choice Information (General Knowledge) and Vocabulary Multiple Choice subtests (12), the WISC-III-UK Picture Completion (12) and Raven’s Standard Progressive Matrices (13). Test scores were adjusted for age within each testing period, and the first principal component was derived.

Within each cohort the cognitive performance measure was adjusted for sex and age and standardized to have mean 0 and standard deviation 1.

4. Genotyping and imputation

All cohorts were genotyped using commercially available genotyping arrays. The study-specific details on genotype platform, genotype calling algorithm, imputation software, and imputation reference dataset are provided in Table S2.

5. Quality control

In CHIC extensive quality control has been performed at the meta-analysis stage (for details, see (7)). We followed CHIC’s protocol and cleaned each GWA summary file from the five additionally recruited replication studies. First, the SNPs with a Minor Allele Frequency

(MAF) $< 1\%$, imputation quality score $< 40\%$, Hardy-Weinberg p -value $< 10^{-6}$ and call rate < 0.95 were excluded. Quantile-Quantile plots of the cleaned summary files were visually inspected, and the genomic control (GC) inflation factor λ (14) was calculated for each cleaned summary file. The Quantile-Quantile plots (Supplementary Figure 1) did not reveal stratification problems. This is confirmed by the values of λ 's, which are all close to 1. Second, following (7), we calculated the average effective sample size per cohort (as a function of the allele frequency and the standard error of the effect size from the association) and compared it with the actual sample size. We found that the average effective sample sizes were consistent with the reported sample sizes in all cohorts.

6. Association analysis

Each cohort was asked to follow a prespecified analysis plan (preregistered on the Open Science Framework website prior to conducting our study; see <https://osf.io/z7fe2/>). This plan requested from each study summary results of the ordinary least squares regression of the standardized measure of cognitive performance on the imputed SNPs. At least four principal components of the Identity-by-State (IBS) matrix (to control for subtle population stratification) were either added as covariates, or used in the standardization of the phenotype. Only individuals from recent Caucasian descent were included. Association software used by the studies is reported in Table S2.

7. Meta-analysis

The meta-analysis was performed with inverse-variance weighting using METAL (15). The necessary inputs from the study-specific GWA summary results were: SNP ID, coded allele (allele to which regression coefficient refers), non-coded allele, strand, beta (regression coefficient), standard error, p -value, and allele frequency for the coded allele.

8. Correction of effect sizes for winner's curse

The “winner's curse” refers to the fact that the estimated effect size for a SNP (and therefore the R^2 associated with the SNP) newly discovered to be statistically significant tends to be much higher than the unbiased effect size estimated subsequently in replication samples. It occurs because, although OLS gives an unbiased *unconditional* estimate of the true parameter value, the expected value of the estimate is biased away from zero conditional on the parameter meeting a threshold for statistical significance. This bias is more highly pronounced the more stringent the significance threshold (and therefore especially pronounced in GWAS because the significance threshold for “genome-wide significant” is especially stringent). In Subsection A, we walk through the (well-known) derivation of the analytic form for the expected value of the winner's curse. In Subsection B, we discuss several known methods for correcting for it. Subsection C contains a comparison of these methods in a simulation study of the current analysis of cognitive performance. We conclude in Subsection D by applying the winner's curse corrections to both Rietveld et al.'s (1) findings—a context where we can compare the winner's-curse-corrected estimates to the unbiased, replication-sample estimates—and to the findings from the current analysis of cognitive performance.

A. Derivation of the winner's curse

We derive the winner's curse for the simple case where outcome Y is truly related to a SNP's genotype $g \in \{0, 1, 2\}$ in accordance with the simple linear regression model:

$$Y = cons + \beta g + \varepsilon$$

where $\varepsilon \sim N(0, \sigma^2)$, and σ^2 and the SNP's MAF m are known. If the sample size n is large and if the SNP is in Hardy-Weinberg equilibrium, then the OLS estimate is drawn from the normal distribution $\hat{\beta} | \beta \sim N(\beta, v^2)$, where $v^2 \equiv \frac{\sigma^2}{2nm(1-m)}$ (and v^2 is known because σ^2 , m , and n are all known). Given statistical significance threshold α , the null hypothesis $\beta = 0$ is rejected if the test statistic, $\frac{\hat{\beta}}{v}$, falls within the $\left(1 - \frac{\alpha}{2}\right)$ percentile right or left tail of this distribution:

$$\frac{\hat{\beta}}{v} > \Phi^{-1}\left(1 - \frac{\alpha}{2}\right),$$

where Φ is the cdf of a standard normal distribution (that has corresponding pdf ϕ). Therefore, conditional on the SNP having been identified as statistically significant at size α , its coefficient $\hat{\beta}$ is distributed as a truncated standard normal distribution with the mass removed in a neighborhood of zero, with pdf:

$$(1) \quad f(\hat{\beta} | \beta, sig_\alpha) = \begin{cases} \frac{\frac{1}{v} \phi\left(\frac{\hat{\beta} - \beta}{v}\right)}{1 - [\Phi(T^+(\beta)) - \Phi(T^-(\beta))]} & \text{if } |\hat{\beta}| > v\Phi^{-1}\left(1 - \frac{\alpha}{2}\right) \\ 0 & \text{if } |\hat{\beta}| \leq v\Phi^{-1}\left(1 - \frac{\alpha}{2}\right) \end{cases},$$

where $T^+(\beta) \equiv \Phi^{-1}\left(1 - \frac{\alpha}{2}\right) - \frac{\beta}{v}$ and $T^-(\beta) \equiv -\Phi^{-1}\left(1 - \frac{\alpha}{2}\right) - \frac{\beta}{v}$. The mean of the distribution described by equation (1) is

$$(2) \quad E(\hat{\beta} | \beta, sig_\alpha) = \beta + v \frac{\Phi(T^+(\beta)) - \Phi(T^-(\beta))}{1 - [\Phi(T^+(\beta)) - \Phi(T^-(\beta))]}.$$

The bias due to the winner's curse is the second term in equation (2). The numerator of this term signs the bias: if $\beta > 0$, then the bias is positive, while if $\beta < 0$, then it is negative. The bias therefore always pushes the estimate away from zero. In order to obtain a more accurate estimate of the SNP's effect size, it is necessary to apply a correction procedure that "shrinks" the OLS estimate toward zero. If α is smaller (that is, the significance threshold is more stringent), then the denominator of the bias term is smaller and hence the bias is larger in magnitude.

B. Correcting for the winner's curse

There are several methods that one might consider to correct for this bias. Here we briefly describe four: inverting the conditional expectation of the OLS estimator, maximum likelihood

estimation (MLE), Bayesian estimation, and empirical-Bayes estimation.

B.1. Inverting the conditional expectation of the OLS estimator

One approach is motivated by the seemingly straightforward idea of inverting the above conditional expectation equation (2) that is a function of the true parameter value:

$$E(\hat{\beta} | \beta, sig_{\alpha}) \equiv g(\beta) = \beta + v \frac{\Phi(T^+(\beta)) - \Phi(T^-(\beta))}{1 - [\Phi(T^+(\beta)) - \Phi(T^-(\beta))]}.$$

While $g(\beta)$ is not analytically invertible, it can be inverted numerically. However, $E(\hat{\beta} | \beta, sig_{\alpha})$ is not observed and so cannot be plugged into $g^{-1}(\cdot)$. The feasible version of this estimator must instead use the observed value $\hat{\beta}$. Unfortunately, though, the estimator $g^{-1}(\hat{\beta})$ is biased: that is, generically $E[g^{-1}(\hat{\beta}) | \beta, sig_{\alpha}] \neq \beta$. To see this, note that $g^{-1}[E(\hat{\beta} | \beta, sig_{\alpha})] = \beta$, and Jensen's inequality implies that $E[g^{-1}(\hat{\beta}) | \beta, sig_{\alpha}]$ is generically *not* equal to $g^{-1}[E(\hat{\beta} | \beta, sig_{\alpha})]$ since $g(\beta)$ is non-linear. Furthermore, it is difficult to assess the direction and amount of bias.

B.2. Maximum Likelihood Estimation

Some researchers have used MLE to correct for the winner's curse (16, 17). To estimate a MLE, we use the pdf of $\hat{\beta} | (\beta, sig_{\alpha})$, which is equation (1) above. Since we only have one observation of $\hat{\beta}$, the likelihood function in this case is simply equation (1). Taking the first-order condition with respect to β and rearranging terms, the ML estimator β_{MLE} is implicitly defined by the equation:

$$\hat{\beta} = \beta_{MLE} + v \frac{\Phi(T^+(\beta_{MLE})) - \Phi(T^-(\beta_{MLE}))}{1 - [\Phi(T^+(\beta_{MLE})) - \Phi(T^-(\beta_{MLE}))]}.$$

The right-hand side of this equation is identical to the right-hand side of equation (2) above. Therefore, the MLE is the same as the estimate obtained from inverting the conditional expectation of the OLS estimator, and thus the MLE will be biased in an identical manner. Via simulation, (16) shows that these methods will over-correct when β is large and under-correct when β is small.

We note a few observations about the bias correction implied by this estimator; similar points will hold for the Bayesian estimators that follow, but we make these observations here because they are particularly straightforward to see for the MLE estimator. First, when the estimated coefficient is large in magnitude, the bias correction is small; that is, the MLE-corrected estimate will be approximately equal to the uncorrected estimate. This can be seen in the above

formula: since $\lim_{|\beta| \rightarrow \infty} \phi(T^+(\beta)) - \phi(T^-(\beta)) = 0$ and $\lim_{|\beta| \rightarrow \infty} \Phi(T^+(\beta)) - \Phi(T^-(\beta)) = 0$, it follows that

$\lim_{|\hat{\beta}| \rightarrow \infty} \beta_{MLE}(\hat{\beta}) = \hat{\beta}$. Intuitively, when the uncorrected estimate is large in magnitude, it is very likely to have been resulted from a true β that is large in magnitude and hence very likely that we would have observed a statistically significant estimate regardless of our sample realization; therefore, the fact that the observed estimate was statistically significant provides little additional information about the value of β .

Second and on the flipside, when the estimated coefficient is close to the significance threshold, the bias correction may be quite large. Intuitively, it is actually fairly likely that a barely statistically significant estimate resulted from a true β that is below the threshold.

B.3. Bayesian and Empirical-Bayes Estimation

Two alternative approaches are Bayesian and are closely related. We follow a derivation similar to (18), who adjust the winner's curse of the odds ratio in a binary setting. However, we consider a more general setting, correcting the underlying β parameters, which are defined over the real line and therefore require a different class of priors and posteriors (for a closely related approach, see (19)). For a normally-distributed prior $\beta \sim N(\mu, \tau^2)$, the posterior is given by the pdf

$$f(\beta | \hat{\beta}, sig_\alpha) = \frac{\phi\left(\left(\beta - \frac{\tau^2 \hat{\beta} + \nu^2 \mu}{\tau^2 + \nu^2}\right) / \sqrt{\frac{\tau^2 \nu^2}{\tau^2 + \nu^2}}\right)}{1 - [\Phi(T^+(\beta)) - \Phi(T^-(\beta))]} \cdot \frac{\phi\left(\left(b - \frac{\tau^2 \hat{\beta} + \nu^2 \mu}{\tau^2 + \nu^2}\right) / \sqrt{\frac{\tau^2 \nu^2}{\tau^2 + \nu^2}}\right)}{\int_b \frac{1}{1 - [\Phi(T^+(b)) - \Phi(T^-(b))]} db}$$

The mean of this distribution is

$$(3) \quad E(\beta | \hat{\beta}, sig_\alpha) = \frac{E[g_1(X)]}{E[g_2(X)]},$$

where $X \sim N\left(\frac{\tau^2 \hat{\beta} + \nu^2 \mu}{\tau^2 + \nu^2}, \frac{\tau^2 \nu^2}{\tau^2 + \nu^2}\right)$, $g_1(x) = \frac{x}{1 - [\Phi(T^+(x)) - \Phi(T^-(x))]}$, and

$$g_2(x) = \frac{1}{1 - [\Phi(T^+(x)) - \Phi(T^-(x))]}.$$

The right-hand side of equation (3) can be evaluated numerically by taking a set of M draws of the random variable X , $\{x_m\}$, and taking the ratio of the sample means of $\{g_1(x_m)\}$ and $\{g_2(x_m)\}$. In the implementations below, we use $M = 10$ million.

The Bayesian and empirical Bayes approaches are distinguished by the way that the parameters of the prior distributions, μ and τ^2 , are chosen. The Bayesian method we consider is to assume an uninformative prior: $\tau \rightarrow \infty$ (and in this case, the choice of μ does not matter). Using this

method, equation (3) is evaluated using $X \sim N(\hat{\beta}, \nu^2)$. Similar to with the MLE correction, the Bayesian (and empirical Bayes) correction will be small when the uncorrected estimate is far from the significance threshold and large when it is close. Intuitively, when the observed estimate is large in magnitude, the probability that the true β that is below the threshold is negligible, so the bias correction has very little impact on the posterior mean.

In the empirical Bayes approach, the data are used to estimate appropriate values for μ and τ^2 . To develop intuition, we first consider a method (simpler than the method we use) that would be appropriate if one had access to OLS estimates for a large random sample of SNPs (for example, from complete GWAS meta-analysis results), $s=1, \dots, S$. Since for each SNP the choice of reference allele is arbitrary, the mean of the true effects across the S SNPs is zero: $\mu=0$. Now, note that since $\hat{\beta}_s | \beta_s \sim N(\beta_s, \nu_s^2)$ and $\beta_s \sim N(0, \tau^2)$, it follows that $\hat{\beta}_s \sim N(0, \tau^2 + \nu_s^2)$. Therefore, τ^2 can be estimated as the variance of all of the $\hat{\beta}_s$ estimates minus the mean of the square of their estimated standard errors:

$$\hat{\tau}^2 = \frac{1}{S-1} \sum_{s=1}^S \hat{\beta}_s^2 - \overline{\hat{\nu}_s^2}.$$

We do not use this approach because assuming $\mu=0$ would be extremely conservative in our context, where the SNPs we study are not a random sample—rather, they were selected as candidates for cognitive performance because they had strong impacts in a previous GWAS on educational attainment.

The empirical-Bayes approach that we employ exploits information available from the GWAS results on educational attainment to inform our choice of μ . Specifically, we set μ equal to the magnitude of a SNP's effect that would be needed in order for the SNP to explain the same fraction of variance in cognitive performance as it explains in educational attainment. To be more precise, let $\hat{\beta}_{educ,s}$ be the estimated effect of SNP s on years of schooling taken from Rietveld et al. (2013). The fraction of variance in years of schooling explained by the SNP can be calculated as $R_{educ,s}^2 = \frac{2m_s(1-m_s)\hat{\beta}_{educ,s}}{\sigma_{educ}^2}$, where m_s is the MAF of SNP s and σ_{educ}^2 is the variance of years of schooling. We can calculate that SNP s would have the same R^2 for cognitive performance if $\beta_{cog,s} = \frac{\sigma_{cog}}{\sigma_{educ}} \hat{\beta}_{educ,s}$, where $\beta_{cog,s}$ is the putative effect of SNP s on cognitive performance, and σ_{cog}^2 is the variance of cognitive performance. Thus, we set the

mean of our prior for the effect of the SNP on cognitive performance as $\mu = \frac{\sigma_{cog}}{\sigma_{educ}} \hat{\beta}_{educ,s}$.

While not as conservative as setting a prior of zero, this prior mean is still likely to be conservative (i.e., too close to zero) to the extent that a SNP's effect on educational attainment works through a more direct effect on the mediating phenotype of cognitive performance; in that case, the SNP would be expected to explain a *larger* fraction of variance in cognitive performance than in years of schooling. We calculate the prior parameter τ^2 similarly as in the mean-zero empirical-Bayes procedure above (but rather than estimating the variance about zero, we estimate the variance about the mean of the prior):

$$\hat{\tau}^2 = \frac{1}{S-1} \sum_{s=1}^S (\hat{\beta}_s - \mu)^2 - \overline{\hat{\sigma}_s^2}.$$

(18) prove that there is no winner’s curse correction that is unbiased for all values of β , but an advantage of a Bayesian approach is that the estimates will be on average unbiased. As an intuitive rationale for a choice for a prior, note that the Bayesian method with a diffuse prior will be unbiased on average across all real-valued effect sizes, while the empirical Bayes method is unbiased across a weighted average of effect sizes with the weights given by the prior. Thus, the empirical-Bayes-corrected estimate should be less biased if the true effect size is local to the mean of the selected prior but more biased if the true value is distant from the mean.

As a final note on implementation: all of the above approaches require a value for $\sigma^2 \equiv \frac{\sigma^2}{2nm(1-m)}$, which we have assumed is known, but it is in fact not known because m and σ^2 are not known. For m , we just use the empirical frequency of the minor allele in our data. We estimate σ^2 iteratively, starting with the naive estimate of β , $b_0 = \hat{\beta}$. Then we calculate $\sigma_0^2 = \text{var}(Y) - 2b_0^2 m(1-m)$. Using σ_0^2 , we estimate $b_1(\sigma_0)$. We iterate this procedure until it converges, giving us estimates of both σ^2 and $\hat{\beta}$. (In the implementations below, we ran the algorithm for ten iterations, but convergence was virtually always apparent after only two.)

C. Simulation Study

We now examine and compare the MLE and Bayesian methods via simulation. To roughly match the analysis of the top three SNP associations with cognitive performance from the main text, we set the sample size $n = 25,000$, MAF $m = 0.4734$, dependent-variable variance $\sigma^2 = 1$ (that is, the dependent variable is standardized), and significance threshold $\alpha = 0.05/69$ (the conventional significance threshold after Bonferroni correction for analysis of 69 SNPs). For each fixed true value of β , in each iteration i of the simulation, we draw an n -length genotype vector g_i , and we draw an n -length error $\varepsilon_i \sim N(0, \sigma^2 I_n)$. In each iteration, we estimate the naïve $\hat{\beta}_i$, which we keep if it passes the significance threshold and ignore otherwise. If we keep $\hat{\beta}_i$, we then estimate $\tilde{\beta}_{MLE,i}$ using maximum likelihood and $\tilde{\beta}_{Bayes,i}$ using the diffuse-prior Bayesian method described above. (We do not perform simulations for an empirical Bayes approach since it is not clear what the right choice should be for an empirical prior for the simulation.) We perform 1,000,000 replications of this simulation.

Supplementary Figure 3 below shows the winner’s-curse corrected estimate as a function of the true β , grouped in bins of the true β that are 0.002 units wide. For each estimate, the light dotted lines in the corresponding color show the interval that contains 95% of the estimates. The figure suggests that there can be significant bias from the winner’s curse in this parameterization when the true β is less than 0.04, but this bias becomes negligible for higher values. It is also evident that neither correction procedure gives an unbiased estimate of the true β for every particular value of β . In this example, it seems that MLE performs slightly better when the true β is very small, while the Bayesian method performs better for medium values of β . If an empirical-Bayes approach were used, it would perform better than the Bayesian approach for the more common values of β and worse elsewhere.

D. Applications

We now apply these winner’s-curse-correction methods to actual data. We begin with the findings of (1) for educational attainment, where we can compare the unbiased replication-stage estimates to the results from applying the winner’s-curse-correction methods to the inflated discovery-stage estimates. The first and fourth columns of Supplementary Table S5, respectively, report the discovery-stage estimates and the replication-stage estimates for the three SNPs that (1) report passed a significance threshold of $p < 5 \times 10^{-8}$ (the linear regression coefficients for the SNP associated with years of education are from (1)’s Table 1, and the logistic regression coefficients for the SNPs associated with college completion have been provided by the SSGAC). The second and third columns, respectively, show the discovery-stage estimates corrected by MLE and by the Bayesian method with a diffuse prior. Supplementary Table S6 is the same, except that it shows the 10 SNPs that passed a suggestive significance threshold of $p < 10^{-6}$ (including the three that are genome-wide significant). The results in the tables indicate that in these data, both correction methods do a reasonable job of predicting the effect size that is estimated in the replication.

Finally, we apply the winner’s-curse-correction methods to the cognitive performance findings reported in the main text. The first column of Supplementary Table S7 shows the effect size estimates for the three education-based SNPs that passed the (Bonferroni-corrected) significance threshold of $p < 0.05/69$. The second, third, and fourth columns, respectively, show the estimates corrected by MLE, by the Bayesian method with a diffuse prior, and by empirical Bayes.

There are two reasons why the corrections as applied to the cognitive performance findings are large relative to the corrections as applied to Rietveld et al.’s (1) findings (despite the fact that the more stringent significance threshold of genome-wide significance used in (1) would tend to generate a larger correction, all else equal). First, the sample size on which the uncorrected estimates are based is much larger in (1) than for the cognitive performance estimates (approximately 100,000 versus 25,000, respectively). Second and more subtly, simulations (not reported here) show that the uncorrected estimates for the cognitive performance results fall within the region around the significance threshold where the corrections are relatively large.

To provide another way of assessing the magnitude of the SNP associations with cognitive performance, the fifth and sixth columns of Supplementary Table S7 show the R^2 associated with the uncorrected estimates and with the empirical-Bayes-corrected estimates. The R^2 , which is defined as the ratio of the variance explained by the SNP to the total phenotypic variance, is here simply equal to the variance explained by the SNP, because the phenotypic variance has been normalized to 1:

$$R^2 = 2m(1-m)\hat{\beta}^2,$$

where $\hat{\beta}$ is either the uncorrected (naïve) effect size estimate or the empirical-Bayes-corrected estimate. The results reported in the table suggest that the winner’s curse adjustment reduces the SNPs’ R^2 from ≈ 0.0006 to ≈ 0.0002 .

9. Bayesian analysis of the credibility of the SNP associations

Here, we report a heuristic Bayesian calculation along the lines of (20) and (21) to assess the likelihood that the three individual SNP associations we find with cognitive performance are false positives attributable to sampling variation. Several simplifying assumptions make the calculations especially straightforward. First, we assume that each SNP has only two (rather

than three) possible genotypes. Second, we assume for each of the three SNPs, there are only two possibilities: either there is no true association (the null hypothesis H_0), or there is a true association that explains a known fraction of phenotypic variance, R^2 (the alternative hypothesis H_1). Let the prior probability of H_1 be denoted by π ; hence the prior probability of H_0 is $1-\pi$. Third, we assume the information available to us is that for each SNP, using a two-sided t -test, we rejected the null hypothesis of no association at the standard significance threshold after Bonferroni correction for testing 69 SNPs, i.e., we rejected H_0 at the significance threshold $\alpha = 0.05/69 \approx 0.00072$.

By Bayes' Rule, the probability that there is a true association given that we observed a significant association is:

$$P(H_1 \mid t > t_{\alpha/2}) = \frac{P(t > t_{\alpha/2} \mid H_1)P(H_1)}{P(t > t_{\alpha/2} \mid H_1)P(H_1) + P(t > t_{\alpha/2} \mid H_0)P(H_0)} = \frac{(\text{power})(\pi)}{(\text{power})(\pi) + (\alpha)(1-\pi)},$$

where “power” (as well as the significance test) is two-sided. Using (22) (<http://pngu.mgh.harvard.edu/~purcell/gpc/qtlassoc.html>), we calculate statistical power for several different values of R^2 and for the sample size of $N = 24,189$ (the actual sample size of the Cognitive Performance Sample).

Supplementary Table S8 shows posterior probabilities that there is a true association, given specific values for R^2 and π . The larger value for R^2 is 0.0006, which roughly corresponds to the estimated magnitude of the association in the Cognitive Performance Sample for each of the three SNPs that are statistically significant after Bonferroni correction (their R^2 's are 0.00064, 0.00058, and 0.00056; see Supplementary Table S4). Because this estimate is likely to be inflated by the winner's curse, we also examine the smaller value of $R^2 = 0.0002$. This value roughly corresponds to the estimated magnitude of the association for each of the three SNPs after adjustment for the winner's curse, as discussed in Supplementary Information section 8 (these winner's-curse-adjusted R^2 's are 0.00027, 0.00019, and 0.0017; see Supplementary Table S7).

In the simple set-up here, we view a prior probability π in the range of 0.2% to 2% as the right order of magnitude for an *arbitrarily* selected SNP to be associated with cognitive performance with effect sizes of order of magnitude $R^2 = 0.0002$. To see why, begin by taking one extreme: suppose all independent associated SNPs had effect sizes $R^2 = 0.0002$. Since the proportion of variance in cognitive performance explained by the linear, additive effect of all SNPs jointly is roughly 0.40 (23, 24), there would be $0.40 / 0.0002 = 2,000$ independent associated SNPs. Given that there are approximately 1 million independent loci in the human genome (25), each of the loci would have prior probability $2,000 / 1 \text{ million} = 0.2\%$. However, in reality, most SNPs associated with cognitive performance surely have smaller effect sizes than $R^2 = 0.0002$. In this simple set-up with only two hypotheses, if we consider any SNP whose association is more than an order of magnitude smaller than $R^2 = 0.0002$ as consistent with the “null hypothesis,” then the largest number of independent SNPs that are non-null is 20,000 (because $0.40 / 0.00002 = 20,000$). In that case, each locus has prior probability $20,000 / 1 \text{ million} = 2\%$.

Since the 69 SNPs we study are not arbitrary but are instead selected from those most strongly associated with educational attainment, the prior probability for each of those SNPs should be much higher than for a randomly selected locus in the genome—indeed, this observation is what motivates the proxy-phenotype method in the first place. Therefore, we view $\pi = 0.1\%$ as an extremely conservative lower bound for the prior probability on the three SNPs being true positives. Since we suspect that a number of the 69 SNPs we study are probably truly associated with cognitive performance, we believe that priors of $\pi = 5\%$ and $\pi = 10\%$ are more reasonable.

Given priors of $\pi = 5\%$ or $\pi = 10\%$, together with a reasonable assumption about the true effect size (the winner's-curse-adjusted R^2 of 0.0002), Supplementary Table S8 indicates that the evidence very strongly favors H_1 over H_0 : the posterior probability of each SNP association being a true positive is 90% or 95%, respectively. According to the table, a proper Bayesian thinker should be skeptical only when the prior probability becomes so conservative that the first stage of selecting SNPs on the basis of their being associated with years of schooling is treated as uninformative (π less than 1%).

10. Selection of theory-based candidate SNPs

To select a set of SNPs that would fairly represent those that would be nominated as candidates on theoretical grounds, we required a method of constraining the search. One challenge for candidate-gene approaches is that any of the thousands of genes that are expressed in the central nervous system could be selected as a theoretical candidate for association with cognitive performance. Therefore, we chose to use only SNPs that had at least one published positive association with IQ, g , or a measure of general cognitive ability, including higher-order facets of IQ such as verbal or spatial IQ (but *not* episodic memory, working memory, dementia, MMSE, autism, schizophrenia, etc.) in a healthy sample, regardless of whether there are any published negative associations (non-replications), as of May 2013. PubMed was used for the searches, and the results were required to be publications in peer-reviewed journals (not conference abstracts, etc.). This selection method should be biased in favor of “good candidates” in the sense that they are more likely to be true associations than would be a randomly chosen set of common SNPs in central-nervous-system-expressed genes. We excluded SNPs that originated as discoveries in GWAS studies, SNPs that were only significant in association with IQ as large haplotypes, and polymorphisms that are not SNPs. The first exclusion was applied because GWAS-discovered SNPs are not traditional candidates, since they were by definition derived in an atheoretical manner. The latter two were applied so as to restrict our set of theory-based candidates to individual SNPs that could be compared directly to the set of SNPs nominated from the results of the years-of-schooling (proxy phenotype) GWAS. Finally, we confirmed that none of the positive associations reported in the literature for the theory-based SNPs used a cohort included in the Cognitive Performance Sample. Our set of theory-based SNPs is listed in Supplementary Table S3.

(While the SNPs comprising the two-SNP haplotype for *APOE*, rs429358 + rs7412, were retained on our initial list, these SNPs were not available in the cohort GWAS results.)

11. Testing the Q–Q plots for the education-associated and the theory-based candidates

To test whether the Q–Q plot for the education-associated SNPs (Figure 2 in the main text) differs from the null of a uniform distribution, we use as our test statistic

$$Z = \frac{\frac{1}{S} \sum_{s=1}^S z_s^2 - 1}{\sqrt{2/S}},$$

where s indexes the $S = 69$ education-associated SNPs, and z_s^2 is the squared z -statistic from the regression of cognitive performance on SNP s . This squared z -statistic captures the strength of the association between cognitive performance and SNP s (while ignoring the sign of the association, which depends on the arbitrary choice of reference allele). Under the null hypothesis, each $z_s \sim N(0,1)$, and thus $z_s^2 \sim \chi^2(1)$, which has mean 1 and variance 2. Therefore, under the null:

$$E(Z) = 0, \text{var}(Z) = \frac{(1/S)^2 S \text{var}(z_s^2)}{2/S} = 1.$$

We calculate a p -value for the test of whether the realized value of the test statistic, $Z = z$, differs from zero using the inverse cdf of the standard normal distribution. As reported in the main text, for the education-associated SNPs, we calculate $z = 5.98$, corresponding to p -value $= 1.12 \times 10^{-9}$.

We test the theory-based SNPs analogously, but with $S = 24$. As reported in the main text, we calculate $z = 1.19$, corresponding to p -value $= 0.12$.

To calculate the 95% confidence bounds around the null hypothesis shown in Figure 2, we use the fact that the s^{th} order statistic out of S from a Uniform(0,1) random variable has a Beta(s , $S-s+1$) distribution (33, p. 230). These confidence bounds differ for the two sets of SNPs because S differs.

12. Biological annotation

In this section, we describe the methods used in our biological annotation analyses. In order to focus on the SNPs most strongly implicated in cognitive performance, we study a subset of the 69 education-associated SNPs described in Supplementary Information section 1. Specifically, we analyze the 14 SNPs that reach a nominal significance level of 5% in the meta-analysis of cognitive performance in the Cognitive Performance Sample. (A more stringent significance threshold would retain too few SNPs for substantial analysis.) Throughout, we refer to these SNPs as the *Nominally-Significant Education-Associated SNPs* (the *NSEA* SNPs).

We conduct five types of analyses. In Subsection A, we examine which non-synonymous coding variants are known to be in strong linkage disequilibrium with the *NSEA* SNPs. In Subsections B and C, we investigate if the *NSEA* SNPs are associated with gene expression levels in, respectively, blood and three distinct brain regions. In Subsection D, to shed light on the biological function of the genes implicated in our analyses, we conduct a gene function prediction analysis. Subsection E, which builds on the analysis from Subsection D, tests whether the loci implicated in our analyses are more enriched for nervous system functioning than SNPs that are similar to our 14 SNPs in terms of minor allele frequency, gene proximity, and gene density, but that are otherwise randomly selected from the GWAS data.

Our analyses here differ in a number of ways from those reported in (1), in which similar biological annotation analyses were conducted in an expanded version of our Education Sample on SNPs reaching $p < 5 \times 10^{-8}$ (genome-wide significance) or $p < 10^{-5}$ (suggestive significance) for association with educational attainment (with the p -value threshold depending on the biological analysis). First and most importantly, by restricting attention to the *NSEA* SNPs, all of our analyses are based on a set of SNPs for which there is especially strong reason to believe that at least some are related to cognitive performance (as opposed to other endophenotypes that matter for educational attainment). Second, our eQTL look-ups (in Subsections B and C) have substantially more statistical power because our gene-expression databases have larger sample sizes. In particular, the brain sample we work with is four times larger than the one analyzed in (1). Third, the gene-prediction analyses we conduct (in Subsection D) are more expansive. Specifically, our analyses include predictions from mouse models about the phenotypic effects of a gene and inferences about the types of tissue in which the gene is expressed. Finally, we report (in Subsection E) formal tests of the hypothesis that the loci implicated in our analyses are more likely than would be expected by chance for otherwise-similar SNPs to be in the vicinity of genes with neuronal functionality. Such formal

tests are novel, as far as we are aware. Subsection F provides a summary of the evidence for biological candidates.

A. Non-Synonymous Variants in Strong LD with Candidate SNPs

We used the software tool HaploReg to identify missense variants in close linkage disequilibrium ($r^2 \geq 0.5$) with at least one of the 14 *NSEA* SNPs. In total we identified 8 such non-synonymous variants in the 1000 Genomes database tagged by 6 *NSEA* SNPs. These 8 variants are within 8 genes: *JMJD1C*, *RECQL4*, *LRRC14*, *SH2B1*, *SDCCAG8*, *DNAJC28*, *GART*, and *SBNO1*. See Supplementary Table S9 for more information about these variants.

B. Blood *cis*-eQTL Lookup

We conducted gene expression analyses from blood using publicly available data (downloadable from <http://genenetwork.nl/bloodeqtlbrowser/>) from a recently published paper by (27). (27) conducted *cis*-eQTL mapping by testing, for a large set of genes, all SNPs within 250 kb of the transcription start site of the gene for association with total RNA expression level of the gene. The publicly available data contain, for each gene, a list of all SNPs that were found to be significantly associated with gene expression using a False Discovery Rate (FDR) of 5%. For a detailed description of the quality control measures applied to the original data and an overview of the statistical framework, see (27). Their meta-analysis is based on a pooled sample of 5,311 individuals with gene expression levels measured from full blood. We looked up the 14 *NSEA* SNPs in this publicly available data and found 8 that were significantly associated with gene expression levels in a total of 19 different genes and transcripts: *LRRC24*, *GPT/PPP1R16A*, *VPS28*, *MFSD3*, *TUFM*, *SPNS1*, *CCDC101*, *SULT1A2/SULT1A1*, *LAT*, *SDCCAG8*, *GART*, *ITSN1*, *RILPL2*, *SETD8*, *STK24*, *TANK*, and *PSMD14*. The effect sizes and statistical significance for the *NSEA* SNPs and strongest eQTL signal for each gene are presented in Supplementary Table S10.

C. Brain *cis*-eQTL Lookup

To investigate if any of the *NSEA* SNPs are associated with gene expression levels in human neural tissue, we utilized data from the Harvard Brain Tissue Research Center. The total sample of 742 individuals is comprised of 376 Alzheimer patients, 193 Huntington patients, and 173 individuals without a known neurological disorder. The dataset contains data on expression probes obtained from postmortem brains and measured in three distinct neural regions: prefrontal cortex, visual cortex, and cerebellum (28). The probe data on the Huntington patients have not previously been reported.

The quality control and probe-data normalization steps are each extensive and are described in detail in Zhang et al. After these steps, 39,579 probes were taken forward as dependent variables for subsequent eQTL analysis.

As is standard, we tested the probes for association with all of the SNPs in the GWAS data; below, we report the results from “looking up” our prioritized SNPs in the results. We eliminated SNPs with a minor allele frequency below 0.01, SNPs that failed a test of Hardy-Weinberg equilibrium at a nominal p -value $< 10^{-6}$, and SNPs with a call rate below 95%. After quality control, 838,958 SNPs remained. We used a Kruskal-Wallis test to test all SNPs within one Mb of the transcription start site of each gene for association with gene expression level of a given probe. We adjusted the resulting p -values to control for testing of many SNPs and probes. To take into account the correlation structures among the probes and among the SNP genotypes, we estimated an empirical FDR: the ratio of the average number of eQTLs found in datasets with randomly permuted sample labels to the number of eQTLs identified in the original data set. Since the number of tests was large, we found that the empirical null distribution converges after a relatively small number of permutation runs; thus, we used ten permutation runs to estimate the empirical FDR. We focus on the associations that survive after constraining the empirical FDR to be less than 10% (which corresponds to a nominal p -value cutoff of approximately 5×10^{-5}).

In the meta-analytic results for the three different brain regions, we looked up a total of 580 SNPs: the original 14 SNPs together with all SNPs in high linkage disequilibrium ($r^2 > 0.5$) with one of these 14 SNPs. We observed 40 significant *cis*-effects for 27 of these 580 SNPs (significant at FDR 10%, as described in the previous paragraph): 13 for prefrontal cortex, 10 for visual cortex, and 15 for cerebellum. These 27 SNPs, which proxy for 6 of the 14 *NSEA* SNPs, regulate gene expression for 18 distinct transcripts (some of which are genes and some of which are non-coding, regulatory RNAs): *LRRC14*, *LRRC24*, *KIFC2*, *AF075035*, *EIF3C*, *LAT*, *NUPRI*, *NFATC2IP*, *TUFM*, *SDCCAG8*, *SBNO1*, *C12ORF65*, *MPHOSPH9*, *TMEM50B*, *GART*, *IFNGR2*, *AK026896*, and *AF33979*. Supplementary Table S11 lists the effect-sizes, p -values, LD metrics, and brain regions.

D. Co-expression-driven Gene Functional Prediction

We used a recently developed method (extensively described and implemented by (29)) to gain insight into the putative functions of the genes in the vicinity of the *NSEA* SNPs. Gene function prediction is based on the idea that genes with shared expression profiles are likely to have related biological functions. For example, if there are 50 genes known to play a role in apoptosis, then a gene with unknown function that is strongly co-expressed with these 50 genes is likely to be part of apoptotic pathways as well. The method described in (29) uses data on co-expression profiles to predict the likely functions of as-of-yet uncharacterized genes and refine our understanding of the function of other genes (achieving this by reconstituting the

existing gene sets – described below). In addition to proposing the method, (29) also report evidence that a prediction coming out of the framework was validated by subsequent wet-lab experiments.

To apply the method, we queried the co-expression database described by (29) with our list of genes (our list is explained below). The query for each gene returned the probable function of the gene or the reconstituted pathway in which it operates (more specific details are given below). In the remainder of this paragraph, we briefly summarize the information from which the co-expression database was generated. The database was generated by linking information about gene expression obtained from published data on approximately 80,000 gene expression profiles (from the database Gene Expression Omnibus (GEO) (30), which itself was generated using data from humans, animals, and/or cell lines) with three other distinct types of information:

1. A list of pathways and gene sets that a given gene is believed to be involved in, obtained from the databases: REACTOME pathways (31), Gene Ontology terms (32), and KEGG pathways (33).
2. The phenotypic effects of perturbing the normal functioning of a given gene in mice (e.g., knock-out models, overexpression), obtained from the Mouse Genetics Initiative database (<http://www.informatics.jax.org>).
3. More than 200 specific tissues, organs, or cell types within which a given gene is highly expressed in the co-expression dataset, for which annotation was obtained from searching the U.S. National Library of Medicine's Medical Subject Headings (MeSH) database (<http://www.nlm.nih.gov/mesh/>).

(In contrast to the functional prediction analysis that we describe here, the analogous analysis in (1) was conducted at a time when the co-expression database included only information from #1 in the above list.)

In our analyses, we queried a list of 83 genes that were derived from the list of 14 *NSEA* SNPs: we included every gene that is located within 250 kb of the 14 SNPs; and if the SNP is located within a gene desert (defined by having no gene located within 250 kb base pairs of the SNP), we included the nearest gene. Two of the 14 SNPs were located within a gene desert: rs1487441 (nearest annotated gene *POU3F2* is located ~700kb away) and rs1606974 (nearest annotated gene *NRXN1* is located ~600kb away).

Among the 83 genes we queried, we found that 15 genes are in relevant gene sets related to reconstituted pathways and biological functions (for specific predictions, see Supplementary Table S12), 23 genes are predicted to cause relevant neuronal phenotypes in mouse models (for specific predictions, see Supplementary Table S13), and 29 genes are highly expressed in nervous-system-related tissues and cell types (for specific tissues and cell types, see Supplementary Table S14). Given that there is overlap between the genes in these three sets, our co-expression analyses identified 36 genes in total as potential biological candidates for cognitive performance (see Supplementary Table S15 for a list of these genes). (Note that *APOE*, which may be associated with cognitive decline in older individuals (6) is *not* among our list of genes. This is perhaps as expected given our results from section 'Polygenic score analyses in the Health and Retirement Study', in which we find that a polygenic score comprised of our educated-associated SNPs is associated with the *level* of cognitive function in older individuals but not with cognitive decline.)

While the full list of all implicated reconstituted pathways is available online at <http://www.ssgac.org>¹, we conclude our discussion of this analysis by listing the top 5 most frequently occurring search terms from the analysis for each category (with the count given in square brackets) listed in the Supplementary Tables S12, S13 and S14:

1. **Gene Ontology: Biological Processes** – neuron-neuron synaptic transmission [3]; neurotransmitter secretion [3]; regulation of neurotransmitter levels [3]; synaptic transmission, glutamatergic [3]; axonogenesis [2].
2. **Gene Ontology: Cellular Compound** – synapse [6]; dendrite [5]; synapse part [5]; cation channel complex [4]; synaptic membrane [4].
3. **Gene Ontology: Molecular Function** – cation channel activity [5], gated channel activity [5]; voltage-gated cation channel activity [5]; voltage-gated channel activity [5]; voltage-gated ion channel activity [5].
4. **KEGG** – Calcium signaling pathway [4], Neuroactive ligand-receptor interaction [3], axon guidance [2], Long-term potentiation [2].
5. **REACTOME** – Neuronal System [6] Potassium Channels [5]; Transmission across Chemical Synapses [5]; Voltage gated Potassium channels [5]; Ras activation upon Ca²⁺ influx through NMDA receptor [4]; Unblocking of NMDA receptor, glutamate binding and activation [4].
6. **Mouse Genome Informatics** – abnormal brain wave pattern [5]; abnormal excitatory postsynaptic currents [5]; abnormal excitatory postsynaptic potential [5]; abnormal inhibitory postsynaptic currents [5]; abnormal CNS synaptic transmission [4].
7. **Site-specific expression** – Prefrontal Cortex [12]; Visual Cortex [12]; Occipital Lobe [12]; Cerebral Cortex [11]; Entorhinal Cortex [11].

E. Evaluating for Enrichment of Genes Related to Neuronal Function

Our prediction analyses showed that all 12 *NSEA* SNPs not located in a gene desert were within 250 kb of at least one gene predicted to be related to neuronal function. While this finding seems impressive, it is well understood that many genes can be linked to neuronal function. It is therefore important to evaluate whether the 12 non-desert *NSEA* SNPs in our analysis are more associated with neuronal function than would be expected by chance. To do so, we calculated an empirical *p*-value using a matching procedure that we describe in this section.

As a first step, for each of the 12 non-desert *NSEA* SNPs, we randomly sampled a vector of 1,000 “matched SNPs” that resembled the *NSEA* SNPs in terms of minor allele frequency, gene density, and distance to nearest gene. For each *NSEA* SNP, we generated the 1,000 matched SNPs using the following algorithm:

1. We identified the set of all SNPs covered by our GWAS data that have a minor allele frequency within 5 percentage points of the given *NSEA* SNP’s minor allele frequency.

¹ The link will be activated on the day of publication of this article. The materials that will be posted online are included as a separate appendix to the submitted manuscript.

2. We discarded SNPs from this set whose gene density differed from the given *NSEA* SNP's gene density by more than 10%, where "gene density" is defined as the total number of genes containing a SNP that is in LD $r^2 > 0.5$ with the focal SNP.

3. We then further discarded SNPs from the set whose distance to the nearest gene exceeds the given *NSEA* SNP's distance to nearest gene by more than 20 kb.

4. Finally, from the remaining SNPs in the set, we randomly sampled 1,000 of them. (Up to this point in the algorithm, there were always more than 1,000 SNPs remaining in the set.)

As a second step, for each of the 12 *NSEA* SNPs and each of their respective 1,000 matched SNPs, we coded a SNP as either "enriched for neuronal functioning" or "not enriched for neuronal functioning." We did so using a version of the gene function prediction procedure outlined in section 4, but we modified the procedure in two ways. First, to make our definition of "enriched for neuronal functioning" in this analysis more stringent and specific to reconstituted *pathways*, we only used the type of information listed in bullet point #1 from section 4: the pathways and gene sets that a given gene is believed to be involved in. Specifically, we manually annotated *all* of the 6,004 functionality terms from the relevant databases (737 REACTOME pathways, 5,083 Gene Ontology terms, and 184 KEGG pathways), categorizing each as either "related to neuronal function" or "not related to neuronal function" depending on the direct or indirect involvement in the central nervous system via anatomy, cellular structure, or physiological processes (information drawn from published literature). We have posted this annotated list on the following website: <http://www.ssgac.org>². Second, rather than identifying genes in the vicinity of a SNP as those genes containing a SNP within a window of 250 kb around the focal SNP (as we did in section 4), here we identify genes in the vicinity of a SNP as those genes containing a SNP that is in LD $r^2 > 0.5$ with the focal SNP; this latter definition is generally more stringent and therefore may be considered more appropriate for the kind of enrichment analysis we conduct here. For each gene in the vicinity of one of the *NSEA* SNPs or in the vicinity of one of the matched SNPs, we code the gene as "related to neuronal function" if and only if at least one of its predicted functionality terms is categorized as "related to neuronal function." We then code each *NSEA* SNP as "enriched for neuronal functioning" if and only if at least one of the genes in its vicinity is "related to neuronal function," and we code each of its respective matched SNPs analogously.

In the final step, we tested the null hypothesis that the 12 *NSEA* SNPs are no more "enriched for neuronal functioning" than would be expected by chance. Using the definition of "enriched for neuronal functioning" from the previous paragraph, 10 out of the 12 *NSEA* SNPs are "enriched for neuronal functioning." For comparison, among the 1,000 random matched sets, we observed 88 sets with at least 10 out of 12 SNPs "enriched for neuronal functioning." Hence, the empirical *p*-value is 0.088. While this *p*-value does not reach the standard statistical significance threshold of 0.05, we nonetheless view it as fairly strong evidence in favor of the biological significance of the *NSEA* SNPs: our procedure of matching the SNPs on minor allele frequency, gene density, and distance to nearest gene leads to a very conservative test because if the properties of the *NSEA* SNPs—say, their distance to nearest gene—is typical of functional SNPs, then the SNPs matched to them are also reasonably likely to be functional. Thus, our test does not just require that the *NSEA* SNPs are more likely to be "enriched for neuronal functioning" than any randomly chosen SNPs, but more likely than SNPs that are already chosen to be reasonably likely to be functional.

² The link will be activated on the day of publication of this article. The materials that will be posted online are included as a separate appendix to the submitted manuscript.

(We note that our approach is an improvement compared to current standard practice in enrichment analysis. Instead of investigating only established functions and links to pathways, we apply functional prediction, which extends over known biology and is likely more accurate and stringent. It is not common practice yet to conduct the kind of statistical test that we introduce here, and we suspect that our results are statistically stronger than those that would be obtained from many published findings using related bioinformatics procedures.)

F. Summary of the Evidence for Biological Candidates

In this section we briefly summarize the cumulative evidence arising from our extensive bioinformatics annotation analyses regarding which genes are associated with cognitive performance. In Supplementary Table S15 we outline the positive findings from our 4 different computational approaches (described above), in total 8 distinct categories: (1) non-synonymous variants; (2) blood eQTL; (3) brain eQTL–prefrontal; (4) brain eQTL–visual; (5) brain eQTL–cerebellum; (6) functional prediction–GO, KEGG, REACTOME; (7) functional prediction–mouse phenotypes; and (8) functional prediction–tissue expression. In the last two columns of Supplementary Table S15, we additionally report the results from looking for overlap between our list of 83 genes and the genes implicated in two recent analyses of neural function:

1. (28) report functional modules constructed using brain-derived gene expression profiles from three regions (prefrontal cortex, visual cortex and cerebellum). We looked up which if any of our 83 genes were reported as clustered into any of the 62 network modules containing at least 50 genetic nodes as defined in (28). Here, we find that six of the genes (*POU3F2*, *CPSF1*, *AKT3*, *NMS*, *TMED2* and *TMEM50B*) map to the neuropeptide hormone specific module (Fisher’s exact test (FET) enrichment p -value = 0.004, analytical framework explained extensively at (28). Furthermore, we combined all neuronal specific modules (synaptic transmission; neurogenesis; neuropeptide hormone and/or nerve myelination) from (28): this approach implicates 12 of the following genes – *POU3F2*, *CPSF1*, *KCNMA1*, *AKT3*, *KIFC2*, *FARP1*, *NMS*, *NRXN1*, *SCRT1*, *TBR1*, *TMED2* and *TMEM50B*, in neuronal-related module functions (FET enrichment p -value = 0.015).
2. (34) identifies genes that code for proteins isolated from the postsynaptic density from human neocortex [hPSD]. We looked up which if any of our 83 genes were reported as part of this protein complex. This exercise implicates the following genes: *FARP1*, *ITSN1*, *NRXN1*, and *TUFM*.

In total we found some supportive evidence for 56 out of the 83 genes. Furthermore, 21 genes were prioritized by at least 3 of the methods, 12 genes by at least 4 methods, and 6 genes by up to 5 methods. These 6 genes that have highly convergent evidence of biological functionality are: *LRRC14*, *KIFC2*, *NRXN1*, *C12ORF65*, *ITSN1* and *TMEM50B*. Furthermore, the results from the above two analyses of blood and brain *cis*-eQTLs indicate that the *NSEA* SNPs or respective proxies affect the gene expression levels of almost half of the 21 top-ranking implicated genes, and hence these analyses may reveal potential regulatory mechanisms. As noted in the main text, in total 4 of the highly prioritised genes (*KCNMA1*, *NRXN1*, *POU3F2*, and *SCRT*) are predicted (in the analysis in the section “Co-expression-driven Gene Functional Prediction” above) to be involved in a particular reconstituted neurotransmitter pathway, labeled in REACTOME as “unblocking of NMDA receptor, glutamate binding and activation.”

13. Polygenic score analyses in family samples

A. Results from analyses in family samples

We used a polygenic score to explain cognitive performance in MCTFR, QIMR, STR, and in the additionally recruited cohort Generation Scotland (GS). To construct the weights for the polygenic score used for each of these cohorts, we performed a meta-analysis on cognitive performance, excluding respectively MCTFR, QIMR, STR, and no cohorts (for GS, we use the complete cognitive performance meta-analysis since GS was not included in the meta-analysis). This resulted in a meta-analysis of $N = 20,822$ for MCTFR, $N = 22,437$ for QIMR, $N = 20,974$ for STR, and $N = 24,189$ for GS. We constructed a linear polygenic score by weighting the 69 education-associated SNPs by the coefficient estimates obtained from these meta-analyses (in QIMR, the SNP rs2970992 was excluded because it exhibited a very high number of Mendelian errors and extreme Hardy-Weinberg irregularity: HWE test $p = 1.98 \times 10^{-17}$). In MCTFR the sample is restricted to 1,346 siblings from 673 families. In QIMR the sample is restricted to 5 siblings from 1 family, 4 siblings from 19 families, 3 siblings from 129 families, and 2 siblings from 479 families, yielding a total of 1469 pseudo-independent siblings. In STR the sample is restricted to 810 DZ twins from 405 distinct families. In GS there are 1,081 siblings from 476 independent families. In each regression the standard errors are clustered (35) at the family level to take into account the non-independence of individuals within a family. The results are reported in Supplementary Table S16. Using both within-family and between-family variation (the top panel: “Without family dummies”), pooling the coefficients across GS, MCTFR, QIMR, and STR with inverse-variance weighting (the right-most column), we find that the score is significantly protectively associated with cognitive performance (p -value = 8.17×10^{-4}). Using only within-family variation (the bottom panel: “With family dummies”), the pooled coefficient has the same sign but is smaller with a larger standard error, and is thus not statistically significant (p -value = 0.36).

B. Power calculations for within-family analysis

In the main text, we claim that “even without stratification, the non-significance of the within-family coefficient is not surprising given the low power of this test.” Here we substantiate that claim.

We estimate the power of this analysis by simulation. We assume that cognitive performance Y of sibling i from family j is determined according to the following simple model:

$$Y_{ij} = \beta s_{ij} + z_j + \varepsilon_{ij},$$

where s_{ij} is the polygenic score, z_j is a family effect, and ε_{ij} is the residual from a projection of Y_{ij} on s_{ij} and z_j in the population and is therefore uncorrelated with both by construction. The variables Y_{ij} and s_{ij} are standardized to have mean 0 and variance 1. We assume that $\varepsilon_{ij} \sim N(0, \sigma_\varepsilon^2)$ and that the family effects are distributed normally in the population: $z_j \sim N(0, \sigma_z^2)$. Since we are interested in testing our power to detect a polygenic score effect within families under the assumption that the size of the effect is the same as it is without family effects, we assume that s_{ij} is uncorrelated with z_j .

To match the empirical fact that the correlation of cognitive performance between siblings is about 0.5, we assume that $\sigma_z^2 = \sigma_\varepsilon^2 \equiv \sigma^2$. Now, note that the explanatory power of the polygenic score is given by:

$$R^2 = \frac{\beta^2 \text{var}(s_{ij})}{\beta^2 \text{var}(s_{ij}) + \text{var}(z_j) + \text{var}(\varepsilon_{ij})} = \frac{\beta^2}{\beta^2 + 2\sigma^2}.$$

In the simulations below, we examine two different values for β , 0.045 and 0.065. For each β , the value of σ^2 is set to satisfy $\beta^2 + 2\sigma^2 = 1$ (which ensures that Y_{ij} has variance 1 and that $R^2 = \beta^2$). Given this, the two values of β correspond to R^2 equal to 0.20% and 0.42%, respectively, which roughly correspond to the lower and upper end of the range of R^2 's we estimate for the score across samples (in Table S16).

For each assumed true value of β , we conduct 500 simulation runs. In each run, we generate data as follows for a sample of 2,182 families that matches the data used in our estimation: 1,950 two-sibling families, 181 three-sibling families, 42 four-sibling families, 4 five-sibling families, 3 six-sibling families, and 2 seven-sibling families. We generate SNP-level data for the parents by assuming that the allele frequency for 69 SNPs matches the empirical frequency measured in our data, that parental genotypes are drawn independently, and that all SNPs are in Hardy-Weinberg equilibrium. Children are then simulated by drawing one allele from each parent with equal probability. The weights to calculate the score are drawn from a normal distribution (with mean 0 and variance scaled such that s_{ij} has variance 1). This data-generating process produces scores that have a within-family correlation of 0.5.

Given the data in each run, we estimate β in two regressions. In the first, we regress Y_{ij} on s_{ij} (i.e., we not include family dummies as covariates); this is the “Without family dummies” model in table S17 discussed below. In the second, we regress Y_{ij} on s_{ij} and z_j ; this is the “With family dummies” model in table S17 discussed below. Note that in the second model, we are estimating the family effect as a fixed effect (even though we model it as a random effect, which is normally distributed, for the purpose of doing the power calculation) because in the analysis of the actual data we estimate the family effect as a fixed effect. In both regressions, we take into account the non-independence of individuals within a family by clustering standard errors within family (35), just as we do in the analysis of the actual data.

We estimate power as the fraction of the 500 runs in which we reject the null hypothesis $\beta = 0$ with a p -value less than 0.05. Table S17 shows the average regression output over the 500 simulations for the two different values of β , 0.045 and 0.065.

As can be seen in table S17, power is much higher in the model estimated without family dummies; it is very nearly 80% even at the lower end of the range of R^2 's. With family dummies, however, the range of R^2 's corresponds to power between 31.2% and 64.2%. Thus, our power to detect a significant effect in the within-family analysis is relatively low even if the true effect size is at the upper end of our range of estimates.

14. Polygenic score analyses in the Health and Retirement Study

A. HRS data description

The Health and Retirement Study (HRS; (36)) is a representative sample of Americans over the age of 50 who have been surveyed every two years since 1992. The survey data from all 10 waves of the study are publicly available. The total sample size of the HRS is 30,671, including respondents who entered the sample in wave 1, replenishment samples who entered in subsequent waves, and spouses of respondents. However, for all analyses using the HRS described in this section and elsewhere in this paper, the sample is restricted to genotyped individuals from European ancestry ($N = 8,652$). Because testing individual SNPs in a sample of this size would have low power, we instead analyze a polygenic score.

To combine the education-associated SNPs into a linear polygenic score that exploits their joint explanatory power, we generated a linear combination of the SNPs' number of reference alleles, weighted by their coefficient estimates from the GWAS meta-analysis of years-of-schooling (as in (37)). In particular, we use the results from the meta-analysis that excludes the HRS; this meta-analysis is described in section 1 above. We construct the score in the HRS using the 60 out of 69 education-associated candidate SNPs available in the imputed genotype data.

We obtained the cognitive measures from the HRS datafile as prepared by RAND (RAND v.L, available at <http://hrsonline.isr.umich.edu>). This datafile contains cognitive scores harmonized across all waves of the study in which the data were collected. We use the two summary cognitive-health measures that are available in more than one wave: Total Word Recall (TWR) and Total Mental Status (TMS). TWR is the sum of scores on immediate and delayed word-recall tasks. In each task, the recall list contains 10 words, and scores ranged from 0-20. TMS is a dementia battery. It is the sum of scores for the following tasks: serial 7's (repeatedly subtracting the number 7), backwards counting from 20, and naming objects, the current date, and the current President and Vice-President. The resulting range is 0-15. Because these batteries focus on identifying cognitive problems and early signs of dementia (rather than measuring cognitive ability among healthy individuals), the resulting variables are viewed as measures of cognitive health (for discussion, see (38) p.10, which is posted online as part of the [HRS data documentation: http://hrsonline.isr.umich.edu/sitedocs/dmc/Lachman_hrscognitive.pdf](http://hrsonline.isr.umich.edu/sitedocs/dmc/Lachman_hrscognitive.pdf)). Below, we also report results for Total Cognition (TC), which is the sum of TWR and TMS, resulting in a range of 0-35. Consistent measures for TWR, TMS, and TC are available in wave 3-9.

Prior to wave 4, all cognitive tests were administered to all respondents. Starting in wave 4, all cognitive tests were administered to new respondents, but for those who had participated in a prior wave, the respondent's age determined which cognitive measures were administered. Respondents 65 years or older received the full set of cognitive tests. Respondents under 65 received the full TWR battery but only two of the tasks comprising TMS (serial 7's and backwards counting from 20). For this reason, we have more observations for the TWR measure than for the TMS and TC measures.

B. HRS regression results

For each of the cognitive measures—TWR, TMS, and TC—we run two sets of regressions: one in which the dependent variable is the cognitive measure itself (the “levels” regressions), and one in which the dependent variable is the difference between the cognitive measure in the current wave and the previous wave (the “changes” regressions). All dependent variables are

standardized to have mean 0 and standard deviation 1. In all analyses we control for gender and an age spline. Knots of the age spline are at 60, 70, and 80, except for the changes regressions for TMS and TC, in which the knots are at 70 and 80 because there are only 9 respondent-wave observations with age < 60. We exclude these nine observations from the analysis. For each dependent variable we run two regression specifications. The first includes as a regressor (in addition to gender and the age spline) the polygenic score, and the second additionally includes as regressors the interactions of the polygenic score with the age spline. Because the data include observations from the same respondent in multiple waves, we cluster the standard errors (35) at the respondent level.

Supplementary Table S18 displays the regression results, with each column representing a different regression specification. The odd-numbered columns include only controls for sex and an age spline, while the even-numbered columns additionally control for interactions between the score and the age spline. For each column, the “ ΔR^2 ” row shows the increase from including the score variables (either just the score, or the score and its interactions, depending on the specification) in the regression.

In the levels regressions (columns 1-6), the increasingly negative coefficients on the age spline indicate that cognitive performance is decreasing with age, as expected. The coefficients on the indicator for being female show that females on average have higher scores in TWR and lower scores on TMS, with the net effect on TC being higher scores. Turning to the main coefficient of interest, in all of the levels regressions a higher value for the score is associated with a higher level of cognitive performance. In terms of magnitude, a one standard-deviation increase in the score is associated with approximately a 0.04 increase in TWR, a 0.06 increase in TMS, and a 0.06 increase in TC.

In the levels regressions that include an interaction between the score and the age spline (columns 2, 4, and 6), we find that the effect of the score is approximately unaffected by age, except possibly for the age category ≥ 80 , where there appears to be some reduction in the magnitude of the protective effect of the score (but statistically significantly only for TWR). This pattern is consistent with the results shown in Figure 3 in the main text.

In the changes regressions (columns 7-12), the negative coefficients on the age spline again reflect that cognitive performance is decreasing with age, and indeed at an increasing rate. The negative coefficient on the indicator for being female in the Δ TMS regressions suggests that the decline is slower for females for this measure, but the coefficients are not statistically distinguishable from zero for the other measures. The coefficient on the score is not significantly distinguishable from zero for any of the measures in the changes regressions. Thus, even though the score is associated with a higher *level* of cognitive performance, it does not appear to be protective against *declines* in cognitive performance.

In the changes regressions that include an interaction between the score and the age spline (columns 8, 10, and 12), we again find a negative coefficient for the age category ≥ 80 (statistically significant for Δ TWR and Δ TC). This negative coefficient means that cognitive performance declines more quickly for those respondents over the age of 80 who have higher values of the score—and hence had higher cognitive performance on average at younger ages. This negative coefficient in the changes regressions is thus consistent with the negative coefficient on the analogous interaction term in the levels regressions.

To probe the robustness of the results to population stratification, we repeated the levels regressions for TWR, TMS, and TC, omitting the interaction between the polygenic score and the age spline as a regressor, and instead including different numbers of principal components of the genome-wide data. For each dependent variable, 20 additional regressions are performed,

in which principal components are iteratively added. Supplementary Figure S4 shows how the coefficients for the polygenic score change as principal components are added. The coefficients for the polygenic score may decline slightly as principal components are added, but the decline is very small, and the coefficients with 20 principal components are essentially the same as those without any principal components. Thus, we find no evidence that population stratification is driving the HRS results.

Table S19 presents the same analyses as those in Table S18, however, in these analyses years of education (0-17+) is added as control variable to the model. There is a slight decrease in sample size, because years of education is missing for a few individuals. In the levels regressions (columns 1-6), the coefficient for the polygenic score remains statistically significant, but the magnitude of the coefficient is about half as large as when educational attainment is not included as a control, and ΔR^2 is much smaller. In the changes regressions (columns 7-12), the polygenic score is not statistically significant.

C. HRS sign tests on the education-associated SNPs

We also tested whether the direction of the SNPs' effects on educational attainment generally coincide with the direction of their effects on cognitive performance. For each of the three dependent variables, we ran 60 regressions, using the 60 out of 69 SNPs available in the HRS data as regressors instead of the polygenic score in regression specifications (2), (4), and (6) from Table S18. For each SNP, we compared the sign of the SNP's coefficient with the sign of the same SNP's coefficient from the meta-analysis of educational attainment that excludes the HRS. We computed the p -value using a binomial distribution with probability 50% of matching the sign. The resulting p -values are: 0.0067 for TWR (39 out of 60 SNPs with identical sign), 0.0775 for TMS (35 out of 60 SNPs with identical sign), and 0.0775 for TC (35 out of 60 SNPs with identical sign).

15. Statistical Framework for the Proxy-Phenotype Method as Applied to Cognitive Performance

A. Statistical power of GWAS vs. candidate-SNP (including proxy-phenotype) method for gene discovery

Consider the problem of estimating the association between a phenotype of interest Y , say cognitive performance, and the genotype g_k of each of $k = 1, 2, \dots, K$ SNPs. The standard approach is to estimate K separate linear regressions of Y on each g_k . After standardizing Y and g_k so that each has mean 0 and variance 1, the regression equations to be estimated can be written as

$$(1) Y = \beta_k g_k + \varepsilon_k,$$

for $k = 1, 2, \dots, K$. (For simplicity, we omit the covariates, which would typically include age, sex, and possibly principal components of genetic data, and to avoid cluttering notation, we suppress indexing variables by individual.) Because Y and g_k are standardized, in a large sample the estimated regression coefficient β_k is equal to the correlation between Y and g_k , and the coefficient of determination is $R^2_{Y,g_k} = \beta_k^2$.

In terms of statistical power, the key difference between a GWAS approach to gene discovery and a candidate-SNP approach is the size and composition of the set of K SNPs. In GWAS, the set includes all SNPs measured by the dense SNP genotyping platform (typically 0.5-2.5 million). The statistical significance threshold is set at the “genome-wide significance” level of $\alpha = 5 \times 10^{-8}$, which can be interpreted as a Bonferroni correction for the effective number of independent loci in European populations (25, 39). In contrast, in a candidate-SNP approach—either theory-based or proxy-phenotype-based— K is a much smaller number of SNPs that the researcher considers to be reasonable candidates for association with the phenotype. In a theory-based method, the candidates are chosen on the basis of what is known or believed about their biological function, while in a proxy-phenotype method, the candidates are chosen on the basis of their association with a proxy phenotype. Either way, in terms of statistical power, the advantage of a candidate-SNP approach is that the Bonferroni-corrected significance threshold can be set at the much less stringent level of $\alpha = 0.05 / K$. The potential disadvantage is that the effect sizes of the most strongly associated SNPs in a candidate-SNP approach may be smaller than in a GWAS, since the method of choosing the candidates may not succeed in selecting those that are most strongly associated with the phenotype of interest.

Table S20 calculates power for GWAS vs. candidate-SNP methods of gene discovery that could be pursued in our Cognitive Performance Sample of size $N = 24,189$. The columns show different effect sizes for a SNP: $R^2 \in \{0.02\%, 0.04\%, 0.06\%, 0.08\%\}$, a range from the size of our estimated winner’s-curse-adjusted effect size for cognitive performance of $R^2 \approx 0.02\%$ up to four times that size. The top row shows statistical power to detect each of these effect sizes at the genome-wide significance threshold, $\alpha = 5 \times 10^{-8}$. The bottom row shows statistical power to detect each of these effect sizes at the experiment-wide significance threshold for 69 SNPs, $\alpha = 0.05 / 69 \approx 0.00072$.

As explained in the next subsection below, our calculations prior to the study (based on the results of Rietveld et al., (1)) led us to expect an effect size of $R^2 \approx 0.08\%$ for the strongest associations in our set of proxy-based candidate SNPs. In that case, our power to detect such associations would have been 85%. In contrast, a direct GWAS on cognitive performance in our Cognitive Performance Sample would have had power of 15% to detect these SNPs. Given our estimated winner’s-curse-adjusted effect size for cognitive performance of $R^2 \approx 0.02\%$, our actual power to detect the largest associations we found was 12%—which in turn suggests that there are roughly 8 times as many SNPs with the same effect sizes as the 3 significant SNPs we identified (since $1/0.12 = 8.33$). A direct GWAS on cognitive performance in our sample would have had power of only 0.06% to detect these SNPs. Therefore, even if there are 25 SNPs with associations of magnitude $R^2 \approx 0.02\%$ with cognitive performance, a GWAS with the available sample size would very likely not have detected any of them.

B. Statistical power of proxy-phenotype method under plausible effect sizes for cognitive performance

Prior to conducting this study, we calculated expected effect sizes using the formal framework introduced by Rietveld et al. (1) (SOM pp. 22-27) and the results reported in that paper. Here we sketch a slightly simplified version of that framework (also note that our notation here differs somewhat). Let $s = 1, \dots, S$ index the SNPs that are causally related to cognitive performance or any other genetically-influenced factor that matters for educational attainment.

We assume that cognitive performance is a simple linear function of the individual's genotype and determined by:

$$(2) Y = \sum_{s=1}^S \beta_{Y,s} g_s + \varepsilon_Y,$$

where g_s is the individual's genotype at SNP s (as above, normalized to have mean zero and variance one), $\beta_{Y,s}$ is the effect of g_s on Y , and ε_Y is a random variable with mean zero that we assume is independent of the g_s 's. The error term ε_Y captures all other factors besides the SNPs, including exogenous environmental factors, that affect cognitive performance.

We assume that the proxy phenotype P , in this context educational attainment, is determined by a simple linear function of cognitive performance and other factors:

$$(3) P = \gamma_Y Y + \gamma_X X + \varepsilon_P.$$

X captures genetically-influenced factors that affect educational attainment, including personality traits (such as perseverance) and early-life health conditions. The error term ε_P captures all other factors, including exogenous environmental factors that affect P . We assume that ε_P is a random variable with mean zero and is independent of Y and X . We normalize P , Y , and X so that they have mean zero and variance one (hence regression coefficients are equal to partial correlation coefficients). Without loss of generality, we assume that both Y and X are oriented in the direction that increases educational attainment: $\gamma_Y > 0$ and $\gamma_X > 0$.

To complete the model, we write X as an analogous linear function of the individual's genotype:

$$(4) X = \sum_{s=1}^S \beta_{X,s} g_s + \varepsilon_X,$$

where $\beta_{X,s}$ is the partial correlation coefficient of g_s with X , and ε_X is a random variable with mean zero that we assume is independent of the g_s 's. Now, educational attainment P can be expressed as a function of the SNP genotypes by substituting equations (2) and (4) into equation (3):

$$(5) P = \sum_{s=1}^S (\gamma_Y \beta_{Y,s} + \gamma_X \beta_{X,s}) g_s + (\gamma_Y \varepsilon_Y + \gamma_X \varepsilon_X + \varepsilon_P) = \sum_{s=1}^S \delta_s g_s + u_Y,$$

where $\delta_s \equiv (\gamma_Y \beta_{Y,s} + \gamma_X \beta_{X,s})$ is the effect of SNP s on educational attainment, and $u_Y \equiv \gamma_Y \varepsilon_Y + \gamma_X \varepsilon_X + \varepsilon_P$ is a mean-zero composite error term that is independent of the g_s 's. Note that a GWAS of educational attainment P estimates the δ_s 's in equation (5). Note that if $\delta_s \neq 0$, then either $\beta_{Y,s} \neq 0$ or $\beta_{X,s} \neq 0$ or both. Therefore, if the GWAS of P credibly identifies a SNP, then that SNP can serve as a plausible "candidate SNP" for genetically influenced factors that matter for P .

To generate a first-pass estimate of the effect size of SNPs associated with cognitive performance, we begin with the special case in which genetic factors matter for educational attainment exclusively through cognitive performance: $\gamma_X = 0$. In that case, $\delta_s = \gamma_Y \beta_{Y,s}$. Rearranging, the R^2 from a regression of cognitive performance on SNP s is equal to the R^2 from a regression of educational attainment on SNP s is divided by the squared phenotypic correlation: $\beta_{Y,s}^2 = \delta_s^2 / \gamma_Y^2$. The largest SNP effects on educational attainment are likely to have

a coefficient of determination of roughly 0.0003 (see Table S20), and since $\gamma_X = 0$, these same SNPs will be the ones with the largest effects on cognitive performance. Using $\delta_s^2 \approx 0.0003$ and an estimated phenotypic correlation of $\gamma_Y = 0.6$ (40, 41) gives $\beta_{Y,s}^2 \approx 0.0008$ (our reading of the evidence is that estimates of the phenotypic correlation have generally been in the range 0.4-0.6; our high-end estimate of the correlation yields a lower, and hence more conservative, estimate of the SNP effect size). As mentioned in the previous subsection, this was our best guess of the effect size before we conducted our study and was the basis of our ex ante power calculations. Although we anticipated that the largest SNP effects on cognitive performance would have $\beta_{Y,s}^2 \approx 0.0008$, what we found was $\beta_{Y,s}^2 = 0.0006$, which became $\beta_{Y,s}^2 = 0.0002$ after correction for the winner’s curse (Table S7).

The more realistic case where $\gamma_X > 0$ opens up the possibility that the SNPs most strongly associated with cognitive performance are not the same SNPs as those most strongly associated with educational attainment. To see this, note that since $\delta_s = \gamma_Y \beta_{Y,s} + \gamma_X \beta_{X,s}$, the SNPs with the largest effect on educational attainment—those most likely to be picked out from a GWAS of educational attainment as candidate SNPs—will tend to be those for which *both* $\beta_{Y,s}$ and $\beta_{X,s}$ are positive and large in magnitude. Rietveld et al. use the term “mono-directional” to refer to such a SNP: a SNP that has pleiotropic effects on Y and X such that it affects P in the same direction through both pathways. A SNP has a stronger association with educational attainment than it does with cognitive performance if $\delta_s > \beta_{Y,s}$.

C. Explaining the negative correlation between coefficients for educational attainment and cognitive performance

As noted in the main text, Figure 1 shows a negative correlation between the coefficients on educational attainment and the coefficients on cognitive performance. Also as mentioned in the text, this negative correlation seems somewhat robust to dropping the most conspicuous possible outlier, although we view the evidence for negative correlation as relatively weak. Here we note that according to the framework developed in this section, a negative correlation between δ_s and $\beta_{Y,s}$ implies that $\beta_{Y,s}$ and $\beta_{X,s}$ are negatively correlated. In words, SNPs that affect cognitive performance more strongly tend to affect other factors that matter for educational attainment (such as personality traits) less strongly, and vice-versa.

D. Relating the genetic correlation between educational attainment and cognitive performance to the above framework

According to the framework above, a GWAS of educational attainment (EA) generates good candidate SNPs for cognitive performance (CP) because CP is an important causal factor in determining EA. Moreover, if CP is the primary genetically-influenced factor that matters for EA ($\gamma_X \approx 0$), then the effect size of the SNPs on CP is expected to be larger when the phenotypic correlation between EA and CP (γ_Y) is *smaller*, because the smaller phenotypic

correlation means that the effect of the SNP on EA is more attenuated relative to its more direct and larger effect on CP.

Intuitively, it might seem that the *genetic* correlation between EA and CP would be at least as relevant as the phenotypic correlation. In this subsection, we address the relevance of the genetic correlation within the context of our formal framework; we conclude that the high genetic correlation can be viewed as providing a justification for using EA as a proxy phenotype for EA, but the argument is somewhat loose.

What *can* be shown formally and straightforwardly is that the statistical power of the proxy-phenotype approach is increasing in $\text{corr}(\delta_s, \beta_{Y,s})$. The assumption that CP is the only genetically-influenced factor that matters for EA ($\gamma_X = 0$) implies that $\text{corr}(\delta_s, \beta_{Y,s}) = 1$. If other genetically-influenced factors also matter for EA ($\gamma_X > 0$), then $\text{corr}(\delta_s, \beta_{Y,s})$ can be smaller than 1, and the SNPs with the largest effects on EA may not be those with the largest effects on CP.

The genetic correlation is a different object: $\text{corr}\left(\sum_{s=1}^S \delta_s g_s, \sum_{s=1}^S \beta_{Y,s} g_s\right)$. In words, the genetic correlation is the correlation between the population polygenic score for EA and the population polygenic score for CP. It follows from this definition that if the genetic correlation is high, a polygenic score estimated from EA is likely to explain more of the variance in CP. However, the genetic correlation does not have direct implications about the statistical power for identifying individual SNPs unless the (unconditional) genetic correlation is equal to the genetic correlation *conditional* on including only the SNPs with largest effect sizes in the polygenic score. The evidence discussed in subsection C above casts some doubt on this assumption. Therefore, while in general we view the high genetic correlation between EA and CP as supportive of our use of EA as a proxy phenotype, we view our overall framework as providing a more solid justification.

E. Setting the p -value threshold for the proxy-based SNPs

The power calculations in Table S21 take as given the fact that we included 69 SNPs in the set of proxy-based candidates. We used 69 SNPs because this is the number that passed our inclusion threshold of $p < 10^{-5}$ from the first-stage GWAS on educational attainment. In this subsection, we explain why we chose this particular inclusion threshold.

We chose our inclusion threshold of $p < 10^{-5}$ prior to conducting any analyses on cognitive performance, on the basis of power calculations using the results from the first-stage GWAS on educational attainment. Our goal was to design the study in a way that would maximize the expected number of true positive results in the second stage analyses on cognitive performance. The optimal threshold trades off between two opposing effects. On the one hand, a less stringent threshold yields a larger number of candidates that are forwarded to the second stage. A larger set of candidates is more likely to contain true positives. On the other hand, a larger number of candidates requires that a more stringent experiment-wide significance level needs to be applied in the second stage to adjust for multiple testing, which decreases power to pick out the true positives from among the set of candidates.

Our calculations are reported in Table S21. Row (1) reports the number of LD-pruned SNPs in the first stage GWAS on EA that passed the p -value threshold of the respective column. Row (2) is the observed average R^2 of these SNPs on EA. The R^2 estimates deviate slightly from those reported in (1) due to the slightly different set of subjects that were included in the two

analyses. The ex-post power (i.e., assuming that the observed average R^2 is the true effect size) to find such an effect size in our EA sample is reported in row (3), again always for the p -value threshold of the respective column. Row (4) reports the posterior belief that a randomly chosen SNP from the set included in the column is truly associated with EA. To calculate this value, we used Bayes' formula, with a conservative prior belief equal to 0.01%, power equal to row (3), and α equal to the respective p -value threshold of the column (see Section 9 for the formula we use, as well as a discussion of why we consider the larger prior belief of 0.02% to be quite conservative).

Row (5) reports the Bonferroni-adjusted p -value threshold for stage 2, given a family-wide significance level of 0.05 and the number of independent hypotheses that will be tested, given by row (1). Row (6) uses the statistical proxy-phenotype framework reported above to calculate the expected average R^2 of SNPs in the second stage on CP. We assumed a phenotypic correlation of 0.6 between EA and CP, and we assumed that the selected SNPs influence EA only through their influence on CP. Row (7) calculates the expected power for a two-sided test given the available sample size in the second stage on CP, as well as the p -value threshold given by row (5) and the expected effect size given by row (6).

Row (8) reports the expected number of true positive SNPs that would be discovered in the study overall, given by multiplying the number of candidate SNPs given by row (1), the posterior belief that these candidates are truly associated with EA (row 4), and the expected power of stage 2 (row 7). The choice of the p -value threshold we have chosen for our study ($p < 10^{-5}$) was given by the column that maximized the value of row (8). The optimal p -value threshold turns out to depend only on the results of the first-stage GWAS on EA, and not on our assumptions about prior beliefs, phenotypic correlation, or available sample size in stage 2. These assumptions influence the absolute magnitudes in row (8) but not their relative magnitudes.

Finally, row (9) reports the expected posterior belief that a SNP associated with CP at the Bonferroni-adjusted p -value is truly associated with CP, using Bayes' formula, prior beliefs equal to row (4) and power equal to row (7). These calculations were included with the analysis plan that was forwarded to cohorts participating in early 2013. The analysis plan was also posted on Open Science Framework on 14 Apr 2013 (see <https://osf.io/z7fe2/>).

Supplementary Figures

Figure S1. Quantile-Quantile plots and Genomic Control λ for the summary results of the five GWA studies after quality control.




Figure S2. Quantile-Quantile plots of the cognitive performance meta-analysis results for the theory-based and education-associated candidate SNPs. The joint plots show in black the QQ-plot for the education-associated candidate SNPs, and in red the theory-based candidate SNPs.




Figure S3. Simulation study of winner's curse corrections: MLE versus diffuse-prior Bayesian. The x -axis is the true effect size β , grouped in bins that are 0.002 standard-deviation units wide. The y -axis is the estimated effect size. The dots show the naïve OLS estimate (red), the MLE-corrected effect size estimate (green), and the Bayesian-corrected effect size estimate (blue). The light dotted lines are 95% confidence intervals around the estimates. For the simulation parameters, see section 8.





Figure S4. Coefficient on the polygenic score in the regressions explaining the level of TWR, TMS, and TC and controlling for an increasing number of principal components. TWR = Total Word Recall, TMS = Total Mental Score.



Supplementary Tables

Table S1. Study design, numbers of individuals, and quality control for GWAS cohorts. “Call rate” refers to the genotyping success rate, i.e., the minimum percentage of successfully genotyped SNPs.

| Study | | | | Sample QC | | Sample in analysis (<i>N</i>) | References |
|------------|---|------------------------------|--------------------------------|-----------|--|---------------------------------|------------|
| Short name | Full name | Study design | Total sample size (<i>N</i>) | Call rate | Other exclusions | | |
| ALSPAC | Avon Longitudinal Study of Parents and Children | Prospective pregnancy cohort | 8,340 | ≥97% | 1) Gender mismatches 2) Minimal or excessive heterozygosity 3) Cryptic relatedness (IBD > 0.1 and IBD < 0.8) 4) Non-European ancestry 5) Missing cognitive performance phenotype | 5,517 | (42) |
| ERF | Erasmus Rucphen Family study | Family-based | 3,658 | ≥95% | 1) Failing IBS checks 2) Sex chromosome checks 3) Ethnic outliers removed 4) Age < 45 years 5) Missing cognitive performance phenotype | 1,076 | (43) |
| GenR | Generation R | Birth-cohort | 6,135 | ≥97.5% | 1) Duplicate samples 2) Gender mismatch 3) Relatedness 4) Missing cognitive performance phenotype | 3,701 | (44) |
| GS | Generation Scotland | Family-based | 10,000 | ≥98% | 1) Sample call rate 0.95 2) SNPs diverging from HWE with a significance $p < 1 \times 10^{-3}$ 3) SNPs with a MAF < 0.01 4) Missing cognitive performance phenotype 5) Only siblings | 1,081 | (45) |
| HU | Harvard/Union Study | Population-based | 415 | ≥93% | 1) Ethnic outliers removed 2) Participants more than 6 SD away from any of the top 10 principal components | 389 | (46) |

| | | | | | | | |
|---------|--|-------------------------------|-------|-----------------------------------|--|-------|------|
| LBC1921 | Lothian Birth Cohort 1921 | Population-based birth-cohort | 517 | ≥95% | 3) Missing cognitive performance phenotype 1) Unresolved gender discrepancy 2) Relatedness 3) Non-Caucasian descent 4) Missing cognitive performance phenotype | 464 | (47) |
| LBC1936 | Lothian Birth Cohort 1936 | Population-based birth-cohort | 1,005 | ≥95% | 1) Unresolved gender discrepancy 2) Relatedness 3) Non-Caucasian descent 4) Missing cognitive performance phenotype | 947 | (48) |
| MCTFR | Minnesota Center For Twin and Family Research | Family-based | 7,438 | ≥99% | 1) >5000 uncalled SNPs 2) Low GenCall score 3) Extreme hetero- or homozygosity 4) Sample mix-up or unable to confirm known genetic relationships 5) Missing cognitive performance phenotype | 3,367 | (49) |
| QIMR | Brisbane Adolescent Twin Study, Queensland Institute of Medical Research | Population-based | 3,899 | ≥95% | 1) Non-European ancestry 2) Missing cognitive performance phenotype | 1,752 | (50) |
| Raine | Western Australian Pregnancy Cohort Study | Prospective pregnancy cohort | 1,593 | ≥97% | 1) Gender mismatch 2) Relatedness 3) Low heterozygosity 4) Missing cognitive performance phenotype | 936 | (51) |
| STR | Swedish Twin Registry | Family-based | 9,836 | ≥97% | 1) Sex-check (heterozygosity of X-chromosomes) 2) Deviations in heterozygosity of more than 5 SD from the population mean 3) Cryptic relatedness check 4) Missing cognitive performance phenotype | 3,215 | (52) |
| TEDS | Twins of Early Development Study | Family-based | 3,747 | Exact percentage unknown (done by | 1) Low call rate 2) Heterozygosity outliers 3) Intensity outliers 4) Ancestry outliers | 2,825 | (53) |

| | |
|------------|--|
| external | 5) Relatedness/duplicates |
| genotyping | 6) Gender mismatches |
| center) | 7) Samples were re-genotyped on a panel of 30 SNPs using Sequenom and were excluded because of low concordance (<90%). |
| | 8) Missing cognitive performance phenotype |

Table S2. Information on genotyping methods, imputation, and association analysis.

| Study | Genotyping platform | Genotyping calling algorithm | Imputation software | Imputation reference dataset | Association software |
|---------|--|----------------------------------|---------------------|------------------------------|----------------------|
| ALSPAC | Illumina HumanHap550 | GenomeStudio | MACH | HapMap 2 CEU | Mach2QTL |
| ERF | Illumina 318K, Affymetrix 250K, Illumina 350K, Illumina 610K | GenCall & BRLMM | MACH/Minimac | 1000Genomes I v3 (GIANT) | ProbABEL |
| GenR | Illumina 610K Quad, 660W Quad | GenomeStudio | MACH | HapMap2 | PLINK |
| GS | Illumina HumanOmniExpressExome- 8 v1.0 | GenomeStudio | MACH | HapMap 2 CEU | N.A. |
| HU | Affymetrix 6.0 | Birdseed | MACH | HapMap2 | PLINK |
| LBC1921 | Illumina Human610_Quadv1 | GenomeStudio | MACH | HapMap 2 CEU | Mach2QTL |
| LBC1936 | Illumina Human610_Quadv1 | GenomeStudio | MACH | HapMap 2 CEU | Mach2QTL |
| MCTFR | Illumina 660W Quad | BeadStudio | Minimac | HapMap2 CEU | RFGLS (R) |
| QIMR | Illumina 610, Illumina 370, Illumina 317 | BeadStudio | MACH | HapMap 2 CEU | Merlin |
| Raine | Illumina Human660W | BeadStudio | MACH | HapMap 2 CEU | Mach2QTL |
| STR | Illumina HumanOmniExpress-12v1_A | GenomeStudio | IMPUTE | HapMap2 CEU | Merlin-offline |
| TEDS | Affymetrix GeneChip 6.0 | Affymetrix Genotyping Console | IMPUTE2 | HapMap 2/3 CEU | SNPTEST |

Table S3. Results for the theory-based candidate SNPs; SNPs are ordered according to their *p*-value in the cognitive performance meta-analysis. The chromosome and basepair position are from the NCBI genome annotation (build 36). The frequency of the coded allele is from the cognitive performance meta-analysis.

| SNP ID | Chromosome | Basepair | Coded allele | Non-coded allele | Frequency coded allele | Years of Education | | Cognitive Performance | |
|------------|------------|-----------|--------------|------------------|------------------------|----------------------------|-----------------------|----------------------------|-----------------------|
| | | | | | | Beta coeff. (standardized) | <i>p</i> -value | Beta coeff. (standardized) | <i>p</i> -value |
| rs1042713 | 5 | 148186633 | a | g | 0.380 | -0.004 | 4.05×10 ⁻¹ | 0.029 | 2.65×10 ⁻³ |
| rs1800497 | 11 | 112776038 | a | g | 0.201 | -0.004 | 5.16×10 ⁻¹ | -0.025 | 2.95×10 ⁻² |
| rs2830102 | 21 | 26456898 | t | c | 0.314 | -0.005 | 2.62×10 ⁻¹ | 0.021 | 5.59×10 ⁻² |
| rs1612902 | 19 | 56191007 | t | c | 0.566 | 0.008 | 7.60×10 ⁻² | -0.020 | 5.75×10 ⁻² |
| rs2274185 | 1 | 158587804 | c | g | 0.942 | -0.001 | 8.94×10 ⁻¹ | 0.037 | 7.95×10 ⁻² |
| rs2251621 | 8 | 31007504 | a | g | 0.041 | 0.010 | 3.83×10 ⁻¹ | -0.052 | 9.09×10 ⁻² |
| rs1799990 | 20 | 4628251 | a | g | 0.636 | 0.011 | 2.16×10 ⁻² | 0.015 | 1.44×10 ⁻¹ |
| rs4680 | 22 | 18331271 | a | g | 0.522 | -0.002 | 6.10×10 ⁻¹ | 0.013 | 1.69×10 ⁻¹ |
| rs1800855 | 4 | 26100215 | a | t | 0.785 | -0.007 | 2.07×10 ⁻¹ | -0.016 | 2.35×10 ⁻¹ |
| rs8191992 | 7 | 136351848 | a | t | 0.542 | 0.001 | 7.93×10 ⁻¹ | -0.012 | 2.55×10 ⁻¹ |
| rs237895 | 3 | 8782423 | t | c | 0.394 | 0.006 | 2.41×10 ⁻¹ | -0.012 | 2.70×10 ⁻¹ |
| rs714939 | 2 | 75688615 | a | g | 0.385 | -0.006 | 1.56×10 ⁻¹ | 0.009 | 3.48×10 ⁻¹ |
| rs821616 | 1 | 230211221 | a | t | 0.719 | 0.010 | 4.71×10 ⁻² | 0.008 | 4.35×10 ⁻¹ |
| rs6489630 | 12 | 5474885 | t | c | 0.191 | 0.000 | 9.40×10 ⁻¹ | 0.009 | 4.72×10 ⁻¹ |
| rs1130214 | 14 | 104330779 | a | c | 0.297 | - | - | 0.008 | 4.74×10 ⁻¹ |
| rs2725385 | 8 | 31047688 | t | c | 0.291 | -0.015 | 1.33×10 ⁻³ | -0.007 | 4.90×10 ⁻¹ |
| rs2760118 | 6 | 24611569 | t | c | 0.349 | -0.003 | 5.61×10 ⁻¹ | 0.005 | 6.03×10 ⁻¹ |
| rs9536314 | 13 | 32526138 | t | g | 0.844 | -0.009 | 1.41×10 ⁻¹ | 0.007 | 6.03×10 ⁻¹ |
| rs363043 | 20 | 10174146 | t | c | 0.294 | -0.002 | 6.33×10 ⁻¹ | 0.005 | 6.19×10 ⁻¹ |
| rs17571 | 11 | 1739170 | a | g | 0.081 | -0.015 | 5.80×10 ⁻² | 0.009 | 6.32×10 ⁻¹ |
| rs760761 | 6 | 15759111 | a | g | 0.212 | -0.003 | 5.56×10 ⁻¹ | 0.006 | 6.51×10 ⁻¹ |
| rs12239747 | 1 | 158587689 | a | g | 0.939 | -0.005 | 6.61×10 ⁻¹ | 0.002 | 9.11×10 ⁻¹ |
| rs6265 | 11 | 27636492 | t | c | 0.186 | 0.010 | 7.65×10 ⁻² | -0.001 | 9.48×10 ⁻¹ |
| rs16944 | 2 | 113311338 | a | g | 0.347 | -0.003 | 5.43×10 ⁻¹ | 0.000 | 9.71×10 ⁻¹ |

Table S4. Results for the education-associated candidate SNPs; SNPs are ordered according to their *p*-value in the cognitive performance meta-analysis. The chromosome and basepair position are from the NCBI genome annotation (build 36). The frequency of the coded allele is from the cognitive performance meta-analysis.

| SNP ID | Chromosome | Basepair | Coded allele | Non-coded allele | Frequency coded allele | Years of Education | | Cognitive performance | |
|------------|------------|-----------|--------------|------------------|------------------------|----------------------------|-----------------------|----------------------------|-----------------------|
| | | | | | | Beta coeff. (standardized) | <i>p</i> -value | Beta coeff. (standardized) | <i>p</i> -value |
| rs1487441 | 6 | 98660615 | a | g | 0.473 | 0.026 | 1.78×10 ⁻⁹ | 0.036 | 1.24×10 ⁻⁴ |
| rs7923609 | 10 | 64803828 | a | g | 0.521 | -0.021 | 1.06×10 ⁻⁶ | -0.034 | 2.58×10 ⁻⁴ |
| rs2721173 | 8 | 145715237 | t | c | 0.473 | -0.020 | 8.61×10 ⁻⁶ | -0.034 | 2.88×10 ⁻⁴ |
| rs8049439 | 16 | 28745016 | t | c | 0.595 | 0.021 | 1.48×10 ⁻⁶ | 0.027 | 4.36×10 ⁻³ |
| rs1606974 | 2 | 51727103 | a | g | 0.124 | 0.031 | 5.39×10 ⁻⁶ | 0.042 | 5.93×10 ⁻³ |
| rs2970992 | 2 | 100688741 | a | c | 0.493 | -0.020 | 8.27×10 ⁻⁶ | -0.025 | 7.03×10 ⁻³ |
| rs3127447 | 10 | 78923267 | a | c | 0.529 | 0.020 | 6.21×10 ⁻⁶ | 0.024 | 9.95×10 ⁻³ |
| rs7847231 | 9 | 117248892 | a | c | 0.620 | -0.020 | 6.73×10 ⁻⁶ | -0.024 | 1.20×10 ⁻² |
| rs4658552 | 1 | 241479559 | t | c | 0.632 | 0.021 | 2.01×10 ⁻⁶ | 0.023 | 1.61×10 ⁻² |
| rs1892700 | 21 | 33938007 | a | g | 0.256 | -0.023 | 2.96×10 ⁻⁶ | -0.024 | 2.39×10 ⁻² |
| rs7980687 | 12 | 122388664 | a | g | 0.200 | 0.029 | 7.14×10 ⁻⁸ | 0.028 | 2.66×10 ⁻² |
| rs1187220 | 18 | 33605724 | t | c | 0.323 | -0.024 | 3.48×10 ⁻⁷ | -0.027 | 3.47×10 ⁻² |
| rs3783006 | 13 | 97909210 | c | g | 0.457 | 0.023 | 3.11×10 ⁻⁷ | 0.022 | 3.84×10 ⁻² |
| rs7309 | 2 | 161800886 | a | g | 0.491 | -0.022 | 2.21×10 ⁻⁷ | -0.019 | 4.26×10 ⁻² |
| rs10166311 | 2 | 162575859 | a | g | 0.326 | 0.023 | 9.50×10 ⁻⁷ | 0.019 | 5.13×10 ⁻² |
| rs3789044 | 1 | 202855724 | a | g | 0.219 | 0.028 | 5.44×10 ⁻⁸ | 0.022 | 5.62×10 ⁻² |
| rs2635047 | 18 | 42990334 | t | c | 0.483 | 0.020 | 5.76×10 ⁻⁶ | 0.019 | 5.94×10 ⁻² |
| rs17176043 | 14 | 36064553 | a | g | 0.946 | 0.043 | 7.17×10 ⁻⁶ | -0.045 | 5.98×10 ⁻² |
| rs1198575 | 1 | 98334848 | t | c | 0.189 | -0.026 | 2.37×10 ⁻⁶ | -0.025 | 7.17×10 ⁻² |
| rs889956 | 2 | 57258338 | a | g | 0.397 | -0.023 | 1.52×10 ⁻⁷ | -0.017 | 7.76×10 ⁻² |
| rs7594192 | 2 | 199159337 | a | g | 0.250 | 0.026 | 1.28×10 ⁻⁷ | 0.018 | 9.98×10 ⁻² |
| rs3753275 | 1 | 8348487 | t | c | 0.824 | -0.030 | 3.97×10 ⁻⁷ | -0.020 | 1.01×10 ⁻¹ |
| rs9289301 | 3 | 128627683 | c | g | 0.155 | 0.031 | 7.77×10 ⁻⁷ | 0.024 | 1.03×10 ⁻¹ |
| rs9858213 | 3 | 49706865 | t | g | 0.288 | 0.028 | 4.85×10 ⁻⁹ | 0.018 | 1.05×10 ⁻¹ |
| rs11191193 | 10 | 103792398 | a | g | 0.653 | 0.023 | 5.65×10 ⁻⁷ | 0.014 | 1.65×10 ⁻¹ |
| rs6732189 | 2 | 161281027 | a | g | 0.526 | -0.023 | 8.44×10 ⁻⁸ | 0.013 | 1.66×10 ⁻¹ |
| rs4073894 | 7 | 104254200 | a | g | 0.202 | 0.024 | 9.32×10 ⁻⁶ | 0.017 | 1.73×10 ⁻¹ |
| rs2066955 | 12 | 80614747 | a | c | 0.237 | 0.023 | 4.77×10 ⁻⁶ | 0.015 | 1.87×10 ⁻¹ |
| rs2966 | 6 | 33797498 | t | c | 0.452 | 0.022 | 3.60×10 ⁻⁷ | -0.012 | 1.89×10 ⁻¹ |
| rs188133 | 15 | 45489734 | a | g | 0.683 | -0.021 | 9.29×10 ⁻⁶ | -0.013 | 2.01×10 ⁻¹ |
| rs11742741 | 5 | 24198698 | a | t | 0.515 | -0.022 | 2.61×10 ⁻⁷ | -0.012 | 2.02×10 ⁻¹ |
| rs10783779 | 12 | 54778147 | t | g | 0.607 | -0.021 | 6.25×10 ⁻⁶ | -0.012 | 2.05×10 ⁻¹ |
| rs4468007 | 9 | 123634160 | t | c | 0.554 | 0.021 | 3.38×10 ⁻⁶ | 0.011 | 2.74×10 ⁻¹ |

| | | | | | | | | | |
|------------|----|-----------|---|---|-------|--------|-----------------------|--------|-----------------------|
| rs9940536 | 16 | 77713418 | t | c | 0.321 | 0.022 | 3.47×10^{-6} | 0.011 | 2.94×10^{-1} |
| rs3731896 | 2 | 219854646 | t | c | 0.174 | 0.029 | 5.21×10^{-6} | -0.013 | 3.06×10^{-1} |
| rs1970584 | 9 | 125150127 | a | c | 0.060 | 0.048 | 4.64×10^{-7} | -0.021 | 3.45×10^{-1} |
| rs6712515 | 2 | 100172946 | t | c | 0.471 | -0.026 | 2.21×10^{-9} | -0.009 | 3.51×10^{-1} |
| rs1478110 | 9 | 1711478 | t | c | 0.480 | -0.023 | 3.54×10^{-7} | -0.011 | 3.59×10^{-1} |
| rs1239771 | 18 | 75666608 | t | c | 0.218 | 0.024 | 9.54×10^{-6} | 0.011 | 3.72×10^{-1} |
| rs12640626 | 4 | 176863266 | a | g | 0.570 | 0.022 | 7.63×10^{-7} | 0.009 | 3.75×10^{-1} |
| rs2955259 | 4 | 171110419 | a | g | 0.569 | 0.024 | 7.04×10^{-8} | 0.009 | 3.77×10^{-1} |
| rs2053831 | 14 | 84049789 | a | g | 0.776 | 0.023 | 8.35×10^{-6} | -0.010 | 3.94×10^{-1} |
| rs7788657 | 7 | 13888666 | t | c | 0.436 | 0.056 | 8.78×10^{-7} | 0.018 | 4.86×10^{-1} |
| rs4451621 | 10 | 12471373 | t | c | 0.536 | -0.023 | 9.73×10^{-7} | 0.008 | 4.37×10^{-1} |
| rs1056667 | 6 | 26618543 | t | c | 0.628 | 0.023 | 5.25×10^{-7} | 0.007 | 4.45×10^{-1} |
| rs10028773 | 4 | 120484707 | c | g | 0.675 | 0.020 | 7.45×10^{-6} | 0.007 | 4.63×10^{-1} |
| rs1360382 | 9 | 23369719 | a | g | 0.042 | -0.024 | 3.41×10^{-7} | -0.007 | 4.81×10^{-1} |
| rs17013497 | 1 | 207061559 | t | c | 0.135 | 0.030 | 6.78×10^{-6} | 0.010 | 4.95×10^{-1} |
| rs6984449 | 8 | 19372239 | a | g | 0.601 | 0.022 | 1.40×10^{-6} | -0.006 | 5.09×10^{-1} |
| rs6882046 | 5 | 88004620 | a | g | 0.727 | -0.024 | 8.63×10^{-7} | -0.006 | 5.57×10^{-1} |
| rs10519388 | 5 | 113879949 | t | c | 0.835 | -0.029 | 5.21×10^{-7} | 0.007 | 5.64×10^{-1} |
| rs362987 | 20 | 10225452 | a | c | 0.522 | 0.020 | 7.80×10^{-6} | 0.005 | 6.19×10^{-1} |
| rs9537938 | 13 | 57551696 | a | g | 0.672 | 0.023 | 4.85×10^{-7} | -0.005 | 6.21×10^{-1} |
| rs7729356 | 5 | 107425114 | a | c | 0.341 | 0.021 | 3.53×10^{-6} | -0.004 | 6.55×10^{-1} |
| rs11590526 | 1 | 116229090 | t | c | 0.077 | -0.039 | 8.50×10^{-6} | 0.008 | 6.63×10^{-1} |
| rs1875714 | 8 | 68590101 | t | c | 0.628 | 0.022 | 2.07×10^{-6} | 0.004 | 6.63×10^{-1} |
| rs12075 | 1 | 157441978 | a | g | 0.577 | -0.022 | 1.33×10^{-6} | -0.004 | 6.64×10^{-1} |
| rs1105881 | 15 | 39859822 | c | g | 0.643 | 0.020 | 6.67×10^{-6} | 0.004 | 6.92×10^{-1} |
| rs10904180 | 10 | 4127661 | t | g | 0.820 | 0.026 | 8.00×10^{-6} | 0.005 | 7.18×10^{-1} |
| rs13401104 | 2 | 236770257 | a | g | 0.176 | -0.032 | 2.74×10^{-8} | -0.004 | 7.67×10^{-1} |
| rs4818225 | 21 | 41551765 | a | g | 0.338 | 0.021 | 5.61×10^{-6} | 0.003 | 7.79×10^{-1} |
| rs334147 | 2 | 127972527 | t | g | 0.929 | -0.046 | 8.67×10^{-6} | -0.005 | 8.16×10^{-1} |
| rs6025281 | 20 | 54994407 | t | c | 0.566 | -0.021 | 1.75×10^{-6} | -0.002 | 8.36×10^{-1} |
| rs10500871 | 11 | 20172332 | t | c | 0.322 | -0.022 | 3.31×10^{-6} | -0.002 | 8.73×10^{-1} |
| rs1995082 | 16 | 75564938 | t | g | 0.865 | -0.029 | 1.97×10^{-6} | -0.002 | 9.12×10^{-1} |
| rs247929 | 12 | 44581175 | c | g | 0.513 | -0.020 | 8.36×10^{-6} | 0.001 | 9.13×10^{-1} |
| rs12134600 | 1 | 72408584 | a | c | 0.116 | 0.038 | 6.18×10^{-8} | -0.001 | 9.38×10^{-1} |
| rs1550582 | 8 | 135611266 | a | g | 0.262 | 0.022 | 7.16×10^{-6} | -0.001 | 9.38×10^{-1} |
| rs2930713 | 9 | 7639442 | t | g | 0.523 | 0.021 | 2.47×10^{-6} | 0.000 | 9.97×10^{-1} |

Table S5. Winner’s curse corrections (MLE and Bayesian) applied to Rietveld et al.’s (2013) SNPs associated with educational attainment at the genome-wide significance threshold ($p < 5 \times 10^{-8}$). Standard errors are reported in parentheses.

| SNP | Discovery-stage estimates | | | Replication- stage estimates |
|------------|---------------------------|------------------|---------------------------------|------------------------------|
| | Naïve (Uncorrected) | MLE Corrected | Bayesian (diffuse) Corrected | |
| rs9320913 | 0.106 (0.018) | 0.070 | 0.065 | 0.077 (0.034) |
| rs11584700 | -0.014 (0.002) | -0.011 | -0.009 | -0.016 (0.005) |
| rs4851266 | 0.012 (0.002) | 0.009 | 0.008 | 0.011 (0.004) |

Table S6. Winner’s curse corrections (MLE and Bayesian) applied to Rietveld et al.’s (1) SNPs associated with educational attainment at a suggestive significance threshold ($p < 10^{-6}$). The SNPs are listed in the same order as in (1) Table 1 (the first four in order of increasing p -value for association with years of schooling, and the last six in order of increasing p -value for association with college completion). SNPs rs9320913, rs11584700, and rs4851266 are also listed in Supplementary Table S5 above (though the corrected estimates here are different because the significance threshold is different). Standard errors are reported in parentheses.

| SNP | Discovery-stage estimates | | | Replication- stage estimates |
|------------|---------------------------|------------------|---------------------------------|------------------------------|
| | Naïve (Uncorrected) | MLE Corrected | Bayesian (diffuse) Corrected | |
| rs9320913 | 0.106 (0.018) | 0.096 | 0.087 | 0.077 (0.034) |
| rs3783006 | 0.096 (0.018) | 0.035 | 0.050 | 0.056 (0.035) |
| rs8049439 | 0.090 (0.018) | 0.008 | 0.039 | 0.065 (0.033) |
| rs13188378 | -0.136 (0.027) | -0.011 | -0.058 | 0.091 (0.067) |
| rs11584700 | -0.014 (0.002) | -0.013 | -0.012 | -0.016 (0.005) |
| rs4851266 | 0.012 (0.002) | 0.011 | 0.010 | 0.011 (0.004) |
| rs2054125 | 0.023 (0.004) | 0.011 | 0.010 | 0.006 (0.008) |
| rs3227 | 0.011 (0.002) | 0.008 | 0.007 | 0.002 (0.004) |
| rs4073894 | 0.012 (0.002) | 0.008 | 0.006 | 0.000 (0.005) |
| rs12640626 | 0.010 (0.002) | 0.001 0.096 | 0.005 | 0.000 (0.004) |

Table S7. Winner’s curse corrections (MLE, Bayesian, and empirical Bayes) applied to the cognitive-performance associations that pass the significance threshold ($p < .05/69$). Standard errors are reported in parentheses. Since the phenotypic variance has been normalized to 1, the estimated R^2 is calculated simply as the amount of phenotypic variance explained: $R^2 = 2m(1-m)\beta^2$, where m is the MAF and β is the effect size estimate.

| SNP | Effect size estimates | | | | Estimated R^2 | |
|-----------|------------------------|------------------|------------------------------------|------------------------------|------------------------|------------------------------|
| | Naïve (Uncorrected) | MLE Corrected | Bayesian (diffuse) Corrected | Empirical Bayes Corrected | Naïve (Uncorrected) | Empirical Bayes Corrected |
| rs1487441 | 0.036 (0.009) | 0.022 | 0.023 | 0.023 | 0.064% | 0.027% |
| rs7923609 | -0.034 (0.009) | -0.013 | -0.020 | -0.020 | 0.058% | 0.019% |
| rs2721173 | -0.034 (0.009) | -0.008 | -0.019 | -0.018 | 0.056% | 0.017% |

Table S8. Posterior probability of true association as a function of effect size (R^2) and prior probability (π).

| | | Effect size (R^2) | |
|-----------------|------|-----------------------------------|-----------------------------------|
| | | $R^2 = 0.0002$ (power = .1186) | $R^2 = 0.0006$ (power = .6658) |
| Prior (π) | 0.1% | 14% | 48% |
| | 1% | 62% | 90% |
| | 5% | 90% | 98% |
| | 10% | 95% | 99% |

Table S9. Results for the functional annotation analysis for the 14 *NSEA* SNPs and respective proxies at considerable LD ($r^2 > 0.5$).

| SNP ID | Proxy SNP | LD | Coded Allele | Non-coded allele | Minor allele frequency | Gene name | Sequence change | Amino acid change |
|-----------|-------------|------|--------------|------------------|------------------------|----------------|-----------------------|-------------------------------|
| rs7923609 | rs1935 | 0.75 | c | g | 0.47 | <i>JMJD1C</i> | GAG \Rightarrow GAC | E [Glu] \Rightarrow D [Asp] |
| rs2721173 | rs4251691 | 0.9 | c | t | 0.46 | <i>RECQL4</i> | CGG \Rightarrow CAG | R [Arg] \Rightarrow Q [Gln] |
| | rs13277542 | 0.8 | t | g | 0.47 | <i>LRRC14</i> | GAA \Rightarrow GCA | E [Glu] \Rightarrow A [Ala] |
| rs8049439 | rs7498665 | 0.69 | a | g | 0.34 | <i>SH2B1</i> | ACA \Rightarrow GCA | T [Thr] \Rightarrow A [Ala] |
| rs4658552 | rs2275155 | 0.64 | a | t | 0.33 | <i>SDCCAG8</i> | GAA \Rightarrow GAT | E [Glu] \Rightarrow D [Asp] |
| rs1892700 | rs139852262 | 0.55 | caatta | c | 0.25 | <i>DNAJC28</i> | | Frameshift |
| | rs8971 | 0.58 | t | c | 0.25 | <i>GART</i> | GAT \Rightarrow GGT | D [Asp] \Rightarrow G [Gly] |
| rs7980687 | rs1060105 | 0.95 | c | t | 0.23 | <i>SBNO1</i> | AGT \Rightarrow AAT | S [Ser] \Rightarrow N [Asn] |

Table S10. Results for the gene expression *cis*-eQTL analysis in blood. SNP ID – nominally significant cognitive performance associated variant; FDR – false discovery rate; LD – linkage disequilibrium; ArrayID – Illumina probe identifier; * – denotes a probe not annotated; NSEA - *Nominally-Significant Education-Associated SNPs*: Best eQTL-SNP – the strongest eQTL SNP for a given probe.

| SNP ID | Coded Allele | NSEA | | | Best eQTL-SNP | | | Gene name | ArrayID |
|-----------|--------------|------------------------|--------|------------------------|---------------|------------------------|--------|------------------------|------------------------|
| | | eQTL <i>p</i> -vaule | Zscore | FDR (5%) | SNP ID | eQTL <i>p</i> -vaule | Zscore | FDR (5%) | |
| rs7923609 | a | 3.4×10 ⁻⁵ | 4.1 | 6.1×10 ⁻⁴ | rs10761725 | 4.1×10 ⁻⁷ | 5.1 | 5.7×10 ⁻⁶ | * |
| rs2721173 | t | 2.1×10 ⁻²⁷ | -24.0 | <<1.0×10 ⁻⁷ | rs6989368 | 7.2×10 ⁻¹³² | -24.4 | <<1.0×10 ⁻⁷ | <i>LRRC24</i> |
| | | 1.2×10 ⁻⁴⁸ | -14.7 | <<1.0×10 ⁻⁷ | rs750472 | 1.6×10 ⁻⁵⁶ | -15.8 | <<1.0×10 ⁻⁷ | <i>GPT/PPP1R16A</i> |
| | | 3.4×10 ⁻²⁷ | -10.8 | <<1.0×10 ⁻⁷ | rs3735840 | 9.8×10 ⁻¹⁹⁸ | 34.4 | <<1.0×10 ⁻⁷ | <i>VPS28</i> |
| | | 1.0×10 ⁻¹⁴ | 7.7 | <<1.0×10 ⁻⁷ | rs3757966 | 7.5×10 ⁻¹⁵ | 7.8 | <<1.0×10 ⁻⁷ | <i>MFSD3</i> |
| rs8049439 | c | 9.8×10 ⁻¹⁹⁸ | 57.7 | <<1.0×10 ⁻⁷ | rs8049439 | 9.8×10 ⁻¹⁹⁸ | 57.7 | <<1.0×10 ⁻⁷ | <i>TUFM</i> |
| | | 9.8×10 ⁻¹⁹⁸ | 35.6 | <<1.0×10 ⁻⁷ | rs8045689 | 9.8×10 ⁻¹⁹⁸ | 50.8 | <<1.0×10 ⁻⁷ | <i>SPNS1</i> |
| | | 2.1×10 ⁻⁴⁹ | -14.8 | <<1.0×10 ⁻⁷ | rs480400 | 1.9×10 ⁻⁸⁴ | 19.5 | <<1.0×10 ⁻⁷ | <i>CCDC101</i> |
| | | 1.2×10 ⁻⁴ | 3.8 | 2.0×10 ⁻³ | rs13331691 | 1.4×10 ⁻⁷ | 5.3 | 2.5×10 ⁻⁶ | <i>SULT1A2/SULT1A1</i> |
| | | 2.5×10 ⁻³ | 3.0 | 0.03 | rs4788115 | 1.6×10 ⁻⁵ | -4.3 | 2.8×10 ⁻⁴ | <i>LAT</i> |
| | | 2.9×10 ⁻³ | 3.0 | 0.04 | rs4788115 | 1.2×10 ⁻⁸ | -5.7 | <<1.0×10 ⁻⁷ | <i>LAT</i> |
| rs4658552 | c | 3.1×10 ⁻¹⁷ | 8.4 | <<1.0×10 ⁻⁷ | rs2275155 | 3.2×10 ⁻²¹ | 9.5 | <<1.0×10 ⁻⁷ | <i>SDCCAG8</i> |
| rs7980687 | a | 1.1×10 ⁻⁵ | -4.4 | 1.8×10 ⁻⁴ | rs1662 | 4.7×10 ⁻⁹³ | 20.5 | <<1.0×10 ⁻⁷ | <i>RILPL2</i> |
| | | 4.3×10 ⁻⁴ | 3.2 | 6.5×10 ⁻³ | rs12366872 | 3.4×10 ⁻¹⁷ | 8.4 | <<1.0×10 ⁻⁷ | <i>SETD8</i> |
| rs1892700 | a | 2.8×10 ⁻³⁶ | 12.4 | <<1.0×10 ⁻⁷ | rs2834217 | 9.8×10 ⁻¹⁹⁸ | -34.8 | <<1.0×10 ⁻⁷ | * |
| | | 1.3×10 ⁻¹³ | -7.4 | <<1.0×10 ⁻⁷ | rs12626309 | 1.7×10 ⁻²¹ | -9.5 | <<1.0×10 ⁻⁷ | <i>GART</i> |
| | | 4.8×10 ⁻¹⁰ | 6.2 | <<1.0×10 ⁻⁷ | rs2251854 | 1.8×10 ⁻¹⁰² | -21.5 | <<1.0×10 ⁻⁷ | <i>ITSN1</i> |
| | | 2.1×10 ⁻⁵ | 4.3 | 3.7×10 ⁻⁴ | rs2834237 | 5.0×10 ⁻⁷ | 5.0 | 6.5×10 ⁻⁶ | <i>GART</i> |
| rs3783006 | c | 6.0×10 ⁻⁶ | 4.5 | 1.0×10 ⁻⁴ | rs4389009 | 1.7×10 ⁻⁴⁰ | -13.3 | <<1.0×10 ⁻⁷ | <i>STK24</i> |
| | | 1.4×10 ⁻³ | 3.2 | 0.02 | rs9513427 | 9.7×10 ⁻⁶ | 4.4 | 1.7×10 ⁻⁴ | <i>STK24</i> |
| rs7309 | a | 5.8×10 ⁻¹⁰ | -6.2 | <<1.0×10 ⁻⁷ | rs1921310 | 1.8×10 ⁻¹³ | -7.4 | <<1.0×10 ⁻⁷ | <i>TANK</i> |
| | | 3.2×10 ⁻⁴ | -3.6 | 4.9×10 ⁻³ | rs11884495 | 2.0×10 ⁻⁴ | -3.7 | 0.003 | <i>PSMD14</i> |

Table S11. Results for the gene expression *cis*-eQTL analysis in brain tissues. SNP ID – nominally significant cognitive performance associated variant; FDR – false discovery rate; LD – linkage disequilibrium; DistanceArrayID – Affimetrix probe identifier; # – genes not considered as biological candidates in subsequent analysis due to distance > 250 kb from a *NSEA* SNP.

| SNP ID | Proxy SNP | LD (r ²) | Distance (kb) | Brain tissue | eQTL <i>P</i> -value | Gene name | ArrayID |
|-----------|------------|----------------------|---------------|-------------------|-----------------------|-----------------|-------------|
| rs2721173 | rs9071 | 1.00 | 6 077 | Prefrontal cortex | 1.3×10 ⁻⁸⁹ | <i>LRRC14</i> | 10025908411 |
| | rs9071 | 1.00 | 6 077 | Cerebellum | 1.3×10 ⁻⁷⁵ | <i>LRRC14</i> | 10025908411 |
| | rs9071 | 1.00 | 6 077 | Visual cortex | 1.5×10 ⁻⁶² | <i>LRRC14</i> | 10025908411 |
| | rs4532636 | 0.67 | 159 994 | Prefrontal cortex | 8.4×10 ⁻³⁵ | <i>LRRC14</i> | 10025908411 |
| | rs4532636 | 0.67 | 159 994 | Cerebellum | 1.2×10 ⁻²⁸ | <i>LRRC14</i> | 10025908411 |
| | rs4532636 | 0.67 | 159 994 | Visual cortex | 1.2×10 ⁻²² | <i>LRRC14</i> | 10025908411 |
| | rs748193 | 0.84 | 62 314 | Cerebellum | 4.3×10 ⁻⁷ | <i>LRRC24</i> | 10023828992 |
| | rs2721195 | 0.87 | 67 418 | Cerebellum | 4.8×10 ⁻⁶ | <i>LRRC24</i> | 10031920304 |
| | rs3757966 | 0.97 | 189 | Prefrontal cortex | 1.3×10 ⁻⁸ | <i>KIFC2</i> | 10025905398 |
| | rs3757936 | 0.67 | 159 994 | Cerebellum | 1.3×10 ⁻⁸ | <i>KIFC2</i> | 10025905398 |
| | rs2958492 | 0.65 | 174 698 | Visual cortex | 2.3×10 ⁻⁶ | <i>AF075035</i> | 10025934744 |
| rs8049439 | rs4788102 | 0.97 | 35 883 | Prefrontal cortex | 1.7×10 ⁻¹³ | <i>EIF3C</i> | 10025912109 |
| | rs12928404 | 0.97 | 9 731 | Prefrontal cortex | 9.7×10 ⁻¹² | <i>EIF3C</i> | 10025912109 |
| | rs4788102 | 0.97 | 35 883 | Cerebellum | 5.4×10 ⁻¹⁸ | <i>EIF3C</i> | 10025912109 |
| | rs12928404 | 0.97 | 9 731 | Cerebellum | 7.6×10 ⁻¹¹ | <i>EIF3C</i> | 10025912109 |
| | rs4788102 | 0.97 | 35 883 | Visual cortex | 1.2×10 ⁻⁹ | <i>EIF3C</i> | 10025912109 |
| | rs12928404 | 0.97 | 9 731 | Visual cortex | 7.6×10 ⁻¹¹ | <i>EIF3C</i> | 10025912109 |
| | rs6565259 | 0.68 | 61 278 | Prefrontal cortex | 8.0×10 ⁻¹⁰ | <i>LAT</i> | 10023818276 |
| | rs12928404 | 0.97 | 9 731 | Prefrontal cortex | 1.3×10 ⁻⁵ | <i>LAT</i> | 10023818276 |
| | rs1968752 | 0.80 | 205 930 | Cerebellum | 3.5×10 ⁻⁵ | <i>NUPRI</i> | 10023813116 |
| | rs12446550 | 0.76 | 294 134 | Cerebellum | 1.4×10 ⁻⁸ | <i>NFATC2IP</i> | 10025913085 |
| | rs8049439 | – | – | Prefrontal cortex | 2.3×10 ⁻⁵ | <i>TUFM</i> | 10025905429 |
| rs4658552 | rs10926978 | 0.86 | 18 718 | Prefrontal cortex | 5.1×10 ⁻⁹ | <i>SDCCAG8</i> | 10025912019 |
| | rs2484639 | 0.54 | 49 431 | Visual cortex | 3.2×10 ⁻⁷ | <i>SDCCAG8</i> | 10025912019 |
| | rs10926975 | 0.56 | 15 154 | Visual cortex | 1.0×10 ⁻⁵ | <i>SDCCAG8</i> | 10025912019 |
| | rs10926975 | 0.56 | 15 154 | Prefrontal cortex | 1.0×10 ⁻⁵ | <i>SDCCAG8</i> | 10025912019 |
| rs7980687 | rs7304782 | 0.57 | 103 267 | Prefrontal cortex | 1.1×10 ⁻⁸ | <i>SBNO1</i> | 10025903955 |
| | rs1727302 | 0.81 | 189 781 | Prefrontal cortex | 2.0×10 ⁻⁶ | <i>SBNO1</i> | 10025903955 |

| | | | | | | | |
|-----------|-----------------------|------|---------|-------------------|-----------------------|-----------------------------|-------------|
| | rs655293 | 0.74 | 294 306 | Cerebellum | 5.6×10^{-10} | <i>C12ORF65</i> | 10025904993 |
| | rs1060105 | 0.94 | 164 920 | Cerebellum | 1.5×10^{-7} | <i>C12ORF65</i> | 10025904993 |
| | rs1060105 | 0.94 | 164 920 | Visual cortex | 5.8×10^{-7} | <i>C12ORF65</i> | 10025904993 |
| | rs7304782 | 0.69 | 103 267 | Visual cortex | 2.4×10^{-6} | <i>C12ORF65</i> | 10025904993 |
| | rs1790098 | 0.80 | 167 230 | Prefrontal cortex | 2.9×10^{-8} | <i>C12ORF65</i> | 10025904993 |
| | rs1060105 | 0.94 | 164 920 | Prefrontal cortex | 1.1×10^{-6} | <i>C12ORF65</i> | 10025904993 |
| | rs937564 [#] | 0.70 | 345 400 | Cerebellum | 1.5×10^{-7} | <i>MPHOSPH9[#]</i> | 10025905642 |
| rs1892700 | rs9647066 | 0.84 | 13 801 | Prefrontal cortex | 1.3×10^{-6} | <i>TMEM50B</i> | 10023807235 |
| | rs8971 | 0.77 | 132 519 | Cerebellum | 7.7×10^{-5} | <i>GART</i> | 10025903876 |
| | rs2834213 | 0.66 | 223 227 | Cerebellum | 2.8×10^{-7} | <i>IFNGR2</i> | 10025902355 |
| rs3783006 | rs9517337 | 0.59 | 70 438 | Cerebellum | 2.1×10^{-5} | <i>AK026896</i> | 10025930847 |
| | rs7338549 | 0.64 | 31 536 | Visual cortex | 2.6×10^{-5} | <i>AF339799</i> | 10025928383 |

Table S12. Results of gene function prediction analysis in 80,000 gene expression profiles. Pathway terms originate from several databases: (1) Gene Ontology Biological Processes [GO-BioProc], (2) Gene Ontology Molecular Function [GO-MolFunc], (3) Gene Ontology Cellular Component [GO-CellComp], (4) REACTOME, and (5) KEGG. Table lists only genes with terms directly related to neuronal or central nervous system function – full predictions are available at – <http://www.ssgac.org>³. *P*-values refer to the correlation between the Gene principal component profile and the reconstituted Term principal component profile, uncorrected for multiple testing; all reported terms meet False Discovery Rate < 0.05. The Annotated column indicates if the gene has previously been listed as a member of that term (Y) or not (N). Results are sorted alphabetically by gene name.

| Gene name | Database | Pathway term | Annotated | <i>P</i> -value |
|---------------|-------------|--|-----------|-----------------------|
| <i>ATXN2L</i> | GO-CellComp | npBAF complex | N | 1.4×10 ⁻⁸ |
| <i>ATXN2L</i> | GO-CellComp | nBAF complex | N | 3.0×10 ⁻⁷ |
| <i>ATXN2L</i> | GO-CellComp | chromatin remodeling complex | N | 7.0×10 ⁻⁷ |
| <i>ATXN2L</i> | GO-CellComp | SWI/SNF-type complex | N | 1.4×10 ⁻⁶ |
| <i>ATXN2L</i> | GO-CellComp | SWI/SNF complex | N | 4.7×10 ⁻⁶ |
| <i>CRYZL1</i> | GO-BiolProc | synaptic vesicle endocytosis | N | 9.1×10 ⁻⁹ |
| <i>FARP1</i> | GO-BiolProc | Axonogenesis | N | 8.0×10 ⁻¹⁰ |
| <i>FARP1</i> | GO-BiolProc | axon guidance | N | 2.0×10 ⁻⁹ |
| <i>FARP1</i> | GO-CellComp | Actomyosin | N | 1.1×10 ⁻⁸ |
| <i>FARP1</i> | GO-CellComp | Synapse | N | 2.0×10 ⁻⁸ |
| <i>FARP1</i> | KEGG | Axon guidance | N | 5.6×10 ⁻⁴ |
| <i>FARP1</i> | REACTOME | Cell-extracellular matrix interactions | N | 1.8×10 ⁻⁸ |
| <i>FARP1</i> | REACTOME | Axon guidance | N | 5.9×10 ⁻⁸ |
| <i>KCNMA1</i> | GO-BiolProc | calcium ion transmembrane transport | N | 2.8×10 ⁻¹² |
| <i>KCNMA1</i> | GO-BiolProc | calcium ion transport | N | 2.6×10 ⁻⁶ |
| <i>KCNMA1</i> | GO-BiolProc | synapse organization | N | 3.9×10 ⁻⁶ |
| <i>KCNMA1</i> | GO-CellComp | Synapse | Y | 1.4×10 ⁻⁶ |
| <i>KCNMA1</i> | GO-CellComp | synapse part | Y | 2.8×10 ⁻⁶ |
| <i>KCNMA1</i> | GO-CellComp | Costamere | N | 3.0×10 ⁻⁶ |
| <i>KCNMA1</i> | GO-CellComp | voltage-gated calcium channel complex | N | 8.8×10 ⁻⁶ |
| <i>KCNMA1</i> | GO-CellComp | calcium channel complex | N | 1.3×10 ⁻⁶ |
| <i>KCNMA1</i> | GO-CellComp | postsynaptic density | N | 3.1×10 ⁻⁵ |

³ The link will be activated on the day of publication of this article. The materials that will be posted online are included as a separate appendix to the submitted manuscript.

| | | | | |
|---------------|-------------|---|---|----------------------|
| <i>KCNMA1</i> | GO-CellComp | dendritic spine head | N | 3.1×10^{-5} |
| <i>KCNMA1</i> | GO-CellComp | Dendrite | N | 4.0×10^{-5} |
| <i>KCNMA1</i> | GO-CellComp | neuron projection terminus | Y | 4.7×10^{-5} |
| <i>KCNMA1</i> | GO-MolFunc | calcium channel activity | N | 2.5×10^{-9} |
| <i>KCNMA1</i> | GO-MolFunc | voltage-gated calcium channel activity | N | 1.1×10^{-8} |
| <i>KCNMA1</i> | GO-MolFunc | cation channel activity | Y | 1.6×10^{-8} |
| <i>KCNMA1</i> | GO-MolFunc | voltage-gated cation channel activity | Y | 5.6×10^{-8} |
| <i>KCNMA1</i> | GO-MolFunc | gated channel activity | Y | 5.6×10^{-7} |
| <i>KCNMA1</i> | GO-MolFunc | solute:cation antiporter activity | N | 7.4×10^{-7} |
| <i>KCNMA1</i> | GO-MolFunc | ion channel activity | Y | 1.2×10^{-6} |
| <i>KCNMA1</i> | GO-MolFunc | substrate-specific channel activity | Y | 1.6×10^{-6} |
| <i>KCNMA1</i> | GO-MolFunc | passive transmembrane transporter activity | Y | 3.3×10^{-6} |
| <i>KCNMA1</i> | GO-MolFunc | channel activity | Y | 3.3×10^{-6} |
| <i>KCNMA1</i> | GO-MolFunc | cation:cation antiporter activity | N | 5.1×10^{-6} |
| <i>KCNMA1</i> | GO-MolFunc | glutamate receptor binding | N | 9.1×10^{-6} |
| <i>KCNMA1</i> | GO-MolFunc | voltage-gated channel activity | Y | 1.7×10^{-6} |
| <i>KCNMA1</i> | GO-MolFunc | voltage-gated ion channel activity | Y | 1.7×10^{-6} |
| <i>KCNMA1</i> | GO-MolFunc | calmodulin binding | N | 2.1×10^{-5} |
| <i>KCNMA1</i> | GO-MolFunc | ion gated channel activity | Y | 2.3×10^{-5} |
| <i>KCNMA1</i> | KEGG | Calcium signaling pathway | N | 3.4×10^{-9} |
| <i>KCNMA1</i> | KEGG | Long-term potentiation | N | 1.9×10^{-7} |
| <i>KCNMA1</i> | KEGG | Vascular smooth muscle contraction | Y | 1.0×10^{-4} |
| <i>KCNMA1</i> | REACTOME | Voltage gated Potassium channels | N | 2.1×10^{-9} |
| <i>KCNMA1</i> | REACTOME | Neuronal System | Y | 5.7×10^{-9} |
| <i>KCNMA1</i> | REACTOME | Unblocking of NMDA receptor, glutamate binding and activation | N | 1.1×10^{-7} |
| <i>KCNMA1</i> | REACTOME | Potassium Channels | Y | 5.2×10^{-7} |
| <i>KCNMA1</i> | REACTOME | Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels | N | 2.6×10^{-6} |
| <i>KCNMA1</i> | REACTOME | Reduction of cytosolic Ca ⁺⁺ levels | N | 5.0×10^{-6} |
| <i>KCNMA1</i> | REACTOME | Smooth Muscle Contraction | N | 5.5×10^{-6} |
| <i>KCNMA1</i> | REACTOME | Platelet calcium homeostasis | N | 7.5×10^{-6} |

| | | | | |
|---------------|-------------|--|---|----------------------|
| <i>KCNMA1</i> | REACTOME | CREB phosphorylation through the activation of CaMKII | N | 7.7×10^{-6} |
| <i>KCNMA1</i> | REACTOME | Transmission across Chemical Synapses | N | 1.0×10^{-5} |
| <i>KCNMA1</i> | REACTOME | Ras activation upon Ca ²⁺ influx through NMDA receptor | N | 1.7×10^{-5} |
| <i>KCNMA1</i> | REACTOME | Activation of NMDA receptor upon glutamate binding and postsynaptic events | N | 2.3×10^{-5} |
| <i>KCNMA1</i> | REACTOME | Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity | N | 4.3×10^{-5} |
| <i>KCNMA1</i> | REACTOME | Trafficking of AMPA receptors | N | 4.3×10^{-5} |
| <i>KIFC2</i> | GO-BiolProc | neurotransmitter secretion | N | 2.3×10^{-9} |
| <i>KIFC2</i> | GO-BiolProc | regulation of synaptic transmission | N | 8.7×10^{-9} |
| <i>KIFC2</i> | GO-BiolProc | regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole | N | 3.9×10^{-8} |
| <i>KIFC2</i> | GO-BiolProc | regulation of transmission of nerve impulse | N | 4.4×10^{-8} |
| <i>KIFC2</i> | GO-BiolProc | regulation of neurological system process | N | 9.5×10^{-8} |
| <i>KIFC2</i> | GO-BiolProc | synaptic vesicle transport | N | 3.3×10^{-7} |
| <i>KIFC2</i> | GO-BiolProc | regulation of neurotransmitter levels | N | 6.2×10^{-7} |
| <i>KIFC2</i> | GO-BiolProc | regulation of synaptic plasticity | N | 8.3×10^{-7} |
| <i>KIFC2</i> | GO-BiolProc | synaptic vesicle exocytosis | N | 9.0×10^{-8} |
| <i>KIFC2</i> | GO-BiolProc | glutamate secretion | N | 1.0×10^{-6} |
| <i>KIFC2</i> | GO-BiolProc | generation of a signal involved in cell-cell signaling | N | 2.3×10^{-6} |
| <i>KIFC2</i> | GO-CellComp | Dendrite | N | 1.3×10^{-7} |
| <i>KIFC2</i> | GO-CellComp | dendritic spine head | N | 1.7×10^{-7} |
| <i>KIFC2</i> | GO-CellComp | postsynaptic density | N | 1.7×10^{-7} |
| <i>KIFC2</i> | GO-CellComp | Synaptosome | N | 1.8×10^{-7} |
| <i>KIFC2</i> | GO-CellComp | dendritic spine | N | 2.8×10^{-7} |
| <i>KIFC2</i> | GO-CellComp | neuron spine | N | 2.8×10^{-7} |
| <i>KIFC2</i> | GO-CellComp | voltage-gated calcium channel complex | N | 3.0×10^{-7} |
| <i>KIFC2</i> | GO-CellComp | synapse part | N | 1.1×10^{-6} |
| <i>KIFC2</i> | GO-CellComp | Synapse | N | 1.1×10^{-6} |
| <i>KIFC2</i> | GO-CellComp | ciliary rootlet | N | 2.3×10^{-6} |
| <i>KIFC2</i> | GO-CellComp | cell body | N | 1.4×10^{-5} |
| <i>KIFC2</i> | GO-CellComp | synaptic membrane | N | 2.2×10^{-5} |

| | | | | |
|--------------|-------------|---|---|-----------------------|
| <i>KIFC2</i> | GO-CellComp | calcium channel complex | N | 2.2×10^{-5} |
| <i>KIFC2</i> | GO-MolFunc | voltage-gated calcium channel activity | N | 1.5×10^{-5} |
| <i>KIFC2</i> | REACTOME | Ras activation upon Ca ²⁺ influx through NMDA receptor | N | 6.8×10^{-9} |
| <i>KIFC2</i> | REACTOME | Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels | N | 1.2×10^{-8} |
| <i>KIFC2</i> | REACTOME | CREB phosphorylation through the activation of CaMKII | N | 9.7×10^{-8} |
| <i>KIFC2</i> | REACTOME | Transmission across Chemical Synapses | N | 3.4×10^{-7} |
| <i>KIFC2</i> | REACTOME | GABA synthesis, release, reuptake and degradation | N | 4.2×10^{-6} |
| <i>KIFC2</i> | REACTOME | Neuronal System | N | 1.1×10^{-5} |
| <i>KIFC2</i> | REACTOME | Dopamine Neurotransmitter Release Cycle | N | 2.3×10^{-5} |
| <i>KIFC2</i> | REACTOME | Serotonin Neurotransmitter Release Cycle | N | 2.3×10^{-5} |
| <i>KIFC2</i> | REACTOME | Trafficking of AMPA receptors | N | 2.9×10^{-5} |
| <i>KIFC2</i> | REACTOME | Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity | N | 2.9×10^{-5} |
| <i>KIFC2</i> | REACTOME | Post NMDA receptor activation events | N | 3.0×10^{-5} |
| <i>KIFC2</i> | REACTOME | NCAM signaling for neurite out-growth | N | 3.1×10^{-5} |
| <i>KIFC2</i> | REACTOME | Neurotransmitter Release Cycle | N | 3.4×10^{-5} |
| <i>KIFC2</i> | REACTOME | CREB phosphorylation through the activation of Ras | N | 3.4×10^{-5} |
| <i>KIFC2</i> | REACTOME | Glutamate Neurotransmitter Release Cycle | N | 3.7×10^{-5} |
| <i>NRXN1</i> | GO-BiolProc | glutamate signaling pathway | N | 2.6×10^{-19} |
| <i>NRXN1</i> | GO-BiolProc | neurotransmitter secretion | N | 1.5×10^{-16} |
| <i>NRXN1</i> | GO-BiolProc | gamma-aminobutyric acid signaling pathway | N | 5.6×10^{-16} |
| <i>NRXN1</i> | GO-BiolProc | synaptic vesicle exocytosis | N | 7.5×10^{-15} |
| <i>NRXN1</i> | GO-BiolProc | regulation of neurotransmitter levels | N | 3.6×10^{-14} |
| <i>NRXN1</i> | GO-BiolProc | regulation of synaptic transmission | Y | 8.4×10^{-14} |
| <i>NRXN1</i> | GO-BiolProc | neurotransmitter transport | N | 8.7×10^{-14} |
| <i>NRXN1</i> | GO-BiolProc | regulation of neurological system process | Y | 2.9×10^{-14} |
| <i>NRXN1</i> | GO-BiolProc | regulation of transmission of nerve impulse | Y | 8.0×10^{-14} |
| <i>NRXN1</i> | GO-BiolProc | neuron-neuron synaptic transmission | Y | 1.1×10^{-12} |
| <i>NRXN1</i> | GO-BiolProc | glutamate secretion | N | 1.1×10^{-12} |
| <i>NRXN1</i> | GO-BiolProc | synaptic vesicle transport | N | 5.8×10^{-12} |

| | | | | |
|--------------|-------------|--|---|-----------------------|
| <i>NRXN1</i> | GO-BiolProc | synaptic transmission, glutamatergic | Y | 2.1×10^{-11} |
| <i>NRXN1</i> | GO-BiolProc | signal release | N | 6.7×10^{-11} |
| <i>NRXN1</i> | GO-BiolProc | generation of a signal involved in cell-cell signaling | N | 6.7×10^{-11} |
| <i>NRXN1</i> | GO-BiolProc | learning or memory | Y | 2.5×10^{-10} |
| <i>NRXN1</i> | GO-BiolProc | cellular potassium ion transport | N | 2.7×10^{-10} |
| <i>NRXN1</i> | GO-BiolProc | potassium ion transmembrane transport | N | 2.7×10^{-10} |
| <i>NRXN1</i> | GO-BiolProc | Axonogenesis | Y | 3.0×10^{-10} |
| <i>NRXN1</i> | GO-BiolProc | regulation of excitatory postsynaptic membrane potential | Y | 4.1×10^{-10} |
| <i>NRXN1</i> | GO-CellComp | presynaptic membrane | Y | 1.7×10^{-26} |
| <i>NRXN1</i> | GO-CellComp | Synapse | Y | 2.5×10^{-23} |
| <i>NRXN1</i> | GO-CellComp | Axon | Y | 5.2×10^{-23} |
| <i>NRXN1</i> | GO-CellComp | axon part | Y | 2.2×10^{-21} |
| <i>NRXN1</i> | GO-CellComp | synapse part | Y | 4.2×10^{-21} |
| <i>NRXN1</i> | GO-CellComp | synaptic membrane | Y | 2.5×10^{-19} |
| <i>NRXN1</i> | GO-CellComp | ion channel complex | N | 1.3×10^{-16} |
| <i>NRXN1</i> | GO-CellComp | outer membrane-bounded periplasmic space | N | 1.4×10^{-16} |
| <i>NRXN1</i> | GO-CellComp | periplasmic space | N | 1.4×10^{-16} |
| <i>NRXN1</i> | GO-CellComp | cation channel complex | N | 1.0×10^{-15} |
| <i>NRXN1</i> | GO-CellComp | main axon | N | 1.1×10^{-15} |
| <i>NRXN1</i> | GO-CellComp | Dendrite | N | 1.6×10^{-15} |
| <i>NRXN1</i> | GO-CellComp | external encapsulating structure part | N | 2.2×10^{-15} |
| <i>NRXN1</i> | GO-CellComp | cell envelope | N | 2.2×10^{-15} |
| <i>NRXN1</i> | GO-CellComp | postsynaptic membrane | N | 2.3×10^{-14} |
| <i>NRXN1</i> | GO-CellComp | synaptic vesicle membrane | N | 1.7×10^{-13} |
| <i>NRXN1</i> | GO-CellComp | Axolemma | N | 2.8×10^{-13} |
| <i>NRXN1</i> | GO-CellComp | terminal button | N | 3.1×10^{-13} |
| <i>NRXN1</i> | GO-CellComp | external encapsulating structure | N | 4.3×10^{-13} |
| <i>NRXN1</i> | GO-CellComp | voltage-gated sodium channel complex | N | $5. \times 10^{-13}$ |
| <i>NRXN1</i> | GO-MolFunc | glutamate receptor activity | N | 2.8×10^{-25} |
| <i>NRXN1</i> | GO-MolFunc | gated channel activity | N | 2.2×10^{-21} |

| | | | | |
|--------------|------------|--|---|-----------------------|
| <i>NRXN1</i> | GO-MolFunc | substrate-specific channel activity | N | 2.4×10^{-19} |
| <i>NRXN1</i> | GO-MolFunc | GABA receptor activity | N | 7.7×10^{-19} |
| <i>NRXN1</i> | GO-MolFunc | passive transmembrane transporter activity | N | 7.0×10^{-19} |
| <i>NRXN1</i> | GO-MolFunc | extracellular ligand-gated ion channel activity | N | 1.1×10^{-17} |
| <i>NRXN1</i> | GO-MolFunc | GABA-A receptor activity | N | 6.8×10^{-17} |
| <i>NRXN1</i> | GO-MolFunc | voltage-gated channel activity | N | 7.9×10^{-17} |
| <i>NRXN1</i> | GO-MolFunc | voltage-gated ion channel activity | N | 7.9×10^{-17} |
| <i>NRXN1</i> | GO-MolFunc | ionotropic glutamate receptor activity | N | 1.5×10^{-16} |
| <i>NRXN1</i> | GO-MolFunc | extracellular-glutamate-gated ion channel activity | N | 1.7×10^{-16} |
| <i>NRXN1</i> | GO-MolFunc | ligand-gated channel activity | N | 4.7×10^{-16} |
| <i>NRXN1</i> | GO-MolFunc | ligand-gated ion channel activity | N | 4.7×10^{-16} |
| <i>NRXN1</i> | GO-MolFunc | voltage-gated cation channel activity | N | 3.5×10^{-15} |
| <i>NRXN1</i> | GO-MolFunc | cation channel activity | N | 5.2×10^{-12} |
| <i>NRXN1</i> | GO-MolFunc | voltage-gated sodium channel activity | N | 5.6×10^{-12} |
| <i>NRXN1</i> | KEGG | Neuroactive ligand-receptor interaction | N | 9.5×10^{-6} |
| <i>NRXN1</i> | KEGG | Axon guidance | N | 2.1×10^{-5} |
| <i>NRXN1</i> | KEGG | ErbB signaling pathway | N | 2.7×10^{-5} |
| <i>NRXN1</i> | KEGG | Long-term potentiation | N | 3.3×10^{-5} |
| <i>NRXN1</i> | KEGG | Amyotrophic lateral sclerosis (ALS) | N | 2.9×10^{-4} |
| <i>NRXN1</i> | KEGG | Long-term depression | N | 6.2×10^{-4} |
| <i>NRXN1</i> | KEGG | Cell adhesion molecules (CAMs) | Y | 9.8×10^{-4} |
| <i>NRXN1</i> | REACTOME | GABA A receptor activation | N | 7.0×10^{-23} |
| <i>NRXN1</i> | REACTOME | Neuronal System | N | 2.6×10^{-22} |
| <i>NRXN1</i> | REACTOME | Ligand-gated ion channel transport | N | 4.0×10^{-22} |
| <i>NRXN1</i> | REACTOME | Transmission across Chemical Synapses | N | 6.4×10^{-20} |
| <i>NRXN1</i> | REACTOME | Interaction between L1 and Ankyrins | N | 1.6×10^{-18} |
| <i>NRXN1</i> | REACTOME | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | N | 1.1×10^{-17} |
| <i>NRXN1</i> | REACTOME | GABA receptor activation | N | 6.7×10^{-17} |
| <i>NRXN1</i> | REACTOME | Class C/3 (Metabotropic glutamate/pheromone receptors) | N | 2.5×10^{-16} |
| <i>NRXN1</i> | REACTOME | Unblocking of NMDA receptor, glutamate binding and activation | N | 1.4×10^{-14} |

| | | | | |
|----------------|-------------|--|---|-----------------------|
| <i>NRXN1</i> | REACTOME | Potassium Channels | N | 5.4×10^{-14} |
| <i>NRXN1</i> | REACTOME | Ion channel transport | N | 3.9×10^{-13} |
| <i>NRXN1</i> | REACTOME | Serotonin Neurotransmitter Release Cycle | N | 7.6×10^{-13} |
| <i>NRXN1</i> | REACTOME | Dopamine Neurotransmitter Release Cycle | N | 7.6×10^{-13} |
| <i>NRXN1</i> | REACTOME | Voltage gated Potassium channels | N | 1.7×10^{-11} |
| <i>NRXN1</i> | REACTOME | L1CAM interactions | N | 5.0×10^{-11} |
| <i>NRXN1</i> | REACTOME | GABA synthesis, release, reuptake and degradation | N | 8.5×10^{-10} |
| <i>NRXN1</i> | REACTOME | Norepinephrine Neurotransmitter Release Cycle | N | 1.7×10^{-9} |
| <i>NRXN1</i> | REACTOME | Activation of NMDA receptor upon glutamate binding and postsynaptic events | N | 2.2×10^{-9} |
| <i>NRXN1</i> | REACTOME | Glutamate Neurotransmitter Release Cycle | N | 5.7×10^{-8} |
| <i>NRXN1</i> | REACTOME | Ionotropic activity of Kainate Receptors | N | 5.9×10^{-8} |
| <i>PITPNM2</i> | GO-CellComp | cation channel complex | N | 1.7×10^{-5} |
| <i>PITPNM2</i> | GO-CellComp | asymmetric synapse | N | 2.3×10^{-5} |
| <i>PITPNM2</i> | GO-MolFunc | diacylglycerol kinase activity | N | 7.03×10^{-7} |
| <i>PITPNM2</i> | GO-MolFunc | cation channel activity | N | 5.7×10^{-6} |
| <i>PITPNM2</i> | GO-MolFunc | voltage-gated cation channel activity | N | 2.5×10^{-5} |
| <i>PITPNM2</i> | GO-MolFunc | GTPase regulator activity | N | 3.3×10^{-5} |
| <i>PITPNM2</i> | GO-MolFunc | nucleoside-triphosphatase regulator activity | N | 4.3×10^{-5} |
| <i>PITPNM2</i> | GO-MolFunc | ion channel activity | N | 5.0×10^{-5} |
| <i>PITPNM2</i> | GO-MolFunc | gated channel activity | N | 6.0×10^{-5} |
| <i>PITPNM2</i> | GO-MolFunc | calmodulin-dependent protein kinase activity | N | 6.1×10^{-5} |
| <i>PITPNM2</i> | GO-MolFunc | substrate-specific channel activity | N | 6.6×10^{-5} |
| <i>PITPNM2</i> | GO-MolFunc | voltage-gated channel activity | N | 1.0×10^{-4} |
| <i>PITPNM2</i> | GO-MolFunc | voltage-gated ion channel activity | N | 1.0×10^{-4} |
| <i>PITPNM2</i> | KEGG | Calcium signaling pathway | N | 1.4×10^{-4} |
| <i>PITPNM2</i> | REACTOME | Voltage gated Potassium channels | N | 1.3×10^{-6} |
| <i>PITPNM2</i> | REACTOME | Potassium Channels | N | 1.4×10^{-6} |
| <i>PITPNM2</i> | REACTOME | Effects of PIP2 hydrolysis | N | 2.1×10^{-6} |
| <i>PITPNM2</i> | REACTOME | Ras activation upon Ca ²⁺ influx through NMDA receptor | N | 1.5×10^{-5} |

| | | | | |
|----------------|-------------|---|---|-----------------------|
| <i>PITPNM2</i> | REACTOME | Neuronal System | N | 2.2×10^{-5} |
| <i>PITPNM2</i> | REACTOME | PLC-gamma1 signalling | N | 6.6×10^{-5} |
| <i>PITPNM2</i> | REACTOME | DAG and IP3 signaling | N | 8.2×10^{-5} |
| <i>PITPNM2</i> | REACTOME | Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels | N | 9.9×10^{-5} |
| <i>POU3F2</i> | GO-BiolProc | central nervous system neuron differentiation | N | 2.9×10^{-28} |
| <i>POU3F2</i> | GO-BiolProc | forebrain generation of neurons | N | 4.1×10^{-22} |
| <i>POU3F2</i> | GO-BiolProc | forebrain neuron differentiation | N | 3.1×10^{-21} |
| <i>POU3F2</i> | GO-BiolProc | telencephalon development | Y | 5.8×10^{-19} |
| <i>POU3F2</i> | GO-BiolProc | forebrain development | Y | 5.3×10^{-19} |
| <i>POU3F2</i> | GO-BiolProc | negative regulation of gliogenesis | N | 9.1×10^{-18} |
| <i>POU3F2</i> | GO-BiolProc | astrocyte differentiation | Y | 1.0×10^{-17} |
| <i>POU3F2</i> | GO-BiolProc | negative regulation of glial cell differentiation | N | 2.9×10^{-17} |
| <i>POU3F2</i> | GO-BiolProc | brain development | Y | 1.6×10^{-16} |
| <i>POU3F2</i> | GO-BiolProc | central nervous system neuron development | N | 2.7×10^{-16} |
| <i>POU3F2</i> | GO-BiolProc | glial cell differentiation | Y | 4.6×10^{-16} |
| <i>POU3F2</i> | GO-BiolProc | regulation of neuron differentiation | Y | 1.6×10^{-15} |
| <i>POU3F2</i> | GO-BiolProc | pallium development | Y | 2.8×10^{-15} |
| <i>POU3F2</i> | GO-BiolProc | cerebral cortex development | Y | 4.7×10^{-15} |
| <i>POU3F2</i> | GO-BiolProc | neuron fate commitment | N | 1.2×10^{-14} |
| <i>POU3F2</i> | GO-BiolProc | regulation of neurogenesis | Y | 1.3×10^{-14} |
| <i>POU3F2</i> | GO-BiolProc | central nervous system projection neuron axonogenesis | N | 1.5×10^{-14} |
| <i>POU3F2</i> | GO-BiolProc | positive regulation of neural precursor cell proliferation | N | 2.2×10^{-14} |
| <i>POU3F2</i> | GO-BiolProc | Gliogenesis | Y | 2.8×10^{-14} |
| <i>POU3F2</i> | GO-BiolProc | cerebral cortex neuron differentiation | N | 3.0×10^{-14} |
| <i>POU3F2</i> | GO-CellComp | neuron projection membrane | N | 2.8×10^{-7} |
| <i>POU3F2</i> | GO-CellComp | Axolemma | N | 9.9×10^{-7} |
| <i>POU3F2</i> | GO-CellComp | Dendrite | N | 1.2×10^{-6} |
| <i>POU3F2</i> | GO-CellComp | external encapsulating structure part | N | 2.6×10^{-6} |
| <i>POU3F2</i> | GO-CellComp | cell envelope | N | 2.6×10^{-6} |

| | | | | |
|---------------|-------------|---|---|-----------------------|
| <i>POU3F2</i> | GO-CellComp | periplasmic space | N | 7.5×10^{-6} |
| <i>POU3F2</i> | GO-CellComp | outer membrane-bounded periplasmic space | N | 7.5×10^{-6} |
| <i>POU3F2</i> | GO-MolFunc | ionotropic glutamate receptor activity | N | 3.7×10^{-6} |
| <i>POU3F2</i> | GO-MolFunc | ephrin receptor activity | N | 5.0×10^{-6} |
| <i>POU3F2</i> | REACTOME | CRMPs in Sema3A signaling | N | 1.1×10^{-5} |
| <i>POU3F2</i> | REACTOME | Unblocking of NMDA receptor, glutamate binding and activation | N | 1.3×10^{-5} |
| <i>SCRT1</i> | GO-BiolProc | potassium ion transport | N | 9.3×10^{-12} |
| <i>SCRT1</i> | GO-BiolProc | visual learning | N | 2.5×10^{-11} |
| <i>SCRT1</i> | GO-BiolProc | locomotory behavior | N | 3.2×10^{-11} |
| <i>SCRT1</i> | GO-BiolProc | mating behavior | N | 2.5×10^{-10} |
| <i>SCRT1</i> | GO-BiolProc | visual behavior | N | 7.0×10^{-10} |
| <i>SCRT1</i> | GO-BiolProc | associative learning | N | 1.1×10^{-9} |
| <i>SCRT1</i> | GO-BiolProc | Learning | N | 1.3×10^{-9} |
| <i>SCRT1</i> | GO-BiolProc | regulation of neurotransmitter levels | N | 1.4×10^{-9} |
| <i>SCRT1</i> | GO-BiolProc | ionotropic glutamate receptor signaling pathway | N | 2.7×10^{-9} |
| <i>SCRT1</i> | GO-BiolProc | neurotransmitter secretion | N | 2.9×10^{-9} |
| <i>SCRT1</i> | GO-BiolProc | neurotransmitter transport | N | 7.5×10^{-9} |
| <i>SCRT1</i> | GO-BiolProc | adult locomotory behavior | N | 8.1×10^{-9} |
| <i>SCRT1</i> | GO-BiolProc | response to tropine | N | 1.3×10^{-8} |
| <i>SCRT1</i> | GO-BiolProc | response to cocaine | N | 1.3×10^{-8} |
| <i>SCRT1</i> | GO-BiolProc | neuron-neuron synaptic transmission | N | 1.3×10^{-8} |
| <i>SCRT1</i> | GO-BiolProc | neuromuscular process | N | 2.8×10^{-8} |
| <i>SCRT1</i> | GO-BiolProc | reproductive behavior | N | 4.3×10^{-8} |
| <i>SCRT1</i> | GO-BiolProc | regulation of postsynaptic membrane potential | N | 5.4×10^{-8} |
| <i>SCRT1</i> | GO-BiolProc | membrane hyperpolarization | N | 6.4×10^{-8} |
| <i>SCRT1</i> | GO-BiolProc | synaptic transmission, glutamatergic | N | 1.0×10^{-7} |
| <i>SCRT1</i> | GO-CellComp | axon part | N | 2.2×10^{-12} |
| <i>SCRT1</i> | GO-CellComp | main axon | N | 1.1×10^{-10} |
| <i>SCRT1</i> | GO-CellComp | synapse part | N | 1.2×10^{-8} |

| | | | | |
|--------------|-------------|---|---|-----------------------|
| <i>SCRT1</i> | GO-CellComp | Axon | N | 1.2×10^{-8} |
| <i>SCRT1</i> | GO-CellComp | voltage-gated potassium channel complex | N | 1.5×10^{-8} |
| <i>SCRT1</i> | GO-CellComp | potassium channel complex | N | 1.5×10^{-8} |
| <i>SCRT1</i> | GO-CellComp | cation channel complex | N | 3.0×10^{-8} |
| <i>SCRT1</i> | GO-CellComp | Synapse | N | 1.2×10^{-7} |
| <i>SCRT1</i> | GO-CellComp | neuron projection terminus | N | 2.9×10^{-7} |
| <i>SCRT1</i> | GO-CellComp | neuronal cell body | N | 3.0×10^{-7} |
| <i>SCRT1</i> | GO-CellComp | cell body | N | 7.0×10^{-7} |
| <i>SCRT1</i> | GO-CellComp | axon terminus | N | 1.4×10^{-6} |
| <i>SCRT1</i> | GO-CellComp | terminal button | N | 2.8×10^{-6} |
| <i>SCRT1</i> | GO-CellComp | dendritic spine head | N | 5.8×10^{-6} |
| <i>SCRT1</i> | GO-CellComp | postsynaptic density | N | 5.8×10^{-6} |
| <i>SCRT1</i> | GO-CellComp | ion channel complex | N | 7.2×10^{-6} |
| <i>SCRT1</i> | GO-CellComp | synaptic membrane | N | 8.8×10^{-6} |
| <i>SCRT1</i> | GO-CellComp | synaptic vesicle membrane | N | 9.2×10^{-6} |
| <i>SCRT1</i> | GO-CellComp | ionotropic glutamate receptor complex | N | 9.9×10^{-6} |
| <i>SCRT1</i> | GO-CellComp | periplasmic space | N | 3.4×10^{-5} |
| <i>SCRT1</i> | GO-MolFunc | potassium ion transmembrane transporter activity | N | 4.5×10^{-10} |
| <i>SCRT1</i> | GO-MolFunc | potassium channel activity | N | 3.4×10^{-9} |
| <i>SCRT1</i> | GO-MolFunc | dopamine binding | N | 4.5×10^{-9} |
| <i>SCRT1</i> | GO-MolFunc | voltage-gated potassium channel activity | N | 7.4×10^{-9} |
| <i>SCRT1</i> | GO-MolFunc | voltage-gated cation channel activity | N | 2.6×10^{-8} |
| <i>SCRT1</i> | GO-MolFunc | voltage-gated ion channel activity | N | 2.4×10^{-7} |
| <i>SCRT1</i> | GO-MolFunc | voltage-gated channel activity | N | 2.4×10^{-7} |
| <i>SCRT1</i> | GO-MolFunc | cation channel activity | N | 9.1×10^{-7} |
| <i>SCRT1</i> | GO-MolFunc | gated channel activity | N | 1.8×10^{-6} |
| <i>SCRT1</i> | GO-MolFunc | delayed rectifier potassium channel activity | N | 2.3×10^{-6} |
| <i>SCRT1</i> | GO-MolFunc | extracellular-glutamate-gated ion channel activity | N | 4.7×10^{-6} |
| <i>SCRT1</i> | GO-MolFunc | inorganic cation transmembrane transporter activity | N | 6.2×10^{-6} |
| <i>SCRT1</i> | GO-MolFunc | ionotropic glutamate receptor activity | N | 1.8×10^{-5} |

| | | | | |
|--------------|-------------|---|---|-----------------------|
| <i>SCRT1</i> | KEGG | Neuroactive ligand-receptor interaction | N | 2.92E-06 |
| <i>SCRT1</i> | KEGG | Calcium signaling pathway | N | 6.67E-04 |
| <i>SCRT1</i> | REACTOME | Voltage gated Potassium channels | N | 7.6×10 ⁻¹² |
| <i>SCRT1</i> | REACTOME | Neuronal System | N | 6.8×10 ⁻¹¹ |
| <i>SCRT1</i> | REACTOME | Potassium Channels | N | 2.1×10 ⁻¹⁰ |
| <i>SCRT1</i> | REACTOME | Unblocking of NMDA receptor, glutamate binding and activation | N | 1.7×10 ⁻⁶ |
| <i>SCRT1</i> | REACTOME | Transmission across Chemical Synapses | N | 7.6×10 ⁻⁶ |
| <i>SCRT1</i> | REACTOME | CREB phosphorylation through the activation of CaMKII | N | 8.0×10 ⁻⁶ |
| <i>SCRT1</i> | REACTOME | GABA synthesis, release, reuptake and degradation | N | 3.5×10 ⁻⁵ |
| <i>SCRT1</i> | REACTOME | Trafficking of AMPA receptors | N | 3.8×10 ⁻⁵ |
| <i>SCRT1</i> | REACTOME | Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity | N | 3.8×10 ⁻⁵ |
| <i>SCRT1</i> | REACTOME | Amine ligand-binding receptors | N | 4.0×10 ⁻⁵ |
| <i>SCRT1</i> | REACTOME | Neurotransmitter Release Cycle | N | 4.6×10 ⁻⁵ |
| <i>SCRT1</i> | REACTOME | Ras activation upon Ca ²⁺ influx through NMDA receptor | N | 5.7×10 ⁻⁵ |
| <i>SCRT1</i> | REACTOME | Dopamine Neurotransmitter Release Cycle | N | 7.0×10 ⁻⁵ |
| <i>SCRT1</i> | REACTOME | Serotonin Neurotransmitter Release Cycle | N | 7.0×10 ⁻⁵ |
| <i>TBR1</i> | GO-BiolProc | behavioral defense response | N | 1.8×10 ⁻³² |
| <i>TBR1</i> | GO-BiolProc | behavioral fear response | N | 3.5×10 ⁻²⁷ |
| <i>TBR1</i> | GO-BiolProc | fear response | N | 6.6×10 ⁻²⁵ |
| <i>TBR1</i> | GO-BiolProc | hippocampus development | N | 2.8×10 ⁻²³ |
| <i>TBR1</i> | GO-BiolProc | pallium development | N | 8.8×10 ⁻²³ |
| <i>TBR1</i> | GO-BiolProc | G-protein coupled acetylcholine receptor signaling pathway | N | 5.3×10 ⁻²² |
| <i>TBR1</i> | GO-BiolProc | axonal fasciculation | N | 2.0×10 ⁻²¹ |
| <i>TBR1</i> | GO-BiolProc | limbic system development | N | 9.4×10 ⁻¹⁸ |
| <i>TBR1</i> | GO-BiolProc | neuron recognition | N | 3.5×10 ⁻¹⁷ |
| <i>TBR1</i> | GO-BiolProc | telencephalon development | N | 2.1×10 ⁻¹⁶ |
| <i>TBR1</i> | GO-BiolProc | multicellular organismal response to stress | N | 2.0×10 ⁻¹⁴ |
| <i>TBR1</i> | GO-BiolProc | forebrain development | N | 4.9×10 ⁻¹⁴ |
| <i>TBR1</i> | GO-BiolProc | cerebral cortex neuron differentiation | N | 1.2×10 ⁻¹³ |

| | | | | |
|-------------|-------------|--|---|-----------------------|
| <i>TBR1</i> | GO-BiolProc | cerebral cortex radially oriented cell migration | N | 1.5×10^{-13} |
| <i>TBR1</i> | GO-BiolProc | potassium ion transport | N | 1.9×10^{-13} |
| <i>TBR1</i> | GO-BiolProc | synaptic transmission, glutamatergic | N | 5.2×10^{-13} |
| <i>TBR1</i> | GO-BiolProc | ionotropic glutamate receptor signaling pathway | N | 3.2×10^{-12} |
| <i>TBR1</i> | GO-BiolProc | neuron-neuron synaptic transmission | N | 8.3×10^{-12} |
| <i>TBR1</i> | GO-BiolProc | learning or memory | N | 1.6×10^{-11} |
| <i>TBR1</i> | GO-BiolProc | regulation of synaptic plasticity | N | 2.4×10^{-11} |
| <i>TBR1</i> | GO-CellComp | synapse part | N | 1.3×10^{-15} |
| <i>TBR1</i> | GO-CellComp | synaptic membrane | N | 5.1×10^{-15} |
| <i>TBR1</i> | GO-CellComp | cation channel complex | N | 5.4×10^{-15} |
| <i>TBR1</i> | GO-CellComp | potassium channel complex | N | 6.5×10^{-15} |
| <i>TBR1</i> | GO-CellComp | voltage-gated potassium channel complex | N | 6.5×10^{-15} |
| <i>TBR1</i> | GO-CellComp | ion channel complex | N | 1.4×10^{-14} |
| <i>TBR1</i> | GO-CellComp | presynaptic membrane | N | 4.7×10^{-13} |
| <i>TBR1</i> | GO-CellComp | Synapse | N | 3.6×10^{-12} |
| <i>TBR1</i> | GO-CellComp | postsynaptic membrane | N | 6.2×10^{-10} |
| <i>TBR1</i> | GO-CellComp | Dendrite | N | 7.3×10^{-10} |
| <i>TBR1</i> | GO-CellComp | asymmetric synapse | N | 5.6×10^{-9} |
| <i>TBR1</i> | GO-CellComp | site of polarized growth | N | 3.0×10^{-8} |
| <i>TBR1</i> | GO-CellComp | growth cone | N | 3.5×10^{-8} |
| <i>TBR1</i> | GO-CellComp | synaptic vesicle membrane | N | 7.1×10^{-8} |
| <i>TBR1</i> | GO-MolFunc | voltage-gated potassium channel activity | N | 2.3×10^{-17} |
| <i>TBR1</i> | GO-MolFunc | potassium channel activity | N | 2.6×10^{-17} |
| <i>TBR1</i> | GO-MolFunc | voltage-gated cation channel activity | N | 7.5×10^{-17} |
| <i>TBR1</i> | GO-MolFunc | voltage-gated channel activity | N | 1.9×10^{-15} |
| <i>TBR1</i> | GO-MolFunc | voltage-gated ion channel activity | N | 1.9×10^{-15} |
| <i>TBR1</i> | GO-MolFunc | acidic amino acid transmembrane transporter activity | N | 2.3×10^{-15} |
| <i>TBR1</i> | GO-MolFunc | L-glutamate transmembrane transporter activity | N | 1.0×10^{-14} |
| <i>TBR1</i> | GO-MolFunc | potassium ion transmembrane transporter activity | N | 6.4×10^{-13} |
| <i>TBR1</i> | GO-MolFunc | gated channel activity | N | 3.8×10^{-12} |

| | | | | |
|-------------|------------|--|---|-----------------------|
| <i>TBR1</i> | GO-MolFunc | ion channel activity | N | 1.2×10^{-10} |
| <i>TBR1</i> | GO-MolFunc | substrate-specific channel activity | N | 1.5×10^{-10} |
| <i>TBR1</i> | GO-MolFunc | G-protein coupled amine receptor activity | N | 1.9×10^{-19} |
| <i>TBR1</i> | GO-MolFunc | metal ion transmembrane transporter activity | N | 6.3×10^{-10} |
| <i>TBR1</i> | GO-MolFunc | cation channel activity | N | 8.2×10^{-10} |
| <i>TBR1</i> | GO-MolFunc | GABA receptor activity | N | 9.1×10^{-10} |
| <i>TBR1</i> | GO-MolFunc | passive transmembrane transporter activity | N | 1.4×10^{-9} |
| <i>TBR1</i> | GO-MolFunc | channel activity | N | 1.4×10^{-9} |
| <i>TBR1</i> | GO-MolFunc | GABA-A receptor activity | N | 2.6×10^{-9} |
| <i>TBR1</i> | KEGG | Calcium signaling pathway | N | 4.1×10^{-6} |
| <i>TBR1</i> | KEGG | Neuroactive ligand-receptor interaction | N | 7.7×10^{-5} |
| <i>TBR1</i> | REACTOME | Voltage gated Potassium channels | N | 2.4×10^{-15} |
| <i>TBR1</i> | REACTOME | GABA A receptor activation | N | 4.2×10^{-14} |
| <i>TBR1</i> | REACTOME | Potassium Channels | N | 4.4×10^{-14} |
| <i>TBR1</i> | REACTOME | Neuronal System | N | 5.6×10^{-14} |
| <i>TBR1</i> | REACTOME | Amine ligand-binding receptors | N | 4.4×10^{-13} |
| <i>TBR1</i> | REACTOME | Glutamate Neurotransmitter Release Cycle | N | 2.4×10^{-11} |
| <i>TBR1</i> | REACTOME | Ligand-gated ion channel transport | N | 3.8×10^{-11} |
| <i>TBR1</i> | REACTOME | Transmission across Chemical Synapses | N | 5.7×10^{-9} |
| <i>TBR1</i> | REACTOME | Sema3A PAK dependent Axon repulsion | N | 1.6×10^{-8} |

Table S13. Results of mouse phenotype prediction analysis in 80,000 gene expression profiles. Phenotypic annotations are obtained from the Mouse Genetics Initiative database (www.informatics.jax.org). Table lists only genes and phenotypic annotations directly related to neuronal or central nervous system function or morphology (marked with an asterix) – full predictions are available at – <http://www.ssgac.org>⁴. *P*-values refer to the correlation between the Gene principal component profile and the reconstituted phenotypic annotation principal component profile, uncorrected for multiple testing; all reported terms meet False Discovery Rate < 0.05. The Annotated column indicates if the gene has previously been linked to a specific mouse phenotype (Y) or not (N). Results are sorted alphabetically by gene name.

| Gene name | Predicted mouse knock-out/-in phenotype | Annotated | <i>P</i> -value |
|-----------------|--|-----------|-----------------------|
| <i>AKT3</i> | abnormal hippocampus pyramidal cell layer | N | 1.7×10^{-13} |
| <i>AKT3</i> | small hippocampus | N | 1.8×10^{-8} |
| <i>AKT3</i> | abnormal neocortex morphology | N | 5.6×10^{-6} |
| <i>AKT3</i> | decreased neuron number | N | 6.5×10^{-6} |
| <i>AKT3</i> | placental labyrinth hypoplasia | N | 1.1×10^{-5} |
| <i>AKT3</i> | abnormal brain ventricle morphology | N | 1.7×10^{-5} |
| <i>AKT3</i> | abnormal sensory capabilities/reflexes/nociception | N | 1.7×10^{-4} |
| <i>AKT3</i> | abnormal hippocampus morphology | N | 1.9×10^{-4} |
| <i>AKT3</i> | abnormal cerebellar foliation | N | 1.9×10^{-4} |
| <i>AKT3</i> | abnormal postnatal subventricular zone morphology | N | 2.5×10^{-4} |
| <i>ARHGAP39</i> | dilated lateral ventricles | N | 3.2×10^{-5} |
| <i>ARHGAP39</i> | abnormal ventral spinal root morphology | N | 9.0×10^{-5} |
| <i>ARHGAP39</i> | abnormal hippocampus layer morphology | N | 1.6×10^{-4} |
| <i>ARHGAP39</i> | dilated third ventricle | N | 2.9×10^{-4} |
| <i>ARHGAP39</i> | abnormal neural crest cell migration | N | 7.9×10^{-4} |
| <i>ARHGAP39</i> | decreased motor neuron number | N | 9.0×10^{-4} |
| <i>ATXN2L</i> | dilated lateral ventricles | N | 4.5×10^{-8} |
| <i>ATXN2L</i> | increased brain size | N | 2.9×10^{-7} |
| <i>ATXN2L</i> | abnormal dendritic cell morphology | N | 4.8×10^{-4} |
| <i>ATXN2L</i> | dilated third ventricle | N | 6.3×10^{-4} |
| <i>C12orf65</i> | impaired olfaction | N | 6.0×10^{-3} |
| <i>C12orf65</i> | abnormal nervous system physiology | N | 7.5×10^{-3} |
| <i>C12orf65</i> | abnormal medulla oblongata morphology | N | 8.2×10^{-3} |

⁴ The link will be activated on the day of publication of this article. The materials that will be posted online are included as a separate appendix to the submitted manuscript.

| | | | |
|-----------------|--|---|-----------------------|
| <i>C12orf65</i> | abnormal neural tube closure | N | 1.4×10^{-2} |
| <i>C12orf65</i> | abnormal seizure response to electrical stimulation | N | 1.6×10^{-2} |
| <i>C12orf65</i> | abnormal hippocampus CA1 region morphology | N | 1.7×10^{-2} |
| <i>C12orf65</i> | absent distortion product otoacoustic emissions | N | 1.8×10^{-2} |
| <i>C12orf65</i> | increased drinking behavior | N | 1.8×10^{-2} |
| <i>CELF4</i> | abnormal CNS synaptic transmission | N | 1.1×10^{-26} |
| <i>CELF4</i> | abnormal synaptic vesicle number | N | 7.6×10^{-22} |
| <i>CELF4</i> | abnormal miniature excitatory postsynaptic currents | N | 4.5×10^{-17} |
| <i>CELF4</i> | increased susceptibility to pharmacologically induced seizures | N | 1.1×10^{-16} |
| <i>CELF4</i> | abnormal inhibitory postsynaptic currents | N | 1.8×10^{-16} |
| <i>CELF4</i> | abnormal synaptic vesicle recycling | N | 2.8×10^{-16} |
| <i>CELF4</i> | abnormal synaptic vesicle morphology | N | 8.8×10^{-16} |
| <i>CELF4</i> | convulsive seizures | N | 2.6×10^{-15} |
| <i>CELF4</i> | reduced long term potentiation | N | 8.2×10^{-15} |
| <i>CELF4</i> | abnormal excitatory postsynaptic potential | N | 2.2×10^{-14} |
| <i>CELF4</i> | increased synaptic depression | N | 1.4×10^{-13} |
| <i>CELF4</i> | tonic-clonic seizures | Y | 6.7×10^{-13} |
| <i>CELF4</i> | enhanced paired-pulse facilitation | N | 7.8×10^{-13} |
| <i>CELF4</i> | abnormal excitatory postsynaptic currents | N | 4.9×10^{-12} |
| <i>CELF4</i> | abnormal brain wave pattern | N | 1.6×10^{-11} |
| <i>CELF4</i> | sporadic seizures | N | 2.1×10^{-11} |
| <i>CELF4</i> | decreased paired-pulse facilitation | N | 3.4×10^{-11} |
| <i>CELF4</i> | impaired coordination | N | 5.7×10^{-11} |
| <i>CELF4</i> | abnormal conditioned taste aversion behaviour | N | 9.7×10^{-11} |
| <i>CRYZL1</i> | abnormal synaptic vesicle recycling | N | 2.1×10^{-4} |
| <i>CYHR1</i> | abnormal brain white matter morphology | N | 4.7×10^{-8} |
| <i>CYHR1</i> | dilated third ventricle | N | 5.1×10^{-5} |
| <i>CYHR1</i> | abnormal astrocyte morphology | N | 1.5×10^{-4} |
| <i>CYHR1</i> | thick interventricular septum | N | 6.7×10^{-4} |

| | | | |
|---------------|---|---|-----------------------|
| <i>DEC1</i> | hydroencephaly | N | 3.2×10^{-3} |
| <i>DEC1</i> | abnormal startle reflex | N | 5.6×10^{-3} |
| <i>DEC1</i> | impaired passive avoidance behavior | N | 1.7×10^{-2} |
| <i>DEC1</i> | abnormal drinking behavior | N | 2.2×10^{-2} |
| <i>FOXH1</i> | abnormal anterior visceral endoderm morphology | N | 1.3×10^{-19} |
| <i>FOXH1</i> | abnormal neural fold formation | Y | 1.4×10^{-14} |
| <i>ITSN1</i> | decreased brain size | N | 2.8×10^{-7} |
| <i>ITSN1</i> | abnormal behavior | N | 3.1×10^{-5} |
| <i>ITSN1</i> | microgliosis | N | 4.1×10^{-5} |
| <i>ITSN1</i> | abnormal hippocampal commissure morphology | N | 7.2×10^{-5} |
| <i>ITSN1</i> | ectopic Purkinje cell | N | 1.3×10^{-4} |
| <i>ITSN1</i> | abnormal otic capsule morphology | N | 1.5×10^{-4} |
| <i>KCNMA1</i> | decreased vasoconstriction | N | 6.7×10^{-8} |
| <i>KCNMA1</i> | abnormal miniature excitatory postsynaptic currents | N | 1.2×10^{-7} |
| <i>KCNMA1</i> | abnormal brain wave pattern | N | 3.0×10^{-6} |
| <i>KCNMA1</i> | limb grasping | N | 5.3×10^{-6} |
| <i>KCNMA1</i> | intracerebral hemorrhage | N | 8.3×10^{-6} |
| <i>KCNMA1</i> | abnormal GABA-mediated receptor currents | N | 9.2×10^{-6} |
| <i>KCNMA1</i> | abnormal synaptic plasticity | N | 1.1×10^{-5} |
| <i>KCNMA1</i> | decreased aggression towards males | N | 1.7×10^{-5} |
| <i>KIFC2</i> | abnormal miniature excitatory postsynaptic currents | N | 6.4×10^{-7} |
| <i>KIFC2</i> | abnormal inhibitory postsynaptic currents | N | 2.7×10^{-6} |
| <i>KIFC2</i> | abnormal spatial learning | N | 3.8×10^{-6} |
| <i>KIFC2</i> | abnormal excitatory postsynaptic currents | N | 5.5×10^{-6} |
| <i>KIFC2</i> | abnormal AMPA-mediated synaptic currents | N | 5.6×10^{-6} |
| <i>KIFC2</i> | reduced long term depression | N | 7.5×10^{-6} |
| <i>KIFC2</i> | abnormal hippocampal mossy fiber morphology | N | 9.4×10^{-6} |
| <i>KIFC2</i> | abnormal long term depression | N | 1.3×10^{-5} |
| <i>KIFC2</i> | enhanced long term potentiation | N | 2.3×10^{-5} |

| | | | |
|---------------|--|---|-----------------------|
| <i>KIFC2</i> | enhanced paired-pulse facilitation | N | 2.7×10^{-5} |
| <i>KIFC2</i> | abnormal synaptic vesicle morphology | N | 4.5×10^{-5} |
| <i>KIFC2</i> | abnormal excitatory postsynaptic potential | N | 5.2×10^{-5} |
| <i>KIFC2</i> | abnormal zygomatic bone morphology | N | 8.3×10^{-5} |
| <i>KIFC2</i> | abnormal anxiety-related response | N | 9.3×10^{-5} |
| <i>KIFC2</i> | abnormal synaptic vesicle recycling | N | 9.9×10^{-5} |
| <i>KIFC2</i> | abnormal brain internal capsule morphology | N | 1.7×10^{-4} |
| <i>KIFC2</i> | clonic seizures | N | 2.0×10^{-4} |
| <i>KIFC2</i> | decreased susceptibility to pharmacologically induced seizures | N | 2.1×10^{-4} |
| <i>KIFC2</i> | abnormal CNS synaptic transmission | N | 2.1×10^{-4} |
| <i>LRRC14</i> | impaired coordination | N | 2.6×10^{-5} |
| <i>LRRC14</i> | dilated third ventricle | N | 1.2×10^{-3} |
| <i>LRRC14</i> | small cerebellum | N | 1.3×10^{-3} |
| <i>LRRC14</i> | impaired contextual conditioning behavior | N | 1.4×10^{-3} |
| <i>LRRC14</i> | impaired hearing | N | 1.6×10^{-3} |
| <i>LRRC14</i> | abnormal axon outgrowth | N | 1.7×10^{-3} |
| <i>LRRC14</i> | abnormal retinal apoptosis | N | 2.3×10^{-3} |
| <i>LRRC14</i> | abnormal lateral ventricle morphology | N | 3.2×10^{-3} |
| <i>LRRC14</i> | dilated lateral ventricles | N | 3.5×10^{-3} |
| <i>LRRC14</i> | abnormal brain white matter morphology | N | 4.1×10^{-3} |
| <i>NRXN1</i> | abnormal inhibitory postsynaptic currents | N | 1.6×10^{-26} |
| <i>NRXN1</i> | abnormal CNS synaptic transmission | N | 2.6×10^{-25} |
| <i>NRXN1</i> | abnormal GABA-mediated receptor currents | N | 2.6×10^{-24} |
| <i>NRXN1</i> | abnormal excitatory postsynaptic currents | N | 1.2×10^{-22} |
| <i>NRXN1</i> | hyperactivity | N | 6.3×10^{-18} |
| <i>NRXN1</i> | abnormal synaptic transmission | N | 1.4×10^{-17} |
| <i>NRXN1</i> | abnormal spatial learning | N | 7.7×10^{-17} |
| <i>NRXN1</i> | abnormal synaptic vesicle number | N | 3.6×10^{-16} |
| <i>NRXN1</i> | abnormal posture | N | 6.4×10^{-16} |
| <i>NRXN1</i> | ataxia | N | 1.4×10^{-14} |

| | | | |
|----------------|---|---|-----------------------|
| <i>NRXN1</i> | abnormal brain wave pattern | N | 2.4×10^{-14} |
| <i>NRXN1</i> | seizures | N | 6.8×10^{-14} |
| <i>NRXN1</i> | convulsive seizures | N | 1.4×10^{-13} |
| <i>NRXN1</i> | abnormal nervous system electrophysiology | N | 4.9×10^{-13} |
| <i>NRXN1</i> | abnormal spatial reference memory | N | 4.9×10^{-13} |
| <i>NRXN1</i> | abnormal excitatory postsynaptic potential | N | 8.1×10^{-13} |
| <i>NRXN1</i> | abnormal hippocampus morphology | N | 1.2×10^{-12} |
| <i>NRXN1</i> | impaired coordination | N | 1.4×10^{-12} |
| <i>NRXN1</i> | increased startle reflex | N | 1.5×10^{-12} |
| <i>NRXN1</i> | abnormal social/conspecific interaction | N | 3.9×10^{-12} |
| <i>NUPR1</i> | increased brain weight | N | 1.7×10^{-7} |
| <i>NUPR1</i> | abnormal hippocampus layer morphology | N | 6.7×10^{-6} |
| <i>NUPR1</i> | abnormal enteric neuron morphology | N | 1.7×10^{-5} |
| <i>PITPNM2</i> | reduced long term depression | N | 4.9×10^{-6} |
| <i>PITPNM2</i> | abnormal behavior | N | 1.2×10^{-4} |
| <i>PITPNM2</i> | abnormal learning/ memory | N | 2.3×10^{-4} |
| <i>PITPNM2</i> | impaired cued conditioning behavior | N | 4.3×10^{-4} |
| <i>PITPNM2</i> | abnormal excitatory postsynaptic potential | N | 5.2×10^{-4} |
| <i>PITPNM2</i> | impaired contextual conditioning behavior | N | 6.6×10^{-4} |
| <i>PITPNM2</i> | abnormal calcium ion homeostasis | N | 8.6×10^{-4} |
| <i>POU3F2</i> | abnormal brain commissure morphology | N | 8.2×10^{-15} |
| <i>POU3F2</i> | enlarged third ventricle | N | 1.2×10^{-14} |
| <i>POU3F2</i> | abnormal hippocampal mossy fiber morphology | N | 2.2×10^{-13} |
| <i>POU3F2</i> | small olfactory bulb | N | 7.7×10^{-12} |
| <i>POU3F2</i> | abnormal radial glial cell morphology | N | 1.1×10^{-11} |
| <i>POU3F2</i> | abnormal cerebral cortex morphology | N | 3.4×10^{-11} |
| <i>POU3F2</i> | abnormal axon guidance | N | 3.5×10^{-10} |
| <i>POU3F2</i> | increased aggression towards mice | N | 8.5×10^{-10} |
| <i>POU3F2</i> | abnormal corticospinal tract morphology | N | 1.4×10^{-10} |

| | | | |
|---------------|---|---|-----------------------|
| <i>POU3F2</i> | decreased brain size | N | 3.4×10^{-9} |
| <i>POU3F2</i> | abnormal hippocampus morphology | N | 8.3×10^{-8} |
| <i>POU3F2</i> | abnormal embryonic/fetal subventricular zone morphology | N | 1.0×10^{-8} |
| <i>POU3F2</i> | decreased corpus callosum size | N | 1.6×10^{-8} |
| <i>POU3F2</i> | abnormal spinal cord interneuron morphology | N | 1.8×10^{-8} |
| <i>POU3F2</i> | abnormal cerebellar foliation | N | 1.9×10^{-8} |
| <i>POU3F2</i> | abnormal cerebrum morphology | N | 3.7×10^{-8} |
| <i>POU3F2</i> | abnormal telencephalon development | N | 4.2×10^{-8} |
| <i>POU3F2</i> | enlarged lateral ventricles | N | 8.5×10^{-8} |
| <i>REEP3</i> | abnormal eating behavior | N | 6.1×10^{-5} |
| <i>REEP3</i> | abnormal myelination | N | 2.2×10^{-3} |
| <i>REEP3</i> | abnormal myelin sheath morphology | N | 2.9×10^{-3} |
| <i>REEP3</i> | abnormal postural reflex | N | 3.1×10^{-3} |
| <i>REEP3</i> | abnormal brain white matter morphology | N | 3.2×10^{-3} |
| <i>SCRT1</i> | impaired conditioned place preference behavior | N | 3.3×10^{-12} |
| <i>SCRT1</i> | abnormal spatial learning | N | 8.6×10^{-12} |
| <i>SCRT1</i> | abnormal spike wave discharge | N | 5.6×10^{-11} |
| <i>SCRT1</i> | impaired behavioral response to addictive substance | N | 1.2×10^{-10} |
| <i>SCRT1</i> | increased exploration in new environment | N | 1.6×10^{-10} |
| <i>SCRT1</i> | absence seizures | N | 1.2×10^{-9} |
| <i>SCRT1</i> | abnormal nervous system electrophysiology | N | 1.2×10^{-9} |
| <i>SCRT1</i> | enhanced coordination | N | 1.8×10^{-9} |
| <i>SCRT1</i> | abnormal inhibitory postsynaptic currents | N | 1.1×10^{-8} |
| <i>SCRT1</i> | decreased vertical activity | N | 1.6×10^{-8} |
| <i>SCRT1</i> | abnormal behavioral response to xenobiotic | N | 1.7×10^{-8} |
| <i>SCRT1</i> | sporadic seizures | N | 2.1×10^{-8} |
| <i>SCRT1</i> | abnormal action potential | N | 2.2×10^{-8} |
| <i>SCRT1</i> | abnormal excitatory postsynaptic currents | N | 2.9×10^{-8} |
| <i>SCRT1</i> | decreased neurotransmitter release | N | 2.9×10^{-8} |
| <i>SCRT1</i> | reduced long term depression | N | 2.9×10^{-8} |

| | | | |
|----------------|---|---|-----------------------|
| <i>SCRT1</i> | ataxia | N | 8.7×10^{-8} |
| <i>SCRT1</i> | abnormal brain wave pattern | N | 2.3×10^{-7} |
| <i>SCRT1</i> | impaired swimming | N | 3.2×10^{-7} |
| <i>SCRT1</i> | impaired coordination | N | 4.0×10^{-7} |
| <i>SNRNP35</i> | abnormal brain morphology | N | 7.1×10^{-4} |
| <i>SNRNP35</i> | abnormal action potential | N | 1.5×10^{-4} |
| <i>SNRNP35</i> | astrocytosis | N | 2.1×10^{-3} |
| <i>SNRNP35</i> | absent T cells | N | 2.3×10^{-3} |
| <i>SNRNP35</i> | neurodegeneration | N | 2.5×10^{-3} |
| <i>SNRNP35</i> | seminiferous tubule degeneration | N | 2.8×10^{-3} |
| <i>SNRNP35</i> | abnormal miniature inhibitory postsynaptic currents | N | 3.4×10^{-3} |
| <i>SPNS1</i> | astrocytosis | N | 5.2×10^{-8} |
| <i>SPNS1</i> | Purkinje cell degeneration | N | 7.8×10^{-6} |
| <i>SPNS1</i> | abnormal cued conditioning behavior | N | 3.5×10^{-5} |
| <i>SPNS1</i> | abnormal Reichert's membrane morphology | N | 2.2×10^{-4} |
| <i>SPNS1</i> | abnormal retinal ganglion layer morphology | N | 2.8×10^{-4} |
| <i>SPNS1</i> | limb grasping | N | 3.4×10^{-4} |
| <i>SPNS1</i> | myeloid hyperplasia | N | 3.8×10^{-4} |
| <i>SPNS1</i> | gliosis | N | 4.3×10^{-4} |
| <i>SPNS1</i> | abnormal anterior visceral endoderm morphology | N | 9.2×10^{-4} |
| <i>SPNS1</i> | microgliosis | N | 1.1×10^{-3} |
| <i>TBR1</i> | abnormal inhibitory postsynaptic currents | N | 2.7×10^{-22} |
| <i>TBR1</i> | reduced long term depression | N | 3.2×10^{-22} |
| <i>TBR1</i> | abnormal spatial learning | N | 1.9×10^{-20} |
| <i>TBR1</i> | abnormal brain wave pattern | N | 1.1×10^{-19} |
| <i>TBR1</i> | absent corpus callosum | N | 4.7×10^{-18} |
| <i>TBR1</i> | sporadic seizures | N | 4.7×10^{-16} |
| <i>TBR1</i> | increased startle reflex | N | 4.8×10^{-16} |
| <i>TBR1</i> | abnormal cerebral cortex morphology | N | 7.1×10^{-16} |

| | | | |
|-------------|--|---|-----------------------|
| <i>TBR1</i> | abnormal neocortex morphology | N | 4.7×10^{-15} |
| <i>TBR1</i> | abnormal long term depression | N | 7.9×10^{-15} |
| <i>TBR1</i> | hyperactivity | N | 1.8×10^{-14} |
| <i>TBR1</i> | abnormal CNS synaptic transmission | N | 4.3×10^{-14} |
| <i>TBR1</i> | increased anxiety-related response | N | 4.4×10^{-13} |
| <i>TBR1</i> | abnormal GABA-mediated receptor currents | N | 5.1×10^{-13} |
| <i>TBR1</i> | increased susceptibility to pharmacologically induced seizures | N | 5.4×10^{-13} |
| <i>TBR1</i> | abnormal synaptic vesicle number | N | 5.9×10^{-13} |
| <i>TBR1</i> | abnormal excitatory postsynaptic currents | N | 2.2×10^{-12} |
| <i>TBR1</i> | abnormal thalamus morphology | N | 3.2×10^{-12} |
| <i>TBR1</i> | abnormal telencephalon development | N | 1.2×10^{-11} |
| <i>TBR1</i> | abnormal excitatory postsynaptic potential | N | 1.7×10^{-8} |

Table S14. Results of the tissue, organ and tissue type specific expression analysis in 80,000 gene expression profiles. The expression profiles were annotation into tissues, organs, or cell types using the MeSH database (<http://www.nlm.nih.gov/mesh/>). Table lists only genes in which show high expression in brain regions or specific nervous system cells – full predictions are available at <http://www.ssgac.org>⁵. Sample count specifies the number of expression profiles annotated with given annotation. AUC (*area under the curve*) gives the estimate how much of the variation on given gene expression profile is explained by a given tissue, organ or tissue type. *P*-values refer to enriched expression for a given gene in specific tissue, organ or tissue type compared to all other annotation terms. Results are sorted alphabetically by gene name.

| Gene name | Tissue, organ or cell type | Sample count | AUC | <i>P</i> -value |
|-----------------|----------------------------|--------------|------|----------------------|
| <i>AKT3</i> | Prefrontal Cortex | 46 | 0.98 | 6×10^{-30} |
| <i>AKT3</i> | Frontal Lobe | 62 | 0.95 | 3×10^{-35} |
| <i>AKT3</i> | Visual Cortex | 34 | 0.94 | 3×10^{-19} |
| <i>AKT3</i> | Occipital Lobe | 42 | 0.94 | 5×10^{-23} |
| <i>AKT3</i> | Cerebral Cortex | 276 | 0.94 | 3×10^{-14} |
| <i>AKT3</i> | Entorhinal Cortex | 83 | 0.94 | 2×10^{-43} |
| <i>AKT3</i> | Temporal Lobe | 91 | 0.94 | 5×10^{-47} |
| <i>AKT3</i> | Cerebellum | 36 | 0.93 | 3×10^{-19} |
| <i>AKT3</i> | Hippocampus | 55 | 0.93 | 7×10^{-28} |
| <i>AKT3</i> | Cerebrum | 344 | 0.92 | 3×10^{-160} |
| <i>AKT3</i> | Parietal Lobe | 17 | 0.91 | 5×10^{-9} |
| <i>ARHGAP39</i> | Hippocampus | 55 | 0.88 | 5×10^{-22} |
| <i>ARHGAP39</i> | Visual Cortex | 34 | 0.87 | 7×10^{-14} |
| <i>ARHGAP39</i> | Neural Stem Cells | 11 | 0.87 | 3×10^{-5} |
| <i>ARHGAP39</i> | Occipital Lobe | 42 | 0.86 | 5×10^{-16} |
| <i>ARHGAP39</i> | Parietal Lobe | 17 | 0.86 | 3×10^{-7} |
| <i>ARHGAP39</i> | Hypothalamus | 15 | 0.85 | 4×10^{-6} |
| <i>ARHGAP39</i> | Ganglia | 11 | 0.83 | 2×10^{-4} |
| <i>ARHGAP39</i> | Cerebral Cortex | 276 | 0.82 | 2×10^{-75} |
| <i>ARHGAP39</i> | Entorhinal Cortex | 83 | 0.82 | 6×10^{-24} |
| <i>ARHGAP39</i> | Cerebrum | 344 | 0.82 | 1×10^{-91} |
| <i>ARHGAP39</i> | Temporal Lobe | 91 | 0.81 | 1×10^{-24} |
| <i>ARHGAP39</i> | Brain | 1274 | 0.78 | 1×10^{-252} |

⁵ The link will be activated on the day of publication of this article. The materials that will be posted online are included as a separate appendix to the submitted manuscript.

| | | | | |
|-----------------|------------------------|------|------|----------------------|
| <i>ARHGAP39</i> | Central Nervous System | 1302 | 0.78 | 2×10^{-251} |
| <i>C12orf65</i> | Hypothalamus | 15 | 0.68 | 1×10^{-2} |
| <i>CRYZL1</i> | Prefrontal Cortex | 46 | 0.95 | 6×10^{-26} |
| <i>CRYZL1</i> | Frontal Lobe | 62 | 0.86 | 1×10^{-22} |
| <i>CRYZL1</i> | Cerebellum | 36 | 0.86 | 9×10^{-14} |
| <i>CRYZL1</i> | Substantia Nigra | 22 | 0.73 | 2×10^{-4} |
| <i>CYHR1</i> | Hypothalamus | 15 | 0.82 | 1×10^{-5} |
| <i>CYHR1</i> | Putamen | 16 | 0.78 | 1×10^{-4} |
| <i>CYHR1</i> | Parotid Gland | 19 | 0.73 | 4×10^{-4} |
| <i>CYHR1</i> | Occipital Lobe | 42 | 0.71 | 2×10^{-6} |
| <i>CYHR1</i> | Visual Cortex | 34 | 0.71 | 2×10^{-5} |
| <i>CYHR1</i> | Cerebellum | 36 | 0.7 | 3×10^{-5} |
| <i>CYHR1</i> | Thalamus | 16 | 0.7 | 7×10^{-3} |
| <i>CYHR1</i> | Astrocytes | 12 | 0.69 | 2×10^{-2} |
| <i>CYHR1</i> | Hippocampus | 55 | 0.67 | 8×10^{-6} |
| <i>DEC1</i> | Substantia Nigra | 22 | 0.78 | 6×10^{-6} |
| <i>DEC1</i> | Thalamus | 16 | 0.75 | 5×10^{-4} |
| <i>DEC1</i> | Mesencephalon | 41 | 0.74 | 7×10^{-8} |
| <i>DEC1</i> | Hypothalamus | 15 | 0.73 | 2×10^{-3} |
| <i>DEC1</i> | Subthalamic Nucleus | 12 | 0.68 | 3×10^{-2} |
| <i>FARP1</i> | Neural Stem Cells | 11 | 0.96 | 1×10^{-7} |
| <i>FARP1</i> | Astrocytes | 12 | 0.84 | 4×10^{-5} |
| <i>FOXH1</i> | Substantia Nigra | 22 | 0.86 | 4×10^{-9} |
| <i>FOXH1</i> | Subthalamic Nucleus | 12 | 0.84 | 5×10^{-5} |
| <i>FOXH1</i> | Thalamus | 16 | 0.82 | 8×10^{-6} |
| <i>FOXH1</i> | Mesencephalon | 41 | 0.8 | 4×10^{-11} |
| <i>FOXH1</i> | Parietal Lobe | 17 | 0.77 | 9×10^{-5} |
| <i>FOXH1</i> | Occipital Lobe | 42 | 0.75 | 4×10^{-8} |
| <i>FOXH1</i> | Visual Cortex | 34 | 0.74 | 9×10^{-7} |

| | | | | |
|---------------|-------------------|-----|------|----------------------|
| <i>FOXH1</i> | Hypothalamus | 15 | 0.74 | 2×10^{-3} |
| <i>ITSN1</i> | Abdominal Fat | 69 | 0.99 | 2×10^{-44} |
| <i>ITSN1</i> | Visual Cortex | 34 | 0.98 | 4×10^{-22} |
| <i>ITSN1</i> | Motor Neurons | 12 | 0.98 | 1×10^{-8} |
| <i>ITSN1</i> | Occipital Lobe | 42 | 0.97 | 4×10^{-26} |
| <i>ITSN1</i> | Prefrontal Cortex | 46 | 0.97 | 8×10^{-26} |
| <i>ITSN1</i> | Frontal Lobe | 62 | 0.96 | 1×10^{-35} |
| <i>ITSN1</i> | Entorhinal Cortex | 83 | 0.96 | 4×10^{-47} |
| <i>ITSN1</i> | Cerebral Cortex | 276 | 0.96 | 1×10^{-150} |
| <i>ITSN1</i> | Temporal Lobe | 91 | 0.95 | 7×10^{-51} |
| <i>ITSN1</i> | Hippocampus | 55 | 0.95 | 7×10^{-31} |
| <i>ITSN1</i> | Spinal Cord | 19 | 0.94 | 2×10^{-11} |
| <i>ITSN1</i> | Cerebrum | 344 | 0.94 | 5×10^{-175} |
| <i>ITSN1</i> | Cicatrix | 19 | 0.94 | 3×10^{-11} |
| <i>ITSN1</i> | Parietal Lobe | 17 | 0.94 | 4×10^{-10} |
| <i>ITSN1</i> | Cerebellum | 36 | 0.92 | 1×10^{-18} |
| <i>JMJD1C</i> | Cerebellum | 36 | 0.91 | 4×10^{-17} |
| <i>JMJD1C</i> | Prefrontal Cortex | 46 | 0.66 | 2×10^{-4} |
| <i>KCNMA1</i> | Visual Cortex | 34 | 0.95 | 7×10^{-20} |
| <i>KCNMA1</i> | Occipital Lobe | 42 | 0.94 | 4×10^{-23} |
| <i>KCNMA1</i> | Prefrontal Cortex | 46 | 0.93 | 2×10^{-24} |
| <i>KCNMA1</i> | Entorhinal Cortex | 83 | 0.93 | 7×10^{-42} |
| <i>KCNMA1</i> | Aortic Valve | 10 | 0.93 | 2×10^{-6} |
| <i>KCNMA1</i> | Muscle, Smooth | 248 | 0.92 | 1×10^{-115} |
| <i>KCNMA1</i> | Cerebral Cortex | 276 | 0.92 | 2×10^{-125} |
| <i>KCNMA1</i> | Frontal Lobe | 62 | 0.91 | 10×10^{-29} |
| <i>KCNMA1</i> | Hippocampus | 55 | 0.9 | 6×10^{-25} |
| <i>KIFC2</i> | Putamen | 16 | 0.99 | 9×10^{-12} |
| <i>KIFC2</i> | Frontal Lobe | 62 | 0.98 | 3×10^{-39} |

| | | | | |
|-----------------|------------------------|------|------|----------------------|
| <i>KIFC2</i> | Parietal Lobe | 17 | 0.98 | 9×10^{-12} |
| <i>KIFC2</i> | Prefrontal Cortex | 46 | 0.98 | 4×10^{-29} |
| <i>KIFC2</i> | Cerebral Cortex | 276 | 0.97 | 6×10^{-162} |
| <i>KIFC2</i> | Entorhinal Cortex | 83 | 0.97 | 7×10^{-50} |
| <i>KIFC2</i> | Temporal Lobe | 91 | 0.97 | 3×10^{-54} |
| <i>KIFC2</i> | Occipital Lobe | 42 | 0.97 | 9×10^{-26} |
| <i>KIFC2</i> | Visual Cortex | 34 | 0.97 | 6×10^{-21} |
| <i>KIFC2</i> | Hippocampus | 55 | 0.96 | 6×10^{-32} |
| <i>KIFC2</i> | Cerebrum | 344 | 0.93 | 4×10^{-168} |
| <i>KIFC2</i> | Hypothalamus | 15 | 0.92 | 2×10^{-8} |
| <i>KIFC2</i> | Thalamus | 16 | 0.88 | 1×10^{-7} |
| <i>KIFC2</i> | Brain | 1274 | 0.82 | 1×10^{-300} |
| <i>KIFC2</i> | Neural Stem Cells | 11 | 0.81 | 3×10^{-4} |
| <i>KIFC2</i> | Central Nervous System | 1302 | 0.81 | 1×10^{-300} |
| <i>KIFC2</i> | Nervous System | 1358 | 0.81 | 7×10^{-300} |
| <i>KIFC2</i> | Substantia Nigra | 22 | 0.8 | 7×10^{-7} |
| <i>MPHOSPH9</i> | Visual Cortex | 34 | 0.82 | 5×10^{-11} |
| <i>MPHOSPH9</i> | Cerebellum | 36 | 0.78 | 3×10^{-9} |
| <i>MPHOSPH9</i> | Neural Stem Cells | 11 | 0.74 | 6×10^{-3} |
| <i>MPHOSPH9</i> | Occipital Lobe | 42 | 0.74 | 1×10^{-7} |
| <i>NPAS2</i> | Prefrontal Cortex | 46 | 0.93 | 3×10^{-24} |
| <i>NPAS2</i> | Frontal Lobe | 62 | 0.91 | 1×10^{-28} |
| <i>NPAS2</i> | Putamen | 16 | 0.9 | 3×10^{-8} |
| <i>NPAS2</i> | Entorhinal Cortex | 83 | 0.85 | 5×10^{-28} |
| <i>NPAS2</i> | Hippocampus | 55 | 0.85 | 6×10^{-19} |
| <i>NPAS2</i> | Cerebral Cortex | 276 | 0.84 | 3×10^{-86} |
| <i>NRXN1</i> | Prefrontal Cortex | 46 | 1 | 2×10^{-31} |
| <i>NRXN1</i> | Cerebellum | 36 | 0.99 | 2×10^{-24} |
| <i>NRXN1</i> | Cerebral Cortex | 276 | 0.99 | 5×10^{-47} |

| | | | | |
|----------------|---------------------|-----|------|----------------------|
| <i>NRXN1</i> | Temporal Lobe | 91 | 0.99 | 5×10^{-58} |
| <i>NRXN1</i> | Entorhinal Cortex | 83 | 0.99 | 5×10^{-53} |
| <i>NRXN1</i> | Occipital Lobe | 42 | 0.99 | 1×10^{-27} |
| <i>NRXN1</i> | Visual Cortex | 34 | 0.98 | 1×10^{-22} |
| <i>NRXN1</i> | Parietal Lobe | 17 | 0.98 | 5×10^{-12} |
| <i>NRXN1</i> | Ganglia | 11 | 0.98 | 4×10^{-8} |
| <i>NRXN1</i> | Thalamus | 16 | 0.97 | 6×10^{-11} |
| <i>NRXN1</i> | Cerebrum | 344 | 0.97 | 4×10^{-195} |
| <i>NRXN1</i> | Mesencephalon | 41 | 0.97 | 6×10^{-25} |
| <i>NRXN1</i> | Putamen | 16 | 0.96 | 1×10^{-11} |
| <i>NRXN1</i> | Substantia Nigra | 22 | 0.96 | 6×10^{-14} |
| <i>NRXN1</i> | Hypothalamus | 15 | 0.96 | 6×10^{-10} |
| <i>NRXN1</i> | Motor Neurons | 12 | 0.95 | 5×10^{-8} |
| <i>NRXN1</i> | Subthalamic Nucleus | 12 | 0.95 | 8×10^{-8} |
| <i>PITPNM2</i> | Frontal Lobe | 62 | 0.88 | 1×10^{-24} |
| <i>PITPNM2</i> | Hippocampus | 55 | 0.87 | 9×10^{-22} |
| <i>PITPNM2</i> | Prefrontal Cortex | 46 | 0.87 | 7×10^{-18} |
| <i>PITPNM2</i> | Putamen | 16 | 0.81 | 1×10^{-5} |
| <i>PITPNM2</i> | Temporal Lobe | 91 | 0.8 | 1×10^{-23} |
| <i>PITPNM2</i> | Cerebral Cortex | 276 | 0.8 | 8×10^{-67} |
| <i>PITPNM2</i> | Entorhinal Cortex | 83 | 0.8 | 8×10^{-21} |
| <i>PITPNM2</i> | Heart Ventricles | 124 | 0.79 | 1×10^{-28} |
| <i>PITPNM2</i> | Hypothalamus | 15 | 0.78 | 2×10^{-4} |
| <i>PITPNM2</i> | Cerebrum | 344 | 0.75 | 3×10^{-56} |
| <i>POU3F2</i> | Neural Stem Cells | 11 | 0.98 | 4×10^{-8} |
| <i>POU3F2</i> | Spinal Cord | 19 | 0.97 | 9×10^{-13} |
| <i>POU3F2</i> | Substantia Nigra | 22 | 0.97 | 2×10^{-14} |
| <i>POU3F2</i> | Visual Cortex | 34 | 0.97 | 5×10^{-21} |
| <i>POU3F2</i> | Prefrontal Cortex | 46 | 0.97 | 6×10^{-28} |
| <i>POU3F2</i> | Occipital Lobe | 42 | 0.97 | 1×10^{-25} |

| | | | | |
|---------------|-----------------------------|-----|------|----------------------|
| <i>POU3F2</i> | Retinal Pigment Epithelium | 12 | 0.97 | 2×10^{-8} |
| <i>POU3F2</i> | Motor Neurons | 12 | 0.97 | 2×10^{-8} |
| <i>POU3F2</i> | Mesencephalon | 41 | 0.96 | 8×10^{-25} |
| <i>POU3F2</i> | Parietal Lobe | 17 | 0.96 | 4×10^{-11} |
| <i>POU3F2</i> | Frontal Lobe | 62 | 0.96 | 4×10^{-36} |
| <i>POU3F2</i> | Cerebral Cortex | 276 | 0.96 | 5×10^{-151} |
| <i>POU3F2</i> | Putamen | 16 | 0.95 | 3×10^{-10} |
| <i>POU3F2</i> | Cerebrum | 344 | 0.95 | 2×10^{-180} |
| <i>POU3F2</i> | Temporal Lobe | 91 | 0.95 | 2×10^{-49} |
| <i>POU3F2</i> | Entorhinal Cortex | 83 | 0.95 | 4×10^{-45} |
| <i>POU3F2</i> | Subthalamic Nucleus | 12 | 0.95 | 9×10^{-8} |
| <i>POU3F2</i> | Hippocampus | 55 | 0.94 | 4×10^{-30} |
| <i>REEP3</i> | Retinal Pigment Epithelium | 12 | 0.96 | 4×10^{-8} |
| <i>REEP3</i> | Neural Stem Cells | 11 | 0.84 | 7×10^{-5} |
| <i>RILPL1</i> | Subthalamic Nucleus | 12 | 0.97 | 2×10^{-8} |
| <i>RILPL1</i> | Substantia Nigra | 22 | 0.96 | 7×10^{-14} |
| <i>RILPL1</i> | Mesencephalon | 41 | 0.96 | 5×10^{-24} |
| <i>RILPL1</i> | Thalamus | 16 | 0.95 | 4×10^{-10} |
| <i>RILPL1</i> | Putamen | 16 | 0.94 | 8×10^{-10} |
| <i>RILPL1</i> | Parietal Lobe | 17 | 0.94 | 4×10^{-10} |
| <i>RILPL1</i> | Temporal Lobe | 91 | 0.93 | 1×10^{-45} |
| <i>RILPL1</i> | Spinal Cord | 19 | 0.93 | 9×10^{-11} |
| <i>RILPL1</i> | Entorhinal Cortex | 83 | 0.93 | 4×10^{-41} |
| <i>RILPL1</i> | Neural Stem Cells | 11 | 0.92 | 1×10^{-6} |
| <i>RILPL1</i> | Cerebral Cortex | 276 | 0.92 | 4×10^{-129} |
| <i>SBNO1</i> | Cerebellum | 36 | 0.87 | 9×10^{-15} |
| <i>SBNO1</i> | Granulocyte Precursor Cells | 30 | 0.86 | 5×10^{-12} |
| <i>SBNO1</i> | Prefrontal Cortex | 46 | 0.82 | 4×10^{-14} |
| <i>SBNO1</i> | Visual Cortex | 34 | 0.8 | 8×10^{-10} |

| | | | | |
|----------------|------------------------|------|------|----------------------|
| <i>SBNO1</i> | Motor Neurons | 12 | 0.76 | 2×10^{-3} |
| <i>SBNO1</i> | Frontal Lobe | 62 | 0.76 | 9×10^{-13} |
| <i>SBNO1</i> | Occipital Lobe | 42 | 0.76 | 7×10^{-9} |
| <i>SLC15A1</i> | Thalamus | 16 | 0.85 | 2×10^{-6} |
| <i>SLC15A1</i> | Putamen | 16 | 0.82 | 1×10^{-5} |
| <i>SLC15A1</i> | Ganglia | 11 | 0.8 | 5×10^{-4} |
| <i>SLC15A1</i> | Subthalamic Nucleus | 12 | 0.74 | 4×10^{-3} |
| <i>SLC15A1</i> | Mesencephalon | 41 | 0.69 | 2×10^{-5} |
| <i>SLC15A1</i> | Substantia Nigra | 22 | 0.69 | 2×10^{-3} |
| <i>SLC15A1</i> | Hypothalamus | 15 | 0.68 | 2×10^{-2} |
| <i>SNRNP35</i> | Visual Cortex | 34 | 0.83 | 2×10^{-11} |
| <i>SNRNP35</i> | Occipital Lobe | 42 | 0.81 | 2×10^{-12} |
| <i>SNRNP35</i> | Subthalamic Nucleus | 12 | 0.76 | 2×10^{-3} |
| <i>SNRNP35</i> | Hypothalamus | 15 | 0.75 | 7×10^{-4} |
| <i>SULT1A2</i> | Hypothalamus | 15 | 0.83 | 9×10^{-6} |
| <i>SULT1A2</i> | Substantia Nigra | 22 | 0.76 | 3×10^{-5} |
| <i>SULT1A2</i> | Ganglia | 11 | 0.75 | 4×10^{-3} |
| <i>TBR1</i> | Prefrontal Cortex | 46 | 0.99 | 1×10^{-30} |
| <i>TBR1</i> | Frontal Lobe | 62 | 0.99 | 2×10^{-40} |
| <i>TBR1</i> | Hippocampus | 55 | 0.92 | 4×10^{-27} |
| <i>TBR1</i> | Parietal Lobe | 17 | 0.89 | 3×10^{-8} |
| <i>TBR1</i> | Cerebral Cortex | 276 | 0.88 | 2×10^{-104} |
| <i>TBR1</i> | Temporal Lobe | 91 | 0.86 | 1×10^{-32} |
| <i>TBR1</i> | Entorhinal Cortex | 83 | 0.85 | 4×10^{-28} |
| <i>TBR1</i> | Subthalamic Nucleus | 12 | 0.81 | 2×10^{-4} |
| <i>TBR1</i> | Cerebrum | 344 | 0.79 | 3×10^{-78} |
| <i>TBR1</i> | Thalamus | 16 | 0.78 | 1×10^{-4} |
| <i>TBR1</i> | Brain | 1274 | 0.75 | 2×10^{-206} |
| <i>TBR1</i> | Central Nervous System | 1302 | 0.75 | 7×10^{-200} |

| | | | | |
|----------------|-------------------|----|------|---------------------|
| <i>TMEM50B</i> | Motor Neurons | 12 | 0.89 | 4×10^{-6} |
| <i>TMEM50B</i> | Thalamus | 16 | 0.87 | 3×10^{-7} |
| <i>TMEM50B</i> | Cerebellum | 36 | 0.87 | 2×10^{-14} |
| <i>TMEM50B</i> | Neural Stem Cells | 11 | 0.84 | 8×10^{-5} |
| <i>TMEM50B</i> | Ganglia | 11 | 0.81 | 4×10^{-4} |
| <i>TMEM50B</i> | Spinal Cord | 19 | 0.78 | 2×10^{-5} |
| <i>TMEM50B</i> | Neurons | 37 | 0.76 | 7×10^{-8} |
| <i>TUFM</i> | Neural Stem Cells | 11 | 0.88 | 1×10^{-5} |
| <i>TUFM</i> | Astrocytes | 12 | 0.71 | 1×10^{-2} |
| <i>VPS28</i> | Neural Stem Cells | 11 | 0.72 | 1×10^{-2} |

Table S15. Implicated candidate genes in cognitive performance associated genomic loci. Table outlines the levels of supportive biological evidence across several annotation analysis – 1) functional SNP annotation (Supplementary Table S9); 2) promising eQTLs in blood (Supplementary Table S10) and brain (Supplementary Table S11); 3) showing relevant coexpression prediction results for reconstituted pathway terms (Supplementary Table S12), mouse phenotypes (Supplementary Table S13) and high site specific expression profiles (Supplementary Table S14). Two last columns give another layer of supportive evidence from literature – A) clustering into modules related to neuronal or central nervous system function (neuronal function; synaptic transmission, neurogenesis, neuropeptide hormone, nerve myelination) constructed using brain derived gene expression profiles (reported in (28)) and B) isolated from the proteasome of human neocortex postsynaptic density [hPSD] (reported in (34)). SNPs rs1487441 and rs1487441 are located in gene deserts, thus the nearest gene is considered for analysis. Only genes with at least one relevant annotation are listed. SNP ID – nominally significant cognitive performance associated variant; * – denotes a gene not annotated within the co-expression database;

| SNP ID | Genes names | nsSNPs | Blood eQTL | Brain eQTL (Prefrontal cortex) | Brain eQTL (Visual cortex) | Brain eQTL (Cerebellum) | Prediction (Brain related functions) | Prediction (Mouse phenotypes) | Region specific expression (Brain) | Modules of neuronal function (Zhang et al) | Postsynaptic density proteome (Bayés et al) | Levels of Evidence |
|-----------|-----------------|--------|------------|--------------------------------|----------------------------|-------------------------|--------------------------------------|-------------------------------|------------------------------------|--|---|--------------------|
| rs1487441 | <i>POU3F2</i> | | | | | | Y | Y | Y | Y | | 4 |
| rs7923609 | <i>JMJD1C</i> | Y | | | | | Y | Y | Y | | | 4 |
| | <i>REEP3</i> | | | | | | | Y | Y | | | 2 |
| rs2721173 | <i>LRRC14</i> | Y | | Y | Y | Y | | Y | | | | 5 |
| | <i>RECQL4</i> | Y | | | | | | | | | | 1 |
| | <i>LRRC24</i> | | Y | | | | na | na | na | | | 1 |
| | <i>MFSD3</i> | | Y | | | | | | | | | 1 |
| | <i>ARHGAP39</i> | | | | | | | Y | Y | | | 2 |
| | <i>GPT</i> | | Y | | | | | | | | | 1 |
| | <i>PPP1R16A</i> | | Y | | | | | | | | | 1 |
| | <i>FOXH1</i> | | | | | | | Y | Y | | | 2 |
| | <i>KIFC2</i> | | | Y | | | Y | Y | Y | Y | | 5 |
| | <i>CYHR1</i> | | | | | | | Y | Y | | | 2 |
| | <i>VPS28</i> | | Y | | | | | | Y | | | 2 |
| | <i>CPSF1</i> | | | | | | | | | Y | | 1 |
| | <i>SCRT1</i> | | | | | | Y | Y | | Y | | 3 |

| | | | | | | | | | | |
|-----------|-----------------|---|---|---|---|-----------|-----------|-----------|-----------|---|
| rs8049439 | <i>ATXN2L</i> | | | | | Y | Y | | | 2 |
| | <i>TUFM</i> | | Y | | | | | Y | | 4 |
| | <i>SH2B1</i> | Y | | | | | | | | 1 |
| | <i>EIF3CL</i> | | | Y | Y | Y | | <i>na</i> | <i>na</i> | 3 |
| | <i>NFATC2IP</i> | | | | | Y | | | Y | 3 |
| | <i>NUPR1</i> | | | | | Y | | Y | | 2 |
| | <i>SPNS1</i> | | Y | | | | | Y | | 2 |
| | <i>LAT</i> | | Y | Y | | | | | | 2 |
| | <i>SULT1A1</i> | | Y | | | | | | | 1 |
| | <i>SULT1A2</i> | | Y | | | | | | Y | 2 |
| | <i>CCDC101</i> | | Y | | | | | | | 1 |
| rs1606974 | <i>NRXN1</i> | | | | | Y | Y | Y | Y | 5 |
| rs2970992 | <i>NPAS2</i> | | | | Y | | | Y | | 2 |
| | <i>NMS</i> | | | | | <i>na</i> | <i>na</i> | <i>na</i> | Y | 1 |
| rs3127447 | <i>KCNMA1</i> | | | | | Y | Y | Y | Y | 4 |
| rs7847231 | <i>DEC1</i> | | | | | | Y | Y | | 2 |
| rs4658552 | <i>SDCCAG8</i> | Y | Y | Y | Y | | | | | 4 |
| | <i>AKT3</i> | | | | | | Y | Y | | 2 |
| rs1892700 | <i>CRYZL1</i> | | | | | Y | Y | Y | | 3 |
| | <i>ITSN1</i> | | Y | | | | Y | Y | Y | 5 |
| | <i>GART</i> | Y | Y | | Y | | | | | 3 |
| | <i>DNAJC28</i> | Y | | Y | | | | | | 2 |
| | <i>TMEM50B</i> | | | Y | Y | Y | | Y | Y | 5 |
| | <i>IFNGR2</i> | | | | Y | Y | | | | 2 |
| rs7980687 | <i>SBNO1</i> | Y | | Y | Y | | | Y | | 4 |
| | <i>SETD8</i> | | Y | | | Y | | | | 2 |
| | <i>RILPL2</i> | | Y | | | | | | | 1 |
| | <i>C12orf65</i> | | | Y | Y | Y | | Y | Y | 5 |
| | <i>MPHOSPH9</i> | | | | | | | Y | | 1 |

| | | | | | | | | |
|-----------|----------------|---|--|---|---|---|---|---|
| | <i>SNRNP35</i> | | | | Y | Y | | 2 |
| | <i>RILPL1</i> | | | | | Y | | 1 |
| | <i>PITPNM2</i> | | | Y | Y | Y | | 3 |
| | <i>TMED2</i> | | | | | | Y | 1 |
| rs1187220 | <i>CELF4</i> | | | Y | Y | Y | | 3 |
| rs3783006 | <i>STK24</i> | Y | | | | | | 1 |
| | <i>FARP1</i> | | | Y | | Y | Y | 3 |
| | <i>SLC15A1</i> | | | | | Y | | 1 |
| rs7309 | <i>TANK</i> | Y | | | | | | 1 |
| | <i>PSMD14</i> | Y | | | | | | 1 |
| | <i>TBR1</i> | | | Y | Y | Y | Y | 4 |

Table S16. Regression of cognitive performance on a polygenic score (*PGS*) in the GS, MCTFR, QIMR, and STR cohorts (coefficients for constructing the *PGS* are from the meta-analysis of cognitive performance, with the meta-analysis sample excluding the respective validation sample). Analyses for GS are based on 1,081 siblings from 476 independent families, analyses for MCTFR are based on 1,346 siblings from 673 independent families, analyses for QIMR are based on 1,426 individuals from 628 independent families, and analyses for STR are based on 810 DZ twins from 405 independent families. ΔR^2 is the incremental R^2 of adding the *PGS* to the regression. The family dummies explain 64.3% of the variance for GS, 72.8% for MCTFR, 68.4% for QIMR, and 77.4% for STR. Standard errors are clustered at the family level. The pooled estimates of are calculated using inverse-variance weighting.

| Analysis | | GS | MCTFR | QIMR | STR | Pooled |
|------------------------|-----------------|--------|--------|--------|--------|-----------------------|
| Without family dummies | Beta | 0.05 | 0.05 | 0.06 | 0.07 | 0.06 |
| | S.E. | 0.04 | 0.03 | 0.03 | 0.04 | 0.02 |
| | <i>p</i> -value | 0.19 | 0.11 | 0.03 | 0.10 | 8.17×10^{-4} |
| | ΔR^2 | 0.0023 | 0.0022 | 0.0041 | 0.0044 | - |
| With family dummies | Beta | -0.05 | 0.05 | 0.03 | 0.08 | 0.03 |
| | S.E. | 0.07 | 0.06 | 0.06 | 0.07 | 0.03 |
| | <i>p</i> -value | 0.41 | 0.36 | 0.61 | 0.26 | 0.36 |
| | ΔR^2 | 0.0007 | 0.0007 | 0.0002 | 0.0015 | - |

Table S17. Simulation Results for Power of Within-Family Analysis

| β [R^2] | Model | Mean($\hat{\beta}$) | Mean(Standard Error) | Power |
|-------------------|------------------------|-----------------------|----------------------|-------|
| 0.045 [0.20%] | Without family dummies | 0.044 | 0.017 | 78.2% |
| | With family dummies | 0.043 | 0.027 | 31.2% |
| 0.065 [0.42%] | Without family dummies | 0.065 | 0.017 | 96.8% |
| | With family dummies | 0.063 | 0.027 | 64.2% |

Table S18. Results from polygenic-score analysis in the Health and Retirement Study. TWR = Total Word Recall, TMS = Total Mental Score, TC = Total Cognition. Standard errors are clustered per individual in the regression and standard errors of the regression coefficients are given in square brackets below the regression coefficients. The regressions for Δ TMS and Δ TC have the knots of the age spline at 70 and 80 and do not include person-wave observations with age < 60. * $p < 0.05$; ** $p < 0.01$. ΔR^2 denotes the increase in R^2 of a model with the score, and score interactions if applicable, compared to a model with only the age spline and sex.

| | (1) TWR | (2) TWR | (3) TMS | (4) TMS | (5) TC | (6) TC | (7) Δ TWR | (8) Δ TWR | (9) Δ TMS | (10) Δ TMS | (11) Δ TC | (12) Δ TC |
|---------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|----------------------|---------------------|---------------------|
| Score | 0.040** [0.007] | 0.047** [0.010] | 0.062** [0.010] | 0.072** [0.012] | 0.057** [0.009] | 0.075** [0.012] | -0.003 [0.002] | -0.005 [0.004] | -0.002 [0.004] | -0.008 [0.006] | -0.001 [0.004] | -0.006 [0.007] |
| Age < 60 | -0.006** [0.002] | -0.006** [0.002] | -0.006* [0.003] | -0.006* [0.003] | -0.007** [0.002] | -0.007** [0.002] | -0.002 [0.001] | -0.002 [0.001] | | | | |
| Age 60-69 | -0.037** [0.002] | -0.037** [0.002] | -0.004* [0.002] | -0.004* [0.002] | -0.031** [0.002] | -0.031** [0.002] | -0.006** [0.001] | -0.006** [0.001] | -0.013* [0.006] | -0.013* [0.006] | -0.023** [0.006] | -0.023** [0.006] |
| Age 70-79 | -0.051** [0.002] | -0.051** [0.002] | -0.018** [0.003] | -0.018** [0.003] | -0.047** [0.003] | -0.047** [0.003] | -0.005** [0.001] | -0.005** [0.001] | -0.007** [0.002] | -0.007** [0.002] | -0.006** [0.002] | -0.006** [0.002] |
| Age \geq 80 | -0.056** [0.004] | -0.056** [0.004] | -0.053** [0.007] | -0.053** [0.007] | -0.066** [0.006] | -0.067** [0.006] | -0.006** [0.002] | -0.006** [0.002] | -0.019** [0.003] | -0.019** [0.003] | -0.015** [0.002] | -0.015** [0.002] |
| Female | 0.345** [0.015] | 0.344** [0.015] | -0.169** [0.019] | -0.169** [0.019] | 0.199** [0.019] | 0.198** [0.019] | 0.002 [0.005] | 0.002 [0.005] | -0.018* [0.009] | -0.018* [0.009] | -0.011 [0.008] | -0.011 [0.008] |
| Age 60-69 \times score | | 0.000 [0.002] | | -0.002 [0.002] | | -0.002 [0.002] | | 0.000 [0.001] | | | | |
| Age 70-79 \times score | | -0.001 [0.003] | | 0.002 [0.003] | | 0.000 [0.003] | | 0.001 [0.001] | | 0.002 [0.001] | | 0.002 [0.001] |
| Age \geq 80 \times score | | -0.008* [0.004] | | -0.004 [0.006] | | -0.008 [0.005] | | -0.004* [0.002] | | -0.003 [0.002] | | -0.005* [0.002] |
| Constant | 0.107 [0.124] | 0.108 [0.124] | 0.764** [0.151] | 0.764** [0.151] | 0.533** [0.143] | 0.534** [0.143] | 0.154* [0.072] | 0.155* [0.071] | 1.008** [0.381] | 1.006** [0.381] | 1.620** [0.395] | 1.619** [0.395] |
| N , person-wave | 49,988 | 49,988 | 32,289 | 32,289 | 32,289 | 32,289 | 40,744 | 40,744 | 20,781 | 20,781 | 20,781 | 20,781 |
| N , persons | 8,652 | 8,652 | 8,539 | 8,539 | 8,539 | 8,539 | 8,543 | 8,543 | 5,248 | 5,248 | 5,248 | 5,248 |
| R^2 | 0.164 | 0.164 | 0.038 | 0.038 | 0.135 | 0.135 | 0.002 | 0.002 | 0.005 | 0.005 | 0.000 | 0.000 |
| ΔR^2 | 0.002 | 0.002 | 0.004 | 0.004 | 0.003 | 0.004 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |

Table S19. Results from polygenic-score analysis in the Health and Retirement Study with years of education added as a control variable. TWR = Total Word Recall, TMS = Total Mental Score, TC = Total Cognition. Standard errors are clustered per individual in the regression and standard errors of the regression coefficients are given in square brackets below the regression coefficients. The regressions for Δ TMS and Δ TC have the knots of the age spline at 70 and 80 and do not include person-wave observations with age < 60. * $p < 0.05$; ** $p < 0.01$. ΔR^2 denotes the increase in R^2 of a model with the score, and score interactions if applicable, compared to a model with only the age spline and sex.

| | (1) | (2) | (3) | (4) | (5) | (6) | (7) | (8) | (9) | (10) | (11) | (12) |
|------------------------------|----------|----------|----------|----------|----------|----------|--------------|--------------|--------------|--------------|-------------|-------------|
| | TWR | TWR | TMS | TMS | TC | TC | Δ TWR | Δ TWR | Δ TMS | Δ TMS | Δ TC | Δ TC |
| Score | 0.014* | 0.022* | 0.031** | 0.043** | 0.024** | 0.045** | -0.002 | -0.005 | -0.003 | -0.010 | -0.002 | -0.007 |
| | [0.007] | [0.009] | [0.009] | [0.012] | [0.008] | [0.011] | [0.002] | [0.004] | [0.004] | [0.006] | [0.004] | [0.007] |
| Age < 60 | -0.003 | -0.003 | -0.000 | -0.000 | -0.001 | -0.001 | -0.002 | -0.002 | | | | |
| | [0.002] | [0.002] | [0.003] | [0.002] | [0.002] | [0.002] | [0.001] | [0.001] | | | | |
| Age 60-69 | -0.032** | -0.032** | -0.002 | -0.002 | -0.029** | -0.029** | -0.006** | -0.006** | -0.013* | -0.013* | -0.023** | -0.023** |
| | [0.002] | [0.002] | [0.002] | [0.002] | [0.002] | [0.002] | [0.001] | [0.001] | [0.006] | [0.006] | [0.006] | [0.006] |
| Age 70-79 | -0.050** | -0.050** | -0.016** | -0.016** | -0.045** | -0.045** | -0.005** | -0.005** | -0.007** | -0.007** | -0.006** | -0.006** |
| | [0.002] | [0.002] | [0.003] | [0.003] | [0.003] | [0.003] | [0.001] | [0.001] | [0.002] | [0.002] | [0.002] | [0.002] |
| Age \geq 80 | -0.054** | -0.054** | -0.051** | -0.051** | -0.064** | -0.064** | -0.006** | -0.006** | -0.019** | -0.019** | -0.015** | -0.015** |
| | [0.004] | [0.004] | [0.007] | [0.006] | [0.006] | [0.005] | [0.002] | [0.002] | [0.003] | [0.003] | [0.002] | [0.002] |
| Female | 0.392** | 0.391** | -0.109** | -0.109** | 0.261** | 0.261** | 0.002 | 0.002 | -0.015 | -0.015 | -0.010 | -0.010 |
| | [0.014] | [0.014] | [0.018] | [0.018] | [0.017] | [0.017] | [0.005] | [0.005] | [0.009] | [0.009] | [0.008] | [0.008] |
| Years of education | 0.101** | 0.101** | 0.120** | 0.120** | 0.127** | 0.127** | 0.000 | 0.000 | 0.004* | 0.004* | 0.001 | 0.001 |
| | [0.003] | [0.003] | [0.004] | [0.004] | [0.004] | [0.004] | [0.001] | [0.001] | [0.002] | [0.002] | [0.002] | [0.002] |
| Age 60-69 \times score | | -0.000 | | -0.002 | | -0.002 | | 0.000 | | | | |
| | | [0.002] | | [0.002] | | [0.002] | | [0.001] | | | | |
| Age 70-79 \times score | | -0.002 | | 0.002 | | -0.000 | | 0.001 | | 0.002 | | 0.002 |
| | | [0.002] | | [0.003] | | [0.003] | | [0.001] | | [0.001] | | [0.001] |
| Age \geq 80 \times score | | -0.007 | | -0.004 | | -0.007 | | -0.004* | | -0.003 | | -0.005* |
| | | [0.004] | | [0.006] | | [0.005] | | [0.002] | | [0.002] | | [0.002] |
| Constant | -1.513** | -1.512** | -1.270** | -1.270** | -1.622** | -1.621** | 0.149* | 0.149* | 0.950* | 0.948* | 1.637** | 1.636** |
| | [0.124] | [0.124] | [0.158] | [0.158] | [0.146] | [0.146] | [0.074] | [0.074] | [0.386] | [0.386] | [0.399] | [0.399] |
| N , person-wave | 49,827 | 49,827 | 32,204 | 32,204 | 32,204 | 32,204 | 40,622 | 40,622 | 20,737 | 20,737 | 20,737 | 20,737 |
| N , persons | 8,615 | 8,615 | 8,504 | 8,504 | 8,504 | 8,504 | 8,506 | 8,506 | 5,235 | 5,235 | 5,235 | 5,235 |
| R^2 | 0.225 | 0.225 | 0.128 | 0.128 | 0.236 | 0.236 | 0.002 | 0.002 | 0.005 | 0.005 | 0.005 | 0.005 |
| ΔR^2 | 0.000 | 0.000 | 0.001 | 0.001 | 0.001 | 0.001 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |

Table S20. Power of GWAS on cognitive performance vs. candidate-SNP method in our Cognitive Performance Sample ($N = 24,189$)

| | Effect size of SNP on cognitive performance (in R^2) | | | |
|--------------------------------------|---|-------|-------|-------|
| | 0.02% | 0.04% | 0.06% | 0.08% |
| GWAS ($\alpha = 5 \times 10^{-8}$) | 0.06% | 1% | 5% | 15% |
| Candidate-SNP ($\alpha = .00072$) | 12% | 39% | 67% | 85% |

Source: Authors' calculations using (22).

Table S21. Ex ante calculations of the expected number of true positive results, given alternative thresholds of including SNPs associated with educational attainment (EA) in the second stage on cognitive performance. Calculations are based on the actual sample sizes for EA in stage 1 ($N = 106,703$) and for cognitive performance in stage 2 ($N = 24,189$). The calculations assume that the effect of a SNP that is truly associated with EA only operates through cognitive performance and no other mediating factor. Under this assumption, the effect size of an EA-associated SNP would be attenuated by the imperfect correlation between EA and cognitive performance (see SI Appendix section 15). (1) and (2) are based on actual results of the stage 1 GWAS, after pruning SNPs for LD (the HapMap 2 CEU genotypes were used as reference panel; the physical threshold for clumping was 1000 kB, and the R^2 threshold for clumping was 0.01). Power in (3) and (7) was calculated using G*Power 3.1 (48, 49). Posterior beliefs in row (4) are calculated using Bayes' formula (21), with prior beliefs equal to 0.01%, power equal to (3), and α equal to the respective p -value threshold of the column. (5) results from dividing the family-wide significance level of 0.05 by (1). (6) results from dividing (2) by the assumed phenotypic correlation between EA and cognitive performance (0.6). (8) reports the expected number of true positives in the second stage by multiplying (1) \times (4) \times (7). (9) is calculated using Bayes' formula (21), with prior beliefs equal to (4), power equal to (7), and α equal to (5). Note that the available sample size for stage 2 and the assumed correlation between EA and cognitive performance only affect the absolute values in (8), whereas the p -value threshold that maximizes (8) depends only on the results of the first-stage GWAS.

| | | <i>p</i> -value threshold for including EA-associated SNPs in the second stage analyses on cognitive performance | | | | | | |
|---|--|--|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| | | 5×10^{-8} | 1×10^{-7} | 1×10^{-6} | 1×10^{-5} | 1×10^{-4} | 1×10^{-3} | 1×10^{-2} |
| <i>Results of stage 1</i> | | | | | | | | |
| (1) | Number of EA-associated candidate SNPs | 3 | 4 | 15 | 69 | 198 | 891 | 3,013 |
| (2) | Avg R^2 of SNPs with EA | 2.80×10^{-4} | 2.73×10^{-4} | 2.33×10^{-4} | 1.98×10^{-4} | 1.65×10^{-4} | 1.25×10^{-4} | 9.11×10^{-5} |
| (3) | Ex-post power (two-sided) in first stage | 55% | 52% | 52% | 57% | 62% | 64% | 71% |
| (4) | Posterior belief that a candidate SNP from (1) is truly associated with EA | 99.9% | 99.8% | 98.1% | 85.1% | 38.3% | 6.0% | 0.7% |
| <i>Ex-ante expectations for stage 2</i> | | | | | | | | |
| (5) | Bonferroni-adjusted p -value for second stage | 1.67×10^{-2} | 1.25×10^{-2} | 3.33×10^{-3} | 7.25×10^{-4} | 2.53×10^{-4} | 5.61×10^{-5} | 1.66×10^{-5} |
| (6) | Expected avg R^2 of SNPs in second stage given (2) | 7.77×10^{-4} | 7.59×10^{-4} | 6.46×10^{-4} | 5.51×10^{-4} | 4.57×10^{-4} | 3.47×10^{-4} | 2.53×10^{-4} |
| (7) | Expected power (two-sided) in second stage given (5) and (6) | 97.4% | 96.3% | 84.6% | 60.7% | 36.9% | 12.9% | 3.3% |
| (8) | Expected true positives second stage | 3 | 4 | 12 | 36 | 28 | 7 | 7 |
| (9) | Posterior belief (true significant), using the p -value threshold of (5) | 100% | 100% | 100% | 100% | 99.9% | 99.5% | 99.5% |

Additional Notes

1. Author contributions

Daniel Benjamin, David Cesarini, and Philipp Koellinger conceived and designed the study and organized the SSGAC consortium. Cornelius Rietveld performed the selection of education-associated SNPs and together with Gail Davies he also performed the quality control and meta-analyses of cohort-specific GWAS results. Anna Vinkhuyzen contributed to the interpretation of the meta-analysis results. The CHIC consortium was organized by George Davey Smith, Ian Deary, Robert Plomin and Peter Visscher. Beben Benyamin and Peter Visscher provided the CHIC meta-analysis results. Patrick Turley developed the correction of effect sizes for the winner's curse and the power calculations for the HRS polygenic score analyses. Christopher Chabris and Olga Rostapshova performed the selection of theory-based candidate SNPs. Daniel Benjamin conducted the Bayesian analysis of the credibility of the SNP associations. Cornelius Rietveld performed the polygenic score analyses in the HRS. Riccardo Marioni, Sarah Medland, Michael Miller, and Cornelius Rietveld performed the polygenic score analyses in the family samples. Tõnu Esko, Valur Emilsson, Rudolf Fehrmann, Lude Franke, Andrew Johnson, Juha Karjalainen and Tune Pers conducted the biological annotation. Daniel Benjamin, David Cesarini, Philipp Koellinger and Cornelius Rietveld wrote the first draft of the manuscript. Daniel Benjamin, David Cesarini, Tõnu Esko, Philipp Koellinger, Cornelius Rietveld and Patrick Turley all wrote substantial portions of the supplementary materials. Cornelius Rietveld prepared most of the tables and figures in the main text and supplementary materials. Christopher Chabris, Ian Deary, Robert Plomin, Vincent Jaddoe, Magnus Johannesson, David Laibson, Steven Pinker, Henning Tiemeier, Nicholas Timpson, Peter Visscher and Mary Ward critically reviewed and edited the manuscript.

2. Cohort-specific contributions

| Cohort | Author | Overseeing (PI) | Genotyping | Phenotyping | Data analysis |
|--------|-----------------------|-----------------|------------|-------------|---------------|
| ALSPAC | George Davey Smith | X | | | |
| | Nicholas Timpson | | X | X | |
| | George McMahon | | | | X |
| | Mary Ward | | | | X |
| ERF | Sven van der Lee | | | | X |
| | Carla Ibrahim-Verbaas | | | | X |
| | Najaf Amin | | | | X |
| | André Uitterlinden | | X | | |
| GenR | Cornelia van Duijn | X | X | X | |
| | Henning Tiemeier | X | | X | |
| | Vincent Jaddoe | X | X | | |
| | Christiaan De Leeuw | | | | X |
| | Danielle Posthuma | X | | | X |
| | Frank Verhulst | X | | | |
| GS | Fernando Rivadeneira | | X | | |
| | Blair Smith | | | X | |
| | David Porteous | | X | X | |
| | Caroline Hayward | | X | | |
| HU | Riccardo Marioni | | | | X |
| | James Lee | | X | X | X |
| | Steven Pinker | X | | | |
| | Christopher Chabris | X | | | |
| | David Laibson | X | | | |
| LBC | Edward Glaeser | X | | | |
| | Gail Davies | | X | | X |
| | David Liewald | | X | | X |
| | | | | | |

| | | | | | |
|-------|--------------------|---|---|---|---|
| MCTFR | John Starr | X | | X | |
| | Ian Deary | X | | X | |
| | Michael B. Miller | | X | X | X |
| | Matt McGue | X | | | |
| | William G. Iacono | X | | | |
| QIMR | Jaime Derringer | | | | X |
| | Sarah Medland | | | | X |
| | Margaret Wright | X | | X | |
| | Narelle Hansell | | | X | X |
| STR | Nicholas Martin | X | X | | |
| | Patrik Magnusson | | X | X | X |
| | Nancy Pedersen | X | | | |
| | Paul Lichtenstein | X | | | |
| | Magnus Johannesson | X | | X | X |
| TEDS | Cornelius Rietveld | | | | X |
| | David Cesarini | | | | X |
| | Robert Plomin | X | | | |
| | Maciej Trzaskowski | | | | X |

3. Additional acknowledgements

The authors of this article are grateful to the Social Science Genetic Association Consortium (<http://www.ssgac.org>) for providing the meta-analysis data on educational attainment. In particular, we thank: Abdel Abdellaoui, Arpana Agrawal, Eva Albrecht, Behrooz Z. Alizadeh, Jüri Allik, John R. Attia, Stefania Bandinelli, John Barnard, François Bastardot, Sebastian E. Baumeister, Jonathan Beauchamp, Kelly S. Benke, David A. Bennett, Klaus Berger, Lawrence F. Bielak, Laura J. Bierut, Jeffrey A. Boatman, Dorret I. Boomsma, Patricia A. Boyle, Ute Bültmann, Harry Campbell, Lynn Cherkas, Mina K. Chung, Francesco Cucca, Mariza de Andrade, Philip L. De Jager, Jan-Emmanuel De Neve, George V. Dedoussis, Panos Deloukas, Maria Dimitriou, Gudny Eiriksdottir, Niina Eklund, Martin F. Elderson, Johan G. Eriksson, Daniel S. Evans, David M. Evans, Jessica D. Faul, Luigi Ferrucci, Krista Fischer, Melissa E. Garcia, Christian Gieger, Håkon K. Gjessing, Patrick J.F. Groenen, Henrik Grönberg, Vilmundur Gudnason, Sara Hägg, Per Hall, Jennifer R. Harris, Juliette M. Harris, Tamara B. Harris, Nicholas D. Hastie, Andrew C. Heath, Dena G. Hernandez, Wolfgang Hoffmann, Adriaan Hofman, Albert Hofman, Rolf Holle, Elizabeth G. Holliday, Christina Holzapfel, Jouke-Jan Hottenga, Min A. Jhun, Thomas Illig, Erik Ingelsson, Bo Jacobsson, Marjo-Riitta Järvelin, Peter K. Joshi, Astanand Jugessur, Marika Kaakinen, Mika Kähönen, Stavroula Kanoni, Jaakkko Kaprio, Sharon L.R. Kardina, Robert M. Kirkpatrick, Ivana Kolcic, Matthew Kowgier, Kati Kristiansson, Robert F. Krueger, Zoltan Kutalik, Jari Lahti, Antti Latvala, Lenore J. Launer, Debbie A. Lawlor, Sang H. Lee, Terho Lethimäki, Jingmei Li, Peter K. Lichtner, Peng Lin, Penelope A. Lind, Yongmei Liu, Kurt Lohman, Marisa Loitfelder, Pamela A. Madden, Tomi E. Mäkinen, Pedro Marques Vidal, Nicolas W. Martin, Marco Masala, Osorio Meirelles, Andres Metspalu, Michelle N. Meyer, Andreas Mielck, Lili Milani, Grant W. Montgomery, Sutapa Mukherjee, Ronny Myhre, Marja-Liisa Nuotio, Dale R. Nyholt, Christopher J. Oldmeadow, Ben A. Oostra, Lyle J. Palmer, Aarno Palotie, Brenda Penninx, Markus Perola, Katja E. Petrovic, Wouter J. Peyrot, Patricia A. Peyser, Ozren Polašek, Martin Preisig, Lydia Quaye, Katri Räikkönen, Olli T. Raitakari, Anu Realo, Eva Reinmaa, John P. Rice, Susan M. Ring, Samuli Ripatti, Thais S. Rizzi, Igor Rudan, Aldo Rustichini, Veikko Salomaa, Antti-Pekka Sarin, David Schlessinger, Helena Schmidt, Reinhold Schmidt, Rodney J. Scott, Konstantin Shakhbazov, Albert V. Smith, Jennifer A. Smith, Harold Snieder, Beate St Pourcain, Jae Hoon Sul, Ida Surakka, Rauli Svento, Toshiko Tanaka, Antonio Terracciano, Alexander Teumer, A. Roy Thurik, Matthijs J.H.M. van der Loos, Frank J.A. van Rooij, David R. Van Wagoner, Erkki Vartiainen, Jorma Viikari, Veronique Vitart, Peter K. Vollenweider, Henry Völzke, Judith M. Vonk, Gérard Waeber, David R. Weir, Jürgen Wellmann, Harm-Jan Westra, H.-Erich Wichmann, Elisabeth Widen, Gonneke Willemsen, James F. Wilson, Alan F. Wright, Jian Yang, Lei Yu, Wei Zhao.

ALSPAC (Avon Longitudinal Study of Parents and Children) – We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The UK Medical Research Council and the Wellcome Trust (Grant ref: 092731) and the University of Bristol provide core support for ALSPAC. The MRC Integrative Epidemiology Unit is supported by the UK Medical Research Council and University of Bristol Integrative Epidemiology Unit MC_UU_12013/1-9.

ERF (Erasmus Rucphen Family Study) – The ERF study as a part of EUROSPAN (European Special Populations Research Network) was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947) and also received funding from the European Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413 by the European Commission under the programme “Quality of Life and Management of the Living Resources” of 5th Framework Programme (no. QLG2-CT-2002-01254). The ERF study was further supported by ENGAGE consortium and CMSB. High-throughput analysis of the ERF data was supported by joint grant from Netherlands Organisation for Scientific Research and the Russian Foundation for Basic Research (NWO-RFBR 047.017.043). We are grateful to all study participants and their relatives, general practitioners and neurologists for their contributions and to P. Veraart for her help in genealogy, J. Vergeer for the supervision of the laboratory work and P. Snijders for his help in data collection.

GenR (Generation R) – The Generation R Study is conducted by the Erasmus Medical Center, Rotterdam in close collaboration with the Erasmus University Rotterdam, the Municipal Health Service Rotterdam area, the Rotterdam Homecare Foundation and the Stichting Trombosedienst & Artsenlaboratorium Rijnmond (STAR), Rotterdam. The authors wish to thank the parents and children that participate in the Generation R Study. The Generation R Study is made possible by financial support from the Erasmus Medical Center, Rotterdam, the Erasmus University Rotterdam, and the Netherlands Organization for Health Research and Development (ZonMw grant numbers 10.000.1003); the present study was supported by an additional grant from the Sophia Foundation for Scientific Research (SSWO; grant 547, 2008) and a VIDI grant to HT from the Netherlands Organization for Scientific Research (NWO; grant number 017.106.370). DP gratefully acknowledges financial support from the Netherlands Organization for Scientific Research (NWO/MaGW VIDI 016-065-318 and NWO/NIHC 433-09-228). CdL gratefully acknowledges financial support from the Netherlands Organization for Scientific Research (NWO Complexity project 645.000.003).

GS (Generation Scotland) – Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006). We are grateful to all the families who took part, the general practitioners and the Scottish School of Primary Care for their help in recruiting them, and the whole Generation Scotland team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, healthcare assistants and nurses. Genotyping of Generation Scotland was funded by the Medical Research Council UK and carried out at the Wellcome Trust Clinical Research Facility at the Western General Hospital, Edinburgh.

HRS (Health and Retirement Study) – HRS is supported by the National Institute on Aging (NIA U01AG009740). The genotyping was funded as a separate award from the National Institute on Aging (RC2 AG036495). Our genotyping was conducted by the NIH Center for Inherited Disease Research (CIDR) at Johns Hopkins University. Genotyping quality control and final preparation of the data were performed by the Genetics Coordinating Center at the University of Washington. HRS genotype data have been deposited in the NIH GWAS repository (dbGaP).

HU (Harvard/Union Study) – This study was supported by the authors’ research funds and a grant from the National Institute on Aging to the National Bureau of Economic Research (T32-AG00186).

LBC 1921 and 1936 (Lothian Birth Cohorts of 1921 and 1936) – We thank the cohort participants and team members who contributed to these studies. Phenotype collection in the Lothian Birth Cohort 1921 was supported by the BBSRC, The Royal Society and The Chief Scientist Office of the Scottish Government. Phenotype collection in the Lothian Birth Cohort 1936 was supported by Age UK (The Disconnected Mind project). Genotyping of the cohorts was funded by the UK Biotechnology and Biological Sciences Research Council (BBSRC). The work was undertaken by The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (MR/K026992/1). Funding from the BBSRC and Medical Research Council is gratefully acknowledged.

MCTFR (Minnesota Center for Twin and Family Research) – The Minnesota Center for Twin and Family Research (MCTFR) is supported by USPHS Grants from the National Institute on Alcohol Abuse and Alcoholism (AA09367 and AA11886), the National Institute on Drug Abuse (DA05147, DA13240, and DA024417), and the National Institute on Mental Health (MH066140). Jaime Derringer was supported by NIH grants DA029377 and MH016880.

STR (Swedish Twin Registry) – The Jan Wallander and Tom Hedelius Foundation, the Ragnar Söderberg Foundation, the Swedish Council for Working Life and Social Research, the Ministry for Higher Education, the Swedish Research Council (M-2005-1112), GenomEUtwin (EU/QLRT-2001-01254; QLG2-CT-2002-01254), NIH DK U01-066134, The Swedish Foundation for Strategic Research (SSF), the Heart and Lung foundation no. 20070481.

TEDS (Twins Early Development Study) – The Twins Early Development Study (TEDS) is supported by a program grant to RP from the UK Medical Research Council [G0901245 and previously G0500079], with additional support from the US National Institutes of Health [HD044454; HD059215]. Genome-wide genotyping was made possible by a grant from the Wellcome Trust to the Wellcome Trust Case Control Consortium 2 project [085475/B/08/Z; 085475/Z/08/Z].

References

1. Rietveld CA et al. (2013) GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. *Science* 340:1467–1471.
2. Davies G et al. (2014) A genome-wide association study implicates the APOE locus in nonpathological cognitive ageing. *Mol Psychiatry* 19:76–87.
3. Harold D et al. (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. *Nat Genet* 41:1088–93.
4. Lambert J-C et al. (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. *Nat Genet* 45:1–9.
5. Schellenberg GD, Montine TJ (2012) The genetics and neuropathology of Alzheimer’s disease. *Acta Neuropathol* 124:305–23.
6. Wisdom NM, Callahan JL, Hawkins KA (2011) The effects of apolipoprotein E on non-impaired cognitive functioning: A meta-analysis. *Neurobiol Aging* 32:63–74.
7. Benjamin B et al. (2014) Childhood intelligence is heritable, highly polygenic and associated with FBNP1L. *Mol Psychiatry* 19:253–258.
8. Liu F et al. (2010) The apolipoprotein E gene and its age-specific effects on cognitive function. *Neurobiol Aging* 31:1831–1833.
9. Smith BH et al. (2013) Cohort Profile: Generation Scotland: Scottish Family Health Study (GS:SFHS). The study, its participants and their potential for genetic research on health and illness. *Int J Epidemiol* 42:689–700.
10. Bors DA, Stokes TL (1998) Raven’s advanced progressive matrices: Norms for first-year university students and the development of a short form. *Educ Psychol Meas* 58:382–398.
11. Carlstedt B (2000) *Cognitive Abilities: Aspects of Structure, Process and Measurement* (Acta Universitatis Gothoburgensis, Göteborg, Sweden).
12. Wechsler D (1992) *Wechsler intelligence scale for children* (Psychological Corporation, London). 3rd Ed.
13. Raven JC, Court JH, Raven J (1996) *Manual for Raven’s Progressive Matrices and Vocabulary Scales* (Oxford University Press).
14. Devlin B, Roeder K (1999) Genomic control for association studies. *Biometrics* 55:997–1004.

15. Willer CJ, Li Y, Abecasis GR (2010) METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* 26:2190–2191.
16. Ghosh A, Zou F, Wright FA (2008) Estimating odds ratios in genome scans: An approximate conditional likelihood approach. *Am J Hum Genet* 82:1064–1074.
17. Zöllner S, Pritchard JK (2007) Overcoming the winner's curse: Estimating penetrance parameters from case-control data. *Am J Hum Genet* 80:605–615.
18. Xu L, Craiu R V., Sun L (2011) Bayesian methods to overcome the winner's curse in genetic studies. *Ann Appl Stat* 5:201–231.
19. Goddard ME, Wray NR, Verbyla K, Visscher PM (2009) Estimating effects and making predictions from genome-wide marker data. *Stat Sci* 24:517–529.
20. Ioannidis JPA, Ioannidis (2005) Why most published research findings are false. *PLoS Med* 2:e124.
21. Benjamin DJ et al. (2012) The promises and pitfalls of genoeconomics. *Annu Rev Econom* 4:627–662.
22. Purcell S, Cherny SS, Sham PC (2003) Genetic Power Calculator : design of linkage and association genetic mapping studies of complex traits. *Bioinformatics* 19:149–150.
23. Davies G et al. (2011) Genome-wide association studies establish that human intelligence is highly heritable and polygenic. *Mol Psychiatry* 16:996–1005.
24. Chabris CF et al. (2012) Most reported genetic associations with general intelligence are probably false positives. *Psychol Sci* 23:1314–1323.
25. International T, Consortium H (2005) A haplotype map of the human genome. *Nature* 437:1299–320.
26. Casella G, Berger RL (2002) *Statistical Inference* (Duxbury Press, Pacific Grove)2nd editio.
27. Westra H-J et al. (2011) MixupMapper: correcting sample mix-ups in genome-wide datasets increases power to detect small genetic effects. *Bioinformatics* 27:2104–2111.
28. Zhang B et al. (2013) Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. *Cell* 153:707–20.
29. Cvejic A et al. (2013) SMIM1 underlies the Vel blood group and influences red blood cell traits. *Nat Genet* 45:542–545.

30. Edgar R (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res* 30:207–210.
31. Croft D et al. (2011) Reactome: a database of reactions, pathways and biological processes. *Nucleic Acids Res* 39:D691–697.
32. Raychaudhuri S et al. (2009) Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions. *PLoS Genet* 5:e1000534.
33. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M (2012) KEGG for integration and interpretation of large-scale molecular data sets. *Nucleic Acids Res* 40:D109–14.
34. Bayés A et al. (2011) Characterization of the proteome, diseases and evolution of the human postsynaptic density. *Nat Neurosci* 14:19–21.
35. Liang K-Y, Zeger SL (1986) Longitudinal data analysis using generalized linear models. *Biometrika* 73:13–22.
36. Juster TF, Suzman R (1995) An overview of the Health and Retirement Study. *J Hum Resour* 20:7–56.
37. Purcell SM et al. (2009) Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* 460:748–752.
38. Lachman M, Spiro A (2002) Critique of Cognitive Measures in the Health Retirement Study (HRS) and the Asset and Health Dynamics among the Oldest Old (AHEAD) Study. Available at: [http://www.researchgate.net/publication/242096659_Critique_of_Cognitive_Measures_in_the_Health_Retirement_Study_\(HRS\)_and_the_Asset_and_Health_Dynamics_among_the_Oldest_Old_\(AHEAD\)_Study/file/9c96052869f0bd6f6a.pdf](http://www.researchgate.net/publication/242096659_Critique_of_Cognitive_Measures_in_the_Health_Retirement_Study_(HRS)_and_the_Asset_and_Health_Dynamics_among_the_Oldest_Old_(AHEAD)_Study/file/9c96052869f0bd6f6a.pdf).
39. McCarthy MI et al. (2008) Genome-wide association studies for complex traits: consensus, uncertainty and challenges. *Nat Rev Genet* 9:356–369.
40. Calvin C et al. (2012) Multivariate genetic analyses of cognition and academic achievement from two population samples of 174,000 and 166,000 school children. *Behav Genet* 42:699–710.
41. Deary IJ, Strand S, Smith P, Fernandes C (2007) Intelligence and educational achievement. *Intelligence* 35:13–21.
42. Fraser A et al. (2012) Cohort Profile: The Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. *Int J Epidemiol* 42:97–110.

43. Slegers K et al. (2007) Cerebrovascular risk factors do not contribute to genetic variance of cognitive function: The ERF study. *Neurobiol Aging* 28:735–741.
44. Tiemeier H et al. (2012) The Generation R Study: A review of design, findings to date, and a study of the 5-HTTLPR by environmental interaction from fetal life onward. *J Am Acad Child Adolesc Psychiatry* 51:1119–1135.e7.
45. Kerr SM et al. (2013) Pedigree and genotyping quality analyses of over 10,000 DNA samples from the Generation Scotland: Scottish Family Health Study. *BMC Med Genet* 14:38.
46. Chabris CF et al. (2013) Why is it hard to find genes that are associated with social science traits? Theoretical and empirical considerations. *Am J Public Health* 103:S152–S166.
47. Deary IJ, Whiteman MC, Starr JM, Whalley LJ, Fox HC (2004) The impact of childhood intelligence on later life: Following up the Scottish mental surveys of 1932 and 1947. *J Pers Soc Psychol* 86:130–147.
48. Deary I et al. (2007) The Lothian Birth Cohort 1936: a study to examine influences on cognitive ageing from age 11 to age 70 and beyond. *BMC Geriatr* 7:28.
49. Miller MB et al. (2012) The Minnesota Center for Twin and Family Research Genome-Wide Association Study. *Twin Res Hum Genet* 15:767.
50. Wright MJ, Martin NG (2004) Brisbane Adolescent Twin Study: Outline of study methods and research projects. *Aust J Psychol* 56:65–78.
51. Newnham JP, Evans SF, Michael CA, Stanley FJ, Landau LI (1993) Effects of frequent ultrasound during pregnancy: a randomised controlled trial. *Lancet* 342:887–891.
52. Magnusson PKE et al. (2013) The Swedish Twin Registry: Establishment of a Biobank and Other Recent Developments. *Twin Res Hum Genet* 16:317.
53. Oliver BR, Plomin R (2007) Twins' Early Development Study (TEDS): A Multivariate, Longitudinal Genetic Investigation of Language, Cognition and Behavior Problems from Childhood Through Adolescence. *Twin Res Hum Genet* 10:96–105.

POU3F2

| Term | P-value | Annotated |
|--|----------|-----------|
| central nervous system neuron differentiation | 2,91E-28 | N |
| forebrain generation of neurons | 4,05E-22 | N |
| forebrain neuron differentiation | 3,08E-21 | N |
| telencephalon development | 5,79E-19 | Y |
| forebrain development | 5,25E-18 | Y |
| negative regulation of gliogenesis | 9,08E-18 | N |
| astrocyte differentiation | 1,02E-17 | Y |
| negative regulation of glial cell differentiation | 2,91E-17 | N |
| brain development | 1,57E-16 | Y |
| central nervous system neuron development | 2,67E-16 | N |
| glial cell differentiation | 4,58E-16 | Y |
| regulation of neuron differentiation | 1,59E-15 | Y |
| pallium development | 2,79E-15 | Y |
| cerebral cortex development | 4,66E-15 | Y |
| neuron fate commitment | 1,18E-14 | N |
| regulation of neurogenesis | 1,25E-14 | Y |
| central nervous system projection neuron axonogenesis | 1,46E-14 | N |
| positive regulation of neural precursor cell proliferation | 2,15E-14 | N |
| gliogenesis | 2,79E-14 | Y |
| cerebral cortex neuron differentiation | 3,02E-14 | N |

JMJD1C

| Term | P-value | Annotated |
|--|----------|-----------|
| regulation of protein import into nucleus, translocation | 1,87E-08 | N |

REEP3

| Term | P-value | Annotated |
|--------------------------------|----------|-----------|
| lysosomal transport | 1,08E-06 | N |
| vacuolar transport | 1,11E-06 | N |
| sphingolipid metabolic process | 1,40E-05 | N |

LRRC14

| Term | P-value | Annotated |
|----------------|----------|-----------|
| Endocytosis | 5,72E-04 | N |
| Tight junction | 1,22E-03 | N |

ARHGAP39**FOXH1**

| Term | P-value | Annotated |
|---|----------|-----------|
| cell migration involved in gastrulation | 5,39E-34 | Y |
| primitive streak formation | 5,82E-28 | N |
| anterior/posterior axis specification | 1,08E-22 | N |
| gastrulation with mouth forming second | 3,62E-21 | N |
| gastrulation | 1,15E-20 | Y |
| endoderm development | 9,78E-19 | N |
| signal transduction involved in regulation of gene expression | 3,08E-14 | N |
| axis specification | 5,11E-13 | N |
| formation of primary germ layer | 7,73E-12 | N |
| mesoderm development | 1,09E-10 | Y |
| somitogenesis | 1,38E-10 | N |
| endoderm formation | 2,31E-10 | N |
| cell fate commitment involved in formation of primary germ layers | 8,47E-10 | N |

| | | |
|---|----------|---|
| blastocyst formation | 1,35E-09 | N |
| heart looping | 2,63E-09 | Y |
| determination of heart left/right asymmetry | 2,63E-09 | Y |
| somite development | 6,65E-09 | N |
| embryonic axis specification | 1,61E-08 | N |
| ncRNA catabolic process | 3,65E-08 | N |
| trophectodermal cell differentiation | 3,73E-08 | N |

KIFC2

| Term | P-value | Annotated |
|--|----------|-----------|
| regulation of receptor activity | 2,06E-09 | N |
| neurotransmitter secretion | 2,31E-09 | N |
| regulation of synaptic transmission | 8,68E-09 | N |
| regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate selective glutama... | 3,93E-08 | N |
| regulation of transmission of nerve impulse | 4,39E-08 | N |
| regulation of neurological system process | 9,50E-08 | N |
| synaptic vesicle transport | 3,34E-07 | N |
| regulation of neurotransmitter levels | 6,16E-07 | N |
| regulation of synaptic plasticity | 8,28E-07 | N |
| synaptic vesicle exocytosis | 8,98E-07 | N |
| glutamate secretion | 1,01E-06 | N |
| generation of a signal involved in cell-cell signaling | 2,27E-06 | N |
| signal release | 2,27E-06 | N |

CYHR1

VPS28

| Term | P-value | Annotated |
|---------------------------|----------|-----------|
| mannose metabolic process | 2,58E-12 | N |

SCRT1

| Term | P-value | Annotated |
|---|----------|-----------|
| potassium ion transport | 9,34E-12 | N |
| visual learning | 2,46E-11 | N |
| locomotory behavior | 3,15E-11 | N |
| mating behavior | 2,53E-10 | N |
| visual behavior | 7,01E-10 | N |
| associative learning | 1,07E-09 | N |
| learning | 1,29E-09 | N |
| regulation of neurotransmitter levels | 1,39E-09 | N |
| ionotropic glutamate receptor signaling pathway | 2,68E-09 | N |
| neurotransmitter secretion | 2,90E-09 | N |
| neurotransmitter transport | 7,48E-09 | N |
| adult locomotory behavior | 8,13E-09 | N |
| response to tropane | 1,28E-08 | N |
| response to cocaine | 1,28E-08 | N |
| neuron-neuron synaptic transmission | 1,33E-08 | N |
| neuromuscular process | 2,84E-08 | N |
| reproductive behavior | 4,27E-08 | N |
| regulation of postsynaptic membrane potential | 5,42E-08 | N |
| membrane hyperpolarization | 6,39E-08 | N |
| synaptic transmission, glutamatergic | 1,04E-07 | N |

ATXN2L

| Term | P-value | Annotated |
|------|---------|-----------|
|------|---------|-----------|

| | | |
|--|----------|---|
| positive regulation of gene expression, epigenetic | 9,87E-13 | N |
| protein-DNA complex disassembly | 3,07E-09 | N |
| nucleosome disassembly | 3,07E-09 | N |
| chromatin disassembly | 3,07E-09 | N |

TUFM

| Term | P-value | Annotated |
|--|----------|-----------|
| mitochondrion organization | 2,55E-17 | N |
| aerobic respiration | 3,38E-15 | N |
| cellular respiration | 7,45E-14 | N |
| oxidative phosphorylation | 4,70E-13 | N |
| respiratory electron transport chain | 6,50E-13 | N |
| quinone cofactor metabolic process | 1,10E-12 | N |
| mitochondrial translation | 1,54E-11 | N |
| cofactor metabolic process | 1,59E-11 | N |
| electron transport chain | 2,15E-11 | N |
| ATP synthesis coupled electron transport | 3,01E-11 | N |
| mitochondrial ATP synthesis coupled electron transport | 3,01E-11 | N |
| energy derivation by oxidation of organic compounds | 6,05E-11 | N |
| mitochondrial RNA metabolic process | 1,69E-10 | N |
| generation of precursor metabolites and energy | 1,76E-10 | N |
| branched chain family amino acid catabolic process | 1,76E-10 | N |
| tRNA metabolic process | 2,52E-10 | N |
| cofactor biosynthetic process | 3,48E-10 | N |
| tricarboxylic acid cycle | 4,25E-10 | N |
| coenzyme metabolic process | 7,42E-10 | N |
| acetyl-CoA catabolic process | 7,63E-10 | N |

SH2B1

NFATC2IP

| Term | P-value | Annotated |
|---|----------|-----------|
| recombinational repair | 3,39E-11 | N |
| double-strand break repair via homologous recombination | 4,67E-11 | N |
| DNA replication | 1,06E-07 | N |
| double-strand break repair | 1,44E-07 | N |
| DNA recombination | 2,29E-07 | N |
| DNA repair | 4,74E-07 | N |

SPNS1

| Term | P-value | Annotated |
|-------------------------------------|----------|-----------|
| lysosome organization | 1,04E-20 | N |
| vacuole organization | 1,45E-18 | N |
| organophosphate metabolic process | 3,04E-13 | N |
| phospholipid metabolic process | 1,15E-12 | N |
| phospholipid biosynthetic process | 1,71E-12 | N |
| ferric iron transport | 1,64E-10 | N |
| transferrin transport | 1,64E-10 | N |
| sphingolipid metabolic process | 1,65E-10 | N |
| sphingoid metabolic process | 3,78E-10 | N |
| ceramide metabolic process | 4,28E-10 | N |
| transition metal ion transport | 4,29E-10 | N |
| membrane lipid metabolic process | 5,92E-10 | N |
| glycosphingolipid metabolic process | 2,51E-08 | N |
| glycolipid metabolic process | 2,94E-08 | N |

| | | |
|--------------------|----------|---|
| iron ion transport | 7,12E-08 | N |
|--------------------|----------|---|

LAT

| Term | P-value | Annotated |
|--|----------|-----------|
| T cell receptor signaling pathway | 2,02E-78 | Y |
| antigen receptor-mediated signaling pathway | 1,35E-71 | Y |
| immune response-activating cell surface receptor signaling pathway | 2,30E-71 | Y |
| immune response-regulating cell surface receptor signaling pathway | 4,87E-71 | Y |
| T cell activation | 5,29E-62 | Y |
| lymphocyte costimulation | 1,12E-56 | N |
| T cell costimulation | 1,12E-56 | N |
| regulation of T cell activation | 4,83E-52 | Y |
| lymphocyte activation | 3,24E-50 | Y |
| T cell selection | 6,20E-50 | N |
| positive regulation of T cell activation | 1,34E-48 | N |
| regulation of cell activation | 3,90E-46 | Y |
| regulation of lymphocyte activation | 1,26E-45 | Y |
| regulation of leukocyte activation | 1,43E-45 | Y |
| leukocyte activation | 1,21E-44 | Y |
| positive regulation of leukocyte activation | 1,01E-43 | N |
| T cell differentiation | 1,14E-43 | N |
| positive T cell selection | 2,71E-43 | N |
| positive regulation of lymphocyte activation | 4,01E-43 | N |
| positive regulation of cell activation | 2,35E-42 | N |

SULT1A1

SULT1A2

| Term | P-value | Annotated |
|--|----------|-----------|
| response to xenobiotic stimulus | 3,47E-08 | Y |
| cellular response to xenobiotic stimulus | 3,47E-08 | Y |
| triglyceride homeostasis | 4,24E-08 | N |
| xenobiotic metabolic process | 5,58E-08 | Y |
| complement activation, alternative pathway | 3,81E-07 | N |

CCDC101

| Term | P-value | Annotated |
|------------------------------|----------|-----------|
| N-acetyltransferase activity | 3,25E-06 | N |
| acetyltransferase activity | 3,81E-06 | N |
| N-acyltransferase activity | 6,12E-06 | N |

NRXN1

| Term | P-value | Annotated |
|---|----------|-----------|
| glutamate signaling pathway | 2,62E-19 | N |
| neurotransmitter secretion | 1,58E-16 | N |
| gamma-aminobutyric acid signaling pathway | 5,57E-16 | N |
| synaptic vesicle exocytosis | 7,47E-15 | N |
| regulation of neurotransmitter levels | 3,56E-14 | N |
| regulation of synaptic transmission | 8,38E-14 | Y |
| neurotransmitter transport | 8,67E-14 | N |
| regulation of neurological system process | 2,88E-13 | Y |
| regulation of transmission of nerve impulse | 7,94E-13 | Y |
| neuron-neuron synaptic transmission | 1,06E-12 | Y |
| glutamate secretion | 1,09E-12 | N |
| synaptic vesicle transport | 5,79E-12 | N |

| | | |
|--|----------|---|
| synaptic transmission, glutamatergic | 2,06E-11 | Y |
| signal release | 6,74E-11 | N |
| generation of a signal involved in cell-cell signaling | 6,74E-11 | N |
| learning or memory | 2,45E-10 | Y |
| cellular potassium ion transport | 2,70E-10 | N |
| potassium ion transmembrane transport | 2,70E-10 | N |
| axonogenesis | 3,02E-10 | Y |
| regulation of excitatory postsynaptic membrane potential | 4,07E-10 | Y |

NUPR1

| Term | P-value | Annotated |
|---|----------|-----------|
| serine family amino acid biosynthetic process | 7,90E-12 | N |
| regulation of fatty acid biosynthetic process | 4,66E-10 | N |
| response to acid | 1,16E-09 | N |
| response to amino acid stimulus | 2,68E-09 | N |
| response to hypoxia | 3,34E-09 | N |
| response to oxygen levels | 4,73E-09 | N |

NPAS2

KCNMA1

| Term | P-value | Annotated |
|--|----------|-----------|
| calcium ion transmembrane transport | 2,84E-12 | N |
| lymphoid progenitor cell differentiation | 3,54E-07 | N |
| calcium ion transport | 2,61E-06 | N |
| divalent inorganic cation transport | 3,40E-06 | N |
| synapse organization | 3,92E-06 | N |

DEC1

SDCCAG8

| Term | P-value | Annotated |
|------------------------------------|----------|-----------|
| negative regulation of JNK cascade | 1,96E-05 | N |

AKT3

CRYZL1

| Term | P-value | Annotated |
|------------------------------|----------|-----------|
| synaptic vesicle endocytosis | 9,05E-09 | N |

ITSN1

SON

| Term | P-value | Annotated |
|--|----------|-----------|
| RNA splicing, via transesterification reactions | 4,37E-17 | N |
| RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 7,22E-17 | N |
| nuclear mRNA splicing, via spliceosome | 7,22E-17 | N |
| RNA splicing | 2,18E-14 | N |
| mRNA processing | 4,98E-14 | N |
| mRNA 3'-end processing | 1,72E-11 | N |
| spliceosome assembly | 3,90E-11 | N |
| histone H3-K4 methylation | 6,12E-11 | N |
| intracellular steroid hormone receptor signaling pathway | 7,67E-11 | N |
| alternative nuclear mRNA splicing, via spliceosome | 1,67E-10 | N |
| RNA 3'-end processing | 1,97E-10 | N |
| RNA localization | 2,59E-10 | N |
| androgen receptor signaling pathway | 2,61E-10 | N |
| mRNA transport | 3,31E-10 | N |

| | | |
|-----------------------------------|----------|---|
| RNA export from nucleus | 3,64E-10 | N |
| chromatin modification | 4,23E-10 | N |
| mRNA export from nucleus | 8,08E-10 | N |
| RNA transport | 9,30E-10 | N |
| establishment of RNA localization | 9,30E-10 | N |
| nucleic acid transport | 9,30E-10 | N |

GART

| Term | P-value | Annotated |
|---|----------|-----------|
| ncRNA metabolic process | 3,42E-26 | N |
| ncRNA processing | 3,69E-24 | N |
| rRNA processing | 3,54E-22 | N |
| ribosome biogenesis | 7,22E-22 | N |
| rRNA metabolic process | 2,36E-21 | N |
| cellular component biogenesis at cellular level | 5,23E-21 | N |
| ribonucleoprotein complex biogenesis | 5,51E-21 | N |
| tRNA metabolic process | 3,14E-20 | N |
| RNA modification | 1,36E-17 | N |
| tRNA processing | 1,04E-15 | N |
| rRNA transcription | 3,86E-15 | N |
| tRNA aminoacylation for protein translation | 1,06E-14 | N |
| ribonucleoside monophosphate biosynthetic process | 2,81E-14 | Y |
| amino acid activation | 1,23E-13 | N |
| tRNA aminoacylation | 1,23E-13 | N |
| nucleobase biosynthetic process | 2,69E-13 | Y |
| spliceosomal snRNP assembly | 6,31E-13 | N |
| nucleobase metabolic process | 1,23E-12 | Y |
| tRNA modification | 2,21E-12 | N |
| ribonucleoside monophosphate metabolic process | 2,27E-12 | Y |

DNAJC28

TMEM50B

| Term | P-value | Annotated |
|---|----------|-----------|
| ER-associated protein catabolic process | 1,78E-09 | N |
| protein N-linked glycosylation via asparagine | 3,33E-09 | N |
| peptidyl-asparagine modification | 3,33E-09 | N |
| protein N-linked glycosylation | 7,26E-09 | N |
| protein folding | 7,82E-09 | N |
| response to unfolded protein | 8,72E-09 | N |
| response to topologically incorrect protein | 1,72E-08 | N |
| protein glycosylation | 2,67E-08 | N |
| macromolecule glycosylation | 2,67E-08 | N |
| cell redox homeostasis | 5,55E-08 | N |
| phospholipid biosynthetic process | 6,59E-08 | N |
| glycosylation | 8,77E-08 | N |

IFNGR2

| Term | P-value | Annotated |
|---|----------|-----------|
| innate immune response-activating signal transduction | 3,69E-22 | N |
| pattern recognition receptor signaling pathway | 9,49E-22 | N |
| I-kappaB kinase/NF-kappaB cascade | 1,95E-21 | N |
| activation of innate immune response | 2,00E-21 | N |
| toll-like receptor signaling pathway | 3,17E-20 | N |
| Toll signaling pathway | 1,29E-17 | N |

| | | |
|--|----------|---|
| positive regulation of NF-kappaB transcription factor activity | 1,41E-17 | N |
| toll-like receptor 4 signaling pathway | 5,07E-16 | N |
| toll-like receptor 2 signaling pathway | 1,52E-15 | N |
| positive regulation of I-kappaB kinase/NF-kappaB cascade | 1,55E-15 | N |
| regulation of I-kappaB kinase/NF-kappaB cascade | 1,68E-15 | N |
| MyD88-dependent toll-like receptor signaling pathway | 2,37E-15 | N |
| positive regulation of innate immune response | 1,12E-14 | N |
| toll-like receptor 1 signaling pathway | 1,19E-14 | N |
| toll-like receptor 3 signaling pathway | 1,43E-14 | N |
| cellular response to mechanical stimulus | 1,93E-14 | N |
| cytoplasmic pattern recognition receptor signaling pathway | 2,06E-14 | N |
| nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway | 2,06E-14 | N |
| nucleotide-binding oligomerization domain containing signaling pathway | 2,06E-14 | N |
| MyD88-independent toll-like receptor signaling pathway | 3,36E-14 | N |

SBNO1

| Term | P-value | Annotated |
|--|----------|-----------|
| protein deubiquitination | 7,80E-07 | N |
| protein ubiquitination involved in ubiquitin-dependent protein catabolic process | 1,08E-06 | N |
| histone lysine methylation | 3,64E-06 | N |

SETD8

RILPL2

| Term | P-value | Annotated |
|---|----------|-----------|
| regulation of T cell activation | 2,55E-08 | N |
| negative regulation of lymphocyte activation | 2,67E-08 | N |
| regulation of lymphocyte activation | 2,84E-08 | N |
| negative regulation of leukocyte activation | 7,22E-08 | N |
| regulation of interleukin-2 biosynthetic process | 8,30E-08 | N |
| regulation of interleukin-2 production | 1,88E-07 | N |
| regulation of leukocyte activation | 2,48E-07 | N |
| negative regulation of leukocyte proliferation | 2,87E-07 | N |
| interleukin-2 production | 3,78E-07 | N |
| regulation of cell activation | 4,14E-07 | N |
| negative regulation of immune system process | 5,04E-07 | N |
| leukocyte apoptosis | 6,10E-07 | N |
| regulation of B cell activation | 8,94E-07 | N |
| negative regulation of cell activation | 9,69E-07 | N |
| positive regulation of interleukin-2 biosynthetic process | 1,11E-06 | N |
| immune response-activating signal transduction | 1,98E-06 | N |
| T cell proliferation | 2,02E-06 | N |
| negative regulation of B cell activation | 2,02E-06 | N |
| immune response-regulating signaling pathway | 2,19E-06 | N |
| negative regulation of T cell activation | 2,52E-06 | N |

C12orf65

MPHOSPH9

| Term | P-value | Annotated |
|-------------------------------|----------|-----------|
| M phase of mitotic cell cycle | 5,68E-09 | Y |
| organelle fission | 5,85E-09 | N |
| mitosis | 6,40E-09 | N |
| nuclear division | 6,40E-09 | N |
| microtubule anchoring | 1,45E-08 | N |
| mitotic prometaphase | 2,11E-08 | N |

| | | |
|---|----------|---|
| cell division | 5,89E-08 | N |
| M phase | 1,67E-07 | N |
| attachment of spindle microtubules to chromosome | 2,10E-07 | N |
| spindle organization | 2,50E-07 | N |
| mitotic sister chromatid segregation | 5,09E-07 | N |
| chromosome segregation | 5,75E-07 | N |
| microtubule cytoskeleton organization | 6,25E-07 | N |
| mitotic spindle organization | 6,91E-07 | N |
| cell cycle arrest | 8,48E-07 | N |
| G2/M transition of mitotic cell cycle | 9,45E-07 | N |
| mitotic metaphase/anaphase transition | 1,28E-06 | N |
| attachment of spindle microtubules to kinetochore | 1,38E-06 | N |
| sister chromatid segregation | 1,51E-06 | N |
| regulation of cell cycle process | 1,65E-06 | N |

SNRNP35

RILPL1

| Term | P-value | Annotated |
|---|----------|-----------|
| nuclear-transcribed mRNA catabolic process | 6,13E-08 | N |
| nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 1,51E-06 | N |
| mRNA catabolic process | 4,59E-06 | N |
| RNA catabolic process | 7,44E-06 | N |

PITPNM2

| Term | P-value | Annotated |
|--|----------|-----------|
| platelet activation | 6,48E-06 | |
| blood coagulation | 1,34E-05 | |
| hemostasis | 1,47E-05 | |
| G-protein coupled acetylcholine receptor signaling pathway | 1,89E-05 | |
| regulation of cAMP metabolic process | 1,94E-05 | |
| regulation of metal ion transport | 2,01E-05 | |
| coagulation | 2,04E-05 | |
| regulation of ion transport | 2,06E-05 | |

STK24

FARP1

| Term | P-value | Annotated |
|---|----------|-----------|
| regulation of cell morphogenesis | 2,78E-10 | N |
| axonogenesis | 8,03E-10 | N |
| axon guidance | 2,02E-09 | N |
| regulation of mesenchymal cell proliferation | 4,54E-09 | N |
| epithelial to mesenchymal transition | 1,07E-08 | N |
| artery development | 1,07E-08 | N |
| regulation of epithelial to mesenchymal transition | 1,47E-08 | N |
| regulation of cell morphogenesis involved in differentiation | 2,21E-08 | N |
| positive regulation of mesenchymal cell proliferation | 4,54E-08 | N |
| regulation of cell development | 5,43E-08 | N |
| ureteric bud development | 6,35E-08 | N |
| embryonic digit morphogenesis | 6,98E-08 | N |
| epithelial tube formation | 9,10E-08 | N |
| positive regulation of epithelial to mesenchymal transition | 9,10E-08 | N |
| positive regulation of cell morphogenesis involved in differentiation | 1,13E-07 | N |
| embryonic cranial skeleton morphogenesis | 1,18E-07 | N |
| embryonic appendage morphogenesis | 1,31E-07 | N |

| | | |
|---|----------|---|
| embryonic limb morphogenesis | 1,31E-07 | N |
| SMAD protein import into nucleus | 1,32E-07 | N |
| mammary gland epithelial cell proliferation | 1,38E-07 | N |

SLC15A1

TANK

| Term | P-value | Annotated |
|--|----------|-----------|
| pattern recognition receptor signaling pathway | 8,19E-13 | N |
| toll-like receptor signaling pathway | 8,92E-13 | N |
| positive regulation of T cell mediated immunity | 9,75E-13 | N |
| innate immune response-activating signal transduction | 1,29E-12 | N |
| positive regulation of innate immune response | 4,22E-12 | N |
| positive regulation of lymphocyte mediated immunity | 6,58E-12 | N |
| positive regulation of leukocyte mediated immunity | 6,58E-12 | N |
| positive regulation of NF-kappaB transcription factor activity | 7,52E-12 | N |
| positive regulation of adaptive immune response based on somatic recombination of imm... | 1,28E-11 | N |
| activation of innate immune response | 1,38E-11 | N |
| toll-like receptor 4 signaling pathway | 1,47E-11 | N |
| alpha-beta T cell proliferation | 1,73E-11 | N |
| positive regulation of adaptive immune response | 2,22E-11 | N |
| positive regulation of interleukin-10 production | 2,68E-11 | N |
| positive regulation of defense response | 6,57E-11 | N |
| toll-like receptor 3 signaling pathway | 7,23E-11 | N |
| Toll signaling pathway | 1,04E-10 | N |
| MyD88-independent toll-like receptor signaling pathway | 1,29E-10 | N |
| regulation of innate immune response | 1,90E-10 | N |
| positive regulation of leukocyte proliferation | 2,03E-10 | N |

PSMD14

| Term | P-value | Annotated |
|--|----------|-----------|
| negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle | 1,29E-48 | Y |
| negative regulation of ligase activity | 5,60E-47 | Y |
| negative regulation of ubiquitin-protein ligase activity | 5,60E-47 | Y |
| positive regulation of ligase activity | 8,59E-47 | Y |
| regulation of cellular amino acid metabolic process | 9,36E-47 | Y |
| positive regulation of ubiquitin-protein ligase activity | 1,13E-46 | Y |
| positive regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle | 2,13E-46 | Y |
| regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle | 1,30E-44 | Y |
| M/G1 transition of mitotic cell cycle | 1,92E-44 | Y |
| regulation of ligase activity | 5,58E-44 | Y |
| signal transduction involved in mitotic cell cycle checkpoint | 1,01E-43 | Y |
| signal transduction involved in mitotic cell cycle G1/S checkpoint | 1,01E-43 | Y |
| signal transduction involved in mitotic cell cycle G1/S transition DNA damage checkpo... | 1,01E-43 | Y |
| signal transduction involved in DNA integrity checkpoint | 1,01E-43 | Y |
| DNA damage response, signal transduction by p53 class mediator resulting in cell cycl... | 1,01E-43 | Y |
| signal transduction involved in DNA damage checkpoint | 1,01E-43 | Y |
| regulation of ubiquitin-protein ligase activity | 1,25E-43 | Y |
| signal transduction involved in cell cycle checkpoint | 1,72E-43 | Y |
| signal transduction involved in G1/S transition checkpoint | 1,72E-43 | Y |
| negative regulation of protein ubiquitination | 4,02E-42 | Y |

TBR1

| Term | P-value | Annotated |
|-----------------------------|----------|-----------|
| behavioral defense response | 1,76E-32 | N |

| | | |
|--|----------|---|
| behavioral fear response | 3,51E-27 | N |
| fear response | 6,58E-25 | N |
| hippocampus development | 2,81E-23 | N |
| pallium development | 8,84E-23 | N |
| G-protein coupled acetylcholine receptor signaling pathway | 5,31E-22 | N |
| axonal fasciculation | 2,02E-21 | N |
| limbic system development | 9,43E-18 | N |
| neuron recognition | 3,49E-17 | N |
| telencephalon development | 2,07E-16 | N |
| multicellular organismal response to stress | 2,03E-14 | N |
| forebrain development | 4,94E-14 | N |
| cerebral cortex neuron differentiation | 1,15E-13 | N |
| cerebral cortex radially oriented cell migration | 1,48E-13 | N |
| potassium ion transport | 1,94E-13 | N |
| synaptic transmission, glutamatergic | 5,15E-13 | N |
| ionotropic glutamate receptor signaling pathway | 3,21E-12 | N |
| neuron-neuron synaptic transmission | 8,34E-12 | N |
| learning or memory | 1,63E-11 | N |
| regulation of synaptic plasticity | 2,39E-11 | N |

POU3F2

| Term | P-value | Annotated |
|--|----------|-----------|
| neuron projection membrane | 2,77E-07 | N |
| axolemma | 9,98E-07 | N |
| dendrite | 1,20E-06 | N |
| external encapsulating structure part | 2,58E-06 | N |
| cell envelope | 2,58E-06 | N |
| periplasmic space | 7,53E-06 | N |
| outer membrane-bounded periplasmic space | 7,53E-06 | N |

REEP3

| Term | P-value | Annotated |
|----------------|----------|-----------|
| early endosome | 7,45E-05 | N |

LRRC14**ARHGAP39****FOXH1**

| Term | P-value | Annotated |
|---------------------------------------|----------|-----------|
| translation initiation factor binding | 6,07E-09 | N |

KIFC2

| Term | P-value | Annotated |
|---------------------------------------|----------|-----------|
| dendrite | 1,26E-07 | N |
| dendritic spine head | 1,74E-07 | N |
| postsynaptic density | 1,74E-07 | N |
| synaptosome | 1,77E-07 | N |
| dendritic spine | 2,77E-07 | N |
| neuron spine | 2,77E-07 | N |
| voltage-gated calcium channel complex | 3,03E-07 | N |
| synapse part | 1,10E-06 | N |
| synapse | 1,14E-06 | N |
| ciliary rootlet | 2,33E-06 | N |
| cell body | 1,44E-05 | N |
| synaptic membrane | 2,15E-05 | N |
| calcium channel complex | 2,16E-05 | N |

CYHR1**VPS28**

| Term | P-value | Annotated |
|--|----------|-----------|
| respiratory chain | 1,30E-09 | N |
| eukaryotic translation initiation factor 3 complex | 1,45E-09 | N |
| mitochondrial respiratory chain | 1,19E-08 | N |

SCRT1

| Term | P-value | Annotated |
|---|----------|-----------|
| axon part | 2,20E-12 | N |
| main axon | 1,07E-10 | N |
| synapse part | 1,18E-08 | N |
| axon | 1,21E-08 | N |
| voltage-gated potassium channel complex | 1,48E-08 | N |
| potassium channel complex | 1,48E-08 | N |
| cation channel complex | 2,97E-08 | N |
| synapse | 1,22E-07 | N |
| neuron projection terminus | 2,92E-07 | N |
| neuronal cell body | 3,00E-07 | N |
| cell body | 6,98E-07 | N |
| axon terminus | 1,35E-06 | N |
| terminal button | 2,84E-06 | N |
| dendritic spine head | 5,76E-06 | N |
| postsynaptic density | 5,76E-06 | N |
| ion channel complex | 7,17E-06 | N |
| synaptic membrane | 8,81E-06 | N |
| synaptic vesicle membrane | 9,15E-06 | N |
| ionotropic glutamate receptor complex | 9,98E-06 | N |
| periplasmic space | 3,43E-05 | N |

ATXN2L

| Term | P-value | Annotated |
|-----------------------------------|----------|-----------|
| npBAF complex | 1,43E-08 | N |
| nuclear chromatin | 4,86E-08 | N |
| nBAF complex | 3,05E-07 | N |
| chromatin remodeling complex | 7,03E-07 | N |
| SWI/SNF-type complex | 1,36E-06 | N |
| PRC1 complex | 1,77E-06 | N |
| SWI/SNF complex | 4,69E-06 | N |
| sex chromosome | 5,76E-06 | N |
| methyltransferase complex | 5,86E-06 | N |
| histone methyltransferase complex | 5,86E-06 | N |

TUFM

| Term | P-value | Annotated |
|------------------------------|----------|-----------|
| mitochondrial matrix | 9,13E-34 | Y |
| mitochondrial inner membrane | 2,48E-23 | N |
| organelle inner membrane | 4,09E-23 | N |
| mitochondrial membrane | 9,90E-23 | N |
| mitochondrial envelope | 1,04E-22 | N |
| mitochondrial nucleoid | 1,33E-22 | Y |
| nucleoid | 2,31E-21 | Y |

| | | |
|---|----------|---|
| mitochondrial membrane part | 4,74E-15 | N |
| respiratory chain | 1,17E-12 | N |
| mitochondrial respiratory chain | 2,93E-12 | N |
| organellar ribosome | 8,49E-12 | N |
| mitochondrial ribosome | 8,49E-12 | N |
| ribosome | 1,72E-10 | N |
| small ribosomal subunit | 4,90E-10 | N |
| organellar small ribosomal subunit | 4,97E-10 | N |
| mitochondrial small ribosomal subunit | 4,97E-10 | N |
| integral to mitochondrial membrane | 5,96E-10 | N |
| respiratory chain complex I | 1,87E-08 | N |
| mitochondrial respiratory chain complex I | 1,87E-08 | N |
| NADH dehydrogenase complex | 1,87E-08 | N |

SH2B1

NFATC2IP

| Term | P-value | Annotated |
|-----------------------------------|----------|-----------|
| PML body | 2,87E-09 | N |
| nuclear body | 1,08E-06 | N |
| methyltransferase complex | 1,64E-06 | N |
| histone methyltransferase complex | 1,64E-06 | N |
| chromosomal part | 1,20E-05 | N |

SPNS1

| Term | P-value | Annotated |
|---|----------|-----------|
| vacuolar part | 1,17E-22 | N |
| vacuolar membrane | 3,96E-22 | N |
| lysosomal membrane | 2,64E-21 | N |
| vacuole | 1,52E-18 | N |
| lysosome | 5,29E-17 | N |
| lytic vacuole | 5,29E-17 | N |
| late endosome | 1,83E-09 | N |
| lysosomal lumen | 7,86E-09 | N |
| vacuolar lumen | 7,88E-09 | N |
| proton-transporting V-type ATPase complex | 2,87E-07 | N |
| intrinsic to endoplasmic reticulum membrane | 5,76E-07 | N |
| integral to endoplasmic reticulum membrane | 1,26E-06 | N |
| endosome membrane | 3,09E-06 | N |
| late endosome membrane | 3,21E-06 | N |
| autophagic vacuole | 3,45E-06 | N |
| endosomal part | 3,76E-06 | N |
| endosome | 7,38E-06 | N |

LAT

| Term | P-value | Annotated |
|----------------------------------|-----------|-----------|
| T cell receptor complex | 5,18E-103 | N |
| external side of plasma membrane | 5,22E-45 | N |
| immunological synapse | 2,02E-32 | Y |
| receptor complex | 3,12E-32 | N |
| cell surface | 6,99E-24 | N |
| integrin complex | 3,24E-14 | N |

SULT1A1

SULT1A2

| Term | P-value | Annotated |
|-----------------------------------|----------|-----------|
| high-density lipoprotein particle | 2,84E-07 | N |

CCDC101

| Term | P-value | Annotated |
|----------------------|----------|-----------|
| Base excision repair | 1,29E-04 | N |

NRXN1

| Term | P-value | Annotated |
|--|----------|-----------|
| presynaptic membrane | 1,71E-26 | Y |
| synapse | 2,47E-23 | Y |
| axon | 5,24E-23 | Y |
| axon part | 2,21E-21 | Y |
| synapse part | 4,15E-21 | Y |
| synaptic membrane | 2,50E-19 | Y |
| ion channel complex | 1,25E-16 | N |
| outer membrane-bounded periplasmic space | 1,42E-16 | N |
| periplasmic space | 1,42E-16 | N |
| cation channel complex | 1,02E-15 | N |
| main axon | 1,05E-15 | N |
| dendrite | 1,59E-15 | N |
| external encapsulating structure part | 2,24E-15 | N |
| cell envelope | 2,24E-15 | N |
| postsynaptic membrane | 2,28E-14 | N |
| synaptic vesicle membrane | 1,74E-13 | N |
| axolemma | 2,80E-13 | N |
| terminal button | 3,10E-13 | N |
| external encapsulating structure | 4,32E-13 | N |
| voltage-gated sodium channel complex | 5,32E-13 | N |

NUPR1

NPAS2

KCNMA1

| Term | P-value | Annotated |
|------|---------|-----------|
|------|---------|-----------|

| | | |
|---------------------------------------|----------|---|
| synapse | 1,35E-08 | Y |
| synapse part | 2,81E-06 | Y |
| costamere | 2,95E-06 | N |
| voltage-gated calcium channel complex | 8,84E-06 | N |
| calcium channel complex | 1,25E-05 | N |
| postsynaptic density | 3,06E-05 | N |
| dendritic spine head | 3,06E-05 | N |
| dendrite | 4,01E-05 | N |
| neuron projection terminus | 4,66E-05 | Y |

DEC1

SDCCAG8

| Term | P-value | Annotated |
|-------------------------------|----------|-----------|
| microtubule organizing center | 2,39E-05 | Y |
| centrosome | 1,14E-04 | Y |

AKT3

| Term | P-value | Annotated |
|-----------------------------|----------|-----------|
| intrinsic to Golgi membrane | 1,12E-05 | N |

CRYZL1

| Term | P-value | Annotated |
|-----------|----------|-----------|
| aggresome | 2,87E-06 | N |

ITSN1

SON

| Term | P-value | Annotated |
|---|----------|-----------|
| nuclear speck | 2,67E-18 | Y |
| nuclear body | 5,80E-18 | Y |
| catalytic step 2 spliceosome | 1,43E-14 | N |
| spliceosomal complex | 3,92E-13 | N |
| Cajal body | 1,35E-08 | N |
| aggresome | 1,54E-08 | N |
| chromatin remodeling complex | 2,49E-08 | N |
| cytoplasmic stress granule | 5,84E-08 | N |
| histone acetyltransferase complex | 9,44E-08 | N |
| inclusion body | 2,36E-06 | N |
| heterogeneous nuclear ribonucleoprotein complex | 3,29E-06 | N |

GART

| Term | P-value | Annotated |
|-------------|----------|-----------|
| preribosome | 5,23E-22 | N |
| nucleolus | 7,58E-22 | N |
| Cajal body | 9,44E-15 | N |

| | | |
|---|----------|---|
| nucleolar part | 7,14E-14 | N |
| nuclear pore | 7,16E-13 | N |
| pore complex | 9,51E-11 | N |
| mitochondrial nucleoid | 1,66E-08 | N |
| nuclear DNA-directed RNA polymerase complex | 2,49E-08 | N |
| DNA-directed RNA polymerase complex | 2,49E-08 | N |
| RNA polymerase complex | 3,28E-08 | N |
| MLL1 complex | 4,72E-08 | N |
| small nucleolar ribonucleoprotein complex | 1,96E-07 | N |
| ribonucleoprotein complex | 2,54E-07 | N |
| nuclear envelope | 2,81E-07 | N |
| nucleoid | 3,18E-07 | N |
| Nup107-160 complex | 1,19E-06 | N |
| nuclear matrix | 2,08E-06 | N |
| histone methyltransferase complex | 3,86E-06 | N |
| methyltransferase complex | 3,86E-06 | N |
| mitochondrial matrix | 8,86E-06 | N |

DNAJC28

TMEM50B

| Term | P-value | Annotated |
|---|----------|-----------|
| dendrite cytoplasm | 1,00E-10 | N |
| endoplasmic reticulum lumen | 1,33E-07 | N |
| endoplasmic reticulum-Golgi intermediate compartm | 1,80E-07 | N |
| cell projection cytoplasm | 4,00E-07 | N |
| integral to endoplasmic reticulum membrane | 6,78E-07 | N |
| oligosaccharyltransferase complex | 1,82E-06 | N |

IFNGR2

| Term | P-value | Annotated |
|------------------|----------|-----------|
| receptor complex | 1,25E-06 | N |
| endosome | 6,73E-06 | N |

SBNO1

| Term | P-value | Annotated |
|-----------------------------------|----------|-----------|
| histone methyltransferase complex | 5,62E-07 | N |
| methyltransferase complex | 5,62E-07 | N |
| nuclear body | 1,12E-05 | N |
| polysome | 1,65E-05 | N |
| nuclear speck | 4,07E-05 | N |
| PcG protein complex | 6,96E-05 | N |

SETD8

RILPL2

| Term | P-value | Annotated |
|--|----------|-----------|
| anchored to external side of plasma membrane | 2,67E-05 | N |

C12orf65 **MPHOSPH9**

| Term | P-value | Annotated |
|--|----------|-----------|
| centrosome | 1,67E-10 | Y |
| microtubule organizing center part | 3,26E-09 | Y |
| centriole | 3,60E-09 | Y |
| nuclear ubiquitin ligase complex | 5,66E-09 | N |
| spindle pole | 1,40E-08 | N |
| kinetochore | 6,33E-08 | N |
| microtubule organizing center | 9,13E-08 | N |
| condensed chromosome kinetochore | 1,48E-07 | N |
| anaphase-promoting complex | 1,68E-07 | N |
| spindle | 3,50E-07 | N |
| condensed chromosome, centromeric region | 8,20E-07 | N |
| condensed chromosome | 1,14E-06 | N |
| chromosome, centromeric region | 1,90E-06 | N |
| spindle microtubule | 1,18E-05 | N |

SNRNP35 **RILPL1**

| Term | P-value | Annotated |
|------------|----------|-----------|
| sarcoplasm | 1,75E-05 | N |
| I band | 9,08E-05 | N |

PITPNM2

| Term | P-value | Annotated |
|------------------------|----------|-----------|
| cation channel complex | 1,65E-05 | N |
| asymmetric synapse | 2,15E-05 | N |

STK24 **FARP1**

| Term | P-value | Annotated |
|-----------------------|----------|-----------|
| cell leading edge | 6,05E-12 | N |
| adherens junction | 2,92E-11 | N |
| anchoring junction | 1,98E-10 | N |
| lamellipodium | 3,22E-10 | N |
| leading edge membrane | 8,05E-10 | N |
| septin complex | 8,18E-09 | N |
| septin cytoskeleton | 8,18E-09 | N |
| stress fiber | 1,09E-08 | N |
| actomyosin | 1,14E-08 | N |

| | | |
|----------------------------------|----------|---|
| cell projection membrane | 2,55E-08 | N |
| actin filament bundle | 5,01E-08 | N |
| focal adhesion | 9,15E-08 | N |
| cell-substrate adherens junction | 3,98E-07 | N |
| cell cortex | 9,40E-07 | N |
| cell-substrate junction | 1,11E-06 | N |
| actin cytoskeleton | 9,10E-06 | N |
| synapse | 1,98E-05 | N |

SLC15A1

TANK

PSMD14

| Term | P-value | Annotated |
|---------------------------------------|----------|-----------|
| proteasome complex | 1,36E-54 | y |
| proteasome accessory complex | 1,49E-42 | N |
| proteasome core complex | 2,62E-26 | N |
| mitochondrial ribosome | 2,35E-11 | N |
| organellar ribosome | 2,35E-11 | N |
| ribonucleoprotein complex | 1,83E-10 | N |
| ribosome | 3,69E-09 | N |
| nuclear envelope | 9,72E-09 | N |
| signalosome | 1,88E-08 | N |
| nuclear pore | 2,33E-08 | N |
| pore complex | 6,28E-08 | N |
| integrator complex | 5,12E-07 | N |
| organellar large ribosomal subunit | 2,06E-06 | N |
| mitochondrial large ribosomal subunit | 2,06E-06 | N |

TBR1

| Term | P-value | Annotated |
|---|----------|-----------|
| synapse part | 1,33E-15 | N |
| synaptic membrane | 5,07E-15 | N |
| cation channel complex | 5,37E-15 | N |
| potassium channel complex | 6,51E-15 | N |
| voltage-gated potassium channel complex | 6,51E-15 | N |
| ion channel complex | 1,40E-13 | N |
| presynaptic membrane | 4,68E-13 | N |
| synapse | 3,59E-12 | N |
| postsynaptic membrane | 6,20E-10 | N |
| dendrite | 7,25E-10 | N |
| asymmetric synapse | 5,60E-09 | N |
| site of polarized growth | 2,96E-08 | N |
| growth cone | 3,54E-08 | N |
| synaptic vesicle membrane | 7,08E-08 | N |

POU3F2

| Term | P-value | Annotated |
|--|----------|-----------|
| HMG box domain binding | 7,52E-07 | N |
| ionotropic glutamate receptor activity | 3,68E-06 | N |
| ephrin receptor activity | 4,97E-06 | N |

JMJD1C

| Term | P-value | Annotated |
|--|----------|-----------|
| mitogen-activated protein kinase binding | 1,12E-08 | N |
| nuclear hormone receptor binding | 1,15E-06 | Y |
| histone acetyltransferase activity | 2,63E-06 | N |
| hormone receptor binding | 4,18E-06 | Y |
| protein kinase binding | 5,80E-06 | N |
| thyroid hormone receptor binding | 7,04E-06 | Y |
| helicase activity | 1,11E-05 | N |
| purine NTP-dependent helicase activity | 1,42E-05 | N |
| ATP-dependent helicase activity | 1,42E-05 | N |
| histone deacetylase binding | 2,02E-05 | N |

REEP3**LRRC14****ARHGAP39**

| Term | P-value | Annotated |
|----------------------------|----------|-----------|
| microtubule motor activity | 5,17E-05 | N |
| Rho GTPase binding | 9,71E-05 | N |

FOXH1**KIFC2**

| Term | P-value | Annotated |
|--|----------|-----------|
| voltage-gated calcium channel activity | 1,56E-05 | N |

CYHR1**VPS28****SCRT1**

| Term | P-value | Annotated |
|--|----------|-----------|
| potassium ion transmembrane transporter activity | 4,45E-10 | N |
| potassium channel activity | 3,44E-09 | N |
| dopamine binding | 4,48E-09 | N |
| voltage-gated potassium channel activity | 7,42E-09 | N |
| voltage-gated cation channel activity | 2,60E-08 | N |
| voltage-gated ion channel activity | 2,35E-07 | N |
| voltage-gated channel activity | 2,35E-07 | N |
| tau-protein kinase activity | 2,91E-07 | N |
| monovalent inorganic cation transmembrane transporter activity | 4,64E-07 | N |

| | | |
|---|----------|---|
| cation channel activity | 9,05E-07 | N |
| metal ion transmembrane transporter activity | 1,06E-06 | N |
| gated channel activity | 1,77E-06 | N |
| delayed rectifier potassium channel activity | 2,29E-06 | N |
| extracellular-glutamate-gated ion channel activity | 4,72E-06 | N |
| inorganic cation transmembrane transporter activity | 6,20E-06 | N |
| ionotropic glutamate receptor activity | 1,78E-05 | N |

ATXN2L

| Term | P-value | Annotated |
|--|----------|-----------|
| transcription cofactor activity | 6,47E-11 | N |
| transcription factor binding transcription factor activity | 8,61E-11 | N |
| protein binding transcription factor activity | 2,03E-10 | N |
| tau-protein kinase activity | 7,03E-10 | N |
| transcription corepressor activity | 1,47E-09 | N |

TUFM

| Term | P-value | Annotated |
|--|----------|-----------|
| 4 iron, 4 sulfur cluster binding | 5,57E-23 | N |
| iron-sulfur cluster binding | 8,95E-15 | N |
| metal cluster binding | 8,95E-15 | N |
| unfolded protein binding | 2,23E-09 | N |
| hydrogen ion transporting ATP synthase activity, rotational mechan | 5,37E-09 | N |
| cofactor binding | 1,02E-08 | N |
| oxidoreductase activity, acting on NADH or NADPH | 1,93E-08 | N |
| ligase activity, forming aminoacyl-tRNA and related compounds | 2,48E-08 | N |
| aminoacyl-tRNA ligase activity | 2,48E-08 | N |
| ligase activity, forming carbon-oxygen bonds | 2,48E-08 | N |
| NADH dehydrogenase (ubiquinone) activity | 2,69E-08 | N |
| NADH dehydrogenase (quinone) activity | 2,69E-08 | N |
| NADH dehydrogenase activity | 2,69E-08 | N |
| oxidoreductase activity, acting on the CH-CH group of donors | 3,94E-08 | N |
| structural constituent of ribosome | 6,53E-08 | N |
| NAD binding | 4,32E-07 | N |
| coenzyme binding | 5,03E-07 | N |
| modified amino acid binding | 6,67E-07 | N |
| oxidoreductase activity, acting on NADH or NADPH, quinone or simi | 7,42E-07 | N |
| translation factor activity, nucleic acid binding | 9,90E-07 | Y |

SH2B1

NFATC2IP

| Term | P-value | Annotated |
|------------------------------------|----------|-----------|
| deoxyribonuclease activity | 9,14E-07 | N |
| methylated histone residue binding | 3,30E-06 | N |

SPNS1

| Term | P-value | Annotated |
|---|----------|-----------|
| hexosaminidase activity | 4,20E-14 | N |
| active transmembrane transporter activity | 2,63E-08 | N |
| ATPase activity, coupled to transmembrane movement of ions | 1,47E-07 | N |
| cation-transporting ATPase activity | 2,47E-07 | N |
| primary active transmembrane transporter activity | 2,94E-07 | N |
| P-P-bond-hydrolysis-driven transmembrane transporter activity | 2,94E-07 | N |

LAT

| Term | P-value | Annotated |
|---|----------|-----------|
| receptor signaling complex scaffold activity | 2,00E-26 | N |
| G-protein coupled chemoattractant receptor activity | 2,26E-22 | N |
| chemokine receptor activity | 2,26E-22 | N |
| C-C chemokine receptor activity | 1,58E-17 | N |
| antigen binding | 1,00E-16 | N |
| tumor necrosis factor receptor binding | 1,12E-16 | N |
| signaling adaptor activity | 3,30E-16 | Y |
| SH2 domain binding | 4,18E-16 | N |
| cytokine receptor activity | 3,47E-15 | N |
| MHC protein binding | 2,15E-14 | N |
| MHC class I protein binding | 2,17E-14 | N |
| tumor necrosis factor receptor superfamily binding | 2,60E-14 | N |
| coreceptor activity | 7,84E-14 | N |
| SH3/SH2 adaptor activity | 1,76E-12 | Y |

SULT1A1**SULT1A2**

| Term | P-value | Annotated |
|---|----------|-----------|
| cargo receptor activity | 4,59E-09 | N |
| lipid binding | 6,00E-09 | N |
| monocarboxylic acid binding | 7,17E-09 | N |
| retinol binding | 1,89E-08 | N |
| retinal binding | 3,60E-08 | N |
| scavenger receptor activity | 4,79E-08 | N |
| bacterial cell surface binding | 7,69E-08 | N |
| isoprenoid binding | 7,82E-08 | N |
| vitamin binding | 8,73E-08 | N |
| retinoid binding | 1,12E-07 | N |
| fatty acid binding | 1,74E-07 | N |
| carboxylic acid binding | 1,10E-06 | N |
| oxidoreductase activity, acting on the CH-CH group of donors, NAD | 1,60E-06 | N |
| calmodulin-dependent protein kinase activity | 2,66E-06 | N |

CCDC101**NRXN1**

| Term | P-value | Annotated |
|--|----------|-----------|
| glutamate receptor activity | 2,79E-25 | N |
| gated channel activity | 2,16E-21 | N |
| ion channel activity | 2,04E-19 | N |
| substrate-specific channel activity | 2,42E-19 | N |
| GABA receptor activity | 7,65E-19 | N |
| passive transmembrane transporter activity | 6,99E-18 | N |
| channel activity | 6,99E-18 | N |
| extracellular ligand-gated ion channel activity | 1,12E-17 | N |
| GABA-A receptor activity | 6,77E-17 | N |
| voltage-gated channel activity | 7,92E-17 | N |
| voltage-gated ion channel activity | 7,92E-17 | N |
| ionotropic glutamate receptor activity | 1,51E-16 | N |
| extracellular-glutamate-gated ion channel activity | 1,71E-16 | N |
| ligand-gated channel activity | 4,65E-16 | N |
| ligand-gated ion channel activity | 4,65E-16 | N |
| voltage-gated cation channel activity | 3,54E-15 | N |
| cation channel activity | 5,15E-12 | N |
| voltage-gated sodium channel activity | 5,62E-12 | N |
| chloride channel activity | 3,10E-11 | N |
| anion channel activity | 4,03E-11 | N |

NUPR1

| Term | P-value | Annotated |
|---|----------|-----------|
| insulin-like growth factor binding | 1,54E-09 | N |
| ligase activity, forming carbon-oxygen bonds | 6,15E-07 | N |
| aminoacyl-tRNA ligase activity | 6,15E-07 | N |
| ligase activity, forming aminoacyl-tRNA and related compounds | 6,15E-07 | N |

NPAS2

| Term | P-value | Annotated |
|-----------------------|----------|-----------|
| Hsp90 protein binding | 8,78E-11 | N |

KCNMA1

| Term | P-value | Annotated |
|--|----------|-----------|
| calcium channel activity | 2,51E-09 | N |
| voltage-gated calcium channel activity | 1,10E-08 | N |
| cation channel activity | 1,56E-08 | Y |
| voltage-gated cation channel activity | 5,63E-08 | Y |
| gated channel activity | 5,58E-07 | Y |
| solute:cation antiporter activity | 7,43E-07 | N |

| | | |
|--|----------|---|
| ion channel activity | 1,21E-06 | Y |
| substrate-specific channel activity | 1,60E-06 | Y |
| passive transmembrane transporter activity | 3,28E-06 | Y |
| channel activity | 3,28E-06 | Y |
| cation:cation antiporter activity | 5,08E-06 | N |
| glutamate receptor binding | 9,05E-06 | N |
| voltage-gated channel activity | 1,66E-05 | Y |
| voltage-gated ion channel activity | 1,66E-05 | Y |
| calmodulin binding | 2,09E-05 | N |
| ion gated channel activity | 2,28E-05 | Y |

DEC1

SDCCAG8

AKT3

| Term | P-value | Annotated |
|--------------------|----------|-----------|
| Rho GTPase binding | 1,68E-06 | N |

CRYZL1

ITSN1

SON

| Term | P-value | Annotated |
|--|----------|-----------|
| RNA-dependent ATPase activity | 6,35E-13 | N |
| ATP-dependent RNA helicase activity | 2,04E-12 | N |
| thyroid hormone receptor binding | 5,69E-12 | N |
| RNA helicase activity | 1,18E-11 | N |
| transcription coactivator activity | 7,30E-11 | N |
| nuclear hormone receptor binding | 9,59E-11 | N |
| hormone receptor binding | 4,08E-09 | N |
| ubiquitin thiolesterase activity | 6,96E-09 | N |
| ATP-dependent helicase activity | 2,22E-08 | N |
| purine NTP-dependent helicase activity | 2,22E-08 | N |
| vitamin D receptor binding | 2,42E-08 | N |
| transcription cofactor activity | 4,47E-08 | N |
| transcription factor binding transcription factor activity | 1,32E-07 | N |
| histone methyltransferase activity (H3-K4 specific) | 1,42E-07 | N |
| protein binding transcription factor activity | 1,46E-07 | N |
| androgen receptor binding | 6,52E-07 | N |

GART

| Term | P-value | Annotated |
|--|----------|-----------|
| transferase activity, transferring one-carbon groups | 7,96E-17 | Y |
| methyltransferase activity | 4,15E-15 | Y |
| RNA polymerase activity | 5,15E-14 | N |
| DNA-directed RNA polymerase activity | 5,15E-14 | N |

| | | |
|---|----------|---|
| RNA methyltransferase activity | 2,04E-13 | N |
| ligase activity, forming aminoacyl-tRNA and related compounds | 1,00E-12 | N |
| aminoacyl-tRNA ligase activity | 1,00E-12 | N |
| ligase activity, forming carbon-oxygen bonds | 1,00E-12 | N |
| S-adenosylmethionine-dependent methyltransferase activity | 4,46E-12 | N |
| tRNA methyltransferase activity | 1,82E-11 | N |
| RNA helicase activity | 6,73E-11 | N |
| DNA helicase activity | 9,00E-11 | N |
| tRNA binding | 6,65E-10 | N |
| helicase activity | 8,93E-10 | N |
| nucleotidyltransferase activity | 2,51E-09 | N |
| ATP-dependent DNA helicase activity | 4,19E-09 | N |
| N-methyltransferase activity | 5,73E-09 | N |
| ATP-dependent helicase activity | 8,06E-09 | N |
| purine NTP-dependent helicase activity | 8,06E-09 | N |
| ATP-dependent RNA helicase activity | 1,71E-08 | N |

DNAJC28

TMEM50B

| Term | P-value | Annotated |
|---|----------|-----------|
| intramolecular oxidoreductase activity, interconverting keto- and enol- | 1,66E-14 | N |
| unfolded protein binding | 3,35E-07 | N |
| oligosaccharyl transferase activity | 6,88E-07 | N |
| oxidoreductase activity, acting on a sulfur group of donors | 1,14E-06 | N |
| cysteine-type endopeptidase activity | 1,58E-06 | N |

IFNGR2

SBNO1

| Term | P-value | Annotated |
|--|----------|-----------|
| N-methyltransferase activity | 5,41E-09 | N |
| histone methyltransferase activity | 1,32E-08 | N |
| histone methyltransferase activity (H3-K4 specific) | 1,66E-08 | N |
| small conjugating protein-specific protease activity | 2,36E-08 | N |
| histone-lysine N-methyltransferase activity | 3,53E-08 | N |
| ubiquitin-specific protease activity | 4,07E-08 | N |
| ubiquitin thiolesterase activity | 4,27E-08 | N |
| lysine N-methyltransferase activity | 1,09E-07 | N |
| protein-lysine N-methyltransferase activity | 1,09E-07 | N |
| cysteine-type peptidase activity | 2,20E-06 | N |

SETD8

RILPL2

C12orf65

MPHOSPH9

| SNRNP35 | | |
|------------------------------------|----------|-----------|
| Term | P-value | Annotated |
| Rho GTPase binding | 3,36E-05 | N |
| insulin receptor substrate binding | 5,66E-05 | N |

| RILPL1 PITPNM2 | | |
|--|----------|-----------|
| Term | P-value | Annotated |
| diacylglycerol kinase activity | 7,03E-07 | N |
| cation channel activity | 5,66E-06 | N |
| voltage-gated cation channel activity | 2,49E-05 | N |
| GTPase regulator activity | 3,34E-05 | N |
| nucleoside-triphosphatase regulator activity | 4,33E-05 | N |
| ion channel activity | 5,03E-05 | N |
| gated channel activity | 5,99E-05 | N |
| calmodulin-dependent protein kinase activity | 6,09E-05 | N |
| substrate-specific channel activity | 6,59E-05 | N |
| voltage-gated channel activity | 1,02E-04 | N |
| voltage-gated ion channel activity | 1,02E-04 | N |

| STK24 | | |
|--|----------|-----------|
| Term | P-value | Annotated |
| Rho guanyl-nucleotide exchange factor activity | 2,63E-08 | N |
| receptor signaling protein activity | 2,27E-06 | N |

| FARP1 | | |
|----------------------|----------|-----------|
| Term | P-value | Annotated |
| beta-catenin binding | 1,82E-11 | N |

| SLC15A1 TANK | | |
|--|----------|-----------|
| Term | P-value | Annotated |
| tumor necrosis factor receptor binding | 1,76E-09 | N |
| tumor necrosis factor receptor superfamily binding | 3,26E-08 | N |

| PSMD14 | | |
|---|----------|-----------|
| Term | P-value | Annotated |
| threonine-type endopeptidase activity | 3,22E-26 | N |
| threonine-type peptidase activity | 3,22E-26 | N |
| unfolded protein binding | 1,52E-15 | N |
| chaperone binding | 4,97E-11 | N |
| RNA polymerase II carboxy-terminal domain kinase activity | 1,27E-10 | N |
| small conjugating protein binding | 3,87E-08 | N |
| ATPase activity | 5,86E-08 | N |

TBR1

| Term | P-value | Annotated |
|--|----------|-----------|
| voltage-gated potassium channel activity | 2,38E-17 | N |
| potassium channel activity | 2,60E-17 | N |
| voltage-gated cation channel activity | 7,53E-17 | N |
| voltage-gated channel activity | 1,91E-15 | N |
| voltage-gated ion channel activity | 1,91E-15 | N |
| acidic amino acid transmembrane transporter activity | 2,28E-15 | N |
| L-glutamate transmembrane transporter activity | 1,04E-14 | N |
| potassium ion transmembrane transporter activity | 6,42E-13 | N |
| gated channel activity | 3,80E-12 | N |
| ion channel activity | 1,20E-10 | N |
| substrate-specific channel activity | 1,51E-10 | N |
| G-protein coupled amine receptor activity | 1,86E-10 | N |
| metal ion transmembrane transporter activity | 6,28E-10 | N |
| cation channel activity | 8,22E-10 | N |
| GABA receptor activity | 9,07E-10 | N |
| passive transmembrane transporter activity | 1,39E-09 | N |
| channel activity | 1,39E-09 | N |
| GABA-A receptor activity | 2,63E-09 | N |

POU3F2

| Term | P-value | Annotated |
|--|----------|-----------|
| Glycosaminoglycan biosynthesis - heparan sulfate | 2,28E-04 | N |
| Notch signaling pathway | 3,65E-04 | N |

JMJD1C

| Term | P-value | Annotated |
|---------------------------|----------|-----------|
| Circadian rhythm - mammal | 4,58E-06 | N |
| Notch signaling pathway | 1,80E-05 | N |

REEP3

| Term | P-value | Annotated |
|-------------------------|----------|-----------|
| Sphingolipid metabolism | 5,92E-05 | N |

LRRC14**ARHGAP39****FOXH1**

| Term | P-value | Annotated |
|-----------------------|----------|-----------|
| Nitrogen metabolism | 4,31E-05 | N |
| Wnt signaling pathway | 7,31E-04 | N |

KIFC2

| Term | P-value | Annotated |
|---------------------------------------|----------|-----------|
| Ubiquitin mediated proteolysis | 3,85E-05 | N |
| Phosphatidylinositol signaling system | 5,19E-04 | N |

CYHR1

| Term | P-value | Annotated |
|----------------------------------|----------|-----------|
| Glycerophospholipid metabolism | 2,13E-05 | N |
| Spliceosome | 3,41E-04 | N |
| Adherens junction | 5,89E-04 | N |
| Regulation of actin cytoskeleton | 5,94E-04 | N |

VPS28

| Term | P-value | Annotated |
|---|----------|-----------|
| Huntington's disease | 1,55E-10 | N |
| Parkinson's disease | 2,02E-10 | N |
| Oxidative phosphorylation | 2,63E-09 | N |
| Alzheimer's disease | 5,63E-09 | N |
| Proteasome | 6,05E-06 | N |
| Endocytosis | 4,83E-05 | Y |
| Amino sugar and nucleotide sugar metabolism | 4,09E-04 | N |
| Glyoxylate and dicarboxylate metabolism | 8,00E-04 | N |

SCRT1

| Term | P-value | Annotated |
|---|----------|-----------|
| Neuroactive ligand-receptor interaction | 2,92E-06 | N |
| Calcium signaling pathway | 6,67E-04 | N |

ATXN2L

| Term | P-value | Annotated |
|---|----------|-----------|
| Valine, leucine and isoleucine biosynthesis | 1,89E-06 | N |
| Aminoacyl-tRNA biosynthesis | 9,56E-06 | N |
| Vasopressin-regulated water reabsorption | 2,36E-05 | N |

TUFM

| Term | P-value | Annotated |
|---|----------|-----------|
| Parkinson's disease | 7,63E-12 | N |
| Huntington's disease | 1,02E-10 | N |
| Valine, leucine and isoleucine degradation | 2,12E-10 | N |
| Oxidative phosphorylation | 3,66E-10 | N |
| Citrate cycle (TCA cycle) | 2,96E-09 | N |
| Alzheimer's disease | 1,27E-08 | N |
| Aminoacyl-tRNA biosynthesis | 2,94E-08 | N |
| Propanoate metabolism | 1,66E-07 | N |
| Butanoate metabolism | 6,01E-07 | N |
| beta-Alanine metabolism | 1,05E-06 | N |
| Selenoamino acid metabolism | 1,38E-06 | N |
| Fatty acid metabolism | 3,30E-06 | N |
| Pyruvate metabolism | 3,97E-06 | N |
| RNA polymerase | 1,67E-05 | N |
| Valine, leucine and isoleucine biosynthesis | 1,75E-05 | N |
| Glycolysis / Gluconeogenesis | 9,40E-05 | N |
| Cardiac muscle contraction | 1,02E-04 | N |
| Lysine degradation | 1,67E-04 | N |
| Oocyte meiosis | 3,69E-04 | N |
| Glyoxylate and dicarboxylate metabolism | 3,84E-04 | N |

SH2B1**NFATC2IP**

| Term | P-value | Annotated |
|--------------------------|----------|-----------|
| DNA replication | 2,30E-06 | N |
| Base excision repair | 8,74E-06 | N |
| Homologous recombination | 4,15E-05 | N |
| Mismatch repair | 1,07E-03 | N |

SPNS1

| Term | P-value | Annotated |
|------|---------|-----------|
|------|---------|-----------|

| | | |
|---|----------|---|
| Lysosome | 6,30E-25 | N |
| Glycerophospholipid metabolism | 1,42E-06 | N |
| Glycosylphosphatidylinositol(GPI)-anchor biosynthesis | 4,33E-06 | N |
| Sphingolipid metabolism | 1,25E-05 | N |
| Other glycan degradation | 2,61E-05 | N |
| Glycosphingolipid biosynthesis - ganglio series | 9,58E-05 | N |
| Glycosaminoglycan degradation | 1,52E-04 | N |
| Glycosphingolipid biosynthesis - globo series | 1,56E-04 | N |
| Glycosaminoglycan biosynthesis - heparan sulfate | 3,16E-04 | N |
| Vibrio cholerae infection | 7,40E-04 | N |

LAT

| Term | P-value | Annotated |
|--|----------|-----------|
| T cell receptor signaling pathway | 1,57E-59 | Y |
| Primary immunodeficiency | 1,44E-58 | N |
| Hematopoietic cell lineage | 2,86E-53 | N |
| Natural killer cell mediated cytotoxicity | 3,03E-17 | Y |
| Cytokine-cytokine receptor interaction | 4,37E-17 | N |
| Chemokine signaling pathway | 3,87E-14 | N |
| Cell adhesion molecules (CAMs) | 2,33E-09 | N |
| Jak-STAT signaling pathway | 1,05E-08 | N |
| Autoimmune thyroid disease | 1,89E-05 | N |
| Fc epsilon RI signaling pathway | 4,98E-05 | Y |
| Allograft rejection | 9,15E-05 | N |
| Regulation of actin cytoskeleton | 2,55E-04 | N |
| Intestinal immune network for IgA production | 3,51E-04 | N |
| Thyroid cancer | 5,67E-04 | N |

SULT1A1

SULT1A2

| Term | P-value | Annotated |
|--|----------|-----------|
| Drug metabolism - cytochrome P450 | 2,47E-10 | N |
| Retinol metabolism | 1,22E-08 | N |
| Metabolism of xenobiotics by cytochrome P450 | 1,48E-08 | N |
| Tyrosine metabolism | 4,36E-08 | N |
| Complement and coagulation cascades | 3,47E-06 | N |
| Histidine metabolism | 7,83E-06 | N |
| Phenylalanine metabolism | 2,76E-05 | N |
| Primary bile acid biosynthesis | 1,11E-04 | N |
| Ascorbate and aldarate metabolism | 1,64E-04 | N |
| Valine, leucine and isoleucine degradation | 3,51E-04 | N |
| Arachidonic acid metabolism | 3,97E-04 | N |
| Selenoamino acid metabolism | 5,02E-04 | N |
| Steroid hormone biosynthesis | 5,21E-04 | N |

| | | |
|---------------------------------|----------|---|
| Fatty acid metabolism | 5,39E-04 | N |
| Drug metabolism - other enzymes | 8,03E-04 | N |

CCDC101

NRXN1

| Term | P-value | Annotated |
|---|----------|-----------|
| Neuroactive ligand-receptor interaction | 9,49E-06 | N |
| Axon guidance | 2,06E-05 | N |
| ErbB signaling pathway | 2,72E-05 | N |
| Long-term potentiation | 3,34E-05 | N |
| Type II diabetes mellitus | 6,29E-05 | N |
| Amyotrophic lateral sclerosis (ALS) | 2,89E-04 | N |
| Long-term depression | 6,16E-04 | N |
| Cell adhesion molecules (CAMs) | 9,76E-04 | Y |

NUPR1

| Term | P-value | Annotated |
|--|----------|-----------|
| Aminoacyl-tRNA biosynthesis | 4,03E-09 | N |
| Nitrogen metabolism | 7,81E-05 | N |
| Glycine, serine and threonine metabolism | 5,54E-04 | N |

NPAS2

KCNMA1

| Term | P-value | Annotated |
|---------------------------------------|----------|-----------|
| Calcium signaling pathway | 3,43E-09 | N |
| Long-term potentiation | 1,93E-07 | N |
| Phosphatidylinositol signaling system | 3,38E-05 | N |
| Vascular smooth muscle contraction | 1,02E-04 | Y |

DEC1

SDCCAG8

AKT3

| Term | P-value | Annotated |
|--|----------|-----------|
| Glycosphingolipid biosynthesis - lacto and neolacto series | 9,78E-06 | N |
| Glutathione metabolism | 3,43E-04 | N |
| Oxidative phosphorylation | 6,42E-04 | N |
| Tight junction | 6,53E-04 | Y |

CRYZL1

| Term | P-value | Annotated |
|---|----------|-----------|
| SNARE interactions in vesicular transport | 7,49E-06 | N |
| One carbon pool by folate | 7,05E-04 | N |

ITSN1

| Term | P-value | Annotated |
|-------------------------|----------|-----------|
| VEGF signaling pathway | 4,49E-04 | N |
| Notch signaling pathway | 1,58E-03 | N |

SON

| Term | P-value | Annotated |
|---------------------|----------|-----------|
| Spliceosome | 4,09E-11 | N |
| Folate biosynthesis | 2,30E-04 | N |

GART

| Term | P-value | Annotated |
|---|----------|-----------|
| Aminoacyl-tRNA biosynthesis | 1,46E-13 | N |
| Valine, leucine and isoleucine biosynthesis | 1,69E-11 | N |
| Pyrimidine metabolism | 5,39E-11 | N |
| RNA polymerase | 1,74E-09 | N |
| Purine metabolism | 4,68E-07 | Y |
| One carbon pool by folate | 8,15E-07 | Y |
| Cysteine and methionine metabolism | 6,73E-06 | N |
| Gap junction | 3,02E-05 | N |
| Long-term potentiation | 3,49E-05 | N |
| Mismatch repair | 4,86E-05 | N |
| Selenoamino acid metabolism | 5,95E-05 | N |
| Non-homologous end-joining | 8,52E-05 | N |
| Alanine, aspartate and glutamate metabolism | 1,69E-04 | N |
| DNA replication | 1,76E-04 | N |
| Nucleotide excision repair | 2,80E-04 | N |
| Spliceosome | 2,87E-04 | N |
| Melanogenesis | 3,06E-04 | N |
| Glycine, serine and threonine metabolism | 9,34E-04 | N |
| Homologous recombination | 9,53E-04 | N |
| Valine, leucine and isoleucine degradation | 1,28E-03 | N |

DNAJC28

TMEM50B

| Term | P-value | Annotated |
|---|----------|-----------|
| Protein export | 9,82E-08 | N |
| Glycerophospholipid metabolism | 5,80E-06 | N |
| N-Glycan biosynthesis | 5,88E-06 | N |
| Non-homologous end-joining | 2,24E-05 | N |
| Riboflavin metabolism | 4,11E-05 | N |
| Glycosylphosphatidylinositol(GPI)-anchor biosynthesis | 7,31E-05 | N |
| Nitrogen metabolism | 1,17E-04 | N |
| Antigen processing and presentation | 1,33E-04 | N |
| Mismatch repair | 5,97E-04 | N |

| | | |
|----------------------------|----------|---|
| Gap junction | 6,98E-04 | N |
| Nucleotide excision repair | 8,24E-04 | N |
| DNA replication | 1,08E-03 | N |

IFNGR2

| Term | P-value | Annotated |
|--|----------|-----------|
| Toll-like receptor signaling pathway | 2,92E-14 | N |
| NOD-like receptor signaling pathway | 4,87E-13 | N |
| B cell receptor signaling pathway | 1,34E-09 | N |
| Apoptosis | 3,70E-09 | N |
| Neurotrophin signaling pathway | 7,43E-09 | N |
| Leishmania infection | 4,46E-08 | Y |
| Small cell lung cancer | 3,86E-07 | N |
| Chemokine signaling pathway | 4,94E-07 | N |
| Epithelial cell signaling in Helicobacter pylori infection | 2,96E-05 | N |
| Ubiquitin mediated proteolysis | 7,87E-05 | N |
| Glycosphingolipid biosynthesis - lacto and neolacto series | 8,19E-05 | N |
| Fc gamma R-mediated phagocytosis | 1,43E-04 | N |
| Acute myeloid leukemia | 1,87E-04 | N |
| Chronic myeloid leukemia | 2,36E-04 | N |
| Pancreatic cancer | 2,38E-04 | N |
| Colorectal cancer | 7,69E-04 | N |

SBNO1

| Term | P-value | Annotated |
|--------------------------------|----------|-----------|
| Basal transcription factors | 1,75E-05 | N |
| Ubiquitin mediated proteolysis | 7,79E-04 | N |

SETD8

| Term | P-value | Annotated |
|---|----------|-----------|
| Prostate cancer | 2,02E-04 | N |
| Renal cell carcinoma | 2,21E-04 | N |
| Progesterone-mediated oocyte maturation | 4,65E-04 | N |
| Neurotrophin signaling pathway | 4,70E-04 | N |
| Chronic myeloid leukemia | 7,29E-04 | N |

RILPL2

| Term | P-value | Annotated |
|-----------------------------------|----------|-----------|
| T cell receptor signaling pathway | 3,26E-04 | N |
| B cell receptor signaling pathway | 9,22E-04 | N |

C12orf65

MPHOSPH9

| Term | P-value | Annotated |
|------|---------|-----------|
|------|---------|-----------|

| | | |
|-----------------|----------|---|
| Thyroid cancer | 5,76E-07 | N |
| Cell cycle | 9,10E-06 | N |
| Oocyte meiosis | 5,66E-04 | N |
| Mismatch repair | 6,38E-04 | N |
| DNA replication | 6,44E-04 | N |

SNRNP35

RILPL1

| Term | P-value | Annotated |
|---------------------------------|----------|-----------|
| Drug metabolism - other enzymes | 9,98E-07 | N |

PITPNM2

| Term | P-value | Annotated |
|---------------------------|----------|-----------|
| Calcium signaling pathway | 1,35E-04 | N |

STK24

| Term | P-value | Annotated |
|----------------------------------|----------|-----------|
| Adherens junction | 1,79E-07 | N |
| Thyroid cancer | 2,22E-04 | N |
| Regulation of actin cytoskeleton | 4,22E-04 | N |
| Renal cell carcinoma | 5,80E-04 | N |
| ErbB signaling pathway | 7,67E-04 | N |

FARP1

| Term | P-value | Annotated |
|----------------------|----------|-----------|
| Adherens junction | 4,25E-08 | N |
| Melanogenesis | 7,86E-08 | N |
| Tight junction | 8,09E-05 | N |
| Basal cell carcinoma | 1,73E-04 | N |
| Axon guidance | 5,55E-04 | N |

SLC15A1

TANK

| Term | P-value | Annotated |
|--|----------|-----------|
| Apoptosis | 3,27E-11 | N |
| Toll-like receptor signaling pathway | 1,14E-09 | N |
| RIG-I-like receptor signaling pathway | 1,27E-09 | N |
| NOD-like receptor signaling pathway | 2,93E-09 | N |
| Cytokine-cytokine receptor interaction | 9,29E-07 | N |
| Leishmania infection | 3,34E-06 | N |
| T cell receptor signaling pathway | 4,71E-06 | N |
| Jak-STAT signaling pathway | 6,56E-06 | N |
| Amyotrophic lateral sclerosis (ALS) | 1,41E-05 | N |
| Pancreatic cancer | 1,73E-04 | N |

| | | |
|--|----------|---|
| Small cell lung cancer | 4,54E-04 | N |
| Epithelial cell signaling in Helicobacter pylori infection | 1,01E-03 | N |

PSMD14

| Term | P-value | Annotated |
|---|----------|-----------|
| Proteasome | 1,89E-45 | Y |
| Ubiquitin mediated proteolysis | 1,34E-07 | N |
| Aminoacyl-tRNA biosynthesis | 9,39E-07 | N |
| RNA degradation | 1,35E-06 | N |
| Spliceosome | 5,67E-06 | N |
| Phosphatidylinositol signaling system | 1,75E-05 | N |
| Inositol phosphate metabolism | 2,80E-05 | N |
| Nucleotide excision repair | 3,11E-05 | N |
| Pathogenic Escherichia coli infection | 5,93E-05 | N |
| Cell cycle | 8,70E-05 | N |
| Valine, leucine and isoleucine biosynthesis | 1,95E-04 | N |
| Vascular smooth muscle contraction | 3,81E-04 | N |
| Lysine degradation | 5,22E-04 | N |

TBR1

| Term | P-value | Annotated |
|---|----------|-----------|
| Calcium signaling pathway | 4,10E-06 | N |
| Neuroactive ligand-receptor interaction | 7,65E-05 | N |

POU3F2

| Term | P-value | Annotated |
|---|----------|-----------|
| CRMPs in Sema3A signaling | 1,05E-05 | N |
| Unblocking of NMDA receptor, glutamate binding and activation | 1,28E-05 | N |

JMJD1C

| Term | P-value | Annotated |
|---|----------|-----------|
| Circadian Clock | 2,67E-09 | N |
| BMAL1:CLOCK/NPAS2 Activates Gene Expression | 2,57E-08 | N |
| Myogenesis | 7,03E-08 | N |
| CDO in myogenesis | 7,03E-08 | N |

REEP3

| Term | P-value | Annotated |
|-----------------------------------|----------|-----------|
| Sphingolipid metabolism | 4,17E-05 | N |
| Sphingolipid de novo biosynthesis | 6,48E-05 | N |

LRRC14**ARHGAP39****FOXH1**

| Term | P-value | Annotated |
|---------------------------------------|----------|-----------|
| Signaling by NODAL | 1,44E-17 | Y |
| FGFR ligand binding and activation | 5,01E-07 | N |
| SHC-mediated cascade | 1,48E-06 | N |
| Negative regulation of FGFR signaling | 1,56E-06 | N |
| FGFR1 ligand binding and activation | 2,93E-06 | N |
| Signaling by BMP | 5,62E-06 | N |
| FRS2-mediated cascade | 6,49E-06 | N |

KIFC2

| Term | P-value | Annotated |
|---|----------|-----------|
| Ras activation upon Ca ²⁺ influx through NMDA receptor | 6,84E-09 | N |
| Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels | 1,19E-08 | N |
| CREB phosphorylation through the activation of CaMKII | 9,65E-08 | N |
| Transmission across Chemical Synapses | 3,39E-07 | N |
| GABA synthesis, release, reuptake and degradation | 4,23E-06 | N |
| Neuronal System | 1,10E-05 | N |
| Dopamine Neurotransmitter Release Cycle | 2,28E-05 | N |
| Serotonin Neurotransmitter Release Cycle | 2,28E-05 | N |
| Trafficking of AMPA receptors | 2,92E-05 | N |
| Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity | 2,92E-05 | N |
| Post NMDA receptor activation events | 3,02E-05 | N |
| NCAM signaling for neurite out-growth | 3,07E-05 | N |
| Neurotransmitter Release Cycle | 3,36E-05 | N |
| CREB phosphorylation through the activation of Ras | 3,37E-05 | N |
| Glutamate Neurotransmitter Release Cycle | 3,72E-05 | N |

CYHR1

| Term | P-value | Annotated |
|--|----------|-----------|
| Assembly of HIV virion | 3,26E-09 | N |
| Membrane binding and targeting of GAG proteins | 3,14E-08 | N |

VPS28

| Term | P-value | Annotated |
|--|----------|-----------|
| Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat prod... | 3,99E-10 | N |

| | | |
|---|----------|---|
| Respiratory electron transport | 5,73E-10 | N |
| Endosomal Sorting Complex Required For Transport (ESCRT) | 6,29E-09 | Y |
| The citric acid (TCA) cycle and respiratory electron transport | 4,51E-08 | N |
| Regulation of mRNA Stability by Proteins that Bind AU-rich Elements | 1,25E-07 | N |

SCRT1

| Term | P-value | Annotated |
|---|----------|-----------|
| Voltage gated Potassium channels | 7,55E-12 | N |
| Neuronal System | 6,75E-11 | N |
| Potassium Channels | 2,11E-10 | N |
| Unblocking of NMDA receptor, glutamate binding and activation | 1,65E-06 | N |
| Transmission across Chemical Synapses | 7,56E-06 | N |
| CREB phosphorylation through the activation of CaMKII | 7,96E-06 | N |
| GABA synthesis, release, reuptake and degradation | 3,55E-05 | N |
| Trafficking of AMPA receptors | 3,81E-05 | N |
| Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity | 3,81E-05 | N |
| Amine ligand-binding receptors | 3,98E-05 | N |
| Neurotransmitter Release Cycle | 4,57E-05 | N |
| Ras activation upon Ca ²⁺ influx through NMDA receptor | 5,68E-05 | N |
| Dopamine Neurotransmitter Release Cycle | 7,01E-05 | N |
| Serotonin Neurotransmitter Release Cycle | 7,01E-05 | N |

ATXN2L

| Term | P-value | Annotated |
|---------------------|----------|-----------|
| EGFR downregulation | 4,94E-08 | N |

TUFM

| Term | P-value | Annotated |
|--|----------|-----------|
| Mitochondrial tRNA aminoacylation | 1,54E-16 | N |
| Citric acid cycle (TCA cycle) | 7,05E-14 | N |
| The citric acid (TCA) cycle and respiratory electron transport | 9,77E-14 | N |
| Pyruvate metabolism and Citric Acid (TCA) cycle | 2,63E-12 | N |
| Respiratory electron transport | 3,35E-11 | N |
| Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat prod... | 5,84E-11 | N |
| Mitochondrial Fatty Acid Beta-Oxidation | 4,42E-10 | N |
| tRNA Aminoacylation | 7,33E-08 | N |
| Gluconeogenesis | 7,47E-08 | N |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | 1,58E-07 | N |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | 2,09E-07 | N |
| Formation of ATP by chemiosmotic coupling | 3,76E-07 | N |
| RNA Polymerase III Chain Elongation | 4,27E-07 | N |
| Branched-chain amino acid catabolism | 1,76E-06 | N |

SH2B1

NFATC2IP

| Term | P-value | Annotated |
|--|----------|-----------|
| G0 and Early G1 | 2,58E-08 | N |
| Activation of ATR in response to replication stress | 1,14E-07 | N |
| G2/M Checkpoints | 1,16E-07 | N |
| Processive synthesis on the C-strand of the telomere | 1,36E-07 | N |
| Fanconi Anemia pathway | 3,92E-07 | N |
| Activation of the pre-replicative complex | 9,49E-07 | N |
| Processive synthesis on the lagging strand | 1,77E-06 | N |
| DNA strand elongation | 2,61E-06 | N |
| Removal of the Flap Intermediate | 3,31E-06 | N |

| | | |
|---|----------|---|
| Telomere C-strand (Lagging Strand) Synthesis | 1,05E-05 | N |
| Unwinding of DNA | 1,17E-05 | N |
| Gap-filling DNA repair synthesis and ligation in TC-NER | 1,76E-05 | N |
| Gap-filling DNA repair synthesis and ligation in GG-NER | 1,76E-05 | N |
| Resolution of Abasic Sites (AP sites) | 1,92E-05 | N |
| Base Excision Repair | 1,92E-05 | N |

SPNS1

| Term | P-value | Annotated |
|--|----------|-----------|
| Glycosphingolipid metabolism | 3,03E-12 | N |
| Sphingolipid metabolism | 2,69E-10 | N |
| Transferrin endocytosis and recycling | 1,11E-09 | N |
| Iron uptake and transport | 1,67E-06 | N |
| Insulin receptor recycling | 1,84E-06 | N |
| Transmembrane transport of small molecules | 4,07E-06 | N |

LAT

| Term | P-value | Annotated |
|--|----------|-----------|
| Generation of second messenger molecules | 4,46E-56 | Y |
| TCR signaling | 9,03E-44 | Y |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 9,44E-42 | N |
| Translocation of ZAP-70 to Immunological synapse | 8,42E-37 | N |
| PD-1 signaling | 1,71E-34 | N |
| Phosphorylation of CD3 and TCR zeta chains | 4,19E-30 | N |
| Costimulation by the CD28 family | 2,58E-27 | N |
| PECAM1 interactions | 1,64E-26 | N |
| Downstream TCR signaling | 4,80E-22 | N |
| The role of Nef in HIV-1 replication and disease pathogenesis | 3,27E-21 | N |
| Adaptive Immune System | 5,70E-19 | Y |
| Chemokine receptors bind chemokines | 2,18E-18 | N |
| Cell surface interactions at the vascular wall | 3,78E-18 | N |
| Regulation of KIT signaling | 4,26E-16 | N |
| CD28 dependent Vav1 pathway | 4,30E-16 | N |
| Hemostasis | 6,10E-16 | Y |
| Platelet activation, signaling and aggregation | 7,32E-16 | Y |
| Platelet Adhesion to exposed collagen | 7,71E-16 | Y |
| Interleukin-2 signaling | 5,08E-13 | N |
| Platelet Aggregation (Plug Formation) | 9,80E-13 | N |

SULT1A1

SULT1A2

| Term | P-value | Annotated |
|---|----------|-----------|
| Biological oxidations | 5,08E-09 | N |
| Phase 1 - Functionalization of compounds | 7,59E-08 | N |
| Ethanol oxidation | 2,11E-07 | N |
| Formation of Fibrin Clot (Clotting Cascade) | 1,25E-05 | N |

CCDC101

NRXN1

| Term | P-value | Annotated |
|---------------------------------------|----------|-----------|
| GABA A receptor activation | 7,01E-23 | N |
| Neuronal System | 2,61E-22 | N |
| Ligand-gated ion channel transport | 4,00E-22 | N |
| Transmission across Chemical Synapses | 6,35E-20 | N |
| Interaction between L1 and Ankyrins | 1,62E-18 | N |

| | | |
|--|----------|---|
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | 1,12E-17 | N |
| GABA receptor activation | 6,71E-17 | N |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | 2,53E-16 | N |
| Unblocking of NMDA receptor, glutamate binding and activation | 1,43E-14 | N |
| Potassium Channels | 5,40E-14 | N |
| Ion channel transport | 3,86E-13 | N |
| Serotonin Neurotransmitter Release Cycle | 7,57E-13 | N |
| Dopamine Neurotransmitter Release Cycle | 7,57E-13 | N |
| Voltage gated Potassium channels | 1,73E-11 | N |
| L1CAM interactions | 4,99E-11 | N |
| GABA synthesis, release, reuptake and degradation | 8,50E-10 | N |
| Norepinephrine Neurotransmitter Release Cycle | 1,73E-09 | N |
| Activation of NMDA receptor upon glutamate binding and postsynaptic events | 2,16E-09 | N |
| Glutamate Neurotransmitter Release Cycle | 5,65E-08 | N |
| Ionotropic activity of Kainate Receptors | 5,90E-08 | N |

NUPR1

| Term | P-value | Annotated |
|---|----------|-----------|
| Cytosolic tRNA aminoacylation | 8,79E-14 | N |
| Amino acid synthesis and interconversion (transamination) | 4,98E-13 | N |
| Activation of Genes by ATF4 | 2,08E-10 | N |
| tRNA Aminoacylation | 1,19E-08 | N |
| PERK regulated gene expression | 1,72E-08 | N |

NPAS2

KCNMA1

| Term | P-value | Annotated |
|---|----------|-----------|
| Voltage gated Potassium channels | 2,12E-09 | N |
| Neuronal System | 5,68E-09 | Y |
| Unblocking of NMDA receptor, glutamate binding and activation | 1,14E-07 | N |
| Potassium Channels | 5,22E-07 | Y |
| Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels | 2,58E-06 | N |
| Reduction of cytosolic Ca++ levels | 4,96E-06 | N |
| Smooth Muscle Contraction | 5,48E-06 | N |
| Platelet calcium homeostasis | 7,49E-06 | N |
| CREB phosphorylation through the activation of CaMKII | 7,74E-06 | N |
| Transmission across Chemical Synapses | 1,01E-05 | N |
| Ras activation upon Ca2+ influx through NMDA receptor | 1,66E-05 | N |
| Activation of NMDA receptor upon glutamate binding and postsynaptic events | 2,29E-05 | N |
| Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity | 4,28E-05 | N |
| Trafficking of AMPA receptors | 4,28E-05 | N |

DEC1

SDCCAG8

AKT3

| Term | P-value | Annotated |
|---|----------|-----------|
| Thrombin signalling through proteinase activated receptors (PARs) | 1,24E-05 | N |

CRYZL1

ITSN1

SON

| Term | P-value | Annotated |
|---|----------|-----------|
| Processing of Capped Intron-Containing Pre-mRNA | 5,67E-18 | N |
| mRNA Splicing - Major Pathway | 2,32E-16 | N |
| mRNA Splicing | 2,32E-16 | N |

| | | |
|---|----------|---|
| mRNA Processing | 5,21E-16 | N |
| mRNA 3'-end processing | 1,07E-12 | N |
| Post-Elongation Processing of Intron-Containing pre-mRNA | 1,07E-12 | N |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | 1,44E-12 | N |
| Transport of Mature Transcript to Cytoplasm | 2,99E-12 | N |
| Cleavage of Growing Transcript in the Termination Region | 1,65E-10 | N |
| RNA Polymerase II Transcription Termination | 1,65E-10 | N |
| Post-Elongation Processing of the Transcript | 1,65E-10 | N |
| mRNA Splicing - Minor Pathway | 2,48E-10 | N |
| Transport of Ribonucleoproteins into the Host Nucleus | 1,90E-08 | N |
| Vpr-mediated nuclear import of PICs | 9,63E-08 | N |
| Transport of the SLBP independent Mature mRNA | 3,02E-07 | N |
| Transport of Mature mRNA Derived from an Intronless Transcript | 3,08E-07 | N |
| Transport of Mature mRNAs Derived from Intronless Transcripts | 4,71E-07 | N |
| RNA Polymerase II Transcription | 4,92E-07 | N |
| NEP/NS2 Interacts with the Cellular Export Machinery | 4,92E-07 | N |
| Transport of the SLBP Dependant Mature mRNA | 5,39E-07 | N |

GART

| Term | P-value | Annotated |
|--|----------|-----------|
| Metabolism of non-coding RNA | 1,16E-19 | N |
| snRNP Assembly | 1,16E-19 | N |
| tRNA Aminoacylation | 5,57E-15 | N |
| Transport of Mature mRNA Derived from an Intronless Transcript | 6,41E-15 | N |
| Transport of Mature mRNAs Derived from Intronless Transcripts | 9,25E-15 | N |
| Purine ribonucleoside monophosphate biosynthesis | 3,91E-14 | N |
| Rev-mediated nuclear export of HIV-1 RNA | 1,97E-13 | N |
| Transport of Ribonucleoproteins into the Host Nucleus | 2,81E-13 | N |
| Interactions of Rev with host cellular proteins | 3,79E-13 | N |
| Export of Viral Ribonucleoproteins from Nucleus | 4,79E-13 | N |
| NEP/NS2 Interacts with the Cellular Export Machinery | 6,37E-13 | N |
| Transport of the SLBP independent Mature mRNA | 1,14E-12 | N |
| Transport of Mature Transcript to Cytoplasm | 1,18E-12 | N |
| Transport of the SLBP Dependant Mature mRNA | 1,52E-12 | N |
| Nuclear import of Rev protein | 2,39E-12 | N |
| Vpr-mediated nuclear import of PICs | 3,39E-12 | N |
| Glucose transport | 7,76E-12 | N |
| Interactions of Vpr with host cellular proteins | 1,98E-11 | N |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | 2,71E-11 | N |
| Metabolism of nucleotides | 3,07E-11 | N |

DNAJC28

TMEM50B

| Term | P-value | Annotated |
|--|----------|-----------|
| Activation of Chaperones by IRE1alpha | 2,11E-09 | N |
| Activation of Chaperones by ATF6-alpha | 4,50E-09 | N |
| Asparagine N-linked glycosylation | 1,90E-08 | N |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 4,37E-08 | N |
| Activation of Chaperone Genes by XBP1(S) | 1,34E-07 | N |
| Early Phase of HIV Life Cycle | 2,62E-07 | N |
| Calnexin/calreticulin cycle | 2,77E-07 | N |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 5,86E-07 | N |
| Unfolded Protein Response | 1,19E-06 | N |

IFNGR2

| Term | P-value | Annotated |
|--|----------|-----------|
| Toll Like Receptor 4 (TLR4) Cascade | 6,51E-20 | N |
| Toll Receptor Cascades | 4,47E-19 | N |
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | 1,98E-18 | N |
| Activated TLR4 signalling | 2,71E-18 | N |
| Viral dsRNA:TLR3:TRIF Complex Activates RIP1 | 3,04E-17 | N |
| Toll Like Receptor TLR6:TLR2 Cascade | 1,27E-16 | N |
| MyD88:Mal cascade initiated on plasma membrane | 1,27E-16 | N |
| Toll Like Receptor TLR1:TLR2 Cascade | 1,27E-16 | N |
| Toll Like Receptor 2 (TLR2) Cascade | 1,27E-16 | N |
| MyD88-independent cascade initiated on plasma membrane | 4,44E-16 | N |
| NFkB and MAP kinases activation mediated by TLR4 signaling repertoire | 1,03E-14 | N |
| MyD88 cascade initiated on plasma membrane | 2,51E-14 | N |
| Toll Like Receptor 10 (TLR10) Cascade | 2,51E-14 | N |
| Toll Like Receptor 5 (TLR5) Cascade | 2,51E-14 | N |
| TRAF6 mediated NF-kB activation | 3,33E-14 | N |
| TRIF mediated TLR3 signaling | 4,28E-14 | N |
| Toll Like Receptor 3 (TLR3) Cascade | 4,28E-14 | N |
| MyD88 dependent cascade initiated on endosome | 7,79E-14 | N |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | 7,79E-14 | N |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 1,30E-13 | N |

SBNO1

| Term | P-value | Annotated |
|---------------------------------|----------|-----------|
| Late Phase of HIV Life Cycle | 7,26E-06 | N |
| Transcription of the HIV genome | 1,32E-05 | N |

SETD8

| Term | P-value | Annotated |
|----------------|----------|-----------|
| Purine salvage | 1,55E-04 | N |

RILPL2

| Term | P-value | Annotated |
|------------------------------|----------|-----------|
| Regulation of IFNG signaling | 3,41E-05 | N |

C12orf65

MPHOSPH9

| Term | P-value | Annotated |
|---|----------|-----------|
| Cell Cycle, Mitotic | 4,72E-09 | N |
| Cell Cycle | 9,45E-09 | N |
| M Phase | 2,38E-08 | N |
| Mitotic Prometaphase | 2,67E-08 | N |
| Centrosome maturation | 1,88E-07 | N |
| Recruitment of mitotic centrosome proteins and complexes | 1,88E-07 | N |
| Loss of Nlp from mitotic centrosomes | 3,06E-07 | N |
| Loss of proteins required for interphase microtubule organization from the centrosome | 3,06E-07 | N |
| G2/M Transition | 5,87E-07 | N |
| Mitotic G2-G2/M phases | 7,71E-07 | N |
| Mitotic M-M/G1 phases | 1,17E-06 | N |
| DNA Replication | 2,26E-06 | N |
| Telomere C-strand (Lagging Strand) Synthesis | 1,77E-05 | N |
| G2/M Checkpoints | 1,93E-05 | N |
| Repair synthesis of patch ~27-30 bases long by DNA polymerase | 2,04E-05 | N |
| Repair synthesis for gap-filling by DNA polymerase in TC-NER | 2,04E-05 | N |
| Extension of Telomeres | 2,80E-05 | N |

| | | |
|---|----------|---|
| APC-Cdc20 mediated degradation of Nek2A | 3,27E-05 | N |
|---|----------|---|

SNRNP35

RILPL1

| Term | P-value | Annotated |
|---|----------|-----------|
| Deadenylation-dependent mRNA decay | 9,03E-07 | N |
| mRNA Processing | 6,52E-06 | N |
| Processing of Capped Intron-Containing Pre-mRNA | 8,99E-06 | N |
| mRNA Splicing - Major Pathway | 1,02E-05 | N |
| mRNA Splicing | 1,02E-05 | N |

PITPNM2

| Term | P-value | Annotated |
|---|----------|-----------|
| Voltage gated Potassium channels | 1,29E-06 | N |
| Potassium Channels | 1,41E-06 | N |
| Effects of PIP2 hydrolysis | 2,09E-06 | N |
| Ras activation uopn Ca2+ influx through NMDA receptor | 1,48E-05 | N |
| Neuronal System | 2,17E-05 | N |
| PLC-gamma1 signalling | 6,59E-05 | N |
| DAG and IP3 signaling | 8,21E-05 | N |
| Hemostasis | 8,24E-05 | N |
| Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels | 9,90E-05 | N |
| Platelet activation, signaling and aggregation | 1,05E-04 | N |

STK24

| Term | P-value | Annotated |
|-----------------------------------|----------|-----------|
| G alpha (12/13) signalling events | 1,78E-07 | N |
| NRAGE signals death through JNK | 8,67E-07 | N |

FARP1

| Term | P-value | Annotated |
|--|----------|-----------|
| Cell-extracellular matrix interactions | 1,78E-08 | N |
| Axon guidance | 5,91E-08 | N |
| Semaphorin interactions | 5,68E-07 | N |
| Rho GTPase cycle | 3,73E-06 | N |
| Signaling by Rho GTPases | 3,73E-06 | N |

SLC15A1

TANK

| Term | P-value | Annotated |
|--|----------|-----------|
| NOD1/2 Signaling Pathway | 1,31E-14 | N |
| Death Receptor Signalling | 3,09E-14 | N |
| Extrinsic Pathway for Apoptosis | 3,09E-14 | N |
| Regulation of IFNG signaling | 9,47E-11 | N |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pa... | 8,32E-10 | N |
| MyD88-independent cascade initiated on plasma membrane | 1,10E-09 | N |
| TRIF mediated TLR3 signaling | 1,20E-09 | N |
| Toll Like Receptor 3 (TLR3) Cascade | 1,20E-09 | N |
| Innate Immune System | 3,76E-09 | Y |
| Activated TLR4 signalling | 6,59E-09 | N |
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | 9,55E-09 | N |
| Toll Like Receptor 4 (TLR4) Cascade | 1,37E-08 | N |
| Toll Receptor Cascades | 1,46E-08 | N |
| TRAF6 mediated NF-kB activation | 1,56E-08 | N |
| NFkB and MAP kinases activation mediated by TLR4 signaling repertoire | 4,16E-08 | N |

| | | |
|---|----------|---|
| Interleukin-1 signaling | 5,64E-08 | N |
| TRAF6 Mediated Induction of proinflammatory cytokines | 1,37E-07 | N |
| MyD88 cascade initiated on plasma membrane | 2,36E-07 | N |
| Toll Like Receptor 10 (TLR10) Cascade | 2,36E-07 | N |
| Toll Like Receptor 5 (TLR5) Cascade | 2,36E-07 | N |

PSMD14

| Term | P-value | Annotated |
|---|----------|-----------|
| CDT1 association with the CDC6:ORC:origin complex | 1,10E-55 | Y |
| Assembly of the pre-replicative complex | 9,20E-53 | Y |
| Cross-presentation of soluble exogenous antigens (endosomes) | 1,81E-51 | Y |
| Regulation of ornithine decarboxylase (ODC) | 1,95E-49 | Y |
| Destabilization of mRNA by AUF1 (hnRNP D0) | 2,58E-49 | Y |
| Orc1 removal from chromatin | 4,06E-49 | Y |
| Switching of origins to a post-replicative state | 4,06E-49 | Y |
| Removal of licensing factors from origins | 6,34E-49 | Y |
| Autodegradation of Cdh1 by Cdh1:APC/C | 7,83E-49 | Y |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | 9,21E-49 | Y |
| Autodegradation of the E3 ubiquitin ligase COP1 | 1,00E-48 | Y |
| SCF-beta-TrCP mediated degradation of Emi1 | 1,05E-48 | Y |
| Stabilization of p53 | 1,08E-48 | Y |
| Vpu mediated degradation of CD4 | 1,54E-48 | Y |
| Vif-mediated degradation of APOBEC3G | 3,90E-48 | Y |
| Ubiquitin-dependent degradation of Cyclin D | 6,57E-48 | Y |
| Ubiquitin-dependent degradation of Cyclin D1 | 6,57E-48 | Y |
| Regulation of DNA replication | 1,27E-47 | Y |
| p53-Independent DNA Damage Response | 1,63E-47 | Y |
| p53-Independent G1/S DNA damage checkpoint | 1,63E-47 | Y |

TBR1

| Term | P-value | Annotated |
|--|----------|-----------|
| Voltage gated Potassium channels | 2,35E-15 | N |
| GABA A receptor activation | 4,18E-14 | N |
| Potassium Channels | 4,41E-14 | N |
| Neuronal System | 5,60E-14 | N |
| Amine ligand-binding receptors | 4,44E-13 | N |
| Glutamate Neurotransmitter Release Cycle | 2,41E-11 | N |
| Ligand-gated ion channel transport | 3,77E-11 | N |
| Transmission across Chemical Synapses | 5,70E-09 | N |
| Sema3A PAK dependent Axon repulsion | 1,62E-08 | N |

POU3F2

| Term | P-value | Annotated |
|---|----------|-----------|
| abnormal brain commissure morphology | 8,24E-15 | N |
| enlarged third ventricle | 1,17E-14 | N |
| abnormal hippocampal mossy fiber morphology | 2,26E-14 | N |
| small olfactory bulb | 7,66E-12 | N |
| abnormal radial glial cell morphology | 1,07E-11 | N |
| abnormal cerebral cortex morphology | 3,42E-11 | N |
| abnormal axon guidance | 3,50E-10 | N |
| increased aggression towards mice | 8,47E-10 | N |
| abnormal corticospinal tract morphology | 1,38E-09 | N |
| decreased brain size | 3,43E-09 | N |
| abnormal hippocampus morphology | 8,28E-09 | N |
| abnormal embryonic/fetal subventricular zone morphology | 1,02E-08 | N |
| decreased corpus callosum size | 1,61E-08 | N |
| abnormal spinal cord interneuron morphology | 1,79E-08 | N |
| abnormal cerebellar foliation | 1,85E-08 | N |
| disorganized pancreatic islets | 2,16E-08 | N |
| abnormal cerebrum morphology | 3,66E-08 | N |
| abnormal telencephalon development | 4,19E-08 | N |
| enlarged lateral ventricles | 8,50E-08 | N |
| abnormal pancreas development | 9,41E-08 | N |

JMJD1C

| Term | P-value | Annotated |
|---|----------|-----------|
| increased cellular sensitivity to ultraviolet irradiation | 8,76E-09 | N |
| abnormal somite development | 5,00E-07 | N |
| kidney inflammation | 6,90E-07 | N |
| thin cerebellar molecular layer | 7,08E-07 | N |
| decreased Purkinje cell number | 7,47E-06 | N |
| abnormal renal glomerulus morphology | 8,38E-06 | N |
| partial postnatal lethality | 1,59E-05 | N |
| increased platelet cell number | 2,03E-05 | N |
| asymmetric rib-sternum attachment | 2,67E-05 | N |
| complete embryonic lethality during organogenesis | 3,20E-05 | N |
| delayed embryo turning | 3,42E-05 | N |
| postnatal lethality | 3,51E-05 | N |
| abnormal spermatid morphology | 7,24E-05 | N |
| abnormal circulating protein level | 8,88E-05 | N |
| globozoospermia | 1,13E-04 | N |
| abnormal cell death | 1,31E-04 | N |
| embryonic growth retardation | 1,33E-04 | N |
| decreased survivor rate | 1,38E-04 | N |
| failure of eyelid fusion | 1,43E-04 | N |

| | | |
|---|----------|---|
| increased single-positive T cell number | 1,62E-04 | N |
|---|----------|---|

REEP3

| Term | P-value | Annotated |
|---|----------|-----------|
| abnormal lysosome morphology | 1,90E-06 | N |
| globozoospermia | 2,36E-05 | N |
| abnormal eating behavior | 6,12E-05 | N |
| cachexia | 7,92E-04 | N |
| decreased trabecular bone volume | 9,63E-04 | N |
| absent vibrissae | 1,08E-03 | N |
| abnormal hair follicle morphology | 1,27E-03 | N |
| thin epidermis | 1,36E-03 | N |
| blepharitis | 2,02E-03 | N |
| abnormal myelination | 2,20E-03 | N |
| increased single-positive T cell number | 2,22E-03 | N |
| complete preweaning lethality | 2,42E-03 | N |
| enlarged sebaceous gland | 2,84E-03 | N |
| abnormal myelin sheath morphology | 2,89E-03 | N |
| induced chromosome breakage | 2,98E-03 | N |
| abnormal postural reflex | 3,07E-03 | N |
| abnormal brain white matter morphology | 3,15E-03 | N |
| postnatal growth retardation | 3,20E-03 | N |
| increased lung adenoma incidence | 3,27E-03 | N |
| intraventricular hemorrhage | 3,31E-03 | |

LRRC14

| Term | P-value | Annotated |
|--|----------|-----------|
| impaired coordination | 2,56E-05 | N |
| premature hair loss | 2,09E-04 | N |
| abnormal thymus corticomedullary boundary morphology | 3,03E-04 | N |
| decreased embryo weight | 3,27E-04 | N |
| dilated third ventricle | 1,20E-03 | N |
| increased keratinocyte proliferation | 1,23E-03 | N |
| small cerebellum | 1,29E-03 | N |
| impaired contextual conditioning behavior | 1,41E-03 | N |
| impaired hearing | 1,58E-03 | N |
| abnormal axon outgrowth | 1,65E-03 | N |
| abnormal retinal apoptosis | 2,30E-03 | N |
| abnormal female meiosis | 2,75E-03 | N |
| abnormal vascular branching morphogenesis | 2,75E-03 | N |
| abnormal lateral ventricle morphology | 3,18E-03 | N |
| mixed cellular infiltration to dermis | 3,43E-03 | N |
| dilated lateral ventricles | 3,46E-03 | N |
| increased circulating alanine transaminase level | 3,81E-03 | N |

| | | |
|--|----------|---|
| decreased prepulse inhibition | 3,92E-03 | N |
| abnormal brain white matter morphology | 4,05E-03 | N |
| increased circulating aspartate transaminase level | 4,34E-03 | N |

ARHGAP39

| Term | P-value | Annotated |
|--|----------|-----------|
| abnormal embryonic cilium morphology | 2,26E-05 | N |
| dilated lateral ventricles | 3,21E-05 | N |
| abnormal ventral spinal root morphology | 8,98E-05 | N |
| abnormal cochlear outer hair cell morphology | 9,02E-05 | N |
| abnormal hippocampus layer morphology | 1,62E-04 | N |
| decreased lymphocyte cell number | 1,83E-04 | N |
| decreased immature B cell number | 2,81E-04 | N |
| polydactyly | 2,85E-04 | N |
| dilated third ventricle | 2,91E-04 | N |
| abnormal organ of Corti morphology | 4,17E-04 | N |
| polycystic kidney | 4,83E-04 | N |
| decreased neutrophil cell number | 4,88E-04 | N |
| herniated diaphragm | 4,92E-04 | N |
| hypotonia | 5,17E-04 | N |
| increased monocyte cell number | 6,57E-04 | N |
| abnormal neural crest cell migration | 7,92E-04 | N |
| decreased motor neuron number | 9,00E-04 | N |
| cochlear hair cell degeneration | 1,09E-03 | N |
| abnormal lymphocyte physiology | 1,21E-03 | N |
| belly spot | 1,24E-03 | N |

FOXH1

| Term | P-value | Annotated |
|---|----------|-----------|
| abnormal primitive streak morphology | 2,96E-31 | Y |
| abnormal primitive streak formation | 3,05E-23 | N |
| abnormal mesoderm development | 1,28E-22 | Y |
| abnormal embryonic-extraembryonic boundary morphology | 4,79E-21 | Y |
| abnormal developmental patterning | 2,50E-20 | N |
| abnormal anterior visceral endoderm morphology | 1,29E-19 | N |
| abnormal rostral-caudal axis patterning | 2,11E-19 | N |
| absent primitive node | 2,13E-18 | Y |
| abnormal ectoderm development | 2,22E-18 | N |
| transposition of great arteries | 5,89E-18 | N |
| abnormal somite development | 7,86E-18 | Y |
| abnormal neural fold formation | 1,36E-15 | Y |
| abnormal axial mesoderm | 2,48E-15 | N |
| abnormal heart looping | 3,51E-14 | Y |
| abnormal embryogenesis/ development | 6,31E-13 | N |

| | | |
|-----------------------------------|----------|---|
| absent mesoderm | 1,17E-12 | N |
| right pulmonary isomerism | 7,26E-12 | N |
| abnormal heart development | 9,15E-12 | Y |
| decreased caudal vertebrae number | 1,77E-11 | N |
| abnormal gastrulation | 1,82E-11 | N |

KIFC2

| Term | P-value | Annotated |
|--|----------|-----------|
| abnormal miniature excitatory postsynaptic currents | 6,38E-07 | N |
| abnormal inhibitory postsynaptic currents | 2,73E-06 | N |
| abnormal spatial learning | 3,81E-06 | N |
| abnormal excitatory postsynaptic currents | 5,50E-06 | N |
| abnormal AMPA-mediated synaptic currents | 5,60E-06 | N |
| reduced long term depression | 7,45E-06 | N |
| abnormal hippocampal mossy fiber morphology | 9,40E-06 | N |
| abnormal long term depression | 1,30E-05 | N |
| enhanced long term potentiation | 2,29E-05 | N |
| enhanced paired-pulse facilitation | 2,72E-05 | N |
| abnormal synaptic vesicle morphology | 4,49E-05 | N |
| abnormal excitatory postsynaptic potential | 5,23E-05 | N |
| abnormal zygomatic bone morphology | 8,26E-05 | N |
| abnormal anxiety-related response | 9,26E-05 | N |
| skin lesions | 9,54E-05 | N |
| abnormal synaptic vesicle recycling | 9,97E-05 | N |
| abnormal brain internal capsule morphology | 1,68E-04 | N |
| clonic seizures | 2,03E-04 | N |
| decreased susceptibility to pharmacologically induced seizures | 2,11E-04 | N |
| abnormal CNS synaptic transmission | 2,11E-04 | N |

CYHR1

| Term | P-value | Annotated |
|--|----------|-----------|
| abnormal brain white matter morphology | 4,74E-08 | N |
| decreased embryo weight | 5,75E-08 | N |
| abnormal lung interstitium morphology | 1,87E-06 | N |
| abnormal reproductive system development | 1,68E-05 | N |
| decreased liver cholesterol level | 2,66E-05 | N |
| abnormal digestion | 4,27E-05 | N |
| dilated third ventricle | 5,09E-05 | N |
| reddish skin | 6,08E-05 | N |
| abnormal astrocyte morphology | 1,54E-04 | N |
| abnormal hematopoietic system physiology | 1,60E-04 | N |
| herniated abdominal wall | 1,63E-04 | N |
| abnormal cell adhesion | 1,64E-04 | N |
| increased keratinocyte proliferation | 2,70E-04 | N |

| | | |
|---|----------|---|
| abnormal epididymal fat pad morphology | 4,92E-04 | N |
| skin lesions | 5,36E-04 | N |
| increased susceptibility to endotoxin shock | 5,73E-04 | N |
| abnormal stomach epithelium morphology | 5,81E-04 | N |
| thick interventricular septum | 6,66E-04 | N |
| decreased circulating insulin level | 7,29E-04 | N |
| abnormal cell migration | 8,07E-04 | N |

VPS28

| Term | P-value | Annotated |
|--|----------|-----------|
| reddish skin | 1,16E-06 | N |
| skin lesions | 2,10E-06 | N |
| large intestinal inflammation | 1,72E-05 | N |
| aneuploidy | 2,85E-05 | N |
| premature hair loss | 2,89E-05 | N |
| alopecia | 1,60E-04 | N |
| increased skin tumor incidence | 2,09E-04 | N |
| increased cellular sensitivity to oxidative stress | 2,27E-04 | N |
| epidermal hyperplasia | 4,84E-04 | N |
| abnormal brain white matter morphology | 5,72E-04 | N |
| abnormal coat appearance | 5,82E-04 | N |
| lung carcinoma | 7,44E-04 | N |
| absent Peyer's patches | 7,58E-04 | N |
| herniated abdominal wall | 7,89E-04 | N |
| diarrhea | 8,46E-04 | N |
| abnormal large intestine crypts of Lieberkuhn morphology | 8,60E-04 | N |
| dilated third ventricle | 1,04E-03 | N |
| abnormal small intestine crypts of Lieberkuhn morphology | 1,15E-03 | N |
| decreased germ cell number | 1,24E-03 | N |
| mixed cellular infiltration to dermis | 1,40E-03 | N |

SCRT1

| Term | P-value | Annotated |
|---|----------|-----------|
| impaired conditioned place preference behavior | 3,30E-12 | N |
| abnormal spatial learning | 8,64E-12 | N |
| abnormal spike wave discharge | 5,55E-11 | N |
| impaired behavioral response to addictive substance | 1,17E-10 | N |
| increased exploration in new environment | 1,60E-10 | N |
| absence seizures | 1,17E-09 | N |
| abnormal nervous system electrophysiology | 1,18E-09 | N |
| enhanced coordination | 1,76E-09 | N |
| abnormal inhibitory postsynaptic currents | 1,13E-08 | N |
| decreased vertical activity | 1,64E-08 | N |
| abnormal behavioral response to xenobiotic | 1,69E-08 | N |

| | | |
|---|----------|---|
| sporadic seizures | 2,07E-08 | N |
| abnormal action potential | 2,15E-08 | N |
| abnormal excitatory postsynaptic currents | 2,89E-08 | N |
| decreased neurotransmitter release | 2,91E-08 | N |
| reduced long term depression | 2,92E-08 | N |
| ataxia | 8,70E-08 | N |
| abnormal brain wave pattern | 2,28E-07 | N |
| impaired swimming | 3,23E-07 | N |
| impaired coordination | 4,00E-07 | N |

ATXN2L

| Term | P-value | Annotated |
|--|----------|-----------|
| dilated lateral ventricles | 4,53E-08 | N |
| decreased susceptibility to viral infection | 1,36E-07 | N |
| increased brain size | 2,85E-07 | N |
| cardia bifida | 7,70E-07 | N |
| abnormal inner cell mass morphology | 1,08E-06 | N |
| abnormal cell death | 1,54E-06 | N |
| small testis | 6,04E-05 | N |
| trabecula carnea hypoplasia | 1,32E-04 | N |
| abnormal gastrulation | 1,95E-04 | N |
| decreased birth body size | 2,03E-04 | N |
| mesangial cell hyperplasia | 3,13E-04 | N |
| thin myocardium compact layer | 3,82E-04 | N |
| abnormal dendritic cell morphology | 4,78E-04 | N |
| abnormal reproductive system physiology | 4,94E-04 | N |
| increased cellular sensitivity to ionizing radiation | 5,19E-04 | N |
| partial postnatal lethality | 5,56E-04 | N |
| dilated kidney collecting duct | 5,90E-04 | N |
| abnormal proerythroblast morphology | 6,08E-04 | N |
| abnormal extraembryonic tissue morphology | 6,16E-04 | N |
| dilated third ventricle | 6,30E-04 | N |

TUFM

| Term | P-value | Annotated |
|--|----------|-----------|
| abnormal mitochondrial morphology | 5,93E-06 | N |
| extended life span | 4,15E-05 | N |
| abnormal mitochondrial physiology | 5,23E-05 | N |
| abnormal aerobic energy metabolism | 7,23E-05 | N |
| astrocytosis | 9,35E-04 | N |
| abnormal mitosis | 1,03E-03 | N |
| abnormal channel response | 1,05E-03 | N |
| reduced male fertility | 1,60E-03 | N |
| decreased erythroid progenitor cell number | 1,90E-03 | N |

| | | |
|--|----------|---|
| abnormal cerebellar cortex morphology | 2,27E-03 | N |
| abnormal cell cycle checkpoint function | 2,35E-03 | N |
| abnormal mechanical nociception | 2,55E-03 | N |
| cryptorchism | 2,86E-03 | N |
| complete embryonic lethality between implantation and placenta | 3,22E-03 | N |
| partial lethality at weaning | 3,82E-03 | N |
| abnormal embryonic neuroepithelial layer differentiation | 3,83E-03 | N |
| abnormal tail bud morphology | 4,69E-03 | N |
| hydroureter | 4,83E-03 | N |
| abnormal mitotic spindle morphology | 5,06E-03 | N |
| vertebral transformation | 5,11E-03 | N |

SH2B1

| Term | P-value | Annotated |
|--|----------|-----------|
| microgliosis | 4,98E-04 | N |
| complete embryonic lethality before implantation | 9,28E-04 | N |
| partial lethality at weaning | 9,61E-04 | N |
| spongiform encephalopathy | 1,16E-03 | N |
| abnormal trophoblast layer morphology | 1,51E-03 | N |
| Leydig cell hyperplasia | 2,19E-03 | N |
| abnormal embryonic neuroepithelial layer differentiation | 2,39E-03 | N |
| absent common myeloid progenitor cells | 3,65E-03 | N |
| failure to form blastocoele | 4,20E-03 | N |
| abnormal oligodendrocyte morphology | 4,45E-03 | N |
| abnormal glycogen homeostasis | 4,51E-03 | N |
| abnormal aorta elastic tissue morphology | 4,67E-03 | N |
| renal tubule atrophy | 5,59E-03 | N |
| hunched posture | 5,60E-03 | N |
| decreased susceptibility to diet-induced obesity | 5,82E-03 | N |
| astrocytosis | 6,01E-03 | N |
| thin ventricular wall | 6,18E-03 | N |
| paraparesis | 6,23E-03 | N |
| inner cell mass degeneration | 6,30E-03 | N |
| incomplete cephalic closure | 6,41E-03 | N |

NFATC2IP

| Term | P-value | Annotated |
|---|----------|-----------|
| abnormal chromosome morphology | 1,07E-09 | N |
| partial embryonic lethality before implantation | 2,09E-05 | N |
| absent somites | 2,61E-05 | N |
| abnormal inner cell mass proliferation | 4,01E-05 | N |
| polyploidy | 1,11E-04 | N |
| abnormal inner cell mass morphology | 1,13E-04 | N |
| abnormal blastocyst morphology | 1,38E-04 | N |

| | | |
|--|----------|---|
| complete embryonic lethality before somite formation | 1,58E-04 | N |
| abnormal outflow tract development | 2,15E-04 | N |
| abnormal cell cycle | 2,91E-04 | N |
| chromosome breakage | 3,22E-04 | N |
| decreased cell proliferation | 4,74E-04 | N |
| decreased ovary weight | 5,98E-04 | N |
| ectopic cerebellar granule cells | 7,51E-04 | N |
| progressive muscle weakness | 7,72E-04 | N |
| absent ovarian follicles | 9,30E-04 | N |
| increased drinking behavior | 1,58E-03 | N |
| chromosomal instability | 1,75E-03 | N |
| abnormal cell nucleus morphology | 2,28E-03 | N |
| increased histiocytic sarcoma incidence | 2,35E-03 | N |

SPNS1

| Term | P-value | Annotated |
|--|----------|-----------|
| abnormal lysosome morphology | 9,16E-10 | N |
| astrocytosis | 5,15E-08 | N |
| Purkinje cell degeneration | 7,77E-06 | N |
| short stride length | 1,22E-05 | N |
| abnormal lysosome physiology | 3,05E-05 | N |
| abnormal cued conditioning behavior | 3,54E-05 | N |
| increased interleukin-2 secretion | 4,94E-05 | N |
| muscular atrophy | 1,64E-04 | N |
| hindlimb paralysis | 1,82E-04 | N |
| abnormal Reichert's membrane morphology | 2,18E-04 | N |
| epidermal hyperplasia | 2,71E-04 | N |
| abnormal retinal ganglion layer morphology | 2,76E-04 | N |
| limb grasping | 3,39E-04 | N |
| myeloid hyperplasia | 3,83E-04 | N |
| absent kidney | 4,07E-04 | N |
| gliosis | 4,30E-04 | N |
| abnormal chromosome morphology | 5,28E-04 | N |
| abnormal anterior visceral endoderm morphology | 9,22E-04 | N |
| microgliosis | 1,07E-03 | N |
| single kidney | 1,07E-03 | N |

LAT

| Term | P-value | Annotated |
|--|----------|-----------|
| arrested T cell differentiation | 1,13E-75 | Y |
| abnormal T cell differentiation | 3,52E-71 | Y |
| decreased CD4-positive T cell number | 5,23E-70 | N |
| abnormal CD8-positive T cell differentiation | 1,67E-67 | N |
| abnormal double-negative T cell morphology | 8,78E-66 | Y |

| | | |
|---|----------|---|
| decreased CD8-positive T cell number | 1,03E-65 | N |
| abnormal positive T cell selection | 1,66E-62 | N |
| abnormal thymocyte activation | 5,83E-62 | Y |
| thymus hypoplasia | 2,43E-55 | Y |
| decreased interleukin-2 secretion | 3,13E-53 | N |
| decreased double-positive T cell number | 2,02E-51 | Y |
| increased T cell apoptosis | 1,83E-49 | N |
| abnormal T cell morphology | 5,46E-48 | Y |
| abnormal T cell activation | 9,40E-48 | Y |
| abnormal T cell subpopulation ratio | 5,31E-47 | Y |
| decreased T cell proliferation | 8,76E-47 | Y |
| absent T cells | 2,29E-46 | Y |
| abnormal CD8-positive T cell morphology | 2,10E-45 | Y |
| decreased T cell number | 2,63E-44 | Y |
| decreased thymocyte number | 2,90E-44 | Y |

SULT1A1

SULT1A2

| Term | P-value | Annotated |
|--|----------|-----------|
| increased sensitivity to induced morbidity/mortality | 1,68E-09 | |
| abnormal pregnancy | 1,69E-08 | |
| abnormal blood coagulation | 1,03E-07 | |
| abnormal circulating amino acid level | 2,18E-07 | |
| abnormal liver physiology | 2,43E-07 | |
| abnormal homeostasis | 9,13E-07 | |
| hepatic steatosis | 9,29E-07 | |
| increased circulating cholesterol level | 2,41E-06 | |
| abnormal lipid homeostasis | 3,78E-06 | |
| abnormal iron level | 3,78E-06 | |
| expanded mesangial matrix | 5,89E-06 | |
| abnormal amino acid level | 8,28E-06 | |
| abnormal enterocyte proliferation | 9,84E-06 | |
| gastrointestinal hemorrhage | 1,04E-05 | |
| increased circulating aldosterone level | 1,27E-05 | |
| increased circulating triglyceride level | 2,83E-05 | |
| abnormal leukocyte morphology | 3,01E-05 | |
| increased circulating ammonia level | 3,47E-05 | |
| abnormal bile salt level | 3,59E-05 | |
| other aberrant phenotype | 4,63E-05 | |

CCDC101

| Term | P-value | Annotated |
|--------------------------------|----------|-----------|
| absent somites | 3,92E-06 | N |
| abnormal chromosome morphology | 2,29E-05 | N |

| | | |
|---|----------|---|
| small Peyer's patches | 2,90E-05 | N |
| decreased immunoglobulin level | 3,17E-04 | N |
| decreased Peyer's patch number | 3,34E-04 | N |
| abnormal cytokine level | 6,78E-04 | N |
| increased hematopoietic stem cell number | 6,90E-04 | N |
| decreased IgM level | 8,30E-04 | N |
| abnormal extraembryonic endoderm formation | 9,16E-04 | N |
| complete embryonic lethality before implantation | 9,18E-04 | N |
| liver hemorrhage | 1,15E-03 | N |
| increased leukocyte cell number | 1,16E-03 | N |
| abnormal enteric nervous system morphology | 1,34E-03 | N |
| abnormal lymphocyte cell number | 1,49E-03 | N |
| abnormal Peyer's patch morphology | 1,52E-03 | N |
| abnormal molar morphology | 1,77E-03 | N |
| abnormal Peyer's patch germinal center morphology | 2,05E-03 | N |
| increased IgG1 level | 2,09E-03 | N |
| decreased IgG level | 2,11E-03 | N |
| abnormal spleen marginal zone morphology | 2,54E-03 | N |

NRXN1

| Term | P-value | Annotated |
|--|----------|-----------|
| abnormal inhibitory postsynaptic currents | 1,60E-26 | N |
| abnormal CNS synaptic transmission | 2,60E-25 | N |
| abnormal GABA-mediated receptor currents | 2,63E-24 | N |
| abnormal excitatory postsynaptic currents | 1,21E-22 | N |
| hyperactivity | 6,32E-18 | N |
| abnormal synaptic transmission | 1,36E-17 | N |
| abnormal spatial learning | 7,66E-17 | N |
| abnormal synaptic vesicle number | 3,62E-16 | N |
| abnormal posture | 6,36E-16 | N |
| ataxia | 1,43E-14 | N |
| abnormal brain wave pattern | 2,38E-14 | N |
| seizures | 6,80E-14 | N |
| convulsive seizures | 1,40E-13 | N |
| abnormal nervous system electrophysiology | 4,86E-13 | N |
| abnormal spatial reference memory | 4,89E-13 | N |
| abnormal excitatory postsynaptic potential | 8,07E-13 | N |
| abnormal hippocampus morphology | 1,16E-12 | N |
| impaired coordination | 1,37E-12 | N |
| increased startle reflex | 1,52E-12 | N |
| abnormal social/conspecific interaction | 3,89E-12 | N |

NUPR1

| Term | P-value | Annotated |
|------|---------|-----------|
|------|---------|-----------|

| | | |
|---|----------|---|
| abnormal aorta wall morphology | 3,39E-08 | N |
| abnormal bone mineralization | 4,70E-08 | N |
| increased cellular sensitivity to hydrogen peroxide | 1,12E-07 | N |
| abnormal aorta tunica media morphology | 1,70E-07 | N |
| increased brain weight | 1,72E-07 | N |
| abnormal compact bone morphology | 2,25E-07 | N |
| abnormal chondrocyte morphology | 4,65E-07 | N |
| decreased trabecular bone thickness | 5,26E-07 | N |
| abnormal skeleton physiology | 5,96E-07 | N |
| hyporesponsive to tactile stimuli | 7,01E-07 | N |
| abnormal bone structure | 1,77E-06 | N |
| decreased bone volume | 3,45E-06 | N |
| abnormal long bone epiphyseal plate morphology | 3,85E-06 | N |
| increased hepatocyte apoptosis | 5,00E-06 | N |
| increased lean body mass | 5,32E-06 | N |
| overexpanded pulmonary alveoli | 6,26E-06 | N |
| abnormal hippocampus layer morphology | 6,70E-06 | N |
| oxidative stress | 1,03E-05 | N |
| abnormal trabecular bone morphology | 1,51E-05 | N |
| abnormal enteric neuron morphology | 1,70E-05 | N |

NPAS2

| Term | P-value | Annotated |
|--|----------|-----------|
| shortened circadian period | 7,01E-16 | N |
| increased incidence of corneal inflammation | 6,87E-13 | N |
| increased circulating aspartate transaminase level | 9,77E-13 | N |
| abnormal tail movements | 2,61E-12 | N |
| increased total fat pad weight | 3,29E-12 | N |
| abnormal circulating hormone level | 5,60E-12 | N |
| decreased uterus weight | 2,06E-10 | N |
| abnormal joint morphology | 1,55E-09 | N |
| early reproductive senescence | 7,12E-09 | N |
| increased bone resorption | 8,64E-09 | N |
| hypotension | 1,17E-08 | Y |
| increased circulating alanine transaminase level | 5,77E-08 | N |
| abnormal hair cycle | 2,11E-07 | N |
| decreased heart weight | 2,33E-07 | N |
| decreased mean systemic arterial blood pressure | 3,28E-07 | Y |
| abnormal metabolism | 5,48E-07 | N |
| abnormal response to injury | 6,87E-07 | Y |
| abnormal vertebral column morphology | 1,38E-06 | N |
| abnormal corneal stroma morphology | 1,45E-06 | N |
| osteoporosis | 2,24E-06 | N |

KCNMA1

| Term | P-value | Annotated |
|---|----------|-----------|
| myoclonus | 2,27E-08 | N |
| decreased vasoconstriction | 6,72E-08 | N |
| abnormal miniature excitatory postsynaptic currents | 1,24E-07 | N |
| abnormal heart left ventricle morphology | 6,69E-07 | N |
| abnormal patella morphology | 6,76E-07 | N |
| distended urinary bladder | 1,79E-06 | N |
| abnormal brain wave pattern | 2,98E-06 | N |
| abnormal cartilage development | 3,24E-06 | N |
| limb grasping | 5,34E-06 | N |
| intracerebral hemorrhage | 8,26E-06 | N |
| abnormal GABA-mediated receptor currents | 9,18E-06 | N |
| decreased mean systemic arterial blood pressure | 1,03E-05 | N |
| abnormal synaptic plasticity | 1,08E-05 | N |
| decreased length of long bones | 1,21E-05 | N |
| decreased aggression towards males | 1,67E-05 | N |
| abnormal pancreatic beta cell physiology | 2,70E-05 | N |
| abnormal tibia morphology | 3,49E-05 | N |
| abnormal long bone epiphysis morphology | 3,54E-05 | N |
| abnormal long bone hypertrophic chondrocyte zone | 3,73E-05 | N |
| abnormal skeleton physiology | 3,93E-05 | N |

DEC1

| Term | P-value | Annotated |
|---|----------|-----------|
| hydrocephaly | 3,16E-03 | N |
| abnormal startle reflex | 5,63E-03 | N |
| absent incisors | 8,57E-03 | N |
| abnormal supraoccipital bone morphology | 1,35E-02 | N |
| abnormal exocrine pancreas morphology | 1,48E-02 | N |
| decreased oocyte number | 1,57E-02 | N |
| abnormal pituitary gland morphology | 1,66E-02 | N |
| impaired passive avoidance behavior | 1,74E-02 | N |
| abnormal milk composition | 2,14E-02 | N |
| abnormal drinking behavior | 2,18E-02 | N |
| abnormal egg cylinder morphology | 2,21E-02 | N |
| absent distortion product otoacoustic emissions | 2,50E-02 | N |
| abnormal platelet physiology | 2,76E-02 | N |
| spinal hemorrhage | 2,84E-02 | N |
| intracerebral hemorrhage | 2,92E-02 | N |
| abnormal acrosome morphology | 3,25E-02 | N |
| muscle spasm | 3,28E-02 | N |
| abnormal eye distance/ position | 3,43E-02 | N |
| rib fusion | 3,54E-02 | N |

| | | |
|----------------------|----------|---|
| stereotypic behavior | 3,80E-02 | N |
|----------------------|----------|---|

SDCCAG8

| Term | P-value | Annotated |
|---|----------|-----------|
| abnormal direction of heart looping | 3,09E-04 | N |
| dilated heart right ventricle | 9,33E-04 | N |
| extramedullary hematopoiesis | 1,03E-03 | N |
| decreased mature ovarian follicle number | 1,26E-03 | N |
| increased triglyceride level | 1,40E-03 | N |
| abnormal left-right axis patterning | 1,71E-03 | N |
| absent embryonic cilia | 1,87E-03 | N |
| myocardial necrosis | 2,22E-03 | N |
| increased pituitary adenoma incidence | 2,35E-03 | N |
| abnormal artery morphology | 2,65E-03 | N |
| prolonged PR interval | 2,76E-03 | N |
| reduced female fertility | 3,07E-03 | N |
| abnormal immune serum protein physiology | 3,37E-03 | N |
| increased leukocyte cell number | 3,42E-03 | N |
| abnormal bone marrow cavity morphology | 4,31E-03 | N |
| abnormal cochlear sensory epithelium morphology | 4,51E-03 | N |
| osteoporosis | 4,64E-03 | N |
| increased cellular sensitivity to gamma-irradiation | 5,44E-03 | N |
| abnormal osteoblast physiology | 5,96E-03 | N |
| abnormal enteric ganglia morphology | 7,37E-03 | N |

AKT3

| Term | P-value | Annotated |
|--|----------|-----------|
| abnormal hippocampus pyramidal cell layer | 1,66E-13 | N |
| small hippocampus | 1,80E-08 | N |
| abnormal neocortex morphology | 5,64E-06 | N |
| decreased neuron number | 6,53E-06 | N |
| placental labyrinth hypoplasia | 1,09E-05 | N |
| decreased circulating thyroxine level | 1,46E-05 | N |
| abnormal brain ventricle morphology | 1,73E-05 | N |
| abnormal heart septum morphology | 2,56E-05 | N |
| abnormal fluid regulation | 8,97E-05 | N |
| decreased circulating triiodothyronine level | 1,46E-04 | N |
| abnormal sensory capabilities/reflexes/nociception | 1,73E-04 | N |
| abnormal hippocampus morphology | 1,87E-04 | N |
| abnormal cerebellar foliation | 1,95E-04 | N |
| decreased triglyceride level | 2,44E-04 | N |
| abnormal postnatal subventricular zone morphology | 2,53E-04 | N |
| skin lesions | 2,60E-04 | N |
| impaired balance | 2,63E-04 | N |

| | | |
|--|----------|---|
| increased susceptibility to weight gain | 2,77E-04 | N |
| abnormal social/consppecific interaction | 3,00E-04 | N |
| abnormal foot pigmentation | 3,25E-04 | N |

CRYZL1

| Term | P-value | Annotated |
|--|----------|-----------|
| increased incidence of induced tumors | 5,06E-06 | N |
| small seminiferous tubules | 2,14E-05 | N |
| decreased double-positive T cell number | 8,41E-05 | N |
| myopathy | 9,57E-05 | N |
| increased susceptibility to atherosclerosis | 1,06E-04 | N |
| abnormal cell-mediated immunity | 1,77E-04 | N |
| abnormal synaptic vesicle recycling | 2,07E-04 | N |
| abnormal adrenal gland secretion | 2,27E-04 | N |
| abnormal bone marrow cell physiology | 2,88E-04 | N |
| failure of initiation of embryo turning | 3,45E-04 | N |
| abnormal muscle fiber morphology | 3,76E-04 | N |
| decreased susceptibility to diet-induced obesity | 3,89E-04 | N |
| enlarged spleen | 6,44E-04 | N |
| abnormal pulmonary alveolus morphology | 6,55E-04 | N |
| abnormal emotion/affect behavior | 7,16E-04 | N |
| increased B cell number | 7,26E-04 | N |
| decreased birth weight | 8,26E-04 | N |
| abnormal Sertoli cell morphology | 8,95E-04 | N |
| decreased corpus callosum size | 9,05E-04 | N |
| abnormal T cell number | 9,29E-04 | N |

ITSN1

| Term | P-value | Annotated |
|--|----------|-----------|
| increased susceptibility to noise-induced hearing loss | 7,77E-08 | N |
| decreased brain size | 2,82E-07 | N |
| increased liver triglyceride level | 9,15E-07 | N |
| increased percent body fat | 2,85E-06 | N |
| increased fat cell size | 9,94E-06 | N |
| abnormal behavior | 3,11E-05 | N |
| microgliosis | 4,08E-05 | N |
| increased spleen iron level | 4,64E-05 | N |
| abnormal crypts of Lieberkuhn morphology | 6,53E-05 | N |
| complete embryonic lethality | 6,64E-05 | N |
| abnormal hippocampal commissure morphology | 7,24E-05 | N |
| decreased circulating free fatty acid level | 7,92E-05 | N |
| decreased thymocyte apoptosis | 1,00E-04 | N |
| abnormal embryonic growth/weight/body size | 1,03E-04 | N |
| decreased hemoglobin content | 1,14E-04 | N |

| | | |
|---------------------------------------|----------|---|
| failure of primitive streak formation | 1,19E-04 | N |
| enlarged lateral ventricles | 1,21E-04 | N |
| ectopic Purkinje cell | 1,29E-04 | N |
| abnormal otic capsule morphology | 1,47E-04 | N |
| abnormal head morphology | 1,67E-04 | N |

SON

| Term | P-value | Annotated |
|--|----------|-----------|
| decreased birth body size | 2,36E-07 | N |
| increased cellular sensitivity to ionizing radiation | 1,62E-06 | N |
| abnormal anterior visceral endoderm morphology | 7,92E-06 | N |
| abnormal DNA replication | 1,12E-05 | N |
| abnormal granulocyte differentiation | 1,31E-05 | N |
| increased incidence of induced tumors | 1,32E-05 | N |
| decreased fetal size | 1,65E-05 | N |
| incomplete embryo turning | 2,20E-05 | N |
| complete perinatal lethality | 2,59E-05 | N |
| pericardial effusion | 2,66E-05 | N |
| ventricular septal defect | 3,52E-05 | N |
| abnormal ectoderm development | 3,62E-05 | N |
| complete embryonic lethality | 4,14E-05 | N |
| partial postnatal lethality | 5,08E-05 | N |
| small branchial arch | 5,15E-05 | N |
| complete embryonic lethality during organogenesis | 5,69E-05 | N |
| increased mortality induced by gamma-irradiation | 5,97E-05 | N |
| abnormal brain internal capsule morphology | 6,07E-05 | N |
| abnormal visceral endoderm morphology | 7,58E-05 | N |
| decreased cell proliferation | 7,77E-05 | N |

GART

| Term | P-value | Annotated |
|--|----------|-----------|
| complete embryonic lethality between implantation and placenta | 3,21E-05 | N |
| abnormal DNA repair | 3,46E-05 | N |
| failure to form blastocoele | 7,42E-05 | N |
| induced chromosome breakage | 7,50E-05 | N |
| absent inner cell mass | 8,38E-05 | N |
| complete embryonic lethality before somite formation | 1,23E-04 | N |
| increased cellular sensitivity to ionizing radiation | 1,23E-04 | N |
| decreased tumor latency | 1,64E-04 | N |
| decreased spleen red pulp amount | 2,63E-04 | N |
| inner cell mass degeneration | 3,38E-04 | N |
| abnormal food intake | 7,30E-04 | N |
| T cell derived lymphoma | 8,00E-04 | N |
| complete embryonic lethality before implantation | 8,24E-04 | N |

| | | |
|--|----------|---|
| abnormal cell cycle checkpoint function | 8,32E-04 | N |
| increased fibrosarcoma incidence | 9,67E-04 | N |
| increased susceptibility to noise-induced hearing loss | 1,15E-03 | N |
| decreased single-positive T cell number | 1,19E-03 | N |
| small hippocampus | 1,40E-03 | N |
| hyperactivity | 1,46E-03 | N |
| abnormal digit morphology | 1,63E-03 | N |

DNAJC28

| Term | P-value | Annotated |
|---|----------|-----------|
| abnormal mitochondrial physiology | 2,54E-04 | N |
| abnormal femur morphology | 5,63E-04 | N |
| abnormal otic vesicle development | 1,02E-03 | N |
| abnormal ovarian folliculogenesis | 1,21E-03 | N |
| reduced female fertility | 1,29E-03 | N |
| partial perinatal lethality | 1,37E-03 | N |
| abnormal skeleton development | 1,82E-03 | N |
| early reproductive senescence | 2,49E-03 | N |
| abnormal ureteric bud morphology | 2,49E-03 | N |
| abnormal stationary movement | 2,54E-03 | N |
| abnormal corpus callosum morphology | 2,59E-03 | N |
| abnormal bone remodeling | 3,33E-03 | N |
| enlarged lateral ventricles | 3,35E-03 | N |
| abnormal thyroid cartilage morphology | 3,97E-03 | N |
| abnormal tibia morphology | 4,01E-03 | N |
| decreased primordial germ cell number | 4,24E-03 | N |
| abnormal kidney morphology | 4,76E-03 | N |
| abnormal reproductive system morphology | 5,07E-03 | N |
| short maxilla | 5,22E-03 | N |
| abnormal cochlear sensory epithelium morphology | 6,08E-03 | N |

TMEM50B

| Term | P-value | Annotated |
|---|----------|-----------|
| increased susceptibility to ischemic brain injury | 1,00E-04 | N |
| abnormal DNA methylation | 1,61E-04 | N |
| arrested T cell differentiation | 1,64E-04 | N |
| partial perinatal lethality | 1,84E-04 | N |
| abnormal type II pneumocyte morphology | 2,75E-04 | N |
| increased cardiomyocyte apoptosis | 2,88E-04 | N |
| decreased double-negative T cell number | 3,69E-04 | N |
| abnormal somite development | 4,47E-04 | N |
| abnormal spongiotrophoblast layer morphology | 5,59E-04 | N |
| myocardial necrosis | 7,18E-04 | N |
| abnormal pericardium morphology | 1,12E-03 | N |

| | | |
|---|----------|---|
| abnormal vas deferens morphology | 1,21E-03 | N |
| abnormal cardiac muscle relaxation | 1,32E-03 | N |
| abnormal immune system organ morphology | 1,34E-03 | N |
| abnormal liver morphology | 1,73E-03 | N |
| abnormal T cell activation | 1,84E-03 | N |
| abnormal double-positive T cell morphology | 2,02E-03 | N |
| decreased gonadal fat pad weight | 2,06E-03 | N |
| increased bone mass | 2,11E-03 | N |
| increased cellular sensitivity to gamma-irradiation | 2,13E-03 | N |

IFNGR2

| Term | P-value | Annotated |
|---|----------|-----------|
| abnormal macrophage physiology | 4,19E-17 | N |
| large intestinal inflammation | 1,38E-15 | N |
| decreased interleukin-12b secretion | 6,30E-15 | N |
| decreased interleukin-12 secretion | 1,03E-12 | N |
| myositis | 5,23E-12 | N |
| decreased circulating tumor necrosis factor level | 9,28E-12 | N |
| decreased tumor necrosis factor secretion | 9,35E-12 | N |
| abnormal tumor necrosis factor level | 4,35E-11 | N |
| increased IgM level | 1,62E-10 | N |
| abnormal mesenteric lymph node morphology | 1,95E-10 | N |
| increased marginal zone B cell number | 2,06E-10 | N |
| decreased interleukin-6 secretion | 7,04E-10 | N |
| decreased interferon-beta secretion | 8,04E-10 | N |
| impaired neutrophil phagocytosis | 1,22E-09 | N |
| abnormal interleukin level | 1,89E-09 | N |
| decreased dendritic cell number | 2,15E-09 | N |
| increased B cell proliferation | 3,53E-09 | N |
| decreased IgG2a level | 3,61E-09 | N |
| decreased susceptibility to induced colitis | 4,56E-09 | N |
| abnormal Peyer's patch morphology | 5,21E-09 | N |

SBNO1

| Term | P-value | Annotated |
|----------------------------------|----------|-----------|
| abnormal spermatocyte morphology | 1,36E-05 | N |
| abnormal spermatid morphology | 2,91E-05 | N |
| male germ cell apoptosis | 3,53E-05 | N |
| right aortic arch | 3,82E-05 | N |
| small testis | 4,14E-05 | N |
| arrest of spermatogenesis | 8,46E-05 | N |
| pericardial effusion | 2,23E-04 | N |
| decreased urine potassium level | 8,89E-04 | N |
| thymus atrophy | 9,84E-04 | N |

| | | |
|--|----------|---|
| spleen atrophy | 1,01E-03 | N |
| abnormal sperm head morphology | 1,18E-03 | N |
| skin papilloma | 1,28E-03 | N |
| abnormal hippocampal commissure morphology | 1,39E-03 | N |
| abnormal digestive system development | 1,42E-03 | N |
| abnormal sperm midpiece morphology | 1,59E-03 | N |
| complete embryonic lethality between implantation and placenta | 1,84E-03 | N |
| decreased male germ cell number | 1,91E-03 | N |
| decreased urine sodium level | 2,14E-03 | N |
| decreased testis weight | 2,34E-03 | N |
| male infertility | 2,93E-03 | N |

SETD8

| Term | P-value | Annotated |
|---|----------|-----------|
| abnormal brain internal capsule morphology | 3,42E-04 | N |
| decreased physiological sensitivity to xenobiotic | 2,45E-03 | N |
| skin papilloma | 2,59E-03 | N |
| abnormal nitric oxide homeostasis | 2,97E-03 | N |
| abnormal DNA replication | 5,10E-03 | N |
| abnormal visceral endoderm morphology | 5,25E-03 | N |
| polydipsia | 5,66E-03 | N |
| abnormal erythropoiesis | 6,07E-03 | N |
| abnormal ventral body wall morphology | 6,33E-03 | N |
| abnormal megakaryocyte differentiation | 6,87E-03 | N |
| polyploidy | 6,94E-03 | N |
| abnormal male reproductive system morphology | 7,75E-03 | N |
| abnormal apoptosis | 7,93E-03 | N |
| decreased follicle stimulating hormone level | 8,40E-03 | N |
| anovulation | 8,82E-03 | N |
| small ovary | 9,64E-03 | N |
| abnormal female reproductive system morphology | 9,81E-03 | N |
| abnormal bone marrow cell physiology | 9,92E-03 | N |
| decreased spleen germinal center size | 1,09E-02 | N |
| short premaxilla | 1,17E-02 | N |

RILPL2

| Term | P-value | Annotated |
|------------------------------------|----------|-----------|
| increased T cell proliferation | 5,85E-11 | N |
| increased interleukin-17 secretion | 1,57E-10 | N |
| enlarged lymph nodes | 5,55E-09 | N |
| increased IgE level | 8,47E-09 | N |
| decreased interleukin-2 secretion | 2,14E-08 | N |
| increased B cell proliferation | 4,05E-08 | N |
| abnormal thymocyte activation | 5,10E-08 | N |

| | | |
|---|----------|---|
| increased susceptibility to experimental autoimmune encephalomyelitis | 6,40E-08 | N |
| abnormal CD4-positive T cell physiology | 8,56E-08 | N |
| abnormal cytokine secretion | 1,02E-07 | N |
| increased IgA level | 1,19E-07 | N |
| abnormal regulatory T cell physiology | 1,38E-07 | N |
| decreased interleukin-4 secretion | 2,45E-07 | N |
| increased IgG2a level | 2,61E-07 | N |
| increased IgG1 level | 2,66E-07 | N |
| abnormal class switch recombination | 3,53E-07 | N |
| increased plasma cell number | 3,56E-07 | N |
| abnormal T cell physiology | 3,66E-07 | N |
| abnormal dendritic cell physiology | 3,96E-07 | N |
| decreased susceptibility to experimental autoimmune encephalomyelitis | 8,26E-07 | N |

C12orf65

| Term | P-value | Annotated |
|---|----------|-----------|
| increased gastrointestinal tumor incidence | 1,17E-03 | N |
| impaired olfaction | 5,98E-03 | N |
| abnormal nervous system physiology | 7,47E-03 | N |
| abnormal colon morphology | 7,61E-03 | N |
| abnormal choroid pigmentation | 8,08E-03 | N |
| abnormal medulla oblongata morphology | 8,19E-03 | N |
| abnormal iris pigmentation | 8,83E-03 | N |
| abnormal chondrocyte morphology | 1,04E-02 | N |
| ovary atrophy | 1,05E-02 | N |
| irregular coat pigmentation | 1,13E-02 | N |
| transposition of great arteries | 1,16E-02 | N |
| abnormal neural tube closure | 1,43E-02 | N |
| abnormal seizure response to electrical stimulation | 1,61E-02 | N |
| abnormal hippocampus CA1 region morphology | 1,71E-02 | N |
| increased cardiomyocyte apoptosis | 1,71E-02 | N |
| absent distortion product otoacoustic emissions | 1,76E-02 | N |
| abnormal pancreas development | 1,77E-02 | N |
| increased drinking behavior | 1,77E-02 | N |
| decreased respiratory quotient | 1,86E-02 | N |
| abnormal intestinal mucosa morphology | 1,92E-02 | N |

MPHOSPH9

| Term | P-value | Annotated |
|-------------------------------------|----------|-----------|
| abnormal mitotic spindle morphology | 7,78E-06 | N |
| abnormal chromosome morphology | 1,53E-05 | N |
| abnormal mitosis | 2,10E-05 | N |
| abnormal cell nucleus morphology | 7,73E-05 | N |
| increased tumor incidence | 1,02E-04 | N |

| | | |
|--|----------|---|
| abnormal spermatogonia proliferation | 2,85E-04 | N |
| small stomach | 4,33E-04 | N |
| abnormal mammary gland epithelium morphology | 4,35E-04 | N |
| cervical vertebral transformation | 5,41E-04 | N |
| increased transitional stage B cell number | 7,79E-04 | N |
| intestinal adenocarcinoma | 7,92E-04 | N |
| increased lymphoma incidence | 9,61E-04 | N |
| failure of zygotic cell division | 1,09E-03 | N |
| dystrophic muscle | 1,15E-03 | N |
| decreased B cell proliferation | 1,17E-03 | N |
| abnormal positive T cell selection | 1,25E-03 | N |
| delayed kidney development | 1,31E-03 | N |
| skin papilloma | 1,66E-03 | N |
| atrioventricular septal defect | 1,68E-03 | N |
| increased B cell apoptosis | 1,72E-03 | N |

SNRNP35

| Term | P-value | Annotated |
|--|----------|-----------|
| decreased lymphocyte cell number | 4,63E-04 | N |
| intestinal inflammation | 6,83E-04 | N |
| abnormal brain morphology | 7,10E-04 | N |
| increased double-positive T cell number | 1,23E-03 | N |
| small placenta | 1,34E-03 | N |
| thymus hypoplasia | 1,42E-03 | N |
| abnormal action potential | 1,47E-03 | N |
| leukemia | 2,07E-03 | N |
| astrocytosis | 2,12E-03 | N |
| absent T cells | 2,32E-03 | N |
| neurodegeneration | 2,54E-03 | N |
| seminiferous tubule degeneration | 2,81E-03 | N |
| decreased double-positive T cell number | 2,88E-03 | N |
| increased circulating luteinizing hormone level | 3,02E-03 | N |
| abnormal cell physiology | 3,33E-03 | N |
| abnormal miniature inhibitory postsynaptic currents | 3,44E-03 | N |
| arrested T cell differentiation | 3,61E-03 | N |
| complete embryonic lethality | 3,69E-03 | N |
| decreased T cell number | 3,80E-03 | N |
| increased cellular sensitivity to ionizing radiation | 3,91E-03 | N |

RILPL1

| Term | P-value | Annotated |
|--------------------------------|----------|-----------|
| skeletal muscle fiber necrosis | 2,97E-07 | N |
| abnormal thymus involution | 5,32E-06 | N |
| absent mature B cells | 5,38E-06 | N |

| | | |
|--|----------|---|
| abnormal B cell morphology | 1,08E-05 | N |
| spleen hypoplasia | 1,51E-05 | N |
| decreased B cell number | 4,02E-05 | N |
| increased macrophage cell number | 5,73E-05 | N |
| arrested B cell differentiation | 5,78E-05 | N |
| increased skeletal muscle fiber size | 6,78E-05 | N |
| abnormal supraoccipital bone morphology | 8,05E-05 | N |
| centrally nucleated skeletal muscle fibers | 9,80E-05 | N |
| abnormal skeletal muscle morphology | 9,97E-05 | N |
| abnormal notochord morphology | 1,01E-04 | N |
| leukemia | 1,19E-04 | N |
| abnormal lymphopoiesis | 1,25E-04 | N |
| abnormal B cell differentiation | 2,22E-04 | N |
| abnormal muscle physiology | 2,44E-04 | N |
| small branchial arch | 3,13E-04 | N |
| increased cochlear inner hair cell number | 3,40E-04 | N |
| increased cochlear outer hair cell number | 3,84E-04 | N |

PITPNM2

| Term | P-value | Annotated |
|---|----------|-----------|
| reduced long term depression | 4,96E-06 | N |
| decreased double-positive T cell number | 1,03E-05 | N |
| uterus hypoplasia | 1,65E-05 | N |
| abnormal T cell physiology | 8,79E-05 | N |
| abnormal behavior | 1,16E-04 | N |
| decreased T cell number | 2,01E-04 | N |
| increased bleeding time | 2,27E-04 | N |
| abnormal learning/ memory | 2,34E-04 | N |
| arrested T cell differentiation | 2,56E-04 | N |
| abnormal T cell differentiation | 2,90E-04 | N |
| abnormal trabecular bone morphology | 3,62E-04 | N |
| impaired cued conditioning behavior | 4,34E-04 | N |
| decreased chemically-elicited antinociception | 5,06E-04 | N |
| abnormal double-negative T cell morphology | 5,12E-04 | N |
| delayed female fertility | 5,14E-04 | N |
| abnormal excitatory postsynaptic potential | 5,15E-04 | N |
| impaired contextual conditioning behavior | 6,63E-04 | N |
| decreased thymocyte number | 7,12E-04 | N |
| abnormal calcium ion homeostasis | 8,60E-04 | N |
| abnormal estrous cycle | 9,59E-04 | N |

STK24

| Term | P-value | Annotated |
|---|----------|-----------|
| abnormal immune system organ morphology | 1,73E-05 | N |

| | | |
|---|----------|---|
| small first branchial arch | 3,72E-05 | N |
| decreased cell proliferation | 4,93E-05 | N |
| abnormal immune system cell morphology | 6,45E-05 | N |
| premature aging | 6,99E-05 | N |
| increased cellular sensitivity to ultraviolet irradiation | 8,26E-05 | N |
| decreased spleen weight | 1,08E-04 | N |
| failure of chorioallantoic fusion | 1,18E-04 | N |
| increased single-positive T cell number | 1,21E-04 | N |
| increased energy expenditure | 1,59E-04 | N |
| abnormal placental labyrinth vasculature morphology | 1,88E-04 | N |
| wavy neural tube | 2,09E-04 | N |
| decreased thymus weight | 2,99E-04 | N |
| short premaxilla | 3,07E-04 | N |
| induced chromosome breakage | 3,20E-04 | N |
| abnormal cerebellar foliation | 3,54E-04 | N |
| liver hypoplasia | 4,42E-04 | N |
| small cerebellum | 4,73E-04 | N |
| B cell derived lymphoma | 4,90E-04 | N |
| embryonic growth retardation | 5,17E-04 | N |

FARP1

| Term | P-value | Annotated |
|---|----------|-----------|
| anal atresia | 4,60E-09 | N |
| cleft secondary palate | 3,03E-08 | N |
| short mandible | 3,56E-08 | N |
| abnormal limb morphology | 4,04E-08 | N |
| abnormal ulna morphology | 4,51E-08 | N |
| decreased chondrocyte cell number | 1,61E-07 | N |
| short radius | 1,66E-07 | N |
| decreased tongue size | 2,16E-07 | N |
| short ulna | 5,12E-07 | N |
| abnormal frontal bone morphology | 7,07E-07 | N |
| dilated kidney collecting duct | 9,06E-07 | N |
| cleft palate | 1,11E-06 | N |
| impaired branching involved in ureteric bud morphogenesis | 1,29E-06 | N |
| short fibula | 2,04E-06 | N |
| delayed kidney development | 2,63E-06 | N |
| abnormal bile duct morphology | 2,70E-06 | N |
| abnormal tarsal bone morphology | 3,22E-06 | N |
| abnormal cell migration | 3,77E-06 | N |
| abnormal cranium morphology | 3,92E-06 | N |
| abnormal spine curvature | 4,01E-06 | N |

SLC15A1

| Term | P-value | Annotated |
|--|----------|-----------|
| increased susceptibility to weight loss | 3,41E-04 | N |
| increased urine potassium level | 1,41E-03 | N |
| abnormal intestinal lipid absorption | 1,48E-03 | N |
| increased kidney weight | 2,68E-03 | N |
| partial embryonic lethality before turning of embryo | 3,86E-03 | N |
| disorganized photoreceptor outer segment | 4,24E-03 | N |
| abnormal sensory capabilities/reflexes/nociception | 5,33E-03 | N |
| abnormal hair cycle | 5,59E-03 | N |
| abnormal triglyceride level | 5,84E-03 | N |
| abnormal circulating lipid level | 7,36E-03 | N |
| abnormal lateral ventricle morphology | 7,92E-03 | N |
| abnormal PNS synaptic transmission | 8,48E-03 | N |
| impaired skin barrier function | 9,23E-03 | N |
| abnormal blood coagulation | 9,73E-03 | N |
| abnormal sperm physiology | 1,01E-02 | N |
| abnormal metatarsal bone morphology | 1,05E-02 | N |
| fusion of atlas and odontoid process | 1,08E-02 | N |
| small prostate gland | 1,09E-02 | N |
| abnormal cholesterol homeostasis | 1,12E-02 | N |
| abnormal thymus corticomedullary boundary morphology | 1,13E-02 | N |

TANK

| Term | P-value | Annotated |
|---|----------|-----------|
| abnormal cytokine secretion | 5,91E-13 | N |
| abnormal Peyer's patch germinal center morphology | 7,48E-12 | N |
| abnormal Peyer's patch morphology | 7,48E-11 | N |
| skin inflammation | 8,06E-11 | N |
| increased IgM level | 1,02E-10 | Y |
| increased interleukin-2 secretion | 1,25E-10 | N |
| decreased IgG2a level | 4,79E-10 | N |
| increased T cell proliferation | 5,11E-10 | N |
| abnormal macrophage physiology | 8,99E-10 | Y |
| abnormal dendritic cell physiology | 1,12E-09 | Y |
| autoimmune response | 1,13E-09 | N |
| abnormal immune system morphology | 1,66E-09 | N |
| abnormal CD8-positive T cell physiology | 9,70E-09 | N |
| abnormal cytotoxic T cell physiology | 1,15E-08 | N |
| decreased susceptibility to endotoxin shock | 1,38E-08 | N |
| increased IgA level | 1,40E-08 | Y |
| absent spleen germinal center | 1,70E-08 | N |
| decreased IgE level | 1,70E-08 | N |
| abnormal mesenteric lymph node morphology | 1,98E-08 | N |
| increased IgG2a level | 2,69E-08 | Y |

PSMD14

| Term | P-value | Annotated |
|---|----------|-----------|
| complete embryonic lethality before implantation | 7,61E-11 | N |
| abnormal blastocyst morphology | 7,32E-09 | N |
| complete embryonic lethality before somite formation | 1,61E-08 | N |
| abnormal inner cell mass proliferation | 3,99E-07 | N |
| inner cell mass degeneration | 1,42E-06 | N |
| embryonic growth arrest | 6,32E-06 | N |
| absent chorion | 4,32E-05 | N |
| complete embryonic lethality before turning of embryo | 4,82E-05 | N |
| mammary adenocarcinoma | 1,83E-04 | N |
| thin retinal inner nuclear layer | 2,46E-04 | N |
| atrial septal defect | 2,50E-04 | N |
| abnormal embryonic-extraembryonic boundary morphology | 3,44E-04 | N |
| proportional dwarf | 4,42E-04 | N |
| failure of embryo implantation | 4,65E-04 | N |
| absent T cells | 4,81E-04 | N |
| paralysis | 5,40E-04 | N |
| decreased response of heart to induced stress | 5,41E-04 | N |
| increased infarction size | 5,54E-04 | N |
| short stride length | 6,16E-04 | N |
| absent amnion | 6,21E-04 | N |

TBR1

| Term | P-value | Annotated |
|--|----------|-----------|
| abnormal inhibitory postsynaptic currents | 2,74E-22 | N |
| reduced long term depression | 3,24E-22 | N |
| abnormal spatial learning | 1,86E-20 | N |
| abnormal brain wave pattern | 1,07E-19 | N |
| absent corpus callosum | 4,73E-18 | N |
| sporadic seizures | 4,74E-16 | N |
| increased startle reflex | 4,78E-16 | N |
| abnormal cerebral cortex morphology | 7,08E-16 | N |
| abnormal neocortex morphology | 4,66E-15 | N |
| abnormal long term depression | 7,92E-15 | N |
| hyperactivity | 1,80E-14 | N |
| abnormal CNS synaptic transmission | 4,33E-14 | N |
| increased anxiety-related response | 4,38E-13 | N |
| abnormal GABA-mediated receptor currents | 5,06E-13 | N |
| increased susceptibility to pharmacologically induced seizures | 5,39E-13 | N |
| abnormal synaptic vesicle number | 5,89E-13 | N |
| abnormal excitatory postsynaptic currents | 2,19E-12 | N |
| abnormal thalamus morphology | 3,19E-12 | N |

| | | |
|--|----------|---|
| abnormal telencephalon development | 1,18E-11 | N |
| abnormal excitatory postsynaptic potential | 1,65E-11 | N |

POU3F2

| Tissue | # samples | AUC | P-value |
|----------------------------|-----------|------|------------|
| Neural Stem Cells | 11 | 0,98 | 4 x 10-8 |
| Spinal Cord | 19 | 0,97 | 9 x 10-13 |
| Substantia Nigra | 22 | 0,97 | 2 x 10-14 |
| Visual Cortex | 34 | 0,97 | 5 x 10-21 |
| Prefrontal Cortex | 46 | 0,97 | 6 x 10-28 |
| Occipital Lobe | 42 | 0,97 | 1 x 10-25 |
| Retinal Pigment Epithelium | 12 | 0,97 | 2 x 10-8 |
| Motor Neurons | 12 | 0,97 | 2 x 10-8 |
| Mesencephalon | 41 | 0,96 | 8 x 10-25 |
| Parietal Lobe | 17 | 0,96 | 4 x 10-11 |
| Frontal Lobe | 62 | 0,96 | 4 x 10-36 |
| Cerebral Cortex | 276 | 0,96 | 5 x 10-151 |
| Putamen | 16 | 0,95 | 3 x 10-10 |
| HEK293 Cells | 100 | 0,95 | 3 x 10-55 |
| Cell Line, Transformed | 102 | 0,95 | 6 x 10-56 |
| Cerebrum | 344 | 0,95 | 2 x 10-180 |
| Temporal Lobe | 91 | 0,95 | 2 x 10-49 |
| Entorhinal Cortex | 83 | 0,95 | 4 x 10-45 |
| Subthalamic Nucleus | 12 | 0,95 | 9 x 10-8 |
| Hippocampus | 55 | 0,94 | 4 x 10-30 |

JMJD1C

| Tissue | # samples | AUC | P-value |
|--------------------------------|-----------|------|------------|
| Neutrophils | 216 | 0,92 | 3 x 10-101 |
| Cerebellum | 36 | 0,91 | 4 x 10-17 |
| Sputum | 151 | 0,9 | 1 x 10-65 |
| Organelles | 12 | 0,87 | 8 x 10-6 |
| Induced Pluripotent Stem Cells | 35 | 0,8 | 6 x 10-10 |
| Precursor Cells, B-Lymphoid | 14 | 0,79 | 2 x 10-4 |
| Pluripotent Stem Cells | 47 | 0,76 | 5 x 10-10 |
| Hand | 11 | 0,73 | 7 x 10-3 |
| Aortic Valve | 10 | 0,73 | 1 x 10-2 |
| T-Lymphocytes, Regulatory | 33 | 0,73 | 7 x 10-6 |
| Knee | 26 | 0,71 | 2 x 10-4 |
| Prefrontal Cortex | 46 | 0,66 | 2 x 10-4 |
| Caco-2 Cells | 44 | 0,65 | 5 x 10-4 |

REEP3

| Tissue | # samples | AUC | P-value |
|----------------------------|-----------|------|-----------|
| Osteoblasts | 26 | 0,96 | 3 x 10-16 |
| Retinal Pigment Epithelium | 12 | 0,96 | 4 x 10-8 |
| Myocytes, Smooth Muscle | 141 | 0,94 | 9 x 10-72 |

| | | | |
|------------------------|-----|------|------------|
| Muscle Cells | 146 | 0,92 | 3 x 10-69 |
| Conjunctiva | 59 | 0,92 | 5 x 10-29 |
| Caco-2 Cells | 44 | 0,92 | 9 x 10-22 |
| Keloid | 10 | 0,92 | 5 x 10-6 |
| Cicatrix | 19 | 0,9 | 1 x 10-9 |
| Macrophages, Alveolar | 117 | 0,89 | 4 x 10-47 |
| Chondrocytes | 19 | 0,88 | 7 x 10-9 |
| Ileum | 59 | 0,88 | 6 x 10-24 |
| Fibroblasts | 392 | 0,88 | 5 x 10-146 |
| Chorion | 15 | 0,87 | 5 x 10-7 |
| Keratinocytes | 48 | 0,86 | 3 x 10-18 |
| Mesenchymal Stem Cells | 145 | 0,86 | 5 x 10-50 |
| Foreskin | 69 | 0,85 | 3 x 10-24 |
| Neural Stem Cells | 11 | 0,84 | 7 x 10-5 |
| Adipocytes | 81 | 0,83 | 7 x 10-25 |
| Islets of Langerhans | 60 | 0,83 | 2 x 10-18 |
| Trophoblasts | 11 | 0,83 | 2 x 10-4 |

LRRC14

| Tissue | # samples | AUC | P-value |
|-----------------------------|-----------|------|------------|
| Jurkat Cells | 21 | 0,84 | 6 x 10-8 |
| Palatine Tonsil | 72 | 0,83 | 9 x 10-22 |
| Hela Cells | 201 | 0,81 | 6 x 10-52 |
| HEK293 Cells | 100 | 0,79 | 2 x 10-24 |
| Cell Line, Transformed | 102 | 0,79 | 1 x 10-24 |
| K562 Cells | 37 | 0,78 | 3 x 10-9 |
| Synovial Fluid | 12 | 0,78 | 9 x 10-4 |
| T-Lymphocytes, Regulatory | 33 | 0,75 | 5 x 10-7 |
| HL-60 Cells | 12 | 0,73 | 6 x 10-3 |
| Parotid Gland | 19 | 0,73 | 6 x 10-4 |
| Mammary Glands, Human | 12 | 0,73 | 7 x 10-3 |
| T-Lymphocytes | 517 | 0,72 | 3 x 10-65 |
| HCT116 Cells | 96 | 0,72 | 2 x 10-13 |
| Lymphocytes | 1737 | 0,69 | 2 x 10-164 |
| Granulocyte Precursor Cells | 30 | 0,69 | 4 x 10-4 |
| Killer Cells, Natural | 84 | 0,68 | 5 x 10-9 |
| B-Lymphocytes | 851 | 0,68 | 10 x 10-70 |
| Plasma | 622 | 0,66 | 5 x 10-45 |
| Plasma Cells | 619 | 0,66 | 6 x 10-44 |
| Salivary Glands | 24 | 0,66 | 8 x 10-3 |

ARHGAP39

| Tissue | # samples | AUC | P-value |
|---------|-----------|------|-----------|
| Trachea | 63 | 0,92 | 4 x 10-31 |

| | | | |
|------------------------|------|------|------------------------|
| Nasal Mucosa | 93 | 0,89 | 1 x 10 ⁻³⁹ |
| Hippocampus | 55 | 0,88 | 5 x 10 ⁻²² |
| Visual Cortex | 34 | 0,87 | 7 x 10 ⁻¹⁴ |
| Neural Stem Cells | 11 | 0,87 | 3 x 10 ⁻⁵ |
| Occipital Lobe | 42 | 0,86 | 5 x 10 ⁻¹⁶ |
| Parietal Lobe | 17 | 0,86 | 3 x 10 ⁻⁷ |
| Hypothalamus | 15 | 0,85 | 4 x 10 ⁻⁶ |
| Ganglia | 11 | 0,83 | 2 x 10 ⁻⁴ |
| Testis | 37 | 0,82 | 10 x 10 ⁻¹² |
| Cerebral Cortex | 276 | 0,82 | 2 x 10 ⁻⁷⁵ |
| Entorhinal Cortex | 83 | 0,82 | 6 x 10 ⁻²⁴ |
| Cerebrum | 344 | 0,82 | 1 x 10 ⁻⁹¹ |
| Fallopian Tubes | 273 | 0,82 | 2 x 10 ⁻⁷² |
| Mammary Glands, Human | 12 | 0,81 | 2 x 10 ⁻⁴ |
| Temporal Lobe | 91 | 0,81 | 1 x 10 ⁻²⁴ |
| Epithelium | 183 | 0,8 | 9 x 10 ⁻⁴⁵ |
| HCT116 Cells | 96 | 0,78 | 2 x 10 ⁻²¹ |
| Brain | 1274 | 0,78 | 1 x 10 ⁻²⁵² |
| Central Nervous System | 1302 | 0,78 | 2 x 10 ⁻²⁵¹ |

FOXH1

| Tissue | # samples | AUC | P-value |
|--------------------------------|-----------|------|------------------------|
| Induced Pluripotent Stem Cells | 35 | 0,99 | 1 x 10 ⁻²³ |
| Pluripotent Stem Cells | 47 | 0,94 | 8 x 10 ⁻²⁶ |
| Embryonic Stem Cells | 83 | 0,9 | 2 x 10 ⁻³⁶ |
| Putamen | 16 | 0,9 | 3 x 10 ⁻⁸ |
| Substantia Nigra | 22 | 0,86 | 4 x 10 ⁻⁹ |
| Subthalamic Nucleus | 12 | 0,84 | 5 x 10 ⁻⁵ |
| Thalamus | 16 | 0,82 | 8 x 10 ⁻⁶ |
| Muscle, Striated | 162 | 0,81 | 1 x 10 ⁻⁴¹ |
| Muscle, Skeletal | 162 | 0,81 | 1 x 10 ⁻⁴¹ |
| Blastocyst | 14 | 0,8 | 9 x 10 ⁻⁵ |
| Mesencephalon | 41 | 0,8 | 4 x 10 ⁻¹¹ |
| Embryoid Bodies | 11 | 0,79 | 1 x 10 ⁻³ |
| Quadriceps Muscle | 82 | 0,78 | 6 x 10 ⁻¹⁹ |
| Parietal Lobe | 17 | 0,77 | 9 x 10 ⁻⁵ |
| Blood Platelets | 30 | 0,76 | 5 x 10 ⁻⁷ |
| Trophoblasts | 11 | 0,75 | 4 x 10 ⁻³ |
| Occipital Lobe | 42 | 0,75 | 4 x 10 ⁻⁸ |
| Visual Cortex | 34 | 0,74 | 9 x 10 ⁻⁷ |
| Muscles | 723 | 0,74 | 1 x 10 ⁻¹¹¹ |
| Hypothalamus | 15 | 0,74 | 2 x 10 ⁻³ |

KIFC2

| Tissue | # samples | AUC | P-value |
|------------------------|-----------|------|-------------|
| Putamen | 16 | 0,99 | 9 x 10-12 |
| Cerebellum | 36 | 0,98 | 1 x 10-23 |
| Frontal Lobe | 62 | 0,98 | 3 x 10-39 |
| Parietal Lobe | 17 | 0,98 | 9 x 10-12 |
| Prefrontal Cortex | 46 | 0,98 | 4 x 10-29 |
| Cerebral Cortex | 276 | 0,97 | 6 x 10-162 |
| Entorhinal Cortex | 83 | 0,97 | 7 x 10-50 |
| Temporal Lobe | 91 | 0,97 | 3 x 10-54 |
| Occipital Lobe | 42 | 0,97 | 9 x 10-26 |
| Visual Cortex | 34 | 0,97 | 6 x 10-21 |
| Hippocampus | 55 | 0,96 | 6 x 10-32 |
| Cerebrum | 344 | 0,93 | 4 x 10-168 |
| Hypothalamus | 15 | 0,92 | 2 x 10-8 |
| Thalamus | 16 | 0,88 | 1 x 10-7 |
| Brain | 1274 | 0,82 | < 10-300 |
| Neural Stem Cells | 11 | 0,81 | 3 x 10-4 |
| Mouth Mucosa | 94 | 0,81 | 1 x 10-25 |
| Central Nervous System | 1302 | 0,81 | 10 x 10-320 |
| Nervous System | 1358 | 0,81 | 7 x 10-323 |
| Substantia Nigra | 22 | 0,8 | 7 x 10-7 |

CYHR1

| Tissue | # samples | AUC | P-value |
|-----------------------|-----------|------|------------|
| Plasma Cells | 619 | 0,91 | 9 x 10-274 |
| Plasma | 622 | 0,91 | 1 x 10-273 |
| Neutrophils | 216 | 0,83 | 5 x 10-63 |
| Hypothalamus | 15 | 0,82 | 1 x 10-5 |
| B-Lymphocytes | 851 | 0,78 | 1 x 10-176 |
| Intestinal Mucosa | 40 | 0,78 | 7 x 10-10 |
| Putamen | 16 | 0,78 | 1 x 10-4 |
| Mammary Glands, Human | 12 | 0,78 | 8 x 10-4 |
| Salivary Glands | 24 | 0,77 | 7 x 10-6 |
| Parietal Lobe | 17 | 0,74 | 7 x 10-4 |
| Parotid Gland | 19 | 0,73 | 4 x 10-4 |
| Occipital Lobe | 42 | 0,71 | 2 x 10-6 |
| Visual Cortex | 34 | 0,71 | 2 x 10-5 |
| Cerebellum | 36 | 0,7 | 3 x 10-5 |
| Thalamus | 16 | 0,7 | 7 x 10-3 |
| Astrocytes | 12 | 0,69 | 2 x 10-2 |
| Adrenal Glands | 129 | 0,68 | 4 x 10-12 |
| Hippocampus | 55 | 0,67 | 8 x 10-6 |
| Osteoblasts | 26 | 0,66 | 4 x 10-3 |
| Adrenal Cortex | 99 | 0,66 | 2 x 10-8 |

VPS28

| Tissue | # samples | AUC | P-value |
|-----------------------|-----------|------|-----------------------|
| Synovial Fluid | 12 | 0,8 | 3 x 10 ⁻⁴ |
| Ileum | 59 | 0,73 | 6 x 10 ⁻¹⁰ |
| Intestine, Small | 112 | 0,73 | 1 x 10 ⁻¹⁶ |
| Neural Stem Cells | 11 | 0,72 | 1 x 10 ⁻² |
| Mammary Glands, Human | 12 | 0,72 | 9 x 10 ⁻³ |
| Omentum | 76 | 0,72 | 6 x 10 ⁻¹¹ |
| Peritoneum | 89 | 0,71 | 6 x 10 ⁻¹² |
| Abdomen | 103 | 0,71 | 2 x 10 ⁻¹³ |
| Retina | 27 | 0,71 | 2 x 10 ⁻⁴ |
| Fallopian Tubes | 273 | 0,69 | 2 x 10 ⁻²⁸ |
| Stomach | 55 | 0,69 | 9 x 10 ⁻⁷ |
| Thyroid Gland | 85 | 0,68 | 1 x 10 ⁻⁸ |
| Eye | 157 | 0,67 | 6 x 10 ⁻¹⁴ |
| Synovial Membrane | 26 | 0,66 | 6 x 10 ⁻³ |
| Joints | 26 | 0,66 | 6 x 10 ⁻³ |
| Ovary | 699 | 0,65 | 1 x 10 ⁻⁴⁴ |
| Vulva | 34 | 0,65 | 3 x 10 ⁻³ |
| Prostate | 352 | 0,64 | 2 x 10 ⁻²⁰ |
| Cecum | 15 | 0,64 | 6 x 10 ⁻² |
| Endometrium | 264 | 0,63 | 6 x 10 ⁻¹⁴ |

SCRT1

| Tissue | # samples | AUC | P-value |
|----------------------------|-----------|------|-----------------------|
| Retinal Pigment Epithelium | 1,20E+01 | 0,8 | 3 x 10 ⁻⁴ |
| Chorion | 1,50E+01 | 0,78 | 1 x 10 ⁻⁴ |
| Sputum | 1,51E+02 | 0,73 | 2 x 10 ⁻²³ |
| Chondrocytes | 1,90E+01 | 0,72 | 1 x 10 ⁻³ |
| K562 Cells | 3,70E+01 | 0,69 | 7 x 10 ⁻⁵ |
| Myocytes, Smooth Muscle | 1,41E+02 | 0,68 | 3 x 10 ⁻¹³ |
| HT29 Cells | 1,70E+01 | 0,67 | 1 x 10 ⁻² |
| Mesenchymal Stem Cells | 1,45E+02 | 0,67 | 2 x 10 ⁻¹² |
| Ileum | 5,90E+01 | 0,66 | 1 x 10 ⁻⁵ |
| Muscle Cells | 1,46E+02 | 0,66 | 1 x 10 ⁻¹¹ |
| Intestinal Mucosa | 4,00E+01 | 0,66 | 6 x 10 ⁻⁴ |
| Clone Cells | 1,15E+02 | 0,65 | 4 x 10 ⁻⁸ |
| Plasma | 6,22E+02 | 0,64 | 5 x 10 ⁻³⁵ |
| Caco-2 Cells | 4,40E+01 | 0,64 | 10 x 10 ⁻⁴ |
| Plasma Cells | 6,19E+02 | 0,64 | 3 x 10 ⁻³⁴ |
| Jurkat Cells | 2,10E+01 | 0,63 | 4 x 10 ⁻² |
| Fetal Blood | 1,51E+02 | 0,63 | 2 x 10 ⁻⁸ |
| Hep G2 Cells | 1,02E+02 | 0,63 | 7 x 10 ⁻⁶ |

| | | | |
|--------------|----------|------|----------------------|
| Retina | 2,70E+01 | 0,63 | 2 x 10 ⁻² |
| Mouth Mucosa | 9,40E+01 | 0,62 | 3 x 10 ⁻⁵ |

ATXN2L

| Tissue | # samples | AUC | P-value |
|-----------------------------|-----------|------|-----------------------|
| Organelles | 12 | 0,86 | 1 x 10 ⁻⁵ |
| Fetal Blood | 151 | 0,76 | 5 x 10 ⁻²⁸ |
| Hep G2 Cells | 102 | 0,75 | 9 x 10 ⁻¹⁸ |
| Parotid Gland | 19 | 0,74 | 4 x 10 ⁻⁴ |
| Salivary Glands | 24 | 0,73 | 1 x 10 ⁻⁴ |
| Blood Platelets | 30 | 0,73 | 2 x 10 ⁻⁵ |
| Jurkat Cells | 21 | 0,71 | 8 x 10 ⁻⁴ |
| Precursor Cells, B-Lymphoid | 14 | 0,71 | 6 x 10 ⁻³ |
| Killer Cells, Natural | 84 | 0,7 | 1 x 10 ⁻¹⁰ |
| Cartilage | 13 | 0,7 | 1 x 10 ⁻² |
| Retinal Pigment Epithelium | 12 | 0,68 | 3 x 10 ⁻² |
| Putamen | 16 | 0,68 | 1 x 10 ⁻² |
| Granulocyte Precursor Cells | 30 | 0,67 | 1 x 10 ⁻³ |
| T-Lymphocytes, Regulatory | 33 | 0,67 | 9 x 10 ⁻⁴ |
| Adrenal Cortex | 99 | 0,65 | 2 x 10 ⁻⁷ |
| Clone Cells | 115 | 0,65 | 4 x 10 ⁻⁸ |
| Trophoblasts | 11 | 0,64 | 1 x 10 ⁻¹ |
| Bone Marrow Cells | 809 | 0,63 | 4 x 10 ⁻³⁹ |
| Adrenal Glands | 129 | 0,63 | 3 x 10 ⁻⁷ |
| Neutrophils | 216 | 0,63 | 5 x 10 ⁻¹¹ |

TUFM

| Tissue | # samples | AUC | P-value |
|--------------------------------|-----------|------|------------------------|
| HL-60 Cells | 12 | 0,95 | 8 x 10 ⁻⁸ |
| HCT116 Cells | 96 | 0,92 | 1 x 10 ⁻⁴⁶ |
| K562 Cells | 37 | 0,89 | 2 x 10 ⁻¹⁶ |
| Neural Stem Cells | 11 | 0,88 | 1 x 10 ⁻⁵ |
| HEK293 Cells | 100 | 0,87 | 4 x 10 ⁻³⁸ |
| Cell Line, Transformed | 102 | 0,87 | 7 x 10 ⁻³⁹ |
| Hep G2 Cells | 102 | 0,85 | 5 x 10 ⁻³⁵ |
| Hela Cells | 201 | 0,82 | 3 x 10 ⁻⁵⁴ |
| Jurkat Cells | 21 | 0,81 | 1 x 10 ⁻⁶ |
| Cell Line, Tumor | 674 | 0,79 | 4 x 10 ⁻¹⁵¹ |
| Tongue | 105 | 0,79 | 9 x 10 ⁻²⁵ |
| Palatine Tonsil | 72 | 0,79 | 3 x 10 ⁻¹⁷ |
| Hepatocytes | 188 | 0,77 | 4 x 10 ⁻³⁷ |
| Glucagon-Secreting Cells | 39 | 0,76 | 3 x 10 ⁻⁸ |
| Clone Cells | 115 | 0,74 | 1 x 10 ⁻¹⁹ |
| Induced Pluripotent Stem Cells | 35 | 0,74 | 1 x 10 ⁻⁶ |

| | | | |
|-----------------------------|-----|------|-----------|
| Pluripotent Stem Cells | 47 | 0,73 | 4 x 10-8 |
| Granulocyte Precursor Cells | 30 | 0,71 | 5 x 10-5 |
| Astrocytes | 12 | 0,71 | 1 x 10-2 |
| Plasma Cells | 619 | 0,71 | 4 x 10-73 |

SH2B1

| Tissue | # samples | AUC | P-value |
|---------------------|-----------|------|------------|
| Hypothalamus | 15 | 0,99 | 6 x 10-11 |
| Thalamus | 16 | 0,98 | 5 x 10-11 |
| Putamen | 16 | 0,96 | 3 x 10-10 |
| Subthalamic Nucleus | 12 | 0,95 | 5 x 10-8 |
| Substantia Nigra | 22 | 0,94 | 1 x 10-12 |
| Ganglia | 11 | 0,92 | 1 x 10-6 |
| Mesencephalon | 41 | 0,9 | 1 x 10-18 |
| Salivary Glands | 24 | 0,88 | 2 x 10-10 |
| Organelles | 12 | 0,86 | 1 x 10-5 |
| Parotid Gland | 19 | 0,85 | 2 x 10-7 |
| Hippocampus | 55 | 0,84 | 2 x 10-18 |
| Parietal Lobe | 17 | 0,8 | 2 x 10-5 |
| Temporal Lobe | 91 | 0,8 | 7 x 10-23 |
| Cerebral Cortex | 276 | 0,78 | 9 x 10-60 |
| Entorhinal Cortex | 83 | 0,78 | 4 x 10-19 |
| Myometrium | 105 | 0,77 | 5 x 10-22 |
| Nasal Mucosa | 93 | 0,75 | 3 x 10-17 |
| Cerebellum | 36 | 0,75 | 2 x 10-7 |
| Neural Stem Cells | 11 | 0,74 | 5 x 10-3 |
| Muscles | 723 | 0,74 | 8 x 10-111 |

NFATC2IP

| Tissue | # samples | AUC | P-value |
|-----------------------------|-----------|------|------------|
| T-Lymphocytes, Regulatory | 33 | 0,91 | 5 x 10-16 |
| Precursor Cells, B-Lymphoid | 14 | 0,9 | 2 x 10-7 |
| Cerebellum | 36 | 0,86 | 7 x 10-14 |
| Blood Platelets | 30 | 0,84 | 6 x 10-11 |
| T-Lymphocytes | 517 | 0,82 | 4 x 10-140 |
| Synovial Fluid | 12 | 0,82 | 2 x 10-4 |
| Palatine Tonsil | 72 | 0,81 | 1 x 10-19 |
| Granulocyte Precursor Cells | 30 | 0,8 | 8 x 10-9 |
| Glucagon-Secreting Cells | 39 | 0,78 | 2 x 10-9 |
| HL-60 Cells | 12 | 0,75 | 2 x 10-3 |
| Killer Cells, Natural | 84 | 0,73 | 9 x 10-14 |
| Lymphoid Tissue | 818 | 0,72 | 2 x 10-101 |
| Hematopoietic Stem Cells | 106 | 0,71 | 6 x 10-14 |
| Lymph Nodes | 671 | 0,7 | 1 x 10-69 |

| | | | |
|--------------------------------|-----|------|-----------|
| Lymph | 683 | 0,69 | 8 x 10-68 |
| Spleen | 23 | 0,68 | 2 x 10-3 |
| HEK293 Cells | 100 | 0,68 | 3 x 10-10 |
| Cell Line, Transformed | 102 | 0,67 | 1 x 10-9 |
| Induced Pluripotent Stem Cells | 35 | 0,66 | 8 x 10-4 |
| Mammary Glands, Human | 12 | 0,66 | 5 x 10-2 |

SPNS1

| Tissue | # samples | AUC | P-value |
|----------------------------|-----------|------|------------|
| Macrophages, Alveolar | 117 | 0,95 | 4 x 10-63 |
| Macrophages | 342 | 0,94 | 2 x 10-175 |
| Hep G2 Cells | 102 | 0,88 | 6 x 10-40 |
| Neural Stem Cells | 11 | 0,87 | 2 x 10-5 |
| Chorion | 15 | 0,84 | 7 x 10-6 |
| U937 Cells | 57 | 0,83 | 7 x 10-18 |
| Synovial Fluid | 12 | 0,82 | 1 x 10-4 |
| Monocytes | 506 | 0,81 | 2 x 10-128 |
| Umbilical Veins | 113 | 0,8 | 6 x 10-28 |
| Retinal Pigment Epithelium | 12 | 0,8 | 4 x 10-4 |
| Endothelial Cells | 196 | 0,79 | 2 x 10-45 |
| Clone Cells | 115 | 0,79 | 4 x 10-27 |
| Veins | 133 | 0,79 | 6 x 10-31 |
| Hepatocytes | 188 | 0,78 | 9 x 10-40 |
| Hela Cells | 201 | 0,76 | 5 x 10-37 |
| Caco-2 Cells | 44 | 0,76 | 3 x 10-9 |
| Myocytes, Smooth Muscle | 141 | 0,76 | 9 x 10-26 |
| Mesenchymal Stem Cells | 145 | 0,75 | 2 x 10-25 |
| HL-60 Cells | 12 | 0,74 | 4 x 10-3 |
| Blood Vessels | 171 | 0,74 | 2 x 10-27 |

LAT

| Tissue | # samples | AUC | P-value |
|---------------------------|-----------|------|------------|
| Blood Platelets | 30 | 0,98 | 2 x 10-19 |
| Jurkat Cells | 21 | 0,96 | 3 x 10-13 |
| T-Lymphocytes, Regulatory | 33 | 0,96 | 5 x 10-20 |
| T-Lymphocytes | 517 | 0,96 | 3 x 10-282 |
| Synovial Fluid | 12 | 0,95 | 5 x 10-8 |
| Palatine Tonsil | 72 | 0,86 | 7 x 10-26 |
| U937 Cells | 57 | 0,86 | 2 x 10-20 |
| Killer Cells, Natural | 84 | 0,84 | 9 x 10-27 |
| Macrophages | 342 | 0,82 | 1 x 10-89 |
| Spleen | 23 | 0,8 | 7 x 10-7 |
| Lymphoid Tissue | 818 | 0,79 | 2 x 10-183 |
| Lymph | 683 | 0,79 | 4 x 10-146 |

| | | | |
|-----------------------|------|------|------------------------|
| Lymph Nodes | 671 | 0,78 | 2 x 10 ⁻¹³⁸ |
| Sputum | 151 | 0,76 | 5 x 10 ⁻²⁹ |
| Macrophages, Alveolar | 117 | 0,75 | 2 x 10 ⁻²⁰ |
| Lymphocytes | 1737 | 0,73 | 8 x 10 ⁻²³⁹ |
| Monocytes | 506 | 0,73 | 6 x 10 ⁻⁷³ |
| Synovial Membrane | 26 | 0,73 | 6 x 10 ⁻⁵ |
| Joints | 26 | 0,73 | 6 x 10 ⁻⁵ |
| Myeloid Cells | 997 | 0,73 | 8 x 10 ⁻¹³¹ |

SULT1A1

SULT1A2

| Tissue | # samples | AUC | P-value |
|-----------------------------|-----------|------|------------------------|
| Intestinal Mucosa | 40 | 0,97 | 9 x 10 ⁻²⁵ |
| Hep G2 Cells | 102 | 0,97 | 6 x 10 ⁻⁶⁰ |
| Ileum | 59 | 0,94 | 3 x 10 ⁻³² |
| Hepatocytes | 188 | 0,91 | 2 x 10 ⁻⁸⁴ |
| Abdominal Fat | 69 | 0,87 | 1 x 10 ⁻²⁶ |
| Subcutaneous Fat, Abdominal | 69 | 0,87 | 1 x 10 ⁻²⁶ |
| Liver | 569 | 0,85 | 3 x 10 ⁻¹⁸⁵ |
| Neutrophils | 216 | 0,84 | 5 x 10 ⁻⁶⁸ |
| Subcutaneous Fat | 120 | 0,84 | 5 x 10 ⁻³⁸ |
| Hypothalamus | 15 | 0,83 | 9 x 10 ⁻⁶ |
| Adipose Tissue | 165 | 0,83 | 8 x 10 ⁻⁴⁹ |
| Putamen | 16 | 0,82 | 8 x 10 ⁻⁶ |
| Substantia Nigra | 22 | 0,76 | 3 x 10 ⁻⁵ |
| Colon, Sigmoid | 27 | 0,76 | 4 x 10 ⁻⁶ |
| Trachea | 63 | 0,75 | 3 x 10 ⁻¹² |
| Ganglia | 11 | 0,75 | 4 x 10 ⁻³ |
| U937 Cells | 57 | 0,75 | 1 x 10 ⁻¹⁰ |
| Thalamus | 16 | 0,74 | 8 x 10 ⁻⁴ |
| Mammary Glands, Human | 12 | 0,73 | 7 x 10 ⁻³ |
| Caco-2 Cells | 44 | 0,73 | 2 x 10 ⁻⁷ |

CCDC101

| Tissue | # samples | AUC | P-value |
|---------------------------|-----------|------|-----------------------|
| Quadriceps Muscle | 82 | 0,87 | 4 x 10 ⁻³¹ |
| U937 Cells | 57 | 0,86 | 3 x 10 ⁻²¹ |
| Muscle, Skeletal | 162 | 0,82 | 2 x 10 ⁻⁴⁵ |
| Muscle, Striated | 162 | 0,82 | 2 x 10 ⁻⁴⁵ |
| Palatine Tonsil | 72 | 0,8 | 5 x 10 ⁻¹⁹ |
| Synovial Fluid | 12 | 0,79 | 4 x 10 ⁻⁴ |
| Hematopoietic Stem Cells | 106 | 0,78 | 4 x 10 ⁻²³ |
| T-Lymphocytes, Regulatory | 33 | 0,75 | 4 x 10 ⁻⁷ |
| Myometrium | 105 | 0,75 | 3 x 10 ⁻¹⁹ |

| | | | |
|-----------------------------|-----|------|------------|
| Plasma Cells | 619 | 0,73 | 3 x 10-88 |
| Plasma | 622 | 0,73 | 1 x 10-88 |
| Muscles | 723 | 0,73 | 2 x 10-101 |
| B-Lymphocytes | 851 | 0,71 | 1 x 10-95 |
| T-Lymphocytes | 517 | 0,7 | 3 x 10-55 |
| Granulocyte Precursor Cells | 30 | 0,7 | 2 x 10-4 |
| Intestinal Mucosa | 40 | 0,69 | 2 x 10-5 |
| Synovial Membrane | 26 | 0,69 | 10 x 10-4 |
| Joints | 26 | 0,69 | 10 x 10-4 |
| Mammary Glands, Human | 12 | 0,69 | 3 x 10-2 |
| Jurkat Cells | 21 | 0,69 | 3 x 10-3 |

NRXN1

| Tissue | # samples | AUC | P-value |
|---------------------|-----------|------|------------|
| Prefrontal Cortex | 46 | 1 | 2 x 10-31 |
| Frontal Lobe | 62 | 0,99 | 2 x 10-41 |
| Cerebellum | 36 | 0,99 | 2 x 10-24 |
| Cerebral Cortex | 276 | 0,99 | 5 x 10-174 |
| Temporal Lobe | 91 | 0,99 | 5 x 10-58 |
| Entorhinal Cortex | 83 | 0,99 | 5 x 10-53 |
| Occipital Lobe | 42 | 0,99 | 1 x 10-27 |
| Hippocampus | 55 | 0,99 | 1 x 10-35 |
| Visual Cortex | 34 | 0,98 | 1 x 10-22 |
| Parietal Lobe | 17 | 0,98 | 5 x 10-12 |
| Ganglia | 11 | 0,98 | 4 x 10-8 |
| Thalamus | 16 | 0,97 | 6 x 10-11 |
| Cerebrum | 344 | 0,97 | 4 x 10-195 |
| Mesencephalon | 41 | 0,97 | 6 x 10-25 |
| Putamen | 16 | 0,96 | 1 x 10-10 |
| Substantia Nigra | 22 | 0,96 | 6 x 10-14 |
| Hypothalamus | 15 | 0,96 | 6 x 10-10 |
| Motor Neurons | 12 | 0,95 | 5 x 10-8 |
| Subthalamic Nucleus | 12 | 0,95 | 8 x 10-8 |
| Atrial Appendage | 10 | 0,94 | 1 x 10-6 |

NUPR1

| Tissue | # samples | AUC | P-value |
|-----------------------------|-----------|------|-----------|
| Keloid | 10 | 0,95 | 8 x 10-7 |
| Cicatrix | 19 | 0,95 | 1 x 10-11 |
| Cartilage | 13 | 0,93 | 1 x 10-7 |
| Abdominal Fat | 69 | 0,91 | 1 x 10-32 |
| Subcutaneous Fat, Abdominal | 69 | 0,91 | 1 x 10-32 |
| Adipocytes | 81 | 0,9 | 2 x 10-36 |
| Subcutaneous Fat | 120 | 0,9 | 1 x 10-50 |

| | | | |
|------------------------|-----|------|------------------------|
| Salivary Glands | 24 | 0,88 | 7 x 10 ⁻¹¹ |
| Intestinal Mucosa | 40 | 0,88 | 4 x 10 ⁻¹⁷ |
| Prostate | 352 | 0,88 | 4 x 10 ⁻¹³⁶ |
| Adipose Tissue | 165 | 0,88 | 2 x 10 ⁻⁶⁴ |
| Mammary Glands, Human | 12 | 0,88 | 6 x 10 ⁻⁶ |
| Parotid Gland | 19 | 0,87 | 3 x 10 ⁻⁸ |
| Telomere | 30 | 0,86 | 6 x 10 ⁻¹² |
| Myometrium | 105 | 0,86 | 9 x 10 ⁻³⁸ |
| Fibroblasts | 392 | 0,86 | 1 x 10 ⁻¹³² |
| Mesenchymal Stem Cells | 145 | 0,86 | 2 x 10 ⁻⁵⁰ |
| Knee | 26 | 0,86 | 3 x 10 ⁻¹⁰ |
| Chondrocytes | 19 | 0,85 | 9 x 10 ⁻⁸ |
| Sputum | 151 | 0,84 | 4 x 10 ⁻⁴⁸ |

NPAS2

| Tissue | # samples | AUC | P-value |
|----------------------------|-----------|------|-----------------------|
| Prefrontal Cortex | 46 | 0,93 | 3 x 10 ⁻²⁴ |
| Cartilage | 13 | 0,92 | 2 x 10 ⁻⁷ |
| Umbilical Veins | 113 | 0,92 | 1 x 10 ⁻⁵² |
| Hepatocytes | 188 | 0,91 | 2 x 10 ⁻⁸⁵ |
| Frontal Lobe | 62 | 0,91 | 1 x 10 ⁻²⁸ |
| Veins | 133 | 0,91 | 1 x 10 ⁻⁵⁸ |
| Putamen | 16 | 0,9 | 3 x 10 ⁻⁸ |
| Hep G2 Cells | 102 | 0,9 | 3 x 10 ⁻⁴⁴ |
| Muscle Cells | 146 | 0,9 | 9 x 10 ⁻⁶² |
| Myocytes, Smooth Muscle | 141 | 0,9 | 1 x 10 ⁻⁵⁹ |
| Heart Ventricles | 124 | 0,89 | 3 x 10 ⁻⁵¹ |
| Umbilical Cord | 180 | 0,89 | 1 x 10 ⁻⁷¹ |
| Retinal Pigment Epithelium | 12 | 0,88 | 4 x 10 ⁻⁶ |
| Mouth Mucosa | 94 | 0,88 | 2 x 10 ⁻³⁶ |
| Blood Vessels | 171 | 0,86 | 4 x 10 ⁻⁵⁹ |
| Heart | 217 | 0,86 | 1 x 10 ⁻⁷³ |
| Endothelial Cells | 196 | 0,86 | 2 x 10 ⁻⁶⁶ |
| Entorhinal Cortex | 83 | 0,85 | 5 x 10 ⁻²⁸ |
| Hippocampus | 55 | 0,85 | 6 x 10 ⁻¹⁹ |
| Cerebral Cortex | 276 | 0,84 | 3 x 10 ⁻⁸⁶ |

KCNMA1

| Tissue | # samples | AUC | P-value |
|----------------------------|-----------|------|-----------------------|
| Myometrium | 105 | 0,98 | 2 x 10 ⁻⁶⁴ |
| Osteoblasts | 26 | 0,97 | 8 x 10 ⁻¹⁷ |
| Retinal Pigment Epithelium | 12 | 0,96 | 3 x 10 ⁻⁸ |
| Cartilage | 13 | 0,96 | 1 x 10 ⁻⁸ |
| Visual Cortex | 34 | 0,95 | 7 x 10 ⁻²⁰ |

| | | | |
|------------------------|-----|------|------------|
| Occipital Lobe | 42 | 0,94 | 4 x 10-23 |
| Prefrontal Cortex | 46 | 0,93 | 2 x 10-24 |
| Entorhinal Cortex | 83 | 0,93 | 7 x 10-42 |
| Aortic Valve | 10 | 0,93 | 2 x 10-6 |
| Mesenchymal Stem Cells | 145 | 0,93 | 2 x 10-70 |
| Temporal Lobe | 91 | 0,92 | 4 x 10-44 |
| Muscle, Smooth | 248 | 0,92 | 1 x 10-115 |
| Cerebral Cortex | 276 | 0,92 | 2 x 10-125 |
| Keloid | 10 | 0,91 | 6 x 10-6 |
| Frontal Lobe | 62 | 0,91 | 10 x 10-29 |
| Hippocampus | 55 | 0,9 | 6 x 10-25 |
| Sputum | 151 | 0,9 | 3 x 10-65 |
| Chondrocytes | 19 | 0,9 | 2 x 10-9 |
| Cicatrix | 19 | 0,88 | 7 x 10-9 |
| Prostate | 352 | 0,88 | 1 x 10-134 |

DEC1

| Tissue | # samples | AUC | P-value |
|-------------------------|-----------|------|-----------|
| Nasopharynx | 30 | 0,87 | 4 x 10-12 |
| Heart Ventricles | 124 | 0,78 | 5 x 10-28 |
| Substantia Nigra | 22 | 0,78 | 6 x 10-6 |
| HCT116 Cells | 96 | 0,77 | 1 x 10-20 |
| Thalamus | 16 | 0,75 | 5 x 10-4 |
| Organelles | 12 | 0,75 | 3 x 10-3 |
| Mesencephalon | 41 | 0,74 | 7 x 10-8 |
| Embryoid Bodies | 11 | 0,74 | 6 x 10-3 |
| Myocytes, Smooth Muscle | 141 | 0,73 | 1 x 10-21 |
| Hypothalamus | 15 | 0,73 | 2 x 10-3 |
| Hep G2 Cells | 102 | 0,73 | 1 x 10-15 |
| Muscle Cells | 146 | 0,71 | 4 x 10-19 |
| Quadriceps Muscle | 82 | 0,71 | 4 x 10-11 |
| Neutrophils | 216 | 0,71 | 3 x 10-26 |
| Neck | 138 | 0,7 | 2 x 10-16 |
| Blastocyst | 14 | 0,7 | 9 x 10-3 |
| Heart | 217 | 0,69 | 2 x 10-21 |
| Umbilical Cord | 180 | 0,68 | 1 x 10-17 |
| Subthalamic Nucleus | 12 | 0,68 | 3 x 10-2 |
| Heart Atria | 13 | 0,68 | 2 x 10-2 |

SDCCAG8

| Tissue | # samples | AUC | P-value |
|-----------------------|-----------|------|-----------|
| Sputum | 151 | 0,96 | 4 x 10-85 |
| Aortic Valve | 10 | 0,89 | 2 x 10-5 |
| Macrophages, Alveolar | 117 | 0,87 | 2 x 10-43 |

| | | | |
|----------------------------|-----|------|-----------------------|
| Foot | 34 | 0,81 | 4 x 10 ⁻¹⁰ |
| Hand | 11 | 0,81 | 4 x 10 ⁻⁴ |
| Macrophages | 342 | 0,8 | 5 x 10 ⁻⁸² |
| Chorion | 15 | 0,78 | 2 x 10 ⁻⁴ |
| K562 Cells | 37 | 0,78 | 6 x 10 ⁻⁹ |
| Knee | 26 | 0,75 | 9 x 10 ⁻⁶ |
| Dendritic Cells | 277 | 0,74 | 5 x 10 ⁻⁴² |
| Tongue | 105 | 0,73 | 3 x 10 ⁻¹⁶ |
| HEK293 Cells | 100 | 0,72 | 2 x 10 ⁻¹⁴ |
| Synovial Fluid | 12 | 0,72 | 9 x 10 ⁻³ |
| Cell Line, Transformed | 102 | 0,72 | 6 x 10 ⁻¹⁴ |
| Retinal Pigment Epithelium | 12 | 0,69 | 2 x 10 ⁻² |
| Testis | 37 | 0,68 | 1 x 10 ⁻⁴ |
| Clone Cells | 115 | 0,68 | 1 x 10 ⁻¹¹ |
| U937 Cells | 57 | 0,67 | 8 x 10 ⁻⁶ |
| HCT116 Cells | 96 | 0,67 | 9 x 10 ⁻⁹ |
| Endothelial Cells | 196 | 0,66 | 5 x 10 ⁻¹⁵ |

AKT3

| Tissue | # samples | AUC | P-value |
|----------------------------|-----------|------|------------------------|
| Prefrontal Cortex | 46 | 0,98 | 6 x 10 ⁻³⁰ |
| Retinal Pigment Epithelium | 12 | 0,97 | 2 x 10 ⁻⁸ |
| Frontal Lobe | 62 | 0,95 | 3 x 10 ⁻³⁵ |
| Retina | 27 | 0,95 | 1 x 10 ⁻¹⁵ |
| Visual Cortex | 34 | 0,94 | 3 x 10 ⁻¹⁹ |
| Occipital Lobe | 42 | 0,94 | 5 x 10 ⁻²³ |
| Cerebral Cortex | 276 | 0,94 | 3 x 10 ⁻¹⁴⁰ |
| Entorhinal Cortex | 83 | 0,94 | 2 x 10 ⁻⁴³ |
| Temporal Lobe | 91 | 0,94 | 5 x 10 ⁻⁴⁷ |
| Cerebellum | 36 | 0,93 | 3 x 10 ⁻¹⁹ |
| Hippocampus | 55 | 0,93 | 7 x 10 ⁻²⁸ |
| Cerebrum | 344 | 0,92 | 3 x 10 ⁻¹⁶⁰ |
| Osteoblasts | 26 | 0,92 | 2 x 10 ⁻¹³ |
| Parietal Lobe | 17 | 0,91 | 5 x 10 ⁻⁹ |
| Veins | 133 | 0,91 | 5 x 10 ⁻⁶⁰ |
| Umbilical Veins | 113 | 0,91 | 3 x 10 ⁻⁵¹ |
| Aortic Valve | 10 | 0,9 | 1 x 10 ⁻⁵ |
| Blood Vessels | 171 | 0,9 | 4 x 10 ⁻⁷³ |
| HEK293 Cells | 100 | 0,9 | 3 x 10 ⁻⁴³ |
| Cicatrix | 19 | 0,9 | 2 x 10 ⁻⁹ |

CRYZL1

| Tissue | # samples | AUC | P-value |
|-------------------|-----------|------|-----------------------|
| Prefrontal Cortex | 46 | 0,95 | 6 x 10 ⁻²⁶ |

| | | | |
|-----------------------------|-----|------|-----------------------|
| Subcutaneous Fat | 120 | 0,91 | 3 x 10 ⁻⁵⁴ |
| Abdominal Fat | 69 | 0,9 | 3 x 10 ⁻³⁰ |
| Subcutaneous Fat, Abdominal | 69 | 0,9 | 3 x 10 ⁻³⁰ |
| Chorion | 15 | 0,87 | 8 x 10 ⁻⁷ |
| Frontal Lobe | 62 | 0,86 | 1 x 10 ⁻²² |
| Cerebellum | 36 | 0,86 | 9 x 10 ⁻¹⁴ |
| K562 Cells | 37 | 0,85 | 2 x 10 ⁻¹³ |
| Adipose Tissue | 165 | 0,84 | 1 x 10 ⁻⁵² |
| Hand | 11 | 0,81 | 4 x 10 ⁻⁴ |
| Jurkat Cells | 21 | 0,8 | 2 x 10 ⁻⁶ |
| Knee | 26 | 0,79 | 2 x 10 ⁻⁷ |
| Trachea | 63 | 0,77 | 1 x 10 ⁻¹³ |
| Retina | 27 | 0,76 | 3 x 10 ⁻⁶ |
| Foot | 34 | 0,74 | 8 x 10 ⁻⁷ |
| Mammary Glands, Human | 12 | 0,73 | 5 x 10 ⁻³ |
| Substantia Nigra | 22 | 0,73 | 2 x 10 ⁻⁴ |
| Myometrium | 105 | 0,72 | 2 x 10 ⁻¹⁵ |
| Chondrocytes | 19 | 0,72 | 10 x 10 ⁻⁴ |
| HEK293 Cells | 100 | 0,71 | 2 x 10 ⁻¹³ |

ITSN1

| Tissue | # samples | AUC | P-value |
|-----------------------------|-----------|------|------------------------|
| Abdominal Fat | 69 | 0,99 | 2 x 10 ⁻⁴⁴ |
| Subcutaneous Fat, Abdominal | 69 | 0,99 | 2 x 10 ⁻⁴⁴ |
| Subcutaneous Fat | 120 | 0,98 | 4 x 10 ⁻⁷⁵ |
| Visual Cortex | 34 | 0,98 | 4 x 10 ⁻²² |
| Adipose Tissue | 165 | 0,98 | 4 x 10 ⁻¹⁰⁰ |
| Motor Neurons | 12 | 0,98 | 1 x 10 ⁻⁸ |
| Occipital Lobe | 42 | 0,97 | 4 x 10 ⁻²⁶ |
| Prefrontal Cortex | 46 | 0,97 | 8 x 10 ⁻²⁸ |
| Aortic Valve | 10 | 0,96 | 4 x 10 ⁻⁷ |
| Frontal Lobe | 62 | 0,96 | 1 x 10 ⁻³⁵ |
| Entorhinal Cortex | 83 | 0,96 | 4 x 10 ⁻⁴⁷ |
| Cerebral Cortex | 276 | 0,96 | 1 x 10 ⁻¹⁵⁰ |
| Temporal Lobe | 91 | 0,95 | 7 x 10 ⁻⁵¹ |
| Hippocampus | 55 | 0,95 | 7 x 10 ⁻³¹ |
| Spinal Cord | 19 | 0,94 | 2 x 10 ⁻¹¹ |
| Cerebrum | 344 | 0,94 | 5 x 10 ⁻¹⁷⁵ |
| Cicatrix | 19 | 0,94 | 3 x 10 ⁻¹¹ |
| Parietal Lobe | 17 | 0,94 | 4 x 10 ⁻¹⁰ |
| Keloid | 10 | 0,93 | 3 x 10 ⁻⁶ |
| Cerebellum | 36 | 0,92 | 1 x 10 ⁻¹⁸ |

SON

| Tissue | # samples | AUC | P-value |
|-----------------------------|-----------|------|-----------------------|
| Precursor Cells, B-Lymphoid | 14 | 0,9 | 2 x 10 ⁻⁷ |
| T-Lymphocytes, Regulatory | 33 | 0,88 | 3 x 10 ⁻¹⁴ |
| Synovial Membrane | 26 | 0,78 | 8 x 10 ⁻⁷ |
| Joints | 26 | 0,78 | 8 x 10 ⁻⁷ |
| Aortic Valve | 10 | 0,77 | 3 x 10 ⁻³ |
| Synovial Fluid | 12 | 0,77 | 1 x 10 ⁻³ |
| Killer Cells, Natural | 84 | 0,76 | 2 x 10 ⁻¹⁶ |
| Neutrophils | 216 | 0,76 | 2 x 10 ⁻³⁹ |
| T-Lymphocytes | 517 | 0,75 | 6 x 10 ⁻⁸² |
| Nasal Mucosa | 93 | 0,73 | 4 x 10 ⁻¹⁴ |
| Sputum | 151 | 0,73 | 9 x 10 ⁻²² |

GART

| Tissue | # samples | AUC | P-value |
|--------------------------------|-----------|------|------------------------|
| K562 Cells | 37 | 0,99 | 3 x 10 ⁻²⁵ |
| Jurkat Cells | 21 | 0,93 | 1 x 10 ⁻¹¹ |
| Cell Line, Transformed | 102 | 0,9 | 2 x 10 ⁻⁴⁵ |
| HEK293 Cells | 100 | 0,9 | 4 x 10 ⁻⁴⁴ |
| HCT116 Cells | 96 | 0,87 | 2 x 10 ⁻³⁶ |
| Induced Pluripotent Stem Cells | 35 | 0,86 | 9 x 10 ⁻¹⁴ |
| Glucagon-Secreting Cells | 39 | 0,86 | 6 x 10 ⁻¹⁵ |
| HL-60 Cells | 12 | 0,85 | 3 x 10 ⁻⁵ |
| Pluripotent Stem Cells | 47 | 0,83 | 6 x 10 ⁻¹⁵ |
| Hela Cells | 201 | 0,81 | 1 x 10 ⁻⁵² |
| U937 Cells | 57 | 0,81 | 4 x 10 ⁻¹⁶ |
| Clone Cells | 115 | 0,79 | 2 x 10 ⁻²⁷ |
| Cell Line, Tumor | 674 | 0,77 | 2 x 10 ⁻¹³⁰ |
| Mammary Glands, Human | 12 | 0,77 | 1 x 10 ⁻³ |
| Embryonic Stem Cells | 83 | 0,74 | 1 x 10 ⁻¹⁴ |
| Islets of Langerhans | 60 | 0,73 | 3 x 10 ⁻¹⁰ |
| Femur | 15 | 0,73 | 2 x 10 ⁻³ |
| Fallopian Tubes | 273 | 0,73 | 9 x 10 ⁻³⁹ |
| Hematopoietic Stem Cells | 106 | 0,69 | 2 x 10 ⁻¹¹ |
| Neural Stem Cells | 11 | 0,69 | 3 x 10 ⁻² |

DNAJC28

| Tissue | # samples | AUC | P-value |
|--------------------------------|-----------|------|-----------------------|
| Atrial Appendage | 10 | 0,95 | 7 x 10 ⁻⁷ |
| Induced Pluripotent Stem Cells | 35 | 0,92 | 1 x 10 ⁻¹⁷ |
| Conjunctiva | 59 | 0,89 | 3 x 10 ⁻²⁵ |
| Pluripotent Stem Cells | 47 | 0,86 | 3 x 10 ⁻¹⁷ |
| Heart Atria | 13 | 0,84 | 2 x 10 ⁻⁵ |
| Sputum | 151 | 0,82 | 6 x 10 ⁻⁴³ |

| | | | |
|----------------------------|-----|------|-----------------------|
| Mammary Glands, Human | 12 | 0,81 | 2 x 10 ⁻⁴ |
| Testis | 37 | 0,8 | 2 x 10 ⁻¹⁰ |
| Retinal Pigment Epithelium | 12 | 0,79 | 6 x 10 ⁻⁴ |
| Heart Ventricles | 124 | 0,78 | 5 x 10 ⁻²⁷ |
| Adipocytes | 81 | 0,77 | 6 x 10 ⁻¹⁷ |
| Heart | 217 | 0,77 | 2 x 10 ⁻⁴² |
| Cumulus Cells | 38 | 0,77 | 1 x 10 ⁻⁸ |
| Jurkat Cells | 21 | 0,77 | 3 x 10 ⁻⁵ |
| Embryonic Stem Cells | 83 | 0,76 | 2 x 10 ⁻¹⁶ |
| Muscle, Skeletal | 162 | 0,76 | 2 x 10 ⁻²⁹ |
| Muscle, Striated | 162 | 0,76 | 2 x 10 ⁻²⁹ |
| HEK293 Cells | 100 | 0,75 | 3 x 10 ⁻¹⁸ |
| Cell Line, Transformed | 102 | 0,75 | 1 x 10 ⁻¹⁷ |
| Mouth Mucosa | 94 | 0,74 | 1 x 10 ⁻¹⁵ |

TMEM50B

| Tissue | # samples | AUC | P-value |
|-----------------------|-----------|------|------------------------|
| Trachea | 63 | 0,95 | 4 x 10 ⁻³⁵ |
| Thyroid Gland | 85 | 0,89 | 9 x 10 ⁻³⁶ |
| Nasal Mucosa | 93 | 0,89 | 4 x 10 ⁻³⁸ |
| Motor Neurons | 12 | 0,89 | 4 x 10 ⁻⁶ |
| Plasma | 622 | 0,88 | 1 x 10 ⁻²²⁸ |
| Plasma Cells | 619 | 0,88 | 4 x 10 ⁻²²⁷ |
| Thalamus | 16 | 0,87 | 3 x 10 ⁻⁷ |
| Cerebellum | 36 | 0,87 | 2 x 10 ⁻¹⁴ |
| Neural Stem Cells | 11 | 0,84 | 8 x 10 ⁻⁵ |
| Synovial Fluid | 12 | 0,81 | 2 x 10 ⁻⁴ |
| Ganglia | 11 | 0,81 | 4 x 10 ⁻⁴ |
| Heart Ventricles | 124 | 0,8 | 4 x 10 ⁻³⁰ |
| Prostate | 352 | 0,79 | 2 x 10 ⁻⁸⁰ |
| Spinal Cord | 19 | 0,78 | 2 x 10 ⁻⁵ |
| Mammary Glands, Human | 12 | 0,78 | 8 x 10 ⁻⁴ |
| Ileum | 59 | 0,78 | 1 x 10 ⁻¹³ |
| Subcutaneous Fat | 120 | 0,77 | 2 x 10 ⁻²⁴ |
| Heart | 217 | 0,77 | 2 x 10 ⁻⁴¹ |
| Adipose Tissue | 165 | 0,76 | 2 x 10 ⁻³¹ |
| Neurons | 37 | 0,76 | 7 x 10 ⁻⁸ |

IFNGR2

| Tissue | # samples | AUC | P-value |
|---------------|-----------|------|------------------------|
| Neutrophils | 216 | 0,97 | 6 x 10 ⁻¹²⁴ |
| Sputum | 151 | 0,94 | 7 x 10 ⁻⁷⁹ |
| Monocytes | 506 | 0,91 | 9 x 10 ⁻²²² |
| Myeloid Cells | 997 | 0,89 | < 10 ⁻³⁰⁰ |

| | | | |
|-----------------------------|-----|------|------------------------|
| Bone Marrow Cells | 809 | 0,89 | 9 x 10 ⁻³¹⁵ |
| Trophoblasts | 11 | 0,86 | 4 x 10 ⁻⁵ |
| Cartilage | 13 | 0,84 | 3 x 10 ⁻⁵ |
| Dendritic Cells | 277 | 0,84 | 4 x 10 ⁻⁸³ |
| Macrophages | 342 | 0,81 | 9 x 10 ⁻⁸⁵ |
| Organelles | 12 | 0,81 | 2 x 10 ⁻⁴ |
| Ileum | 59 | 0,77 | 5 x 10 ⁻¹³ |
| Femur | 15 | 0,74 | 1 x 10 ⁻³ |
| Telomere | 30 | 0,71 | 7 x 10 ⁻⁵ |
| Knee | 26 | 0,71 | 3 x 10 ⁻⁴ |
| Macrophages, Alveolar | 117 | 0,69 | 4 x 10 ⁻¹³ |
| Abdominal Fat | 69 | 0,69 | 3 x 10 ⁻⁸ |
| Subcutaneous Fat, Abdominal | 69 | 0,69 | 3 x 10 ⁻⁸ |
| Spleen | 23 | 0,69 | 2 x 10 ⁻³ |
| Cicatrix | 19 | 0,69 | 5 x 10 ⁻³ |
| Intestinal Mucosa | 40 | 0,68 | 6 x 10 ⁻⁵ |

SBNO1

| Tissue | # samples | AUC | P-value |
|--------------------------------|-----------|------|-----------------------|
| HL-60 Cells | 12 | 0,96 | 4 x 10 ⁻⁸ |
| K562 Cells | 37 | 0,96 | 8 x 10 ⁻²² |
| Precursor Cells, B-Lymphoid | 14 | 0,92 | 4 x 10 ⁻⁸ |
| Cerebellum | 36 | 0,87 | 9 x 10 ⁻¹⁵ |
| Granulocyte Precursor Cells | 30 | 0,86 | 5 x 10 ⁻¹² |
| Caco-2 Cells | 44 | 0,82 | 1 x 10 ⁻¹³ |
| Prefrontal Cortex | 46 | 0,82 | 4 x 10 ⁻¹⁴ |
| Testis | 37 | 0,81 | 4 x 10 ⁻¹¹ |
| Visual Cortex | 34 | 0,8 | 8 x 10 ⁻¹⁰ |
| Pluripotent Stem Cells | 47 | 0,79 | 6 x 10 ⁻¹² |
| Induced Pluripotent Stem Cells | 35 | 0,79 | 3 x 10 ⁻⁹ |
| Cumulus Cells | 38 | 0,79 | 7 x 10 ⁻¹⁰ |
| Jurkat Cells | 21 | 0,79 | 5 x 10 ⁻⁶ |
| Osteoblasts | 26 | 0,78 | 7 x 10 ⁻⁷ |
| Hematopoietic Stem Cells | 106 | 0,78 | 6 x 10 ⁻²³ |
| T-Lymphocytes, Regulatory | 33 | 0,78 | 4 x 10 ⁻⁸ |
| Motor Neurons | 12 | 0,76 | 2 x 10 ⁻³ |
| Frontal Lobe | 62 | 0,76 | 9 x 10 ⁻¹³ |
| Occipital Lobe | 42 | 0,76 | 7 x 10 ⁻⁹ |
| Embryonic Stem Cells | 83 | 0,76 | 7 x 10 ⁻¹⁶ |

SETD8

| Tissue | # samples | AUC | P-value |
|------------|-----------|------|-----------------------|
| Sputum | 151 | 0,93 | 2 x 10 ⁻⁷⁵ |
| K562 Cells | 37 | 0,91 | 9 x 10 ⁻¹⁸ |

| | | | |
|-----------------------------|-----|------|------------|
| Myocytes, Smooth Muscle | 141 | 0,84 | 5 x 10-45 |
| Jurkat Cells | 21 | 0,82 | 3 x 10-7 |
| Muscle Cells | 146 | 0,82 | 5 x 10-40 |
| Prostate | 352 | 0,81 | 4 x 10-92 |
| Quadriceps Muscle | 82 | 0,78 | 6 x 10-19 |
| HCT116 Cells | 96 | 0,78 | 1 x 10-21 |
| Cell Line, Transformed | 102 | 0,77 | 9 x 10-22 |
| HEK293 Cells | 100 | 0,77 | 3 x 10-21 |
| Trophoblasts | 11 | 0,77 | 2 x 10-3 |
| Hela Cells | 201 | 0,77 | 1 x 10-38 |
| Synovial Fluid | 12 | 0,76 | 2 x 10-3 |
| Granulocyte Precursor Cells | 30 | 0,74 | 5 x 10-6 |
| Keratinocytes | 48 | 0,71 | 3 x 10-7 |
| Blastocyst | 14 | 0,71 | 6 x 10-3 |
| HT29 Cells | 17 | 0,7 | 4 x 10-3 |
| Muscle, Smooth | 248 | 0,7 | 10 x 10-28 |
| Astrocytes | 12 | 0,69 | 2 x 10-2 |
| Organelles | 12 | 0,69 | 3 x 10-2 |

RILPL2

| Tissue | # samples | AUC | P-value |
|-----------------------------|-----------|------|------------|
| Neutrophils | 216 | 0,95 | 1 x 10-113 |
| Granulocyte Precursor Cells | 30 | 0,89 | 9 x 10-14 |
| Sputum | 151 | 0,89 | 6 x 10-61 |
| HL-60 Cells | 12 | 0,89 | 4 x 10-6 |
| Bone Marrow Cells | 809 | 0,86 | 1 x 10-264 |
| Myeloid Cells | 997 | 0,85 | 1 x 10-309 |
| Monocytes | 506 | 0,81 | 1 x 10-129 |
| Macrophages | 342 | 0,8 | 2 x 10-83 |
| Hematopoietic Stem Cells | 106 | 0,78 | 8 x 10-24 |
| Macrophages, Alveolar | 117 | 0,78 | 8 x 10-26 |
| U937 Cells | 57 | 0,78 | 3 x 10-13 |
| Parotid Gland | 19 | 0,77 | 4 x 10-5 |
| Salivary Glands | 24 | 0,75 | 2 x 10-5 |
| Aortic Valve | 10 | 0,72 | 1 x 10-2 |
| Synovial Fluid | 12 | 0,72 | 7 x 10-3 |
| Conjunctiva | 59 | 0,71 | 1 x 10-8 |
| T-Lymphocytes | 517 | 0,71 | 2 x 10-59 |
| Palatine Tonsil | 72 | 0,7 | 2 x 10-9 |
| Blood Platelets | 30 | 0,7 | 2 x 10-4 |
| Osteoblasts | 26 | 0,7 | 6 x 10-4 |

C12orf65

| Tissue | # samples | AUC | P-value |
|--------|-----------|-----|---------|
|--------|-----------|-----|---------|

| | | | |
|-----------------------------|------|------|-------------------------|
| Jurkat Cells | 21 | 0,89 | 5 x 10 ⁻¹⁰ |
| K562 Cells | 37 | 0,88 | 2 x 10 ⁻¹⁵ |
| T-Lymphocytes, Regulatory | 33 | 0,87 | 9 x 10 ⁻¹⁴ |
| T-Lymphocytes | 517 | 0,87 | 10 x 10 ⁻¹⁸⁰ |
| Oocytes | 15 | 0,84 | 4 x 10 ⁻⁶ |
| Precursor Cells, B-Lymphoid | 14 | 0,83 | 2 x 10 ⁻⁵ |
| Hela Cells | 201 | 0,79 | 1 x 10 ⁻⁴⁵ |
| Cell Line, Transformed | 102 | 0,76 | 1 x 10 ⁻¹⁹ |
| HCT116 Cells | 96 | 0,76 | 5 x 10 ⁻¹⁸ |
| HEK293 Cells | 100 | 0,76 | 1 x 10 ⁻¹⁸ |
| Palatine Tonsil | 72 | 0,74 | 3 x 10 ⁻¹² |
| Lymphocytes | 1737 | 0,73 | 4 x 10 ⁻²³⁹ |
| HL-60 Cells | 12 | 0,72 | 8 x 10 ⁻³ |
| Clone Cells | 115 | 0,72 | 6 x 10 ⁻¹⁶ |
| Killer Cells, Natural | 84 | 0,72 | 9 x 10 ⁻¹² |
| Germ Cells | 33 | 0,71 | 4 x 10 ⁻⁵ |
| Hypothalamus | 15 | 0,68 | 1 x 10 ⁻² |
| HT29 Cells | 17 | 0,67 | 2 x 10 ⁻² |
| Synovial Fluid | 12 | 0,67 | 5 x 10 ⁻² |
| Intestinal Mucosa | 40 | 0,66 | 5 x 10 ⁻⁴ |

MPHOSPH9

| Tissue | # samples | AUC | P-value |
|--------------------------------|-----------|------|-----------------------|
| Jurkat Cells | 21 | 0,92 | 2 x 10 ⁻¹¹ |
| K562 Cells | 37 | 0,89 | 3 x 10 ⁻¹⁶ |
| T-Lymphocytes, Regulatory | 33 | 0,86 | 6 x 10 ⁻¹³ |
| Granulocyte Precursor Cells | 30 | 0,85 | 3 x 10 ⁻¹¹ |
| HEK293 Cells | 100 | 0,85 | 1 x 10 ⁻³³ |
| Cell Line, Transformed | 102 | 0,85 | 4 x 10 ⁻³⁴ |
| HL-60 Cells | 12 | 0,84 | 6 x 10 ⁻⁵ |
| Visual Cortex | 34 | 0,82 | 5 x 10 ⁻¹¹ |
| Precursor Cells, B-Lymphoid | 14 | 0,79 | 2 x 10 ⁻⁴ |
| Cerebellum | 36 | 0,78 | 3 x 10 ⁻⁹ |
| T-Lymphocytes | 517 | 0,76 | 2 x 10 ⁻⁸⁹ |
| Induced Pluripotent Stem Cells | 35 | 0,74 | 7 x 10 ⁻⁷ |
| Neural Stem Cells | 11 | 0,74 | 6 x 10 ⁻³ |
| HCT116 Cells | 96 | 0,74 | 4 x 10 ⁻¹⁶ |
| Occipital Lobe | 42 | 0,74 | 1 x 10 ⁻⁷ |
| Synovial Fluid | 12 | 0,72 | 8 x 10 ⁻³ |
| Embryonic Stem Cells | 83 | 0,71 | 2 x 10 ⁻¹¹ |
| Pluripotent Stem Cells | 47 | 0,7 | 1 x 10 ⁻⁶ |
| Hela Cells | 201 | 0,68 | 4 x 10 ⁻¹⁸ |
| Retina | 27 | 0,65 | 9 x 10 ⁻³ |

SNRNP35

| Tissue | # samples | AUC | P-value |
|---------------------------|-----------|------|------------|
| Blood Platelets | 30 | 0,99 | 2 x 10-20 |
| Quadriceps Muscle | 82 | 0,97 | 2 x 10-48 |
| Muscle, Skeletal | 162 | 0,92 | 5 x 10-76 |
| Muscle, Striated | 162 | 0,92 | 5 x 10-76 |
| Atrial Appendage | 10 | 0,91 | 6 x 10-6 |
| Heart Atria | 13 | 0,9 | 6 x 10-7 |
| Muscles | 723 | 0,85 | 1 x 10-224 |
| Palatine Tonsil | 72 | 0,84 | 9 x 10-24 |
| Visual Cortex | 34 | 0,83 | 2 x 10-11 |
| Neutrophils | 216 | 0,82 | 2 x 10-58 |
| Occipital Lobe | 42 | 0,81 | 2 x 10-12 |
| T-Lymphocytes, Regulatory | 33 | 0,81 | 1 x 10-9 |
| Synovial Fluid | 12 | 0,78 | 9 x 10-4 |
| Subthalamic Nucleus | 12 | 0,76 | 2 x 10-3 |
| Nasopharynx | 30 | 0,76 | 7 x 10-7 |
| Conjunctiva | 59 | 0,76 | 1 x 10-11 |
| Hypothalamus | 15 | 0,75 | 7 x 10-4 |
| Arteries | 25 | 0,75 | 1 x 10-5 |
| Salivary Glands | 24 | 0,73 | 7 x 10-5 |
| Parotid Gland | 19 | 0,73 | 4 x 10-4 |

RILPL1

| Tissue | # samples | AUC | P-value |
|---------------------|-----------|------|------------|
| Atrial Appendage | 10 | 1 | 5 x 10-8 |
| Heart Atria | 13 | 1 | 5 x 10-10 |
| Heart Ventricles | 124 | 0,99 | 2 x 10-80 |
| Quadriceps Muscle | 82 | 0,99 | 4 x 10-53 |
| Muscle, Skeletal | 162 | 0,98 | 6 x 10-101 |
| Muscle, Striated | 162 | 0,98 | 6 x 10-101 |
| Heart | 217 | 0,98 | 7 x 10-134 |
| Subthalamic Nucleus | 12 | 0,97 | 2 x 10-8 |
| Substantia Nigra | 22 | 0,96 | 7 x 10-14 |
| Muscles | 723 | 0,96 | < 10-300 |
| Mesencephalon | 41 | 0,96 | 5 x 10-24 |
| Thalamus | 16 | 0,95 | 4 x 10-10 |
| Putamen | 16 | 0,94 | 8 x 10-10 |
| Parietal Lobe | 17 | 0,94 | 4 x 10-10 |
| Embryoid Bodies | 11 | 0,93 | 6 x 10-7 |
| Temporal Lobe | 91 | 0,93 | 1 x 10-45 |
| Spinal Cord | 19 | 0,93 | 9 x 10-11 |
| Entorhinal Cortex | 83 | 0,93 | 4 x 10-41 |
| Neural Stem Cells | 11 | 0,92 | 1 x 10-6 |

| | | | |
|-----------------|-----|------|------------------------|
| Cerebral Cortex | 276 | 0,92 | 4 x 10 ⁻¹²⁹ |
|-----------------|-----|------|------------------------|

PITPNM2

| Tissue | # samples | AUC | P-value |
|----------------------------|-----------|------|-----------------------|
| Hep G2 Cells | 102 | 0,89 | 3 x 10 ⁻⁴³ |
| Frontal Lobe | 62 | 0,88 | 1 x 10 ⁻²⁴ |
| Hippocampus | 55 | 0,87 | 9 x 10 ⁻²² |
| Prefrontal Cortex | 46 | 0,87 | 7 x 10 ⁻¹⁸ |
| Hepatocytes | 188 | 0,86 | 7 x 10 ⁻⁶⁵ |
| Jurkat Cells | 21 | 0,83 | 1 x 10 ⁻⁷ |
| Putamen | 16 | 0,81 | 1 x 10 ⁻⁵ |
| Temporal Lobe | 91 | 0,8 | 1 x 10 ⁻²³ |
| Cerebral Cortex | 276 | 0,8 | 8 x 10 ⁻⁶⁷ |
| Entorhinal Cortex | 83 | 0,8 | 8 x 10 ⁻²¹ |
| Heart Ventricles | 124 | 0,79 | 1 x 10 ⁻²⁸ |
| Retinal Pigment Epithelium | 12 | 0,78 | 7 x 10 ⁻⁴ |
| Hypothalamus | 15 | 0,78 | 2 x 10 ⁻⁴ |
| Trophoblasts | 11 | 0,78 | 2 x 10 ⁻³ |
| Cerebrum | 344 | 0,75 | 3 x 10 ⁻⁵⁶ |
| Synovial Membrane | 26 | 0,74 | 2 x 10 ⁻⁵ |
| Joints | 26 | 0,74 | 2 x 10 ⁻⁵ |
| Endothelial Cells | 196 | 0,74 | 7 x 10 ⁻³¹ |
| Myocytes, Smooth Muscle | 141 | 0,74 | 4 x 10 ⁻²² |
| Synovial Fluid | 12 | 0,73 | 5 x 10 ⁻³ |

STK24

| Tissue | # samples | AUC | P-value |
|-----------------------------|-----------|------|------------------------|
| Conjunctiva | 59 | 0,94 | 3 x 10 ⁻³² |
| Blood Platelets | 30 | 0,94 | 1 x 10 ⁻¹⁶ |
| Precursor Cells, B-Lymphoid | 14 | 0,92 | 6 x 10 ⁻⁸ |
| Nasal Mucosa | 93 | 0,9 | 9 x 10 ⁻⁴⁰ |
| Caco-2 Cells | 44 | 0,88 | 7 x 10 ⁻¹⁸ |
| Mouth Mucosa | 94 | 0,87 | 3 x 10 ⁻³⁶ |
| T-Lymphocytes, Regulatory | 33 | 0,86 | 5 x 10 ⁻¹³ |
| Neck | 138 | 0,84 | 2 x 10 ⁻⁴³ |
| Mucous Membrane | 480 | 0,82 | 2 x 10 ⁻¹³⁰ |
| Ileum | 59 | 0,81 | 1 x 10 ⁻¹⁶ |
| Keratinocytes | 48 | 0,81 | 2 x 10 ⁻¹³ |
| Head | 297 | 0,8 | 10 x 10 ⁻⁷² |
| Urinary Bladder | 70 | 0,79 | 3 x 10 ⁻¹⁷ |
| Membranes | 521 | 0,79 | 7 x 10 ⁻¹¹¹ |
| U937 Cells | 57 | 0,78 | 2 x 10 ⁻¹³ |
| Neutrophils | 216 | 0,78 | 8 x 10 ⁻⁴⁵ |
| Vulva | 34 | 0,77 | 4 x 10 ⁻⁸ |

| | | | |
|-------------------|-----|------|-----------|
| Sputum | 151 | 0,77 | 9 x 10-31 |
| Pelvis | 10 | 0,77 | 4 x 10-3 |
| Intestinal Mucosa | 40 | 0,76 | 1 x 10-8 |

FARP1

| Tissue | # samples | AUC | P-value |
|----------------------------|-----------|------|-------------|
| Neural Stem Cells | 11 | 0,96 | 1 x 10-7 |
| Hep G2 Cells | 102 | 0,94 | 2 x 10-52 |
| Cicatrix | 19 | 0,94 | 5 x 10-11 |
| Embryoid Bodies | 11 | 0,93 | 10 x 10-7 |
| Keloid | 10 | 0,91 | 6 x 10-6 |
| Osteoblasts | 26 | 0,89 | 7 x 10-12 |
| Retinal Pigment Epithelium | 12 | 0,89 | 3 x 10-6 |
| Parotid Gland | 19 | 0,88 | 7 x 10-9 |
| Salivary Glands | 24 | 0,88 | 1 x 10-10 |
| Fibroblasts | 392 | 0,86 | 3 x 10-133 |
| Hepatocytes | 188 | 0,86 | 7 x 10-64 |
| Endometrium | 264 | 0,85 | 3 x 10-84 |
| Astrocytes | 12 | 0,84 | 4 x 10-5 |
| Thyroid Gland | 85 | 0,84 | 2 x 10-27 |
| Liver | 569 | 0,84 | 2 x 10-170 |
| Embryonic Stem Cells | 83 | 0,82 | 2 x 10-24 |
| Organelles | 12 | 0,82 | 1 x 10-4 |
| Kidney | 614 | 0,82 | 10 x 10-163 |
| Myocytes, Smooth Muscle | 141 | 0,82 | 7 x 10-39 |
| Chondrocytes | 19 | 0,82 | 2 x 10-6 |

SLC15A1

| Tissue | # samples | AUC | P-value |
|-----------------------|-----------|------|-----------|
| Thalamus | 16 | 0,85 | 2 x 10-6 |
| Putamen | 16 | 0,82 | 1 x 10-5 |
| Ganglia | 11 | 0,8 | 5 x 10-4 |
| Pelvis | 10 | 0,78 | 2 x 10-3 |
| Cervix Uteri | 38 | 0,75 | 9 x 10-8 |
| Palatine Tonsil | 72 | 0,75 | 6 x 10-13 |
| Subthalamic Nucleus | 12 | 0,74 | 4 x 10-3 |
| Cecum | 15 | 0,73 | 2 x 10-3 |
| Esophagus | 13 | 0,73 | 4 x 10-3 |
| Killer Cells, Natural | 84 | 0,71 | 1 x 10-11 |
| Thyroid Gland | 85 | 0,71 | 1 x 10-11 |
| Ileum | 59 | 0,71 | 3 x 10-8 |
| Neutrophils | 216 | 0,7 | 7 x 10-24 |
| Omentum | 76 | 0,7 | 3 x 10-9 |
| Abdomen | 103 | 0,69 | 8 x 10-12 |

| | | | |
|-----------------------------|----|------|----------------------|
| Mesencephalon | 41 | 0,69 | 2 x 10 ⁻⁵ |
| Substantia Nigra | 22 | 0,69 | 2 x 10 ⁻³ |
| Precursor Cells, B-Lymphoid | 14 | 0,69 | 2 x 10 ⁻² |
| Peritoneum | 89 | 0,68 | 3 x 10 ⁻⁹ |
| Hypothalamus | 15 | 0,68 | 2 x 10 ⁻² |

TANK

| Tissue | # samples | AUC | P-value |
|-----------------------------|-----------|------|------------------------|
| Sputum | 151 | 0,95 | 7 x 10 ⁻⁸³ |
| Neutrophils | 216 | 0,94 | 1 x 10 ⁻¹¹¹ |
| HT29 Cells | 17 | 0,89 | 2 x 10 ⁻⁸ |
| Myeloid Cells | 997 | 0,85 | 2 x 10 ⁻³¹² |
| Bone Marrow Cells | 809 | 0,85 | 3 x 10 ⁻²⁵⁴ |
| Synovial Fluid | 12 | 0,85 | 3 x 10 ⁻⁵ |
| Monocytes | 506 | 0,84 | 2 x 10 ⁻¹⁵² |
| Macrophages | 342 | 0,81 | 4 x 10 ⁻⁸⁵ |
| Chorion | 15 | 0,78 | 2 x 10 ⁻⁴ |
| Umbilical Veins | 113 | 0,78 | 3 x 10 ⁻²⁴ |
| Killer Cells, Natural | 84 | 0,77 | 4 x 10 ⁻¹⁸ |
| Cicatrix | 19 | 0,77 | 4 x 10 ⁻⁵ |
| Dendritic Cells | 277 | 0,77 | 3 x 10 ⁻⁵⁴ |
| Precursor Cells, B-Lymphoid | 14 | 0,75 | 1 x 10 ⁻³ |
| Macrophages, Alveolar | 117 | 0,75 | 8 x 10 ⁻²¹ |
| Oocytes | 15 | 0,74 | 1 x 10 ⁻³ |
| Keloid | 10 | 0,74 | 9 x 10 ⁻³ |
| HCT116 Cells | 96 | 0,73 | 2 x 10 ⁻¹⁵ |
| Veins | 133 | 0,73 | 1 x 10 ⁻²⁰ |
| Fetal Blood | 151 | 0,72 | 6 x 10 ⁻²¹ |

PSMD14

| Tissue | # samples | AUC | P-value |
|--------------------------|-----------|------|------------------------|
| K562 Cells | 37 | 0,97 | 9 x 10 ⁻²³ |
| HCT116 Cells | 96 | 0,97 | 4 x 10 ⁻⁵⁶ |
| U937 Cells | 57 | 0,95 | 2 x 10 ⁻³¹ |
| Jurkat Cells | 21 | 0,92 | 3 x 10 ⁻¹¹ |
| HL-60 Cells | 12 | 0,89 | 4 x 10 ⁻⁶ |
| Tongue | 105 | 0,87 | 5 x 10 ⁻³⁹ |
| Glucagon-Secreting Cells | 39 | 0,84 | 2 x 10 ⁻¹³ |
| Clone Cells | 115 | 0,83 | 4 x 10 ⁻³⁵ |
| Cell Line, Tumor | 674 | 0,83 | 9 x 10 ⁻¹⁹¹ |
| Nasopharynx | 30 | 0,81 | 2 x 10 ⁻⁹ |
| Pluripotent Stem Cells | 47 | 0,81 | 2 x 10 ⁻¹³ |
| HT29 Cells | 17 | 0,81 | 1 x 10 ⁻⁵ |
| Islets of Langerhans | 60 | 0,8 | 3 x 10 ⁻¹⁶ |

| | | | |
|--------------------------------|-----|------|-----------|
| Induced Pluripotent Stem Cells | 35 | 0,8 | 4 x 10-10 |
| Cell Line, Transformed | 102 | 0,8 | 2 x 10-26 |
| HEK293 Cells | 100 | 0,8 | 1 x 10-25 |
| Neural Stem Cells | 11 | 0,79 | 8 x 10-4 |
| Hela Cells | 201 | 0,77 | 3 x 10-41 |
| Hep G2 Cells | 102 | 0,77 | 5 x 10-21 |
| Stromal Cells | 54 | 0,77 | 8 x 10-12 |

TBR1

| Tissue | # samples | AUC | P-value |
|-------------------------|-----------|------|------------|
| Prefrontal Cortex | 46 | 0,99 | 1 x 10-30 |
| Frontal Lobe | 62 | 0,99 | 2 x 10-40 |
| Hippocampus | 55 | 0,92 | 4 x 10-27 |
| Parietal Lobe | 17 | 0,89 | 3 x 10-8 |
| Cerebral Cortex | 276 | 0,88 | 2 x 10-104 |
| Temporal Lobe | 91 | 0,86 | 1 x 10-32 |
| Entorhinal Cortex | 83 | 0,85 | 4 x 10-28 |
| Nasopharynx | 30 | 0,84 | 8 x 10-11 |
| Keloid | 10 | 0,84 | 2 x 10-4 |
| Trophoblasts | 11 | 0,83 | 1 x 10-4 |
| Heart Ventricles | 124 | 0,83 | 2 x 10-36 |
| Blastocyst | 14 | 0,83 | 2 x 10-5 |
| Subthalamic Nucleus | 12 | 0,81 | 2 x 10-4 |
| Cerebrum | 344 | 0,79 | 3 x 10-78 |
| Myocytes, Smooth Muscle | 141 | 0,78 | 2 x 10-31 |
| Cicatrix | 19 | 0,78 | 2 x 10-5 |
| Thalamus | 16 | 0,78 | 1 x 10-4 |
| Muscle Cells | 146 | 0,76 | 4 x 10-27 |
| Brain | 1274 | 0,75 | 2 x 10-206 |
| Central Nervous System | 1302 | 0,75 | 7 x 10-200 |

| Related to | Gene Set ID | Gene Set Name |
|-------------------|-------------|---|
| neuronal function | | |
| 0 | GO:0051084 | 'De Novo' Posttranslational Protein Folding |
| 0 | GO:0006458 | 'De Novo' Protein Folding |
| 0 | GO:0005545 | 1-Phosphatidylinositol Binding |
| 0 | GO:0016303 | 1-Phosphatidylinositol-3-Kinase Activity |
| 0 | GO:0051537 | 2 Iron, 2 Sulfur Cluster Binding |
| 0 | GO:0006103 | 2-Oxoglutarate Metabolic Process |
| 0 | GO:0009394 | 2'-Deoxyribonucleotide Metabolic Process |
| 0 | GO:0003854 | 3-Beta-Hydroxy-Delta5-Steroid Dehydrogenase Activity |
| 0 | GO:0008408 | 3'-5' Exonuclease Activity |
| 0 | GO:0000175 | 3'-5'-Exoribonuclease Activity |
| 0 | GO:0050427 | 3'-Phosphoadenosine 5'-Phosphosulfate Metabolic Process |
| 0 | GO:0004115 | 3',5'-Cyclic-Amp Phosphodiesterase Activity |
| 0 | GO:0047555 | 3',5'-Cyclic-Gmp Phosphodiesterase Activity |
| 0 | GO:0004114 | 3',5'-Cyclic-Nucleotide Phosphodiesterase Activity |
| 0 | GO:0051539 | 4 Iron, 4 Sulfur Cluster Binding |
| 0 | GO:0031672 | A Band |
| 0 | GO:0006085 | Acetyl-CoA Biosynthetic Process |
| 0 | GO:0006086 | Acetyl-CoA Biosynthetic Process From Pyruvate |
| 0 | GO:0046356 | Acetyl-CoA Catabolic Process |
| 0 | GO:0006084 | Acetyl-CoA Metabolic Process |
| 1 | GO:0042166 | Acetylcholine Binding |
| 1 | GO:0015464 | Acetylcholine Receptor Activity |
| 1 | GO:0004889 | Acetylcholine-Activated Cation-Selective Channel Activity |
| 1 | GO:0005892 | Acetylcholine-Gated Channel Complex |
| 0 | GO:0008376 | Acetylgalactosaminyltransferase Activity |
| 0 | GO:0008375 | Acetylglucosaminyltransferase Activity |
| 0 | GO:0016407 | Acetyltransferase Activity |
| 0 | GO:0003993 | Acid Phosphatase Activity |
| 0 | GO:0046717 | Acid Secretion |
| 0 | GO:0016881 | Acid-Amino Acid Ligase Activity |
| 0 | GO:0016878 | Acid-Thiol Ligase Activity |
| 0 | GO:0015172 | Acidic Amino Acid Transmembrane Transporter Activity |
| 0 | GO:0015800 | Acidic Amino Acid Transport |
| 0 | GO:0002080 | Acrosomal Membrane |
| 0 | GO:0001669 | Acrosomal Vesicle |
| 0 | GO:0007340 | Acrosome Reaction |
| 0 | GO:0003779 | Actin Binding |
| 0 | GO:0015629 | Actin Cytoskeleton |
| 0 | GO:0030036 | Actin Cytoskeleton Organization |
| 0 | GO:0031532 | Actin Cytoskeleton Reorganization |
| 0 | GO:0005884 | Actin Filament |
| 0 | GO:0051015 | Actin Filament Binding |
| 0 | GO:0032432 | Actin Filament Bundle |
| 0 | GO:0051017 | Actin Filament Bundle Assembly |
| 0 | GO:0051693 | Actin Filament Capping |
| 0 | GO:0030042 | Actin Filament Depolymerization |
| 0 | GO:0007015 | Actin Filament Organization |
| 0 | GO:0030041 | Actin Filament Polymerization |
| 0 | GO:0030048 | Actin Filament-Based Movement |
| 0 | GO:0030029 | Actin Filament-Based Process |
| 0 | GO:0003785 | Actin Monomer Binding |
| 0 | GO:0008154 | Actin Polymerization Or Depolymerization |
| 0 | GO:0070252 | Actin-Mediated Cell Contraction |
| 0 | GO:0033275 | Actin-Myosin Filament Sliding |

| | | |
|---|------------|---|
| 0 | GO:0042805 | Actinin Binding |
| 0 | GO:0050798 | Activated T Cell Proliferation |
| 0 | GO:0033613 | Activating Transcription Factor Binding |
| 0 | GO:0007190 | Activation Of Adenylate Cyclase Activity |
| 0 | GO:0006919 | Activation Of Cysteine-Type Endopeptidase Activity Involved In Apoptotic Process |
| 0 | GO:0008635 | Activation Of Cysteine-Type Endopeptidase Activity Involved In Apoptotic Process By Cytochrome C |
| 0 | GO:0002253 | Activation Of Immune Response |
| 0 | GO:0002218 | Activation Of Innate Immune Response |
| 0 | GO:0042976 | Activation Of Janus Kinase Activity |
| 0 | GO:0007257 | Activation Of Jun Kinase Activity |
| 0 | GO:0000187 | Activation Of Mapk Activity |
| 0 | GO:0000186 | Activation Of Mapkk Activity |
| 0 | GO:0007250 | Activation Of Nf-Kappab-Inducing Kinase Activity |
| 0 | GO:0007202 | Activation Of Phospholipase C Activity |
| 0 | GO:0008633 | Activation Of Pro-Apoptotic Gene Products |
| 0 | GO:0034199 | Activation Of Protein Kinase A Activity |
| 0 | GO:0032147 | Activation Of Protein Kinase Activity |
| 0 | GO:0032148 | Activation Of Protein Kinase B Activity |
| 0 | GO:0032856 | Activation Of Ras Gtpase Activity |
| 0 | GO:0032862 | Activation Of Rho Gtpase Activity |
| 0 | GO:0022804 | Active Transmembrane Transporter Activity |
| 0 | GO:0048185 | Activin Binding |
| 0 | GO:0032924 | Activin Receptor Signaling Pathway |
| 0 | GO:0017002 | Activin-Activated Receptor Activity |
| 0 | GO:0042641 | Actomyosin |
| 0 | GO:0031032 | Actomyosin Structure Organization |
| 0 | GO:0002526 | Acute Inflammatory Response |
| 0 | GO:0002438 | Acute Inflammatory Response To Antigenic Stimulus |
| 0 | GO:0006953 | Acute-Phase Response |
| 0 | GO:0071616 | Acyl-CoA Biosynthetic Process |
| 0 | GO:0003995 | Acyl-CoA Dehydrogenase Activity |
| 0 | GO:0006637 | Acyl-CoA Metabolic Process |
| 0 | GO:0046463 | Acylglycerol Biosynthetic Process |
| 0 | GO:0046464 | Acylglycerol Catabolic Process |
| 0 | GO:0006639 | Acylglycerol Metabolic Process |
| 0 | GO:0016411 | Acylglycerol O-Acyltransferase Activity |
| 0 | GO:0005671 | Ada2/Gcn5/Ada3 Transcription Activator Complex |
| 0 | GO:0023058 | Adaptation Of Signaling Pathway |
| 0 | GO:0002250 | Adaptive Immune Response |
| 0 | GO:0002460 | Adaptive Immune Response Based On Somatic Recombination Of Immune Receptors Built From Immunoglobulin Superfamily Domains |
| 0 | GO:0021984 | Adenohypophysis Development |
| 0 | GO:0004016 | Adenylate Cyclase Activity |
| 0 | GO:0007189 | Adenylate Cyclase-Activating G-Protein Coupled Receptor Signaling Pathway |
| 0 | GO:0007193 | Adenylate Cyclase-Inhibiting G-Protein Coupled Receptor Signaling Pathway |
| 0 | GO:0007188 | Adenylate Cyclase-Modulating G-Protein Coupled Receptor Signaling Pathway |
| 0 | GO:0070566 | Adenylyltransferase Activity |
| 0 | GO:0005912 | Adherens Junction |
| 0 | GO:0034332 | Adherens Junction Organization |
| 0 | GO:0060612 | Adipose Tissue Development |
| 0 | GO:0043531 | Adp Binding |
| 0 | GO:0030325 | Adrenal Gland Development |
| 1 | GO:0030534 | Adult Behavior |
| 1 | GO:0008343 | Adult Feeding Behavior |
| 0 | GO:0007512 | Adult Heart Development |
| 0 | GO:0008344 | Adult Locomotory Behavior |
| 0 | GO:0007628 | Adult Walking Behavior |

| | | |
|---|------------|--|
| 0 | GO:0009060 | Aerobic Respiration |
| 0 | GO:0016235 | Aggresome |
| 0 | GO:0007568 | Aging |
| 0 | GO:0043178 | Alcohol Binding |
| 0 | GO:0046165 | Alcohol Biosynthetic Process |
| 0 | GO:0046164 | Alcohol Catabolic Process |
| 0 | GO:0019400 | Alditol Metabolic Process |
| 0 | GO:0004033 | Aldo-Keto Reductase (Nadp) Activity |
| 0 | GO:0043450 | Alkene Biosynthetic Process |
| 0 | GO:0032281 | Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Selective Glutamate Receptor Complex |
| 0 | GO:0046631 | Alpha-Beta T Cell Activation |
| 0 | GO:0002287 | Alpha-Beta T Cell Activation Involved In Immune Response |
| 0 | GO:0046632 | Alpha-Beta T Cell Differentiation |
| 0 | GO:0002293 | Alpha-Beta T Cell Differentiation Involved In Immune Response |
| 0 | GO:0046633 | Alpha-Beta T Cell Proliferation |
| 0 | GO:0043014 | Alpha-Tubulin Binding |
| 0 | GO:0000380 | Alternative Nuclear Mrna Splicing, Via Spliceosome |
| 0 | GO:0001667 | Ameboidal Cell Migration |
| 0 | GO:0043176 | Amine Binding |
| 0 | GO:0009309 | Amine Biosynthetic Process |
| 0 | GO:0009310 | Amine Catabolic Process |
| 0 | GO:0005275 | Amine Transmembrane Transporter Activity |
| 0 | GO:0015837 | Amine Transport |
| 0 | GO:0043038 | Amino Acid Activation |
| 0 | GO:0016597 | Amino Acid Binding |
| 0 | GO:0043090 | Amino Acid Import |
| 0 | GO:0003333 | Amino Acid Transmembrane Transport |
| 0 | GO:0015171 | Amino Acid Transmembrane Transporter Activity |
| 0 | GO:0006865 | Amino Acid Transport |
| 0 | GO:0006040 | Amino Sugar Metabolic Process |
| 0 | GO:0004812 | Aminoacyl-Trna Ligase Activity |
| 0 | GO:0006023 | Aminoglycan Biosynthetic Process |
| 0 | GO:0006026 | Aminoglycan Catabolic Process |
| 0 | GO:0006022 | Aminoglycan Metabolic Process |
| 0 | GO:0004177 | Aminopeptidase Activity |
| 0 | GO:0016208 | Amp Binding |
| 0 | GO:0042987 | Amyloid Precursor Protein Catabolic Process |
| 0 | GO:0042982 | Amyloid Precursor Protein Metabolic Process |
| 0 | GO:0042640 | Anagen |
| 0 | GO:0051322 | Anaphase |
| 0 | GO:0005680 | Anaphase-Promoting Complex |
| 0 | GO:0031145 | Anaphase-Promoting Complex-Dependent Proteasomal Ubiquitin-Dependent Protein Catabolic Process |
| 0 | GO:0048532 | Anatomical Structure Arrangement |
| 0 | GO:0060249 | Anatomical Structure Homeostasis |
| 0 | GO:0071695 | Anatomical Structure Maturation |
| 0 | GO:0031362 | Anchored To External Side Of Plasma Membrane |
| 0 | GO:0031225 | Anchored To Membrane |
| 0 | GO:0046658 | Anchored To Plasma Membrane |
| 0 | GO:0030934 | Anchoring Collagen |
| 0 | GO:0070161 | Anchoring Junction |
| 0 | GO:0006702 | Androgen Biosynthetic Process |
| 0 | GO:0008209 | Androgen Metabolic Process |
| 0 | GO:0050681 | Androgen Receptor Binding |
| 0 | GO:0030521 | Androgen Receptor Signaling Pathway |
| 0 | GO:0001525 | Angiogenesis |
| 0 | GO:0060055 | Angiogenesis Involved In Wound Healing |

| | | |
|---|------------|---|
| 0 | GO:0043168 | Anion Binding |
| 0 | GO:0005253 | Anion Channel Activity |
| 0 | GO:0055081 | Anion Homeostasis |
| 0 | GO:0008509 | Anion Transmembrane Transporter Activity |
| 0 | GO:0006820 | Anion Transport |
| 0 | GO:0015301 | Anion:Anion Antiporter Activity |
| 0 | GO:0015296 | Anion:Cation Symporter Activity |
| 0 | GO:0009948 | Anterior/Posterior Axis Specification |
| 0 | GO:0008595 | Anterior/Posterior Axis Specification, Embryo |
| 0 | GO:0009952 | Anterior/Posterior Pattern Specification |
| 0 | GO:0006916 | Anti-Apoptosis |
| 0 | GO:0003823 | Antigen Binding |
| 0 | GO:0019882 | Antigen Processing And Presentation |
| 0 | GO:0019884 | Antigen Processing And Presentation Of Exogenous Antigen |
| 0 | GO:0002478 | Antigen Processing And Presentation Of Exogenous Peptide Antigen |
| 0 | GO:0048002 | Antigen Processing And Presentation Of Peptide Antigen |
| 0 | GO:0002474 | Antigen Processing And Presentation Of Peptide Antigen Via Mhc Class I |
| 0 | GO:0002495 | Antigen Processing And Presentation Of Peptide Antigen Via Mhc Class II |
| 0 | GO:0002504 | Antigen Processing And Presentation Of Peptide Or Polysaccharide Antigen Via Mhc Class II |
| 0 | GO:0050851 | Antigen Receptor-Mediated Signaling Pathway |
| 0 | GO:0016209 | Antioxidant Activity |
| 0 | GO:0015297 | Antiporter Activity |
| 0 | GO:0035904 | Aorta Development |
| 0 | GO:0035909 | Aorta Morphogenesis |
| 0 | GO:0030119 | Ap-Type Membrane Coat Adaptor Complex |
| 0 | GO:0043297 | Apical Junction Assembly |
| 0 | GO:0043296 | Apical Junction Complex |
| 0 | GO:0045177 | Apical Part Of Cell |
| 0 | GO:0016324 | Apical Plasma Membrane |
| 0 | GO:0045176 | Apical Protein Localization |
| 0 | GO:0016327 | Apicolateral Plasma Membrane |
| 0 | GO:0034185 | Apolipoprotein Binding |
| 0 | GO:0043277 | Apoptotic Cell Clearance |
| 0 | GO:0006309 | Apoptotic Dna Fragmentation |
| 0 | GO:0008637 | Apoptotic Mitochondrial Changes |
| 0 | GO:0030262 | Apoptotic Nuclear Change |
| 0 | GO:0060561 | Apoptotic Process Involved In Morphogenesis |
| 0 | GO:0016505 | Apoptotic Protease Activator Activity |
| 0 | GO:0048736 | Appendage Development |
| 0 | GO:0035107 | Appendage Morphogenesis |
| 0 | GO:0050482 | Arachidonic Acid Secretion |
| 0 | GO:0008060 | Arf Gtpase Activator Activity |
| 0 | GO:0005086 | Arf Guanyl-Nucleotide Exchange Factor Activity |
| 0 | GO:0032011 | Arf Protein Signal Transduction |
| 0 | GO:0006525 | Arginine Metabolic Process |
| 0 | GO:0070330 | Aromatase Activity |
| 0 | GO:0009074 | Aromatic Amino Acid Family Catabolic Process |
| 0 | GO:0009072 | Aromatic Amino Acid Family Metabolic Process |
| 0 | GO:0019438 | Aromatic Compound Biosynthetic Process |
| 0 | GO:0019439 | Aromatic Compound Catabolic Process |
| 0 | GO:0060840 | Artery Development |
| 0 | GO:0048844 | Artery Morphogenesis |
| 0 | GO:0004065 | Arylsulfatase Activity |
| 0 | GO:0009067 | Aspartate Family Amino Acid Biosynthetic Process |
| 0 | GO:0009068 | Aspartate Family Amino Acid Catabolic Process |
| 0 | GO:0009066 | Aspartate Family Amino Acid Metabolic Process |

| | | |
|---|------------|---|
| 0 | GO:0004190 | Aspartic-Type Endopeptidase Activity |
| 0 | GO:0070001 | Aspartic-Type Peptidase Activity |
| 0 | GO:0008306 | Associative Learning |
| 1 | GO:0014002 | Astrocyte Development |
| 1 | GO:0048708 | Astrocyte Differentiation |
| 0 | GO:0008105 | Asymmetric Protein Localization |
| 0 | GO:0032279 | Asymmetric Synapse |
| 0 | GO:0006754 | Atp Biosynthetic Process |
| 0 | GO:0006200 | Atp Catabolic Process |
| 0 | GO:0015991 | Atp Hydrolysis Coupled Proton Transport |
| 0 | GO:0046034 | Atp Metabolic Process |
| 0 | GO:0042773 | Atp Synthesis Coupled Electron Transport |
| 0 | GO:0015986 | Atp Synthesis Coupled Proton Transport |
| 0 | GO:0043044 | Atp-Dependent Chromatin Remodeling |
| 0 | GO:0004003 | Atp-Dependent Dna Helicase Activity |
| 0 | GO:0008026 | Atp-Dependent Helicase Activity |
| 0 | GO:0004004 | Atp-Dependent Rna Helicase Activity |
| 0 | GO:0016887 | Atpase Activity |
| 0 | GO:0042623 | Atpase Activity, Coupled |
| 0 | GO:0043492 | Atpase Activity, Coupled To Movement Of Substances |
| 0 | GO:0042625 | Atpase Activity, Coupled To Transmembrane Movement Of Ions |
| 0 | GO:0015662 | Atpase Activity, Coupled To Transmembrane Movement Of Ions, Phosphorylative Mechanism |
| 0 | GO:0042626 | Atpase Activity, Coupled To Transmembrane Movement Of Substances |
| 0 | GO:0051117 | Atpase Binding |
| 0 | GO:0060590 | Atpase Regulator Activity |
| 0 | GO:0051313 | Attachment Of Spindle Microtubules To Chromosome |
| 0 | GO:0008608 | Attachment Of Spindle Microtubules To Kinetochore |
| 0 | GO:0017091 | Au-Rich Element Binding |
| 0 | GO:0060117 | Auditory Receptor Cell Development |
| 0 | GO:0042491 | Auditory Receptor Cell Differentiation |
| 0 | GO:0048483 | Autonomic Nervous System Development |
| 0 | GO:0005776 | Autophagic Vacuole |
| 0 | GO:0000045 | Autophagic Vacuole Assembly |
| 0 | GO:0000421 | Autophagic Vacuole Membrane |
| 0 | GO:0006914 | Autophagy |
| 0 | GO:0003401 | Axis Elongation |
| 0 | GO:0009798 | Axis Specification |
| 0 | GO:0030673 | Axolemma |
| 1 | GO:0030424 | Axon |
| 1 | GO:0008088 | Axon Cargo Transport |
| 1 | GO:0008366 | Axon Ensheatment |
| 1 | GO:0032291 | Axon Ensheatment In Central Nervous System |
| 1 | GO:0048675 | Axon Extension |
| 1 | GO:0048846 | Axon Extension Involved In Axon Guidance |
| 1 | GO:0007411 | Axon Guidance |
| 1 | GO:0033267 | Axon Part |
| 1 | GO:0031103 | Axon Regeneration |
| 1 | GO:0043679 | Axon Terminus |
| 1 | GO:0007413 | Axonal Fasciculation |
| 0 | GO:0005858 | Axonemal Dynein Complex |
| 0 | GO:0005930 | Axoneme |
| 0 | GO:0044447 | Axoneme Part |
| 1 | GO:0007409 | Axonogenesis |
| 0 | GO:0042113 | B Cell Activation |
| 0 | GO:0002312 | B Cell Activation Involved In Immune Response |
| 0 | GO:0001783 | B Cell Apoptotic Process |

| | | |
|---|------------|--|
| 0 | GO:0030183 | B Cell Differentiation |
| 0 | GO:0001782 | B Cell Homeostasis |
| 0 | GO:0019724 | B Cell Mediated Immunity |
| 0 | GO:0042100 | B Cell Proliferation |
| 0 | GO:0050853 | B Cell Receptor Signaling Pathway |
| 0 | GO:0051635 | Bacterial Cell Surface Binding |
| 0 | GO:0005605 | Basal Lamina |
| 0 | GO:0045178 | Basal Part Of Cell |
| 0 | GO:0009925 | Basal Plasma Membrane |
| 0 | GO:0006284 | Base-Excision Repair |
| 0 | GO:0005604 | Basement Membrane |
| 0 | GO:0015802 | Basic Amino Acid Transport |
| 0 | GO:0016323 | Basolateral Plasma Membrane |
| 1 | GO:0007610 | Behavior |
| 1 | GO:0002209 | Behavioral Defense Response |
| 1 | GO:0001662 | Behavioral Fear Response |
| 0 | GO:0051705 | Behavioral Interaction Between Organisms |
| 1 | GO:0048266 | Behavioral Response To Pain |
| 0 | GO:0042537 | Benzene-Containing Compound Metabolic Process |
| 0 | GO:0001540 | Beta-Amyloid Binding |
| 0 | GO:0008013 | Beta-Catenin Binding |
| 0 | GO:0048487 | Beta-Tubulin Binding |
| 0 | GO:0015838 | Betaine Transport |
| 0 | GO:0043425 | Bhlh Transcription Factor Binding |
| 0 | GO:0015701 | Bicarbonate Transport |
| 0 | GO:0015721 | Bile Acid And Bile Salt Transport |
| 0 | GO:0006699 | Bile Acid Biosynthetic Process |
| 0 | GO:0008206 | Bile Acid Metabolic Process |
| 0 | GO:0007339 | Binding Of Sperm To Zona Pellucida |
| 0 | GO:0060090 | Binding, Bridging |
| 0 | GO:0031214 | Biom mineral Tissue Development |
| 0 | GO:0001824 | Blastocyst Development |
| 0 | GO:0001825 | Blastocyst Formation |
| 0 | GO:0001832 | Blastocyst Growth |
| 0 | GO:0007350 | Blastoderm Segmentation |
| 0 | GO:0008015 | Blood Circulation |
| 0 | GO:0007596 | Blood Coagulation |
| 0 | GO:0072378 | Blood Coagulation, Fibrin Clot Formation |
| 0 | GO:0007597 | Blood Coagulation, Intrinsic Pathway |
| 0 | GO:0001568 | Blood Vessel Development |
| 0 | GO:0043534 | Blood Vessel Endothelial Cell Migration |
| 0 | GO:0048514 | Blood Vessel Morphogenesis |
| 0 | GO:0001974 | Blood Vessel Remodeling |
| 0 | GO:0030509 | Bmp Signaling Pathway |
| 0 | GO:0007589 | Body Fluid Secretion |
| 0 | GO:0010171 | Body Morphogenesis |
| 0 | GO:0060348 | Bone Development |
| 0 | GO:0030282 | Bone Mineralization |
| 0 | GO:0060349 | Bone Morphogenesis |
| 0 | GO:0046849 | Bone Remodeling |
| 0 | GO:0045453 | Bone Resorption |
| 1 | GO:0007420 | Brain Development |
| 1 | GO:0048854 | Brain Morphogenesis |
| 0 | GO:0060602 | Branch Elongation Of An Epithelium |
| 0 | GO:0009083 | Branched Chain Family Amino Acid Catabolic Process |
| 0 | GO:0009081 | Branched Chain Family Amino Acid Metabolic Process |

| | | |
|---|------------|--|
| 0 | GO:0060444 | Branching Involved In Mammary Gland Duct Morphogenesis |
| 0 | GO:0060442 | Branching Involved In Prostate Gland Morphogenesis |
| 0 | GO:0060445 | Branching Involved In Salivary Gland Morphogenesis |
| 0 | GO:0001658 | Branching Involved In Ureteric Bud Morphogenesis |
| 0 | GO:0048754 | Branching Morphogenesis Of A Tube |
| 0 | GO:0050873 | Brown Fat Cell Differentiation |
| 0 | GO:0005903 | Brush Border |
| 0 | GO:0031526 | Brush Border Membrane |
| 0 | GO:0016408 | C-Acyltransferase Activity |
| 0 | GO:0016493 | C-C Chemokine Receptor Activity |
| 0 | GO:0018410 | C-Terminal Protein Amino Acid Modification |
| 0 | GO:0006501 | C-Terminal Protein Lipidation |
| 0 | GO:0006700 | C21-Steroid Hormone Biosynthetic Process |
| 0 | GO:0008207 | C21-Steroid Hormone Metabolic Process |
| 0 | GO:0070742 | C2H2 Zinc Finger Domain Binding |
| 0 | GO:0045296 | Cadherin Binding |
| 1 | GO:0015030 | Cajal Body |
| 1 | GO:0005227 | Calcium Activated Cation Channel Activity |
| 1 | GO:0005262 | Calcium Channel Activity |
| 1 | GO:0034704 | Calcium Channel Complex |
| 1 | GO:0005246 | Calcium Channel Regulator Activity |
| 0 | GO:0055074 | Calcium Ion Homeostasis |
| 0 | GO:0070509 | Calcium Ion Import |
| 1 | GO:0070588 | Calcium Ion Transmembrane Transport |
| 1 | GO:0015085 | Calcium Ion Transmembrane Transporter Activity |
| 0 | GO:0006816 | Calcium Ion Transport |
| 0 | GO:0060402 | Calcium Ion Transport Into Cytosol |
| 1 | GO:0017156 | Calcium Ion-Dependent Exocytosis |
| 1 | GO:0015269 | Calcium-Activated Potassium Channel Activity |
| 1 | GO:0016339 | Calcium-Dependent Cell-Cell Adhesion |
| 0 | GO:0004198 | Calcium-Dependent Cysteine-Type Endopeptidase Activity |
| 0 | GO:0005544 | Calcium-Dependent Phospholipid Binding |
| 0 | GO:0048306 | Calcium-Dependent Protein Binding |
| 0 | GO:0016338 | Calcium-Independent Cell-Cell Adhesion |
| 1 | GO:0019722 | Calcium-Mediated Signaling |
| 1 | GO:0015278 | Calcium-Release Channel Activity |
| 0 | GO:0005516 | Calmodulin Binding |
| 0 | GO:0004683 | Calmodulin-Dependent Protein Kinase Activity |
| 0 | GO:0043010 | Camera-Type Eye Development |
| 0 | GO:0048593 | Camera-Type Eye Morphogenesis |
| 0 | GO:0060219 | Camera-Type Eye Photoreceptor Cell Differentiation |
| 0 | GO:0030552 | Camp Binding |
| 0 | GO:0006171 | Camp Biosynthetic Process |
| 0 | GO:0006198 | Camp Catabolic Process |
| 0 | GO:0046058 | Camp Metabolic Process |
| 0 | GO:0004691 | Camp-Dependent Protein Kinase Activity |
| 0 | GO:0005952 | Camp-Dependent Protein Kinase Complex |
| 0 | GO:0008603 | Camp-Dependent Protein Kinase Regulator Activity |
| 0 | GO:0019933 | Camp-Mediated Signaling |
| 0 | GO:0060070 | Canonical Wnt Receptor Signaling Pathway |
| 0 | GO:0030246 | Carbohydrate Binding |
| 0 | GO:0016051 | Carbohydrate Biosynthetic Process |
| 0 | GO:0016052 | Carbohydrate Catabolic Process |
| 0 | GO:0033500 | Carbohydrate Homeostasis |
| 0 | GO:0019200 | Carbohydrate Kinase Activity |
| 0 | GO:0019203 | Carbohydrate Phosphatase Activity |

| | | |
|---|------------|---|
| 0 | GO:0015144 | Carbohydrate Transmembrane Transporter Activity |
| 0 | GO:0008643 | Carbohydrate Transport |
| 0 | GO:0016830 | Carbon-Carbon Lyase Activity |
| 0 | GO:0016884 | Carbon-Nitrogen Ligase Activity, With Glutamine As Amido-N-Donor |
| 0 | GO:0016840 | Carbon-Nitrogen Lyase Activity |
| 0 | GO:0016835 | Carbon-Oxygen Lyase Activity |
| 0 | GO:0016846 | Carbon-Sulfur Lyase Activity |
| 0 | GO:0004089 | Carbonate Dehydratase Activity |
| 0 | GO:0016831 | Carboxy-Lyase Activity |
| 0 | GO:0004091 | Carboxylesterase Activity |
| 0 | GO:0031406 | Carboxylic Acid Binding |
| 0 | GO:0046394 | Carboxylic Acid Biosynthetic Process |
| 0 | GO:0046395 | Carboxylic Acid Catabolic Process |
| 0 | GO:0046943 | Carboxylic Acid Transmembrane Transporter Activity |
| 0 | GO:0046942 | Carboxylic Acid Transport |
| 0 | GO:0052689 | Carboxylic Ester Hydrolase Activity |
| 0 | GO:0004180 | Carboxypeptidase Activity |
| 0 | GO:0003230 | Cardiac Atrium Development |
| 0 | GO:0003209 | Cardiac Atrium Morphogenesis |
| 0 | GO:0055006 | Cardiac Cell Development |
| 0 | GO:0035051 | Cardiac Cell Differentiation |
| 0 | GO:0003205 | Cardiac Chamber Development |
| 0 | GO:0003207 | Cardiac Chamber Formation |
| 0 | GO:0003206 | Cardiac Chamber Morphogenesis |
| 0 | GO:0060317 | Cardiac Epithelial To Mesenchymal Transition |
| 0 | GO:0010659 | Cardiac Muscle Cell Apoptotic Process |
| 0 | GO:0055013 | Cardiac Muscle Cell Development |
| 0 | GO:0055007 | Cardiac Muscle Cell Differentiation |
| 0 | GO:0060038 | Cardiac Muscle Cell Proliferation |
| 0 | GO:0060048 | Cardiac Muscle Contraction |
| 0 | GO:0003300 | Cardiac Muscle Hypertrophy |
| 0 | GO:0048738 | Cardiac Muscle Tissue Development |
| 0 | GO:0055017 | Cardiac Muscle Tissue Growth |
| 0 | GO:0055008 | Cardiac Muscle Tissue Morphogenesis |
| 0 | GO:0055003 | Cardiac Myofibril Assembly |
| 0 | GO:0003215 | Cardiac Right Ventricle Morphogenesis |
| 0 | GO:0003279 | Cardiac Septum Development |
| 0 | GO:0060411 | Cardiac Septum Morphogenesis |
| 0 | GO:0003231 | Cardiac Ventricle Development |
| 0 | GO:0003211 | Cardiac Ventricle Formation |
| 0 | GO:0003208 | Cardiac Ventricle Morphogenesis |
| 0 | GO:0010002 | Cardioblast Differentiation |
| 0 | GO:0038024 | Cargo Receptor Activity |
| 0 | GO:0015879 | Carnitine Transport |
| 0 | GO:0001502 | Cartilage Condensation |
| 0 | GO:0051216 | Cartilage Development |
| 0 | GO:0060351 | Cartilage Development Involved In Endochondral Bone Morphogenesis |
| 0 | GO:0060536 | Cartilage Morphogenesis |
| 0 | GO:0071013 | Catalytic Step 2 Spliceosome |
| 0 | GO:0009713 | Catechol-Containing Compound Biosynthetic Process |
| 0 | GO:0009712 | Catechol-Containing Compound Metabolic Process |
| 0 | GO:0042423 | Catecholamine Biosynthetic Process |
| 0 | GO:0006584 | Catecholamine Metabolic Process |
| 0 | GO:0050432 | Catecholamine Secretion |
| 0 | GO:0051937 | Catecholamine Transport |
| 0 | GO:0035411 | Catenin Import Into Nucleus |

| | | |
|---|------------|---|
| 0 | GO:0005261 | Cation Channel Activity |
| 0 | GO:0034703 | Cation Channel Complex |
| 0 | GO:0055080 | Cation Homeostasis |
| 0 | GO:0019829 | Cation-Transporting Atpase Activity |
| 0 | GO:0005416 | Cation:Amino Acid Symporter Activity |
| 0 | GO:0015491 | Cation:Cation Antiporter Activity |
| 0 | GO:0005901 | Caveola |
| 0 | GO:0048020 | Ccr Chemokine Receptor Binding |
| 0 | GO:0035710 | Cd4-Positive, Alpha-Beta T Cell Activation |
| 0 | GO:0043367 | Cd4-Positive, Alpha-Beta T Cell Differentiation |
| 0 | GO:0002294 | Cd4-Positive, Alpha-Beta T Cell Differentiation Involved In Immune Response |
| 0 | GO:0002263 | Cell Activation Involved In Immune Response |
| 0 | GO:0033627 | Cell Adhesion Mediated By Integrin |
| 0 | GO:0050839 | Cell Adhesion Molecule Binding |
| 0 | GO:0007569 | Cell Aging |
| 0 | GO:0044297 | Cell Body |
| 0 | GO:0060326 | Cell Chemotaxis |
| 0 | GO:0005938 | Cell Cortex |
| 0 | GO:0044448 | Cell Cortex Part |
| 0 | GO:0007050 | Cell Cycle Arrest |
| 0 | GO:0000075 | Cell Cycle Checkpoint |
| 0 | GO:0033205 | Cell Cycle Cytokinesis |
| 1 | GO:0021533 | Cell Differentiation In Hindbrain |
| 1 | GO:0021515 | Cell Differentiation In Spinal Cord |
| 0 | GO:0060706 | Cell Differentiation Involved In Embryonic Placenta Development |
| 0 | GO:0061005 | Cell Differentiation Involved In Kidney Development |
| 0 | GO:0072202 | Cell Differentiation Involved In Metanephros Development |
| 0 | GO:0051301 | Cell Division |
| 0 | GO:0032153 | Cell Division Site |
| 0 | GO:0032155 | Cell Division Site Part |
| 0 | GO:0030313 | Cell Envelope |
| 0 | GO:0045165 | Cell Fate Commitment |
| 0 | GO:0060795 | Cell Fate Commitment Involved In Formation Of Primary Germ Layer |
| 0 | GO:0001709 | Cell Fate Determination |
| 0 | GO:0001708 | Cell Fate Specification |
| 0 | GO:0016049 | Cell Growth |
| 0 | GO:0034329 | Cell Junction Assembly |
| 0 | GO:0034330 | Cell Junction Organization |
| 0 | GO:0001906 | Cell Killing |
| 0 | GO:0031252 | Cell Leading Edge |
| 0 | GO:0048469 | Cell Maturation |
| 0 | GO:0042074 | Cell Migration Involved In Gastrulation |
| 0 | GO:0002042 | Cell Migration Involved In Sprouting Angiogenesis |
| 0 | GO:0030031 | Cell Projection Assembly |
| 0 | GO:0032838 | Cell Projection Cytoplasm |
| 0 | GO:0031253 | Cell Projection Membrane |
| 1 | GO:0021846 | Cell Proliferation In Forebrain |
| 0 | GO:0072111 | Cell Proliferation Involved In Kidney Development |
| 0 | GO:0072203 | Cell Proliferation Involved In Metanephros Development |
| 0 | GO:0008037 | Cell Recognition |
| 0 | GO:0045454 | Cell Redox Homeostasis |
| 0 | GO:0009986 | Cell Surface |
| 0 | GO:0043498 | Cell Surface Binding |
| 0 | GO:0061311 | Cell Surface Receptor Signaling Pathway Involved In Heart Development |
| 0 | GO:0006884 | Cell Volume Homeostasis |
| 0 | GO:0016998 | Cell Wall Macromolecule Catabolic Process |

| | | |
|---|------------|--|
| 0 | GO:0044036 | Cell Wall Macromolecule Metabolic Process |
| 0 | GO:0071554 | Cell Wall Organization Or Biogenesis |
| 0 | GO:0005913 | Cell-Cell Adherens Junction |
| 0 | GO:0016337 | Cell-Cell Adhesion |
| 0 | GO:0033631 | Cell-Cell Adhesion Mediated By Integrin |
| 0 | GO:0044291 | Cell-Cell Contact Zone |
| 0 | GO:0005911 | Cell-Cell Junction |
| 0 | GO:0007043 | Cell-Cell Junction Assembly |
| 0 | GO:0045216 | Cell-Cell Junction Organization |
| 0 | GO:0009988 | Cell-Cell Recognition |
| 0 | GO:0045168 | Cell-Cell Signaling Involved In Cell Fate Commitment |
| 0 | GO:0007160 | Cell-Matrix Adhesion |
| 0 | GO:0005924 | Cell-Substrate Adherens Junction |
| 0 | GO:0031589 | Cell-Substrate Adhesion |
| 0 | GO:0030055 | Cell-Substrate Junction |
| 0 | GO:0007044 | Cell-Substrate Junction Assembly |
| 0 | GO:0006081 | Cellular Aldehyde Metabolic Process |
| 0 | GO:0043449 | Cellular Alkene Metabolic Process |
| 0 | GO:0043603 | Cellular Amide Metabolic Process |
| 0 | GO:0044106 | Cellular Amine Metabolic Process |
| 0 | GO:0008652 | Cellular Amino Acid Biosynthetic Process |
| 0 | GO:0009063 | Cellular Amino Acid Catabolic Process |
| 0 | GO:0006520 | Cellular Amino Acid Metabolic Process |
| 0 | GO:0030002 | Cellular Anion Homeostasis |
| 0 | GO:0006725 | Cellular Aromatic Compound Metabolic Process |
| 0 | GO:0042401 | Cellular Biogenic Amine Biosynthetic Process |
| 0 | GO:0042402 | Cellular Biogenic Amine Catabolic Process |
| 0 | GO:0006576 | Cellular Biogenic Amine Metabolic Process |
| 0 | GO:0006874 | Cellular Calcium Ion Homeostasis |
| 0 | GO:0034637 | Cellular Carbohydrate Biosynthetic Process |
| 0 | GO:0044275 | Cellular Carbohydrate Catabolic Process |
| 0 | GO:0030003 | Cellular Cation Homeostasis |
| 0 | GO:0010927 | Cellular Component Assembly Involved In Morphogenesis |
| 0 | GO:0071843 | Cellular Component Biogenesis At Cellular Level |
| 0 | GO:0022411 | Cellular Component Disassembly |
| 0 | GO:0071845 | Cellular Component Disassembly At Cellular Level |
| 0 | GO:0006921 | Cellular Component Disassembly Involved In Apoptotic Process |
| 0 | GO:0043954 | Cellular Component Maintenance |
| 0 | GO:0006878 | Cellular Copper Ion Homeostasis |
| 0 | GO:0006968 | Cellular Defense Response |
| 0 | GO:0072503 | Cellular Divalent Inorganic Cation Homeostasis |
| 0 | GO:0045123 | Cellular Extravasation |
| 0 | GO:0006073 | Cellular Glucan Metabolic Process |
| 0 | GO:0001678 | Cellular Glucose Homeostasis |
| 0 | GO:0034754 | Cellular Hormone Metabolic Process |
| 0 | GO:0006873 | Cellular Ion Homeostasis |
| 0 | GO:0006879 | Cellular Iron Ion Homeostasis |
| 0 | GO:0044242 | Cellular Lipid Catabolic Process |
| 0 | GO:0034622 | Cellular Macromolecular Complex Assembly |
| 0 | GO:0034623 | Cellular Macromolecular Complex Disassembly |
| 0 | GO:0006944 | Cellular Membrane Fusion |
| 0 | GO:0043094 | Cellular Metabolic Compound Salvage |
| 0 | GO:0006875 | Cellular Metal Ion Homeostasis |
| 0 | GO:0042398 | Cellular Modified Amino Acid Biosynthetic Process |
| 0 | GO:0006575 | Cellular Modified Amino Acid Metabolic Process |
| 0 | GO:0030004 | Cellular Monovalent Inorganic Cation Homeostasis |

| | | |
|---|------------|---|
| 0 | GO:0033059 | Cellular Pigmentation |
| 0 | GO:0033692 | Cellular Polysaccharide Biosynthetic Process |
| 0 | GO:0044247 | Cellular Polysaccharide Catabolic Process |
| 0 | GO:0044264 | Cellular Polysaccharide Metabolic Process |
| 1 | GO:0071804 | Cellular Potassium Ion Transport |
| 0 | GO:0048610 | Cellular Process Involved In Reproduction |
| 0 | GO:0022412 | Cellular Process Involved In Reproduction In Multicellular Organism |
| 0 | GO:0044257 | Cellular Protein Catabolic Process |
| 0 | GO:0043623 | Cellular Protein Complex Assembly |
| 0 | GO:0043624 | Cellular Protein Complex Disassembly |
| 0 | GO:0045333 | Cellular Respiration |
| 0 | GO:0071214 | Cellular Response To Abiotic Stimulus |
| 0 | GO:0071229 | Cellular Response To Acid |
| 0 | GO:0071418 | Cellular Response To Amine Stimulus |
| 0 | GO:0071230 | Cellular Response To Amino Acid Stimulus |
| 0 | GO:0071216 | Cellular Response To Biotic Stimulus |
| 0 | GO:0071277 | Cellular Response To Calcium Ion |
| 0 | GO:0071320 | Cellular Response To Camp |
| 0 | GO:0071322 | Cellular Response To Carbohydrate Stimulus |
| 0 | GO:0071384 | Cellular Response To Corticosteroid Stimulus |
| 0 | GO:0071345 | Cellular Response To Cytokine Stimulus |
| 0 | GO:0071549 | Cellular Response To Dexamethasone Stimulus |
| 0 | GO:0035690 | Cellular Response To Drug |
| 0 | GO:0071359 | Cellular Response To Dsrna |
| 0 | GO:0071495 | Cellular Response To Endogenous Stimulus |
| 0 | GO:0071391 | Cellular Response To Estrogen Stimulus |
| 0 | GO:0071496 | Cellular Response To External Stimulus |
| 0 | GO:0031668 | Cellular Response To Extracellular Stimulus |
| 0 | GO:0044344 | Cellular Response To Fibroblast Growth Factor Stimulus |
| 0 | GO:0071377 | Cellular Response To Glucagon Stimulus |
| 0 | GO:0071385 | Cellular Response To Glucocorticoid Stimulus |
| 0 | GO:0042149 | Cellular Response To Glucose Starvation |
| 0 | GO:0071333 | Cellular Response To Glucose Stimulus |
| 0 | GO:0071371 | Cellular Response To Gonadotropin Stimulus |
| 0 | GO:0071363 | Cellular Response To Growth Factor Stimulus |
| 0 | GO:0071378 | Cellular Response To Growth Hormone Stimulus |
| 0 | GO:0034605 | Cellular Response To Heat |
| 0 | GO:0071331 | Cellular Response To Hexose Stimulus |
| 0 | GO:0032870 | Cellular Response To Hormone Stimulus |
| 0 | GO:0070301 | Cellular Response To Hydrogen Peroxide |
| 0 | GO:0071456 | Cellular Response To Hypoxia |
| 0 | GO:0071241 | Cellular Response To Inorganic Substance |
| 0 | GO:0032869 | Cellular Response To Insulin Stimulus |
| 0 | GO:0071346 | Cellular Response To Interferon-Gamma |
| 0 | GO:0071347 | Cellular Response To Interleukin-1 |
| 0 | GO:0071479 | Cellular Response To Ionizing Radiation |
| 0 | GO:0071482 | Cellular Response To Light Stimulus |
| 0 | GO:0071396 | Cellular Response To Lipid |
| 0 | GO:0071222 | Cellular Response To Lipopolysaccharide |
| 0 | GO:0071285 | Cellular Response To Lithium Ion |
| 0 | GO:0071260 | Cellular Response To Mechanical Stimulus |
| 0 | GO:0071248 | Cellular Response To Metal Ion |
| 0 | GO:0071219 | Cellular Response To Molecule Of Bacterial Origin |
| 0 | GO:0071326 | Cellular Response To Monosaccharide Stimulus |
| 0 | GO:0031670 | Cellular Response To Nutrient |
| 0 | GO:0031669 | Cellular Response To Nutrient Levels |

| | | |
|---|------------|--|
| 0 | GO:0071407 | Cellular Response To Organic Cyclic Compound |
| 0 | GO:0071417 | Cellular Response To Organic Nitrogen |
| 0 | GO:0034599 | Cellular Response To Oxidative Stress |
| 0 | GO:0071453 | Cellular Response To Oxygen Levels |
| 0 | GO:0071450 | Cellular Response To Oxygen Radical |
| 0 | GO:0071375 | Cellular Response To Peptide Hormone Stimulus |
| 0 | GO:0071478 | Cellular Response To Radiation |
| 0 | GO:0034614 | Cellular Response To Reactive Oxygen Species |
| 0 | GO:0071300 | Cellular Response To Retinoic Acid |
| 0 | GO:0009267 | Cellular Response To Starvation |
| 0 | GO:0071383 | Cellular Response To Steroid Hormone Stimulus |
| 0 | GO:0071451 | Cellular Response To Superoxide |
| 0 | GO:0035967 | Cellular Response To Topologically Incorrect Protein |
| 0 | GO:0071560 | Cellular Response To Transforming Growth Factor Beta Stimulus |
| 0 | GO:0071356 | Cellular Response To Tumor Necrosis Factor |
| 0 | GO:0071357 | Cellular Response To Type I Interferon |
| 0 | GO:0034620 | Cellular Response To Unfolded Protein |
| 0 | GO:0034644 | Cellular Response To Uv |
| 0 | GO:0035924 | Cellular Response To Vascular Endothelial Growth Factor Stimulus |
| 0 | GO:0071295 | Cellular Response To Vitamin |
| 0 | GO:0071299 | Cellular Response To Vitamin A |
| 0 | GO:0071305 | Cellular Response To Vitamin D |
| 0 | GO:0071466 | Cellular Response To Xenobiotic Stimulus |
| 0 | GO:0090398 | Cellular Senescence |
| 0 | GO:0006882 | Cellular Zinc Ion Homeostasis |
| 0 | GO:0034080 | CenH3-Containing Nucleosome Assembly At Centromere |
| 1 | GO:0022010 | Central Nervous System Myelination |
| 1 | GO:0021955 | Central Nervous System Neuron Axonogenesis |
| 1 | GO:0021954 | Central Nervous System Neuron Development |
| 1 | GO:0021953 | Central Nervous System Neuron Differentiation |
| 1 | GO:0021952 | Central Nervous System Projection Neuron Axonogenesis |
| 0 | GO:0005814 | Centriole |
| 0 | GO:0007099 | Centriole Replication |
| 0 | GO:0034508 | Centromere Complex Assembly |
| 0 | GO:0005721 | Centromeric Heterochromatin |
| 0 | GO:0005813 | Centrosome |
| 0 | GO:0007098 | Centrosome Cycle |
| 0 | GO:0051298 | Centrosome Duplication |
| 0 | GO:0051297 | Centrosome Organization |
| 0 | GO:0046513 | Ceramide Biosynthetic Process |
| 0 | GO:0006672 | Ceramide Metabolic Process |
| 1 | GO:0021695 | Cerebellar Cortex Development |
| 1 | GO:0021697 | Cerebellar Cortex Formation |
| 1 | GO:0021696 | Cerebellar Cortex Morphogenesis |
| 1 | GO:0021680 | Cerebellar Purkinje Cell Layer Development |
| 1 | GO:0021549 | Cerebellum Development |
| 1 | GO:0021587 | Cerebellum Morphogenesis |
| 1 | GO:0021795 | Cerebral Cortex Cell Migration |
| 1 | GO:0021987 | Cerebral Cortex Development |
| 1 | GO:0021895 | Cerebral Cortex Neuron Differentiation |
| 1 | GO:0021799 | Cerebral Cortex Radially Oriented Cell Migration |
| 0 | GO:0030553 | Cgmp Binding |
| 0 | GO:0006182 | Cgmp Biosynthetic Process |
| 0 | GO:0046068 | Cgmp Metabolic Process |
| 0 | GO:0019934 | Cgmp-Mediated Signaling |
| 1 | GO:0015267 | Channel Activity |

| | | |
|---|------------|---|
| 1 | GO:0016248 | Channel Inhibitor Activity |
| 1 | GO:0016247 | Channel Regulator Activity |
| 0 | GO:0051087 | Chaperone Binding |
| 0 | GO:0051085 | Chaperone Mediated Protein Folding Requiring Cofactor |
| 0 | GO:0051131 | Chaperone-Mediated Protein Complex Assembly |
| 0 | GO:0061077 | Chaperone-Mediated Protein Folding |
| 0 | GO:0042056 | Chemoattractant Activity |
| 0 | GO:0008009 | Chemokine Activity |
| 0 | GO:0042033 | Chemokine Biosynthetic Process |
| 0 | GO:0050755 | Chemokine Metabolic Process |
| 0 | GO:0032602 | Chemokine Production |
| 0 | GO:0004950 | Chemokine Receptor Activity |
| 0 | GO:0042379 | Chemokine Receptor Binding |
| 0 | GO:0070098 | Chemokine-Mediated Signaling Pathway |
| 0 | GO:0005254 | Chloride Channel Activity |
| 0 | GO:0034707 | Chloride Channel Complex |
| 0 | GO:0015108 | Chloride Transmembrane Transporter Activity |
| 0 | GO:0006821 | Chloride Transport |
| 0 | GO:0015485 | Cholesterol Binding |
| 0 | GO:0006695 | Cholesterol Biosynthetic Process |
| 0 | GO:0006707 | Cholesterol Catabolic Process |
| 0 | GO:0033344 | Cholesterol Efflux |
| 0 | GO:0034435 | Cholesterol Esterification |
| 0 | GO:0042632 | Cholesterol Homeostasis |
| 0 | GO:0008203 | Cholesterol Metabolic Process |
| 0 | GO:0010878 | Cholesterol Storage |
| 0 | GO:0030301 | Cholesterol Transport |
| 0 | GO:0017127 | Cholesterol Transporter Activity |
| 0 | GO:0002063 | Chondrocyte Development |
| 0 | GO:0002062 | Chondrocyte Differentiation |
| 0 | GO:0030204 | Chondroitin Sulfate Metabolic Process |
| 0 | GO:0050650 | Chondroitin Sulfate Proteoglycan Biosynthetic Process |
| 0 | GO:0050654 | Chondroitin Sulfate Proteoglycan Metabolic Process |
| 0 | GO:0043009 | Chordate Embryonic Development |
| 0 | GO:0000785 | Chromatin |
| 0 | GO:0031497 | Chromatin Assembly |
| 0 | GO:0006333 | Chromatin Assembly Or Disassembly |
| 0 | GO:0003682 | Chromatin Binding |
| 0 | GO:0031498 | Chromatin Disassembly |
| 0 | GO:0031490 | Chromatin Dna Binding |
| 0 | GO:0016568 | Chromatin Modification |
| 0 | GO:0006325 | Chromatin Organization |
| 0 | GO:0006338 | Chromatin Remodeling |
| 0 | GO:0031055 | Chromatin Remodeling At Centromere |
| 0 | GO:0016585 | Chromatin Remodeling Complex |
| 0 | GO:0006342 | Chromatin Silencing |
| 0 | GO:0044427 | Chromosomal Part |
| 0 | GO:0030261 | Chromosome Condensation |
| 0 | GO:0050000 | Chromosome Localization |
| 0 | GO:0070192 | Chromosome Organization Involved In Meiosis |
| 0 | GO:0007059 | Chromosome Segregation |
| 0 | GO:0000775 | Chromosome, Centromeric Region |
| 0 | GO:0000781 | Chromosome, Telomeric Region |
| 0 | GO:0002544 | Chronic Inflammatory Response |
| 0 | GO:0001539 | Ciliary Or Flagellar Motility |
| 0 | GO:0035253 | Ciliary Rootlet |

| | | |
|---|------------|---|
| 0 | GO:0005929 | Cilium |
| 0 | GO:0042384 | Cilium Assembly |
| 0 | GO:0035085 | Cilium Axoneme |
| 0 | GO:0060271 | Cilium Morphogenesis |
| 0 | GO:0044441 | Cilium Part |
| 1 | GO:0048512 | Circadian Behavior |
| 1 | GO:0007623 | Circadian Rhythm |
| 1 | GO:0042745 | Circadian Sleep/Wake Cycle |
| 1 | GO:0022410 | Circadian Sleep/Wake Cycle Process |
| 1 | GO:0050802 | Circadian Sleep/Wake Cycle, Sleep |
| 1 | GO:0003013 | Circulatory System Process |
| 0 | GO:0005801 | Cis-Golgi Network |
| 0 | GO:0016859 | Cis-Trans Isomerase Activity |
| 0 | GO:0030131 | Clathrin Adaptor Complex |
| 0 | GO:0030276 | Clathrin Binding |
| 0 | GO:0030118 | Clathrin Coat |
| 0 | GO:0030132 | Clathrin Coat Of Coated Pit |
| 0 | GO:0030128 | Clathrin Coat Of Endocytic Vesicle |
| 0 | GO:0030130 | Clathrin Coat Of Trans-Golgi Network Vesicle |
| 0 | GO:0030665 | Clathrin Coated Vesicle Membrane |
| 0 | GO:0060198 | Clathrin Sculpted Vesicle |
| 0 | GO:0030125 | Clathrin Vesicle Coat |
| 0 | GO:0045334 | Clathrin-Coated Endocytic Vesicle |
| 0 | GO:0030669 | Clathrin-Coated Endocytic Vesicle Membrane |
| 0 | GO:0030136 | Clathrin-Coated Vesicle |
| 0 | GO:0032154 | Cleavage Furrow |
| 0 | GO:0070410 | Co-Smad Binding |
| 0 | GO:0016289 | Coa Hydrolase Activity |
| 0 | GO:0050817 | Coagulation |
| 0 | GO:0048475 | Coated Membrane |
| 0 | GO:0005905 | Coated Pit |
| 0 | GO:0030135 | Coated Vesicle |
| 0 | GO:0030662 | Coated Vesicle Membrane |
| 0 | GO:0090102 | Cochlea Development |
| 0 | GO:0090103 | Cochlea Morphogenesis |
| 0 | GO:0015936 | Coenzyme A Metabolic Process |
| 0 | GO:0050662 | Coenzyme Binding |
| 0 | GO:0009108 | Coenzyme Biosynthetic Process |
| 0 | GO:0009109 | Coenzyme Catabolic Process |
| 0 | GO:0006732 | Coenzyme Metabolic Process |
| 0 | GO:0048037 | Cofactor Binding |
| 0 | GO:0051188 | Cofactor Biosynthetic Process |
| 0 | GO:0051187 | Cofactor Catabolic Process |
| 0 | GO:0051186 | Cofactor Metabolic Process |
| 0 | GO:0051181 | Cofactor Transport |
| 0 | GO:0051184 | Cofactor Transporter Activity |
| 0 | GO:0050890 | Cognition |
| 0 | GO:0008278 | Cohesin Complex |
| 0 | GO:0005581 | Collagen |
| 0 | GO:0005518 | Collagen Binding |
| 0 | GO:0032964 | Collagen Biosynthetic Process |
| 0 | GO:0030574 | Collagen Catabolic Process |
| 0 | GO:0030199 | Collagen Fibril Organization |
| 0 | GO:0032963 | Collagen Metabolic Process |
| 0 | GO:0002065 | Columnar/Cuboidal Epithelial Cell Differentiation |
| 1 | GO:0043218 | Compact Myelin |

| | | |
|---|------------|---|
| 0 | GO:0006956 | Complement Activation |
| 0 | GO:0006957 | Complement Activation, Alternative Pathway |
| 0 | GO:0006958 | Complement Activation, Classical Pathway |
| 0 | GO:0000793 | Condensed Chromosome |
| 0 | GO:0000777 | Condensed Chromosome Kinetochore |
| 0 | GO:0000940 | Condensed Chromosome Outer Kinetochore |
| 0 | GO:0000779 | Condensed Chromosome, Centromeric Region |
| 0 | GO:0000794 | Condensed Nuclear Chromosome |
| 0 | GO:0000780 | Condensed Nuclear Chromosome, Centromeric Region |
| 0 | GO:0005922 | Connexon Complex |
| 0 | GO:0043292 | Contractile Fiber |
| 0 | GO:0044449 | Contractile Fiber Part |
| 0 | GO:0060026 | Convergent Extension |
| 0 | GO:0030663 | Copi Coated Vesicle Membrane |
| 0 | GO:0048205 | Copi Coating Of Golgi Vesicle |
| 0 | GO:0030126 | Copi Vesicle Coat |
| 0 | GO:0030137 | Copi-Coated Vesicle |
| 0 | GO:0035964 | Copi-Coated Vesicle Budding |
| 0 | GO:0005507 | Copper Ion Binding |
| 0 | GO:0055070 | Copper Ion Homeostasis |
| 0 | GO:0006825 | Copper Ion Transport |
| 0 | GO:0007620 | Copulation |
| 0 | GO:0001047 | Core Promoter Binding |
| 0 | GO:0001159 | Core Promoter Proximal Region Dna Binding |
| 0 | GO:0000987 | Core Promoter Proximal Region Sequence-Specific Dna Binding |
| 0 | GO:0001046 | Core Promoter Sequence-Specific Dna Binding |
| 0 | GO:0015026 | Coreceptor Activity |
| 0 | GO:0001533 | Cornified Envelope |
| 0 | GO:0060976 | Coronary Vasculature Development |
| 0 | GO:0030864 | Cortical Actin Cytoskeleton |
| 0 | GO:0030866 | Cortical Actin Cytoskeleton Organization |
| 0 | GO:0030863 | Cortical Cytoskeleton |
| 0 | GO:0030865 | Cortical Cytoskeleton Organization |
| 0 | GO:0031958 | Corticosteroid Receptor Signaling Pathway |
| 0 | GO:0043034 | Costamere |
| 0 | GO:0006613 | Cotranslational Protein Targeting To Membrane |
| 0 | GO:0016569 | Covalent Chromatin Modification |
| 1 | GO:0021545 | Cranial Nerve Development |
| 1 | GO:0021602 | Cranial Nerve Morphogenesis |
| 1 | GO:0060363 | Cranial Suture Morphogenesis |
| 0 | GO:0097094 | Craniofacial Suture Morphogenesis |
| 0 | GO:0080008 | Cul4 Ring Ubiquitin Ligase Complex |
| 0 | GO:0031461 | Cullin-Ring Ubiquitin Ligase Complex |
| 0 | GO:0009975 | Cyclase Activity |
| 0 | GO:0030551 | Cyclic Nucleotide Binding |
| 0 | GO:0009190 | Cyclic Nucleotide Biosynthetic Process |
| 0 | GO:0009214 | Cyclic Nucleotide Catabolic Process |
| 0 | GO:0009187 | Cyclic Nucleotide Metabolic Process |
| 0 | GO:0004690 | Cyclic Nucleotide-Dependent Protein Kinase Activity |
| 0 | GO:0004112 | Cyclic-Nucleotide Phosphodiesterase Activity |
| 0 | GO:0019935 | Cyclic-Nucleotide-Mediated Signaling |
| 0 | GO:0030332 | Cyclin Binding |
| 0 | GO:0004693 | Cyclin-Dependent Protein Kinase Activity |
| 0 | GO:0000307 | Cyclin-Dependent Protein Kinase Holoenzyme Complex |
| 0 | GO:0004861 | Cyclin-Dependent Protein Kinase Inhibitor Activity |
| 0 | GO:0016538 | Cyclin-Dependent Protein Kinase Regulator Activity |

| | | |
|---|------------|--|
| 0 | GO:0008656 | Cysteine-Type Endopeptidase Activator Activity Involved In Apoptotic Process |
| 0 | GO:0004197 | Cysteine-Type Endopeptidase Activity |
| 0 | GO:0004869 | Cysteine-Type Endopeptidase Inhibitor Activity |
| 0 | GO:0043027 | Cysteine-Type Endopeptidase Inhibitor Activity Involved In Apoptotic Process |
| 0 | GO:0043028 | Cysteine-Type Endopeptidase Regulator Activity Involved In Apoptotic Process |
| 0 | GO:0008234 | Cysteine-Type Peptidase Activity |
| 0 | GO:0004129 | Cytochrome-C Oxidase Activity |
| 0 | GO:0005125 | Cytokine Activity |
| 0 | GO:0019955 | Cytokine Binding |
| 0 | GO:0042089 | Cytokine Biosynthetic Process |
| 0 | GO:0042107 | Cytokine Metabolic Process |
| 0 | GO:0001816 | Cytokine Production |
| 0 | GO:0002367 | Cytokine Production Involved In Immune Response |
| 0 | GO:0004896 | Cytokine Receptor Activity |
| 0 | GO:0005126 | Cytokine Receptor Binding |
| 0 | GO:0050663 | Cytokine Secretion |
| 0 | GO:0019221 | Cytokine-Mediated Signaling Pathway |
| 0 | GO:0000910 | Cytokinesis |
| 0 | GO:0019835 | Cytolysis |
| 0 | GO:0005868 | Cytoplasmic Dynein Complex |
| 0 | GO:0060205 | Cytoplasmic Membrane-Bounded Vesicle Lumen |
| 0 | GO:0005881 | Cytoplasmic Microtubule |
| 0 | GO:0031122 | Cytoplasmic Microtubule Organization |
| 0 | GO:0000932 | Cytoplasmic Mrna Processing Body |
| 0 | GO:0002753 | Cytoplasmic Pattern Recognition Receptor Signaling Pathway |
| 0 | GO:0051220 | Cytoplasmic Sequestering Of Protein |
| 0 | GO:0042994 | Cytoplasmic Sequestering Of Transcription Factor |
| 0 | GO:0010494 | Cytoplasmic Stress Granule |
| 0 | GO:0030659 | Cytoplasmic Vesicle Membrane |
| 0 | GO:0044433 | Cytoplasmic Vesicle Part |
| 0 | GO:0008093 | Cytoskeletal Adaptor Activity |
| 0 | GO:0007016 | Cytoskeletal Anchoring At Plasma Membrane |
| 0 | GO:0030705 | Cytoskeleton-Dependent Intracellular Transport |
| 0 | GO:0051480 | Cytosolic Calcium Ion Homeostasis |
| 0 | GO:0060401 | Cytosolic Calcium Ion Transport |
| 0 | GO:0022625 | Cytosolic Large Ribosomal Subunit |
| 0 | GO:0044445 | Cytosolic Part |
| 0 | GO:0022626 | Cytosolic Ribosome |
| 0 | GO:0022627 | Cytosolic Small Ribosomal Subunit |
| 0 | GO:0003684 | Damaged Dna Binding |
| 0 | GO:0019213 | Deacetylase Activity |
| 0 | GO:0019239 | Deaminase Activity |
| 0 | GO:0005035 | Death Receptor Activity |
| 0 | GO:0005123 | Death Receptor Binding |
| 0 | GO:0046697 | Decidualization |
| 0 | GO:0042742 | Defense Response To Bacterium |
| 0 | GO:0050832 | Defense Response To Fungus |
| 0 | GO:0050829 | Defense Response To Gram-Negative Bacterium |
| 0 | GO:0050830 | Defense Response To Gram-Positive Bacterium |
| 0 | GO:0051607 | Defense Response To Virus |
| 0 | GO:0060216 | Definitive Hemopoiesis |
| 0 | GO:0005251 | Delayed Rectifier Potassium Channel Activity |
| 0 | GO:0032451 | Demethylase Activity |
| 0 | GO:0070988 | Demethylation |
| 1 | GO:0030425 | Dendrite |
| 1 | GO:0032839 | Dendrite Cytoplasm |

| | | |
|---|------------|---|
| 1 | GO:0016358 | Dendrite Development |
| 1 | GO:0048813 | Dendrite Morphogenesis |
| 1 | GO:0002407 | Dendritic Cell Chemotaxis |
| 1 | GO:0043198 | Dendritic Shaft |
| 1 | GO:0043197 | Dendritic Spine |
| 1 | GO:0060996 | Dendritic Spine Development |
| 1 | GO:0044327 | Dendritic Spine Head |
| 1 | GO:0060997 | Dendritic Spine Morphogenesis |
| 1 | GO:0097061 | Dendritic Spine Organization |
| 0 | GO:0004536 | Deoxyribonuclease Activity |
| 0 | GO:0009263 | Deoxyribonucleotide Biosynthetic Process |
| 0 | GO:0009264 | Deoxyribonucleotide Catabolic Process |
| 0 | GO:0009262 | Deoxyribonucleotide Metabolic Process |
| 0 | GO:0016311 | Dephosphorylation |
| 0 | GO:0002029 | Desensitization Of G-Protein Coupled Receptor Protein Signaling Pathway |
| 0 | GO:0030057 | Desmosome |
| 0 | GO:0009582 | Detection Of Abiotic Stimulus |
| 0 | GO:0016045 | Detection Of Bacterium |
| 0 | GO:0009595 | Detection Of Biotic Stimulus |
| 0 | GO:0009593 | Detection Of Chemical Stimulus |
| 0 | GO:0050907 | Detection Of Chemical Stimulus Involved In Sensory Perception |
| 0 | GO:0050911 | Detection Of Chemical Stimulus Involved In Sensory Perception Of Smell |
| 0 | GO:0050912 | Detection Of Chemical Stimulus Involved In Sensory Perception Of Taste |
| 0 | GO:0009581 | Detection Of External Stimulus |
| 0 | GO:0009583 | Detection Of Light Stimulus |
| 0 | GO:0050962 | Detection Of Light Stimulus Involved In Sensory Perception |
| 0 | GO:0050908 | Detection Of Light Stimulus Involved In Visual Perception |
| 0 | GO:0050982 | Detection Of Mechanical Stimulus |
| 0 | GO:0050974 | Detection Of Mechanical Stimulus Involved In Sensory Perception |
| 0 | GO:0051606 | Detection Of Stimulus |
| 0 | GO:0050906 | Detection Of Stimulus Involved In Sensory Perception |
| 0 | GO:0009584 | Detection Of Visible Light |
| 0 | GO:0008340 | Determination Of Adult Lifespan |
| 0 | GO:0009855 | Determination Of Bilateral Symmetry |
| 0 | GO:0061371 | Determination Of Heart Left/Right Asymmetry |
| 0 | GO:0007368 | Determination Of Left/Right Symmetry |
| 0 | GO:0046545 | Development Of Primary Female Sexual Characteristics |
| 0 | GO:0046546 | Development Of Primary Male Sexual Characteristics |
| 0 | GO:0045137 | Development Of Primary Sexual Characteristics |
| 0 | GO:0045136 | Development Of Secondary Sexual Characteristics |
| 0 | GO:0048588 | Developmental Cell Growth |
| 0 | GO:0048589 | Developmental Growth |
| 0 | GO:0060560 | Developmental Growth Involved In Morphogenesis |
| 0 | GO:0031128 | Developmental Induction |
| 0 | GO:0021700 | Developmental Maturation |
| 0 | GO:0048066 | Developmental Pigmentation |
| 0 | GO:0003006 | Developmental Process Involved In Reproduction |
| 0 | GO:0010623 | Developmental Programmed Cell Death |
| 0 | GO:0004143 | Diacylglycerol Kinase Activity |
| 0 | GO:0043648 | Dicarboxylic Acid Metabolic Process |
| 0 | GO:0005310 | Dicarboxylic Acid Transmembrane Transporter Activity |
| 0 | GO:0006835 | Dicarboxylic Acid Transport |
| 0 | GO:0060600 | Dichotomous Subdivision Of An Epithelial Terminal Unit |
| 1 | GO:0021536 | Diencephalon Development |
| 0 | GO:0007586 | Digestion |
| 0 | GO:0055123 | Digestive System Development |

| | | |
|---|------------|---|
| 0 | GO:0022600 | Digestive System Process |
| 0 | GO:0048565 | Digestive Tract Development |
| 0 | GO:0048546 | Digestive Tract Morphogenesis |
| 0 | GO:0034312 | Diol Biosynthetic Process |
| 0 | GO:0034311 | Diol Metabolic Process |
| 0 | GO:0051213 | Dioxygenase Activity |
| 0 | GO:0016805 | Dipeptidase Activity |
| 0 | GO:0008239 | Dipeptidyl-Peptidase Activity |
| 0 | GO:0015036 | Disulfide Oxidoreductase Activity |
| 0 | GO:0016101 | Diterpenoid Metabolic Process |
| 0 | GO:0072507 | Divalent Inorganic Cation Homeostasis |
| 0 | GO:0072509 | Divalent Inorganic Cation Transmembrane Transporter Activity |
| 0 | GO:0072511 | Divalent Inorganic Cation Transport |
| 0 | GO:0070838 | Divalent Metal Ion Transport |
| 0 | GO:0006305 | Dna Alkylation |
| 0 | GO:0008301 | Dna Binding, Bending |
| 0 | GO:0071897 | Dna Biosynthetic Process |
| 0 | GO:0006308 | Dna Catabolic Process |
| 0 | GO:0000737 | Dna Catabolic Process, Endonucleolytic |
| 0 | GO:0071103 | Dna Conformation Change |
| 0 | GO:0000077 | Dna Damage Checkpoint |
| 0 | GO:0030330 | Dna Damage Response, Signal Transduction By P53 Class Mediator |
| 0 | GO:0006977 | Dna Damage Response, Signal Transduction By P53 Class Mediator Resulting In Cell Cycle Arrest |
| 0 | GO:0042771 | Dna Damage Response, Signal Transduction By P53 Class Mediator Resulting In Induction Of Apoptosis |
| 0 | GO:0006978 | Dna Damage Response, Signal Transduction By P53 Class Mediator Resulting In Transcription Of P21 Class Mediator |
| 0 | GO:0008630 | Dna Damage Response, Signal Transduction Resulting In Induction Of Apoptosis |
| 0 | GO:0042772 | Dna Damage Response, Signal Transduction Resulting In Transcription |
| 0 | GO:0035510 | Dna Dealkylation |
| 0 | GO:0080111 | Dna Demethylation |
| 0 | GO:0032508 | Dna Duplex Unwinding |
| 0 | GO:0044349 | Dna Excision |
| 0 | GO:0032392 | Dna Geometric Change |
| 0 | GO:0003678 | Dna Helicase Activity |
| 0 | GO:0033202 | Dna Helicase Complex |
| 0 | GO:0015074 | Dna Integration |
| 0 | GO:0031570 | Dna Integrity Checkpoint |
| 0 | GO:0006266 | Dna Ligation |
| 0 | GO:0006306 | Dna Methylation |
| 0 | GO:0043046 | Dna Methylation Involved In Gamete Generation |
| 0 | GO:0006304 | Dna Modification |
| 0 | GO:0019104 | Dna N-Glycosylase Activity |
| 0 | GO:0006323 | Dna Packaging |
| 0 | GO:0034061 | Dna Polymerase Activity |
| 0 | GO:0042575 | Dna Polymerase Complex |
| 0 | GO:0006310 | Dna Recombination |
| 0 | GO:0006281 | Dna Repair |
| 0 | GO:0006260 | Dna Replication |
| 0 | GO:0000076 | Dna Replication Checkpoint |
| 0 | GO:0006336 | Dna Replication-Independent Nucleosome Assembly |
| 0 | GO:0034724 | Dna Replication-Independent Nucleosome Organization |
| 0 | GO:0000217 | Dna Secondary Structure Binding |
| 0 | GO:0022616 | Dna Strand Elongation |
| 0 | GO:0006271 | Dna Strand Elongation Involved In Dna Replication |
| 0 | GO:0003906 | Dna-(Apurinic Or Apyrimidinic Site) Lyase Activity |
| 0 | GO:0008094 | Dna-Dependent Atpase Activity |
| 0 | GO:0006261 | Dna-Dependent Dna Replication |

| | | |
|---|------------|---|
| 0 | GO:0006270 | Dna-Dependent Dna Replication Initiation |
| 0 | GO:0003887 | Dna-Directed Dna Polymerase Activity |
| 0 | GO:0003899 | Dna-Directed Rna Polymerase Activity |
| 0 | GO:0000428 | Dna-Directed Rna Polymerase Complex |
| 0 | GO:0005665 | Dna-Directed Rna Polymerase Ii, Core Complex |
| 0 | GO:0016591 | Dna-Directed Rna Polymerase Ii, Holoenzyme |
| 0 | GO:0006488 | Dolichol-Linked Oligosaccharide Biosynthetic Process |
| 1 | GO:0035240 | Dopamine Binding |
| 1 | GO:0042417 | Dopamine Metabolic Process |
| 1 | GO:0050780 | Dopamine Receptor Binding |
| 1 | GO:0007212 | Dopamine Receptor Signaling Pathway |
| 1 | GO:0014046 | Dopamine Secretion |
| 1 | GO:0015872 | Dopamine Transport |
| 1 | GO:0021516 | Dorsal Spinal Cord Development |
| 0 | GO:0009950 | Dorsal/Ventral Axis Specification |
| 0 | GO:0021904 | Dorsal/Ventral Neural Tube Patterning |
| 0 | GO:0009953 | Dorsal/Ventral Pattern Formation |
| 0 | GO:0006302 | Double-Strand Break Repair |
| 0 | GO:0000724 | Double-Strand Break Repair Via Homologous Recombination |
| 0 | GO:0006303 | Double-Strand Break Repair Via Nonhomologous End Joining |
| 0 | GO:0003690 | Double-Stranded Dna Binding |
| 0 | GO:0003725 | Double-Stranded Rna Binding |
| 0 | GO:0008144 | Drug Binding |
| 0 | GO:0042737 | Drug Catabolic Process |
| 0 | GO:0017144 | Drug Metabolic Process |
| 0 | GO:0015238 | Drug Transmembrane Transporter Activity |
| 0 | GO:0015893 | Drug Transport |
| 0 | GO:0031050 | Dsrna Fragmentation |
| 0 | GO:0008831 | Dtdp-4-Dehydrorhamnose Reductase Activity |
| 0 | GO:0045502 | Dynein Binding |
| 0 | GO:0030286 | Dynein Complex |
| 0 | GO:0016010 | Dystrophin-Associated Glycoprotein Complex |
| 0 | GO:0070888 | E-Box Binding |
| 0 | GO:0043583 | Ear Development |
| 0 | GO:0042471 | Ear Morphogenesis |
| 0 | GO:0005769 | Early Endosome |
| 0 | GO:0031901 | Early Endosome Membrane |
| 0 | GO:0045022 | Early Endosome To Late Endosome Transport |
| 0 | GO:0042755 | Eating Behavior |
| 0 | GO:0007398 | Ectoderm Development |
| 0 | GO:0071696 | Ectodermal Placode Development |
| 0 | GO:0060788 | Ectodermal Placode Formation |
| 0 | GO:0071697 | Ectodermal Placode Morphogenesis |
| 0 | GO:0009055 | Electron Carrier Activity |
| 0 | GO:0022900 | Electron Transport Chain |
| 0 | GO:0007204 | Elevation Of Cytosolic Calcium Ion Concentration |
| 0 | GO:0051482 | Elevation Of Cytosolic Calcium Ion Concentration Involved In Phospholipase C-Activating G-Protein Coupled Signaling Pathway |
| 0 | GO:0009792 | Embryo Development Ending In Birth Or Egg Hatching |
| 0 | GO:0007566 | Embryo Implantation |
| 0 | GO:0035113 | Embryonic Appendage Morphogenesis |
| 0 | GO:0000578 | Embryonic Axis Specification |
| 0 | GO:0031076 | Embryonic Camera-Type Eye Development |
| 0 | GO:0048596 | Embryonic Camera-Type Eye Morphogenesis |
| 0 | GO:0048701 | Embryonic Cranial Skeleton Morphogenesis |
| 0 | GO:0048566 | Embryonic Digestive Tract Development |
| 0 | GO:0048557 | Embryonic Digestive Tract Morphogenesis |

| | | |
|---|------------|--|
| 0 | GO:0042733 | Embryonic Digit Morphogenesis |
| 0 | GO:0001838 | Embryonic Epithelial Tube Formation |
| 0 | GO:0048048 | Embryonic Eye Morphogenesis |
| 0 | GO:0048617 | Embryonic Foregut Morphogenesis |
| 0 | GO:0035115 | Embryonic Forelimb Morphogenesis |
| 0 | GO:0035050 | Embryonic Heart Tube Development |
| 0 | GO:0003143 | Embryonic Heart Tube Morphogenesis |
| 0 | GO:0035162 | Embryonic Hemopoiesis |
| 0 | GO:0035116 | Embryonic Hindlimb Morphogenesis |
| 0 | GO:0030326 | Embryonic Limb Morphogenesis |
| 0 | GO:0048598 | Embryonic Morphogenesis |
| 0 | GO:0048568 | Embryonic Organ Development |
| 0 | GO:0048562 | Embryonic Organ Morphogenesis |
| 0 | GO:0009880 | Embryonic Pattern Specification |
| 0 | GO:0001892 | Embryonic Placenta Development |
| 0 | GO:0060669 | Embryonic Placenta Morphogenesis |
| 0 | GO:0072498 | Embryonic Skeletal Joint Development |
| 0 | GO:0048706 | Embryonic Skeletal System Development |
| 0 | GO:0048704 | Embryonic Skeletal System Morphogenesis |
| 0 | GO:0048703 | Embryonic Viscerocranium Morphogenesis |
| 0 | GO:0003197 | Endocardial Cushion Development |
| 0 | GO:0003203 | Endocardial Cushion Morphogenesis |
| 0 | GO:0003416 | Endochondral Bone Growth |
| 0 | GO:0060350 | Endochondral Bone Morphogenesis |
| 0 | GO:0001958 | Endochondral Ossification |
| 0 | GO:0060986 | Endocrine Hormone Secretion |
| 0 | GO:0031018 | Endocrine Pancreas Development |
| 0 | GO:0050886 | Endocrine Process |
| 0 | GO:0035270 | Endocrine System Development |
| 0 | GO:0032456 | Endocytic Recycling |
| 0 | GO:0030139 | Endocytic Vesicle |
| 0 | GO:0030666 | Endocytic Vesicle Membrane |
| 0 | GO:0006897 | Endocytosis |
| 0 | GO:0004520 | Endodeoxyribonuclease Activity |
| 0 | GO:0016888 | Endodeoxyribonuclease Activity, Producing 5'-Phosphomonoesters |
| 0 | GO:0007492 | Endoderm Development |
| 0 | GO:0001706 | Endoderm Formation |
| 0 | GO:0004519 | Endonuclease Activity |
| 0 | GO:0016894 | Endonuclease Activity, Active With Either Ribo- Or Deoxyribonucleic Acids And Producing 3'-Phosphomonoesters |
| 0 | GO:0016893 | Endonuclease Activity, Active With Either Ribo- Or Deoxyribonucleic Acids And Producing 5'-Phosphomonoesters |
| 0 | GO:0004175 | Endopeptidase Activity |
| 0 | GO:0004866 | Endopeptidase Inhibitor Activity |
| 0 | GO:0061135 | Endopeptidase Regulator Activity |
| 0 | GO:0032469 | Endoplasmic Reticulum Calcium Ion Homeostasis |
| 0 | GO:0005788 | Endoplasmic Reticulum Lumen |
| 0 | GO:0007029 | Endoplasmic Reticulum Organization |
| 0 | GO:0030968 | Endoplasmic Reticulum Unfolded Protein Response |
| 0 | GO:0005793 | Endoplasmic Reticulum-Golgi Intermediate Compartment |
| 0 | GO:0033116 | Endoplasmic Reticulum-Golgi Intermediate Compartment Membrane |
| 0 | GO:0004521 | Endoribonuclease Activity |
| 0 | GO:0016891 | Endoribonuclease Activity, Producing 5'-Phosphomonoesters |
| 0 | GO:0044440 | Endosomal Part |
| 0 | GO:0016197 | Endosomal Transport |
| 0 | GO:0005768 | Endosome |
| 0 | GO:0010008 | Endosome Membrane |
| 0 | GO:0007032 | Endosome Organization |

| | | |
|---|------------|--|
| 0 | GO:0008333 | Endosome To Lysosome Transport |
| 0 | GO:0001885 | Endothelial Cell Development |
| 0 | GO:0045446 | Endothelial Cell Differentiation |
| 0 | GO:0043542 | Endothelial Cell Migration |
| 0 | GO:0001935 | Endothelial Cell Proliferation |
| 0 | GO:0003158 | Endothelium Development |
| 0 | GO:0015988 | Energy Coupled Proton Transport, Against Electrochemical Gradient |
| 0 | GO:0015985 | Energy Coupled Proton Transport, Down Electrochemical Gradient |
| 0 | GO:0015980 | Energy Derivation By Oxidation Of Organic Compounds |
| 0 | GO:0006112 | Energy Reserve Metabolic Process |
| 0 | GO:0035326 | Enhancer Binding |
| 0 | GO:0001158 | Enhancer Sequence-Specific Dna Binding |
| 1 | GO:0007272 | Ensheathment Of Neurons |
| 1 | GO:0048484 | Enteric Nervous System Development |
| 0 | GO:0051806 | Entry Into Cell Of Other Organism Involved In Symbiotic Interaction |
| 0 | GO:0044409 | Entry Into Host |
| 0 | GO:0030260 | Entry Into Host Cell |
| 0 | GO:0051828 | Entry Into Other Organism Involved In Symbiotic Interaction |
| 0 | GO:0008047 | Enzyme Activator Activity |
| 0 | GO:0004857 | Enzyme Inhibitor Activity |
| 0 | GO:0005003 | Ephrin Receptor Activity |
| 0 | GO:0046875 | Ephrin Receptor Binding |
| 0 | GO:0048013 | Ephrin Receptor Signaling Pathway |
| 0 | GO:0009913 | Epidermal Cell Differentiation |
| 0 | GO:0005154 | Epidermal Growth Factor Receptor Binding |
| 0 | GO:0007173 | Epidermal Growth Factor Receptor Signaling Pathway |
| 0 | GO:0008544 | Epidermis Development |
| 0 | GO:0048730 | Epidermis Morphogenesis |
| 0 | GO:0002064 | Epithelial Cell Development |
| 0 | GO:0030855 | Epithelial Cell Differentiation |
| 0 | GO:0035850 | Epithelial Cell Differentiation Involved In Kidney Development |
| 0 | GO:0060742 | Epithelial Cell Differentiation Involved In Prostate Gland Development |
| 0 | GO:0002070 | Epithelial Cell Maturation |
| 0 | GO:0010631 | Epithelial Cell Migration |
| 0 | GO:0003382 | Epithelial Cell Morphogenesis |
| 0 | GO:0050673 | Epithelial Cell Proliferation |
| 0 | GO:0060767 | Epithelial Cell Proliferation Involved In Prostate Gland Development |
| 0 | GO:0090136 | Epithelial Cell-Cell Adhesion |
| 0 | GO:0010669 | Epithelial Structure Maintenance |
| 0 | GO:0001837 | Epithelial To Mesenchymal Transition |
| 0 | GO:0060441 | Epithelial Tube Branching Involved In Lung Morphogenesis |
| 0 | GO:0072175 | Epithelial Tube Formation |
| 0 | GO:0060562 | Epithelial Tube Morphogenesis |
| 0 | GO:0060429 | Epithelium Development |
| 0 | GO:0090132 | Epithelium Migration |
| 0 | GO:0030134 | Er To Golgi Transport Vesicle |
| 0 | GO:0012507 | Er To Golgi Transport Vesicle Membrane |
| 0 | GO:0006888 | Er To Golgi Vesicle-Mediated Transport |
| 0 | GO:0030433 | Er-Associated Protein Catabolic Process |
| 0 | GO:0006984 | Er-Nucleus Signaling Pathway |
| 0 | GO:0070371 | Erk1 And Erk2 Cascade |
| 0 | GO:0048821 | Erythrocyte Development |
| 0 | GO:0030218 | Erythrocyte Differentiation |
| 0 | GO:0034101 | Erythrocyte Homeostasis |
| 0 | GO:0030010 | Establishment Of Cell Polarity |
| 0 | GO:0051303 | Establishment Of Chromosome Localization |

| | | |
|---|------------|---|
| 0 | GO:0032401 | Establishment Of Melanosome Localization |
| 0 | GO:0051654 | Establishment Of Mitochondrion Localization |
| 0 | GO:0040001 | Establishment Of Mitotic Spindle Localization |
| 0 | GO:0000132 | Establishment Of Mitotic Spindle Orientation |
| 0 | GO:0051656 | Establishment Of Organelle Localization |
| 0 | GO:0051905 | Establishment Of Pigment Granule Localization |
| 0 | GO:0001736 | Establishment Of Planar Polarity |
| 0 | GO:0090177 | Establishment Of Planar Polarity Involved In Neural Tube Closure |
| 0 | GO:0042249 | Establishment Of Planar Polarity Of Embryonic Epithelium |
| 0 | GO:0090150 | Establishment Of Protein Localization In Membrane |
| 0 | GO:0072655 | Establishment Of Protein Localization In Mitochondrion |
| 0 | GO:0090002 | Establishment Of Protein Localization In Plasma Membrane |
| 0 | GO:0072594 | Establishment Of Protein Localization To Organelle |
| 0 | GO:0072663 | Establishment Of Protein Localization To Peroxisome |
| 0 | GO:0051236 | Establishment Of Rna Localization |
| 0 | GO:0051293 | Establishment Of Spindle Localization |
| 0 | GO:0051294 | Establishment Of Spindle Orientation |
| 0 | GO:0007164 | Establishment Of Tissue Polarity |
| 0 | GO:0051650 | Establishment Of Vesicle Localization |
| 0 | GO:0035088 | Establishment Or Maintenance Of Apical/Basal Cell Polarity |
| 0 | GO:0061245 | Establishment Or Maintenance Of Bipolar Cell Polarity |
| 0 | GO:0007163 | Establishment Or Maintenance Of Cell Polarity |
| 0 | GO:0045197 | Establishment Or Maintenance Of Epithelial Cell Apical/Basal Polarity |
| 0 | GO:0004303 | Estradiol 17-Beta-Dehydrogenase Activity |
| 0 | GO:0008210 | Estrogen Metabolic Process |
| 0 | GO:0030331 | Estrogen Receptor Binding |
| 0 | GO:0042439 | Ethanolamine-Containing Compound Metabolic Process |
| 0 | GO:0043499 | Eukaryotic Cell Surface Binding |
| 0 | GO:0005852 | Eukaryotic Translation Initiation Factor 3 Complex |
| 0 | GO:0005231 | Excitatory Extracellular Ligand-Gated Ion Channel Activity |
| 1 | GO:0060076 | Excitatory Synapse |
| 0 | GO:0007588 | Excretion |
| 0 | GO:0010458 | Exit From Mitosis |
| 0 | GO:0035272 | Exocrine System Development |
| 0 | GO:0006887 | Exocytosis |
| 0 | GO:0035145 | Exon-Exon Junction Complex |
| 0 | GO:0004527 | Exonuclease Activity |
| 0 | GO:0016796 | Exonuclease Activity, Active With Either Ribo- Or Deoxyribonucleic Acids And Producing 5'-Phosphomonoesters |
| 0 | GO:0043928 | Exonucleolytic Nuclear-Transcribed Mrna Catabolic Process Involved In Deadenylation-Dependent Decay |
| 0 | GO:0008238 | Exopeptidase Activity |
| 0 | GO:0004532 | Exoribonuclease Activity |
| 0 | GO:0016896 | Exoribonuclease Activity, Producing 5'-Phosphomonoesters |
| 0 | GO:0000178 | Exosome (Rnase Complex) |
| 0 | GO:0030312 | External Encapsulating Structure |
| 0 | GO:0044462 | External Encapsulating Structure Part |
| 0 | GO:0009897 | External Side Of Plasma Membrane |
| 0 | GO:0005230 | Extracellular Ligand-Gated Ion Channel Activity |
| 0 | GO:0031012 | Extracellular Matrix |
| 0 | GO:0050840 | Extracellular Matrix Binding |
| 0 | GO:0022617 | Extracellular Matrix Disassembly |
| 0 | GO:0030198 | Extracellular Matrix Organization |
| 0 | GO:0044420 | Extracellular Matrix Part |
| 0 | GO:0005201 | Extracellular Matrix Structural Constituent |
| 0 | GO:0045226 | Extracellular Polysaccharide Biosynthetic Process |
| 0 | GO:0046379 | Extracellular Polysaccharide Metabolic Process |
| 0 | GO:0043062 | Extracellular Structure Organization |

| | | |
|---|------------|---|
| 0 | GO:0005234 | Extracellular-Glutamate-Gated Ion Channel Activity |
| 0 | GO:0031234 | Extrinsic To Internal Side Of Plasma Membrane |
| 0 | GO:0019898 | Extrinsic To Membrane |
| 0 | GO:0019897 | Extrinsic To Plasma Membrane |
| 0 | GO:0001654 | Eye Development |
| 0 | GO:0048592 | Eye Morphogenesis |
| 0 | GO:0042462 | Eye Photoreceptor Cell Development |
| 0 | GO:0001754 | Eye Photoreceptor Cell Differentiation |
| 0 | GO:0060324 | Face Development |
| 0 | GO:0060325 | Face Morphogenesis |
| 0 | GO:0043240 | Fanconi Anaemia Nuclear Complex |
| 0 | GO:0005916 | Fascia Adherens |
| 0 | GO:0045444 | Fat Cell Differentiation |
| 0 | GO:0042362 | Fat-Soluble Vitamin Biosynthetic Process |
| 0 | GO:0006775 | Fat-Soluble Vitamin Metabolic Process |
| 0 | GO:0006635 | Fatty Acid Beta-Oxidation |
| 0 | GO:0033540 | Fatty Acid Beta-Oxidation Using Acyl-CoA Oxidase |
| 0 | GO:0005504 | Fatty Acid Binding |
| 0 | GO:0006633 | Fatty Acid Biosynthetic Process |
| 0 | GO:0009062 | Fatty Acid Catabolic Process |
| 0 | GO:0015645 | Fatty Acid Ligase Activity |
| 0 | GO:0006631 | Fatty Acid Metabolic Process |
| 0 | GO:0019395 | Fatty Acid Oxidation |
| 0 | GO:0015908 | Fatty Acid Transport |
| 0 | GO:0000062 | Fatty-Acyl-CoA Binding |
| 0 | GO:0046949 | Fatty-Acyl-CoA Biosynthetic Process |
| 0 | GO:0035337 | Fatty-Acyl-CoA Metabolic Process |
| 1 | GO:0042596 | Fear Response |
| 1 | GO:0007631 | Feeding Behavior |
| 0 | GO:0007292 | Female Gamete Generation |
| 0 | GO:0008585 | Female Gonad Development |
| 0 | GO:0007143 | Female Meiosis |
| 0 | GO:0007565 | Female Pregnancy |
| 0 | GO:0046660 | Female Sex Differentiation |
| 0 | GO:0015682 | Ferric Iron Transport |
| 0 | GO:0008198 | Ferrous Iron Binding |
| 0 | GO:0015093 | Ferrous Iron Transmembrane Transporter Activity |
| 0 | GO:0015684 | Ferrous Iron Transport |
| 0 | GO:0009566 | Fertilization |
| 0 | GO:0001660 | Fever Generation |
| 0 | GO:0005583 | Fibrillar Collagen |
| 0 | GO:0042730 | Fibrinolysis |
| 0 | GO:0017134 | Fibroblast Growth Factor Binding |
| 0 | GO:0005104 | Fibroblast Growth Factor Receptor Binding |
| 0 | GO:0008543 | Fibroblast Growth Factor Receptor Signaling Pathway |
| 0 | GO:0010761 | Fibroblast Migration |
| 0 | GO:0048144 | Fibroblast Proliferation |
| 0 | GO:0001968 | Fibronectin Binding |
| 0 | GO:0031941 | Filamentous Actin |
| 0 | GO:0030175 | Filopodium |
| 0 | GO:0046847 | Filopodium Assembly |
| 0 | GO:0031527 | Filopodium Membrane |
| 0 | GO:0005528 | Fk506 Binding |
| 0 | GO:0019861 | Flagellum |
| 0 | GO:0044460 | Flagellum Part |
| 0 | GO:0050660 | Flavin Adenine Dinucleotide Binding |

| | | |
|---|------------|---|
| 0 | GO:0042044 | Fluid Transport |
| 0 | GO:0010181 | Fmn Binding |
| 0 | GO:0090077 | Foam Cell Differentiation |
| 0 | GO:0005925 | Focal Adhesion |
| 0 | GO:0048041 | Focal Adhesion Assembly |
| 0 | GO:0005542 | Folic Acid Binding |
| 0 | GO:0006760 | Folic Acid-Containing Compound Metabolic Process |
| 1 | GO:0021885 | Forebrain Cell Migration |
| 1 | GO:0030900 | Forebrain Development |
| 1 | GO:0021872 | Forebrain Generation Of Neurons |
| 1 | GO:0048853 | Forebrain Morphogenesis |
| 1 | GO:0021879 | Forebrain Neuron Differentiation |
| 1 | GO:0021871 | Forebrain Regionalization |
| 0 | GO:0007440 | Foregut Morphogenesis |
| 0 | GO:0035136 | Forelimb Morphogenesis |
| 0 | GO:0001704 | Formation Of Primary Germ Layer |
| 0 | GO:0009378 | Four-Way Junction Helicase Activity |
| 0 | GO:0005109 | Frizzled Binding |
| 0 | GO:0006000 | Fructose Metabolic Process |
| 0 | GO:0006004 | Fucose Metabolic Process |
| 0 | GO:0008417 | Fucosyltransferase Activity |
| 0 | GO:0001965 | G-Protein Alpha-Subunit Binding |
| 0 | GO:0031683 | G-Protein Beta/Gamma-Subunit Complex Binding |
| 0 | GO:0007213 | G-Protein Coupled Acetylcholine Receptor Signaling Pathway |
| 0 | GO:0008227 | G-Protein Coupled Amine Receptor Activity |
| 0 | GO:0001637 | G-Protein Coupled Chemoattractant Receptor Activity |
| 0 | GO:0007216 | G-Protein Coupled Glutamate Receptor Signaling Pathway |
| 0 | GO:0001608 | G-Protein Coupled Nucleotide Receptor Activity |
| 0 | GO:0008528 | G-Protein Coupled Peptide Receptor Activity |
| 0 | GO:0045028 | G-Protein Coupled Purinergic Nucleotide Receptor Activity |
| 0 | GO:0004930 | G-Protein Coupled Receptor Activity |
| 0 | GO:0001664 | G-Protein Coupled Receptor Binding |
| 0 | GO:0007187 | G-Protein Coupled Receptor Signaling Pathway, Coupled To Cyclic Nucleotide Second Messenger |
| 0 | GO:0051318 | G1 Phase |
| 0 | GO:0000080 | G1 Phase Of Mitotic Cell Cycle |
| 0 | GO:0071779 | G1/S Transition Checkpoint |
| 0 | GO:0000082 | G1/S Transition Of Mitotic Cell Cycle |
| 0 | GO:0031576 | G2/M Transition Checkpoint |
| 0 | GO:0031572 | G2/M Transition Dna Damage Checkpoint |
| 0 | GO:0000086 | G2/M Transition Of Mitotic Cell Cycle |
| 1 | GO:0016917 | Gaba Receptor Activity |
| 1 | GO:0004890 | Gaba-A Receptor Activity |
| 0 | GO:0008378 | Galactosyltransferase Activity |
| 0 | GO:0007276 | Gamete Generation |
| 0 | GO:0007214 | Gamma-Aminobutyric Acid Signaling Pathway |
| 0 | GO:0015812 | Gamma-Aminobutyric Acid Transport |
| 0 | GO:0045295 | Gamma-Catenin Binding |
| 0 | GO:0043015 | Gamma-Tubulin Binding |
| 0 | GO:0000930 | Gamma-Tubulin Complex |
| 0 | GO:0001573 | Ganglioside Metabolic Process |
| 0 | GO:0005921 | Gap Junction |
| 0 | GO:0005243 | Gap Junction Channel Activity |
| 0 | GO:0015669 | Gas Transport |
| 0 | GO:0007369 | Gastrulation |
| 0 | GO:0001702 | Gastrulation With Mouth Forming Second |
| 0 | GO:0022836 | Gated Channel Activity |

| | | |
|---|------------|--|
| 0 | GO:0019003 | Gdp Binding |
| 0 | GO:0016458 | Gene Silencing |
| 0 | GO:0035195 | Gene Silencing By Mirna |
| 0 | GO:0031047 | Gene Silencing By Rna |
| 0 | GO:0003001 | Generation Of A Signal Involved In Cell-Cell Signaling |
| 0 | GO:0006091 | Generation Of Precursor Metabolites And Energy |
| 0 | GO:0071514 | Genetic Imprinting |
| 0 | GO:0048806 | Genitalia Development |
| 0 | GO:0035112 | Genitalia Morphogenesis |
| 0 | GO:0007281 | Germ Cell Development |
| 0 | GO:0008354 | Germ Cell Migration |
| 0 | GO:0043073 | Germ Cell Nucleus |
| 0 | GO:0060293 | Germ Plasm |
| 0 | GO:0002467 | Germinal Center Formation |
| 0 | GO:0048732 | Gland Development |
| 0 | GO:0022612 | Gland Morphogenesis |
| 1 | GO:0021782 | Glial Cell Development |
| 1 | GO:0010001 | Glial Cell Differentiation |
| 1 | GO:0021781 | Glial Cell Fate Commitment |
| 1 | GO:0014009 | Glial Cell Proliferation |
| 1 | GO:0042063 | Gliogenesis |
| 0 | GO:0032835 | Glomerulus Development |
| 0 | GO:0072012 | Glomerulus Vasculature Development |
| 0 | GO:0009250 | Glucan Biosynthetic Process |
| 0 | GO:0009251 | Glucan Catabolic Process |
| 0 | GO:0044042 | Glucan Metabolic Process |
| 0 | GO:0006704 | Glucocorticoid Biosynthetic Process |
| 0 | GO:0008211 | Glucocorticoid Metabolic Process |
| 0 | GO:0006094 | Gluconeogenesis |
| 0 | GO:0006041 | Glucosamine Metabolic Process |
| 0 | GO:0006007 | Glucose Catabolic Process |
| 0 | GO:0042593 | Glucose Homeostasis |
| 0 | GO:0046323 | Glucose Import |
| 0 | GO:0006006 | Glucose Metabolic Process |
| 0 | GO:0005355 | Glucose Transmembrane Transporter Activity |
| 0 | GO:0015758 | Glucose Transport |
| 0 | GO:0015926 | Glucosidase Activity |
| 0 | GO:0046527 | Glucosyltransferase Activity |
| 0 | GO:0015020 | Glucuronosyltransferase Activity |
| 1 | GO:0006536 | Glutamate Metabolic Process |
| 1 | GO:0008066 | Glutamate Receptor Activity |
| 1 | GO:0035254 | Glutamate Receptor Binding |
| 1 | GO:0007215 | Glutamate Receptor Signaling Pathway |
| 1 | GO:0014047 | Glutamate Secretion |
| 0 | GO:0009084 | Glutamine Family Amino Acid Biosynthetic Process |
| 0 | GO:0009065 | Glutamine Family Amino Acid Catabolic Process |
| 0 | GO:0009064 | Glutamine Family Amino Acid Metabolic Process |
| 0 | GO:0006541 | Glutamine Metabolic Process |
| 0 | GO:0006750 | Glutathione Biosynthetic Process |
| 0 | GO:0006749 | Glutathione Metabolic Process |
| 0 | GO:0004602 | Glutathione Peroxidase Activity |
| 0 | GO:0004364 | Glutathione Transferase Activity |
| 0 | GO:0046504 | Glycerol Ether Biosynthetic Process |
| 0 | GO:0044269 | Glycerol Ether Catabolic Process |
| 0 | GO:0006662 | Glycerol Ether Metabolic Process |
| 0 | GO:0006071 | Glycerol Metabolic Process |

| | | |
|---|------------|--|
| 0 | GO:0045017 | Glycerolipid Biosynthetic Process |
| 0 | GO:0046503 | Glycerolipid Catabolic Process |
| 0 | GO:0046486 | Glycerolipid Metabolic Process |
| 0 | GO:0046474 | Glycerophospholipid Biosynthetic Process |
| 0 | GO:0006650 | Glycerophospholipid Metabolic Process |
| 0 | GO:0016594 | Glycine Binding |
| 0 | GO:0006544 | Glycine Metabolic Process |
| 0 | GO:0005978 | Glycogen Biosynthetic Process |
| 0 | GO:0005980 | Glycogen Catabolic Process |
| 0 | GO:0005977 | Glycogen Metabolic Process |
| 0 | GO:0051861 | Glycolipid Binding |
| 0 | GO:0009247 | Glycolipid Biosynthetic Process |
| 0 | GO:0006664 | Glycolipid Metabolic Process |
| 0 | GO:0006096 | Glycolysis |
| 0 | GO:0001948 | Glycoprotein Binding |
| 0 | GO:0009101 | Glycoprotein Biosynthetic Process |
| 0 | GO:0006516 | Glycoprotein Catabolic Process |
| 0 | GO:0009100 | Glycoprotein Metabolic Process |
| 0 | GO:0005539 | Glycosaminoglycan Binding |
| 0 | GO:0006024 | Glycosaminoglycan Biosynthetic Process |
| 0 | GO:0006027 | Glycosaminoglycan Catabolic Process |
| 0 | GO:0030203 | Glycosaminoglycan Metabolic Process |
| 0 | GO:0006688 | Glycosphingolipid Biosynthetic Process |
| 0 | GO:0006687 | Glycosphingolipid Metabolic Process |
| 0 | GO:0070085 | Glycosylation |
| 0 | GO:0006677 | Glycosylceramide Metabolic Process |
| 0 | GO:0019002 | Gmp Binding |
| 0 | GO:0031985 | Golgi Cisterna |
| 0 | GO:0032580 | Golgi Cisterna Membrane |
| 0 | GO:0005796 | Golgi Lumen |
| 0 | GO:0000139 | Golgi Membrane |
| 0 | GO:0007030 | Golgi Organization |
| 0 | GO:0005795 | Golgi Stack |
| 0 | GO:0006895 | Golgi To Endosome Transport |
| 0 | GO:0043001 | Golgi To Plasma Membrane Protein Transport |
| 0 | GO:0006893 | Golgi To Plasma Membrane Transport |
| 0 | GO:0017119 | Golgi Transport Complex |
| 0 | GO:0048200 | Golgi Transport Vesicle Coating |
| 0 | GO:0048194 | Golgi Vesicle Budding |
| 0 | GO:0048193 | Golgi Vesicle Transport |
| 0 | GO:0005798 | Golgi-Associated Vesicle |
| 0 | GO:0030660 | Golgi-Associated Vesicle Membrane |
| 0 | GO:0008406 | Gonad Development |
| 0 | GO:0006506 | Gpi Anchor Biosynthetic Process |
| 0 | GO:0006505 | Gpi Anchor Metabolic Process |
| 0 | GO:0071621 | Granulocyte Chemotaxis |
| 0 | GO:0030851 | Granulocyte Differentiation |
| 1 | GO:0007625 | Grooming Behavior |
| 0 | GO:0030426 | Growth Cone |
| 0 | GO:0008083 | Growth Factor Activity |
| 0 | GO:0019838 | Growth Factor Binding |
| 0 | GO:0070851 | Growth Factor Receptor Binding |
| 0 | GO:0060396 | Growth Hormone Receptor Signaling Pathway |
| 0 | GO:0030252 | Growth Hormone Secretion |
| 0 | GO:0044110 | Growth Involved In Symbiotic Interaction |
| 0 | GO:0044117 | Growth Of Symbiont In Host |

| | | |
|---|------------|--|
| 0 | GO:0044116 | Growth Of Symbiont Involved In Interaction With Host |
| 0 | GO:0003417 | Growth Plate Cartilage Development |
| 0 | GO:0005525 | Gtp Binding |
| 0 | GO:0006184 | Gtp Catabolic Process |
| 0 | GO:0046039 | Gtp Metabolic Process |
| 0 | GO:0030742 | Gtp-Dependent Protein Binding |
| 0 | GO:0005096 | Gtpase Activator Activity |
| 0 | GO:0003924 | Gtpase Activity |
| 0 | GO:0051020 | Gtpase Binding |
| 0 | GO:0005095 | Gtpase Inhibitor Activity |
| 0 | GO:0030695 | Gtpase Regulator Activity |
| 0 | GO:0019001 | Guanyl Nucleotide Binding |
| 0 | GO:0032561 | Guanyl Ribonucleotide Binding |
| 0 | GO:0005085 | Guanyl-Nucleotide Exchange Factor Activity |
| 0 | GO:0004385 | Guanylate Kinase Activity |
| 0 | GO:0043189 | H4/H2A Histone Acetyltransferase Complex |
| 0 | GO:0042633 | Hair Cycle |
| 0 | GO:0022405 | Hair Cycle Process |
| 0 | GO:0001942 | Hair Follicle Development |
| 0 | GO:0048820 | Hair Follicle Maturation |
| 0 | GO:0031069 | Hair Follicle Morphogenesis |
| 0 | GO:0060322 | Head Development |
| 0 | GO:0060323 | Head Morphogenesis |
| 0 | GO:0060047 | Heart Contraction |
| 0 | GO:0007507 | Heart Development |
| 0 | GO:0060914 | Heart Formation |
| 0 | GO:0060419 | Heart Growth |
| 0 | GO:0001947 | Heart Looping |
| 0 | GO:0003007 | Heart Morphogenesis |
| 0 | GO:0003015 | Heart Process |
| 0 | GO:0060347 | Heart Trabecula Formation |
| 0 | GO:0061384 | Heart Trabecula Morphogenesis |
| 0 | GO:0003170 | Heart Valve Development |
| 0 | GO:0003179 | Heart Valve Morphogenesis |
| 0 | GO:0031649 | Heat Generation |
| 0 | GO:0031072 | Heat Shock Protein Binding |
| 0 | GO:0008158 | Hedgehog Receptor Activity |
| 0 | GO:0004386 | Helicase Activity |
| 0 | GO:0020037 | Heme Binding |
| 0 | GO:0006783 | Heme Biosynthetic Process |
| 0 | GO:0042168 | Heme Metabolic Process |
| 0 | GO:0015002 | Heme-Copper Terminal Oxidase Activity |
| 0 | GO:0031581 | Hemidesmosome Assembly |
| 0 | GO:0020027 | Hemoglobin Metabolic Process |
| 0 | GO:0030097 | Hemopoiesis |
| 0 | GO:0048534 | Hemopoietic Or Lymphoid Organ Development |
| 0 | GO:0002244 | Hemopoietic Progenitor Cell Differentiation |
| 0 | GO:0007599 | Hemostasis |
| 0 | GO:0043395 | Heparan Sulfate Proteoglycan Binding |
| 0 | GO:0015012 | Heparan Sulfate Proteoglycan Biosynthetic Process |
| 0 | GO:0030201 | Heparan Sulfate Proteoglycan Metabolic Process |
| 0 | GO:0034483 | Heparan Sulfate Sulfotransferase Activity |
| 0 | GO:0008201 | Heparin Binding |
| 0 | GO:0061008 | Hepaticobiliary System Development |
| 0 | GO:0000792 | Heterochromatin |
| 0 | GO:0018130 | Heterocycle Biosynthetic Process |

| | | |
|---|------------|---|
| 0 | GO:0030530 | Heterogeneous Nuclear Ribonucleoprotein Complex |
| 0 | GO:0007157 | Heterophilic Cell-Cell Adhesion |
| 1 | GO:0005834 | Heterotrimeric G-Protein Complex |
| 0 | GO:0015929 | Hexosaminidase Activity |
| 0 | GO:0019319 | Hexose Biosynthetic Process |
| 0 | GO:0019320 | Hexose Catabolic Process |
| 0 | GO:0019318 | Hexose Metabolic Process |
| 0 | GO:0015149 | Hexose Transmembrane Transporter Activity |
| 0 | GO:0008645 | Hexose Transport |
| 0 | GO:0034364 | High-Density Lipoprotein Particle |
| 0 | GO:0034375 | High-Density Lipoprotein Particle Remodeling |
| 1 | GO:0030902 | Hindbrain Development |
| 1 | GO:0021575 | Hindbrain Morphogenesis |
| 0 | GO:0035137 | Hindlimb Morphogenesis |
| 0 | GO:0035329 | Hippo Signaling Cascade |
| 1 | GO:0021766 | Hippocampus Development |
| 0 | GO:0016573 | Histone Acetylation |
| 0 | GO:0004402 | Histone Acetyltransferase Activity |
| 0 | GO:0035035 | Histone Acetyltransferase Binding |
| 0 | GO:0000123 | Histone Acetyltransferase Complex |
| 0 | GO:0042393 | Histone Binding |
| 0 | GO:0004407 | Histone Deacetylase Activity |
| 0 | GO:0031078 | Histone Deacetylase Activity (H3-K14 Specific) |
| 0 | GO:0032129 | Histone Deacetylase Activity (H3-K9 Specific) |
| 0 | GO:0034739 | Histone Deacetylase Activity (H4-K16 Specific) |
| 0 | GO:0042826 | Histone Deacetylase Binding |
| 0 | GO:0000118 | Histone Deacetylase Complex |
| 0 | GO:0016575 | Histone Deacetylation |
| 0 | GO:0032452 | Histone Demethylase Activity |
| 0 | GO:0016577 | Histone Demethylation |
| 0 | GO:0016578 | Histone Deubiquitination |
| 0 | GO:0043486 | Histone Exchange |
| 0 | GO:0043968 | Histone H2A Acetylation |
| 0 | GO:0033522 | Histone H2A Ubiquitination |
| 0 | GO:0043966 | Histone H3 Acetylation |
| 0 | GO:0051568 | Histone H3-K4 Methylation |
| 0 | GO:0051567 | Histone H3-K9 Methylation |
| 0 | GO:0043967 | Histone H4 Acetylation |
| 0 | GO:0035173 | Histone Kinase Activity |
| 0 | GO:0070076 | Histone Lysine Demethylation |
| 0 | GO:0034968 | Histone Lysine Methylation |
| 0 | GO:0016571 | Histone Methylation |
| 0 | GO:0042054 | Histone Methyltransferase Activity |
| 0 | GO:0042800 | Histone Methyltransferase Activity (H3-K4 Specific) |
| 0 | GO:0035097 | Histone Methyltransferase Complex |
| 0 | GO:0016570 | Histone Modification |
| 0 | GO:0010390 | Histone Monoubiquitination |
| 0 | GO:0008334 | Histone Mrna Metabolic Process |
| 0 | GO:0016572 | Histone Phosphorylation |
| 0 | GO:0016574 | Histone Ubiquitination |
| 0 | GO:0018024 | Histone-Lysine N-Methyltransferase Activity |
| 0 | GO:0071837 | Hmg Box Domain Binding |
| 0 | GO:0048872 | Homeostasis Of Number Of Cells |
| 0 | GO:0048873 | Homeostasis Of Number Of Cells Within A Tissue |
| 0 | GO:0007156 | Homophilic Cell Adhesion |
| 0 | GO:0034109 | Homotypic Cell-Cell Adhesion |

| | | |
|---|------------|--|
| 0 | GO:0030897 | Hops Complex |
| 0 | GO:0005179 | Hormone Activity |
| 0 | GO:0042562 | Hormone Binding |
| 0 | GO:0042446 | Hormone Biosynthetic Process |
| 0 | GO:0042445 | Hormone Metabolic Process |
| 0 | GO:0051427 | Hormone Receptor Binding |
| 0 | GO:0046879 | Hormone Secretion |
| 0 | GO:0009914 | Hormone Transport |
| 0 | GO:0009755 | Hormone-Mediated Signaling Pathway |
| 0 | GO:0030544 | Hsp70 Protein Binding |
| 0 | GO:0051879 | Hsp90 Protein Binding |
| 0 | GO:0006959 | Humoral Immune Response |
| 0 | GO:0002455 | Humoral Immune Response Mediated By Circulating Immunoglobulin |
| 0 | GO:0005540 | Hyaluronic Acid Binding |
| 0 | GO:0016836 | Hydro-Lyase Activity |
| 0 | GO:0015078 | Hydrogen Ion Transmembrane Transporter Activity |
| 0 | GO:0046933 | Hydrogen Ion Transporting Atp Synthase Activity, Rotational Mechanism |
| 0 | GO:0042744 | Hydrogen Peroxide Catabolic Process |
| 0 | GO:0042743 | Hydrogen Peroxide Metabolic Process |
| 0 | GO:0006818 | Hydrogen Transport |
| 0 | GO:0016820 | Hydrolase Activity, Acting On Acid Anhydrides, Catalyzing Transmembrane Movement Of Substances |
| 0 | GO:0016810 | Hydrolase Activity, Acting On Carbon-Nitrogen (But Not Peptide) Bonds |
| 0 | GO:0016814 | Hydrolase Activity, Acting On Carbon-Nitrogen (But Not Peptide) Bonds, In Cyclic Amidines |
| 0 | GO:0016811 | Hydrolase Activity, Acting On Carbon-Nitrogen (But Not Peptide) Bonds, In Linear Amides |
| 0 | GO:0016813 | Hydrolase Activity, Acting On Carbon-Nitrogen (But Not Peptide) Bonds, In Linear Amidines |
| 0 | GO:0016798 | Hydrolase Activity, Acting On Glycosyl Bonds |
| 0 | GO:0016799 | Hydrolase Activity, Hydrolyzing N-Glycosyl Compounds |
| 0 | GO:0004553 | Hydrolase Activity, Hydrolyzing O-Glycosyl Compounds |
| 0 | GO:0006972 | Hyperosmotic Response |
| 1 | GO:0021854 | Hypothalamus Development |
| 0 | GO:0031674 | I Band |
| 0 | GO:0007249 | I-Kappab Kinase/Nf-Kappab Cascade |
| 0 | GO:0070411 | I-Smad Binding |
| 0 | GO:0046456 | Icosanoid Biosynthetic Process |
| 0 | GO:0006690 | Icosanoid Metabolic Process |
| 0 | GO:0004953 | Icosanoid Receptor Activity |
| 0 | GO:0032309 | Icosanoid Secretion |
| 0 | GO:0071715 | Icosanoid Transport |
| 0 | GO:0002252 | Immune Effector Process |
| 0 | GO:0002429 | Immune Response-Activating Cell Surface Receptor Signaling Pathway |
| 0 | GO:0002757 | Immune Response-Activating Signal Transduction |
| 0 | GO:0002768 | Immune Response-Regulating Cell Surface Receptor Signaling Pathway |
| 0 | GO:0002764 | Immune Response-Regulating Signaling Pathway |
| 0 | GO:0019865 | Immunoglobulin Binding |
| 0 | GO:0016064 | Immunoglobulin Mediated Immune Response |
| 0 | GO:0002377 | Immunoglobulin Production |
| 0 | GO:0002381 | Immunoglobulin Production Involved In Immunoglobulin Mediated Immune Response |
| 0 | GO:0048305 | Immunoglobulin Secretion |
| 0 | GO:0001772 | Immunological Synapse |
| 0 | GO:0001701 | In Utero Embryonic Development |
| 0 | GO:0000188 | Inactivation Of Mapk Activity |
| 0 | GO:0016234 | Inclusion Body |
| 0 | GO:0046218 | Indolalkylamine Catabolic Process |
| 0 | GO:0006586 | Indolalkylamine Metabolic Process |
| 0 | GO:0042436 | Indole-Containing Compound Catabolic Process |
| 0 | GO:0042430 | Indole-Containing Compound Metabolic Process |

| | | |
|---|------------|---|
| 0 | GO:0006917 | Induction Of Apoptosis |
| 0 | GO:0008624 | Induction Of Apoptosis By Extracellular Signals |
| 0 | GO:0008629 | Induction Of Apoptosis By Intracellular Signals |
| 0 | GO:0008625 | Induction Of Apoptosis Via Death Domain Receptors |
| 0 | GO:0050930 | Induction Of Positive Chemotaxis |
| 0 | GO:0012502 | Induction Of Programmed Cell Death |
| 0 | GO:0006954 | Inflammatory Response |
| 0 | GO:0002437 | Inflammatory Response To Antigenic Stimulus |
| 0 | GO:0019059 | Initiation Of Viral Infection |
| 0 | GO:0045087 | Innate Immune Response |
| 0 | GO:0002758 | Innate Immune Response-Activating Signal Transduction |
| 0 | GO:0001833 | Inner Cell Mass Cell Proliferation |
| 0 | GO:0048839 | Inner Ear Development |
| 0 | GO:0042472 | Inner Ear Morphogenesis |
| 0 | GO:0060119 | Inner Ear Receptor Cell Development |
| 0 | GO:0060113 | Inner Ear Receptor Cell Differentiation |
| 0 | GO:0060122 | Inner Ear Receptor Stereocilium Organization |
| 0 | GO:0031011 | Ino80 Complex |
| 0 | GO:0005452 | Inorganic Anion Exchanger Activity |
| 0 | GO:0015103 | Inorganic Anion Transmembrane Transporter Activity |
| 0 | GO:0015698 | Inorganic Anion Transport |
| 0 | GO:0022890 | Inorganic Cation Transmembrane Transporter Activity |
| 0 | GO:0048017 | Inositol Lipid-Mediated Signaling |
| 0 | GO:0004428 | Inositol Or Phosphatidylinositol Kinase Activity |
| 0 | GO:0004437 | Inositol Or Phosphatidylinositol Phosphatase Activity |
| 0 | GO:0032958 | Inositol Phosphate Biosynthetic Process |
| 0 | GO:0043647 | Inositol Phosphate Metabolic Process |
| 0 | GO:0052745 | Inositol Phosphate Phosphatase Activity |
| 0 | GO:0048016 | Inositol Phosphate-Mediated Signaling |
| 0 | GO:0007320 | Insemination |
| 0 | GO:0005158 | Insulin Receptor Binding |
| 0 | GO:0008286 | Insulin Receptor Signaling Pathway |
| 0 | GO:0043560 | Insulin Receptor Substrate Binding |
| 0 | GO:0030073 | Insulin Secretion |
| 0 | GO:0035773 | Insulin Secretion Involved In Cellular Response To Glucose Stimulus |
| 0 | GO:0005520 | Insulin-Like Growth Factor Binding |
| 0 | GO:0005159 | Insulin-Like Growth Factor Receptor Binding |
| 0 | GO:0048009 | Insulin-Like Growth Factor Receptor Signaling Pathway |
| 0 | GO:0030176 | Integral To Endoplasmic Reticulum Membrane |
| 0 | GO:0030173 | Integral To Golgi Membrane |
| 0 | GO:0000299 | Integral To Membrane Of Membrane Fraction |
| 0 | GO:0032592 | Integral To Mitochondrial Membrane |
| 0 | GO:0031301 | Integral To Organelle Membrane |
| 0 | GO:0005779 | Integral To Peroxisomal Membrane |
| 0 | GO:0032039 | Integrator Complex |
| 0 | GO:0005178 | Integrin Binding |
| 0 | GO:0008305 | Integrin Complex |
| 0 | GO:0007229 | Integrin-Mediated Signaling Pathway |
| 0 | GO:0051701 | Interaction With Host |
| 0 | GO:0051702 | Interaction With Symbiont |
| 0 | GO:0014704 | Intercalated Disc |
| 0 | GO:0032607 | Interferon-Alpha Production |
| 0 | GO:0032608 | Interferon-Beta Production |
| 0 | GO:0042095 | Interferon-Gamma Biosynthetic Process |
| 0 | GO:0032609 | Interferon-Gamma Production |
| 0 | GO:0060333 | Interferon-Gamma-Mediated Signaling Pathway |

| | | |
|---|------------|---|
| 0 | GO:0032611 | Interleukin-1 Beta Production |
| 0 | GO:0050702 | Interleukin-1 Beta Secretion |
| 0 | GO:0032612 | Interleukin-1 Production |
| 0 | GO:0005149 | Interleukin-1 Receptor Binding |
| 0 | GO:0050701 | Interleukin-1 Secretion |
| 0 | GO:0070498 | Interleukin-1-Mediated Signaling Pathway |
| 0 | GO:0032613 | Interleukin-10 Production |
| 0 | GO:0032615 | Interleukin-12 Production |
| 0 | GO:0032616 | Interleukin-13 Production |
| 0 | GO:0032620 | Interleukin-17 Production |
| 0 | GO:0042094 | Interleukin-2 Biosynthetic Process |
| 0 | GO:0032623 | Interleukin-2 Production |
| 0 | GO:0032633 | Interleukin-4 Production |
| 0 | GO:0042226 | Interleukin-6 Biosynthetic Process |
| 0 | GO:0032635 | Interleukin-6 Production |
| 0 | GO:0042228 | Interleukin-8 Biosynthetic Process |
| 0 | GO:0032637 | Interleukin-8 Production |
| 0 | GO:0005882 | Intermediate Filament |
| 0 | GO:0045111 | Intermediate Filament Cytoskeleton |
| 0 | GO:0045104 | Intermediate Filament Cytoskeleton Organization |
| 0 | GO:0045109 | Intermediate Filament Organization |
| 0 | GO:0045103 | Intermediate Filament-Based Process |
| 0 | GO:0018393 | Internal Peptidyl-Lysine Acetylation |
| 0 | GO:0006475 | Internal Protein Amino Acid Acetylation |
| 0 | GO:0009898 | Internal Side Of Plasma Membrane |
| 0 | GO:0051325 | Interphase |
| 0 | GO:0051329 | Interphase Of Mitotic Cell Cycle |
| 0 | GO:0044419 | Interspecies Interaction Between Organisms |
| 0 | GO:0005614 | Interstitial Matrix |
| 0 | GO:0050892 | Intestinal Absorption |
| 0 | GO:0030299 | Intestinal Cholesterol Absorption |
| 0 | GO:0006891 | Intra-Golgi Vesicle-Mediated Transport |
| 0 | GO:0030520 | Intracellular Estrogen Receptor Signaling Pathway |
| 0 | GO:0005217 | Intracellular Ligand-Gated Ion Channel Activity |
| 0 | GO:0032365 | Intracellular Lipid Transport |
| 0 | GO:0051452 | Intracellular Ph Reduction |
| 0 | GO:0030522 | Intracellular Receptor Mediated Signaling Pathway |
| 0 | GO:0030518 | Intracellular Steroid Hormone Receptor Signaling Pathway |
| 0 | GO:0016860 | Intramolecular Oxidoreductase Activity |
| 0 | GO:0016861 | Intramolecular Oxidoreductase Activity, Interconverting Aldoses And Ketoses |
| 0 | GO:0016862 | Intramolecular Oxidoreductase Activity, Interconverting Keto- And Enol-Groups |
| 0 | GO:0016863 | Intramolecular Oxidoreductase Activity, Transposing C=C Bonds |
| 0 | GO:0016866 | Intramolecular Transferase Activity |
| 0 | GO:0070059 | Intrinsic Apoptotic Signaling Pathway In Response To Endoplasmic Reticulum Stress |
| 0 | GO:0031227 | Intrinsic To Endoplasmic Reticulum Membrane |
| 0 | GO:0031233 | Intrinsic To External Side Of Plasma Membrane |
| 0 | GO:0031228 | Intrinsic To Golgi Membrane |
| 0 | GO:0031235 | Intrinsic To Internal Side Of Plasma Membrane |
| 0 | GO:0031300 | Intrinsic To Organelle Membrane |
| 0 | GO:0031231 | Intrinsic To Peroxisomal Membrane |
| 0 | GO:0005242 | Inward Rectifier Potassium Channel Activity |
| 0 | GO:0005216 | Ion Channel Activity |
| 0 | GO:0034702 | Ion Channel Complex |
| 0 | GO:0008200 | Ion Channel Inhibitor Activity |
| 0 | GO:0022839 | Ion Gated Channel Activity |
| 0 | GO:0034220 | Ion Transmembrane Transport |

| | | |
|---|------------|---|
| 1 | GO:0004970 | Ionotropic Glutamate Receptor Activity |
| 1 | GO:0035255 | Ionotropic Glutamate Receptor Binding |
| 1 | GO:0008328 | Ionotropic Glutamate Receptor Complex |
| 1 | GO:0035235 | Ionotropic Glutamate Receptor Signaling Pathway |
| 0 | GO:0005506 | Iron Ion Binding |
| 0 | GO:0055072 | Iron Ion Homeostasis |
| 0 | GO:0005381 | Iron Ion Transmembrane Transporter Activity |
| 0 | GO:0006826 | Iron Ion Transport |
| 0 | GO:0016226 | Iron-Sulfur Cluster Assembly |
| 0 | GO:0051536 | Iron-Sulfur Cluster Binding |
| 0 | GO:0016853 | Isomerase Activity |
| 0 | GO:0019840 | Isoprenoid Binding |
| 0 | GO:0008299 | Isoprenoid Biosynthetic Process |
| 0 | GO:0006720 | Isoprenoid Metabolic Process |
| 0 | GO:0045190 | Isotype Switching |
| 0 | GO:0048291 | Isotype Switching To IgG Isotypes |
| 0 | GO:0007259 | Jak-Stat Cascade |
| 0 | GO:0007254 | Jnk Cascade |
| 0 | GO:0045095 | Keratin Filament |
| 0 | GO:0031424 | Keratinization |
| 0 | GO:0030216 | Keratinocyte Differentiation |
| 0 | GO:0043616 | Keratinocyte Proliferation |
| 0 | GO:0001822 | Kidney Development |
| 0 | GO:0072073 | Kidney Epithelium Development |
| 0 | GO:0072074 | Kidney Mesenchyme Development |
| 0 | GO:0060993 | Kidney Morphogenesis |
| 0 | GO:0031640 | Killing Of Cells Of Other Organism |
| 0 | GO:0019209 | Kinase Activator Activity |
| 0 | GO:0019900 | Kinase Binding |
| 0 | GO:0019210 | Kinase Inhibitor Activity |
| 0 | GO:0019207 | Kinase Regulator Activity |
| 0 | GO:0019894 | Kinesin Binding |
| 0 | GO:0005871 | Kinesin Complex |
| 0 | GO:0000776 | Kinetochore |
| 0 | GO:0043092 | L-Amino Acid Import |
| 0 | GO:0015179 | L-Amino Acid Transmembrane Transporter Activity |
| 0 | GO:0015807 | L-Amino Acid Transport |
| 0 | GO:0031418 | L-Ascorbic Acid Binding |
| 0 | GO:0042354 | L-Fucose Metabolic Process |
| 0 | GO:0005313 | L-Glutamate Transmembrane Transporter Activity |
| 0 | GO:0015813 | L-Glutamate Transport |
| 0 | GO:0060716 | Labyrinthine Layer Blood Vessel Development |
| 0 | GO:0060711 | Labyrinthine Layer Development |
| 0 | GO:0060713 | Labyrinthine Layer Morphogenesis |
| 0 | GO:0007595 | Lactation |
| 0 | GO:0030027 | Lamellipodium |
| 0 | GO:0030032 | Lamellipodium Assembly |
| 0 | GO:0031258 | Lamellipodium Membrane |
| 0 | GO:0043236 | Laminin Binding |
| 0 | GO:0043256 | Laminin Complex |
| 0 | GO:0015934 | Large Ribosomal Subunit |
| 0 | GO:0005770 | Late Endosome |
| 0 | GO:0031902 | Late Endosome Membrane |
| 0 | GO:0048368 | Lateral Mesoderm Development |
| 0 | GO:0016328 | Lateral Plasma Membrane |
| 0 | GO:0060601 | Lateral Sprouting From An Epithelium |

| | | |
|---|------------|--|
| 0 | GO:0031256 | Leading Edge Membrane |
| 1 | GO:0007612 | Learning |
| 1 | GO:0007611 | Learning Or Memory |
| 0 | GO:0002088 | Lens Development In Camera-Type Eye |
| 0 | GO:0070307 | Lens Fiber Cell Development |
| 0 | GO:0070306 | Lens Fiber Cell Differentiation |
| 0 | GO:0002089 | Lens Morphogenesis In Camera-Type Eye |
| 0 | GO:0045321 | Leukocyte Activation |
| 0 | GO:0002366 | Leukocyte Activation Involved In Immune Response |
| 0 | GO:0071887 | Leukocyte Apoptotic Process |
| 0 | GO:0007159 | Leukocyte Cell-Cell Adhesion |
| 0 | GO:0030595 | Leukocyte Chemotaxis |
| 0 | GO:0043299 | Leukocyte Degranulation |
| 0 | GO:0002521 | Leukocyte Differentiation |
| 0 | GO:0001776 | Leukocyte Homeostasis |
| 0 | GO:0001909 | Leukocyte Mediated Cytotoxicity |
| 0 | GO:0002443 | Leukocyte Mediated Immunity |
| 0 | GO:0050900 | Leukocyte Migration |
| 0 | GO:0070661 | Leukocyte Proliferation |
| 0 | GO:0019370 | Leukotriene Biosynthetic Process |
| 0 | GO:0006691 | Leukotriene Metabolic Process |
| 0 | GO:0033327 | Leydig Cell Differentiation |
| 0 | GO:0004879 | Ligand-Activated Sequence-Specific Dna Binding Rna Polymerase Ii Transcription Factor Activity |
| 0 | GO:0016922 | Ligand-Dependent Nuclear Receptor Binding |
| 0 | GO:0030374 | Ligand-Dependent Nuclear Receptor Transcription Coactivator Activity |
| 0 | GO:0022834 | Ligand-Gated Channel Activity |
| 0 | GO:0015276 | Ligand-Gated Ion Channel Activity |
| 0 | GO:0003706 | Ligand-Regulated Transcription Factor Activity |
| 0 | GO:0016874 | Ligase Activity |
| 0 | GO:0016876 | Ligase Activity, Forming Aminoacyl-Trna And Related Compounds |
| 0 | GO:0016879 | Ligase Activity, Forming Carbon-Nitrogen Bonds |
| 0 | GO:0016875 | Ligase Activity, Forming Carbon-Oxygen Bonds |
| 0 | GO:0016877 | Ligase Activity, Forming Carbon-Sulfur Bonds |
| 0 | GO:0060174 | Limb Bud Formation |
| 0 | GO:0060173 | Limb Development |
| 0 | GO:0035108 | Limb Morphogenesis |
| 1 | GO:0021761 | Limbic System Development |
| 0 | GO:0016298 | Lipase Activity |
| 0 | GO:0055102 | Lipase Inhibitor Activity |
| 0 | GO:0008289 | Lipid Binding |
| 0 | GO:0008610 | Lipid Biosynthetic Process |
| 0 | GO:0016042 | Lipid Catabolic Process |
| 0 | GO:0044241 | Lipid Digestion |
| 0 | GO:0030259 | Lipid Glycosylation |
| 0 | GO:0055088 | Lipid Homeostasis |
| 0 | GO:0001727 | Lipid Kinase Activity |
| 0 | GO:0010876 | Lipid Localization |
| 0 | GO:0030258 | Lipid Modification |
| 0 | GO:0034440 | Lipid Oxidation |
| 0 | GO:0005811 | Lipid Particle |
| 0 | GO:0046834 | Lipid Phosphorylation |
| 0 | GO:0019915 | Lipid Storage |
| 0 | GO:0006869 | Lipid Transport |
| 0 | GO:0005319 | Lipid Transporter Activity |
| 0 | GO:0001530 | Lipopolysaccharide Binding |
| 0 | GO:0009103 | Lipopolysaccharide Biosynthetic Process |

| | | |
|---|------------|--|
| 0 | GO:0008653 | Lipopolysaccharide Metabolic Process |
| 0 | GO:0031663 | Lipopolysaccharide-Mediated Signaling Pathway |
| 0 | GO:0042158 | Lipoprotein Biosynthetic Process |
| 0 | GO:0042157 | Lipoprotein Metabolic Process |
| 0 | GO:0071813 | Lipoprotein Particle Binding |
| 0 | GO:0030228 | Lipoprotein Particle Receptor Activity |
| 0 | GO:0070325 | Lipoprotein Particle Receptor Binding |
| 0 | GO:0042953 | Lipoprotein Transport |
| 0 | GO:0001889 | Liver Development |
| 0 | GO:0051668 | Localization Within Membrane |
| 1 | GO:0007626 | Locomotory Behavior |
| 0 | GO:0001676 | Long-Chain Fatty Acid Metabolic Process |
| 0 | GO:0015909 | Long-Chain Fatty Acid Transport |
| 0 | GO:0004467 | Long-Chain Fatty Acid-CoA Ligase Activity |
| 0 | GO:0035338 | Long-Chain Fatty-Acyl-CoA Biosynthetic Process |
| 0 | GO:0035336 | Long-Chain Fatty-Acyl-CoA Metabolic Process |
| 1 | GO:0007616 | Long-Term Memory |
| 0 | GO:0060291 | Long-Term Synaptic Potentiation |
| 0 | GO:0034362 | Low-Density Lipoprotein Particle |
| 0 | GO:0030169 | Low-Density Lipoprotein Particle Binding |
| 0 | GO:0034383 | Low-Density Lipoprotein Particle Clearance |
| 0 | GO:0050750 | Low-Density Lipoprotein Particle Receptor Binding |
| 0 | GO:0034374 | Low-Density Lipoprotein Particle Remodeling |
| 0 | GO:0005041 | Low-Density Lipoprotein Receptor Activity |
| 0 | GO:0032799 | Low-Density Lipoprotein Receptor Particle Metabolic Process |
| 0 | GO:0030275 | Lrr Domain Binding |
| 0 | GO:0048286 | Lung Alveolus Development |
| 0 | GO:0060479 | Lung Cell Differentiation |
| 0 | GO:0030324 | Lung Development |
| 0 | GO:0060487 | Lung Epithelial Cell Differentiation |
| 0 | GO:0060428 | Lung Epithelium Development |
| 0 | GO:0060425 | Lung Morphogenesis |
| 0 | GO:0016829 | Lyase Activity |
| 0 | GO:0048535 | Lymph Node Development |
| 0 | GO:0001945 | Lymph Vessel Development |
| 0 | GO:0046649 | Lymphocyte Activation |
| 0 | GO:0002285 | Lymphocyte Activation Involved In Immune Response |
| 0 | GO:0070227 | Lymphocyte Apoptotic Process |
| 0 | GO:0048247 | Lymphocyte Chemotaxis |
| 0 | GO:0031294 | Lymphocyte Costimulation |
| 0 | GO:0030098 | Lymphocyte Differentiation |
| 0 | GO:0002260 | Lymphocyte Homeostasis |
| 0 | GO:0002449 | Lymphocyte Mediated Immunity |
| 0 | GO:0072676 | Lymphocyte Migration |
| 0 | GO:0046651 | Lymphocyte Proliferation |
| 0 | GO:0002320 | Lymphoid Progenitor Cell Differentiation |
| 0 | GO:0016278 | Lysine N-Methyltransferase Activity |
| 0 | GO:0004622 | Lysophospholipase Activity |
| 0 | GO:0043202 | Lysosomal Lumen |
| 0 | GO:0005765 | Lysosomal Membrane |
| 0 | GO:0007041 | Lysosomal Transport |
| 0 | GO:0005764 | Lysosome |
| 0 | GO:0007040 | Lysosome Organization |
| 0 | GO:0001619 | Lysosphingolipid And Lysophosphatidic Acid Receptor Activity |
| 0 | GO:0000323 | Lytic Vacuole |
| 0 | GO:0000279 | M Phase |

| | | |
|---|------------|---|
| 0 | GO:0051327 | M Phase Of Meiotic Cell Cycle |
| 0 | GO:0000087 | M Phase Of Mitotic Cell Cycle |
| 0 | GO:0000216 | M/G1 Transition Of Mitotic Cell Cycle |
| 0 | GO:0016236 | Macroautophagy |
| 0 | GO:0005527 | Macrolide Binding |
| 0 | GO:0032984 | Macromolecular Complex Disassembly |
| 0 | GO:0034367 | Macromolecular Complex Remodeling |
| 0 | GO:0043413 | Macromolecule Glycosylation |
| 0 | GO:0043414 | Macromolecule Methylation |
| 0 | GO:0022884 | Macromolecule Transmembrane Transporter Activity |
| 0 | GO:0042116 | Macrophage Activation |
| 0 | GO:0048246 | Macrophage Chemotaxis |
| 0 | GO:0010742 | Macrophage Derived Foam Cell Differentiation |
| 0 | GO:0030225 | Macrophage Differentiation |
| 0 | GO:0000287 | Magnesium Ion Binding |
| 1 | GO:0044304 | Main Axon |
| 0 | GO:0045005 | Maintenance Of Fidelity Involved In Dna-Dependent Dna Replication |
| 0 | GO:0051235 | Maintenance Of Location |
| 0 | GO:0051651 | Maintenance Of Location In Cell |
| 0 | GO:0072595 | Maintenance Of Protein Localization To Organelle |
| 0 | GO:0045185 | Maintenance Of Protein Location |
| 0 | GO:0032507 | Maintenance Of Protein Location In Cell |
| 0 | GO:0051457 | Maintenance Of Protein Location In Nucleus |
| 0 | GO:0048232 | Male Gamete Generation |
| 0 | GO:0030539 | Male Genitalia Development |
| 0 | GO:0001673 | Male Germ Cell Nucleus |
| 0 | GO:0008584 | Male Gonad Development |
| 0 | GO:0007140 | Male Meiosis |
| 0 | GO:0007141 | Male Meiosis I |
| 0 | GO:0030238 | Male Sex Determination |
| 0 | GO:0046661 | Male Sex Differentiation |
| 0 | GO:0060749 | Mammary Gland Alveolus Development |
| 0 | GO:0030879 | Mammary Gland Development |
| 0 | GO:0060603 | Mammary Gland Duct Morphogenesis |
| 0 | GO:0060644 | Mammary Gland Epithelial Cell Differentiation |
| 0 | GO:0033598 | Mammary Gland Epithelial Cell Proliferation |
| 0 | GO:0061180 | Mammary Gland Epithelium Development |
| 0 | GO:0060056 | Mammary Gland Involution |
| 0 | GO:0061377 | Mammary Gland Lobule Development |
| 0 | GO:0060443 | Mammary Gland Morphogenesis |
| 0 | GO:0030145 | Manganese Ion Binding |
| 0 | GO:0005537 | Mannose Binding |
| 0 | GO:0006013 | Mannose Metabolic Process |
| 0 | GO:0015923 | Mannosidase Activity |
| 0 | GO:0015924 | Mannosyl-Oligosaccharide Mannosidase Activity |
| 0 | GO:0000030 | Mannosyltransferase Activity |
| 0 | GO:0004707 | Map Kinase Activity |
| 0 | GO:0004708 | Map Kinase Kinase Activity |
| 0 | GO:0004709 | Map Kinase Kinase Kinase Activity |
| 0 | GO:0033549 | Map Kinase Phosphatase Activity |
| 0 | GO:0017017 | Map Kinase Tyrosine/Serine/Threonine Phosphatase Activity |
| 0 | GO:0000165 | Mapk Cascade |
| 0 | GO:0045576 | Mast Cell Activation |
| 0 | GO:0002279 | Mast Cell Activation Involved In Immune Response |
| 0 | GO:0043303 | Mast Cell Degranulation |
| 0 | GO:0002448 | Mast Cell Mediated Immunity |

| | | |
|---|------------|--|
| 0 | GO:0001893 | Maternal Placenta Development |
| 0 | GO:0060135 | Maternal Process Involved In Female Pregnancy |
| 0 | GO:0007618 | Mating |
| 1 | GO:0007617 | Mating Behavior |
| 0 | GO:0000460 | Maturation Of 5.8S Rrna |
| 0 | GO:0042490 | Mechanoreceptor Differentiation |
| 0 | GO:0016592 | Mediator Complex |
| 0 | GO:0030219 | Megakaryocyte Differentiation |
| 0 | GO:0007126 | Meiosis |
| 0 | GO:0007127 | Meiosis I |
| 0 | GO:0051321 | Meiotic Cell Cycle |
| 0 | GO:0045132 | Meiotic Chromosome Segregation |
| 0 | GO:0007128 | Meiotic Prophase I |
| 0 | GO:0006582 | Melanin Metabolic Process |
| 0 | GO:0030318 | Melanocyte Differentiation |
| 0 | GO:0042470 | Melanosome |
| 0 | GO:0032400 | Melanosome Localization |
| 0 | GO:0032438 | Melanosome Organization |
| 0 | GO:0006900 | Membrane Budding |
| 0 | GO:0030117 | Membrane Coat |
| 0 | GO:0051899 | Membrane Depolarization |
| 0 | GO:0022406 | Membrane Docking |
| 0 | GO:0061025 | Membrane Fusion |
| 0 | GO:0060081 | Membrane Hyperpolarization |
| 0 | GO:0010324 | Membrane Invagination |
| 0 | GO:0046467 | Membrane Lipid Biosynthetic Process |
| 0 | GO:0046466 | Membrane Lipid Catabolic Process |
| 0 | GO:0006643 | Membrane Lipid Metabolic Process |
| 0 | GO:0006509 | Membrane Protein Ectodomain Proteolysis |
| 0 | GO:0031293 | Membrane Protein Intracellular Domain Proteolysis |
| 0 | GO:0033619 | Membrane Protein Proteolysis |
| 0 | GO:0045121 | Membrane Raft |
| 1 | GO:0007613 | Memory |
| 0 | GO:0014031 | Mesenchymal Cell Development |
| 0 | GO:0048762 | Mesenchymal Cell Differentiation |
| 0 | GO:0010463 | Mesenchymal Cell Proliferation |
| 0 | GO:0060231 | Mesenchymal To Epithelial Transition |
| 0 | GO:0003337 | Mesenchymal To Epithelial Transition Involved In Metanephros Morphogenesis |
| 0 | GO:0060485 | Mesenchyme Development |
| 0 | GO:0072132 | Mesenchyme Morphogenesis |
| 0 | GO:0007498 | Mesoderm Development |
| 0 | GO:0001707 | Mesoderm Formation |
| 0 | GO:0048332 | Mesoderm Morphogenesis |
| 0 | GO:0048333 | Mesodermal Cell Differentiation |
| 0 | GO:0001710 | Mesodermal Cell Fate Commitment |
| 0 | GO:0007501 | Mesodermal Cell Fate Specification |
| 0 | GO:0072163 | Mesonephric Epithelium Development |
| 0 | GO:0072164 | Mesonephric Tubule Development |
| 0 | GO:0001823 | Mesonephros Development |
| 0 | GO:0051540 | Metal Cluster Binding |
| 0 | GO:0055065 | Metal Ion Homeostasis |
| 0 | GO:0046873 | Metal Ion Transmembrane Transporter Activity |
| 0 | GO:0031163 | Metallo-Sulfur Cluster Assembly |
| 0 | GO:0004181 | Metallo-carboxypeptidase Activity |
| 0 | GO:0004222 | Metallo-endopeptidase Activity |
| 0 | GO:0008191 | Metallo-endopeptidase Inhibitor Activity |

| | | |
|---|------------|--|
| 0 | GO:0048551 | Metalloenzyme Inhibitor Activity |
| 0 | GO:0010576 | Metalloenzyme Regulator Activity |
| 0 | GO:0008235 | Metalloexopeptidase Activity |
| 0 | GO:0008237 | Metallopeptidase Activity |
| 0 | GO:0072207 | Metanephric Epithelium Development |
| 0 | GO:0072224 | Metanephric Glomerulus Development |
| 0 | GO:0072075 | Metanephric Mesenchyme Development |
| 0 | GO:0072210 | Metanephric Nephron Development |
| 0 | GO:0072243 | Metanephric Nephron Epithelium Development |
| 0 | GO:0072273 | Metanephric Nephron Morphogenesis |
| 0 | GO:0072234 | Metanephric Nephron Tubule Development |
| 0 | GO:0072283 | Metanephric Renal Vesicle Morphogenesis |
| 0 | GO:0072170 | Metanephric Tubule Development |
| 0 | GO:0001656 | Metanephros Development |
| 0 | GO:0003338 | Metanephros Morphogenesis |
| 0 | GO:0051310 | Metaphase Plate Congression |
| 1 | GO:0022037 | Metencephalon Development |
| 0 | GO:0009086 | Methionine Biosynthetic Process |
| 0 | GO:0006555 | Methionine Metabolic Process |
| 0 | GO:0035064 | Methylated Histone Residue Binding |
| 0 | GO:0032259 | Methylation |
| 0 | GO:0008168 | Methyltransferase Activity |
| 0 | GO:0034708 | Methyltransferase Complex |
| 0 | GO:0042288 | Mhc Class I Protein Binding |
| 0 | GO:0042612 | Mhc Class I Protein Complex |
| 0 | GO:0032393 | Mhc Class I Receptor Activity |
| 0 | GO:0045342 | Mhc Class II Biosynthetic Process |
| 0 | GO:0042613 | Mhc Class II Protein Complex |
| 0 | GO:0042287 | Mhc Protein Binding |
| 0 | GO:0042611 | Mhc Protein Complex |
| 0 | GO:0042579 | Microbody |
| 0 | GO:0031907 | Microbody Lumen |
| 0 | GO:0031903 | Microbody Membrane |
| 0 | GO:0044438 | Microbody Part |
| 0 | GO:0000146 | Microfilament Motor Activity |
| 0 | GO:0001774 | Microglial Cell Activation |
| 0 | GO:0005792 | Microsome |
| 0 | GO:0005874 | Microtubule |
| 0 | GO:0034453 | Microtubule Anchoring |
| 0 | GO:0005875 | Microtubule Associated Complex |
| 0 | GO:0005932 | Microtubule Basal Body |
| 0 | GO:0008017 | Microtubule Binding |
| 0 | GO:0001578 | Microtubule Bundle Formation |
| 0 | GO:0000226 | Microtubule Cytoskeleton Organization |
| 0 | GO:0007019 | Microtubule Depolymerization |
| 0 | GO:0003777 | Microtubule Motor Activity |
| 0 | GO:0007020 | Microtubule Nucleation |
| 0 | GO:0005815 | Microtubule Organizing Center |
| 0 | GO:0031023 | Microtubule Organizing Center Organization |
| 0 | GO:0044450 | Microtubule Organizing Center Part |
| 0 | GO:0051010 | Microtubule Plus-End Binding |
| 0 | GO:0046785 | Microtubule Polymerization |
| 0 | GO:0031109 | Microtubule Polymerization Or Depolymerization |
| 0 | GO:0009434 | Microtubule-Based Flagellum |
| 0 | GO:0044442 | Microtubule-Based Flagellum Part |
| 0 | GO:0007018 | Microtubule-Based Movement |

| | | |
|---|------------|--|
| 0 | GO:0007017 | Microtubule-Based Process |
| 0 | GO:0010970 | Microtubule-Based Transport |
| 0 | GO:0005902 | Microvillus |
| 0 | GO:0031528 | Microvillus Membrane |
| 0 | GO:0030496 | Midbody |
| 1 | GO:0030901 | Midbrain Development |
| 1 | GO:0030917 | Midbrain-Hindbrain Boundary Development |
| 0 | GO:0042474 | Middle Ear Morphogenesis |
| 0 | GO:0007494 | Midgut Development |
| 0 | GO:0008212 | Mineralocorticoid Metabolic Process |
| 0 | GO:0006298 | Mismatch Repair |
| 0 | GO:0030983 | Mismatched Dna Binding |
| 0 | GO:0042775 | Mitochondrial Atp Synthesis Coupled Electron Transport |
| 0 | GO:0042776 | Mitochondrial Atp Synthesis Coupled Proton Transport |
| 0 | GO:0051882 | Mitochondrial Depolarization |
| 0 | GO:0006120 | Mitochondrial Electron Transport, Nadh To Ubiquinone |
| 0 | GO:0005740 | Mitochondrial Envelope |
| 0 | GO:0000266 | Mitochondrial Fission |
| 0 | GO:0000002 | Mitochondrial Genome Maintenance |
| 0 | GO:0005743 | Mitochondrial Inner Membrane |
| 0 | GO:0005758 | Mitochondrial Intermembrane Space |
| 0 | GO:0005762 | Mitochondrial Large Ribosomal Subunit |
| 0 | GO:0005759 | Mitochondrial Matrix |
| 0 | GO:0031966 | Mitochondrial Membrane |
| 0 | GO:0007006 | Mitochondrial Membrane Organization |
| 0 | GO:0044455 | Mitochondrial Membrane Part |
| 0 | GO:0042645 | Mitochondrial Nucleoid |
| 0 | GO:0005741 | Mitochondrial Outer Membrane |
| 0 | GO:0005753 | Mitochondrial Proton-Transporting Atp Synthase Complex |
| 0 | GO:0005746 | Mitochondrial Respiratory Chain |
| 0 | GO:0033108 | Mitochondrial Respiratory Chain Complex Assembly |
| 0 | GO:0005747 | Mitochondrial Respiratory Chain Complex I |
| 0 | GO:0032981 | Mitochondrial Respiratory Chain Complex I Assembly |
| 0 | GO:0097031 | Mitochondrial Respiratory Chain Complex I Biogenesis |
| 0 | GO:0005761 | Mitochondrial Ribosome |
| 0 | GO:0000959 | Mitochondrial Rna Metabolic Process |
| 0 | GO:0005763 | Mitochondrial Small Ribosomal Subunit |
| 0 | GO:0032543 | Mitochondrial Translation |
| 0 | GO:0006839 | Mitochondrial Transport |
| 0 | GO:0051646 | Mitochondrion Localization |
| 0 | GO:0007005 | Mitochondrion Organization |
| 0 | GO:0051019 | Mitogen-Activated Protein Kinase Binding |
| 0 | GO:0031434 | Mitogen-Activated Protein Kinase Kinase Binding |
| 0 | GO:0031435 | Mitogen-Activated Protein Kinase Kinase Kinase Binding |
| 0 | GO:0007067 | Mitosis |
| 0 | GO:0000090 | Mitotic Anaphase |
| 0 | GO:0007093 | Mitotic Cell Cycle Checkpoint |
| 0 | GO:0031575 | Mitotic Cell Cycle G1/S Transition Checkpoint |
| 0 | GO:0031571 | Mitotic Cell Cycle G1/S Transition Dna Damage Checkpoint |
| 0 | GO:0007094 | Mitotic Cell Cycle Spindle Assembly Checkpoint |
| 0 | GO:0071174 | Mitotic Cell Cycle Spindle Checkpoint |
| 0 | GO:0007076 | Mitotic Chromosome Condensation |
| 0 | GO:0007080 | Mitotic Metaphase Plate Congression |
| 0 | GO:0007091 | Mitotic Metaphase/Anaphase Transition |
| 0 | GO:0000236 | Mitotic Prometaphase |
| 0 | GO:0006312 | Mitotic Recombination |

| | | |
|---|------------|--|
| 0 | GO:0000070 | Mitotic Sister Chromatid Segregation |
| 0 | GO:0007052 | Mitotic Spindle Organization |
| 0 | GO:0071339 | MLL1 Complex |
| 0 | GO:0051851 | Modification By Host Of Symbiont Morphology Or Physiology |
| 0 | GO:0044003 | Modification By Symbiont Of Host Morphology Or Physiology |
| 0 | GO:0035821 | Modification Of Morphology Or Physiology Of Other Organism |
| 0 | GO:0051817 | Modification Of Morphology Or Physiology Of Other Organism Involved In Symbiotic Interaction |
| 0 | GO:0043632 | Modification-Dependent Macromolecule Catabolic Process |
| 0 | GO:0019941 | Modification-Dependent Protein Catabolic Process |
| 0 | GO:0072341 | Modified Amino Acid Binding |
| 0 | GO:0052472 | Modulation By Host Of Symbiont Transcription |
| 0 | GO:0043921 | Modulation By Host Of Viral Transcription |
| 0 | GO:0044144 | Modulation Of Growth Of Symbiont Involved In Interaction With Host |
| 0 | GO:0052312 | Modulation Of Transcription In Other Organism Involved In Symbiotic Interaction |
| 0 | GO:0042303 | Molting Cycle |
| 0 | GO:0022404 | Molting Cycle Process |
| 0 | GO:0015844 | Monoamine Transport |
| 0 | GO:0033293 | Monocarboxylic Acid Binding |
| 0 | GO:0072329 | Monocarboxylic Acid Catabolic Process |
| 0 | GO:0032787 | Monocarboxylic Acid Metabolic Process |
| 0 | GO:0008028 | Monocarboxylic Acid Transmembrane Transporter Activity |
| 0 | GO:0015718 | Monocarboxylic Acid Transport |
| 0 | GO:0002548 | Monocyte Chemotaxis |
| 0 | GO:0030224 | Monocyte Differentiation |
| 0 | GO:0071674 | Mononuclear Cell Migration |
| 0 | GO:0032943 | Mononuclear Cell Proliferation |
| 0 | GO:0004497 | Monoxygenase Activity |
| 0 | GO:0048029 | Monosaccharide Binding |
| 0 | GO:0046364 | Monosaccharide Biosynthetic Process |
| 0 | GO:0046365 | Monosaccharide Catabolic Process |
| 0 | GO:0005996 | Monosaccharide Metabolic Process |
| 0 | GO:0015145 | Monosaccharide Transmembrane Transporter Activity |
| 0 | GO:0015749 | Monosaccharide Transport |
| 0 | GO:0055067 | Monovalent Inorganic Cation Homeostasis |
| 0 | GO:0015077 | Monovalent Inorganic Cation Transmembrane Transporter Activity |
| 0 | GO:0015672 | Monovalent Inorganic Cation Transport |
| 0 | GO:0061138 | Morphogenesis Of A Branching Epithelium |
| 0 | GO:0001763 | Morphogenesis Of A Branching Structure |
| 0 | GO:0001738 | Morphogenesis Of A Polarized Epithelium |
| 0 | GO:0060572 | Morphogenesis Of An Epithelial Bud |
| 0 | GO:0060571 | Morphogenesis Of An Epithelial Fold |
| 0 | GO:0002011 | Morphogenesis Of An Epithelial Sheet |
| 0 | GO:0002009 | Morphogenesis Of An Epithelium |
| 0 | GO:0016331 | Morphogenesis Of Embryonic Epithelium |
| 0 | GO:0031514 | Motile Cilium |
| 0 | GO:0003774 | Motor Activity |
| 1 | GO:0008045 | Motor Axon Guidance |
| 0 | GO:0052192 | Movement In Environment Of Other Organism Involved In Symbiotic Interaction |
| 0 | GO:0052126 | Movement In Host Environment |
| 0 | GO:0031124 | Mrna 3'-End Processing |
| 0 | GO:0003730 | Mrna 3'-Utr Binding |
| 0 | GO:0003729 | Mrna Binding |
| 0 | GO:0006370 | Mrna Capping |
| 0 | GO:0006402 | Mrna Catabolic Process |
| 0 | GO:0006379 | Mrna Cleavage |
| 0 | GO:0005849 | Mrna Cleavage Factor Complex |

| | | |
|---|------------|--|
| 0 | GO:0006406 | Mrna Export From Nucleus |
| 0 | GO:0006378 | Mrna Polyadenylation |
| 0 | GO:0006397 | Mrna Processing |
| 0 | GO:0006376 | Mrna Splice Site Selection |
| 0 | GO:0048255 | Mrna Stabilization |
| 0 | GO:0051028 | Mrna Transport |
| 0 | GO:0035264 | Multicellular Organism Growth |
| 0 | GO:0010259 | Multicellular Organismal Aging |
| 0 | GO:0044243 | Multicellular Organismal Catabolic Process |
| 0 | GO:0048871 | Multicellular Organismal Homeostasis |
| 0 | GO:0044259 | Multicellular Organismal Macromolecule Metabolic Process |
| 0 | GO:0044236 | Multicellular Organismal Metabolic Process |
| 0 | GO:0050879 | Multicellular Organismal Movement |
| 0 | GO:0033057 | Multicellular Organismal Reproductive Behavior |
| 0 | GO:0033555 | Multicellular Organismal Response To Stress |
| 0 | GO:0050891 | Multicellular Organismal Water Homeostasis |
| 0 | GO:0005771 | Multivesicular Body |
| 0 | GO:0043500 | Muscle Adaptation |
| 0 | GO:0010657 | Muscle Cell Apoptotic Process |
| 0 | GO:0055001 | Muscle Cell Development |
| 0 | GO:0042692 | Muscle Cell Differentiation |
| 0 | GO:0042693 | Muscle Cell Fate Commitment |
| 0 | GO:0046716 | Muscle Cell Homeostasis |
| 0 | GO:0014812 | Muscle Cell Migration |
| 0 | GO:0033002 | Muscle Cell Proliferation |
| 0 | GO:0006936 | Muscle Contraction |
| 0 | GO:0048747 | Muscle Fiber Development |
| 0 | GO:0030049 | Muscle Filament Sliding |
| 0 | GO:0014896 | Muscle Hypertrophy |
| 0 | GO:0005859 | Muscle Myosin Complex |
| 0 | GO:0007517 | Muscle Organ Development |
| 0 | GO:0048644 | Muscle Organ Morphogenesis |
| 0 | GO:0061061 | Muscle Structure Development |
| 0 | GO:0003012 | Muscle System Process |
| 0 | GO:0060537 | Muscle Tissue Development |
| 0 | GO:0060415 | Muscle Tissue Morphogenesis |
| 0 | GO:0050881 | Musculoskeletal Movement |
| 0 | GO:0002755 | Myd88-Dependent Toll-Like Receptor Signaling Pathway |
| 0 | GO:0002756 | Myd88-Independent Toll-Like Receptor Signaling Pathway |
| 1 | GO:0032288 | Myelin Assembly |
| 1 | GO:0043209 | Myelin Sheath |
| 1 | GO:0042552 | Myelination |
| 1 | GO:0022011 | Myelination In Peripheral Nervous System |
| 0 | GO:0002275 | Myeloid Cell Activation Involved In Immune Response |
| 0 | GO:0033028 | Myeloid Cell Apoptotic Process |
| 0 | GO:0030099 | Myeloid Cell Differentiation |
| 0 | GO:0002262 | Myeloid Cell Homeostasis |
| 0 | GO:0001773 | Myeloid Dendritic Cell Activation |
| 0 | GO:0043011 | Myeloid Dendritic Cell Differentiation |
| 0 | GO:0002274 | Myeloid Leukocyte Activation |
| 0 | GO:0061082 | Myeloid Leukocyte Cytokine Production |
| 0 | GO:0002573 | Myeloid Leukocyte Differentiation |
| 0 | GO:0002444 | Myeloid Leukocyte Mediated Immunity |
| 0 | GO:0045445 | Myoblast Differentiation |
| 0 | GO:0007520 | Myoblast Fusion |
| 0 | GO:0030016 | Myofibril |

| | | |
|---|------------|--|
| 0 | GO:0030239 | Myofibril Assembly |
| 0 | GO:0017022 | Myosin Binding |
| 0 | GO:0016459 | Myosin Complex |
| 0 | GO:0032982 | Myosin Filament |
| 0 | GO:0016460 | Myosin II Complex |
| 0 | GO:0014902 | Myotube Differentiation |
| 0 | GO:0006044 | N-Acetylglucosamine Metabolic Process |
| 0 | GO:0008080 | N-Acetyltransferase Activity |
| 0 | GO:0016410 | N-Acyltransferase Activity |
| 0 | GO:0008170 | N-Methyltransferase Activity |
| 0 | GO:0031365 | N-Terminal Protein Amino Acid Modification |
| 0 | GO:0051287 | Nad Binding |
| 0 | GO:0009435 | Nad Biosynthetic Process |
| 0 | GO:0019674 | Nad Metabolic Process |
| 0 | GO:0017136 | Nad-Dependent Histone Deacetylase Activity |
| 0 | GO:0032041 | Nad-Dependent Histone Deacetylase Activity (H3-K14 Specific) |
| 0 | GO:0046969 | Nad-Dependent Histone Deacetylase Activity (H3-K9 Specific) |
| 0 | GO:0046970 | Nad-Dependent Histone Deacetylase Activity (H4-K16 Specific) |
| 0 | GO:0034979 | Nad-Dependent Protein Deacetylase Activity |
| 0 | GO:0003950 | Nad+ Adp-Ribosyltransferase Activity |
| 0 | GO:0070403 | Nad+ Binding |
| 0 | GO:0050136 | Nadh Dehydrogenase (Quinone) Activity |
| 0 | GO:0008137 | Nadh Dehydrogenase (Ubiquinone) Activity |
| 0 | GO:0003954 | Nadh Dehydrogenase Activity |
| 0 | GO:0030964 | Nadh Dehydrogenase Complex |
| 0 | GO:0010257 | Nadh Dehydrogenase Complex Assembly |
| 0 | GO:0050661 | Nadp Binding |
| 0 | GO:0006739 | Nadp Metabolic Process |
| 0 | GO:0006740 | Nadph Regeneration |
| 0 | GO:0030101 | Natural Killer Cell Activation |
| 0 | GO:0001779 | Natural Killer Cell Differentiation |
| 0 | GO:0042267 | Natural Killer Cell Mediated Cytotoxicity |
| 0 | GO:0002228 | Natural Killer Cell Mediated Immunity |
| 1 | GO:0071565 | Nbaf Complex |
| 0 | GO:0034661 | Ncrna Catabolic Process |
| 0 | GO:0034660 | Ncrna Metabolic Process |
| 0 | GO:0034470 | Ncrna Processing |
| 0 | GO:0070265 | Necrotic Cell Death |
| 0 | GO:0022401 | Negative Adaptation Of Signaling Pathway |
| 0 | GO:0050919 | Negative Chemotaxis |
| 0 | GO:0030835 | Negative Regulation Of Actin Filament Depolymerization |
| 0 | GO:0030837 | Negative Regulation Of Actin Filament Polymerization |
| 0 | GO:0002820 | Negative Regulation Of Adaptive Immune Response |
| 0 | GO:0002823 | Negative Regulation Of Adaptive Immune Response Based On Somatic Recombination Of Immune Receptors Built From Immunoglobulin Superfamily Domains |
| 0 | GO:0007194 | Negative Regulation Of Adenylate Cyclase Activity |
| 0 | GO:0046636 | Negative Regulation Of Alpha-Beta T Cell Activation |
| 0 | GO:0046639 | Negative Regulation Of Alpha-Beta T Cell Differentiation |
| 0 | GO:0051953 | Negative Regulation Of Amine Transport |
| 0 | GO:0060766 | Negative Regulation Of Androgen Receptor Signaling Pathway |
| 0 | GO:0016525 | Negative Regulation Of Angiogenesis |
| 0 | GO:0050858 | Negative Regulation Of Antigen Receptor-Mediated Signaling Pathway |
| 0 | GO:0048712 | Negative Regulation Of Astrocyte Differentiation |
| 1 | GO:0030517 | Negative Regulation Of Axon Extension |
| 1 | GO:0050771 | Negative Regulation Of Axonogenesis |
| 0 | GO:0050869 | Negative Regulation Of B Cell Activation |
| 0 | GO:0030889 | Negative Regulation Of B Cell Proliferation |

| | | |
|---|------------|---|
| 1 | GO:0048521 | Negative Regulation Of Behavior |
| 0 | GO:0051100 | Negative Regulation Of Binding |
| 0 | GO:0070168 | Negative Regulation Of Biomineral Tissue Development |
| 0 | GO:0030195 | Negative Regulation Of Blood Coagulation |
| 0 | GO:0045776 | Negative Regulation Of Blood Pressure |
| 0 | GO:0030514 | Negative Regulation Of Bmp Signaling Pathway |
| 0 | GO:0030502 | Negative Regulation Of Bone Mineralization |
| 0 | GO:0046851 | Negative Regulation Of Bone Remodeling |
| 0 | GO:0051926 | Negative Regulation Of Calcium Ion Transport |
| 0 | GO:0030818 | Negative Regulation Of Camp Biosynthetic Process |
| 0 | GO:0030815 | Negative Regulation Of Camp Metabolic Process |
| 0 | GO:0090090 | Negative Regulation Of Canonical Wnt Receptor Signaling Pathway |
| 0 | GO:0045912 | Negative Regulation Of Carbohydrate Metabolic Process |
| 0 | GO:0009895 | Negative Regulation Of Catabolic Process |
| 0 | GO:0043086 | Negative Regulation Of Catalytic Activity |
| 0 | GO:0050866 | Negative Regulation Of Cell Activation |
| 0 | GO:0007162 | Negative Regulation Of Cell Adhesion |
| 0 | GO:0045786 | Negative Regulation Of Cell Cycle |
| 0 | GO:0010948 | Negative Regulation Of Cell Cycle Process |
| 0 | GO:0010721 | Negative Regulation Of Cell Development |
| 0 | GO:0045596 | Negative Regulation Of Cell Differentiation |
| 0 | GO:0030308 | Negative Regulation Of Cell Growth |
| 0 | GO:0030336 | Negative Regulation Of Cell Migration |
| 0 | GO:0010771 | Negative Regulation Of Cell Morphogenesis Involved In Differentiation |
| 0 | GO:2000146 | Negative Regulation Of Cell Motility |
| 0 | GO:0031345 | Negative Regulation Of Cell Projection Organization |
| 0 | GO:0008285 | Negative Regulation Of Cell Proliferation |
| 0 | GO:0022408 | Negative Regulation Of Cell-Cell Adhesion |
| 0 | GO:0001953 | Negative Regulation Of Cell-Matrix Adhesion |
| 0 | GO:0010812 | Negative Regulation Of Cell-Substrate Adhesion |
| 0 | GO:0010677 | Negative Regulation Of Cellular Carbohydrate Metabolic Process |
| 0 | GO:0031330 | Negative Regulation Of Cellular Catabolic Process |
| 0 | GO:0051271 | Negative Regulation Of Cellular Component Movement |
| 0 | GO:0051129 | Negative Regulation Of Cellular Component Organization |
| 0 | GO:0032269 | Negative Regulation Of Cellular Protein Metabolic Process |
| 0 | GO:0050922 | Negative Regulation Of Chemotaxis |
| 0 | GO:0032331 | Negative Regulation Of Chondrocyte Differentiation |
| 0 | GO:2001251 | Negative Regulation Of Chromosome Organization |
| 0 | GO:0050819 | Negative Regulation Of Coagulation |
| 0 | GO:0031280 | Negative Regulation Of Cyclase Activity |
| 0 | GO:0030803 | Negative Regulation Of Cyclic Nucleotide Biosynthetic Process |
| 0 | GO:0030800 | Negative Regulation Of Cyclic Nucleotide Metabolic Process |
| 0 | GO:0045736 | Negative Regulation Of Cyclin-Dependent Protein Kinase Activity |
| 0 | GO:2000117 | Negative Regulation Of Cysteine-Type Endopeptidase Activity |
| 0 | GO:0043154 | Negative Regulation Of Cysteine-Type Endopeptidase Activity Involved In Apoptotic Process |
| 0 | GO:0042036 | Negative Regulation Of Cytokine Biosynthetic Process |
| 0 | GO:0001818 | Negative Regulation Of Cytokine Production |
| 0 | GO:0050710 | Negative Regulation Of Cytokine Secretion |
| 0 | GO:0001960 | Negative Regulation Of Cytokine-Mediated Signaling Pathway |
| 0 | GO:0051494 | Negative Regulation Of Cytoskeleton Organization |
| 0 | GO:0031348 | Negative Regulation Of Defense Response |
| 0 | GO:0048640 | Negative Regulation Of Developmental Growth |
| 0 | GO:0051093 | Negative Regulation Of Developmental Process |
| 0 | GO:0043392 | Negative Regulation Of Dna Binding |
| 0 | GO:0051053 | Negative Regulation Of Dna Metabolic Process |
| 0 | GO:0045910 | Negative Regulation Of Dna Recombination |

| | | |
|---|------------|---|
| 0 | GO:0008156 | Negative Regulation Of Dna Replication |
| 0 | GO:2000104 | Negative Regulation Of Dna-Dependent Dna Replication |
| 0 | GO:0045806 | Negative Regulation Of Endocytosis |
| 0 | GO:0010951 | Negative Regulation Of Endopeptidase Activity |
| 0 | GO:0010596 | Negative Regulation Of Endothelial Cell Migration |
| 0 | GO:0001937 | Negative Regulation Of Endothelial Cell Proliferation |
| 0 | GO:0042059 | Negative Regulation Of Epidermal Growth Factor Receptor Signaling Pathway |
| 0 | GO:0030857 | Negative Regulation Of Epithelial Cell Differentiation |
| 0 | GO:0050680 | Negative Regulation Of Epithelial Cell Proliferation |
| 0 | GO:0010719 | Negative Regulation Of Epithelial To Mesenchymal Transition |
| 0 | GO:0070373 | Negative Regulation Of Erk1 And Erk2 Cascade |
| 0 | GO:0045920 | Negative Regulation Of Exocytosis |
| 0 | GO:0045599 | Negative Regulation Of Fat Cell Differentiation |
| 0 | GO:0045922 | Negative Regulation Of Fatty Acid Metabolic Process |
| 0 | GO:0051918 | Negative Regulation Of Fibrinolysis |
| 0 | GO:0040037 | Negative Regulation Of Fibroblast Growth Factor Receptor Signaling Pathway |
| 0 | GO:0048147 | Negative Regulation Of Fibroblast Proliferation |
| 1 | GO:0045744 | Negative Regulation Of G-Protein Coupled Receptor Protein Signaling Pathway |
| 0 | GO:0010972 | Negative Regulation Of G2/M Transition Of Mitotic Cell Cycle |
| 0 | GO:0045814 | Negative Regulation Of Gene Expression, Epigenetic |
| 1 | GO:0045686 | Negative Regulation Of Glial Cell Differentiation |
| 1 | GO:0014014 | Negative Regulation Of Gliogenesis |
| 0 | GO:0045926 | Negative Regulation Of Growth |
| 0 | GO:0044130 | Negative Regulation Of Growth Of Symbiont In Host |
| 0 | GO:0044146 | Negative Regulation Of Growth Of Symbiont Involved In Interaction With Host |
| 0 | GO:0045822 | Negative Regulation Of Heart Contraction |
| 0 | GO:0031057 | Negative Regulation Of Histone Modification |
| 0 | GO:0032845 | Negative Regulation Of Homeostatic Process |
| 0 | GO:0046888 | Negative Regulation Of Hormone Secretion |
| 0 | GO:0051346 | Negative Regulation Of Hydrolase Activity |
| 0 | GO:0043124 | Negative Regulation Of I-KappaB Kinase/NF-KappaB Cascade |
| 0 | GO:0002698 | Negative Regulation Of Immune Effector Process |
| 0 | GO:0050777 | Negative Regulation Of Immune Response |
| 0 | GO:0002683 | Negative Regulation Of Immune System Process |
| 0 | GO:0050728 | Negative Regulation Of Inflammatory Response |
| 0 | GO:0046627 | Negative Regulation Of Insulin Receptor Signaling Pathway |
| 0 | GO:0046676 | Negative Regulation Of Insulin Secretion |
| 0 | GO:0032689 | Negative Regulation Of Interferon-Gamma Production |
| 0 | GO:0032703 | Negative Regulation Of Interleukin-2 Production |
| 0 | GO:0032715 | Negative Regulation Of Interleukin-6 Production |
| 0 | GO:0010741 | Negative Regulation Of Intracellular Protein Kinase Cascade |
| 0 | GO:0090317 | Negative Regulation Of Intracellular Protein Transport |
| 0 | GO:0033144 | Negative Regulation Of Intracellular Steroid Hormone Receptor Signaling Pathway |
| 0 | GO:0032387 | Negative Regulation Of Intracellular Transport |
| 0 | GO:0032413 | Negative Regulation Of Ion Transmembrane Transporter Activity |
| 0 | GO:0043271 | Negative Regulation Of Ion Transport |
| 0 | GO:0046426 | Negative Regulation Of Jak-Stat Cascade |
| 0 | GO:0046329 | Negative Regulation Of Jnk Cascade |
| 0 | GO:0043508 | Negative Regulation Of Jun Kinase Activity |
| 0 | GO:0033673 | Negative Regulation Of Kinase Activity |
| 0 | GO:0002695 | Negative Regulation Of Leukocyte Activation |
| 0 | GO:2000107 | Negative Regulation Of Leukocyte Apoptotic Process |
| 0 | GO:0002704 | Negative Regulation Of Leukocyte Mediated Immunity |
| 0 | GO:0070664 | Negative Regulation Of Leukocyte Proliferation |
| 0 | GO:0051352 | Negative Regulation Of Ligase Activity |
| 0 | GO:0051055 | Negative Regulation Of Lipid Biosynthetic Process |

| | | |
|---|------------|---|
| 0 | GO:0050995 | Negative Regulation Of Lipid Catabolic Process |
| 0 | GO:0045833 | Negative Regulation Of Lipid Metabolic Process |
| 0 | GO:0010888 | Negative Regulation Of Lipid Storage |
| 0 | GO:0032369 | Negative Regulation Of Lipid Transport |
| 0 | GO:0040013 | Negative Regulation Of Locomotion |
| 0 | GO:0051350 | Negative Regulation Of Lyase Activity |
| 0 | GO:0051250 | Negative Regulation Of Lymphocyte Activation |
| 0 | GO:0070229 | Negative Regulation Of Lymphocyte Apoptotic Process |
| 0 | GO:0045620 | Negative Regulation Of Lymphocyte Differentiation |
| 0 | GO:0002707 | Negative Regulation Of Lymphocyte Mediated Immunity |
| 0 | GO:0050672 | Negative Regulation Of Lymphocyte Proliferation |
| 0 | GO:0010745 | Negative Regulation Of Macrophage Derived Foam Cell Differentiation |
| 0 | GO:0043407 | Negative Regulation Of Map Kinase Activity |
| 0 | GO:0043409 | Negative Regulation Of Mapk Cascade |
| 0 | GO:0007026 | Negative Regulation Of Microtubule Depolymerization |
| 0 | GO:0031111 | Negative Regulation Of Microtubule Polymerization Or Depolymerization |
| 0 | GO:0045839 | Negative Regulation Of Mitosis |
| 0 | GO:0045930 | Negative Regulation Of Mitotic Cell Cycle |
| 0 | GO:0045841 | Negative Regulation Of Mitotic Metaphase/Anaphase Transition |
| 0 | GO:0032945 | Negative Regulation Of Mononuclear Cell Proliferation |
| 0 | GO:0032769 | Negative Regulation Of Monooxygenase Activity |
| 0 | GO:0050686 | Negative Regulation Of Mrna Processing |
| 0 | GO:0043901 | Negative Regulation Of Multi-Organism Process |
| 0 | GO:0051241 | Negative Regulation Of Multicellular Organismal Process |
| 0 | GO:0010656 | Negative Regulation Of Muscle Cell Apoptotic Process |
| 0 | GO:0051148 | Negative Regulation Of Muscle Cell Differentiation |
| 0 | GO:0045932 | Negative Regulation Of Muscle Contraction |
| 0 | GO:0048635 | Negative Regulation Of Muscle Organ Development |
| 0 | GO:0045638 | Negative Regulation Of Myeloid Cell Differentiation |
| 0 | GO:0002762 | Negative Regulation Of Myeloid Leukocyte Differentiation |
| 1 | GO:2000178 | Negative Regulation Of Neural Precursor Cell Proliferation |
| 1 | GO:0050768 | Negative Regulation Of Neurogenesis |
| 1 | GO:0031645 | Negative Regulation Of Neurological System Process |
| 1 | GO:0043524 | Negative Regulation Of Neuron Apoptotic Process |
| 1 | GO:0045665 | Negative Regulation Of Neuron Differentiation |
| 1 | GO:0010977 | Negative Regulation Of Neuron Projection Development |
| 0 | GO:0042347 | Negative Regulation Of Nf-Kappab Import Into Nucleus |
| 0 | GO:0032088 | Negative Regulation Of Nf-Kappab Transcription Factor Activity |
| 0 | GO:0045746 | Negative Regulation Of Notch Signaling Pathway |
| 0 | GO:0051784 | Negative Regulation Of Nuclear Division |
| 0 | GO:0046823 | Negative Regulation Of Nucleocytoplasmic Transport |
| 0 | GO:0030809 | Negative Regulation Of Nucleotide Biosynthetic Process |
| 0 | GO:0045980 | Negative Regulation Of Nucleotide Metabolic Process |
| 1 | GO:0048715 | Negative Regulation Of Oligodendrocyte Differentiation |
| 0 | GO:0010639 | Negative Regulation Of Organelle Organization |
| 0 | GO:0030279 | Negative Regulation Of Ossification |
| 0 | GO:0045668 | Negative Regulation Of Osteoblast Differentiation |
| 0 | GO:0045671 | Negative Regulation Of Osteoclast Differentiation |
| 0 | GO:0051354 | Negative Regulation Of Oxidoreductase Activity |
| 0 | GO:0010466 | Negative Regulation Of Peptidase Activity |
| 0 | GO:0090278 | Negative Regulation Of Peptide Hormone Secretion |
| 0 | GO:0002792 | Negative Regulation Of Peptide Secretion |
| 0 | GO:0033137 | Negative Regulation Of Peptidyl-Serine Phosphorylation |
| 0 | GO:0050732 | Negative Regulation Of Peptidyl-Tyrosine Phosphorylation |
| 0 | GO:0045936 | Negative Regulation Of Phosphate Metabolic Process |
| 0 | GO:0010563 | Negative Regulation Of Phosphorus Metabolic Process |

| | | |
|---|------------|---|
| 0 | GO:0042326 | Negative Regulation Of Phosphorylation |
| 0 | GO:0032435 | Negative Regulation Of Proteasomal Ubiquitin-Dependent Protein Catabolic Process |
| 0 | GO:0032091 | Negative Regulation Of Protein Binding |
| 0 | GO:0042177 | Negative Regulation Of Protein Catabolic Process |
| 0 | GO:0031333 | Negative Regulation Of Protein Complex Assembly |
| 0 | GO:0043242 | Negative Regulation Of Protein Complex Disassembly |
| 0 | GO:0042308 | Negative Regulation Of Protein Import Into Nucleus |
| 0 | GO:0006469 | Negative Regulation Of Protein Kinase Activity |
| 0 | GO:0051898 | Negative Regulation Of Protein Kinase B Signaling Cascade |
| 0 | GO:0051248 | Negative Regulation Of Protein Metabolic Process |
| 0 | GO:0031400 | Negative Regulation Of Protein Modification Process |
| 0 | GO:0001933 | Negative Regulation Of Protein Phosphorylation |
| 0 | GO:0032272 | Negative Regulation Of Protein Polymerization |
| 0 | GO:0050709 | Negative Regulation Of Protein Secretion |
| 0 | GO:0071901 | Negative Regulation Of Protein Serine/Threonine Kinase Activity |
| 0 | GO:0051224 | Negative Regulation Of Protein Transport |
| 0 | GO:0061099 | Negative Regulation Of Protein Tyrosine Kinase Activity |
| 0 | GO:0031397 | Negative Regulation Of Protein Ubiquitination |
| 0 | GO:0045861 | Negative Regulation Of Proteolysis |
| 0 | GO:0046580 | Negative Regulation Of Ras Protein Signal Transduction |
| 0 | GO:2000242 | Negative Regulation Of Reproductive Process |
| 0 | GO:0002832 | Negative Regulation Of Response To Biotic Stimulus |
| 0 | GO:0060761 | Negative Regulation Of Response To Cytokine Stimulus |
| 0 | GO:2001021 | Negative Regulation Of Response To Dna Damage Stimulus |
| 0 | GO:0032102 | Negative Regulation Of Response To External Stimulus |
| 0 | GO:0032105 | Negative Regulation Of Response To Extracellular Stimulus |
| 0 | GO:0032108 | Negative Regulation Of Response To Nutrient Levels |
| 0 | GO:0033119 | Negative Regulation Of Rna Splicing |
| 0 | GO:0045749 | Negative Regulation Of S Phase Of Mitotic Cell Cycle |
| 0 | GO:0051048 | Negative Regulation Of Secretion |
| 0 | GO:0043433 | Negative Regulation Of Sequence-Specific Dna Binding Transcription Factor Activity |
| 0 | GO:0051283 | Negative Regulation Of Sequestering Of Calcium Ion |
| 0 | GO:0009968 | Negative Regulation Of Signal Transduction |
| 0 | GO:0051058 | Negative Regulation Of Small Gtpase Mediated Signal Transduction |
| 0 | GO:0048662 | Negative Regulation Of Smooth Muscle Cell Proliferation |
| 0 | GO:0045879 | Negative Regulation Of Smoothened Signaling Pathway |
| 0 | GO:0010894 | Negative Regulation Of Steroid Biosynthetic Process |
| 0 | GO:0045939 | Negative Regulation Of Steroid Metabolic Process |
| 0 | GO:0070303 | Negative Regulation Of Stress-Activated Protein Kinase Signaling Cascade |
| 0 | GO:0045843 | Negative Regulation Of Striated Muscle Tissue Development |
| 1 | GO:0050805 | Negative Regulation Of Synaptic Transmission |
| 0 | GO:0003085 | Negative Regulation Of Systemic Arterial Blood Pressure |
| 0 | GO:0050868 | Negative Regulation Of T Cell Activation |
| 0 | GO:0045581 | Negative Regulation Of T Cell Differentiation |
| 0 | GO:0042130 | Negative Regulation Of T Cell Proliferation |
| 0 | GO:0050860 | Negative Regulation Of T Cell Receptor Signaling Pathway |
| 0 | GO:0034104 | Negative Regulation Of Tissue Remodeling |
| 0 | GO:0032007 | Negative Regulation Of Tor Signaling Cascade |
| 0 | GO:0042992 | Negative Regulation Of Transcription Factor Import Into Nucleus |
| 0 | GO:0000122 | Negative Regulation Of Transcription From Rna Polymerase Ii Promoter |
| 0 | GO:0051348 | Negative Regulation Of Transferase Activity |
| 0 | GO:0030512 | Negative Regulation Of Transforming Growth Factor Beta Receptor Signaling Pathway |
| 0 | GO:0017148 | Negative Regulation Of Translation |
| 0 | GO:0045947 | Negative Regulation Of Translational Initiation |
| 0 | GO:0090101 | Negative Regulation Of Transmembrane Receptor Protein Serine/Threonine Kinase Signaling Pathway |
| 0 | GO:0034763 | Negative Regulation Of Transmembrane Transport |

| | | |
|---|------------|---|
| 0 | GO:0051970 | Negative Regulation Of Transmission Of Nerve Impulse |
| 0 | GO:0051051 | Negative Regulation Of Transport |
| 0 | GO:0032410 | Negative Regulation Of Transporter Activity |
| 0 | GO:0032720 | Negative Regulation Of Tumor Necrosis Factor Production |
| 0 | GO:0032480 | Negative Regulation Of Type I Interferon Production |
| 0 | GO:0051444 | Negative Regulation Of Ubiquitin-Protein Ligase Activity |
| 0 | GO:0051436 | Negative Regulation Of Ubiquitin-Protein Ligase Activity Involved In Mitotic Cell Cycle |
| 0 | GO:0045071 | Negative Regulation Of Viral Genome Replication |
| 0 | GO:0048525 | Negative Regulation Of Viral Reproduction |
| 0 | GO:0032897 | Negative Regulation Of Viral Transcription |
| 0 | GO:0030178 | Negative Regulation Of Wnt Receptor Signaling Pathway |
| 0 | GO:0043383 | Negative T Cell Selection |
| 0 | GO:0045060 | Negative Thymic T Cell Selection |
| 0 | GO:0072006 | Nephron Development |
| 0 | GO:0072009 | Nephron Epithelium Development |
| 0 | GO:0072088 | Nephron Epithelium Morphogenesis |
| 0 | GO:0072028 | Nephron Morphogenesis |
| 0 | GO:0072080 | Nephron Tubule Development |
| 0 | GO:0072160 | Nephron Tubule Epithelial Cell Differentiation |
| 0 | GO:0072079 | Nephron Tubule Formation |
| 0 | GO:0072078 | Nephron Tubule Morphogenesis |
| 1 | GO:0021675 | Nerve Development |
| 1 | GO:0048011 | Nerve Growth Factor Receptor Signaling Pathway |
| 1 | GO:0014032 | Neural Crest Cell Development |
| 1 | GO:0014033 | Neural Crest Cell Differentiation |
| 1 | GO:0001755 | Neural Crest Cell Migration |
| 1 | GO:0001840 | Neural Plate Development |
| 1 | GO:0060896 | Neural Plate Pattern Specification |
| 1 | GO:0061351 | Neural Precursor Cell Proliferation |
| 1 | GO:0003407 | Neural Retina Development |
| 1 | GO:0001843 | Neural Tube Closure |
| 1 | GO:0021915 | Neural Tube Development |
| 1 | GO:0001841 | Neural Tube Formation |
| 1 | GO:0021532 | Neural Tube Patterning |
| 1 | GO:0007405 | Neuroblast Proliferation |
| 1 | GO:0060053 | Neurofilament Cytoskeleton |
| 1 | GO:0001976 | Neurological System Process Involved In Regulation Of Systemic Arterial Blood Pressure |
| 0 | GO:0031594 | Neuromuscular Junction |
| 0 | GO:0007528 | Neuromuscular Junction Development |
| 0 | GO:0050905 | Neuromuscular Process |
| 0 | GO:0050885 | Neuromuscular Process Controlling Balance |
| 0 | GO:0050884 | Neuromuscular Process Controlling Posture |
| 0 | GO:0007274 | Neuromuscular Synaptic Transmission |
| 1 | GO:0051402 | Neuron Apoptotic Process |
| 1 | GO:0007158 | Neuron Cell-Cell Adhesion |
| 1 | GO:0070997 | Neuron Death |
| 1 | GO:0048663 | Neuron Fate Commitment |
| 1 | GO:0048665 | Neuron Fate Specification |
| 1 | GO:0042551 | Neuron Maturation |
| 1 | GO:0001764 | Neuron Migration |
| 1 | GO:0032589 | Neuron Projection Membrane |
| 1 | GO:0031102 | Neuron Projection Regeneration |
| 1 | GO:0044306 | Neuron Projection Terminus |
| 1 | GO:0008038 | Neuron Recognition |
| 1 | GO:0044309 | Neuron Spine |
| 1 | GO:0007270 | Neuron-Neuron Synaptic Transmission |

| | | |
|---|------------|--|
| 1 | GO:0043025 | Neuronal Cell Body |
| 1 | GO:0005184 | Neuropeptide Hormone Activity |
| 1 | GO:0008188 | Neuropeptide Receptor Activity |
| 1 | GO:0071855 | Neuropeptide Receptor Binding |
| 1 | GO:0007218 | Neuropeptide Signaling Pathway |
| 1 | GO:0043526 | Neuroprotection |
| 1 | GO:0042165 | Neurotransmitter Binding |
| 1 | GO:0042136 | Neurotransmitter Biosynthetic Process |
| 1 | GO:0042133 | Neurotransmitter Metabolic Process |
| 1 | GO:0030594 | Neurotransmitter Receptor Activity |
| 1 | GO:0007269 | Neurotransmitter Secretion |
| 1 | GO:0006836 | Neurotransmitter Transport |
| 1 | GO:0005326 | Neurotransmitter Transporter Activity |
| 1 | GO:0001504 | Neurotransmitter Uptake |
| 1 | GO:0005328 | Neurotransmitter:Sodium Symporter Activity |
| 0 | GO:0015175 | Neutral Amino Acid Transmembrane Transporter Activity |
| 0 | GO:0015804 | Neutral Amino Acid Transport |
| 0 | GO:0046460 | Neutral Lipid Biosynthetic Process |
| 0 | GO:0046461 | Neutral Lipid Catabolic Process |
| 0 | GO:0006638 | Neutral Lipid Metabolic Process |
| 0 | GO:0042119 | Neutrophil Activation |
| 0 | GO:0030593 | Neutrophil Chemotaxis |
| 0 | GO:0002446 | Neutrophil Mediated Immunity |
| 0 | GO:0051059 | Nf-KappaB Binding |
| 0 | GO:0042348 | Nf-KappaB Import Into Nucleus |
| 0 | GO:0019359 | Nicotinamide Nucleotide Biosynthetic Process |
| 0 | GO:0046496 | Nicotinamide Nucleotide Metabolic Process |
| 0 | GO:0006809 | Nitric Oxide Biosynthetic Process |
| 0 | GO:0007263 | Nitric Oxide Mediated Signal Transduction |
| 0 | GO:0046209 | Nitric Oxide Metabolic Process |
| 0 | GO:0071705 | Nitrogen Compound Transport |
| 0 | GO:0071941 | Nitrogen Cycle Metabolic Process |
| 0 | GO:0006607 | Nls-Bearing Substrate Import Into Nucleus |
| 0 | GO:0035567 | Non-Canonical Wnt Receptor Signaling Pathway |
| 0 | GO:0004715 | Non-Membrane Spanning Protein Tyrosine Kinase Activity |
| 0 | GO:0000726 | Non-Recombinational Repair |
| 0 | GO:0031513 | Nonmotile Primary Cilium |
| 1 | GO:0048243 | Norepinephrine Secretion |
| 1 | GO:0015874 | Norepinephrine Transport |
| 0 | GO:0043584 | Nose Development |
| 0 | GO:0005112 | Notch Binding |
| 0 | GO:0007220 | Notch Receptor Processing |
| 0 | GO:0007219 | Notch Signaling Pathway |
| 0 | GO:0030903 | Notochord Development |
| 1 | GO:0071564 | Npbaf Complex |
| 0 | GO:0035267 | Nua4 Histone Acetyltransferase Complex |
| 0 | GO:0016604 | Nuclear Body |
| 0 | GO:0000790 | Nuclear Chromatin |
| 0 | GO:0000228 | Nuclear Chromosome |
| 0 | GO:0044454 | Nuclear Chromosome Part |
| 0 | GO:0000784 | Nuclear Chromosome, Telomeric Region |
| 0 | GO:0000280 | Nuclear Division |
| 0 | GO:0055029 | Nuclear Dna-Directed Rna Polymerase Complex |
| 0 | GO:0005635 | Nuclear Envelope |
| 0 | GO:0006998 | Nuclear Envelope Organization |
| 0 | GO:0051168 | Nuclear Export |

| | | |
|---|------------|---|
| 0 | GO:0005720 | Nuclear Heterochromatin |
| 0 | GO:0035257 | Nuclear Hormone Receptor Binding |
| 0 | GO:0051170 | Nuclear Import |
| 0 | GO:0005637 | Nuclear Inner Membrane |
| 0 | GO:0016363 | Nuclear Matrix |
| 0 | GO:0031965 | Nuclear Membrane |
| 0 | GO:0000398 | Nuclear Mrna Splicing, Via Spliceosome |
| 0 | GO:0005640 | Nuclear Outer Membrane |
| 0 | GO:0034399 | Nuclear Periphery |
| 0 | GO:0005643 | Nuclear Pore |
| 0 | GO:0043596 | Nuclear Replication Fork |
| 0 | GO:0043601 | Nuclear Replisome |
| 0 | GO:0016607 | Nuclear Speck |
| 0 | GO:0000783 | Nuclear Telomere Cap Complex |
| 0 | GO:0051169 | Nuclear Transport |
| 0 | GO:0000152 | Nuclear Ubiquitin Ligase Complex |
| 0 | GO:0000956 | Nuclear-Transcribed Mrna Catabolic Process |
| 0 | GO:0000288 | Nuclear-Transcribed Mrna Catabolic Process, Deadenylation-Dependent Decay |
| 0 | GO:0000291 | Nuclear-Transcribed Mrna Catabolic Process, Exonucleolytic |
| 0 | GO:0000184 | Nuclear-Transcribed Mrna Catabolic Process, Nonsense-Mediated Decay |
| 0 | GO:0000289 | Nuclear-Transcribed Mrna Poly(A) Tail Shortening |
| 0 | GO:0004518 | Nuclease Activity |
| 0 | GO:0090305 | Nucleic Acid Phosphodiester Bond Hydrolysis |
| 0 | GO:0050657 | Nucleic Acid Transport |
| 0 | GO:0046112 | Nucleobase Biosynthetic Process |
| 0 | GO:0009112 | Nucleobase Metabolic Process |
| 0 | GO:0015851 | Nucleobase Transport |
| 0 | GO:0034654 | Nucleobase-Containing Compound Biosynthetic Process |
| 0 | GO:0019205 | Nucleobase-Containing Compound Kinase Activity |
| 0 | GO:0015932 | Nucleobase-Containing Compound Transmembrane Transporter Activity |
| 0 | GO:0015931 | Nucleobase-Containing Compound Transport |
| 0 | GO:0015949 | Nucleobase-Containing Small Molecule Interconversion |
| 0 | GO:0006913 | Nucleocytoplasmic Transport |
| 0 | GO:0005487 | Nucleocytoplasmic Transporter Activity |
| 0 | GO:0009295 | Nucleoid |
| 0 | GO:0044452 | Nucleolar Part |
| 0 | GO:0005730 | Nucleolus |
| 0 | GO:0001882 | Nucleoside Binding |
| 0 | GO:0009163 | Nucleoside Biosynthetic Process |
| 0 | GO:0033865 | Nucleoside Bisphosphate Metabolic Process |
| 0 | GO:0009164 | Nucleoside Catabolic Process |
| 0 | GO:0009132 | Nucleoside Diphosphate Metabolic Process |
| 0 | GO:0019206 | Nucleoside Kinase Activity |
| 0 | GO:0009116 | Nucleoside Metabolic Process |
| 0 | GO:0009124 | Nucleoside Monophosphate Biosynthetic Process |
| 0 | GO:0009125 | Nucleoside Monophosphate Catabolic Process |
| 0 | GO:0009123 | Nucleoside Monophosphate Metabolic Process |
| 0 | GO:0043174 | Nucleoside Salvage |
| 0 | GO:0009142 | Nucleoside Triphosphate Biosynthetic Process |
| 0 | GO:0060589 | Nucleoside-Triphosphatase Regulator Activity |
| 0 | GO:0000786 | Nucleosome |
| 0 | GO:0006334 | Nucleosome Assembly |
| 0 | GO:0006337 | Nucleosome Disassembly |
| 0 | GO:0034728 | Nucleosome Organization |
| 0 | GO:0008252 | Nucleotidase Activity |
| 0 | GO:0009165 | Nucleotide Biosynthetic Process |

| | | |
|---|------------|--|
| 0 | GO:0019201 | Nucleotide Kinase Activity |
| 0 | GO:0046939 | Nucleotide Phosphorylation |
| 0 | GO:0016502 | Nucleotide Receptor Activity |
| 0 | GO:0035872 | Nucleotide-Binding Domain, Leucine Rich Repeat Containing Receptor Signaling Pathway |
| 0 | GO:0070423 | Nucleotide-Binding Oligomerization Domain Containing Signaling Pathway |
| 0 | GO:0006289 | Nucleotide-Excision Repair |
| 0 | GO:0000718 | Nucleotide-Excision Repair, Dna Damage Removal |
| 0 | GO:0006297 | Nucleotide-Excision Repair, Dna Gap Filling |
| 0 | GO:0009225 | Nucleotide-Sugar Metabolic Process |
| 0 | GO:0016779 | Nucleotidyltransferase Activity |
| 0 | GO:0051647 | Nucleus Localization |
| 0 | GO:0006997 | Nucleus Organization |
| 0 | GO:0031080 | Nup107-160 Complex |
| 0 | GO:0016581 | Nurd Complex |
| 0 | GO:0008374 | O-Acyltransferase Activity |
| 0 | GO:0008171 | O-Methyltransferase Activity |
| 0 | GO:0070160 | Occluding Junction |
| 0 | GO:0042476 | Odontogenesis |
| 0 | GO:0042475 | Odontogenesis Of Dentin-Containing Tooth |
| 0 | GO:0021772 | Olfactory Bulb Development |
| 0 | GO:0021889 | Olfactory Bulb Interneuron Differentiation |
| 0 | GO:0021988 | Olfactory Lobe Development |
| 0 | GO:0004984 | Olfactory Receptor Activity |
| 0 | GO:0014003 | Oligodendrocyte Development |
| 0 | GO:0048709 | Oligodendrocyte Differentiation |
| 0 | GO:0009312 | Oligosaccharide Biosynthetic Process |
| 0 | GO:0009311 | Oligosaccharide Metabolic Process |
| 0 | GO:0004576 | Oligosaccharyl Transferase Activity |
| 0 | GO:0008250 | Oligosaccharyltransferase Complex |
| 0 | GO:0008242 | Omega Peptidase Activity |
| 0 | GO:0006730 | One-Carbon Metabolic Process |
| 0 | GO:0048599 | Oocyte Development |
| 0 | GO:0009994 | Oocyte Differentiation |
| 0 | GO:0001556 | Oocyte Maturation |
| 0 | GO:0048477 | Oogenesis |
| 0 | GO:0048645 | Organ Formation |
| 0 | GO:0035265 | Organ Growth |
| 0 | GO:0001759 | Organ Induction |
| 0 | GO:0031100 | Organ Regeneration |
| 0 | GO:0000315 | Organellar Large Ribosomal Subunit |
| 0 | GO:0000313 | Organellar Ribosome |
| 0 | GO:0000314 | Organellar Small Ribosomal Subunit |
| 0 | GO:0070925 | Organelle Assembly |
| 0 | GO:0031970 | Organelle Envelope Lumen |
| 0 | GO:0048285 | Organelle Fission |
| 0 | GO:0048284 | Organelle Fusion |
| 0 | GO:0019866 | Organelle Inner Membrane |
| 0 | GO:0051640 | Organelle Localization |
| 0 | GO:0031968 | Organelle Outer Membrane |
| 0 | GO:0031984 | Organelle Subcompartment |
| 0 | GO:0072384 | Organelle Transport Along Microtubule |
| 0 | GO:0016053 | Organic Acid Biosynthetic Process |
| 0 | GO:0016054 | Organic Acid Catabolic Process |
| 0 | GO:0005342 | Organic Acid Transmembrane Transporter Activity |
| 0 | GO:0015849 | Organic Acid Transport |
| 0 | GO:0005343 | Organic Acid:Sodium Symporter Activity |

| | | |
|---|------------|---|
| 0 | GO:0015850 | Organic Alcohol Transport |
| 0 | GO:0008514 | Organic Anion Transmembrane Transporter Activity |
| 0 | GO:0015711 | Organic Anion Transport |
| 0 | GO:0015101 | Organic Cation Transmembrane Transporter Activity |
| 0 | GO:0015695 | Organic Cation Transport |
| 0 | GO:0018904 | Organic Ether Metabolic Process |
| 0 | GO:0071702 | Organic Substance Transport |
| 0 | GO:0090407 | Organophosphate Biosynthetic Process |
| 0 | GO:0046434 | Organophosphate Catabolic Process |
| 0 | GO:0019637 | Organophosphate Metabolic Process |
| 0 | GO:0001503 | Ossification |
| 0 | GO:0002076 | Osteoblast Development |
| 0 | GO:0001649 | Osteoblast Differentiation |
| 0 | GO:0033687 | Osteoblast Proliferation |
| 0 | GO:0030316 | Osteoclast Differentiation |
| 0 | GO:0071599 | Otic Vesicle Development |
| 0 | GO:0030916 | Otic Vesicle Formation |
| 0 | GO:0071600 | Otic Vesicle Morphogenesis |
| 0 | GO:0019867 | Outer Membrane |
| 0 | GO:0030288 | Outer Membrane-Bounded Periplasmic Space |
| 0 | GO:0003151 | Outflow Tract Morphogenesis |
| 0 | GO:0001541 | Ovarian Follicle Development |
| 0 | GO:0030728 | Ovulation |
| 0 | GO:0042698 | Ovulation Cycle |
| 0 | GO:0022602 | Ovulation Cycle Process |
| 0 | GO:0001542 | Ovulation From Ovarian Follicle |
| 0 | GO:0061039 | Ovum-Producing Ovary Development |
| 0 | GO:0006107 | Oxaloacetate Metabolic Process |
| 0 | GO:0006119 | Oxidative Phosphorylation |
| 0 | GO:0016675 | Oxidoreductase Activity, Acting On A Heme Group Of Donors |
| 0 | GO:0016676 | Oxidoreductase Activity, Acting On A Heme Group Of Donors, Oxygen As Acceptor |
| 0 | GO:0016667 | Oxidoreductase Activity, Acting On A Sulfur Group Of Donors |
| 0 | GO:0016725 | Oxidoreductase Activity, Acting On Ch Or Ch2 Groups |
| 0 | GO:0016614 | Oxidoreductase Activity, Acting On Ch-Oh Group Of Donors |
| 0 | GO:0016651 | Oxidoreductase Activity, Acting On Nadh Or Nadph |
| 0 | GO:0050664 | Oxidoreductase Activity, Acting On Nadh Or Nadph, Oxygen As Acceptor |
| 0 | GO:0016655 | Oxidoreductase Activity, Acting On Nadh Or Nadph, Quinone Or Similar Compound As Acceptor |
| 0 | GO:0016705 | Oxidoreductase Activity, Acting On Paired Donors, With Incorporation Or Reduction Of Molecular Oxygen |
| 0 | GO:0016706 | Oxidoreductase Activity, Acting On Paired Donors, With Incorporation Or Reduction Of Molecular Oxygen, 2-Oxoglutarate As One Donor, And Incorporation Of One Atom Each Of Oxygen Into Both Donors |
| 0 | GO:0016709 | Oxidoreductase Activity, Acting On Paired Donors, With Incorporation Or Reduction Of Molecular Oxygen, Nadh Or Nadph As One Donor, And Incorporation Of One Atom Of Oxygen |
| 0 | GO:0016712 | Oxidoreductase Activity, Acting On Paired Donors, With Incorporation Or Reduction Of Molecular Oxygen, Reduced Flavin Or Flavoprotein As One Donor, And Incorporation Of One Atom Of Oxygen |
| 0 | GO:0016684 | Oxidoreductase Activity, Acting On Peroxide As Acceptor |
| 0 | GO:0016701 | Oxidoreductase Activity, Acting On Single Donors With Incorporation Of Molecular Oxygen |
| 0 | GO:0016702 | Oxidoreductase Activity, Acting On Single Donors With Incorporation Of Molecular Oxygen, Incorporation Of Two Atoms Of Oxygen |
| 0 | GO:0016903 | Oxidoreductase Activity, Acting On The Aldehyde Or Oxo Group Of Donors |
| 0 | GO:0016624 | Oxidoreductase Activity, Acting On The Aldehyde Or Oxo Group Of Donors, Disulfide As Acceptor |
| 0 | GO:0016620 | Oxidoreductase Activity, Acting On The Aldehyde Or Oxo Group Of Donors, Nad Or Nadp As Acceptor |
| 0 | GO:0016627 | Oxidoreductase Activity, Acting On The Ch-Ch Group Of Donors |
| 0 | GO:0016628 | Oxidoreductase Activity, Acting On The Ch-Ch Group Of Donors, Nad Or Nadp As Acceptor |
| 0 | GO:0016634 | Oxidoreductase Activity, Acting On The Ch-Ch Group Of Donors, Oxygen As Acceptor |
| 0 | GO:0016645 | Oxidoreductase Activity, Acting On The Ch-Nh Group Of Donors |
| 0 | GO:0016646 | Oxidoreductase Activity, Acting On The Ch-Nh Group Of Donors, Nad Or Nadp As Acceptor |
| 0 | GO:0016638 | Oxidoreductase Activity, Acting On The Ch-Nh2 Group Of Donors |
| 0 | GO:0016641 | Oxidoreductase Activity, Acting On The Ch-Nh2 Group Of Donors, Oxygen As Acceptor |
| 0 | GO:0016616 | Oxidoreductase Activity, Acting On The Ch-Oh Group Of Donors, Nad Or Nadp As Acceptor |
| 0 | GO:0006733 | Oxidoreduction Coenzyme Metabolic Process |

| | | |
|---|------------|---|
| 0 | GO:0019825 | Oxygen Binding |
| 0 | GO:0043186 | P Granule |
| 0 | GO:0015450 | P-P-Bond-Hydrolysis-Driven Protein Transmembrane Transporter Activity |
| 0 | GO:0015405 | P-P-Bond-Hydrolysis-Driven Transmembrane Transporter Activity |
| 0 | GO:0002039 | P53 Binding |
| 0 | GO:0060021 | Palate Development |
| 1 | GO:0021543 | Pallium Development |
| 0 | GO:0016409 | Palmitoyltransferase Activity |
| 0 | GO:0031016 | Pancreas Development |
| 0 | GO:0015939 | Pantothenate Metabolic Process |
| 0 | GO:0048486 | Parasympathetic Nervous System Development |
| 0 | GO:0048339 | Paraxial Mesoderm Development |
| 0 | GO:0007567 | Parturition |
| 0 | GO:0022803 | Passive Transmembrane Transporter Activity |
| 0 | GO:0060389 | Pathway-Restricted Smad Protein Phosphorylation |
| 0 | GO:0001871 | Pattern Binding |
| 0 | GO:0008329 | Pattern Recognition Receptor Activity |
| 0 | GO:0002221 | Pattern Recognition Receptor Signaling Pathway |
| 0 | GO:0007389 | Pattern Specification Process |
| 0 | GO:0001569 | Patterning Of Blood Vessels |
| 0 | GO:0031519 | Pcg Protein Complex |
| 0 | GO:0030165 | Pdz Domain Binding |
| 0 | GO:0043084 | Penile Erection |
| 0 | GO:0019321 | Pentose Metabolic Process |
| 0 | GO:0006098 | Pentose-Phosphate Shunt |
| 0 | GO:0016504 | Peptidase Activator Activity |
| 0 | GO:0030414 | Peptidase Inhibitor Activity |
| 0 | GO:0061134 | Peptidase Regulator Activity |
| 0 | GO:0042605 | Peptide Antigen Binding |
| 0 | GO:0042277 | Peptide Binding |
| 0 | GO:0043043 | Peptide Biosynthetic Process |
| 0 | GO:0018149 | Peptide Cross-Linking |
| 0 | GO:0017046 | Peptide Hormone Binding |
| 0 | GO:0016486 | Peptide Hormone Processing |
| 0 | GO:0051428 | Peptide Hormone Receptor Binding |
| 0 | GO:0030072 | Peptide Hormone Secretion |
| 0 | GO:0006518 | Peptide Metabolic Process |
| 0 | GO:0001653 | Peptide Receptor Activity |
| 0 | GO:0002790 | Peptide Secretion |
| 0 | GO:0015833 | Peptide Transport |
| 0 | GO:0018195 | Peptidyl-Arginine Modification |
| 0 | GO:0018196 | Peptidyl-Asparagine Modification |
| 0 | GO:0018198 | Peptidyl-Cysteine Modification |
| 0 | GO:0017187 | Peptidyl-Glutamic Acid Carboxylation |
| 0 | GO:0018200 | Peptidyl-Glutamic Acid Modification |
| 0 | GO:0018202 | Peptidyl-Histidine Modification |
| 0 | GO:0018394 | Peptidyl-Lysine Acetylation |
| 0 | GO:0018022 | Peptidyl-Lysine Methylation |
| 0 | GO:0018205 | Peptidyl-Lysine Modification |
| 0 | GO:0018208 | Peptidyl-Proline Modification |
| 0 | GO:0003755 | Peptidyl-Prolyl Cis-Trans Isomerase Activity |
| 0 | GO:0018209 | Peptidyl-Serine Modification |
| 0 | GO:0018105 | Peptidyl-Serine Phosphorylation |
| 0 | GO:0018210 | Peptidyl-Threonine Modification |
| 0 | GO:0018107 | Peptidyl-Threonine Phosphorylation |
| 0 | GO:0035335 | Peptidyl-Tyrosine Dephosphorylation |

| | | |
|---|------------|--|
| 0 | GO:0018212 | Peptidyl-Tyrosine Modification |
| 0 | GO:0018108 | Peptidyl-Tyrosine Phosphorylation |
| 0 | GO:0060039 | Pericardium Development |
| 0 | GO:0000242 | Pericentriolar Material |
| 0 | GO:0043204 | Perikaryon |
| 0 | GO:0048471 | Perinuclear Region Of Cytoplasm |
| 1 | GO:0032292 | Peripheral Nervous System Axon Ensheatment |
| 1 | GO:0007422 | Peripheral Nervous System Development |
| 1 | GO:0048935 | Peripheral Nervous System Neuron Development |
| 1 | GO:0048934 | Peripheral Nervous System Neuron Differentiation |
| 0 | GO:0042597 | Periplasmic Space |
| 0 | GO:0004601 | Peroxidase Activity |
| 0 | GO:0005782 | Peroxisomal Matrix |
| 0 | GO:0005778 | Peroxisomal Membrane |
| 0 | GO:0044439 | Peroxisomal Part |
| 0 | GO:0043574 | Peroxisomal Transport |
| 0 | GO:0005777 | Peroxisome |
| 0 | GO:0007031 | Peroxisome Organization |
| 0 | GO:0045851 | Ph Reduction |
| 0 | GO:0001891 | Phagocytic Cup |
| 0 | GO:0045335 | Phagocytic Vesicle |
| 0 | GO:0030670 | Phagocytic Vesicle Membrane |
| 0 | GO:0006909 | Phagocytosis |
| 0 | GO:0006911 | Phagocytosis, Engulfment |
| 0 | GO:0060037 | Pharyngeal System Development |
| 0 | GO:0014821 | Phasic Smooth Muscle Contraction |
| 0 | GO:0018958 | Phenol-Containing Compound Metabolic Process |
| 0 | GO:0016791 | Phosphatase Activity |
| 0 | GO:0019902 | Phosphatase Binding |
| 0 | GO:0019212 | Phosphatase Inhibitor Activity |
| 0 | GO:0019208 | Phosphatase Regulator Activity |
| 0 | GO:0042301 | Phosphate Ion Binding |
| 0 | GO:0055062 | Phosphate Ion Homeostasis |
| 0 | GO:0015114 | Phosphate Ion Transmembrane Transporter Activity |
| 0 | GO:0006817 | Phosphate Ion Transport |
| 0 | GO:0008195 | Phosphatidate Phosphatase Activity |
| 0 | GO:0006656 | Phosphatidylcholine Biosynthetic Process |
| 0 | GO:0046470 | Phosphatidylcholine Metabolic Process |
| 0 | GO:0035004 | Phosphatidylinositol 3-Kinase Activity |
| 0 | GO:0043548 | Phosphatidylinositol 3-Kinase Binding |
| 0 | GO:0014065 | Phosphatidylinositol 3-Kinase Cascade |
| 0 | GO:0005942 | Phosphatidylinositol 3-Kinase Complex |
| 0 | GO:0035091 | Phosphatidylinositol Binding |
| 0 | GO:0006661 | Phosphatidylinositol Biosynthetic Process |
| 0 | GO:0034593 | Phosphatidylinositol Bisphosphate Phosphatase Activity |
| 0 | GO:0052742 | Phosphatidylinositol Kinase Activity |
| 0 | GO:0046488 | Phosphatidylinositol Metabolic Process |
| 0 | GO:0016307 | Phosphatidylinositol Phosphate Kinase Activity |
| 0 | GO:0004435 | Phosphatidylinositol Phospholipase C Activity |
| 0 | GO:0046854 | Phosphatidylinositol Phosphorylation |
| 0 | GO:0032266 | Phosphatidylinositol-3-Phosphate Binding |
| 0 | GO:0043325 | Phosphatidylinositol-3,4-Bisphosphate Binding |
| 0 | GO:0005547 | Phosphatidylinositol-3,4,5-Trisphosphate Binding |
| 0 | GO:0080025 | Phosphatidylinositol-3,5-Bisphosphate Binding |
| 0 | GO:0005546 | Phosphatidylinositol-4,5-Bisphosphate Binding |
| 0 | GO:0048015 | Phosphatidylinositol-Mediated Signaling |

| | | |
|---|------------|---|
| 0 | GO:0001786 | Phosphatidylserine Binding |
| 0 | GO:0004623 | Phospholipase A2 Activity |
| 0 | GO:0004620 | Phospholipase Activity |
| 0 | GO:0043274 | Phospholipase Binding |
| 0 | GO:0004629 | Phospholipase C Activity |
| 0 | GO:0007200 | Phospholipase C-Activating G-Protein Coupled Receptor Signaling Pathway |
| 0 | GO:0004859 | Phospholipase Inhibitor Activity |
| 0 | GO:0005543 | Phospholipid Binding |
| 0 | GO:0008654 | Phospholipid Biosynthetic Process |
| 0 | GO:0009395 | Phospholipid Catabolic Process |
| 0 | GO:0046839 | Phospholipid Dephosphorylation |
| 0 | GO:0006644 | Phospholipid Metabolic Process |
| 0 | GO:0015914 | Phospholipid Transport |
| 0 | GO:0005548 | Phospholipid Transporter Activity |
| 0 | GO:0004012 | Phospholipid-Translocating Atpase Activity |
| 0 | GO:0051219 | Phosphoprotein Binding |
| 0 | GO:0004721 | Phosphoprotein Phosphatase Activity |
| 0 | GO:0008081 | Phosphoric Diester Hydrolase Activity |
| 0 | GO:0042578 | Phosphoric Ester Hydrolase Activity |
| 0 | GO:0016849 | Phosphorus-Oxygen Lyase Activity |
| 0 | GO:0016780 | Phosphotransferase Activity, For Other Substituted Phosphate Groups |
| 0 | GO:0016775 | Phosphotransferase Activity, Nitrogenous Group As Acceptor |
| 0 | GO:0016776 | Phosphotransferase Activity, Phosphate Group As Acceptor |
| 0 | GO:0001784 | Phosphotyrosine Binding |
| 0 | GO:0009881 | Photoreceptor Activity |
| 0 | GO:0042461 | Photoreceptor Cell Development |
| 0 | GO:0046530 | Photoreceptor Cell Differentiation |
| 0 | GO:0045494 | Photoreceptor Cell Maintenance |
| 0 | GO:0032391 | Photoreceptor Connecting Cilium |
| 0 | GO:0001917 | Photoreceptor Inner Segment |
| 0 | GO:0001750 | Photoreceptor Outer Segment |
| 0 | GO:0007602 | Phototransduction |
| 0 | GO:0007603 | Phototransduction, Visible Light |
| 0 | GO:0046148 | Pigment Biosynthetic Process |
| 0 | GO:0050931 | Pigment Cell Differentiation |
| 0 | GO:0048770 | Pigment Granule |
| 0 | GO:0051875 | Pigment Granule Localization |
| 0 | GO:0048753 | Pigment Granule Organization |
| 0 | GO:0051904 | Pigment Granule Transport |
| 0 | GO:0042440 | Pigment Metabolic Process |
| 0 | GO:0043473 | Pigmentation |
| 1 | GO:0021983 | Pituitary Gland Development |
| 0 | GO:0060674 | Placenta Blood Vessel Development |
| 0 | GO:0001890 | Placenta Development |
| 0 | GO:0090179 | Planar Cell Polarity Pathway Involved In Neural Tube Closure |
| 0 | GO:0034358 | Plasma Lipoprotein Particle |
| 0 | GO:0034377 | Plasma Lipoprotein Particle Assembly |
| 0 | GO:0034381 | Plasma Lipoprotein Particle Clearance |
| 0 | GO:0071827 | Plasma Lipoprotein Particle Organization |
| 0 | GO:0034369 | Plasma Lipoprotein Particle Remodeling |
| 0 | GO:0045026 | Plasma Membrane Fusion |
| 0 | GO:0007009 | Plasma Membrane Organization |
| 0 | GO:0030168 | Platelet Activation |
| 0 | GO:0031091 | Platelet Alpha Granule |
| 0 | GO:0031093 | Platelet Alpha Granule Lumen |
| 0 | GO:0002576 | Platelet Degranulation |

| | | |
|---|------------|--|
| 0 | GO:0048407 | Platelet-Derived Growth Factor Binding |
| 0 | GO:0005161 | Platelet-Derived Growth Factor Receptor Binding |
| 0 | GO:0048008 | Platelet-Derived Growth Factor Receptor Signaling Pathway |
| 0 | GO:0016605 | Pml Body |
| 0 | GO:0045495 | Pole Plasm |
| 0 | GO:0070717 | Poly-Purine Tract Binding |
| 0 | GO:0006595 | Polyamine Metabolic Process |
| 0 | GO:0019751 | Polyol Metabolic Process |
| 0 | GO:0004653 | Polypeptide N-Acetylgalactosaminyltransferase Activity |
| 0 | GO:0030247 | Polysaccharide Binding |
| 0 | GO:0000271 | Polysaccharide Biosynthetic Process |
| 0 | GO:0000272 | Polysaccharide Catabolic Process |
| 0 | GO:0005976 | Polysaccharide Metabolic Process |
| 0 | GO:0005844 | Polysome |
| 0 | GO:0031593 | Polyubiquitin Binding |
| 0 | GO:0046930 | Pore Complex |
| 0 | GO:0006779 | Porphyrin-Containing Compound Biosynthetic Process |
| 0 | GO:0006778 | Porphyrin-Containing Compound Metabolic Process |
| 0 | GO:0050918 | Positive Chemotaxis |
| 0 | GO:0032233 | Positive Regulation Of Actin Filament Bundle Assembly |
| 0 | GO:0030838 | Positive Regulation Of Actin Filament Polymerization |
| 0 | GO:0042104 | Positive Regulation Of Activated T Cell Proliferation |
| 0 | GO:0002675 | Positive Regulation Of Acute Inflammatory Response |
| 0 | GO:0002821 | Positive Regulation Of Adaptive Immune Response |
| 0 | GO:0002824 | Positive Regulation Of Adaptive Immune Response Based On Somatic Recombination Of Immune Receptors Built From Immunoglobulin Superfamily Domains |
| 0 | GO:0045762 | Positive Regulation Of Adenylate Cyclase Activity |
| 0 | GO:0010579 | Positive Regulation Of Adenylate Cyclase Activity Involved In G-Protein Coupled Receptor Signaling Pathway |
| 0 | GO:0046635 | Positive Regulation Of Alpha-Beta T Cell Activation |
| 0 | GO:0046638 | Positive Regulation Of Alpha-Beta T Cell Differentiation |
| 0 | GO:0046641 | Positive Regulation Of Alpha-Beta T Cell Proliferation |
| 0 | GO:0051954 | Positive Regulation Of Amine Transport |
| 0 | GO:0045766 | Positive Regulation Of Angiogenesis |
| 0 | GO:0045768 | Positive Regulation Of Anti-Apoptosis |
| 0 | GO:0002579 | Positive Regulation Of Antigen Processing And Presentation |
| 0 | GO:0032781 | Positive Regulation Of Atpase Activity |
| 1 | GO:0045773 | Positive Regulation Of Axon Extension |
| 1 | GO:0050772 | Positive Regulation Of Axonogenesis |
| 0 | GO:0050871 | Positive Regulation Of B Cell Activation |
| 0 | GO:0002714 | Positive Regulation Of B Cell Mediated Immunity |
| 0 | GO:0030890 | Positive Regulation Of B Cell Proliferation |
| 1 | GO:0048520 | Positive Regulation Of Behavior |
| 0 | GO:0051099 | Positive Regulation Of Binding |
| 0 | GO:0070169 | Positive Regulation Of Biomineral Tissue Development |
| 0 | GO:0030194 | Positive Regulation Of Blood Coagulation |
| 0 | GO:0045777 | Positive Regulation Of Blood Pressure |
| 0 | GO:0043536 | Positive Regulation Of Blood Vessel Endothelial Cell Migration |
| 0 | GO:0030513 | Positive Regulation Of Bmp Signaling Pathway |
| 0 | GO:0030501 | Positive Regulation Of Bone Mineralization |
| 0 | GO:0046852 | Positive Regulation Of Bone Remodeling |
| 0 | GO:0045780 | Positive Regulation Of Bone Resorption |
| 0 | GO:0090190 | Positive Regulation Of Branching Involved In Ureteric Bud Morphogenesis |
| 0 | GO:0051928 | Positive Regulation Of Calcium Ion Transport |
| 0 | GO:0010524 | Positive Regulation Of Calcium Ion Transport Into Cytosol |
| 0 | GO:0050850 | Positive Regulation Of Calcium-Mediated Signaling |
| 0 | GO:0030819 | Positive Regulation Of Camp Biosynthetic Process |
| 0 | GO:0030816 | Positive Regulation Of Camp Metabolic Process |

| | | |
|---|------------|---|
| 0 | GO:0090263 | Positive Regulation Of Canonical Wnt Receptor Signaling Pathway |
| 0 | GO:0045913 | Positive Regulation Of Carbohydrate Metabolic Process |
| 0 | GO:0060045 | Positive Regulation Of Cardiac Muscle Cell Proliferation |
| 0 | GO:0061036 | Positive Regulation Of Cartilage Development |
| 0 | GO:0009896 | Positive Regulation Of Catabolic Process |
| 0 | GO:0033605 | Positive Regulation Of Catecholamine Secretion |
| 0 | GO:2000516 | Positive Regulation Of Cd4-Positive, Alpha-Beta T Cell Activation |
| 0 | GO:0043372 | Positive Regulation Of Cd4-Positive, Alpha-Beta T Cell Differentiation |
| 0 | GO:0050867 | Positive Regulation Of Cell Activation |
| 0 | GO:0045785 | Positive Regulation Of Cell Adhesion |
| 0 | GO:0033630 | Positive Regulation Of Cell Adhesion Mediated By Integrin |
| 0 | GO:0045787 | Positive Regulation Of Cell Cycle |
| 0 | GO:0071158 | Positive Regulation Of Cell Cycle Arrest |
| 0 | GO:0090068 | Positive Regulation Of Cell Cycle Process |
| 0 | GO:0010720 | Positive Regulation Of Cell Development |
| 0 | GO:0045597 | Positive Regulation Of Cell Differentiation |
| 0 | GO:0051781 | Positive Regulation Of Cell Division |
| 0 | GO:0030307 | Positive Regulation Of Cell Growth |
| 0 | GO:0031343 | Positive Regulation Of Cell Killing |
| 0 | GO:0030335 | Positive Regulation Of Cell Migration |
| 0 | GO:0010770 | Positive Regulation Of Cell Morphogenesis Involved In Differentiation |
| 0 | GO:2000147 | Positive Regulation Of Cell Motility |
| 0 | GO:0031346 | Positive Regulation Of Cell Projection Organization |
| 0 | GO:0022409 | Positive Regulation Of Cell-Cell Adhesion |
| 0 | GO:0001954 | Positive Regulation Of Cell-Matrix Adhesion |
| 0 | GO:0010811 | Positive Regulation Of Cell-Substrate Adhesion |
| 0 | GO:0010676 | Positive Regulation Of Cellular Carbohydrate Metabolic Process |
| 0 | GO:0031331 | Positive Regulation Of Cellular Catabolic Process |
| 0 | GO:0044089 | Positive Regulation Of Cellular Component Biogenesis |
| 0 | GO:0051272 | Positive Regulation Of Cellular Component Movement |
| 0 | GO:0051130 | Positive Regulation Of Cellular Component Organization |
| 0 | GO:0032270 | Positive Regulation Of Cellular Protein Metabolic Process |
| 0 | GO:0045080 | Positive Regulation Of Chemokine Biosynthetic Process |
| 0 | GO:0032722 | Positive Regulation Of Chemokine Production |
| 0 | GO:0050921 | Positive Regulation Of Chemotaxis |
| 0 | GO:0032376 | Positive Regulation Of Cholesterol Transport |
| 0 | GO:0032332 | Positive Regulation Of Chondrocyte Differentiation |
| 0 | GO:2001252 | Positive Regulation Of Chromosome Organization |
| 1 | GO:0042753 | Positive Regulation Of Circadian Rhythm |
| 0 | GO:0050820 | Positive Regulation Of Coagulation |
| 0 | GO:0032967 | Positive Regulation Of Collagen Biosynthetic Process |
| 0 | GO:0010714 | Positive Regulation Of Collagen Metabolic Process |
| 0 | GO:0031281 | Positive Regulation Of Cyclase Activity |
| 0 | GO:0030804 | Positive Regulation Of Cyclic Nucleotide Biosynthetic Process |
| 0 | GO:0030801 | Positive Regulation Of Cyclic Nucleotide Metabolic Process |
| 0 | GO:0045737 | Positive Regulation Of Cyclin-Dependent Protein Kinase Activity |
| 0 | GO:2001056 | Positive Regulation Of Cysteine-Type Endopeptidase Activity |
| 0 | GO:0043280 | Positive Regulation Of Cysteine-Type Endopeptidase Activity Involved In Apoptotic Process |
| 0 | GO:0042108 | Positive Regulation Of Cytokine Biosynthetic Process |
| 0 | GO:0001819 | Positive Regulation Of Cytokine Production |
| 0 | GO:0002720 | Positive Regulation Of Cytokine Production Involved In Immune Response |
| 0 | GO:0050715 | Positive Regulation Of Cytokine Secretion |
| 0 | GO:0001961 | Positive Regulation Of Cytokine-Mediated Signaling Pathway |
| 0 | GO:0032467 | Positive Regulation Of Cytokinesis |
| 0 | GO:0051495 | Positive Regulation Of Cytoskeleton Organization |
| 0 | GO:0031349 | Positive Regulation Of Defense Response |

| | | |
|---|------------|---|
| 0 | GO:0002230 | Positive Regulation Of Defense Response To Virus By Host |
| 1 | GO:0050775 | Positive Regulation Of Dendrite Morphogenesis |
| 0 | GO:0048639 | Positive Regulation Of Developmental Growth |
| 0 | GO:0043388 | Positive Regulation Of Dna Binding |
| 0 | GO:0051054 | Positive Regulation Of Dna Metabolic Process |
| 0 | GO:0045911 | Positive Regulation Of Dna Recombination |
| 0 | GO:0045739 | Positive Regulation Of Dna Repair |
| 0 | GO:0045740 | Positive Regulation Of Dna Replication |
| 0 | GO:0045807 | Positive Regulation Of Endocytosis |
| 0 | GO:0010950 | Positive Regulation Of Endopeptidase Activity |
| 0 | GO:0010595 | Positive Regulation Of Endothelial Cell Migration |
| 0 | GO:0001938 | Positive Regulation Of Endothelial Cell Proliferation |
| 0 | GO:0045742 | Positive Regulation Of Epidermal Growth Factor Receptor Signaling Pathway |
| 0 | GO:0045684 | Positive Regulation Of Epidermis Development |
| 0 | GO:0030858 | Positive Regulation Of Epithelial Cell Differentiation |
| 0 | GO:0010634 | Positive Regulation Of Epithelial Cell Migration |
| 0 | GO:0050679 | Positive Regulation Of Epithelial Cell Proliferation |
| 0 | GO:0010718 | Positive Regulation Of Epithelial To Mesenchymal Transition |
| 0 | GO:0070374 | Positive Regulation Of Erk1 And Erk2 Cascade |
| 0 | GO:0045648 | Positive Regulation Of Erythrocyte Differentiation |
| 0 | GO:0090004 | Positive Regulation Of Establishment Of Protein Localization In Plasma Membrane |
| 0 | GO:0045921 | Positive Regulation Of Exocytosis |
| 0 | GO:0045600 | Positive Regulation Of Fat Cell Differentiation |
| 0 | GO:0045723 | Positive Regulation Of Fatty Acid Biosynthetic Process |
| 0 | GO:0045923 | Positive Regulation Of Fatty Acid Metabolic Process |
| 0 | GO:0048146 | Positive Regulation Of Fibroblast Proliferation |
| 0 | GO:0051491 | Positive Regulation Of Filopodium Assembly |
| 0 | GO:0045745 | Positive Regulation Of G-Protein Coupled Receptor Protein Signaling Pathway |
| 0 | GO:0045815 | Positive Regulation Of Gene Expression, Epigenetic |
| 1 | GO:0045687 | Positive Regulation Of Glial Cell Differentiation |
| 1 | GO:0014015 | Positive Regulation Of Gliogenesis |
| 0 | GO:0046326 | Positive Regulation Of Glucose Import |
| 0 | GO:0010907 | Positive Regulation Of Glucose Metabolic Process |
| 0 | GO:0010828 | Positive Regulation Of Glucose Transport |
| 0 | GO:0045725 | Positive Regulation Of Glycogen Biosynthetic Process |
| 0 | GO:0070875 | Positive Regulation Of Glycogen Metabolic Process |
| 0 | GO:0045821 | Positive Regulation Of Glycolysis |
| 0 | GO:0045927 | Positive Regulation Of Growth |
| 0 | GO:0043547 | Positive Regulation Of Gtpase Activity |
| 0 | GO:0045823 | Positive Regulation Of Heart Contraction |
| 0 | GO:0010460 | Positive Regulation Of Heart Rate |
| 0 | GO:0031652 | Positive Regulation Of Heat Generation |
| 0 | GO:0035066 | Positive Regulation Of Histone Acetylation |
| 0 | GO:0031058 | Positive Regulation Of Histone Modification |
| 0 | GO:0032846 | Positive Regulation Of Homeostatic Process |
| 0 | GO:0046886 | Positive Regulation Of Hormone Biosynthetic Process |
| 0 | GO:0032352 | Positive Regulation Of Hormone Metabolic Process |
| 0 | GO:0046887 | Positive Regulation Of Hormone Secretion |
| 0 | GO:0002922 | Positive Regulation Of Humoral Immune Response |
| 0 | GO:0051345 | Positive Regulation Of Hydrolase Activity |
| 0 | GO:0043123 | Positive Regulation Of I-Kappab Kinase/Nf-Kappab Cascade |
| 0 | GO:0002699 | Positive Regulation Of Immune Effector Process |
| 0 | GO:0050778 | Positive Regulation Of Immune Response |
| 0 | GO:0002684 | Positive Regulation Of Immune System Process |
| 0 | GO:0002891 | Positive Regulation Of Immunoglobulin Mediated Immune Response |
| 0 | GO:0050729 | Positive Regulation Of Inflammatory Response |

| | | |
|---|------------|--|
| 0 | GO:0045089 | Positive Regulation Of Innate Immune Response |
| 0 | GO:0032024 | Positive Regulation Of Insulin Secretion |
| 0 | GO:0043568 | Positive Regulation Of Insulin-Like Growth Factor Receptor Signaling Pathway |
| 0 | GO:0032728 | Positive Regulation Of Interferon-Beta Production |
| 0 | GO:0045078 | Positive Regulation Of Interferon-Gamma Biosynthetic Process |
| 0 | GO:0032729 | Positive Regulation Of Interferon-Gamma Production |
| 0 | GO:0032731 | Positive Regulation Of Interleukin-1 Beta Production |
| 0 | GO:0050718 | Positive Regulation Of Interleukin-1 Beta Secretion |
| 0 | GO:0032732 | Positive Regulation Of Interleukin-1 Production |
| 0 | GO:0050716 | Positive Regulation Of Interleukin-1 Secretion |
| 0 | GO:0032733 | Positive Regulation Of Interleukin-10 Production |
| 0 | GO:0032735 | Positive Regulation Of Interleukin-12 Production |
| 0 | GO:0032740 | Positive Regulation Of Interleukin-17 Production |
| 0 | GO:0045086 | Positive Regulation Of Interleukin-2 Biosynthetic Process |
| 0 | GO:0032755 | Positive Regulation Of Interleukin-6 Production |
| 0 | GO:0032757 | Positive Regulation Of Interleukin-8 Production |
| 0 | GO:0010740 | Positive Regulation Of Intracellular Protein Kinase Cascade |
| 0 | GO:0090316 | Positive Regulation Of Intracellular Protein Transport |
| 0 | GO:0032388 | Positive Regulation Of Intracellular Transport |
| 0 | GO:0032414 | Positive Regulation Of Ion Transmembrane Transporter Activity |
| 0 | GO:0043270 | Positive Regulation Of Ion Transport |
| 0 | GO:0045830 | Positive Regulation Of Isotype Switching |
| 0 | GO:0046427 | Positive Regulation Of Jak-Stat Cascade |
| 0 | GO:0046330 | Positive Regulation Of Jnk Cascade |
| 0 | GO:0043507 | Positive Regulation Of Jun Kinase Activity |
| 0 | GO:0090184 | Positive Regulation Of Kidney Development |
| 0 | GO:0033674 | Positive Regulation Of Kinase Activity |
| 0 | GO:0002696 | Positive Regulation Of Leukocyte Activation |
| 0 | GO:2000108 | Positive Regulation Of Leukocyte Apoptotic Process |
| 0 | GO:0002690 | Positive Regulation Of Leukocyte Chemotaxis |
| 0 | GO:0001912 | Positive Regulation Of Leukocyte Mediated Cytotoxicity |
| 0 | GO:0002705 | Positive Regulation Of Leukocyte Mediated Immunity |
| 0 | GO:0002687 | Positive Regulation Of Leukocyte Migration |
| 0 | GO:0070665 | Positive Regulation Of Leukocyte Proliferation |
| 0 | GO:0051351 | Positive Regulation Of Ligase Activity |
| 0 | GO:0060193 | Positive Regulation Of Lipase Activity |
| 0 | GO:0046889 | Positive Regulation Of Lipid Biosynthetic Process |
| 0 | GO:0050996 | Positive Regulation Of Lipid Catabolic Process |
| 0 | GO:0090218 | Positive Regulation Of Lipid Kinase Activity |
| 0 | GO:0045834 | Positive Regulation Of Lipid Metabolic Process |
| 0 | GO:0010884 | Positive Regulation Of Lipid Storage |
| 0 | GO:0032370 | Positive Regulation Of Lipid Transport |
| 0 | GO:0040017 | Positive Regulation Of Locomotion |
| 0 | GO:0051349 | Positive Regulation Of Lyase Activity |
| 0 | GO:0051251 | Positive Regulation Of Lymphocyte Activation |
| 0 | GO:0045621 | Positive Regulation Of Lymphocyte Differentiation |
| 0 | GO:0002708 | Positive Regulation Of Lymphocyte Mediated Immunity |
| 0 | GO:0050671 | Positive Regulation Of Lymphocyte Proliferation |
| 0 | GO:0010744 | Positive Regulation Of Macrophage Derived Foam Cell Differentiation |
| 0 | GO:0043406 | Positive Regulation Of Map Kinase Activity |
| 0 | GO:0043410 | Positive Regulation Of Mapk Cascade |
| 0 | GO:0033005 | Positive Regulation Of Mast Cell Activation |
| 0 | GO:0051044 | Positive Regulation Of Membrane Protein Ectodomain Proteolysis |
| 0 | GO:0002053 | Positive Regulation Of Mesenchymal Cell Proliferation |
| 0 | GO:0031116 | Positive Regulation Of Microtubule Polymerization |
| 0 | GO:0031112 | Positive Regulation Of Microtubule Polymerization Or Depolymerization |

| | | |
|---|------------|--|
| 0 | GO:0010822 | Positive Regulation Of Mitochondrion Organization |
| 0 | GO:0045840 | Positive Regulation Of Mitosis |
| 0 | GO:0045931 | Positive Regulation Of Mitotic Cell Cycle |
| 0 | GO:0032946 | Positive Regulation Of Mononuclear Cell Proliferation |
| 0 | GO:0032770 | Positive Regulation Of Monooxygenase Activity |
| 0 | GO:0040018 | Positive Regulation Of Multicellular Organism Growth |
| 0 | GO:0044253 | Positive Regulation Of Multicellular Organismal Metabolic Process |
| 0 | GO:0051240 | Positive Regulation Of Multicellular Organismal Process |
| 0 | GO:0051149 | Positive Regulation Of Muscle Cell Differentiation |
| 0 | GO:0045933 | Positive Regulation Of Muscle Contraction |
| 0 | GO:0048636 | Positive Regulation Of Muscle Organ Development |
| 0 | GO:0045639 | Positive Regulation Of Myeloid Cell Differentiation |
| 0 | GO:0002763 | Positive Regulation Of Myeloid Leukocyte Differentiation |
| 0 | GO:0032816 | Positive Regulation Of Natural Killer Cell Activation |
| 0 | GO:0045954 | Positive Regulation Of Natural Killer Cell Mediated Cytotoxicity |
| 0 | GO:0002717 | Positive Regulation Of Natural Killer Cell Mediated Immunity |
| 1 | GO:0051962 | Positive Regulation Of Nervous System Development |
| 1 | GO:2000179 | Positive Regulation Of Neural Precursor Cell Proliferation |
| 1 | GO:0002052 | Positive Regulation Of Neuroblast Proliferation |
| 1 | GO:0050769 | Positive Regulation Of Neurogenesis |
| 1 | GO:0031646 | Positive Regulation Of Neurological System Process |
| 1 | GO:0043525 | Positive Regulation Of Neuron Apoptotic Process |
| 1 | GO:0045666 | Positive Regulation Of Neuron Differentiation |
| 1 | GO:0010976 | Positive Regulation Of Neuron Projection Development |
| 0 | GO:0090023 | Positive Regulation Of Neutrophil Chemotaxis |
| 0 | GO:0042346 | Positive Regulation Of Nf-Kappab Import Into Nucleus |
| 0 | GO:0051092 | Positive Regulation Of Nf-Kappab Transcription Factor Activity |
| 0 | GO:0045429 | Positive Regulation Of Nitric Oxide Biosynthetic Process |
| 0 | GO:0051000 | Positive Regulation Of Nitric-Oxide Synthase Activity |
| 0 | GO:0045747 | Positive Regulation Of Notch Signaling Pathway |
| 0 | GO:0051785 | Positive Regulation Of Nuclear Division |
| 0 | GO:0046824 | Positive Regulation Of Nucleocytoplasmic Transport |
| 0 | GO:0030810 | Positive Regulation Of Nucleotide Biosynthetic Process |
| 0 | GO:0045981 | Positive Regulation Of Nucleotide Metabolic Process |
| 0 | GO:0046622 | Positive Regulation Of Organ Growth |
| 0 | GO:0010638 | Positive Regulation Of Organelle Organization |
| 0 | GO:0032892 | Positive Regulation Of Organic Acid Transport |
| 0 | GO:0045778 | Positive Regulation Of Ossification |
| 0 | GO:0045669 | Positive Regulation Of Osteoblast Differentiation |
| 0 | GO:0045672 | Positive Regulation Of Osteoclast Differentiation |
| 0 | GO:0051353 | Positive Regulation Of Oxidoreductase Activity |
| 0 | GO:0010862 | Positive Regulation Of Pathway-Restricted Smad Protein Phosphorylation |
| 0 | GO:0010952 | Positive Regulation Of Peptidase Activity |
| 0 | GO:0090277 | Positive Regulation Of Peptide Hormone Secretion |
| 0 | GO:0002793 | Positive Regulation Of Peptide Secretion |
| 0 | GO:2000758 | Positive Regulation Of Peptidyl-Lysine Acetylation |
| 0 | GO:0033138 | Positive Regulation Of Peptidyl-Serine Phosphorylation |
| 0 | GO:0010800 | Positive Regulation Of Peptidyl-Threonine Phosphorylation |
| 0 | GO:0050731 | Positive Regulation Of Peptidyl-Tyrosine Phosphorylation |
| 0 | GO:0050766 | Positive Regulation Of Phagocytosis |
| 0 | GO:0010922 | Positive Regulation Of Phosphatase Activity |
| 0 | GO:0045937 | Positive Regulation Of Phosphate Metabolic Process |
| 0 | GO:0043552 | Positive Regulation Of Phosphatidylinositol 3-Kinase Activity |
| 0 | GO:0014068 | Positive Regulation Of Phosphatidylinositol 3-Kinase Cascade |
| 0 | GO:0010518 | Positive Regulation Of Phospholipase Activity |
| 0 | GO:0010863 | Positive Regulation Of Phospholipase C Activity |

| | | |
|---|------------|--|
| 0 | GO:0010562 | Positive Regulation Of Phosphorus Metabolic Process |
| 0 | GO:0042327 | Positive Regulation Of Phosphorylation |
| 0 | GO:0050927 | Positive Regulation Of Positive Chemotaxis |
| 0 | GO:0002702 | Positive Regulation Of Production Of Molecular Mediator Of Immune Response |
| 0 | GO:0032436 | Positive Regulation Of Proteasomal Ubiquitin-Dependent Protein Catabolic Process |
| 0 | GO:0031954 | Positive Regulation Of Protein Autophosphorylation |
| 0 | GO:0032092 | Positive Regulation Of Protein Binding |
| 0 | GO:0045732 | Positive Regulation Of Protein Catabolic Process |
| 0 | GO:0031334 | Positive Regulation Of Protein Complex Assembly |
| 0 | GO:0043243 | Positive Regulation Of Protein Complex Disassembly |
| 0 | GO:0090312 | Positive Regulation Of Protein Deacetylation |
| 0 | GO:0042307 | Positive Regulation Of Protein Import Into Nucleus |
| 0 | GO:0045860 | Positive Regulation Of Protein Kinase Activity |
| 0 | GO:0051897 | Positive Regulation Of Protein Kinase B Signaling Cascade |
| 0 | GO:0051247 | Positive Regulation Of Protein Metabolic Process |
| 0 | GO:0031401 | Positive Regulation Of Protein Modification Process |
| 0 | GO:0032461 | Positive Regulation Of Protein Oligomerization |
| 0 | GO:0001934 | Positive Regulation Of Protein Phosphorylation |
| 0 | GO:0032273 | Positive Regulation Of Protein Polymerization |
| 0 | GO:0050714 | Positive Regulation Of Protein Secretion |
| 0 | GO:0071902 | Positive Regulation Of Protein Serine/Threonine Kinase Activity |
| 0 | GO:0051222 | Positive Regulation Of Protein Transport |
| 0 | GO:0061098 | Positive Regulation Of Protein Tyrosine Kinase Activity |
| 0 | GO:0031398 | Positive Regulation Of Protein Ubiquitination |
| 0 | GO:0045862 | Positive Regulation Of Proteolysis |
| 0 | GO:0032855 | Positive Regulation Of Rac Gtpase Activity |
| 0 | GO:0032320 | Positive Regulation Of Ras Gtpase Activity |
| 0 | GO:0046579 | Positive Regulation Of Ras Protein Signal Transduction |
| 0 | GO:2000379 | Positive Regulation Of Reactive Oxygen Species Metabolic Process |
| 0 | GO:2000273 | Positive Regulation Of Receptor Activity |
| 0 | GO:0048260 | Positive Regulation Of Receptor-Mediated Endocytosis |
| 0 | GO:0090200 | Positive Regulation Of Release Of Cytochrome C From Mitochondria |
| 0 | GO:0051281 | Positive Regulation Of Release Of Sequestered Calcium Ion Into Cytosol |
| 0 | GO:0035815 | Positive Regulation Of Renal Sodium Excretion |
| 0 | GO:2000243 | Positive Regulation Of Reproductive Process |
| 0 | GO:0060760 | Positive Regulation Of Response To Cytokine Stimulus |
| 0 | GO:2001022 | Positive Regulation Of Response To Dna Damage Stimulus |
| 0 | GO:0032103 | Positive Regulation Of Response To External Stimulus |
| 0 | GO:0032321 | Positive Regulation Of Rho Gtpase Activity |
| 0 | GO:0051047 | Positive Regulation Of Secretion |
| 0 | GO:0051091 | Positive Regulation Of Sequence-Specific Dna Binding Transcription Factor Activity |
| 0 | GO:0048643 | Positive Regulation Of Skeletal Muscle Tissue Development |
| 0 | GO:0051057 | Positive Regulation Of Small Gtpase Mediated Signal Transduction |
| 0 | GO:0014911 | Positive Regulation Of Smooth Muscle Cell Migration |
| 0 | GO:0048661 | Positive Regulation Of Smooth Muscle Cell Proliferation |
| 0 | GO:0045987 | Positive Regulation Of Smooth Muscle Contraction |
| 0 | GO:0045880 | Positive Regulation Of Smoothed Signaling Pathway |
| 0 | GO:0010765 | Positive Regulation Of Sodium Ion Transport |
| 0 | GO:0010893 | Positive Regulation Of Steroid Biosynthetic Process |
| 0 | GO:0045940 | Positive Regulation Of Steroid Metabolic Process |
| 0 | GO:0032373 | Positive Regulation Of Sterol Transport |
| 0 | GO:0051496 | Positive Regulation Of Stress Fiber Assembly |
| 0 | GO:0032874 | Positive Regulation Of Stress-Activated Mapk Cascade |
| 0 | GO:0070304 | Positive Regulation Of Stress-Activated Protein Kinase Signaling Cascade |
| 0 | GO:0051155 | Positive Regulation Of Striated Muscle Cell Differentiation |
| 0 | GO:0045844 | Positive Regulation Of Striated Muscle Tissue Development |

| | | |
|---|------------|---|
| 0 | GO:0045885 | Positive Regulation Of Survival Gene Product Expression |
| 1 | GO:0051965 | Positive Regulation Of Synapse Assembly |
| 1 | GO:0050806 | Positive Regulation Of Synaptic Transmission |
| 0 | GO:0003084 | Positive Regulation Of Systemic Arterial Blood Pressure |
| 0 | GO:0050870 | Positive Regulation Of T Cell Activation |
| 0 | GO:0045582 | Positive Regulation Of T Cell Differentiation |
| 0 | GO:0001916 | Positive Regulation Of T Cell Mediated Cytotoxicity |
| 0 | GO:0002711 | Positive Regulation Of T Cell Mediated Immunity |
| 0 | GO:0042102 | Positive Regulation Of T Cell Proliferation |
| 0 | GO:0002827 | Positive Regulation Of T-Helper 1 Type Immune Response |
| 0 | GO:0045624 | Positive Regulation Of T-Helper Cell Differentiation |
| 0 | GO:0034105 | Positive Regulation Of Tissue Remodeling |
| 0 | GO:0032008 | Positive Regulation Of Tor Signaling Cascade |
| 0 | GO:0042993 | Positive Regulation Of Transcription Factor Import Into Nucleus |
| 0 | GO:0051347 | Positive Regulation Of Transferase Activity |
| 0 | GO:0071636 | Positive Regulation Of Transforming Growth Factor Beta Production |
| 0 | GO:0030511 | Positive Regulation Of Transforming Growth Factor Beta Receptor Signaling Pathway |
| 0 | GO:0045727 | Positive Regulation Of Translation |
| 0 | GO:0090100 | Positive Regulation Of Transmembrane Receptor Protein Serine/Threonine Kinase Signaling Pathway |
| 0 | GO:0034764 | Positive Regulation Of Transmembrane Transport |
| 0 | GO:0051971 | Positive Regulation Of Transmission Of Nerve Impulse |
| 0 | GO:0051050 | Positive Regulation Of Transport |
| 0 | GO:0032411 | Positive Regulation Of Transporter Activity |
| 0 | GO:0032760 | Positive Regulation Of Tumor Necrosis Factor Production |
| 0 | GO:0032481 | Positive Regulation Of Type I Interferon Production |
| 0 | GO:0042531 | Positive Regulation Of Tyrosine Phosphorylation Of Stat Protein |
| 0 | GO:0042517 | Positive Regulation Of Tyrosine Phosphorylation Of Stat3 Protein |
| 0 | GO:0042523 | Positive Regulation Of Tyrosine Phosphorylation Of Stat5 Protein |
| 0 | GO:0051443 | Positive Regulation Of Ubiquitin-Protein Ligase Activity |
| 0 | GO:0051437 | Positive Regulation Of Ubiquitin-Protein Ligase Activity Involved In Mitotic Cell Cycle |
| 0 | GO:0030949 | Positive Regulation Of Vascular Endothelial Growth Factor Receptor Signaling Pathway |
| 0 | GO:0045907 | Positive Regulation Of Vasoconstriction |
| 0 | GO:0045909 | Positive Regulation Of Vasodilation |
| 0 | GO:0045070 | Positive Regulation Of Viral Genome Replication |
| 0 | GO:0048524 | Positive Regulation Of Viral Reproduction |
| 0 | GO:0050434 | Positive Regulation Of Viral Transcription |
| 0 | GO:0030177 | Positive Regulation Of Wnt Receptor Signaling Pathway |
| 0 | GO:0010575 | Positive Regulation Vascular Endothelial Growth Factor Production |
| 0 | GO:0043368 | Positive T Cell Selection |
| 0 | GO:0009791 | Post-Embryonic Development |
| 0 | GO:0009886 | Post-Embryonic Morphogenesis |
| 0 | GO:0048569 | Post-Embryonic Organ Development |
| 0 | GO:0006892 | Post-Golgi Vesicle-Mediated Transport |
| 0 | GO:0043687 | Post-Translational Protein Modification |
| 0 | GO:0006301 | Postreplication Repair |
| 1 | GO:0014069 | Postsynaptic Density |
| 1 | GO:0045211 | Postsynaptic Membrane |
| 0 | GO:0016441 | Posttranscriptional Gene Silencing |
| 0 | GO:0035194 | Posttranscriptional Gene Silencing By Rna |
| 0 | GO:0010608 | Posttranscriptional Regulation Of Gene Expression |
| 1 | GO:0005267 | Potassium Channel Activity |
| 1 | GO:0034705 | Potassium Channel Complex |
| 1 | GO:0015459 | Potassium Channel Regulator Activity |
| 1 | GO:0071805 | Potassium Ion Transmembrane Transport |
| 1 | GO:0015079 | Potassium Ion Transmembrane Transporter Activity |
| 1 | GO:0006813 | Potassium Ion Transport |

| | | |
|---|------------|--|
| 0 | GO:0008556 | Potassium-Transporting Atpase Activity |
| 0 | GO:0035102 | Prc1 Complex |
| 0 | GO:0000407 | Pre-Autophagosomal Structure |
| 0 | GO:0016254 | Preassembly Of Gpi Anchor In Er Membrane |
| 0 | GO:0016272 | Prefoldin Complex |
| 0 | GO:0004659 | Prenyltransferase Activity |
| 0 | GO:0060134 | Prepulse Inhibition |
| 0 | GO:0030684 | Preribosome |
| 1 | GO:0042734 | Presynaptic Membrane |
| 0 | GO:0015399 | Primary Active Transmembrane Transporter Activity |
| 0 | GO:0072372 | Primary Cilium |
| 1 | GO:0014020 | Primary Neural Tube Formation |
| 0 | GO:0090009 | Primitive Streak Formation |
| 0 | GO:0035196 | Production Of Mirnas Involved In Gene Silencing By Mirna |
| 0 | GO:0002532 | Production Of Molecular Mediator Involved In Inflammatory Response |
| 0 | GO:0002440 | Production Of Molecular Mediator Of Immune Response |
| 0 | GO:0070918 | Production Of Small Rna Involved In Gene Silencing By Rna |
| 0 | GO:0070064 | Proline-Rich Region Binding |
| 0 | GO:0045120 | Pronucleus |
| 0 | GO:0051324 | Prophase |
| 0 | GO:0001516 | Prostaglandin Biosynthetic Process |
| 0 | GO:0006693 | Prostaglandin Metabolic Process |
| 0 | GO:0046457 | Prostanoid Biosynthetic Process |
| 0 | GO:0006692 | Prostanoid Metabolic Process |
| 0 | GO:0004954 | Prostanoid Receptor Activity |
| 0 | GO:0030850 | Prostate Gland Development |
| 0 | GO:0060740 | Prostate Gland Epithelium Morphogenesis |
| 0 | GO:0060736 | Prostate Gland Growth |
| 0 | GO:0060512 | Prostate Gland Morphogenesis |
| 0 | GO:0060525 | Prostate Glandular Acinus Development |
| 0 | GO:0002020 | Protease Binding |
| 0 | GO:0010498 | Proteasomal Protein Catabolic Process |
| 0 | GO:0043161 | Proteasomal Ubiquitin-Dependent Protein Catabolic Process |
| 0 | GO:0022624 | Proteasome Accessory Complex |
| 0 | GO:0000502 | Proteasome Complex |
| 0 | GO:0005839 | Proteasome Core Complex |
| 0 | GO:0006473 | Protein Acetylation |
| 0 | GO:0072376 | Protein Activation Cascade |
| 0 | GO:0043543 | Protein Acylation |
| 0 | GO:0006471 | Protein Adp-Ribosylation |
| 0 | GO:0008213 | Protein Alkylation |
| 0 | GO:0046777 | Protein Autophosphorylation |
| 0 | GO:0016540 | Protein Autoprocessing |
| 0 | GO:0051865 | Protein Autoubiquitination |
| 0 | GO:0000988 | Protein Binding Transcription Factor Activity |
| 0 | GO:0030674 | Protein Binding, Bridging |
| 0 | GO:0008022 | Protein C-Terminus Binding |
| 0 | GO:0018214 | Protein Carboxylation |
| 0 | GO:0030163 | Protein Catabolic Process |
| 0 | GO:0032403 | Protein Complex Binding |
| 0 | GO:0043241 | Protein Complex Disassembly |
| 0 | GO:0032947 | Protein Complex Scaffold |
| 0 | GO:0033558 | Protein Deacetylase Activity |
| 0 | GO:0006476 | Protein Deacetylation |
| 0 | GO:0035601 | Protein Deacylation |
| 0 | GO:0008214 | Protein Dealkylation |

| | | |
|---|------------|--|
| 0 | GO:0006482 | Protein Demethylation |
| 0 | GO:0006470 | Protein Dephosphorylation |
| 0 | GO:0051261 | Protein Depolymerization |
| 0 | GO:0031648 | Protein Destabilization |
| 0 | GO:0016579 | Protein Deubiquitination |
| 0 | GO:0015035 | Protein Disulfide Oxidoreductase Activity |
| 0 | GO:0006611 | Protein Export From Nucleus |
| 0 | GO:0006457 | Protein Folding |
| 0 | GO:0006486 | Protein Glycosylation |
| 0 | GO:0046982 | Protein Heterodimerization Activity |
| 0 | GO:0051291 | Protein Heterooligomerization |
| 0 | GO:0004673 | Protein Histidine Kinase Activity |
| 0 | GO:0042803 | Protein Homodimerization Activity |
| 0 | GO:0051260 | Protein Homooligomerization |
| 0 | GO:0051289 | Protein Homotetramerization |
| 0 | GO:0070207 | Protein Homotrimerization |
| 0 | GO:0017038 | Protein Import |
| 0 | GO:0006606 | Protein Import Into Nucleus |
| 0 | GO:0000060 | Protein Import Into Nucleus, Translocation |
| 0 | GO:0016558 | Protein Import Into Peroxisome Matrix |
| 0 | GO:0051205 | Protein Insertion Into Membrane |
| 0 | GO:0070979 | Protein K11-Linked Ubiquitination |
| 0 | GO:0071108 | Protein K48-Linked Deubiquitination |
| 0 | GO:0070936 | Protein K48-Linked Ubiquitination |
| 0 | GO:0070536 | Protein K63-Linked Deubiquitination |
| 0 | GO:0070534 | Protein K63-Linked Ubiquitination |
| 0 | GO:0051018 | Protein Kinase A Binding |
| 0 | GO:0010737 | Protein Kinase A Signaling Cascade |
| 0 | GO:0030295 | Protein Kinase Activator Activity |
| 0 | GO:0043491 | Protein Kinase B Signaling Cascade |
| 0 | GO:0019901 | Protein Kinase Binding |
| 0 | GO:0004697 | Protein Kinase C Activity |
| 0 | GO:0005080 | Protein Kinase C Binding |
| 0 | GO:0070528 | Protein Kinase C Signaling Cascade |
| 0 | GO:0007205 | Protein Kinase C-Activating G-Protein Coupled Receptor Signaling Pathway |
| 0 | GO:0004860 | Protein Kinase Inhibitor Activity |
| 0 | GO:0019887 | Protein Kinase Regulator Activity |
| 0 | GO:0006497 | Protein Lipidation |
| 0 | GO:0034394 | Protein Localization At Cell Surface |
| 0 | GO:0070972 | Protein Localization In Endoplasmic Reticulum |
| 0 | GO:0034067 | Protein Localization In Golgi Apparatus |
| 0 | GO:0072657 | Protein Localization In Membrane |
| 0 | GO:0070585 | Protein Localization In Mitochondrion |
| 0 | GO:0072659 | Protein Localization In Plasma Membrane |
| 0 | GO:0034502 | Protein Localization To Chromosome |
| 0 | GO:0034504 | Protein Localization To Nucleus |
| 0 | GO:0033365 | Protein Localization To Organelle |
| 0 | GO:0072662 | Protein Localization To Peroxisome |
| 0 | GO:0051604 | Protein Maturation |
| 0 | GO:0006479 | Protein Methylation |
| 0 | GO:0008276 | Protein Methyltransferase Activity |
| 0 | GO:0032446 | Protein Modification By Small Protein Conjugation |
| 0 | GO:0070647 | Protein Modification By Small Protein Conjugation Or Removal |
| 0 | GO:0070646 | Protein Modification By Small Protein Removal |
| 0 | GO:0006513 | Protein Monoubiquitination |
| 0 | GO:0006487 | Protein N-Linked Glycosylation |

| | | |
|---|------------|--|
| 0 | GO:0018279 | Protein N-Linked Glycosylation Via Asparagine |
| 0 | GO:0047485 | Protein N-Terminus Binding |
| 0 | GO:0006493 | Protein O-Linked Glycosylation |
| 0 | GO:0051259 | Protein Oligomerization |
| 0 | GO:0018345 | Protein Palmitoylation |
| 0 | GO:0000413 | Protein Peptidyl-Prolyl Isomerization |
| 0 | GO:0051721 | Protein Phosphatase 2A Binding |
| 0 | GO:0019903 | Protein Phosphatase Binding |
| 0 | GO:0004864 | Protein Phosphatase Inhibitor Activity |
| 0 | GO:0019888 | Protein Phosphatase Regulator Activity |
| 0 | GO:0000159 | Protein Phosphatase Type 2A Complex |
| 0 | GO:0008601 | Protein Phosphatase Type 2A Regulator Activity |
| 0 | GO:0045309 | Protein Phosphorylated Amino Acid Binding |
| 0 | GO:0051258 | Protein Polymerization |
| 0 | GO:0000209 | Protein Polyubiquitination |
| 0 | GO:0016485 | Protein Processing |
| 0 | GO:0042026 | Protein Refolding |
| 0 | GO:0009306 | Protein Secretion |
| 0 | GO:0043621 | Protein Self-Association |
| 0 | GO:0030291 | Protein Serine/Threonine Kinase Inhibitor Activity |
| 0 | GO:0004722 | Protein Serine/Threonine Phosphatase Activity |
| 0 | GO:0008287 | Protein Serine/Threonine Phosphatase Complex |
| 0 | GO:0004712 | Protein Serine/Threonine/Tyrosine Kinase Activity |
| 0 | GO:0050821 | Protein Stabilization |
| 0 | GO:0016925 | Protein Sumoylation |
| 0 | GO:0006605 | Protein Targeting |
| 0 | GO:0006612 | Protein Targeting To Membrane |
| 0 | GO:0006626 | Protein Targeting To Mitochondrion |
| 0 | GO:0006625 | Protein Targeting To Peroxisome |
| 0 | GO:0051262 | Protein Tetramerization |
| 0 | GO:0008320 | Protein Transmembrane Transporter Activity |
| 0 | GO:0008565 | Protein Transporter Activity |
| 0 | GO:0070206 | Protein Trimerization |
| 0 | GO:0030296 | Protein Tyrosine Kinase Activator Activity |
| 0 | GO:0004713 | Protein Tyrosine Kinase Activity |
| 0 | GO:0004725 | Protein Tyrosine Phosphatase Activity |
| 0 | GO:0008138 | Protein Tyrosine/Serine/Threonine Phosphatase Activity |
| 0 | GO:0016567 | Protein Ubiquitination |
| 0 | GO:0042787 | Protein Ubiquitination Involved In Ubiquitin-Dependent Protein Catabolic Process |
| 0 | GO:0018298 | Protein-Chromophore Linkage |
| 0 | GO:0032993 | Protein-Dna Complex |
| 0 | GO:0065004 | Protein-Dna Complex Assembly |
| 0 | GO:0032986 | Protein-Dna Complex Disassembly |
| 0 | GO:0071824 | Protein-Dna Complex Subunit Organization |
| 0 | GO:0016500 | Protein-Hormone Receptor Activity |
| 0 | GO:0032994 | Protein-Lipid Complex |
| 0 | GO:0065005 | Protein-Lipid Complex Assembly |
| 0 | GO:0071814 | Protein-Lipid Complex Binding |
| 0 | GO:0034368 | Protein-Lipid Complex Remodeling |
| 0 | GO:0071825 | Protein-Lipid Complex Subunit Organization |
| 0 | GO:0016279 | Protein-Lysine N-Methyltransferase Activity |
| 0 | GO:0005578 | Proteinaceous Extracellular Matrix |
| 0 | GO:0043394 | Proteoglycan Binding |
| 0 | GO:0030166 | Proteoglycan Biosynthetic Process |
| 0 | GO:0006029 | Proteoglycan Metabolic Process |
| 0 | GO:0051603 | Proteolysis Involved In Cellular Protein Catabolic Process |

| | | |
|---|------------|---|
| 0 | GO:0015992 | Proton Transport |
| 0 | GO:0045259 | Proton-Transporting Atp Synthase Complex |
| 0 | GO:0045263 | Proton-Transporting Atp Synthase Complex, Coupling Factor F(O) |
| 0 | GO:0046961 | Proton-Transporting Atpase Activity, Rotational Mechanism |
| 0 | GO:0016469 | Proton-Transporting Two-Sector Atpase Complex |
| 0 | GO:0033178 | Proton-Transporting Two-Sector Atpase Complex, Catalytic Domain |
| 0 | GO:0033177 | Proton-Transporting Two-Sector Atpase Complex, Proton-Transporting Domain |
| 0 | GO:0033176 | Proton-Transporting V-Type Atpase Complex |
| 0 | GO:0033180 | Proton-Transporting V-Type Atpase, V1 Domain |
| 0 | GO:0009954 | Proximal/Distal Pattern Formation |
| 0 | GO:0031143 | Pseudopodium |
| 0 | GO:0031269 | Pseudopodium Assembly |
| 0 | GO:0031268 | Pseudopodium Organization |
| 0 | GO:0009982 | Pseudouridine Synthase Activity |
| 0 | GO:0001522 | Pseudouridine Synthesis |
| 0 | GO:0042559 | Pteridine-Containing Compound Biosynthetic Process |
| 0 | GO:0042558 | Pteridine-Containing Compound Metabolic Process |
| 0 | GO:0009113 | Purine Base Biosynthetic Process |
| 0 | GO:0006144 | Purine Base Metabolic Process |
| 0 | GO:0070035 | Purine Ntp-Dependent Helicase Activity |
| 0 | GO:0042451 | Purine Nucleoside Biosynthetic Process |
| 0 | GO:0034032 | Purine Nucleoside Bisphosphate Metabolic Process |
| 0 | GO:0042278 | Purine Nucleoside Metabolic Process |
| 0 | GO:0009127 | Purine Nucleoside Monophosphate Biosynthetic Process |
| 0 | GO:0009126 | Purine Nucleoside Monophosphate Metabolic Process |
| 0 | GO:0009145 | Purine Nucleoside Triphosphate Biosynthetic Process |
| 0 | GO:0006164 | Purine Nucleotide Biosynthetic Process |
| 0 | GO:0046129 | Purine Ribonucleoside Biosynthetic Process |
| 0 | GO:0034035 | Purine Ribonucleoside Bisphosphate Metabolic Process |
| 0 | GO:0046128 | Purine Ribonucleoside Metabolic Process |
| 0 | GO:0009168 | Purine Ribonucleoside Monophosphate Biosynthetic Process |
| 0 | GO:0009167 | Purine Ribonucleoside Monophosphate Metabolic Process |
| 0 | GO:0009206 | Purine Ribonucleoside Triphosphate Biosynthetic Process |
| 0 | GO:0009152 | Purine Ribonucleotide Biosynthetic Process |
| 0 | GO:0072522 | Purine-Containing Compound Biosynthetic Process |
| 0 | GO:0043101 | Purine-Containing Compound Salvage |
| 0 | GO:0072530 | Purine-Containing Compound Transmembrane Transport |
| 1 | GO:0001614 | Purinergic Nucleotide Receptor Activity |
| 1 | GO:0035586 | Purinergic Receptor Activity |
| 1 | GO:0035587 | Purinergic Receptor Signaling Pathway |
| 0 | GO:0019363 | Pyridine Nucleotide Biosynthetic Process |
| 0 | GO:0019362 | Pyridine Nucleotide Metabolic Process |
| 0 | GO:0072525 | Pyridine-Containing Compound Biosynthetic Process |
| 0 | GO:0072524 | Pyridine-Containing Compound Metabolic Process |
| 0 | GO:0030170 | Pyridoxal Phosphate Binding |
| 0 | GO:0006206 | Pyrimidine Base Metabolic Process |
| 0 | GO:0009219 | Pyrimidine Deoxyribonucleotide Metabolic Process |
| 0 | GO:0046134 | Pyrimidine Nucleoside Biosynthetic Process |
| 0 | GO:0046135 | Pyrimidine Nucleoside Catabolic Process |
| 0 | GO:0006213 | Pyrimidine Nucleoside Metabolic Process |
| 0 | GO:0009148 | Pyrimidine Nucleoside Triphosphate Biosynthetic Process |
| 0 | GO:0009147 | Pyrimidine Nucleoside Triphosphate Metabolic Process |
| 0 | GO:0006221 | Pyrimidine Nucleotide Biosynthetic Process |
| 0 | GO:0006220 | Pyrimidine Nucleotide Metabolic Process |
| 0 | GO:0046131 | Pyrimidine Ribonucleoside Metabolic Process |
| 0 | GO:0009220 | Pyrimidine Ribonucleotide Biosynthetic Process |

| | | |
|---|------------|---|
| 0 | GO:0009218 | Pyrimidine Ribonucleotide Metabolic Process |
| 0 | GO:0072528 | Pyrimidine-Containing Compound Biosynthetic Process |
| 0 | GO:0072529 | Pyrimidine-Containing Compound Catabolic Process |
| 0 | GO:0072527 | Pyrimidine-Containing Compound Metabolic Process |
| 0 | GO:0072531 | Pyrimidine-Containing Compound Transmembrane Transport |
| 0 | GO:0006090 | Pyruvate Metabolic Process |
| 0 | GO:0050997 | Quaternary Ammonium Group Binding |
| 0 | GO:0015697 | Quaternary Ammonium Group Transport |
| 0 | GO:0048038 | Quinone Binding |
| 0 | GO:0042375 | Quinone Cofactor Metabolic Process |
| 0 | GO:0070412 | R-Smad Binding |
| 0 | GO:0005097 | Rab Gtpase Activator Activity |
| 0 | GO:0017137 | Rab Gtpase Binding |
| 0 | GO:0030675 | Rac Gtpase Activator Activity |
| 0 | GO:0048365 | Rac Gtpase Binding |
| 0 | GO:0016601 | Rac Protein Signal Transduction |
| 0 | GO:0016854 | Racemase And Epimerase Activity |
| 0 | GO:0008536 | Ran Gtpase Binding |
| 0 | GO:0005099 | Ras Gtpase Activator Activity |
| 0 | GO:0017016 | Ras Gtpase Binding |
| 0 | GO:0005088 | Ras Guanyl-Nucleotide Exchange Factor Activity |
| 0 | GO:0007265 | Ras Protein Signal Transduction |
| 0 | GO:0072593 | Reactive Oxygen Species Metabolic Process |
| 0 | GO:0030546 | Receptor Activator Activity |
| 0 | GO:0048019 | Receptor Antagonist Activity |
| 0 | GO:0032800 | Receptor Biosynthetic Process |
| 0 | GO:0043113 | Receptor Clustering |
| 0 | GO:0043235 | Receptor Complex |
| 0 | GO:0007168 | Receptor Guanylyl Cyclase Signaling Pathway |
| 0 | GO:0030547 | Receptor Inhibitor Activity |
| 0 | GO:0031623 | Receptor Internalization |
| 0 | GO:0043112 | Receptor Metabolic Process |
| 0 | GO:0001881 | Receptor Recycling |
| 0 | GO:0030545 | Receptor Regulator Activity |
| 0 | GO:0030159 | Receptor Signaling Complex Scaffold Activity |
| 0 | GO:0005057 | Receptor Signaling Protein Activity |
| 0 | GO:0004702 | Receptor Signaling Protein Serine/Threonine Kinase Activity |
| 0 | GO:0004716 | Receptor Signaling Protein Tyrosine Kinase Activity |
| 0 | GO:0030971 | Receptor Tyrosine Kinase Binding |
| 0 | GO:0006898 | Receptor-Mediated Endocytosis |
| 0 | GO:0035825 | Reciprocal Dna Recombination |
| 0 | GO:0007131 | Reciprocal Meiotic Recombination |
| 0 | GO:0000725 | Recombinational Repair |
| 0 | GO:0055037 | Recycling Endosome |
| 0 | GO:0055038 | Recycling Endosome Membrane |
| 0 | GO:0060004 | Reflex |
| 0 | GO:0031099 | Regeneration |
| 0 | GO:0003002 | Regionalization |
| 0 | GO:0045055 | Regulated Secretory Pathway |
| 0 | GO:0010510 | Regulation Of Acetyl-CoA Biosynthetic Process From Pyruvate |
| 0 | GO:0032956 | Regulation Of Actin Cytoskeleton Organization |
| 0 | GO:0032231 | Regulation Of Actin Filament Bundle Assembly |
| 0 | GO:0030834 | Regulation Of Actin Filament Depolymerization |
| 0 | GO:0030832 | Regulation Of Actin Filament Length |
| 0 | GO:0030833 | Regulation Of Actin Filament Polymerization |
| 0 | GO:0032970 | Regulation Of Actin Filament-Based Process |

| | | |
|---|------------|---|
| 0 | GO:0008064 | Regulation Of Actin Polymerization Or Depolymerization |
| 1 | GO:0001508 | Regulation Of Action Potential |
| 1 | GO:0019228 | Regulation Of Action Potential In Neuron |
| 0 | GO:0046006 | Regulation Of Activated T Cell Proliferation |
| 0 | GO:0032925 | Regulation Of Activin Receptor Signaling Pathway |
| 0 | GO:0002673 | Regulation Of Acute Inflammatory Response |
| 0 | GO:0002819 | Regulation Of Adaptive Immune Response |
| 0 | GO:0002822 | Regulation Of Adaptive Immune Response Based On Somatic Recombination Of Immune Receptors Built From Immunoglobulin Superfamily Domains |
| 0 | GO:0045761 | Regulation Of Adenylate Cyclase Activity |
| 0 | GO:0010578 | Regulation Of Adenylate Cyclase Activity Involved In G-Protein Coupled Receptor Signaling Pathway |
| 1 | GO:2000311 | Regulation Of Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionate Selective Glutamate Receptor Activity |
| 0 | GO:0046634 | Regulation Of Alpha-Beta T Cell Activation |
| 0 | GO:0046637 | Regulation Of Alpha-Beta T Cell Differentiation |
| 0 | GO:0046640 | Regulation Of Alpha-Beta T Cell Proliferation |
| 0 | GO:0000381 | Regulation Of Alternative Nuclear Mrna Splicing, Via Spliceosome |
| 0 | GO:0051952 | Regulation Of Amine Transport |
| 0 | GO:0051955 | Regulation Of Amino Acid Transport |
| 0 | GO:0022603 | Regulation Of Anatomical Structure Morphogenesis |
| 0 | GO:0090066 | Regulation Of Anatomical Structure Size |
| 0 | GO:0060765 | Regulation Of Androgen Receptor Signaling Pathway |
| 0 | GO:0045765 | Regulation Of Angiogenesis |
| 0 | GO:0044070 | Regulation Of Anion Transport |
| 0 | GO:0045767 | Regulation Of Anti-Apoptosis |
| 0 | GO:0002577 | Regulation Of Antigen Processing And Presentation |
| 0 | GO:0050854 | Regulation Of Antigen Receptor-Mediated Signaling Pathway |
| 0 | GO:0032098 | Regulation Of Appetite |
| 0 | GO:0032312 | Regulation Of Arf Gtpase Activity |
| 0 | GO:0032012 | Regulation Of Arf Protein Signal Transduction |
| 0 | GO:0048710 | Regulation Of Astrocyte Differentiation |
| 0 | GO:0043462 | Regulation Of Atpase Activity |
| 0 | GO:0010506 | Regulation Of Autophagy |
| 1 | GO:0030516 | Regulation Of Axon Extension |
| 1 | GO:0048841 | Regulation Of Axon Extension Involved In Axon Guidance |
| 1 | GO:0048679 | Regulation Of Axon Regeneration |
| 1 | GO:0050770 | Regulation Of Axonogenesis |
| 0 | GO:0050864 | Regulation Of B Cell Activation |
| 0 | GO:0002902 | Regulation Of B Cell Apoptotic Process |
| 0 | GO:0045577 | Regulation Of B Cell Differentiation |
| 0 | GO:0002712 | Regulation Of B Cell Mediated Immunity |
| 0 | GO:0030888 | Regulation Of B Cell Proliferation |
| 1 | GO:0050795 | Regulation Of Behavior |
| 0 | GO:0051098 | Regulation Of Binding |
| 0 | GO:0070167 | Regulation Of Biomineral Tissue Development |
| 0 | GO:0030193 | Regulation Of Blood Coagulation |
| 0 | GO:0008217 | Regulation Of Blood Pressure |
| 0 | GO:0043535 | Regulation Of Blood Vessel Endothelial Cell Migration |
| 0 | GO:0050880 | Regulation Of Blood Vessel Size |
| 0 | GO:0002016 | Regulation Of Blood Volume By Renin-Angiotensin |
| 0 | GO:0030510 | Regulation Of Bmp Signaling Pathway |
| 0 | GO:0030500 | Regulation Of Bone Mineralization |
| 0 | GO:0046850 | Regulation Of Bone Remodeling |
| 0 | GO:0045124 | Regulation Of Bone Resorption |
| 0 | GO:0090189 | Regulation Of Branching Involved In Ureteric Bud Morphogenesis |
| 0 | GO:0051924 | Regulation Of Calcium Ion Transport |
| 0 | GO:0010522 | Regulation Of Calcium Ion Transport Into Cytosol |
| 1 | GO:0051925 | Regulation Of Calcium Ion Transport Via Voltage-Gated Calcium Channel Activity |

| | | |
|---|------------|---|
| 1 | GO:0017158 | Regulation Of Calcium Ion-Dependent Exocytosis |
| 1 | GO:0050848 | Regulation Of Calcium-Mediated Signaling |
| 0 | GO:0030817 | Regulation Of Camp Biosynthetic Process |
| 0 | GO:0030814 | Regulation Of Camp Metabolic Process |
| 0 | GO:0060828 | Regulation Of Canonical Wnt Receptor Signaling Pathway |
| 0 | GO:0043255 | Regulation Of Carbohydrate Biosynthetic Process |
| 0 | GO:0043470 | Regulation Of Carbohydrate Catabolic Process |
| 0 | GO:0006109 | Regulation Of Carbohydrate Metabolic Process |
| 0 | GO:0060043 | Regulation Of Cardiac Muscle Cell Proliferation |
| 0 | GO:0055117 | Regulation Of Cardiac Muscle Contraction |
| 0 | GO:0010611 | Regulation Of Cardiac Muscle Hypertrophy |
| 0 | GO:0055024 | Regulation Of Cardiac Muscle Tissue Development |
| 0 | GO:0055021 | Regulation Of Cardiac Muscle Tissue Growth |
| 0 | GO:0051890 | Regulation Of Cardioblast Differentiation |
| 0 | GO:0061035 | Regulation Of Cartilage Development |
| 0 | GO:0009894 | Regulation Of Catabolic Process |
| 0 | GO:0042069 | Regulation Of Catecholamine Metabolic Process |
| 0 | GO:0050433 | Regulation Of Catecholamine Secretion |
| 0 | GO:0035412 | Regulation Of Catenin Import Into Nucleus |
| 0 | GO:2000514 | Regulation Of Cd4-Positive, Alpha-Beta T Cell Activation |
| 0 | GO:0043370 | Regulation Of Cd4-Positive, Alpha-Beta T Cell Differentiation |
| 0 | GO:0043088 | Regulation Of Cdc42 Gtpase Activity |
| 0 | GO:0032489 | Regulation Of Cdc42 Protein Signal Transduction |
| 0 | GO:0050865 | Regulation Of Cell Activation |
| 0 | GO:0030155 | Regulation Of Cell Adhesion |
| 0 | GO:0033628 | Regulation Of Cell Adhesion Mediated By Integrin |
| 0 | GO:0090342 | Regulation Of Cell Aging |
| 0 | GO:0071156 | Regulation Of Cell Cycle Arrest |
| 0 | GO:0010564 | Regulation Of Cell Cycle Process |
| 0 | GO:0060284 | Regulation Of Cell Development |
| 0 | GO:0051302 | Regulation Of Cell Division |
| 0 | GO:0010453 | Regulation Of Cell Fate Commitment |
| 0 | GO:0042659 | Regulation Of Cell Fate Specification |
| 0 | GO:0001558 | Regulation Of Cell Growth |
| 0 | GO:0031341 | Regulation Of Cell Killing |
| 0 | GO:0030334 | Regulation Of Cell Migration |
| 0 | GO:0022604 | Regulation Of Cell Morphogenesis |
| 0 | GO:0010769 | Regulation Of Cell Morphogenesis Involved In Differentiation |
| 0 | GO:2000145 | Regulation Of Cell Motility |
| 0 | GO:0060491 | Regulation Of Cell Projection Assembly |
| 0 | GO:0031344 | Regulation Of Cell Projection Organization |
| 0 | GO:0008360 | Regulation Of Cell Shape |
| 0 | GO:0008361 | Regulation Of Cell Size |
| 0 | GO:0022407 | Regulation Of Cell-Cell Adhesion |
| 0 | GO:0001952 | Regulation Of Cell-Matrix Adhesion |
| 0 | GO:0010810 | Regulation Of Cell-Substrate Adhesion |
| 0 | GO:0090109 | Regulation Of Cell-Substrate Junction Assembly |
| 0 | GO:0033238 | Regulation Of Cellular Amine Metabolic Process |
| 0 | GO:0006521 | Regulation Of Cellular Amino Acid Metabolic Process |
| 0 | GO:0043471 | Regulation Of Cellular Carbohydrate Catabolic Process |
| 0 | GO:0010675 | Regulation Of Cellular Carbohydrate Metabolic Process |
| 0 | GO:0031329 | Regulation Of Cellular Catabolic Process |
| 0 | GO:0044087 | Regulation Of Cellular Component Biogenesis |
| 0 | GO:0051270 | Regulation Of Cellular Component Movement |
| 0 | GO:0032535 | Regulation Of Cellular Component Size |
| 0 | GO:0010565 | Regulation Of Cellular Ketone Metabolic Process |

| | | |
|---|------------|--|
| 0 | GO:0060341 | Regulation Of Cellular Localization |
| 0 | GO:0030641 | Regulation Of Cellular Ph |
| 0 | GO:0090287 | Regulation Of Cellular Response To Growth Factor Stimulus |
| 0 | GO:0080135 | Regulation Of Cellular Response To Stress |
| 0 | GO:0046605 | Regulation Of Centrosome Cycle |
| 0 | GO:0010824 | Regulation Of Centrosome Duplication |
| 0 | GO:0030826 | Regulation Of Cgmp Biosynthetic Process |
| 0 | GO:0030823 | Regulation Of Cgmp Metabolic Process |
| 0 | GO:0045073 | Regulation Of Chemokine Biosynthetic Process |
| 0 | GO:0032642 | Regulation Of Chemokine Production |
| 0 | GO:0050920 | Regulation Of Chemotaxis |
| 0 | GO:0045540 | Regulation Of Cholesterol Biosynthetic Process |
| 0 | GO:0010874 | Regulation Of Cholesterol Efflux |
| 0 | GO:0090181 | Regulation Of Cholesterol Metabolic Process |
| 0 | GO:0010885 | Regulation Of Cholesterol Storage |
| 0 | GO:0032374 | Regulation Of Cholesterol Transport |
| 0 | GO:0032330 | Regulation Of Chondrocyte Differentiation |
| 0 | GO:0033044 | Regulation Of Chromosome Organization |
| 0 | GO:0051983 | Regulation Of Chromosome Segregation |
| 1 | GO:0042752 | Regulation Of Circadian Rhythm |
| 1 | GO:0042749 | Regulation Of Circadian Sleep/Wake Cycle |
| 1 | GO:0045187 | Regulation Of Circadian Sleep/Wake Cycle, Sleep |
| 0 | GO:0050818 | Regulation Of Coagulation |
| 0 | GO:0051196 | Regulation Of Coenzyme Metabolic Process |
| 0 | GO:0051193 | Regulation Of Cofactor Metabolic Process |
| 0 | GO:0032965 | Regulation Of Collagen Biosynthetic Process |
| 0 | GO:0010712 | Regulation Of Collagen Metabolic Process |
| 0 | GO:0031279 | Regulation Of Cyclase Activity |
| 0 | GO:0030802 | Regulation Of Cyclic Nucleotide Biosynthetic Process |
| 0 | GO:0030799 | Regulation Of Cyclic Nucleotide Metabolic Process |
| 0 | GO:0000079 | Regulation Of Cyclin-Dependent Protein Kinase Activity |
| 0 | GO:2000116 | Regulation Of Cysteine-Type Endopeptidase Activity |
| 0 | GO:0043281 | Regulation Of Cysteine-Type Endopeptidase Activity Involved In Apoptotic Process |
| 0 | GO:0042035 | Regulation Of Cytokine Biosynthetic Process |
| 0 | GO:0001817 | Regulation Of Cytokine Production |
| 0 | GO:0002718 | Regulation Of Cytokine Production Involved In Immune Response |
| 0 | GO:0050707 | Regulation Of Cytokine Secretion |
| 0 | GO:0001959 | Regulation Of Cytokine-Mediated Signaling Pathway |
| 0 | GO:0032465 | Regulation Of Cytokinesis |
| 0 | GO:0051493 | Regulation Of Cytoskeleton Organization |
| 0 | GO:0031347 | Regulation Of Defense Response |
| 0 | GO:0050688 | Regulation Of Defense Response To Virus |
| 0 | GO:0050691 | Regulation Of Defense Response To Virus By Host |
| 0 | GO:0050690 | Regulation Of Defense Response To Virus By Virus |
| 1 | GO:0050773 | Regulation Of Dendrite Development |
| 1 | GO:0048814 | Regulation Of Dendrite Morphogenesis |
| 1 | GO:0060998 | Regulation Of Dendritic Spine Development |
| 1 | GO:0061001 | Regulation Of Dendritic Spine Morphogenesis |
| 0 | GO:0035303 | Regulation Of Dephosphorylation |
| 0 | GO:0048638 | Regulation Of Developmental Growth |
| 0 | GO:0048070 | Regulation Of Developmental Pigmentation |
| 0 | GO:0044058 | Regulation Of Digestive System Process |
| 0 | GO:0051101 | Regulation Of Dna Binding |
| 0 | GO:0043516 | Regulation Of Dna Damage Response, Signal Transduction By P53 Class Mediator |
| 0 | GO:0051052 | Regulation Of Dna Metabolic Process |
| 0 | GO:0000018 | Regulation Of Dna Recombination |

| | | |
|---|------------|--|
| 0 | GO:0006282 | Regulation Of Dna Repair |
| 0 | GO:0006275 | Regulation Of Dna Replication |
| 0 | GO:0090329 | Regulation Of Dna-Dependent Dna Replication |
| 1 | GO:0042053 | Regulation Of Dopamine Metabolic Process |
| 1 | GO:0014059 | Regulation Of Dopamine Secretion |
| 0 | GO:0045995 | Regulation Of Embryonic Development |
| 0 | GO:0044060 | Regulation Of Endocrine Process |
| 0 | GO:0030100 | Regulation Of Endocytosis |
| 0 | GO:0052548 | Regulation Of Endopeptidase Activity |
| 0 | GO:0045601 | Regulation Of Endothelial Cell Differentiation |
| 0 | GO:0010594 | Regulation Of Endothelial Cell Migration |
| 0 | GO:0001936 | Regulation Of Endothelial Cell Proliferation |
| 0 | GO:0045604 | Regulation Of Epidermal Cell Differentiation |
| 0 | GO:0042058 | Regulation Of Epidermal Growth Factor Receptor Signaling Pathway |
| 0 | GO:0007176 | Regulation Of Epidermal Growth Factor-Activated Receptor Activity |
| 0 | GO:0045682 | Regulation Of Epidermis Development |
| 0 | GO:0030856 | Regulation Of Epithelial Cell Differentiation |
| 0 | GO:2000696 | Regulation Of Epithelial Cell Differentiation Involved In Kidney Development |
| 0 | GO:0010632 | Regulation Of Epithelial Cell Migration |
| 0 | GO:0050678 | Regulation Of Epithelial Cell Proliferation |
| 0 | GO:0060768 | Regulation Of Epithelial Cell Proliferation Involved In Prostate Gland Development |
| 0 | GO:0010717 | Regulation Of Epithelial To Mesenchymal Transition |
| 0 | GO:0070372 | Regulation Of Erk1 And Erk2 Cascade |
| 0 | GO:0045646 | Regulation Of Erythrocyte Differentiation |
| 0 | GO:0090175 | Regulation Of Establishment Of Planar Polarity |
| 0 | GO:0090178 | Regulation Of Establishment Of Planar Polarity Involved In Neural Tube Closure |
| 0 | GO:0070201 | Regulation Of Establishment Of Protein Localization |
| 0 | GO:0090003 | Regulation Of Establishment Of Protein Localization In Plasma Membrane |
| 1 | GO:0060079 | Regulation Of Excitatory Postsynaptic Membrane Potential |
| 0 | GO:0044062 | Regulation Of Excretion |
| 0 | GO:0007096 | Regulation Of Exit From Mitosis |
| 0 | GO:0017157 | Regulation Of Exocytosis |
| 0 | GO:0061387 | Regulation Of Extent Of Cell Growth |
| 0 | GO:0045598 | Regulation Of Fat Cell Differentiation |
| 0 | GO:0031998 | Regulation Of Fatty Acid Beta-Oxidation |
| 0 | GO:0042304 | Regulation Of Fatty Acid Biosynthetic Process |
| 0 | GO:0019217 | Regulation Of Fatty Acid Metabolic Process |
| 0 | GO:0046320 | Regulation Of Fatty Acid Oxidation |
| 0 | GO:2000191 | Regulation Of Fatty Acid Transport |
| 0 | GO:0051917 | Regulation Of Fibrinolysis |
| 0 | GO:0040036 | Regulation Of Fibroblast Growth Factor Receptor Signaling Pathway |
| 0 | GO:0048145 | Regulation Of Fibroblast Proliferation |
| 0 | GO:0051489 | Regulation Of Filopodium Assembly |
| 0 | GO:0051893 | Regulation Of Focal Adhesion Assembly |
| 1 | GO:0008277 | Regulation Of G-Protein Coupled Receptor Protein Signaling Pathway |
| 0 | GO:2000045 | Regulation Of G1/S Transition Of Mitotic Cell Cycle |
| 0 | GO:0010389 | Regulation Of G2/M Transition Of Mitotic Cell Cycle |
| 0 | GO:0010470 | Regulation Of Gastrulation |
| 0 | GO:0006349 | Regulation Of Gene Expression By Genetic Imprinting |
| 0 | GO:0040029 | Regulation Of Gene Expression, Epigenetic |
| 0 | GO:0060968 | Regulation Of Gene Silencing |
| 0 | GO:0043467 | Regulation Of Generation Of Precursor Metabolites And Energy |
| 1 | GO:0045685 | Regulation Of Glial Cell Differentiation |
| 1 | GO:0060251 | Regulation Of Glial Cell Proliferation |
| 1 | GO:0014013 | Regulation Of Gliogenesis |
| 0 | GO:0090192 | Regulation Of Glomerulus Development |

| | | |
|---|------------|---|
| 0 | GO:0010962 | Regulation Of Glucan Biosynthetic Process |
| 0 | GO:0006111 | Regulation Of Gluconeogenesis |
| 0 | GO:0046324 | Regulation Of Glucose Import |
| 0 | GO:0010906 | Regulation Of Glucose Metabolic Process |
| 0 | GO:0010827 | Regulation Of Glucose Transport |
| 1 | GO:0014048 | Regulation Of Glutamate Secretion |
| 0 | GO:0005979 | Regulation Of Glycogen Biosynthetic Process |
| 0 | GO:0070873 | Regulation Of Glycogen Metabolic Process |
| 0 | GO:0006110 | Regulation Of Glycolysis |
| 0 | GO:0010559 | Regulation Of Glycoprotein Biosynthetic Process |
| 0 | GO:0071622 | Regulation Of Granulocyte Chemotaxis |
| 0 | GO:0030852 | Regulation Of Granulocyte Differentiation |
| 0 | GO:0040008 | Regulation Of Growth |
| 0 | GO:0060123 | Regulation Of Growth Hormone Secretion |
| 0 | GO:0044126 | Regulation Of Growth Of Symbiont In Host |
| 0 | GO:0033124 | Regulation Of Gtp Catabolic Process |
| 0 | GO:0043087 | Regulation Of Gtpase Activity |
| 0 | GO:0042634 | Regulation Of Hair Cycle |
| 0 | GO:0051797 | Regulation Of Hair Follicle Development |
| 0 | GO:0008016 | Regulation Of Heart Contraction |
| 0 | GO:0060420 | Regulation Of Heart Growth |
| 0 | GO:2000826 | Regulation Of Heart Morphogenesis |
| 0 | GO:0002027 | Regulation Of Heart Rate |
| 0 | GO:0031650 | Regulation Of Heat Generation |
| 0 | GO:0035065 | Regulation Of Histone Acetylation |
| 0 | GO:0031063 | Regulation Of Histone Deacetylation |
| 0 | GO:0051569 | Regulation Of Histone H3-K4 Methylation |
| 0 | GO:0031060 | Regulation Of Histone Methylation |
| 0 | GO:0031056 | Regulation Of Histone Modification |
| 0 | GO:0032844 | Regulation Of Homeostatic Process |
| 0 | GO:0046885 | Regulation Of Hormone Biosynthetic Process |
| 0 | GO:0010817 | Regulation Of Hormone Levels |
| 0 | GO:0032350 | Regulation Of Hormone Metabolic Process |
| 0 | GO:0046883 | Regulation Of Hormone Secretion |
| 0 | GO:0002920 | Regulation Of Humoral Immune Response |
| 0 | GO:0043122 | Regulation Of I-Kappab Kinase/Nf-Kappab Cascade |
| 0 | GO:0002697 | Regulation Of Immune Effector Process |
| 0 | GO:0050776 | Regulation Of Immune Response |
| 0 | GO:0002889 | Regulation Of Immunoglobulin Mediated Immune Response |
| 0 | GO:0002637 | Regulation Of Immunoglobulin Production |
| 0 | GO:0051023 | Regulation Of Immunoglobulin Secretion |
| 0 | GO:0050727 | Regulation Of Inflammatory Response |
| 0 | GO:0002861 | Regulation Of Inflammatory Response To Antigenic Stimulus |
| 0 | GO:0045088 | Regulation Of Innate Immune Response |
| 0 | GO:0046626 | Regulation Of Insulin Receptor Signaling Pathway |
| 0 | GO:0050796 | Regulation Of Insulin Secretion |
| 0 | GO:0061178 | Regulation Of Insulin Secretion Involved In Cellular Response To Glucose Stimulus |
| 0 | GO:0043567 | Regulation Of Insulin-Like Growth Factor Receptor Signaling Pathway |
| 0 | GO:0032647 | Regulation Of Interferon-Alpha Production |
| 0 | GO:0032648 | Regulation Of Interferon-Beta Production |
| 0 | GO:0045072 | Regulation Of Interferon-Gamma Biosynthetic Process |
| 0 | GO:0032649 | Regulation Of Interferon-Gamma Production |
| 0 | GO:0060334 | Regulation Of Interferon-Gamma-Mediated Signaling Pathway |
| 0 | GO:0032651 | Regulation Of Interleukin-1 Beta Production |
| 0 | GO:0050706 | Regulation Of Interleukin-1 Beta Secretion |
| 0 | GO:0032652 | Regulation Of Interleukin-1 Production |

| | | |
|---|------------|--|
| 0 | GO:0050704 | Regulation Of Interleukin-1 Secretion |
| 0 | GO:0032653 | Regulation Of Interleukin-10 Production |
| 0 | GO:0032655 | Regulation Of Interleukin-12 Production |
| 0 | GO:0032660 | Regulation Of Interleukin-17 Production |
| 0 | GO:0045076 | Regulation Of Interleukin-2 Biosynthetic Process |
| 0 | GO:0032663 | Regulation Of Interleukin-2 Production |
| 0 | GO:0032673 | Regulation Of Interleukin-4 Production |
| 0 | GO:0045408 | Regulation Of Interleukin-6 Biosynthetic Process |
| 0 | GO:0032675 | Regulation Of Interleukin-6 Production |
| 0 | GO:0032677 | Regulation Of Interleukin-8 Production |
| 0 | GO:2000602 | Regulation Of Interphase Of Mitotic Cell Cycle |
| 0 | GO:0033146 | Regulation Of Intracellular Estrogen Receptor Signaling Pathway |
| 0 | GO:0051453 | Regulation Of Intracellular Ph |
| 0 | GO:0010627 | Regulation Of Intracellular Protein Kinase Cascade |
| 0 | GO:0033157 | Regulation Of Intracellular Protein Transport |
| 0 | GO:0033143 | Regulation Of Intracellular Steroid Hormone Receptor Signaling Pathway |
| 0 | GO:0032386 | Regulation Of Intracellular Transport |
| 0 | GO:2000021 | Regulation Of Ion Homeostasis |
| 0 | GO:0034765 | Regulation Of Ion Transmembrane Transport |
| 0 | GO:0032412 | Regulation Of Ion Transmembrane Transporter Activity |
| 0 | GO:0043269 | Regulation Of Ion Transport |
| 0 | GO:0045191 | Regulation Of Isotype Switching |
| 0 | GO:0048302 | Regulation Of Isotype Switching To IgG Isotypes |
| 0 | GO:0046425 | Regulation Of Jak-Stat Cascade |
| 0 | GO:0046328 | Regulation Of Jnk Cascade |
| 0 | GO:0043506 | Regulation Of Jun Kinase Activity |
| 0 | GO:0045616 | Regulation Of Keratinocyte Differentiation |
| 0 | GO:0090183 | Regulation Of Kidney Development |
| 0 | GO:0010591 | Regulation Of Lamellipodium Assembly |
| 0 | GO:0002694 | Regulation Of Leukocyte Activation |
| 0 | GO:2000106 | Regulation Of Leukocyte Apoptotic Process |
| 0 | GO:0002688 | Regulation Of Leukocyte Chemotaxis |
| 0 | GO:0043300 | Regulation Of Leukocyte Degranulation |
| 0 | GO:0001910 | Regulation Of Leukocyte Mediated Cytotoxicity |
| 0 | GO:0002703 | Regulation Of Leukocyte Mediated Immunity |
| 0 | GO:0002685 | Regulation Of Leukocyte Migration |
| 0 | GO:0070663 | Regulation Of Leukocyte Proliferation |
| 0 | GO:0051340 | Regulation Of Ligase Activity |
| 0 | GO:0060191 | Regulation Of Lipase Activity |
| 0 | GO:0046890 | Regulation Of Lipid Biosynthetic Process |
| 0 | GO:0050994 | Regulation Of Lipid Catabolic Process |
| 0 | GO:0043550 | Regulation Of Lipid Kinase Activity |
| 0 | GO:0019216 | Regulation Of Lipid Metabolic Process |
| 0 | GO:0010883 | Regulation Of Lipid Storage |
| 0 | GO:0032368 | Regulation Of Lipid Transport |
| 0 | GO:0051004 | Regulation Of Lipoprotein Lipase Activity |
| 0 | GO:0040012 | Regulation Of Locomotion |
| 1 | GO:0048169 | Regulation Of Long-Term Neuronal Synaptic Plasticity |
| 0 | GO:0051339 | Regulation Of Lyase Activity |
| 0 | GO:0051249 | Regulation Of Lymphocyte Activation |
| 0 | GO:0070228 | Regulation Of Lymphocyte Apoptotic Process |
| 0 | GO:0045619 | Regulation Of Lymphocyte Differentiation |
| 0 | GO:0002706 | Regulation Of Lymphocyte Mediated Immunity |
| 0 | GO:0050670 | Regulation Of Lymphocyte Proliferation |
| 0 | GO:0043030 | Regulation Of Macrophage Activation |
| 0 | GO:0010743 | Regulation Of Macrophage Derived Foam Cell Differentiation |

| | | |
|---|------------|--|
| 0 | GO:0045649 | Regulation Of Macrophage Differentiation |
| 0 | GO:0033599 | Regulation Of Mammary Gland Epithelial Cell Proliferation |
| 0 | GO:0043405 | Regulation Of Map Kinase Activity |
| 0 | GO:0043408 | Regulation Of Mapk Cascade |
| 0 | GO:0033003 | Regulation Of Mast Cell Activation |
| 0 | GO:0033006 | Regulation Of Mast Cell Activation Involved In Immune Response |
| 0 | GO:0043304 | Regulation Of Mast Cell Degranulation |
| 0 | GO:0045652 | Regulation Of Megakaryocyte Differentiation |
| 0 | GO:0040020 | Regulation Of Meiosis |
| 0 | GO:0051445 | Regulation Of Meiotic Cell Cycle |
| 0 | GO:0003254 | Regulation Of Membrane Depolarization |
| 0 | GO:0042391 | Regulation Of Membrane Potential |
| 0 | GO:0051043 | Regulation Of Membrane Protein Ectodomain Proteolysis |
| 0 | GO:0010464 | Regulation Of Mesenchymal Cell Proliferation |
| 0 | GO:0010959 | Regulation Of Metal Ion Transport |
| 0 | GO:0072215 | Regulation Of Metanephros Development |
| 0 | GO:0045346 | Regulation Of Mhc Class Ii Biosynthetic Process |
| 0 | GO:0070507 | Regulation Of Microtubule Cytoskeleton Organization |
| 0 | GO:0031114 | Regulation Of Microtubule Depolymerization |
| 0 | GO:0031113 | Regulation Of Microtubule Polymerization |
| 0 | GO:0031110 | Regulation Of Microtubule Polymerization Or Depolymerization |
| 0 | GO:0032886 | Regulation Of Microtubule-Based Process |
| 0 | GO:0051900 | Regulation Of Mitochondrial Depolarization |
| 0 | GO:0046902 | Regulation Of Mitochondrial Membrane Permeability |
| 0 | GO:0051881 | Regulation Of Mitochondrial Membrane Potential |
| 0 | GO:0010821 | Regulation Of Mitochondrion Organization |
| 0 | GO:0007088 | Regulation Of Mitosis |
| 0 | GO:0007346 | Regulation Of Mitotic Cell Cycle |
| 0 | GO:0030071 | Regulation Of Mitotic Metaphase/Anaphase Transition |
| 0 | GO:0032944 | Regulation Of Mononuclear Cell Proliferation |
| 0 | GO:0032768 | Regulation Of Monooxygenase Activity |
| 0 | GO:0060688 | Regulation Of Morphogenesis Of A Branching Structure |
| 0 | GO:0050684 | Regulation Of Mrna Processing |
| 0 | GO:0043488 | Regulation Of Mrna Stability |
| 0 | GO:0043900 | Regulation Of Multi-Organism Process |
| 0 | GO:0040014 | Regulation Of Multicellular Organism Growth |
| 0 | GO:0044246 | Regulation Of Multicellular Organismal Metabolic Process |
| 0 | GO:0043502 | Regulation Of Muscle Adaptation |
| 0 | GO:0010660 | Regulation Of Muscle Cell Apoptotic Process |
| 0 | GO:0051147 | Regulation Of Muscle Cell Differentiation |
| 0 | GO:0006937 | Regulation Of Muscle Contraction |
| 0 | GO:0014743 | Regulation Of Muscle Hypertrophy |
| 0 | GO:0048634 | Regulation Of Muscle Organ Development |
| 0 | GO:0090257 | Regulation Of Muscle System Process |
| 1 | GO:0031641 | Regulation Of Myelination |
| 0 | GO:0033032 | Regulation Of Myeloid Cell Apoptotic Process |
| 0 | GO:0045637 | Regulation Of Myeloid Cell Differentiation |
| 0 | GO:0002761 | Regulation Of Myeloid Leukocyte Differentiation |
| 0 | GO:0002886 | Regulation Of Myeloid Leukocyte Mediated Immunity |
| 0 | GO:0045661 | Regulation Of Myoblast Differentiation |
| 0 | GO:0010830 | Regulation Of Myotube Differentiation |
| 0 | GO:0032814 | Regulation Of Natural Killer Cell Activation |
| 0 | GO:0042269 | Regulation Of Natural Killer Cell Mediated Cytotoxicity |
| 0 | GO:0002715 | Regulation Of Natural Killer Cell Mediated Immunity |
| 0 | GO:0051960 | Regulation Of Nervous System Development |
| 1 | GO:2000177 | Regulation Of Neural Precursor Cell Proliferation |

| | | |
|---|------------|---|
| 1 | GO:0050767 | Regulation Of Neurogenesis |
| 1 | GO:0031644 | Regulation Of Neurological System Process |
| 1 | GO:0043523 | Regulation Of Neuron Apoptotic Process |
| 1 | GO:0045664 | Regulation Of Neuron Differentiation |
| 1 | GO:0010975 | Regulation Of Neuron Projection Development |
| 1 | GO:0070570 | Regulation Of Neuron Projection Regeneration |
| 1 | GO:0048168 | Regulation Of Neuronal Synaptic Plasticity |
| 1 | GO:0001505 | Regulation Of Neurotransmitter Levels |
| 1 | GO:0046928 | Regulation Of Neurotransmitter Secretion |
| 1 | GO:0051588 | Regulation Of Neurotransmitter Transport |
| 0 | GO:0090022 | Regulation Of Neutrophil Chemotaxis |
| 0 | GO:0042345 | Regulation Of Nf-Kappab Import Into Nucleus |
| 0 | GO:0045428 | Regulation Of Nitric Oxide Biosynthetic Process |
| 0 | GO:0050999 | Regulation Of Nitric-Oxide Synthase Activity |
| 1 | GO:0014061 | Regulation Of Norepinephrine Secretion |
| 0 | GO:0008593 | Regulation Of Notch Signaling Pathway |
| 0 | GO:0051783 | Regulation Of Nuclear Division |
| 0 | GO:0048024 | Regulation Of Nuclear Mrna Splicing, Via Spliceosome |
| 0 | GO:0032069 | Regulation Of Nuclease Activity |
| 0 | GO:0046822 | Regulation Of Nucleocytoplasmic Transport |
| 0 | GO:0030808 | Regulation Of Nucleotide Biosynthetic Process |
| 0 | GO:0030811 | Regulation Of Nucleotide Catabolic Process |
| 0 | GO:0006140 | Regulation Of Nucleotide Metabolic Process |
| 0 | GO:0042481 | Regulation Of Odontogenesis |
| 1 | GO:0048713 | Regulation Of Oligodendrocyte Differentiation |
| 0 | GO:0003156 | Regulation Of Organ Formation |
| 0 | GO:0046620 | Regulation Of Organ Growth |
| 0 | GO:2000027 | Regulation Of Organ Morphogenesis |
| 0 | GO:0033043 | Regulation Of Organelle Organization |
| 0 | GO:0032890 | Regulation Of Organic Acid Transport |
| 0 | GO:0030278 | Regulation Of Ossification |
| 0 | GO:0045667 | Regulation Of Osteoblast Differentiation |
| 0 | GO:0033688 | Regulation Of Osteoblast Proliferation |
| 0 | GO:0045670 | Regulation Of Osteoclast Differentiation |
| 0 | GO:0051341 | Regulation Of Oxidoreductase Activity |
| 0 | GO:0060393 | Regulation Of Pathway-Restricted Smad Protein Phosphorylation |
| 0 | GO:0052547 | Regulation Of Peptidase Activity |
| 0 | GO:0090276 | Regulation Of Peptide Hormone Secretion |
| 0 | GO:0002791 | Regulation Of Peptide Secretion |
| 0 | GO:0090087 | Regulation Of Peptide Transport |
| 0 | GO:2000756 | Regulation Of Peptidyl-Lysine Acetylation |
| 0 | GO:0033135 | Regulation Of Peptidyl-Serine Phosphorylation |
| 0 | GO:0010799 | Regulation Of Peptidyl-Threonine Phosphorylation |
| 0 | GO:0050730 | Regulation Of Peptidyl-Tyrosine Phosphorylation |
| 0 | GO:0006885 | Regulation Of Ph |
| 0 | GO:0050764 | Regulation Of Phagocytosis |
| 0 | GO:0010921 | Regulation Of Phosphatase Activity |
| 0 | GO:0043551 | Regulation Of Phosphatidylinositol 3-Kinase Activity |
| 0 | GO:0014066 | Regulation Of Phosphatidylinositol 3-Kinase Cascade |
| 0 | GO:0010517 | Regulation Of Phospholipase Activity |
| 0 | GO:0043666 | Regulation Of Phosphoprotein Phosphatase Activity |
| 0 | GO:0097006 | Regulation Of Plasma Lipoprotein Particle Levels |
| 0 | GO:0010543 | Regulation Of Platelet Activation |
| 0 | GO:0032885 | Regulation Of Polysaccharide Biosynthetic Process |
| 0 | GO:0032881 | Regulation Of Polysaccharide Metabolic Process |
| 0 | GO:0050926 | Regulation Of Positive Chemotaxis |

| | | |
|---|------------|--|
| 1 | GO:0060078 | Regulation Of Postsynaptic Membrane Potential |
| 1 | GO:0043266 | Regulation Of Potassium Ion Transport |
| 0 | GO:0002700 | Regulation Of Production Of Molecular Mediator Of Immune Response |
| 0 | GO:0061136 | Regulation Of Proteasomal Protein Catabolic Process |
| 0 | GO:0032434 | Regulation Of Proteasomal Ubiquitin-Dependent Protein Catabolic Process |
| 0 | GO:0031952 | Regulation Of Protein Autophosphorylation |
| 0 | GO:0043393 | Regulation Of Protein Binding |
| 0 | GO:0042176 | Regulation Of Protein Catabolic Process |
| 0 | GO:0043254 | Regulation Of Protein Complex Assembly |
| 0 | GO:0043244 | Regulation Of Protein Complex Disassembly |
| 0 | GO:0090311 | Regulation Of Protein Deacetylation |
| 0 | GO:0035304 | Regulation Of Protein Dephosphorylation |
| 0 | GO:0046825 | Regulation Of Protein Export From Nucleus |
| 0 | GO:0043496 | Regulation Of Protein Homodimerization Activity |
| 0 | GO:0032462 | Regulation Of Protein Homooligomerization |
| 0 | GO:0042306 | Regulation Of Protein Import Into Nucleus |
| 0 | GO:0033158 | Regulation Of Protein Import Into Nucleus, Translocation |
| 0 | GO:0051896 | Regulation Of Protein Kinase B Signaling Cascade |
| 0 | GO:0032880 | Regulation Of Protein Localization |
| 0 | GO:0032459 | Regulation Of Protein Oligomerization |
| 0 | GO:0032271 | Regulation Of Protein Polymerization |
| 0 | GO:0070613 | Regulation Of Protein Processing |
| 0 | GO:0050708 | Regulation Of Protein Secretion |
| 0 | GO:0071900 | Regulation Of Protein Serine/Threonine Kinase Activity |
| 0 | GO:0031647 | Regulation Of Protein Stability |
| 0 | GO:0051223 | Regulation Of Protein Transport |
| 0 | GO:0061097 | Regulation Of Protein Tyrosine Kinase Activity |
| 0 | GO:0031396 | Regulation Of Protein Ubiquitination |
| 0 | GO:2000058 | Regulation Of Protein Ubiquitination Involved In Ubiquitin-Dependent Protein Catabolic Process |
| 0 | GO:0030162 | Regulation Of Proteolysis |
| 0 | GO:0031272 | Regulation Of Pseudopodium Assembly |
| 0 | GO:0033121 | Regulation Of Purine Nucleotide Catabolic Process |
| 0 | GO:0032313 | Regulation Of Rab Gtpase Activity |
| 0 | GO:0032483 | Regulation Of Rab Protein Signal Transduction |
| 0 | GO:0032314 | Regulation Of Rac Gtpase Activity |
| 0 | GO:0035020 | Regulation Of Rac Protein Signal Transduction |
| 0 | GO:0032318 | Regulation Of Ras Gtpase Activity |
| 0 | GO:0046578 | Regulation Of Ras Protein Signal Transduction |
| 0 | GO:2000377 | Regulation Of Reactive Oxygen Species Metabolic Process |
| 0 | GO:0010469 | Regulation Of Receptor Activity |
| 0 | GO:0010869 | Regulation Of Receptor Biosynthetic Process |
| 0 | GO:0002090 | Regulation Of Receptor Internalization |
| 0 | GO:0001919 | Regulation Of Receptor Recycling |
| 0 | GO:0048259 | Regulation Of Receptor-Mediated Endocytosis |
| 0 | GO:0090199 | Regulation Of Release Of Cytochrome C From Mitochondria |
| 0 | GO:0051279 | Regulation Of Release Of Sequestered Calcium Ion Into Cytosol |
| 0 | GO:0035813 | Regulation Of Renal Sodium Excretion |
| 0 | GO:2000241 | Regulation Of Reproductive Process |
| 0 | GO:0043576 | Regulation Of Respiratory Gaseous Exchange |
| 1 | GO:0002087 | Regulation Of Respiratory Gaseous Exchange By Neurological System Process |
| 0 | GO:0044065 | Regulation Of Respiratory System Process |
| 0 | GO:0002831 | Regulation Of Response To Biotic Stimulus |
| 0 | GO:0060759 | Regulation Of Response To Cytokine Stimulus |
| 0 | GO:2001020 | Regulation Of Response To Dna Damage Stimulus |
| 0 | GO:0032101 | Regulation Of Response To External Stimulus |
| 0 | GO:0032104 | Regulation Of Response To Extracellular Stimulus |

| | | |
|---|------------|--|
| 0 | GO:0032095 | Regulation Of Response To Food |
| 0 | GO:0060330 | Regulation Of Response To Interferon-Gamma |
| 0 | GO:0032107 | Regulation Of Response To Nutrient Levels |
| 0 | GO:0032319 | Regulation Of Rho Gtpase Activity |
| 0 | GO:0035023 | Regulation Of Rho Protein Signal Transduction |
| 0 | GO:0043484 | Regulation Of Rna Splicing |
| 0 | GO:0043487 | Regulation Of Rna Stability |
| 0 | GO:0033261 | Regulation Of S Phase |
| 0 | GO:0007090 | Regulation Of S Phase Of Mitotic Cell Cycle |
| 0 | GO:0051046 | Regulation Of Secretion |
| 0 | GO:0051931 | Regulation Of Sensory Perception |
| 0 | GO:0051930 | Regulation Of Sensory Perception Of Pain |
| 0 | GO:0051090 | Regulation Of Sequence-Specific Dna Binding Transcription Factor Activity |
| 0 | GO:0051282 | Regulation Of Sequestering Of Calcium Ion |
| 0 | GO:2001014 | Regulation Of Skeletal Muscle Cell Differentiation |
| 0 | GO:0048742 | Regulation Of Skeletal Muscle Fiber Development |
| 0 | GO:0048641 | Regulation Of Skeletal Muscle Tissue Development |
| 0 | GO:0051056 | Regulation Of Small Gtpase Mediated Signal Transduction |
| 0 | GO:0051150 | Regulation Of Smooth Muscle Cell Differentiation |
| 0 | GO:0014910 | Regulation Of Smooth Muscle Cell Migration |
| 0 | GO:0048660 | Regulation Of Smooth Muscle Cell Proliferation |
| 0 | GO:0006940 | Regulation Of Smooth Muscle Contraction |
| 0 | GO:0008589 | Regulation Of Smoothened Signaling Pathway |
| 0 | GO:0002028 | Regulation Of Sodium Ion Transport |
| 0 | GO:2000736 | Regulation Of Stem Cell Differentiation |
| 0 | GO:0050810 | Regulation Of Steroid Biosynthetic Process |
| 0 | GO:0090030 | Regulation Of Steroid Hormone Biosynthetic Process |
| 0 | GO:0019218 | Regulation Of Steroid Metabolic Process |
| 0 | GO:0032371 | Regulation Of Sterol Transport |
| 0 | GO:0051492 | Regulation Of Stress Fiber Assembly |
| 0 | GO:0032872 | Regulation Of Stress-Activated Mapk Cascade |
| 0 | GO:0070302 | Regulation Of Stress-Activated Protein Kinase Signaling Cascade |
| 0 | GO:0010662 | Regulation Of Striated Muscle Cell Apoptotic Process |
| 0 | GO:0051153 | Regulation Of Striated Muscle Cell Differentiation |
| 0 | GO:0006942 | Regulation Of Striated Muscle Contraction |
| 0 | GO:0016202 | Regulation Of Striated Muscle Tissue Development |
| 0 | GO:0045884 | Regulation Of Survival Gene Product Expression |
| 0 | GO:0043903 | Regulation Of Symbiosis, Encompassing Mutualism Through Parasitism |
| 1 | GO:0051963 | Regulation Of Synapse Assembly |
| 1 | GO:0050807 | Regulation Of Synapse Organization |
| 1 | GO:0050803 | Regulation Of Synapse Structure And Activity |
| 1 | GO:0048167 | Regulation Of Synaptic Plasticity |
| 1 | GO:0050804 | Regulation Of Synaptic Transmission |
| 1 | GO:0032225 | Regulation Of Synaptic Transmission, Dopaminergic |
| 1 | GO:0032228 | Regulation Of Synaptic Transmission, Gabaergic |
| 1 | GO:0051966 | Regulation Of Synaptic Transmission, Glutamatergic |
| 0 | GO:0044057 | Regulation Of System Process |
| 0 | GO:0003073 | Regulation Of Systemic Arterial Blood Pressure |
| 0 | GO:0001990 | Regulation Of Systemic Arterial Blood Pressure By Hormone |
| 0 | GO:0003081 | Regulation Of Systemic Arterial Blood Pressure By Renin-Angiotensin |
| 0 | GO:0003044 | Regulation Of Systemic Arterial Blood Pressure Mediated By A Chemical Signal |
| 0 | GO:0050863 | Regulation Of T Cell Activation |
| 0 | GO:0070232 | Regulation Of T Cell Apoptotic Process |
| 0 | GO:0045580 | Regulation Of T Cell Differentiation |
| 0 | GO:0033081 | Regulation Of T Cell Differentiation In Thymus |
| 0 | GO:0001914 | Regulation Of T Cell Mediated Cytotoxicity |

| | | |
|---|------------|---|
| 0 | GO:0002709 | Regulation Of T Cell Mediated Immunity |
| 0 | GO:0042129 | Regulation Of T Cell Proliferation |
| 0 | GO:0050856 | Regulation Of T Cell Receptor Signaling Pathway |
| 0 | GO:0002825 | Regulation Of T-Helper 1 Type Immune Response |
| 0 | GO:0045622 | Regulation Of T-Helper Cell Differentiation |
| 0 | GO:0051972 | Regulation Of Telomerase Activity |
| 0 | GO:0032204 | Regulation Of Telomere Maintenance |
| 0 | GO:0002026 | Regulation Of The Force Of Heart Contraction |
| 0 | GO:0070243 | Regulation Of Thymocyte Apoptotic Process |
| 0 | GO:0034103 | Regulation Of Tissue Remodeling |
| 0 | GO:0034121 | Regulation Of Toll-Like Receptor Signaling Pathway |
| 0 | GO:0032006 | Regulation Of Tor Signaling Cascade |
| 0 | GO:0032784 | Regulation Of Transcription Elongation, Dna-Dependent |
| 0 | GO:0042990 | Regulation Of Transcription Factor Import Into Nucleus |
| 0 | GO:0034339 | Regulation Of Transcription From Rna Polymerase Ii Promoter By Nuclear Hormone Receptor |
| 0 | GO:0006359 | Regulation Of Transcription From Rna Polymerase Iii Promoter |
| 0 | GO:0060260 | Regulation Of Transcription Initiation From Rna Polymerase Ii Promoter |
| 0 | GO:2000142 | Regulation Of Transcription Initiation, Dna-Dependent |
| 0 | GO:0000083 | Regulation Of Transcription Involved In G1/S Phase Of Mitotic Cell Cycle |
| 0 | GO:2000677 | Regulation Of Transcription Regulatory Region Dna Binding |
| 0 | GO:0071634 | Regulation Of Transforming Growth Factor Beta Production |
| 0 | GO:0017015 | Regulation Of Transforming Growth Factor Beta Receptor Signaling Pathway |
| 0 | GO:0006417 | Regulation Of Translation |
| 0 | GO:0043555 | Regulation Of Translation In Response To Stress |
| 0 | GO:0006446 | Regulation Of Translational Initiation |
| 0 | GO:0090092 | Regulation Of Transmembrane Receptor Protein Serine/Threonine Kinase Signaling Pathway |
| 0 | GO:0034762 | Regulation Of Transmembrane Transport |
| 0 | GO:0022898 | Regulation Of Transmembrane Transporter Activity |
| 1 | GO:0051969 | Regulation Of Transmission Of Nerve Impulse |
| 0 | GO:0032409 | Regulation Of Transporter Activity |
| 0 | GO:0090207 | Regulation Of Triglyceride Metabolic Process |
| 0 | GO:0035150 | Regulation Of Tube Size |
| 0 | GO:0042534 | Regulation Of Tumor Necrosis Factor Biosynthetic Process |
| 0 | GO:0032680 | Regulation Of Tumor Necrosis Factor Production |
| 0 | GO:0002828 | Regulation Of Type 2 Immune Response |
| 0 | GO:0032479 | Regulation Of Type I Interferon Production |
| 0 | GO:0060338 | Regulation Of Type I Interferon-Mediated Signaling Pathway |
| 0 | GO:0042509 | Regulation Of Tyrosine Phosphorylation Of Stat Protein |
| 0 | GO:0042510 | Regulation Of Tyrosine Phosphorylation Of Stat1 Protein |
| 0 | GO:0042516 | Regulation Of Tyrosine Phosphorylation Of Stat3 Protein |
| 0 | GO:0042522 | Regulation Of Tyrosine Phosphorylation Of Stat5 Protein |
| 0 | GO:0051438 | Regulation Of Ubiquitin-Protein Ligase Activity |
| 0 | GO:0051439 | Regulation Of Ubiquitin-Protein Ligase Activity Involved In Mitotic Cell Cycle |
| 0 | GO:0035809 | Regulation Of Urine Volume |
| 0 | GO:0010574 | Regulation Of Vascular Endothelial Growth Factor Production |
| 0 | GO:0030947 | Regulation Of Vascular Endothelial Growth Factor Receptor Signaling Pathway |
| 0 | GO:0043114 | Regulation Of Vascular Permeability |
| 0 | GO:0019229 | Regulation Of Vasoconstriction |
| 0 | GO:0042312 | Regulation Of Vasodilation |
| 0 | GO:0060627 | Regulation Of Vesicle-Mediated Transport |
| 0 | GO:0045069 | Regulation Of Viral Genome Replication |
| 0 | GO:0050792 | Regulation Of Viral Reproduction |
| 0 | GO:0046782 | Regulation Of Viral Transcription |
| 0 | GO:0030111 | Regulation Of Wnt Receptor Signaling Pathway |
| 0 | GO:0061041 | Regulation Of Wound Healing |
| 0 | GO:0000975 | Regulatory Region Dna Binding |

| | | |
|---|------------|---|
| 0 | GO:0001067 | Regulatory Region Nucleic Acid Binding |
| 0 | GO:0001836 | Release Of Cytochrome C From Mitochondria |
| 0 | GO:0051209 | Release Of Sequestered Calcium Ion Into Cytosol |
| 0 | GO:0019430 | Removal Of Superoxide Radicals |
| 0 | GO:0035812 | Renal Sodium Excretion |
| 0 | GO:0072001 | Renal System Development |
| 0 | GO:0003014 | Renal System Process |
| 0 | GO:0003071 | Renal System Process Involved In Regulation Of Systemic Arterial Blood Pressure |
| 0 | GO:0061326 | Renal Tubule Development |
| 0 | GO:0061333 | Renal Tubule Morphogenesis |
| 0 | GO:0072087 | Renal Vesicle Development |
| 0 | GO:0072077 | Renal Vesicle Morphogenesis |
| 0 | GO:0005657 | Replication Fork |
| 0 | GO:0030894 | Replisome |
| 0 | GO:0070491 | Repressing Transcription Factor Binding |
| 0 | GO:0019098 | Reproductive Behavior |
| 0 | GO:0048608 | Reproductive Structure Development |
| 0 | GO:0045730 | Respiratory Burst |
| 0 | GO:0070469 | Respiratory Chain |
| 0 | GO:0045271 | Respiratory Chain Complex I |
| 0 | GO:0022904 | Respiratory Electron Transport Chain |
| 0 | GO:0007585 | Respiratory Gaseous Exchange |
| 0 | GO:0060541 | Respiratory System Development |
| 0 | GO:0003016 | Respiratory System Process |
| 0 | GO:0030323 | Respiratory Tube Development |
| 0 | GO:0001101 | Response To Acid |
| 0 | GO:0014823 | Response To Activity |
| 0 | GO:0043279 | Response To Alkaloid |
| 0 | GO:0014075 | Response To Amine Stimulus |
| 0 | GO:0043200 | Response To Amino Acid Stimulus |
| 0 | GO:0001975 | Response To Amphetamine |
| 0 | GO:0046677 | Response To Antibiotic |
| 0 | GO:0046685 | Response To Arsenic-Containing Substance |
| 0 | GO:0033198 | Response To Atp |
| 1 | GO:0048678 | Response To Axon Injury |
| 0 | GO:0009617 | Response To Bacterium |
| 0 | GO:0009607 | Response To Biotic Stimulus |
| 0 | GO:0046686 | Response To Cadmium Ion |
| 0 | GO:0031000 | Response To Caffeine |
| 0 | GO:0051592 | Response To Calcium Ion |
| 0 | GO:0051591 | Response To Camp |
| 0 | GO:0009743 | Response To Carbohydrate Stimulus |
| 0 | GO:0070723 | Response To Cholesterol |
| 0 | GO:0042220 | Response To Cocaine |
| 0 | GO:0009409 | Response To Cold |
| 0 | GO:0046688 | Response To Copper Ion |
| 0 | GO:0031960 | Response To Corticosteroid Stimulus |
| 0 | GO:0051412 | Response To Corticosterone Stimulus |
| 0 | GO:0051414 | Response To Cortisol Stimulus |
| 0 | GO:0034097 | Response To Cytokine Stimulus |
| 0 | GO:0071548 | Response To Dexamethasone Stimulus |
| 0 | GO:0002021 | Response To Dietary Excess |
| 0 | GO:0034285 | Response To Disaccharide Stimulus |
| 0 | GO:0042493 | Response To Drug |
| 0 | GO:0043331 | Response To Dsrna |
| 0 | GO:0051602 | Response To Electrical Stimulus |

| | | |
|---|------------|---|
| 0 | GO:0034976 | Response To Endoplasmic Reticulum Stress |
| 0 | GO:0032355 | Response To Estradiol Stimulus |
| 0 | GO:0043627 | Response To Estrogen Stimulus |
| 0 | GO:0045471 | Response To Ethanol |
| 0 | GO:0043330 | Response To Exogenous Dsrna |
| 0 | GO:0009991 | Response To Extracellular Stimulus |
| 0 | GO:0070542 | Response To Fatty Acid |
| 0 | GO:0071774 | Response To Fibroblast Growth Factor Stimulus |
| 0 | GO:0034405 | Response To Fluid Shear Stress |
| 0 | GO:0051593 | Response To Folic Acid |
| 0 | GO:0032354 | Response To Follicle-Stimulating Hormone Stimulus |
| 0 | GO:0032094 | Response To Food |
| 0 | GO:0060992 | Response To Fungicide |
| 0 | GO:0009620 | Response To Fungus |
| 0 | GO:0010332 | Response To Gamma Radiation |
| 0 | GO:0033762 | Response To Glucagon Stimulus |
| 0 | GO:0051384 | Response To Glucocorticoid Stimulus |
| 0 | GO:0009749 | Response To Glucose Stimulus |
| 0 | GO:0034698 | Response To Gonadotropin Stimulus |
| 0 | GO:0009629 | Response To Gravity |
| 0 | GO:0070848 | Response To Growth Factor Stimulus |
| 0 | GO:0060416 | Response To Growth Hormone Stimulus |
| 0 | GO:0009408 | Response To Heat |
| 0 | GO:0009635 | Response To Herbicide |
| 0 | GO:0009746 | Response To Hexose Stimulus |
| 0 | GO:0042542 | Response To Hydrogen Peroxide |
| 0 | GO:0055093 | Response To Hyperoxia |
| 0 | GO:0001666 | Response To Hypoxia |
| 0 | GO:0010035 | Response To Inorganic Substance |
| 0 | GO:0017085 | Response To Insecticide |
| 0 | GO:0032868 | Response To Insulin Stimulus |
| 0 | GO:0034341 | Response To Interferon-Gamma |
| 0 | GO:0070555 | Response To Interleukin-1 |
| 0 | GO:0070670 | Response To Interleukin-4 |
| 0 | GO:0070741 | Response To Interleukin-6 |
| 0 | GO:0010212 | Response To Ionizing Radiation |
| 0 | GO:0010039 | Response To Iron Ion |
| 0 | GO:0014072 | Response To Isoquinoline Alkaloid |
| 0 | GO:0010288 | Response To Lead Ion |
| 0 | GO:0009416 | Response To Light Stimulus |
| 0 | GO:0033993 | Response To Lipid |
| 0 | GO:0032496 | Response To Lipopolysaccharide |
| 0 | GO:0010226 | Response To Lithium Ion |
| 0 | GO:0032026 | Response To Magnesium Ion |
| 0 | GO:0010042 | Response To Manganese Ion |
| 0 | GO:0009612 | Response To Mechanical Stimulus |
| 0 | GO:0046689 | Response To Mercury Ion |
| 0 | GO:0010038 | Response To Metal Ion |
| 0 | GO:0051597 | Response To Methylmercury |
| 0 | GO:0051385 | Response To Mineralocorticoid Stimulus |
| 0 | GO:0002237 | Response To Molecule Of Bacterial Origin |
| 0 | GO:0034284 | Response To Monosaccharide Stimulus |
| 0 | GO:0043278 | Response To Morphine |
| 0 | GO:0035094 | Response To Nicotine |
| 0 | GO:0007584 | Response To Nutrient |
| 0 | GO:0031667 | Response To Nutrient Levels |

| | | |
|---|------------|--|
| 0 | GO:0014070 | Response To Organic Cyclic Compound |
| 0 | GO:0010243 | Response To Organic Nitrogen |
| 0 | GO:0006970 | Response To Osmotic Stress |
| 0 | GO:0051707 | Response To Other Organism |
| 0 | GO:0006979 | Response To Oxidative Stress |
| 0 | GO:0070482 | Response To Oxygen Levels |
| 0 | GO:0000305 | Response To Oxygen Radical |
| 0 | GO:0048265 | Response To Pain |
| 0 | GO:0043434 | Response To Peptide Hormone Stimulus |
| 0 | GO:0032494 | Response To Peptidoglycan |
| 0 | GO:0009268 | Response To Ph |
| 0 | GO:0032570 | Response To Progesterone Stimulus |
| 0 | GO:0034695 | Response To Prostaglandin E Stimulus |
| 0 | GO:0034694 | Response To Prostaglandin Stimulus |
| 0 | GO:0001562 | Response To Protozoan |
| 0 | GO:0014074 | Response To Purine-Containing Compound |
| 0 | GO:0009314 | Response To Radiation |
| 0 | GO:0000302 | Response To Reactive Oxygen Species |
| 0 | GO:0032526 | Response To Retinoic Acid |
| 0 | GO:0009651 | Response To Salt Stress |
| 0 | GO:0010269 | Response To Selenium Ion |
| 0 | GO:0042594 | Response To Starvation |
| 0 | GO:0048545 | Response To Steroid Hormone Stimulus |
| 0 | GO:0009744 | Response To Sucrose Stimulus |
| 0 | GO:0000303 | Response To Superoxide |
| 0 | GO:0009266 | Response To Temperature Stimulus |
| 0 | GO:0033574 | Response To Testosterone Stimulus |
| 0 | GO:0035966 | Response To Topologically Incorrect Protein |
| 0 | GO:0009636 | Response To Toxin |
| 0 | GO:0071559 | Response To Transforming Growth Factor Beta Stimulus |
| 0 | GO:0014073 | Response To Tropane |
| 0 | GO:0002347 | Response To Tumor Cell |
| 0 | GO:0034612 | Response To Tumor Necrosis Factor |
| 0 | GO:0034340 | Response To Type I Interferon |
| 0 | GO:0006986 | Response To Unfolded Protein |
| 0 | GO:0009411 | Response To Uv |
| 0 | GO:0009615 | Response To Virus |
| 0 | GO:0033273 | Response To Vitamin |
| 0 | GO:0033189 | Response To Vitamin A |
| 0 | GO:0033280 | Response To Vitamin D |
| 0 | GO:0033197 | Response To Vitamin E |
| 0 | GO:0010165 | Response To X-Ray |
| 0 | GO:0009410 | Response To Xenobiotic Stimulus |
| 0 | GO:0010043 | Response To Zinc Ion |
| 0 | GO:0060041 | Retina Development In Camera-Type Eye |
| 0 | GO:0060042 | Retina Morphogenesis In Camera-Type Eye |
| 0 | GO:0016918 | Retinal Binding |
| 0 | GO:0031290 | Retinal Ganglion Cell Axon Guidance |
| 0 | GO:0042573 | Retinoic Acid Metabolic Process |
| 0 | GO:0042974 | Retinoic Acid Receptor Binding |
| 0 | GO:0048384 | Retinoic Acid Receptor Signaling Pathway |
| 0 | GO:0005501 | Retinoid Binding |
| 0 | GO:0001523 | Retinoid Metabolic Process |
| 0 | GO:0046965 | Retinoid X Receptor Binding |
| 0 | GO:0019841 | Retinol Binding |
| 0 | GO:0004745 | Retinol Dehydrogenase Activity |

| | | |
|---|------------|--|
| 0 | GO:0042572 | Retinol Metabolic Process |
| 0 | GO:0042147 | Retrograde Transport, Endosome To Golgi |
| 0 | GO:0000301 | Retrograde Transport, Vesicle Recycling Within Golgi |
| 0 | GO:0006890 | Retrograde Vesicle-Mediated Transport, Golgi To Er |
| 0 | GO:0043691 | Reverse Cholesterol Transport |
| 0 | GO:0005100 | Rho Gtpase Activator Activity |
| 0 | GO:0017048 | Rho Gtpase Binding |
| 0 | GO:0005089 | Rho Guanyl-Nucleotide Exchange Factor Activity |
| 0 | GO:0007266 | Rho Protein Signal Transduction |
| 1 | GO:0007622 | Rhythmic Behavior |
| 0 | GO:0048511 | Rhythmic Process |
| 0 | GO:0004540 | Ribonuclease Activity |
| 0 | GO:0030529 | Ribonucleoprotein Complex |
| 0 | GO:0022618 | Ribonucleoprotein Complex Assembly |
| 0 | GO:0043021 | Ribonucleoprotein Complex Binding |
| 0 | GO:0022613 | Ribonucleoprotein Complex Biogenesis |
| 0 | GO:0071826 | Ribonucleoprotein Complex Subunit Organization |
| 0 | GO:0035770 | Ribonucleoprotein Granule |
| 0 | GO:0042455 | Ribonucleoside Biosynthetic Process |
| 0 | GO:0033875 | Ribonucleoside Bisphosphate Metabolic Process |
| 0 | GO:0042454 | Ribonucleoside Catabolic Process |
| 0 | GO:0009185 | Ribonucleoside Diphosphate Metabolic Process |
| 0 | GO:0009119 | Ribonucleoside Metabolic Process |
| 0 | GO:0009156 | Ribonucleoside Monophosphate Biosynthetic Process |
| 0 | GO:0009161 | Ribonucleoside Monophosphate Metabolic Process |
| 0 | GO:0009201 | Ribonucleoside Triphosphate Biosynthetic Process |
| 0 | GO:0009260 | Ribonucleotide Biosynthetic Process |
| 0 | GO:0042274 | Ribosomal Small Subunit Biogenesis |
| 0 | GO:0005840 | Ribosome |
| 0 | GO:0043022 | Ribosome Binding |
| 0 | GO:0042254 | Ribosome Biogenesis |
| 0 | GO:0031123 | Rna 3'-End Processing |
| 0 | GO:0009452 | Rna Capping |
| 0 | GO:0006401 | Rna Catabolic Process |
| 0 | GO:0006405 | Rna Export From Nucleus |
| 0 | GO:0003724 | Rna Helicase Activity |
| 0 | GO:0006403 | Rna Localization |
| 0 | GO:0001510 | Rna Methylation |
| 0 | GO:0008173 | Rna Methyltransferase Activity |
| 0 | GO:0009451 | Rna Modification |
| 0 | GO:0043631 | Rna Polyadenylation |
| 0 | GO:0034062 | Rna Polymerase Activity |
| 0 | GO:0030880 | Rna Polymerase Complex |
| 0 | GO:0008353 | Rna Polymerase Ii Carboxy-Terminal Domain Kinase Activity |
| 0 | GO:0000978 | Rna Polymerase Ii Core Promoter Proximal Region Sequence-Specific Dna Binding |
| 0 | GO:0000982 | Rna Polymerase Ii Core Promoter Proximal Region Sequence-Specific Dna Binding Transcription Factor Activity |
| 0 | GO:0001078 | Rna Polymerase Ii Core Promoter Proximal Region Sequence-Specific Dna Binding Transcription Factor Activity Involved In Negative Regulation Of Transcription |
| 0 | GO:0001077 | Rna Polymerase Ii Core Promoter Proximal Region Sequence-Specific Dna Binding Transcription Factor Activity Involved In Positive Regulation Of Transcription |
| 0 | GO:0000979 | Rna Polymerase Ii Core Promoter Sequence-Specific Dna Binding |
| 0 | GO:0003705 | Rna Polymerase Ii Distal Enhancer Sequence-Specific Dna Binding Transcription Factor Activity |
| 0 | GO:0001012 | Rna Polymerase Ii Regulatory Region Dna Binding |
| 0 | GO:0000977 | Rna Polymerase Ii Regulatory Region Sequence-Specific Dna Binding |
| 0 | GO:0001105 | Rna Polymerase Ii Transcription Coactivator Activity |
| 0 | GO:0001104 | Rna Polymerase Ii Transcription Cofactor Activity |
| 0 | GO:0001106 | Rna Polymerase Ii Transcription Corepressor Activity |
| 0 | GO:0001085 | Rna Polymerase Ii Transcription Factor Binding |

| | | |
|---|------------|---|
| 0 | GO:0001076 | Rna Polymerase Ii Transcription Factor Binding Transcription Factor Activity |
| 0 | GO:0001191 | Rna Polymerase Ii Transcription Factor Binding Transcription Factor Activity Involved In Negative Regulation Of Transcription |
| 0 | GO:0001190 | Rna Polymerase Ii Transcription Factor Binding Transcription Factor Activity Involved In Positive Regulation Of Transcription |
| 0 | GO:0008380 | Rna Splicing |
| 0 | GO:0000375 | Rna Splicing, Via Transesterification Reactions |
| 0 | GO:0000377 | Rna Splicing, Via Transesterification Reactions With Bulged Adenosine As Nucleophile |
| 0 | GO:0043489 | Rna Stabilization |
| 0 | GO:0050658 | Rna Transport |
| 0 | GO:0008186 | Rna-Dependent Atpase Activity |
| 0 | GO:0006278 | Rna-Dependent Dna Replication |
| 1 | GO:0021903 | Rostrocaudal Neural Tube Patterning |
| 0 | GO:0005791 | Rough Endoplasmic Reticulum |
| 0 | GO:0030867 | Rough Endoplasmic Reticulum Membrane |
| 0 | GO:0019843 | Rrna Binding |
| 0 | GO:0016072 | Rrna Metabolic Process |
| 0 | GO:0006364 | Rrna Processing |
| 0 | GO:0009303 | Rrna Transcription |
| 0 | GO:0001726 | Ruffle |
| 0 | GO:0032587 | Ruffle Membrane |
| 0 | GO:0031529 | Ruffle Organization |
| 0 | GO:0051320 | S Phase |
| 0 | GO:0000084 | S Phase Of Mitotic Cell Cycle |
| 0 | GO:0008757 | S-Adenosylmethionine-Dependent Methyltransferase Activity |
| 0 | GO:0070461 | Saga-Type Complex |
| 0 | GO:0007431 | Salivary Gland Development |
| 0 | GO:0007435 | Salivary Gland Morphogenesis |
| 0 | GO:0042383 | Sarcolemma |
| 0 | GO:0030017 | Sarcomere |
| 0 | GO:0045214 | Sarcomere Organization |
| 0 | GO:0016528 | Sarcoplasm |
| 0 | GO:0016529 | Sarcoplasmic Reticulum |
| 0 | GO:0033017 | Sarcoplasmic Reticulum Membrane |
| 0 | GO:0005044 | Scavenger Receptor Activity |
| 0 | GO:0019005 | Scf Ubiquitin Ligase Complex |
| 0 | GO:0031146 | Scf-Dependent Proteasomal Ubiquitin-Dependent Protein Catabolic Process |
| 1 | GO:0014044 | Schwann Cell Development |
| 1 | GO:0014037 | Schwann Cell Differentiation |
| 0 | GO:0019932 | Second-Messenger-Mediated Signaling |
| 0 | GO:0015291 | Secondary Active Transmembrane Transporter Activity |
| 0 | GO:0019748 | Secondary Metabolic Process |
| 0 | GO:0030141 | Secretory Granule |
| 0 | GO:0034774 | Secretory Granule Lumen |
| 0 | GO:0030667 | Secretory Granule Membrane |
| 0 | GO:0007379 | Segment Specification |
| 0 | GO:0035282 | Segmentation |
| 0 | GO:0008430 | Selenium Binding |
| 0 | GO:0007423 | Sensory Organ Development |
| 0 | GO:0007600 | Sensory Perception |
| 0 | GO:0007606 | Sensory Perception Of Chemical Stimulus |
| 0 | GO:0050953 | Sensory Perception Of Light Stimulus |
| 0 | GO:0050954 | Sensory Perception Of Mechanical Stimulus |
| 0 | GO:0019233 | Sensory Perception Of Pain |
| 0 | GO:0007608 | Sensory Perception Of Smell |
| 0 | GO:0007605 | Sensory Perception Of Sound |
| 0 | GO:0050909 | Sensory Perception Of Taste |
| 0 | GO:0031105 | Septin Complex |

| | | |
|---|------------|--|
| 0 | GO:0032156 | Septin Cytoskeleton |
| 0 | GO:0000981 | Sequence-Specific Dna Binding Rna Polymerase Ii Transcription Factor Activity |
| 0 | GO:0051208 | Sequestering Of Calcium Ion |
| 0 | GO:0051238 | Sequestering Of Metal Ion |
| 0 | GO:0030730 | Sequestering Of Triglyceride |
| 0 | GO:0009070 | Serine Family Amino Acid Biosynthetic Process |
| 0 | GO:0009071 | Serine Family Amino Acid Catabolic Process |
| 0 | GO:0009069 | Serine Family Amino Acid Metabolic Process |
| 0 | GO:0017171 | Serine Hydrolase Activity |
| 0 | GO:0004252 | Serine-Type Endopeptidase Activity |
| 0 | GO:0004867 | Serine-Type Endopeptidase Inhibitor Activity |
| 0 | GO:0070008 | Serine-Type Exopeptidase Activity |
| 0 | GO:0008236 | Serine-Type Peptidase Activity |
| 0 | GO:0051378 | Serotonin Binding |
| 0 | GO:0004993 | Serotonin Receptor Activity |
| 0 | GO:0007210 | Serotonin Receptor Signaling Pathway |
| 0 | GO:0060008 | Sertoli Cell Differentiation |
| 0 | GO:0000803 | Sex Chromosome |
| 0 | GO:0007530 | Sex Determination |
| 0 | GO:0007548 | Sex Differentiation |
| 0 | GO:0019953 | Sexual Reproduction |
| 0 | GO:0042169 | Sh2 Domain Binding |
| 0 | GO:0017124 | Sh3 Domain Binding |
| 0 | GO:0005070 | Sh3/Sh2 Adaptor Activity |
| 0 | GO:0046459 | Short-Chain Fatty Acid Metabolic Process |
| 0 | GO:0008373 | Sialyltransferase Activity |
| 0 | GO:0023061 | Signal Release |
| 0 | GO:0005048 | Signal Sequence Binding |
| 0 | GO:0072331 | Signal Transduction By P53 Class Mediator |
| 0 | GO:0072332 | Signal Transduction By P53 Class Mediator Resulting In Induction Of Apoptosis |
| 0 | GO:0042770 | Signal Transduction In Response To Dna Damage |
| 0 | GO:0072395 | Signal Transduction Involved In Cell Cycle Checkpoint |
| 0 | GO:0072422 | Signal Transduction Involved In Dna Damage Checkpoint |
| 0 | GO:0072401 | Signal Transduction Involved In Dna Integrity Checkpoint |
| 0 | GO:0072404 | Signal Transduction Involved In G1/S Transition Checkpoint |
| 0 | GO:0072413 | Signal Transduction Involved In Mitotic Cell Cycle Checkpoint |
| 0 | GO:0072474 | Signal Transduction Involved In Mitotic Cell Cycle G1/S Checkpoint |
| 0 | GO:0072431 | Signal Transduction Involved In Mitotic Cell Cycle G1/S Transition Dna Damage Checkpoint |
| 0 | GO:0023019 | Signal Transduction Involved In Regulation Of Gene Expression |
| 0 | GO:0035591 | Signaling Adaptor Activity |
| 0 | GO:0008180 | Signalosome |
| 0 | GO:0007338 | Single Fertilization |
| 0 | GO:0003697 | Single-Stranded Dna Binding |
| 0 | GO:0003727 | Single-Stranded Rna Binding |
| 0 | GO:0007062 | Sister Chromatid Cohesion |
| 0 | GO:0000819 | Sister Chromatid Segregation |
| 0 | GO:0030427 | Site Of Polarized Growth |
| 0 | GO:0035914 | Skeletal Muscle Cell Differentiation |
| 0 | GO:0003009 | Skeletal Muscle Contraction |
| 0 | GO:0048741 | Skeletal Muscle Fiber Development |
| 0 | GO:0060538 | Skeletal Muscle Organ Development |
| 0 | GO:0007519 | Skeletal Muscle Tissue Development |
| 0 | GO:0043403 | Skeletal Muscle Tissue Regeneration |
| 0 | GO:0001501 | Skeletal System Development |
| 0 | GO:0048705 | Skeletal System Morphogenesis |
| 0 | GO:0043588 | Skin Development |

| | | |
|---|------------|--|
| 0 | GO:0030431 | Sleep |
| 0 | GO:0046332 | Smad Binding |
| 0 | GO:0007183 | Smad Protein Complex Assembly |
| 0 | GO:0007184 | Smad Protein Import Into Nucleus |
| 0 | GO:0060395 | Smad Protein Signal Transduction |
| 0 | GO:0032182 | Small Conjugating Protein Binding |
| 0 | GO:0019787 | Small Conjugating Protein Ligase Activity |
| 0 | GO:0019783 | Small Conjugating Protein-Specific Protease Activity |
| 0 | GO:0031267 | Small Gtpase Binding |
| 0 | GO:0007264 | Small Gtpase Mediated Signal Transduction |
| 0 | GO:0005083 | Small Gtpase Regulator Activity |
| 0 | GO:0044283 | Small Molecule Biosynthetic Process |
| 0 | GO:0044282 | Small Molecule Catabolic Process |
| 0 | GO:0030532 | Small Nuclear Ribonucleoprotein Complex |
| 0 | GO:0005732 | Small Nucleolar Ribonucleoprotein Complex |
| 0 | GO:0008641 | Small Protein Activating Enzyme Activity |
| 0 | GO:0015935 | Small Ribosomal Subunit |
| 0 | GO:0005790 | Smooth Endoplasmic Reticulum |
| 0 | GO:0051145 | Smooth Muscle Cell Differentiation |
| 0 | GO:0014909 | Smooth Muscle Cell Migration |
| 0 | GO:0048659 | Smooth Muscle Cell Proliferation |
| 0 | GO:0006939 | Smooth Muscle Contraction |
| 0 | GO:0048745 | Smooth Muscle Tissue Development |
| 0 | GO:0007224 | Smoothened Signaling Pathway |
| 0 | GO:0005484 | Snap Receptor Activity |
| 0 | GO:0000149 | Snare Binding |
| 0 | GO:0031201 | Snare Complex |
| 0 | GO:0017069 | Snrna Binding |
| 0 | GO:0016073 | Snrna Metabolic Process |
| 0 | GO:0016180 | Snrna Processing |
| 1 | GO:0035176 | Social Behavior |
| 0 | GO:0005272 | Sodium Channel Activity |
| 0 | GO:0034706 | Sodium Channel Complex |
| 0 | GO:0071436 | Sodium Ion Export |
| 0 | GO:0055078 | Sodium Ion Homeostasis |
| 0 | GO:0035725 | Sodium Ion Transmembrane Transport |
| 0 | GO:0015081 | Sodium Ion Transmembrane Transporter Activity |
| 0 | GO:0006814 | Sodium Ion Transport |
| 0 | GO:0043252 | Sodium-Independent Organic Anion Transport |
| 0 | GO:0005283 | Sodium:Amino Acid Symporter Activity |
| 0 | GO:0017153 | Sodium:Dicarboxylate Symporter Activity |
| 0 | GO:0005625 | Soluble Fraction |
| 0 | GO:0015298 | Solute:Cation Antiporter Activity |
| 0 | GO:0015294 | Solute:Cation Symporter Activity |
| 0 | GO:0015299 | Solute:Hydrogen Antiporter Activity |
| 0 | GO:0015295 | Solute:Hydrogen Symporter Activity |
| 0 | GO:0015370 | Solute:Sodium Symporter Activity |
| 0 | GO:0015300 | Solute:Solute Antiporter Activity |
| 0 | GO:0016444 | Somatic Cell Dna Recombination |
| 0 | GO:0002200 | Somatic Diversification Of Immune Receptors |
| 0 | GO:0002562 | Somatic Diversification Of Immune Receptors Via Germline Recombination Within A Single Locus |
| 0 | GO:0016445 | Somatic Diversification Of Immunoglobulins |
| 0 | GO:0002208 | Somatic Diversification Of Immunoglobulins Involved In Immune Response |
| 0 | GO:0016447 | Somatic Recombination Of Immunoglobulin Gene Segments |
| 0 | GO:0002204 | Somatic Recombination Of Immunoglobulin Genes Involved In Immune Response |
| 0 | GO:0048103 | Somatic Stem Cell Division |

| | | |
|---|------------|--|
| 0 | GO:0035019 | Somatic Stem Cell Maintenance |
| 0 | GO:0061053 | Somite Development |
| 0 | GO:0001756 | Somitogenesis |
| 0 | GO:0010092 | Specification Of Organ Identity |
| 0 | GO:0009799 | Specification Of Symmetry |
| 0 | GO:0030317 | Sperm Motility |
| 0 | GO:0035036 | Sperm-Egg Recognition |
| 0 | GO:0007286 | Spermatid Development |
| 0 | GO:0048515 | Spermatid Differentiation |
| 0 | GO:0007289 | Spermatid Nucleus Differentiation |
| 0 | GO:0007283 | Spermatogenesis |
| 0 | GO:0046520 | Sphingoid Biosynthetic Process |
| 0 | GO:0046519 | Sphingoid Metabolic Process |
| 0 | GO:0046625 | Sphingolipid Binding |
| 0 | GO:0030148 | Sphingolipid Biosynthetic Process |
| 0 | GO:0030149 | Sphingolipid Catabolic Process |
| 0 | GO:0006665 | Sphingolipid Metabolic Process |
| 0 | GO:0006684 | Sphingomyelin Metabolic Process |
| 0 | GO:0021527 | Spinal Cord Association Neuron Differentiation |
| 0 | GO:0021510 | Spinal Cord Development |
| 0 | GO:0021513 | Spinal Cord Dorsal/Ventral Patterning |
| 0 | GO:0021522 | Spinal Cord Motor Neuron Differentiation |
| 0 | GO:0021511 | Spinal Cord Patterning |
| 0 | GO:0005819 | Spindle |
| 0 | GO:0051225 | Spindle Assembly |
| 0 | GO:0071173 | Spindle Assembly Checkpoint |
| 0 | GO:0090307 | Spindle Assembly Involved In Mitosis |
| 0 | GO:0031577 | Spindle Checkpoint |
| 0 | GO:0051653 | Spindle Localization |
| 0 | GO:0005876 | Spindle Microtubule |
| 0 | GO:0051233 | Spindle Midzone |
| 0 | GO:0007051 | Spindle Organization |
| 0 | GO:0000922 | Spindle Pole |
| 0 | GO:0048536 | Spleen Development |
| 0 | GO:0005681 | Spliceosomal Complex |
| 0 | GO:0000245 | Spliceosomal Complex Assembly |
| 0 | GO:0000387 | Spliceosomal Snmp Assembly |
| 0 | GO:0002040 | Sprouting Angiogenesis |
| 0 | GO:0032933 | Srebp-Mediated Signaling Pathway |
| 0 | GO:0030914 | Staga Complex |
| 0 | GO:0001964 | Startle Response |
| 0 | GO:0048864 | Stem Cell Development |
| 0 | GO:0048863 | Stem Cell Differentiation |
| 0 | GO:0017145 | Stem Cell Division |
| 0 | GO:0019827 | Stem Cell Maintenance |
| 0 | GO:0072089 | Stem Cell Proliferation |
| 0 | GO:0032420 | Stereocilium |
| 0 | GO:0032421 | Stereocilium Bundle |
| 0 | GO:0005496 | Steroid Binding |
| 0 | GO:0006694 | Steroid Biosynthetic Process |
| 0 | GO:0006706 | Steroid Catabolic Process |
| 0 | GO:0016229 | Steroid Dehydrogenase Activity |
| 0 | GO:0033764 | Steroid Dehydrogenase Activity, Acting On The Ch-Oh Group Of Donors, Nad Or Nadp As Acceptor |
| 0 | GO:0034433 | Steroid Esterification |
| 0 | GO:0043401 | Steroid Hormone Mediated Signaling Pathway |
| 0 | GO:0003707 | Steroid Hormone Receptor Activity |

| | | |
|---|------------|--|
| 0 | GO:0035258 | Steroid Hormone Receptor Binding |
| 0 | GO:0008395 | Steroid Hydroxylase Activity |
| 0 | GO:0008202 | Steroid Metabolic Process |
| 0 | GO:0032934 | Sterol Binding |
| 0 | GO:0016126 | Sterol Biosynthetic Process |
| 0 | GO:0016127 | Sterol Catabolic Process |
| 0 | GO:0034434 | Sterol Esterification |
| 0 | GO:0055092 | Sterol Homeostasis |
| 0 | GO:0016125 | Sterol Metabolic Process |
| 0 | GO:0015918 | Sterol Transport |
| 0 | GO:0015248 | Sterol Transporter Activity |
| 0 | GO:0001725 | Stress Fiber |
| 0 | GO:0043149 | Stress Fiber Assembly |
| 0 | GO:0051403 | Stress-Activated Mapk Cascade |
| 0 | GO:0031098 | Stress-Activated Protein Kinase Signaling Cascade |
| 0 | GO:0014888 | Striated Muscle Adaptation |
| 0 | GO:0010658 | Striated Muscle Cell Apoptotic Process |
| 0 | GO:0055002 | Striated Muscle Cell Development |
| 0 | GO:0051146 | Striated Muscle Cell Differentiation |
| 0 | GO:0014855 | Striated Muscle Cell Proliferation |
| 0 | GO:0006941 | Striated Muscle Contraction |
| 0 | GO:0014897 | Striated Muscle Hypertrophy |
| 0 | GO:0005865 | Striated Muscle Thin Filament |
| 0 | GO:0014706 | Striated Muscle Tissue Development |
| 0 | GO:0021756 | Striatum Development |
| 0 | GO:0005200 | Structural Constituent Of Cytoskeleton |
| 0 | GO:0005212 | Structural Constituent Of Eye Lens |
| 0 | GO:0008307 | Structural Constituent Of Muscle |
| 0 | GO:0003735 | Structural Constituent Of Ribosome |
| 0 | GO:0043566 | Structure-Specific Dna Binding |
| 1 | GO:0021544 | Subpallium Development |
| 0 | GO:0034446 | Substrate Adhesion-Dependent Cell Spreading |
| 0 | GO:0006929 | Substrate-Dependent Cell Migration |
| 0 | GO:0022838 | Substrate-Specific Channel Activity |
| 0 | GO:0001967 | Suckling Behavior |
| 0 | GO:0051119 | Sugar Transmembrane Transporter Activity |
| 0 | GO:0050308 | Sugar-Phosphatase Activity |
| 0 | GO:0015116 | Sulfate Transmembrane Transporter Activity |
| 0 | GO:0008272 | Sulfate Transport |
| 0 | GO:0051923 | Sulfation |
| 0 | GO:0008146 | Sulfotransferase Activity |
| 0 | GO:0000097 | Sulfur Amino Acid Biosynthetic Process |
| 0 | GO:0000096 | Sulfur Amino Acid Metabolic Process |
| 0 | GO:0044272 | Sulfur Compound Biosynthetic Process |
| 0 | GO:0006790 | Sulfur Compound Metabolic Process |
| 0 | GO:0008484 | Sulfuric Ester Hydrolase Activity |
| 0 | GO:0042554 | Superoxide Anion Generation |
| 0 | GO:0006801 | Superoxide Metabolic Process |
| 1 | GO:0016514 | Swi/Snf Complex |
| 1 | GO:0070603 | Swi/Snf-Type Complex |
| 0 | GO:0044403 | Symbiosis, Encompassing Mutualism Through Parasitism |
| 1 | GO:0048485 | Sympathetic Nervous System Development |
| 0 | GO:0015293 | Symporter Activity |
| 1 | GO:0045202 | Synapse |
| 1 | GO:0007416 | Synapse Assembly |
| 1 | GO:0050808 | Synapse Organization |

| | | |
|---|------------|--|
| 1 | GO:0044456 | Synapse Part |
| 1 | GO:0007129 | Synapsis |
| 1 | GO:0097060 | Synaptic Membrane |
| 1 | GO:0007271 | Synaptic Transmission, Cholinergic |
| 1 | GO:0001963 | Synaptic Transmission, Dopaminergic |
| 1 | GO:0051932 | Synaptic Transmission, Gabaergic |
| 1 | GO:0035249 | Synaptic Transmission, Glutamatergic |
| 1 | GO:0008021 | Synaptic Vesicle |
| 1 | GO:0048488 | Synaptic Vesicle Endocytosis |
| 1 | GO:0016079 | Synaptic Vesicle Exocytosis |
| 1 | GO:0030672 | Synaptic Vesicle Membrane |
| 1 | GO:0048489 | Synaptic Vesicle Transport |
| 1 | GO:0000795 | Synaptonemal Complex |
| 1 | GO:0007130 | Synaptonemal Complex Assembly |
| 1 | GO:0070193 | Synaptonemal Complex Organization |
| 1 | GO:0019717 | Synaptosome |
| 0 | GO:0006949 | Syncytium Formation |
| 0 | GO:0000768 | Syncytium Formation By Plasma Membrane Fusion |
| 0 | GO:0019905 | Syntaxin Binding |
| 0 | GO:0017075 | Syntaxin-1 Binding |
| 0 | GO:0042110 | T Cell Activation |
| 0 | GO:0002286 | T Cell Activation Involved In Immune Response |
| 0 | GO:0070231 | T Cell Apoptotic Process |
| 0 | GO:0031295 | T Cell Costimulation |
| 0 | GO:0002369 | T Cell Cytokine Production |
| 0 | GO:0030217 | T Cell Differentiation |
| 0 | GO:0033077 | T Cell Differentiation In Thymus |
| 0 | GO:0002292 | T Cell Differentiation Involved In Immune Response |
| 0 | GO:0043029 | T Cell Homeostasis |
| 0 | GO:0002360 | T Cell Lineage Commitment |
| 0 | GO:0001913 | T Cell Mediated Cytotoxicity |
| 0 | GO:0002456 | T Cell Mediated Immunity |
| 0 | GO:0042098 | T Cell Proliferation |
| 0 | GO:0042101 | T Cell Receptor Complex |
| 0 | GO:0050852 | T Cell Receptor Signaling Pathway |
| 0 | GO:0045058 | T Cell Selection |
| 0 | GO:0045063 | T-Helper 1 Cell Differentiation |
| 0 | GO:0042088 | T-Helper 1 Type Immune Response |
| 0 | GO:0042093 | T-Helper Cell Differentiation |
| 0 | GO:0030315 | T-Tubule |
| 0 | GO:0035121 | Tail Morphogenesis |
| 0 | GO:0008527 | Taste Receptor Activity |
| 0 | GO:0050321 | Tau-Protein Kinase Activity |
| 0 | GO:0017025 | Tbp-Class Protein Binding |
| 1 | GO:0022029 | Telencephalon Cell Migration |
| 1 | GO:0021537 | Telencephalon Development |
| 0 | GO:0000782 | Telomere Cap Complex |
| 0 | GO:0000723 | Telomere Maintenance |
| 0 | GO:0000722 | Telomere Maintenance Via Recombination |
| 0 | GO:0032201 | Telomere Maintenance Via Semi-Conservative Replication |
| 0 | GO:0007004 | Telomere Maintenance Via Telomerase |
| 0 | GO:0010833 | Telomere Maintenance Via Telomere Lengthening |
| 0 | GO:0032200 | Telomere Organization |
| 0 | GO:0042162 | Telomeric Dna Binding |
| 0 | GO:0001659 | Temperature Homeostasis |
| 0 | GO:0043195 | Terminal Button |

| | | |
|---|------------|---|
| 0 | GO:0038032 | Termination Of G-Protein Coupled Receptor Signaling Pathway |
| 0 | GO:0006363 | Termination Of Rna Polymerase I Transcription |
| 0 | GO:0006369 | Termination Of Rna Polymerase Ii Transcription |
| 0 | GO:0006386 | Termination Of Rna Polymerase Iii Transcription |
| 0 | GO:0023021 | Termination Of Signal Transduction |
| 0 | GO:0006721 | Terpenoid Metabolic Process |
| 0 | GO:0046906 | Tetrapyrrole Binding |
| 0 | GO:0033014 | Tetrapyrrole Biosynthetic Process |
| 0 | GO:0033013 | Tetrapyrrole Metabolic Process |
| 1 | GO:0021794 | Thalamus Development |
| 0 | GO:0035384 | Thioester Biosynthetic Process |
| 0 | GO:0035383 | Thioester Metabolic Process |
| 0 | GO:0016790 | Thiolester Hydrolase Activity |
| 0 | GO:0004298 | Threonine-Type Endopeptidase Activity |
| 0 | GO:0070003 | Threonine-Type Peptidase Activity |
| 0 | GO:0045061 | Thymic T Cell Selection |
| 0 | GO:0070242 | Thymocyte Apoptotic Process |
| 0 | GO:0048538 | Thymus Development |
| 0 | GO:0030878 | Thyroid Gland Development |
| 0 | GO:0042403 | Thyroid Hormone Metabolic Process |
| 0 | GO:0046966 | Thyroid Hormone Receptor Binding |
| 0 | GO:0005923 | Tight Junction |
| 0 | GO:0070830 | Tight Junction Assembly |
| 0 | GO:0001894 | Tissue Homeostasis |
| 0 | GO:0090130 | Tissue Migration |
| 0 | GO:0048729 | Tissue Morphogenesis |
| 0 | GO:0042246 | Tissue Regeneration |
| 0 | GO:0048771 | Tissue Remodeling |
| 0 | GO:0031432 | Titin Binding |
| 0 | GO:0002507 | Tolerance Induction |
| 0 | GO:0008063 | Toll Signaling Pathway |
| 0 | GO:0034130 | Toll-Like Receptor 1 Signaling Pathway |
| 0 | GO:0034134 | Toll-Like Receptor 2 Signaling Pathway |
| 0 | GO:0034138 | Toll-Like Receptor 3 Signaling Pathway |
| 0 | GO:0034142 | Toll-Like Receptor 4 Signaling Pathway |
| 0 | GO:0002224 | Toll-Like Receptor Signaling Pathway |
| 0 | GO:0043586 | Tongue Development |
| 0 | GO:0043587 | Tongue Morphogenesis |
| 0 | GO:0034505 | Tooth Mineralization |
| 0 | GO:0031929 | Tor Signaling Cascade |
| 0 | GO:0015643 | Toxin Binding |
| 0 | GO:0060343 | Trabecula Formation |
| 0 | GO:0061383 | Trabecula Morphogenesis |
| 0 | GO:0060438 | Trachea Development |
| 0 | GO:0005802 | Trans-Golgi Network |
| 0 | GO:0030140 | Trans-Golgi Network Transport Vesicle |
| 0 | GO:0012510 | Trans-Golgi Network Transport Vesicle Membrane |
| 0 | GO:0008483 | Transaminase Activity |
| 0 | GO:0003713 | Transcription Coactivator Activity |
| 0 | GO:0003712 | Transcription Cofactor Activity |
| 0 | GO:0003714 | Transcription Corepressor Activity |
| 0 | GO:0008023 | Transcription Elongation Factor Complex |
| 0 | GO:0006362 | Transcription Elongation From Rna Polymerase I Promoter |
| 0 | GO:0006368 | Transcription Elongation From Rna Polymerase Ii Promoter |
| 0 | GO:0006385 | Transcription Elongation From Rna Polymerase Iii Promoter |
| 0 | GO:0006354 | Transcription Elongation, Dna-Dependent |

| | | |
|---|------------|---|
| 0 | GO:0008134 | Transcription Factor Binding |
| 0 | GO:0000989 | Transcription Factor Binding Transcription Factor Activity |
| 0 | GO:0005667 | Transcription Factor Complex |
| 0 | GO:0042991 | Transcription Factor Import Into Nucleus |
| 0 | GO:0005669 | Transcription Factor Tfid Complex |
| 0 | GO:0033276 | Transcription Factor Tftc Complex |
| 0 | GO:0006360 | Transcription From Rna Polymerase I Promoter |
| 0 | GO:0006383 | Transcription From Rna Polymerase Iii Promoter |
| 0 | GO:0006361 | Transcription Initiation From Rna Polymerase I Promoter |
| 0 | GO:0006367 | Transcription Initiation From Rna Polymerase Ii Promoter |
| 0 | GO:0006352 | Transcription Initiation, Dna-Dependent |
| 0 | GO:0044212 | Transcription Regulatory Region Dna Binding |
| 0 | GO:0000976 | Transcription Regulatory Region Sequence-Specific Dna Binding |
| 0 | GO:0006353 | Transcription Termination, Dna-Dependent |
| 0 | GO:0006283 | Transcription-Coupled Nucleotide-Excision Repair |
| 0 | GO:0017053 | Transcriptional Repressor Complex |
| 0 | GO:0070633 | Transepithelial Transport |
| 0 | GO:0016746 | Transferase Activity, Transferring Acyl Groups |
| 0 | GO:0016747 | Transferase Activity, Transferring Acyl Groups Other Than Amino-Acyl Groups |
| 0 | GO:0016765 | Transferase Activity, Transferring Alkyl Or Aryl (Other Than Methyl) Groups |
| 0 | GO:0016755 | Transferase Activity, Transferring Amino-Acyl Groups |
| 0 | GO:0016757 | Transferase Activity, Transferring Glycosyl Groups |
| 0 | GO:0016758 | Transferase Activity, Transferring Hexosyl Groups |
| 0 | GO:0016769 | Transferase Activity, Transferring Nitrogenous Groups |
| 0 | GO:0016741 | Transferase Activity, Transferring One-Carbon Groups |
| 0 | GO:0016763 | Transferase Activity, Transferring Pentosyl Groups |
| 0 | GO:0016782 | Transferase Activity, Transferring Sulfur-Containing Groups |
| 0 | GO:0033572 | Transferrin Transport |
| 0 | GO:0050431 | Transforming Growth Factor Beta Binding |
| 0 | GO:0071604 | Transforming Growth Factor Beta Production |
| 0 | GO:0005160 | Transforming Growth Factor Beta Receptor Binding |
| 0 | GO:0007179 | Transforming Growth Factor Beta Receptor Signaling Pathway |
| 0 | GO:0005072 | Transforming Growth Factor Beta Receptor, Cytoplasmic Mediator Activity |
| 0 | GO:0005024 | Transforming Growth Factor Beta-Activated Receptor Activity |
| 0 | GO:0046915 | Transition Metal Ion Transmembrane Transporter Activity |
| 0 | GO:0000041 | Transition Metal Ion Transport |
| 0 | GO:0006412 | Translation |
| 0 | GO:0003746 | Translation Elongation Factor Activity |
| 0 | GO:0008135 | Translation Factor Activity, Nucleic Acid Binding |
| 0 | GO:0003743 | Translation Initiation Factor Activity |
| 0 | GO:0031369 | Translation Initiation Factor Binding |
| 0 | GO:0045182 | Translation Regulator Activity |
| 0 | GO:0090079 | Translation Regulator Activity, Nucleic Acid Binding |
| 0 | GO:0006414 | Translational Elongation |
| 0 | GO:0006413 | Translational Initiation |
| 0 | GO:0006415 | Translational Termination |
| 0 | GO:0019199 | Transmembrane Receptor Protein Kinase Activity |
| 0 | GO:0019198 | Transmembrane Receptor Protein Phosphatase Activity |
| 0 | GO:0004675 | Transmembrane Receptor Protein Serine/Threonine Kinase Activity |
| 0 | GO:0007178 | Transmembrane Receptor Protein Serine/Threonine Kinase Signaling Pathway |
| 0 | GO:0004714 | Transmembrane Receptor Protein Tyrosine Kinase Activity |
| 0 | GO:0005001 | Transmembrane Receptor Protein Tyrosine Phosphatase Activity |
| 0 | GO:0030133 | Transport Vesicle |
| 0 | GO:0030658 | Transport Vesicle Membrane |
| 0 | GO:0006099 | Tricarboxylic Acid Cycle |
| 0 | GO:0019432 | Triglyceride Biosynthetic Process |

| | | |
|---|------------|---|
| 0 | GO:0019433 | Triglyceride Catabolic Process |
| 0 | GO:0070328 | Triglyceride Homeostasis |
| 0 | GO:0004806 | Triglyceride Lipase Activity |
| 0 | GO:0006641 | Triglyceride Metabolic Process |
| 0 | GO:0034385 | Triglyceride-Rich Lipoprotein Particle |
| 0 | GO:0007351 | Tripartite Regional Subdivision |
| 0 | GO:0072506 | Trivalent Inorganic Anion Homeostasis |
| 0 | GO:0043039 | Trna Aminoacylation |
| 0 | GO:0006418 | Trna Aminoacylation For Protein Translation |
| 0 | GO:0000049 | Trna Binding |
| 0 | GO:0006399 | Trna Metabolic Process |
| 0 | GO:0008175 | Trna Methyltransferase Activity |
| 0 | GO:0006400 | Trna Modification |
| 0 | GO:0008033 | Trna Processing |
| 0 | GO:0004549 | Trna-Specific Ribonuclease Activity |
| 0 | GO:0001829 | Trophectodermal Cell Differentiation |
| 0 | GO:0005523 | Tropomyosin Binding |
| 0 | GO:0006569 | Tryptophan Catabolic Process |
| 0 | GO:0006568 | Tryptophan Metabolic Process |
| 0 | GO:0060606 | Tube Closure |
| 0 | GO:0035295 | Tube Development |
| 0 | GO:0035148 | Tube Formation |
| 0 | GO:0035239 | Tube Morphogenesis |
| 0 | GO:0015631 | Tubulin Binding |
| 0 | GO:0004835 | Tubulin-Tyrosine Ligase Activity |
| 0 | GO:0042533 | Tumor Necrosis Factor Biosynthetic Process |
| 0 | GO:0032640 | Tumor Necrosis Factor Production |
| 0 | GO:0005164 | Tumor Necrosis Factor Receptor Binding |
| 0 | GO:0032813 | Tumor Necrosis Factor Receptor Superfamily Binding |
| 0 | GO:0071706 | Tumor Necrosis Factor Superfamily Cytokine Production |
| 0 | GO:0005031 | Tumor Necrosis Factor-Activated Receptor Activity |
| 0 | GO:0033209 | Tumor Necrosis Factor-Mediated Signaling Pathway |
| 0 | GO:0000155 | Two-Component Sensor Activity |
| 0 | GO:0042092 | Type 2 Immune Response |
| 0 | GO:0003309 | Type B Pancreatic Cell Differentiation |
| 0 | GO:0045351 | Type I Interferon Biosynthetic Process |
| 0 | GO:0032606 | Type I Interferon Production |
| 0 | GO:0060337 | Type I Interferon-Mediated Signaling Pathway |
| 0 | GO:0007260 | Tyrosine Phosphorylation Of Stat Protein |
| 0 | GO:0042508 | Tyrosine Phosphorylation Of Stat1 Protein |
| 0 | GO:0042503 | Tyrosine Phosphorylation Of Stat3 Protein |
| 0 | GO:0042506 | Tyrosine Phosphorylation Of Stat5 Protein |
| 0 | GO:0005689 | U12-Type Spliceosomal Complex |
| 0 | GO:0043130 | Ubiquitin Binding |
| 0 | GO:0000151 | Ubiquitin Ligase Complex |
| 0 | GO:0031625 | Ubiquitin Protein Ligase Binding |
| 0 | GO:0004221 | Ubiquitin Thiolesterase Activity |
| 0 | GO:0006511 | Ubiquitin-Dependent Protein Catabolic Process |
| 0 | GO:0004842 | Ubiquitin-Protein Ligase Activity |
| 0 | GO:0004843 | Ubiquitin-Specific Protease Activity |
| 0 | GO:0035250 | Udp-Galactosyltransferase Activity |
| 0 | GO:0008194 | Udp-Glycosyltransferase Activity |
| 0 | GO:0051082 | Unfolded Protein Binding |
| 0 | GO:0006636 | Unsaturated Fatty Acid Biosynthetic Process |
| 0 | GO:0033559 | Unsaturated Fatty Acid Metabolic Process |
| 0 | GO:0046415 | Urate Metabolic Process |

| | | |
|---|------------|---|
| 0 | GO:0001657 | Ureteric Bud Development |
| 0 | GO:0060675 | Ureteric Bud Morphogenesis |
| 0 | GO:0001655 | Urogenital System Development |
| 0 | GO:0060065 | Uterus Development |
| 0 | GO:0033151 | V(D)J Recombination |
| 0 | GO:0005775 | Vacuolar Lumen |
| 0 | GO:0005774 | Vacuolar Membrane |
| 0 | GO:0044437 | Vacuolar Part |
| 0 | GO:0016471 | Vacuolar Proton-Transporting V-Type Atpase Complex |
| 0 | GO:0007034 | Vacuolar Transport |
| 0 | GO:0005773 | Vacuole |
| 0 | GO:0007033 | Vacuole Organization |
| 0 | GO:0060068 | Vagina Development |
| 0 | GO:0010573 | Vascular Endothelial Growth Factor Production |
| 0 | GO:0048010 | Vascular Endothelial Growth Factor Receptor Signaling Pathway |
| 0 | GO:0003018 | Vascular Process In Circulatory System |
| 0 | GO:0014829 | Vascular Smooth Muscle Contraction |
| 0 | GO:0001944 | Vasculature Development |
| 0 | GO:0001570 | Vasculogenesis |
| 0 | GO:0042310 | Vasoconstriction |
| 0 | GO:0042311 | Vasodilation |
| 0 | GO:0060841 | Venous Blood Vessel Development |
| 1 | GO:0021517 | Ventral Spinal Cord Development |
| 1 | GO:0021514 | Ventral Spinal Cord Interneuron Differentiation |
| 0 | GO:0055015 | Ventricular Cardiac Muscle Cell Development |
| 0 | GO:0055012 | Ventricular Cardiac Muscle Cell Differentiation |
| 0 | GO:0003229 | Ventricular Cardiac Muscle Tissue Development |
| 0 | GO:0055010 | Ventricular Cardiac Muscle Tissue Morphogenesis |
| 0 | GO:0003281 | Ventricular Septum Development |
| 0 | GO:0060412 | Ventricular Septum Morphogenesis |
| 0 | GO:0021591 | Ventricular System Development |
| 0 | GO:0000038 | Very Long-Chain Fatty Acid Metabolic Process |
| 0 | GO:0034361 | Very-Low-Density Lipoprotein Particle |
| 0 | GO:0030120 | Vesicle Coat |
| 0 | GO:0006901 | Vesicle Coating |
| 0 | GO:0048278 | Vesicle Docking |
| 0 | GO:0006904 | Vesicle Docking Involved In Exocytosis |
| 0 | GO:0006906 | Vesicle Fusion |
| 0 | GO:0051648 | Vesicle Localization |
| 0 | GO:0031983 | Vesicle Lumen |
| 0 | GO:0012506 | Vesicle Membrane |
| 0 | GO:0016050 | Vesicle Organization |
| 0 | GO:0006903 | Vesicle Targeting |
| 0 | GO:0048199 | Vesicle Targeting, To, From Or Within Golgi |
| 0 | GO:0047496 | Vesicle Transport Along Microtubule |
| 0 | GO:0042598 | Vesicular Fraction |
| 0 | GO:0046718 | Viral Entry Into Host Cell |
| 0 | GO:0019080 | Viral Genome Expression |
| 0 | GO:0019079 | Viral Genome Replication |
| 0 | GO:0019058 | Viral Infectious Cycle |
| 0 | GO:0016032 | Viral Reproduction |
| 0 | GO:0022415 | Viral Reproductive Process |
| 0 | GO:0019083 | Viral Transcription |
| 0 | GO:0019048 | Virus-Host Interaction |
| 1 | GO:0007632 | Visual Behavior |
| 1 | GO:0008542 | Visual Learning |

| | | |
|---|------------|--|
| 0 | GO:0007601 | Visual Perception |
| 0 | GO:0006776 | Vitamin A Metabolic Process |
| 0 | GO:0070279 | Vitamin B6 Binding |
| 0 | GO:0019842 | Vitamin Binding |
| 0 | GO:0009110 | Vitamin Biosynthetic Process |
| 0 | GO:0042359 | Vitamin D Metabolic Process |
| 0 | GO:0042809 | Vitamin D Receptor Binding |
| 0 | GO:0006766 | Vitamin Metabolic Process |
| 0 | GO:0051180 | Vitamin Transport |
| 0 | GO:0051183 | Vitamin Transporter Activity |
| 1 | GO:0008308 | Voltage-Gated Anion Channel Activity |
| 1 | GO:0005245 | Voltage-Gated Calcium Channel Activity |
| 1 | GO:0005891 | Voltage-Gated Calcium Channel Complex |
| 1 | GO:0022843 | Voltage-Gated Cation Channel Activity |
| 1 | GO:0022832 | Voltage-Gated Channel Activity |
| 1 | GO:0005247 | Voltage-Gated Chloride Channel Activity |
| 1 | GO:0005244 | Voltage-Gated Ion Channel Activity |
| 1 | GO:0005249 | Voltage-Gated Potassium Channel Activity |
| 1 | GO:0008076 | Voltage-Gated Potassium Channel Complex |
| 1 | GO:0005248 | Voltage-Gated Sodium Channel Activity |
| 1 | GO:0001518 | Voltage-Gated Sodium Channel Complex |
| 0 | GO:0030104 | Water Homeostasis |
| 0 | GO:0005372 | Water Transmembrane Transporter Activity |
| 0 | GO:0006833 | Water Transport |
| 0 | GO:0006767 | Water-Soluble Vitamin Metabolic Process |
| 0 | GO:0050872 | White Fat Cell Differentiation |
| 0 | GO:0022829 | Wide Pore Channel Activity |
| 0 | GO:0016055 | Wnt Receptor Signaling Pathway |
| 0 | GO:0007223 | Wnt Receptor Signaling Pathway, Calcium Modulating Pathway |
| 0 | GO:0060071 | Wnt Receptor Signaling Pathway, Planar Cell Polarity Pathway |
| 0 | GO:0042813 | Wnt-Activated Receptor Activity |
| 0 | GO:0017147 | Wnt-Protein Binding |
| 0 | GO:0044319 | Wound Healing, Spreading Of Cells |
| 0 | GO:0035313 | Wound Healing, Spreading Of Epidermal Cells |
| 0 | GO:0050699 | Ww Domain Binding |
| 0 | GO:0006805 | Xenobiotic Metabolic Process |
| 0 | GO:0001741 | Xy Body |
| 0 | GO:0030018 | Z Disc |
| 0 | GO:0055069 | Zinc Ion Homeostasis |
| 0 | GO:0071577 | Zinc Ion Transmembrane Transport |
| 0 | GO:0005385 | Zinc Ion Transmembrane Transporter Activity |
| 0 | GO:0006829 | Zinc Ion Transport |
| 0 | GO:0031638 | Zymogen Activation |
| 0 | GO:0042588 | Zymogen Granule |

Related to neuronal

| function | Gene Set ID | Gene Set Name |
|----------|--|---|
| 0 | REACTOME_3_-UTR-MEDIATED_TRANSLATIONAL_REGULATION | 3 -Utr-Mediated Translational Regulation |
| 0 | REACTOME_A_THIRD_PROTEOLYTIC_CLEAVAGE_RELEASES_NICD | A Third Proteolytic Cleavage Releases Nicd |
| 0 | REACTOME_ABC-FAMILY_PROTEINS_MEDIATED_TRANSPORT | Abc-Family Proteins Mediated Transport |
| 0 | REACTOME_ABCA_TRANSPORTERS_IN_LIPID_HOMEOSTASIS | Abca Transporters In Lipid Homeostasis |
| 0 | REACTOME_ABORTIVE_ELONGATION_OF_HIV-1_TRANSCRIPT_IN_THE_ABSENCE_OF_TAT | Abortive Elongation Of Hiv-1 Transcript In The Absence Of Tat |
| 1 | REACTOME_ACETYLCHOLINE_BINDING_AND_DOWNSTREAM_EVENTS | Acetylcholine Binding And Downstream Events |
| 1 | REACTOME_ACETYLCHOLINE_NEUROTRANSMITTER_RELEASE_CYCLE | Acetylcholine Neurotransmitter Release Cycle |
| 0 | REACTOME_ACTIVATED_AMPK_STIMULATES_FATTY-ACID_OXIDATION_IN_MUSCLE | Activated Ampk Stimulates Fatty-Acid Oxidation In Muscle |
| 0 | REACTOME_ACTIVATED_TAK1_MEDIATES_P38_MAPK_ACTIVATION | Activated Tak1 Mediates P38 Mapk Activation |
| 0 | REACTOME_ACTIVATED_TLR4_SIGNALLING | Activated Tlr4 Signalling |
| 0 | REACTOME_ACTIVATION_OF_APCC_AND_APCCDC20_MEDIATED_DEGRADATION_OF_MITOTIC_PROTEINS | Activation Of Apcc And Apccdc20 Mediated Degradation Of Mitotic Proteins |
| 0 | REACTOME_ACTIVATION_OF_ATR_IN_RESPONSE_TO_REPLICATION_STRESS | Activation Of Atr In Response To Replication Stress |
| 0 | REACTOME_ACTIVATION_OF_BH3-ONLY_PROTEINS | Activation Of Bh3-Only Proteins |
| 1 | REACTOME_ACTIVATION_OF_CA-PERMEABLE_KAINATE_RECEPTOR | Activation Of Ca-Permeable Kainate Receptor |
| 0 | REACTOME_ACTIVATION_OF_CHAPERONE_GENES_BY_XBP1S | Activation Of Chaperone Genes By Xbp1S |
| 0 | REACTOME_ACTIVATION_OF_CHAPERONES_BY_ATF6-ALPHA | Activation Of Chaperones By Atf6-Alpha |
| 0 | REACTOME_ACTIVATION_OF_CHAPERONES_BY_IRE1ALPHA | Activation Of Chaperones By Ire1Alpha |
| 0 | REACTOME_ACTIVATION_OF_DNA_FRAGMENTATION_FACTOR | Activation Of Dna Fragmentation Factor |
| 1 | REACTOME_ACTIVATION_OF_G_PROTEIN_GATED_POTASSIUM_CHANNELS | Activation Of G Protein Gated Potassium Channels |
| 1 | REACTOME_ACTIVATION_OF_GABAB_RECEPTORS | Activation Of Gabab Receptors |
| 0 | REACTOME_ACTIVATION_OF_GENES_BY_ATF4 | Activation Of Genes By Atf4 |
| 1 | REACTOME_ACTIVATION_OF_KAINATE_RECEPTORS_UPON_GLUTAMATE_BINDING | Activation Of Kainate Receptors Upon Glutamate Binding |
| 1 | REACTOME_ACTIVATION_OF_NICOTINIC_ACETYLCHOLINE_RECEPTORS | Activation Of Nicotinic Acetylcholine Receptors |
| 1 | REACTOME_ACTIVATION_OF_NMDA_RECEPTOR_UPON_GLUTAMATE_BINDING_AND_POSTSYNAPTIC_EVENTS | Activation Of Nmda Receptor Upon Glutamate Binding And Postsynaptic Events |
| 0 | REACTOME_ACTIVATION_OF_RAC | Activation Of Rac |
| 0 | REACTOME_ACTIVATION_OF_THE_AP-1_FAMILY_OF_TRANSCRIPTION_FACTORS | Activation Of The Ap-1 Family Of Transcription Factors |
| 0 | REACTOME_ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP-BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S | Activation Of The Mrna Upon Binding Of The Cap-Binding Complex And Eifs And Subsequent Binding To 43S |
| 0 | REACTOME_ACTIVATION_OF_THE_PRE-REPLICATIVE_COMPLEX | Activation Of The Pre-Replicative Complex |
| 0 | REACTOME_ADAPTIVE_IMMUNE_SYSTEM | Adaptive Immune System |
| 0 | REACTOME_ADENYLATE_CYCLASE_ACTIVATING_PATHWAY | Adenylate Cyclase Activating Pathway |
| 0 | REACTOME_ADENYLATE_CYCLASE_INHIBITORY_PATHWAY | Adenylate Cyclase Inhibitory Pathway |
| 0 | REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS | Adherens Junctions Interactions |
| 0 | REACTOME_ADP_SIGNALLING_THROUGH_P2Y_PURINOCEPTOR_1 | Adp Signalling Through P2Y Purinoceptor 1 |
| 0 | REACTOME_ADP_SIGNALLING_THROUGH_P2Y_PURINOCEPTOR_12 | Adp Signalling Through P2Y Purinoceptor 12 |
| 0 | REACTOME_ADVANCED_GLYCOSYLATION_ENDPRODUCT_RECEPTOR_SIGNALING | Advanced Glycosylation Endproduct Receptor Signaling |
| 0 | REACTOME_AKT_PHOSPHORYLATES_TARGETS_IN_THE_CYTOSOL | Akt Phosphorylates Targets In The Cytosol |
| 0 | REACTOME_AMINE_COMPOUND_SLC_TRANSPORTERS | Amine Compound Slc Transporters |
| 0 | REACTOME_AMINE_LIGAND-BINDING_RECEPTORS | Amine Ligand-Binding Receptors |
| 0 | REACTOME_AMINE-DERIVED_HORMONES | Amine-Derived Hormones |
| 0 | REACTOME_AMINO_ACID_AND_OLIGOPEPTIDE_SLC_TRANSPORTERS | Amino Acid And Oligopeptide Slc Transporters |
| 0 | REACTOME_AMINO_ACID_SYNTHESIS_AND_INTERCONVERSION_TRANSAMINATION | Amino Acid Synthesis And Interconversion Transamination |
| 0 | REACTOME_AMINO_ACID_TRANSPORT_ACROSS_THE_PLASMA_MEMBRANE | Amino Acid Transport Across The Plasma Membrane |
| 0 | REACTOME_AMYLOIDS | Amyloids |
| 0 | REACTOME_ANDROGEN_BIOSYNTHESIS | Androgen Biosynthesis |
| 0 | REACTOME_ANTIGEN_PRESENTATION_FOLDING_ASSEMBLY_AND_PEPTIDE_LOADING_OF_CLASS_I_MHC | Antigen Presentation Folding Assembly And Peptide Loading Of Class I Mhc |
| 0 | REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION | Antigen Processing Ubiquitination Proteasome Degradation |
| 0 | REACTOME_ANTIGEN_PROCESSING-CROSS_PRESENTATION | Antigen Processing-Cross Presentation |
| 0 | REACTOME_ANTIVIRAL_MECHANISM_BY_IFN-STIMULATED_GENES | Antiviral Mechanism By Ifn-Stimulated Genes |
| 0 | REACTOME_APC-CDC20_MEDIATED_DEGRADATION_OF_NEK2A | Apc-Cdc20 Mediated Degradation Of Nek2A |
| 0 | REACTOME_APCC-MEDIATED_DEGRADATION_OF_CELL_CYCLE_PROTEINS | Apcc-Mediated Degradation Of Cell Cycle Proteins |
| 0 | REACTOME_APCCDC20_MEDIATED_DEGRADATION_OF_CYCLIN_B | Apccdc20 Mediated Degradation Of Cyclin B |
| 0 | REACTOME_APCCDC20_MEDIATED_DEGRADATION_OF_MITOTIC_PROTEINS | Apccdc20 Mediated Degradation Of Mitotic Proteins |
| 0 | REACTOME_APCCDC20_MEDIATED_DEGRADATION_OF_SECURIN | Apccdc20 Mediated Degradation Of Securin |
| 0 | REACTOME_APCCDH1_MEDIATED_DEGRADATION_OF_CDC20_AND_OTHER_APCCDH1_TARGETED_PROTEIN: APOPTOSIS | Apccdh1 Mediated Degradation Of Cdc20 And Other Apccdh1 Targeted Proteins In Late Mitosisearly G1 Apoptosis |
| 0 | REACTOME_APOPTOSIS | Apoptosis |
| 0 | REACTOME_APOPTOSIS_INDUCED_DNA_FRAGMENTATION | Apoptosis Induced Dna Fragmentation |
| 0 | REACTOME_APOPTOTIC_CLEAVAGE_OF_CELL_ADHESION__PROTEINS | Apoptotic Cleavage Of Cell Adhesion Proteins |

| | | |
|---|---|--|
| 0 | REACTOME_APOPTOTIC_CLEAVAGE_OF_CELLULAR_PROTEINS | Apoptotic Cleavage Of Cellular Proteins |
| 0 | REACTOME_APOPTOTIC_EXECUTION__PHASE | Apoptotic Execution Phase |
| 0 | REACTOME_AQUAPORIN-MEDIATED_TRANSPORT | Aquaporin-Mediated Transport |
| 0 | REACTOME_ARMS-MEDIATED_ACTIVATION | Arms-Mediated Activation |
| 0 | REACTOME_ASPARAGINE_N-LINKED_GLYCOSYLATION | Asparagine N-Linked Glycosylation |
| 0 | REACTOME_ASSEMBLY_OF_HIV_VIRION | Assembly Of HIV Virion |
| 0 | REACTOME_ASSEMBLY_OF_THE_PRE-REPLICATIVE_COMPLEX | Assembly Of The Pre-Replicative Complex |
| 0 | REACTOME_ASSOCIATION_OF_LICENSING_FACTORS_WITH_THE_PRE-REPLICATIVE_COMPLEX | Association Of Licensing Factors With The Pre-Replicative Complex |
| 0 | REACTOME_ASSOCIATION_OF_TRICCT_WITH_TARGET_PROTEINS_DURING_BIOSYNTHESIS | Association Of Tricct With Target Proteins During Biosynthesis |
| 0 | REACTOME_AUTODEGRADATION_OF_CDH1_BY_CDH1APCC | Autodegradation Of Cdh1 By Cdh1Apcc |
| 0 | REACTOME_AUTODEGRADATION_OF_THE_E3_UBIQUITIN_LIGASE_COP1 | Autodegradation Of The E3 Ubiquitin Ligase Cop1 |
| 1 | REACTOME_AXON_GUIDANCE | Axon Guidance |
| 0 | REACTOME_BASE_EXCISION_REPAIR | Base Excision Repair |
| 0 | REACTOME_BASE-FREE_SUGAR-PHOSPHATE_REMOVAL_VIA_THE_SINGLE-NUCLEOTIDE_REPLACEMENT_PATHWAY | Base-Free Sugar-Phosphate Removal Via The Single-Nucleotide Replacement Pathway |
| 0 | REACTOME_BASIGIN_INTERACTIONS | Basigin Interactions |
| 0 | REACTOME_BETA_DEFENSINS | Beta Defensins |
| 0 | REACTOME_BETA-CATENIN_PHOSPHORYLATION_CASCADE | Beta-Catenin Phosphorylation Cascade |
| 0 | REACTOME_BILE_ACID_AND_BILE_SALT_METABOLISM | Bile Acid And Bile Salt Metabolism |
| 0 | REACTOME_BILE_SALT_AND_ORGANIC_ANION_SLC_TRANSPORTERS | Bile Salt And Organic Anion Slc Transporters |
| 0 | REACTOME_BIOLOGICAL_OXIDATIONS | Biological Oxidations |
| 0 | REACTOME_BIOSYNTHESIS_OF_THE_N-GLYCAN_PRECURSOR_DOLICHOL_LIPID-LINKED_OLIGOSACCHARIDE_LLO | Biosynthesis Of The N-Glycan Precursor Dolichol Lipid-Linked Oligosaccharide Llo And Transfer To A Nascent Protein |
| 0 | REACTOME_BMAL1CLOCKNPAS2_ACTIVATES_GENE_EXPRESSION | Bmal1Clocknpas2 Activates Gene Expression |
| 0 | REACTOME_BOTULINUM_NEUROTOXICITY | Botulinum Neurotoxicity |
| 0 | REACTOME_BRANCHED-CHAIN_AMINO_ACID_CATABOLISM | Branched-Chain Amino Acid Catabolism |
| 1 | REACTOME_CA-DEPENDENT_EVENTS | Ca-Dependent Events |
| 0 | REACTOME_CALCITONIN-LIKE_LIGAND_RECEPTORS | Calcitonin-Like Ligand Receptors |
| 0 | REACTOME_CALMODULIN_INDUCED_EVENTS | Calmodulin Induced Events |
| 0 | REACTOME_CALNEXINCALRETICULIN_CYCLE | Calnexincalreticulin Cycle |
| 0 | REACTOME_CAM_PATHWAY | Cam Pathway |
| 0 | REACTOME_CAP-DEPENDENT_TRANSLATION_INITIATION | Cap-Dependent Translation Initiation |
| 0 | REACTOME_CASPASE-MEDIATED_CLEAVAGE_OF_CYTOSKELETAL_PROTEINS | Caspase-Mediated Cleavage Of Cytoskeletal Proteins |
| 0 | REACTOME_CD28_CO-STIMULATION | Cd28 Co-Stimulation |
| 0 | REACTOME_CD28_DEPENDENT_PI3KAKT_SIGNALING | Cd28 Dependent Pi3Kakt Signaling |
| 0 | REACTOME_CD28_DEPENDENT_VAV1_PATHWAY | Cd28 Dependent Vav1 Pathway |
| 0 | REACTOME_CDC20PHOSPHO-APCC_MEDIATED_DEGRADATION_OF_CYCLIN_A | Cdc20Phospho-Apcc Mediated Degradation Of Cyclin A |
| 0 | REACTOME_CDC6_ASSOCIATION_WITH_THE_ORCORIGIN_COMPLEX | Cdc6 Association With The Orcorigin Complex |
| 0 | REACTOME_CDK-MEDIATED_PHOSPHORYLATION_AND_REMOVAL_OF_CDC6 | Cdk-Mediated Phosphorylation And Removal Of Cdc6 |
| 0 | REACTOME_CDO_IN_MYOGENESIS | Cdo In Myogenesis |
| 0 | REACTOME_CDT1_ASSOCIATION_WITH_THE_CDC6ORCORIGIN_COMPLEX | Cdt1 Association With The Cdc6Orcorigin Complex |
| 0 | REACTOME_CELL_CYCLE | Cell Cycle |
| 0 | REACTOME_CELL_CYCLE_CHECKPOINTS | Cell Cycle Checkpoints |
| 0 | REACTOME_CELL_CYCLE_MITOTIC | Cell Cycle Mitotic |
| 0 | REACTOME_CELL_DEATH_SIGNALLING_VIA_NRAGE_NRF1_AND_NADE | Cell Death Signalling Via Nrage Nrf1 And Nade |
| 0 | REACTOME_CELL_JUNCTION_ORGANIZATION | Cell Junction Organization |
| 0 | REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL | Cell Surface Interactions At The Vascular Wall |
| 0 | REACTOME_CELL-CELL_COMMUNICATION | Cell-Cell Communication |
| 0 | REACTOME_CELL-CELL_JUNCTION_ORGANIZATION | Cell-Cell Junction Organization |
| 0 | REACTOME_CELL-EXTRACELLULAR_MATRIX_INTERACTIONS | Cell-Extracellular Matrix Interactions |
| 0 | REACTOME_CENTROSOME_MATURATION | Centrosome Maturation |
| 0 | REACTOME_CGMP_EFFECTS | Cgmp Effects |
| 0 | REACTOME_CHAPERONIN-MEDIATED_PROTEIN_FOLDING | Chaperonin-Mediated Protein Folding |
| 0 | REACTOME_CHEMOKINE_RECEPTORS_BIND_CHEMOKINES | Chemokine Receptors Bind Chemokines |
| 0 | REACTOME_CHOLESTEROL_BIOSYNTHESIS | Cholesterol Biosynthesis |
| 0 | REACTOME_CHROMOSOME_MAINTENANCE | Chromosome Maintenance |
| 0 | REACTOME_CHYLOMICRON-MEDIATED_LIPID_TRANSPORT | Chylomicron-Mediated Lipid Transport |
| 1 | REACTOME_CIRCADIAN_CLOCK | Circadian Clock |
| 0 | REACTOME_CITRIC_ACID_CYCLE_TCA_CYCLE | Citric Acid Cycle Tca Cycle |
| 0 | REACTOME_CLASS_A1_RHODOPSIN-LIKE_RECEPTORS | Class A1 Rhodopsin-Like Receptors |
| 0 | REACTOME_CLASS_B2_SECRETIN_FAMILY_RECEPTORS | Class B2 Secretin Family Receptors |

| | | |
|---|--|---|
| 1 | REACTOME_CLASS_C3_METABOTROPIC_Glutamatepheromone_Receptors | Class C3 Metabotropic Glutamatepheromone Receptors |
| 0 | REACTOME_CLASS_I_MHC_Mediated_Antigen_Processing_Presentation | Class I Mhc Mediated Antigen Processing Presentation |
| 0 | REACTOME_CLASSICAL_Antibody-Mediated_Complement_Activation | Classical Antibody-Mediated Complement Activation |
| 0 | REACTOME_Clathrin_Derived_Vesicle_Budding | Clathrin Derived Vesicle Budding |
| 0 | REACTOME_Cleavage_Of_Growing_Transcript_In_The_Termination_Region | Cleavage Of Growing Transcript In The Termination Region |
| 0 | REACTOME_COMMON_Pathway | Common Pathway |
| 0 | REACTOME_COMPLEMENT_Cascade | Complement Cascade |
| 0 | REACTOME_CONVERSION_From_Apcccdc20_To_Apcccdh1_In_Late_Anaphase | Conversion From Apcccdc20 To Apcccdh1 In Late Anaphase |
| 0 | REACTOME_COOPERATION_Of_Prefoldin_And_Triccct_In_Actin_And_Tubulin_Folding | Cooperation Of Prefoldin And Triccct In Actin And Tubulin Folding |
| 0 | REACTOME_COPI_Mediated_Transport | Copi Mediated Transport |
| 0 | REACTOME_COSTIMULATION_By_The_Cd28_Family | Costimulation By The Cd28 Family |
| 0 | REACTOME_CREATION_Of_C4_And_C2_Activators | Creation Of C4 And C2 Activators |
| 1 | REACTOME_CREB_Phosphorylation_Through_The_Activation_Of_Camkii | Creb Phosphorylation Through The Activation Of Camkii |
| 1 | REACTOME_CREB_Phosphorylation_Through_The_Activation_Of_Ras | Creb Phosphorylation Through The Activation Of Ras |
| 1 | REACTOME_CRMPs_In_Sema3A_Signaling | Crmps In Sema3A Signaling |
| 0 | REACTOME_CROSS-Presentation_Of_Soluble_Exogenous_Antigens_Endosomes | Cross-Presentation Of Soluble Exogenous Antigens Endosomes |
| 0 | REACTOME_CTLA4_Inhibitory_Signaling | Ctla4 Inhibitory Signaling |
| 0 | REACTOME_CYCLIN_Ab1_Associated_Events_During_G2M_Transition | Cyclin Ab1 Associated Events During G2M Transition |
| 0 | REACTOME_CYCLIN_Acdk2-Associated_Events_At_S_Phase_Entry | Cyclin Acdk2-Associated Events At S Phase Entry |
| 0 | REACTOME_CYCLIN_D_Associated_Events_In_G1 | Cyclin D Associated Events In G1 |
| 0 | REACTOME_CYCLIN_E_Associated_Events_During_G1S_Transition | Cyclin E Associated Events During G1S Transition |
| 0 | REACTOME_Cytochrome_P450_-_Arranged_By_Substrate_Type | Cytochrome P450 - Arranged By Substrate Type |
| 0 | REACTOME_Cytokine_Signaling_In_Immune_System | Cytokine Signaling In Immune System |
| 0 | REACTOME_Cytosolic_Sulfonation_Of_Small_Molecules | Cytosolic Sulfonation Of Small Molecules |
| 0 | REACTOME_Cytosolic_Trna_Aminoacylation | Cytosolic Trna Aminoacylation |
| 1 | REACTOME_DAG_And_Ip3_Signaling | Dag And Ip3 Signaling |
| 1 | REACTOME_DARPP-32_Events | Darpp-32 Events |
| 1 | REACTOME_DCC_Mediated_Attractive_Signaling | Dcc Mediated Attractive Signaling |
| 0 | REACTOME_DEADENYLATION_Of_Mrna | Deadenylation Of Mrna |
| 0 | REACTOME_DEADENYLATION-DEPENDENT_Mrna_Decay | Deadenylation-Dependent Mrna Decay |
| 0 | REACTOME_DEATH_Receptor_Signalling | Death Receptor Signalling |
| 0 | REACTOME_DEFENSINS | Defensins |
| 0 | REACTOME_DEGRADATION_Of_Beta-Catenin_By_The_Destruction_Complex | Degradation Of Beta-Catenin By The Destruction Complex |
| 1 | REACTOME_DEPOLARIZATION_Of_The_Presynaptic_Terminal_Triggers_The_Opening_Of_Calcium_Channels | Depolarization Of The Presynaptic Terminal Triggers The Opening Of Calcium Channels |
| 0 | REACTOME_DEPOSITION_Of_New_Cenpa-Containing_Nucleosomes_At_The_Centromere | Deposition Of New Cenpa-Containing Nucleosomes At The Centromere |
| 0 | REACTOME_DESTABILIZATION_Of_Mrna_By_Auf1_Hnrnp_D0 | Destabilization Of Mrna By Auf1 Hnrnp D0 |
| 0 | REACTOME_DESTABILIZATION_Of_Mrna_By_Butyrate_Response_Factor_1_Brf1 | Destabilization Of Mrna By Butyrate Response Factor 1 Brf1 |
| 0 | REACTOME_DESTABILIZATION_Of_Mrna_By_Ksrp | Destabilization Of Mrna By Ksrp |
| 0 | REACTOME_DESTABILIZATION_Of_Mrna_By_Tristetraprolin_Ttp | Destabilization Of Mrna By Tristetraprolin Ttp |
| 0 | REACTOME_DEVELOPMENTAL_BIOLOGY | Developmental Biology |
| 0 | REACTOME_DIABETES_Pathways | Diabetes Pathways |
| 0 | REACTOME_DNA_REPAIR | Dna Repair |
| 0 | REACTOME_DNA_REPLICATION | Dna Replication |
| 0 | REACTOME_DNA_REPLICATION_Pre-Initiation | Dna Replication Pre-Initiation |
| 0 | REACTOME_DNA_STRAND_Elongation | Dna Strand Elongation |
| 1 | REACTOME_DOPAMINE_Neurotransmitter_Release_Cycle | Dopamine Neurotransmitter Release Cycle |
| 0 | REACTOME_DOUBLE-STRAND_BREAK_Repair | Double-Strand Break Repair |
| 0 | REACTOME_DOWNREGULATION_Of_Errb2Erbb3_Signaling | Downregulation Of Errb2Erbb3 Signaling |
| 0 | REACTOME_DOWNSTREAM_SIGNAL_Transduction | Downstream Signal Transduction |
| 0 | REACTOME_DOWNSTREAM_Signaling_Of_Activated_Fgfr | Downstream Signaling Of Activated Fgfr |
| 0 | REACTOME_DOWNSTREAM_Tcr_Signaling | Downstream Tcr Signaling |
| 1 | REACTOME_DSCAM_Interactions | Dscam Interactions |
| 0 | REACTOME_DUAL_Incision_Reaction_In_Gg-Ner | Dual Incision Reaction In Gg-Ner |
| 0 | REACTOME_DUAL_Incision_Reaction_In_Tc-Ner | Dual Incision Reaction In Tc-Ner |
| 0 | REACTOME_E2F_Mediated_Regulation_Of_Dna_Replication | E2F Mediated Regulation Of Dna Replication |
| 0 | REACTOME_E2F-ENABLED_Inhibition_Of_Pre-Replication_Complex_Formation | E2F-Enabled Inhibition Of Pre-Replication Complex Formation |
| 0 | REACTOME_EARLY_Phase_Of_Hiv_Life_Cycle | Early Phase Of Hiv Life Cycle |
| 0 | REACTOME_EFFECTS_Of_Pip2_Hydrolysis | Effects Of Pip2 Hydrolysis |
| 0 | REACTOME_EGFR_Downregulation | Egfr Downregulation |

| | | |
|---|--|---|
| 0 | REACTOME_EGFR_INTERACTS_WITH_PHOSPHOLIPASE_C-GAMMA | Egfr Interacts With Phospholipase C-Gamma |
| 0 | REACTOME_EICOSANOID_LIGAND-BINDING_RECEPTORS | Eicosanoid Ligand-Binding Receptors |
| 0 | REACTOME_ELONGATION_ARREST_AND_RECOVERY | Elongation Arrest And Recovery |
| 0 | REACTOME_ENDOGENOUS_STEROLS | Endogenous Sterols |
| 0 | REACTOME_ENDOSOMAL_SORTING_COMPLEX_REQUIRED_FOR_TRANSPORT_ESCRT | Endosomal Sorting Complex Required For Transport Escrt |
| 0 | REACTOME_ENERGY_DEPENDENT_REGULATION_OF_MTOR_BY_LKB1-AMPK | Energy Dependent Regulation Of Mtor By Lkb1-Ampk |
| 0 | REACTOME_ENOS_ACTIVATION_AND_REGULATION | Enos Activation And Regulation |
| 0 | REACTOME_ER-PHAGOSOME_PATHWAY | Er-Phagosome Pathway |
| 0 | REACTOME_ERKMAPK_TARGETS | Erkmapk Targets |
| 0 | REACTOME_ERKS_ARE_INACTIVATED | Erks Are Inactivated |
| 0 | REACTOME_ETHANOL_OXIDATION | Ethanol Oxidation |
| 0 | REACTOME_EUKARYOTIC_TRANSLATION_ELONGATION | Eukaryotic Translation Elongation |
| 0 | REACTOME_EUKARYOTIC_TRANSLATION_INITIATION | Eukaryotic Translation Initiation |
| 0 | REACTOME_EUKARYOTIC_TRANSLATION_TERMINATION | Eukaryotic Translation Termination |
| 0 | REACTOME_EXPORT_OF_VIRAL_RIBONUCLEOPROTEINS_FROM_NUCLEUS | Export Of Viral Ribonucleoproteins From Nucleus |
| 0 | REACTOME_EXTENSION_OF_TELOMERES | Extension Of Telomeres |
| 0 | REACTOME_EXTRINSIC_PATHWAY_FOR_APOPTOSIS | Extrinsic Pathway For Apoptosis |
| 0 | REACTOME_FACILITATIVE_NA-INDEPENDENT_GLUCOSE_TRANSPORTERS | Facilitative Na-Independent Glucose Transporters |
| 0 | REACTOME_FACTORS_INVOLVED_IN_MEGAKARYOCYTE_DEVELOPMENT_AND_PLATELET_PRODUCTION | Factors Involved In Megakaryocyte Development And Platelet Production |
| 0 | REACTOME_FANCONI_ANEMIA_PATHWAY | Fanconi Anemia Pathway |
| 0 | REACTOME_FATTY_ACID_TRIACYLGLYCEROL_AND_KETONE_BODY_METABOLISM | Fatty Acid Triacylglycerol And Ketone Body Metabolism |
| 0 | REACTOME_FATTY_ACYL-COA_BIOSYNTHESIS | Fatty Acyl-Coa Biosynthesis |
| 0 | REACTOME_FGFR_LIGAND_BINDING_AND_ACTIVATION | Fgfr Ligand Binding And Activation |
| 0 | REACTOME_FGFR1_LIGAND_BINDING_AND_ACTIVATION | Fgfr1 Ligand Binding And Activation |
| 0 | REACTOME_FGFR1C_LIGAND_BINDING_AND_ACTIVATION | Fgfr1C Ligand Binding And Activation |
| 0 | REACTOME_FGFR2_LIGAND_BINDING_AND_ACTIVATION | Fgfr2 Ligand Binding And Activation |
| 0 | REACTOME_FGFR2C_LIGAND_BINDING_AND_ACTIVATION | Fgfr2C Ligand Binding And Activation |
| 0 | REACTOME_FGFR3_LIGAND_BINDING_AND_ACTIVATION | Fgfr3 Ligand Binding And Activation |
| 0 | REACTOME_FGFR3C_LIGAND_BINDING_AND_ACTIVATION | Fgfr3C Ligand Binding And Activation |
| 0 | REACTOME_FGFR4_LIGAND_BINDING_AND_ACTIVATION | Fgfr4 Ligand Binding And Activation |
| 0 | REACTOME_FORMATION_OF_A_POOL_OF_FREE_40S_SUBUNITS | Formation Of A Pool Of Free 40S Subunits |
| 0 | REACTOME_FORMATION_OF_ATP_BY_CHEMIOSMOTIC_COUPLING | Formation Of Atp By Chemiosmotic Coupling |
| 0 | REACTOME_FORMATION_OF_FIBRIN_CLOT_CLOTTING_CASCADE | Formation Of Fibrin Clot Clotting Cascade |
| 0 | REACTOME_FORMATION_OF_HIV-1_ELONGATION_COMPLEX_CONTAINING_HIV-1_TAT | Formation Of Hiv-1 Elongation Complex Containing Hiv-1 Tat |
| 0 | REACTOME_FORMATION_OF_HIV-1_ELONGATION_COMPLEX_IN_THE_ABSENCE_OF_HIV-1_TAT | Formation Of Hiv-1 Elongation Complex In The Absence Of Hiv-1 Tat |
| 0 | REACTOME_FORMATION_OF_INCISION_COMPLEX_IN_GG-NER | Formation Of Incision Complex In Gg-Ner |
| 0 | REACTOME_FORMATION_OF_RNA_POL_II_ELONGATION_COMPLEX | Formation Of Rna Pol Ii Elongation Complex |
| 0 | REACTOME_FORMATION_OF_THE_EARLY_ELONGATION_COMPLEX | Formation Of The Early Elongation Complex |
| 0 | REACTOME_FORMATION_OF_THE_HIV-1_EARLY_ELONGATION_COMPLEX | Formation Of The Hiv-1 Early Elongation Complex |
| 0 | REACTOME_FORMATION_OF_THE_TERNARY_COMPLEX_AND_SUBSEQUENTLY_THE_43S_COMPLEX | Formation Of The Ternary Complex And Subsequently The 43S Complex |
| 0 | REACTOME_FORMATION_OF_TRANSCRIPTION-COUPLED_NER_TC-NER_REPAIR_COMPLEX | Formation Of Transcription-Coupled Ner Tc-Ner Repair Complex |
| 0 | REACTOME_FORMATION_OF_TUBULIN_FOLDING_INTERMEDIATES_BY_CCTTRIC | Formation Of Tubulin Folding Intermediates By Ccttric |
| 0 | REACTOME_FRS2-MEDIATED_ACTIVATION | Frs2-Mediated Activation |
| 0 | REACTOME_FRS2-MEDIATED_CASCADE | Frs2-Mediated Cascade |
| 0 | REACTOME_G_ALPHA_1213_SIGNALLING_EVENTS | G Alpha 1213 Signalling Events |
| 0 | REACTOME_G_ALPHA_I_SIGNALLING_EVENTS | G Alpha I Signalling Events |
| 0 | REACTOME_G_ALPHA_Q_SIGNALLING_EVENTS | G Alpha Q Signalling Events |
| 0 | REACTOME_G_ALPHA_S_SIGNALLING_EVENTS | G Alpha S Signalling Events |
| 0 | REACTOME_G_ALPHA_Z_SIGNALLING_EVENTS | G Alpha Z Signalling Events |
| 0 | REACTOME_G_BETAGAMMA_SIGNALLING_THROUGH_PI3KGAMMA | G Betagamma Signalling Through Pi3Kgamma |
| 0 | REACTOME_G_BETAGAMMA_SIGNALLING_THROUGH_PLG_BETA | G Betagamma Signalling Through Plc Beta |
| 1 | REACTOME_G_PROTEIN_GATED_POTASSIUM_CHANNELS | G Protein Gated Potassium Channels |
| 1 | REACTOME_G-PROTEIN_ACTIVATION | G-Protein Activation |
| 1 | REACTOME_G-PROTEIN_BETAGAMMA_SIGNALLING | G-Protein Betagamma Signalling |
| 1 | REACTOME_G-PROTEIN_MEDIATED_EVENTS | G-Protein Mediated Events |
| 0 | REACTOME_G0_AND_EARLY_G1 | G0 And Early G1 |
| 0 | REACTOME_G1_PHASE | G1 Phase |
| 0 | REACTOME_G1S_DNA_DAMAGE_CHECKPOINTS | G1S Dna Damage Checkpoints |
| 0 | REACTOME_G1S_TRANSITION | G1S Transition |

| | | |
|---|--|---|
| 0 | REACTOME_G1S-SPECIFIC_TRANSCRIPTION | G1S-Specific Transcription |
| 0 | REACTOME_G2M_CHECKPOINTS | G2M Checkpoints |
| 0 | REACTOME_G2M_TRANSITION | G2M Transition |
| 1 | REACTOME_GAB1_SIGNALOSOME | Gab1 Signalosome |
| 1 | REACTOME_GABA_A_RECEPTOR_ACTIVATION | Gaba A Receptor Activation |
| 1 | REACTOME_GABA_B_RECEPTOR_ACTIVATION | Gaba B Receptor Activation |
| 1 | REACTOME_GABA_RECEPTOR_ACTIVATION | Gaba Receptor Activation |
| 1 | REACTOME_GABA_SYNTHESIS_RELEASE_REUPTAKE_AND_DEGRADATION | Gaba Synthesis Release Reuptake And Degradation |
| 0 | REACTOME_GAMMA-CARBOXYLATION_TRANSPORT_AND_AMINO-TERMINAL_CLEAVAGE_OF_PROTEINS | Gamma-Carboxylation Transport And Amino-Terminal Cleavage Of Proteins |
| 0 | REACTOME_GAP_JUNCTION_ASSEMBLY | Gap Junction Assembly |
| 0 | REACTOME_GAP_JUNCTION_DEGRADATION | Gap Junction Degradation |
| 0 | REACTOME_GAP_JUNCTION_TRAFFICKING | Gap Junction Trafficking |
| 0 | REACTOME_GAP_JUNCTION_TRAFFICKING_AND_REGULATION | Gap Junction Trafficking And Regulation |
| 0 | REACTOME_GAP-FILLING_DNA_REPAIR_SYNTHESIS_AND_LIGATION_IN_GG-NER | Gap-Filling Dna Repair Synthesis And Ligation In Gg-Ner |
| 0 | REACTOME_GAP-FILLING_DNA_REPAIR_SYNTHESIS_AND_LIGATION_IN_TC-NER | Gap-Filling Dna Repair Synthesis And Ligation In Tc-Ner |
| 0 | REACTOME_GENERATION_OF_SECOND_MESSENGER_MOLECULES | Generation Of Second Messenger Molecules |
| 0 | REACTOME_GENERIC_TRANSCRIPTION_PATHWAY | Generic Transcription Pathway |
| 0 | REACTOME_GLOBAL_GENOMIC_NER_GG-NER | Global Genomic Ner Gg-Ner |
| 0 | REACTOME_GLUCAGON_SIGNALING_IN_METABOLIC_REGULATION | Glucagon Signaling In Metabolic Regulation |
| 0 | REACTOME_GLUCAGON-TYPE_LIGAND_RECEPTORS | Glucagon-Type Ligand Receptors |
| 0 | REACTOME_GLUONEOGENESIS | Gluconeogenesis |
| 0 | REACTOME_GLUCOSE_METABOLISM | Glucose Metabolism |
| 0 | REACTOME_GLUCOSE_TRANSPORT | Glucose Transport |
| 1 | REACTOME_GLUTAMATE_BINDING_ACTIVATION_OF_AMPA_RECEPTORS_AND_SYNAPTIC_PLASTICITY | Glutamate Binding Activation Of Ampa Receptors And Synaptic Plasticity |
| 1 | REACTOME_GLUTAMATE_NEUROTRANSMITTER_RELEASE_CYCLE | Glutamate Neurotransmitter Release Cycle |
| 0 | REACTOME_GLUTATHIONE_CONJUGATION | Glutathione Conjugation |
| 0 | REACTOME_GLUTATHIONE_SYNTHESIS_AND_RECYCLING | Glutathione Synthesis And Recycling |
| 0 | REACTOME_GLYCOGEN_BREAKDOWN_GLYCOGENOLYSIS | Glycogen Breakdown Glycogenolysis |
| 0 | REACTOME_GLYCOLYSIS | Glycolysis |
| 0 | REACTOME_GLYCOSPHINGOLIPID_METABOLISM | Glycosphingolipid Metabolism |
| 0 | REACTOME_GOLGI_ASSOCIATED_VESICLE_BIOGENESIS | Golgi Associated Vesicle Biogenesis |
| 0 | REACTOME_GOLGI_TO_ER_RETROGRADE_TRANSPORT | Golgi To Er Retrograde Transport |
| 1 | REACTOME_GPCR_LIGAND_BINDING | Gpcr Ligand Binding |
| 0 | REACTOME_GPVI-MEDIATED_ACTIVATION_CASCADE | Gpvi-Mediated Activation Cascade |
| 0 | REACTOME_GRB2_EVENTS_IN_EGFR_SIGNALING | Grb2 Events In Egfr Signaling |
| 0 | REACTOME_GRB2_EVENTS_IN_ERBB2_SIGNALING | Grb2 Events In Erbb2 Signaling |
| 0 | REACTOME_GRB2SOS_PROVIDES_LINKAGE_TO_MAPK_SIGNALING_FOR_INTERGRINS | Grb2Sos Provides Linkage To Mapk Signaling For Intergrins |
| 0 | REACTOME_GROWTH_HORMONE_RECEPTOR_SIGNALING | Growth Hormone Receptor Signaling |
| 0 | REACTOME_GTP_HYDROLYSIS_AND_JOINING_OF_THE_60S_RIBOSOMAL_SUBUNIT | Gtp Hydrolysis And Joining Of The 60S Ribosomal Subunit |
| 0 | REACTOME_HDL-MEDIATED_LIPID_TRANSPORT | Hdl-Mediated Lipid Transport |
| 0 | REACTOME_HEMOSTASIS | Hemostasis |
| 0 | REACTOME_HEXOSE_TRANSPORT | Hexose Transport |
| 1 | REACTOME_HIGHLY_CALCIIUM_PERMEABLE_POSTSYNAPTIC_NICOTINIC_ACETYLCHOLINE_RECEPTORS | Highly Calcium Permeable Postsynaptic Nicotinic Acetylcholine Receptors |
| 0 | REACTOME_HIV_INFECTION | Hiv Infection |
| 0 | REACTOME_HIV_LIFE_CYCLE | Hiv Life Cycle |
| 0 | REACTOME_HIV-1_ELONGATION_ARREST_AND_RECOVERY | Hiv-1 Elongation Arrest And Recovery |
| 0 | REACTOME_HIV-1_TRANSCRIPTION_ELONGATION | Hiv-1 Transcription Elongation |
| 0 | REACTOME_HIV-1_TRANSCRIPTION_INITIATION | Hiv-1 Transcription Initiation |
| 0 | REACTOME_HOMOLOGOUS_RECOMBINATION_REPAIR | Homologous Recombination Repair |
| 0 | REACTOME_HOMOLOGOUS_RECOMBINATION_REPAIR_OF_REPLICATION-INDEPENDENT_DOUBLE-STRAND_BREAKS | Homologous Recombination Repair Of Replication-Independent Double-Strand Breaks |
| 0 | REACTOME_HORMONE_LIGAND-BINDING_RECEPTORS | Hormone Ligand-Binding Receptors |
| 0 | REACTOME_HORMONE-SENSITIVE_LIPASE_HSL-MEDIATED_TRIACYLGLYCEROL_HYDROLYSIS | Hormone-Sensitive Lipase Hsl-Mediated Triacylglycerol Hydrolysis |
| 0 | REACTOME_HOST_INTERACTIONS_OF_HIV_FACTORS | Host Interactions Of Hiv Factors |
| 0 | REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON-LYMPHOID_CELL | Immunoregulatory Interactions Between A Lymphoid And A Non-Lymphoid Cell |
| 0 | REACTOME_INACTIVATION_OF_APCC_VIA_DIRECT_INHIBITION_OF_THE_APCC_COMPLEX | Inactivation Of Apcc Via Direct Inhibition Of The Apcc Complex |
| 0 | REACTOME_INCRETIN_SYNTHESIS_SECRETION_AND_INACTIVATION | Incretin Synthesis Secretion And Inactivation |
| 0 | REACTOME_INFLAMMASOMES | Inflammasomes |
| 0 | REACTOME_INFLUENZA_INFECTION | Influenza Infection |
| 0 | REACTOME_INFLUENZA_LIFE_CYCLE | Influenza Life Cycle |

| | | |
|---|---|--|
| 0 | REACTOME_INFLUENZA_VIRAL_RNA_TRANSCRIPTION_AND_REPLICATION | Influenza Viral Rna Transcription And Replication |
| 1 | REACTOME_INHIBITION_OF_VOLTAGE_GATED_CA2_CHANNELS_VIA_GBETAGAMMA_SUBUNITS | Inhibition Of Voltage Gated Ca2 Channels Via Gbetagamma Subunits |
| 0 | REACTOME_INHIBITION_OF_ADENYLATE_CYCLASE_PATHWAY | Inhibition Of Adenylate Cyclase Pathway |
| 0 | REACTOME_INHIBITION_OF_INSULIN_SECRETION_BY_ADRENALINENORADRENALINE | Inhibition Of Insulin Secretion By Adrenalinenoradrenaline |
| 0 | REACTOME_INHIBITION_OF_REPLICATION_INITIATION_OF_DAMAGED_DNA_BY_RBE2F1 | Inhibition Of Replication Initiation Of Damaged Dna By Rbe2F1 |
| 0 | REACTOME_INHIBITION_OF_THE_PROTEOLYTIC_ACTIVITY_OF_APCC_REQUIRED_FOR_THE_ONSET_OF_ANAPHASE | Inhibition Of The Proteolytic Activity Of Apcc Required For The Onset Of Anaphase By Mitotic Spindle Checkpoint Components |
| 0 | REACTOME_INITIAL_TRIGGERING_OF_COMPLEMENT | Initial Triggering Of Complement |
| 0 | REACTOME_INNATE_IMMUNE_SYSTEM | Innate Immune System |
| 0 | REACTOME_INSULIN_RECEPTOR_RECYCLING | Insulin Receptor Recycling |
| 0 | REACTOME_INSULIN_RECEPTOR_SIGNALLING_CASCADE | Insulin Receptor Signalling Cascade |
| 0 | REACTOME_INSULIN_SYNTHESIS_AND_PROCESSING | Insulin Synthesis And Processing |
| 0 | REACTOME_INTEGRATION_OF_ENERGY_METABOLISM | Integration Of Energy Metabolism |
| 0 | REACTOME_INTEGRIN_ALPHAIIIB_BETA3_SIGNALING | Integrin AlphaIIB Beta3 Signaling |
| 0 | REACTOME_INTEGRIN_CELL_SURFACE_INTERACTIONS | Integrin Cell Surface Interactions |
| 0 | REACTOME_INTERACTION_BETWEEN_L1_AND_ANKYRINS | Interaction Between L1 And Ankyrins |
| 0 | REACTOME_INTERACTIONS_OF_REV_WITH_HOST_CELLULAR_PROTEINS | Interactions Of Rev With Host Cellular Proteins |
| 0 | REACTOME_INTERACTIONS_OF_VPR_WITH_HOST_CELLULAR_PROTEINS | Interactions Of Vpr With Host Cellular Proteins |
| 0 | REACTOME_INTERFERON_ALPHABETA_SIGNALING | Interferon Alphabeta Signaling |
| 0 | REACTOME_INTERFERON_GAMMA_SIGNALING | Interferon Gamma Signaling |
| 0 | REACTOME_INTERFERON_SIGNALING | Interferon Signaling |
| 0 | REACTOME_INTERLEUKIN_RECEPTOR_SHC_SIGNALING | Interleukin Receptor Shc Signaling |
| 0 | REACTOME_INTERLEUKIN-1_SIGNALING | Interleukin-1 Signaling |
| 0 | REACTOME_INTERLEUKIN-2_SIGNALING | Interleukin-2 Signaling |
| 0 | REACTOME_INTERLEUKIN-3_5_AND_GM-CSF_SIGNALING | Interleukin-3 5 And Gm-Csf Signaling |
| 0 | REACTOME_INTERLEUKIN-6_SIGNALING | Interleukin-6 Signaling |
| 0 | REACTOME_INTERLEUKIN-7_SIGNALING | Interleukin-7 Signaling |
| 0 | REACTOME_INTRINSIC_PATHWAY | Intrinsic Pathway |
| 0 | REACTOME_INTRINSIC_PATHWAY_FOR_APOPTOSIS | Intrinsic Pathway For Apoptosis |
| 0 | REACTOME_INWARDLY_RECTIFYING_K_CHANNELS | Inwardly Rectifying K Channels |
| 0 | REACTOME_ION_CHANNEL_TRANSPORT | Ion Channel Transport |
| 0 | REACTOME_ION_TRANSPORT_BY_P-TYPE_ATPASES | Ion Transport By P-Type Atpases |
| 0 | REACTOME_IONOTROPIC_ACTIVITY_OF_KAINATE_RECEPTORS | Ionotropic Activity Of Kainate Receptors |
| 0 | REACTOME_IRAK2_MEDIATED_ACTIVATION_OF_TAK1_COMPLEX | Irak2 Mediated Activation Of Tak1 Complex |
| 0 | REACTOME_IRAK2_MEDIATED_ACTIVATION_OF_TAK1_COMPLEX_UPON_TLR78_OR_9_STIMULATION | Irak2 Mediated Activation Of Tak1 Complex Upon Tlr78 Or 9 Stimulation |
| 0 | REACTOME_IRON_UPTAKE_AND_TRANSPORT | Iron Uptake And Transport |
| 0 | REACTOME_IRS-MEDIATED_SIGNALLING | Irs-Mediated Signalling |
| 0 | REACTOME_IRS-RELATED_EVENTS | Irs-Related Events |
| 0 | REACTOME_ISG15_ANTIVIRAL_MECHANISM | Isg15 Antiviral Mechanism |
| 0 | REACTOME_JNK_C-JUN_KINASES_PHOSPHORYLATION_AND_ACTIVATION_MEDIATED_BY_ACTIVATED_HUMAN_TAK1 | Jnk C-Jun Kinases Phosphorylation And Activation Mediated By Activated Human Tak1 |
| 0 | REACTOME_KINESINS | Kinesins |
| 0 | REACTOME_L13A-MEDIATED_TRANSLATIONAL_SILENCING_OF_CERULOPLASMIN_EXPRESSION | L13A-Mediated Translational Silencing Of Ceruloplasmin Expression |
| 0 | REACTOME_L1CAM_INTERACTIONS | L1Cam Interactions |
| 0 | REACTOME_LAGGING_STRAND_SYNTHESIS | Lagging Strand Synthesis |
| 0 | REACTOME_LATE_PHASE_OF_HIV_LIFE_CYCLE | Late Phase Of Hiv Life Cycle |
| 0 | REACTOME_LEADING_STRAND_SYNTHESIS | Leading Strand Synthesis |
| 0 | REACTOME_LIGAND-GATED_ION_CHANNEL_TRANSPORT | Ligand-Gated Ion Channel Transport |
| 0 | REACTOME_LIPID_DIGESTION_MOBILIZATION_AND_TRANSPORT | Lipid Digestion Mobilization And Transport |
| 0 | REACTOME_LIPOPROTEIN_METABOLISM | Lipoprotein Metabolism |
| 0 | REACTOME_LOSS_OF_NLP_FROM_MITOTIC_CENTROSOMES | Loss Of Nlp From Mitotic Centrosomes |
| 0 | REACTOME_LOSS_OF_PROTEINS_REQUIRED_FOR_INTERPHASE_MICROTUBULE_ORGANIZATIONFROM_THE_CENTROSOME | Loss Of Proteins Required For Interphase Microtubule Organizationfrom The Centrosome |
| 0 | REACTOME_LYSOSOME_VESICLE_BIOGENESIS | Lysosome Vesicle Biogenesis |
| 0 | REACTOME_M_PHASE | M Phase |
| 0 | REACTOME_MAP_KINASE_ACTIVATION_IN_TLR_CASCADE | Map Kinase Activation In Tlr Cascade |
| 0 | REACTOME_MAPK_TARGETS_NUCLEAR_EVENTS_MEDIATED_BY_MAP_KINASES | Mapk Targets Nuclear Events Mediated By Map Kinases |
| 0 | REACTOME_MEIOSIS | Meiosis |
| 0 | REACTOME_MEIOTIC_RECOMBINATION | Meiotic Recombination |
| 0 | REACTOME_MEIOTIC_SYNAPSIS | Meiotic Synapsis |
| 0 | REACTOME_MEMBRANE_BINDING_AND_TARGETING_OF_GAG_PROTEINS | Membrane Binding And Targeting Of Gag Proteins |
| 0 | REACTOME_MEMBRANE_TRAFFICKING | Membrane Trafficking |

| | | |
|---|---|--|
| 0 | REACTOME_METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES | Metabolism Of Amino Acids And Derivatives |
| 0 | REACTOME_METABOLISM_OF_CARBOHYDRATES | Metabolism Of Carbohydrates |
| 0 | REACTOME_METABOLISM_OF_LIPIDS_AND_LIPOPROTEINS | Metabolism Of Lipids And Lipoproteins |
| 0 | REACTOME_METABOLISM_OF_MRNA | Metabolism Of Mrna |
| 0 | REACTOME_METABOLISM_OF_NITRIC_OXIDE | Metabolism Of Nitric Oxide |
| 0 | REACTOME_METABOLISM_OF_NON-CODING_RNA | Metabolism Of Non-Coding Rna |
| 0 | REACTOME_METABOLISM_OF_NUCLEOTIDES | Metabolism Of Nucleotides |
| 0 | REACTOME_METABOLISM_OF_POLYAMINES | Metabolism Of Polyamines |
| 0 | REACTOME_METABOLISM_OF_PORPHYRINS | Metabolism Of Porphyrins |
| 0 | REACTOME_METABOLISM_OF_PROTEINS | Metabolism Of Proteins |
| 0 | REACTOME_METABOLISM_OF_RNA | Metabolism Of Rna |
| 0 | REACTOME_METABOLISM_OF_STEROID_HORMONES_AND_VITAMINS_A_AND_D | Metabolism Of Steroid Hormones And Vitamins A And D |
| 0 | REACTOME_METABOLISM_OF_VITAMINS_AND_COFACTORS | Metabolism Of Vitamins And Cofactors |
| 0 | REACTOME_METABOLISM_OF_WATER-SOLUBLE_VITAMINS_AND_COFACTORS | Metabolism Of Water-Soluble Vitamins And Cofactors |
| 0 | REACTOME_METAL_ION_SLC_TRANSPORTERS | Metal Ion Slc Transporters |
| 0 | REACTOME_MG1_TRANSITION | Mg1 Transition |
| 0 | REACTOME_MICRORNA_MIRNA_BIOGENESIS | Micrna Mirna Biogenesis |
| 0 | REACTOME_MITOCHONDRIAL_FATTY_ACID_BETA-OXIDATION | Mitochondrial Fatty Acid Beta-Oxidation |
| 0 | REACTOME_MITOCHONDRIAL_TRNA_AMINOACYLATION | Mitochondrial Trna Aminoacylation |
| 0 | REACTOME_MITOTIC_G1-G1S_PHASES | Mitotic G1-G1S Phases |
| 0 | REACTOME_MITOTIC_G2-G2M_PHASES | Mitotic G2-G2M Phases |
| 0 | REACTOME_MITOTIC_M-MG1_PHASES | Mitotic M-Mg1 Phases |
| 0 | REACTOME_MITOTIC_PROMETAPHASE | Mitotic Prometaphase |
| 0 | REACTOME_MITOTIC_SPINDLE_CHECKPOINT | Mitotic Spindle Checkpoint |
| 0 | REACTOME_MRNA_3-END_PROCESSING | Mrna 3-End Processing |
| 0 | REACTOME_MRNA_CAPPING | Mrna Capping |
| 0 | REACTOME_MRNA_DECAY_BY_3_TO_5_EXORIBONUCLEASE | Mrna Decay By 3 To 5 Exoribonuclease |
| 0 | REACTOME_MRNA_DECAY_BY_5_TO_3_EXORIBONUCLEASE | Mrna Decay By 5 To 3 Exoribonuclease |
| 0 | REACTOME_MRNA_PROCESSING | Mrna Processing |
| 0 | REACTOME_MRNA_SPLICING | Mrna Splicing |
| 0 | REACTOME_MRNA_SPLICING_-_MAJOR_PATHWAY | Mrna Splicing - Major Pathway |
| 0 | REACTOME_MRNA_SPLICING_-_MINOR_PATHWAY | Mrna Splicing - Minor Pathway |
| 0 | REACTOME_MTOR_SIGNALLING | Mtor Signalling |
| 0 | REACTOME_MTORC1-MEDIATED_SIGNALLING | Mtorc1-Mediated Signalling |
| 0 | REACTOME_MUSCLE_CONTRACTION | Muscle Contraction |
| 0 | REACTOME_MYD88_CASCADE_INITIATED_ON_PLASMA_MEMBRANE | Myd88 Cascade Initiated On Plasma Membrane |
| 0 | REACTOME_MYD88_DEPENDENT_CASCADE_INITIATED_ON_ENDOSOME | Myd88 Dependent Cascade Initiated On Endosome |
| 0 | REACTOME_MYD88-INDEPENDENT_CASCADE_INITIATED_ON_PLASMA_MEMBRANE | Myd88-Independent Cascade Initiated On Plasma Membrane |
| 0 | REACTOME_MYD88MAL_CASCADE_INITIATED_ON_PLASMA_MEMBRANE | Myd88Mal Cascade Initiated On Plasma Membrane |
| 0 | REACTOME_MYOGENESIS | Myogenesis |
| 0 | REACTOME_N-GLYCAN_ANTENNAE_ELONGATION | N-Glycan Antennae Elongation |
| 0 | REACTOME_N-GLYCAN_ANTENNAE_ELONGATION_IN_THE_MEDIALTRANS-GOLGI | N-Glycan Antennae Elongation In The Medialtrans-Golgi |
| 0 | REACTOME_N-GLYCAN_TRIMMING_IN_THE_ER_AND_CALNEXINCALRETICULIN_CYCLE | N-Glycan Trimming In The Er And Calnexincalreticulin Cycle |
| 1 | REACTOME_NACL-_DEPENDENT_NEUROTRANSMITTER_TRANSPORTERS | Nacl- Dependent Neurotransmitter Transporters |
| 1 | REACTOME_NCAM_SIGNALING_FOR_NEURITE_OUT-GROWTH | Ncam Signaling For Neurite Out-Growth |
| 1 | REACTOME_NCAM1_INTERACTIONS | Ncam1 Interactions |
| 0 | REACTOME_NEF_MEDIATED_DOWNREGULATION_OF_MHC_CLASS_I_COMPLEX_CELL_SURFACE_EXPRESSION | Nef Mediated Downregulation Of Mhc Class I Complex Cell Surface Expression |
| 0 | REACTOME_NEF-MEDIATES_DOWN_MODULATION_OF_CELL_SURFACE_RECEPTORS_BY_RECRUITING_THEM_TO_CLATHRIN_ADAPTERS | Nef-Mediates Down Modulation Of Cell Surface Receptors By Recruiting Them To Clathrin Adapters |
| 0 | REACTOME_NEGATIVE_REGULATION_OF_FGFR_SIGNALING | Negative Regulation Of Fgfr Signaling |
| 0 | REACTOME_NEGATIVE_REGULATORS_OF_RIG-IMDA5_SIGNALING | Negative Regulators Of Rig-Imda5 Signaling |
| 0 | REACTOME_NEPHRIN_INTERACTIONS | Nephrin Interactions |
| 0 | REACTOME_NEPNS2_INTERACTS_WITH_THE_CELLULAR_EXPORT_MACHINERY | Nepns2 Interacts With The Cellular Export Machinery |
| 1 | REACTOME_NETRIN-1_SIGNALING | Netrin-1 Signaling |
| 1 | REACTOME_NEURONAL_SYSTEM | Neuronal System |
| 1 | REACTOME_NEUROTRANSMITTER_RECEPTOR_BINDING_AND_DOWNSTREAM_TRANSMISSION_IN_THE_POSTSYNAPTIC_CELL | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell |
| 1 | REACTOME_NEUROTRANSMITTER_RELEASE_CYCLE | Neurotransmitter Release Cycle |
| 0 | REACTOME_NF-KB_ACTIVATION_THROUGH_FADD RIP-1_PATHWAY_MEDIATED_BY_CASPASE-8_AND_-10 | Nf-Kb Activation Through Faddrip-1 Pathway Mediated By Caspase-8 And -10 |
| 0 | REACTOME_NF-KB_IS_ACTIVATED_AND_SIGNALS_SURVIVAL | Nf-Kb Is Activated And Signals Survival |
| 0 | REACTOME_NFKB_AND_MAP_KINASES_ACTIVATION_MEDIATED_BY_TLR4_SIGNALING_REPERTOIRE | Nfkb And Map Kinases Activation Mediated By Tlr4 Signaling Repertoire |

| | | |
|---|--|--|
| 0 | REACTOME_NGF_SIGNALLING_VIA_TRKA_FROM_THE_PLASMA_MEMBRANE | Ngf Signalling Via Trka From The Plasma Membrane |
| 0 | REACTOME_NICD_TRAFFICS_TO_NUCLEUS | Nicd Traffics To Nucleus |
| 0 | REACTOME_NITRIC_OXIDE_STIMULATES_GUANYLATE_CYCLASE | Nitric Oxide Stimulates Guanylate Cyclase |
| 0 | REACTOME_NOD12_SIGNALING_PATHWAY | Nod12 Signaling Pathway |
| 0 | REACTOME_NONSENSE_MEDIATED_DECAY_ENHANCED_BY_THE_EXON_JUNCTION_COMPLEX | Nonsense Mediated Decay Enhanced By The Exon Junction Complex |
| 0 | REACTOME_NONSENSE_MEDIATED_DECAY_INDEPENDENT_OF_THE_EXON_JUNCTION_COMPLEX | Nonsense Mediated Decay Independent Of The Exon Junction Complex |
| 0 | REACTOME_NONSENSE-MEDIATED_DECAY | Nonsense-Mediated Decay |
| 1 | REACTOME_NOREPINEPHRINE_NEUROTRANSMITTER_RELEASE_CYCLE | Norepinephrine Neurotransmitter Release Cycle |
| 0 | REACTOME_NOTCH-HLH_TRANSCRIPTION_PATHWAY | Notch-Hlh Transcription Pathway |
| 0 | REACTOME_NRAGE_SIGNALS_DEATH_THROUGH_JNK | Nrage Signals Death Through Jnk |
| 0 | REACTOME_NRIF_SIGNALS_CELL_DEATH_FROM_THE_NUCLEUS | Nrif Signals Cell Death From The Nucleus |
| 0 | REACTOME_NUCLEAR_EVENTS_KINASE_AND_TRANSCRIPTION_FACTOR_ACTIVATION | Nuclear Events Kinase And Transcription Factor Activation |
| 0 | REACTOME_NUCLEAR_IMPORT_OF_REV_PROTEIN | Nuclear Import Of Rev Protein |
| 0 | REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY | Nuclear Receptor Transcription Pathway |
| 0 | REACTOME_NUCLEAR_SIGNALING_BY_ERBB4 | Nuclear Signaling By Erbb4 |
| 0 | REACTOME_NUCLEOSOME_ASSEMBLY | Nucleosome Assembly |
| 0 | REACTOME_NUCLEOTIDE_EXCISION_REPAIR | Nucleotide Excision Repair |
| 0 | REACTOME_NUCLEOTIDE-BINDING_DOMAIN_LEUCINE_RICH_REPEAT_CONTAINING_RECEPTOR_NLR_SIGNALING | Nucleotide-Binding Domain Leucine Rich Repeat Containing Receptor Nlr Signaling Pathways |
| 0 | REACTOME_NUCLEOTIDE-LIKE_PURINERGIC_RECEPTORS | Nucleotide-Like Purinergic Receptors |
| 0 | REACTOME_O-LINKED_GLYCOSYLATION_OF_MUCINS | O-Linked Glycosylation Of Mucins |
| 0 | REACTOME_OLFACTORY_SIGNALING_PATHWAY | Olfactory Signaling Pathway |
| 1 | REACTOME_OPIOID_SIGNALLING | Opioid Signalling |
| 0 | REACTOME_ORC1_REMOVAL_FROM_CHROMATIN | Orc1 Removal From Chromatin |
| 0 | REACTOME_ORGANIC_CATIONANIONZITTERION_TRANSPORT | Organic Cationanionzwitterion Transport |
| 0 | REACTOME_OTHER_SEMAPHORIN_INTERACTIONS | Other Semaphorin Interactions |
| 0 | REACTOME_P130CAS_LINKAGE_TO_MAPK_SIGNALING_FOR_INTEGRINS | P130Cas Linkage To Mapk Signaling For Integrins |
| 0 | REACTOME_P2Y_RECEPTORS | P2Y Receptors |
| 0 | REACTOME_P38MAPK_EVENTS | P38Mapk Events |
| 0 | REACTOME_P53-DEPENDENT_G1_DNA_DAMAGE_RESPONSE | P53-Dependent G1 Dna Damage Response |
| 0 | REACTOME_P53-DEPENDENT_G1S_DNA_DAMAGE_CHECKPOINT | P53-Dependent G1S Dna Damage Checkpoint |
| 0 | REACTOME_P53-INDEPENDENT_DNA_DAMAGE_RESPONSE | P53-Independent Dna Damage Response |
| 0 | REACTOME_P53-INDEPENDENT_G1S_DNA_DAMAGE_CHECKPOINT | P53-Independent G1S Dna Damage Checkpoint |
| 1 | REACTOME_P75_NTR_RECEPTOR-MEDIATED_SIGNALLING | P75 Ntr Receptor-Mediated Signalling |
| 1 | REACTOME_P75NTR_RECRUITS_SIGNALLING_COMPLEXES | P75Ntr Recruits Signalling Complexes |
| 0 | REACTOME_P75NTR_SIGNALS_VIA_NF-KB | P75Ntr Signals Via Nf-Kb |
| 0 | REACTOME_PACKAGING_OF_TELOMERE_ENDS | Packaging Of Telomere Ends |
| 0 | REACTOME_PASSIVE_TRANSPORT_BY_AQUAPORINS | Passive Transport By Aquaporins |
| 0 | REACTOME_PAUSING_AND_RECOVERY_OF_ELONGATION | Pausing And Recovery Of Elongation |
| 0 | REACTOME_PAUSING_AND_RECOVERY_OF_HIV-1_ELONGATION | Pausing And Recovery Of Hiv-1 Elongation |
| 0 | REACTOME_PAUSING_AND_RECOVERY_OF_TAT-MEDIATED_HIV-1_ELONGATION | Pausing And Recovery Of Tat-Mediated Hiv-1 Elongation |
| 0 | REACTOME_PD-1_SIGNALING | Pd-1 Signaling |
| 0 | REACTOME_PECAM1_INTERACTIONS | Pecam1 Interactions |
| 0 | REACTOME_PEPTIDE_CHAIN_ELONGATION | Peptide Chain Elongation |
| 0 | REACTOME_PEPTIDE_HORMONE_BIOSYNTHESIS | Peptide Hormone Biosynthesis |
| 0 | REACTOME_PEPTIDE_LIGAND-BINDING_RECEPTORS | Peptide Ligand-Binding Receptors |
| 0 | REACTOME_PERK_REGULATED_GENE_EXPRESSION | Perk Regulated Gene Expression |
| 0 | REACTOME_PEROXISOMAL_LIPID_METABOLISM | Peroxisomal Lipid Metabolism |
| 0 | REACTOME_PHASE_1_-_FUNCTIONALIZATION_OF_COMPOUNDS | Phase 1 - Functionalization Of Compounds |
| 0 | REACTOME_PHASE_II_CONJUGATION | Phase Ii Conjugation |
| 0 | REACTOME_PHOSPHOLIPASE_C-MEDIATED_CASCADE | Phospholipase C-Mediated Cascade |
| 0 | REACTOME_PHOSPHORYLATION_OF_CD3_AND_TCR_ZETA_CHAINS | Phosphorylation Of Cd3 And Tcr Zeta Chains |
| 0 | REACTOME_PHOSPHORYLATION_OF_THE_APCC | Phosphorylation Of The Apcc |
| 0 | REACTOME_PI-3K_CASCADE | Pi-3K Cascade |
| 0 | REACTOME_PI3K_CASCADE | PI3K Cascade |
| 0 | REACTOME_PI3K_EVENTS_IN_ERBB2_SIGNALING | PI3K Events In Erbb2 Signaling |
| 0 | REACTOME_PI3K_EVENTS_IN_ERBB4_SIGNALING | PI3K Events In Erbb4 Signaling |
| 0 | REACTOME_PI3KAKT_ACTIVATION | PI3Kakt Activation |
| 0 | REACTOME_PIP3_ACTIVATES_AKT_SIGNALING | Pip3 Activates Akt Signaling |
| 0 | REACTOME_PKA_ACTIVATION | Pka Activation |

| | | |
|---|--|---|
| 0 | REACTOME_PKA_ACTIVATION_IN_GLUCAGON_SIGNALLING | Pka Activation In Glucagon Signalling |
| 0 | REACTOME_PKA-MEDIATED_PHOSPHORYLATION_OF_CREB | Pka-Mediated Phosphorylation Of Creb |
| 0 | REACTOME_PKB-MEDIATED_EVENTS | Pkb-Mediated Events |
| 0 | REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION | Platelet Activation Signaling And Aggregation |
| 0 | REACTOME_PLATELET_ADHESION_TO_EXPOSED_COLLAGEN | Platelet Adhesion To Exposed Collagen |
| 0 | REACTOME_PLATELET_AGGREGATION_PLUG_FORMATION | Platelet Aggregation Plug Formation |
| 0 | REACTOME_PLATELET_CALCIIUM_HOMEOSTASIS | Platelet Calcium Homeostasis |
| 0 | REACTOME_PLATELET_DEGRANULATION | Platelet Degranulation |
| 0 | REACTOME_PLATELET_HOMEOSTASIS | Platelet Homeostasis |
| 0 | REACTOME_PLATELET_SENSITIZATION_BY_LDL | Platelet Sensitization By Ldl |
| 0 | REACTOME_PLC_BETA_MEDIATED_EVENTS | Plc Beta Mediated Events |
| 0 | REACTOME_PLC-GAMMA1_SIGNALLING | Plc-Gamma1 Signalling |
| 0 | REACTOME_PLCG1_EVENTS_IN_ERBB2_SIGNALING | Plcg1 Events In Erbb2 Signaling |
| 0 | REACTOME_POLYMERASE_SWITCHING | Polymerase Switching |
| 0 | REACTOME_POLYMERASE_SWITCHING_ON_THE_C-STRAND_OF_THE_TELOMERE | Polymerase Switching On The C-Strand Of The Telomere |
| 1 | REACTOME_POST_NMDA_RECEPTOR_ACTIVATION_EVENTS | Post Nmda Receptor Activation Events |
| 0 | REACTOME_POST-CHAPERONIN_TUBULIN_FOLDING_PATHWAY | Post-Chaperonin Tubulin Folding Pathway |
| 0 | REACTOME_POST-ELONGATION_PROCESSING_OF_INTRON-CONTAINING_PRE-MRNA | Post-Elongation Processing Of Intron-Containing Pre-Mrna |
| 0 | REACTOME_POST-ELONGATION_PROCESSING_OF_INTRONLESS_PRE-MRNA | Post-Elongation Processing Of Intronless Pre-Mrna |
| 0 | REACTOME_POST-ELONGATION_PROCESSING_OF_THE_TRANSCRIPT | Post-Elongation Processing Of The Transcript |
| 0 | REACTOME_POST-TRANSLATIONAL_MODIFICATION_SYNTHESIS_OF_GPI-ANCHORED_PROTEINS | Post-Translational Modification Synthesis Of Gpi-Anchored Proteins |
| 0 | REACTOME_POST-TRANSLATIONAL_PROTEIN_MODIFICATION | Post-Translational Protein Modification |
| 1 | REACTOME_POSTSYNAPTIC_NICOTINIC_ACETYLCHOLINE_RECEPTORS | Postsynaptic Nicotinic Acetylcholine Receptors |
| 1 | REACTOME_POTASSIUM_CHANNELS | Potassium Channels |
| 0 | REACTOME_PPARA_ACTIVATES_GENE_EXPRESSION | Ppara Activates Gene Expression |
| 0 | REACTOME_PREFOLDIN_MEDIATED_TRANSFER_OF_SUBSTRATE__TO_CCTTRIC | Prefoldin Mediated Transfer Of Substrate To Ccttric |
| 1 | REACTOME_PRESYNAPTIC_FUNCTION_OF_KAINATE_RECEPTORS | Presynaptic Function Of Kainate Receptors |
| 1 | REACTOME_PRESYNAPTIC_NICOTINIC_ACETYLCHOLINE_RECEPTORS | Presynaptic Nicotinic Acetylcholine Receptors |
| 0 | REACTOME_PROCESSING_OF_CAPPED_INTRON-CONTAINING_PRE-MRNA | Processing Of Capped Intron-Containing Pre-Mrna |
| 0 | REACTOME_PROCESSING_OF_CAPPED_INTRONLESS_PRE-MRNA | Processing Of Capped Intronless Pre-Mrna |
| 0 | REACTOME_PROCESSING_OF_INTRONLESS_PRE-MRNAS | Processing Of Intronless Pre-Mrnas |
| 0 | REACTOME_PROCESSIVE_SYNTHESIS_ON_THE_C-STRAND_OF_THE_TELOMERE | Processive Synthesis On The C-Strand Of The Telomere |
| 0 | REACTOME_PROCESSIVE_SYNTHESIS_ON_THE_LAGGING_STRAND | Processive Synthesis On The Lagging Strand |
| 1 | REACTOME_PROLACTIN_RECEPTOR_SIGNALING | Prolactin Receptor Signaling |
| 0 | REACTOME_PROLONGED_ERK_ACTIVATION_EVENTS | Prolonged Erk Activation Events |
| 0 | REACTOME_PROSTACYCLIN_SIGNALLING_THROUGH_PROSTACYCLIN_RECEPTOR | Prostacyclin Signalling Through Prostacyclin Receptor |
| 0 | REACTOME_PROSTANOID_METABOLISM | Prostanoid Metabolism |
| 0 | REACTOME_PROTEIN_FOLDING | Protein Folding |
| 0 | REACTOME_PROTEOLYTIC_CLEAVAGE_OF_SNARE_COMPLEX_PROTEINS | Proteolytic Cleavage Of Snare Complex Proteins |
| 0 | REACTOME_PTM_GAMMA_CARBOXYLATION_HYPUSINE_FORMATION_AND_ARYLSULFATASE_ACTIVATION | Ptm Gamma Carboxylation Hypusine Formation And Arylsulfatase Activation |
| 0 | REACTOME_PURINE_METABOLISM | Purine Metabolism |
| 0 | REACTOME_PURINE_RIBONUCLEOSIDE_MONOPHOSPHATE_BIOSYNTHESIS | Purine Ribonucleoside Monophosphate Biosynthesis |
| 0 | REACTOME_PURINE_SALVAGE | Purine Salvage |
| 0 | REACTOME_PYRIMIDINE_CATABOLISM | Pyrimidine Catabolism |
| 0 | REACTOME_PYRIMIDINE_METABOLISM | Pyrimidine Metabolism |
| 0 | REACTOME_PYRUVATE_METABOLISM | Pyruvate Metabolism |
| 0 | REACTOME_PYRUVATE_METABOLISM_AND_CITRIC_ACID_TCA_CYCLE | Pyruvate Metabolism And Citric Acid Tca Cycle |
| 0 | REACTOME_RAFMAP_KINASE_CASCADE | Rafmap Kinase Cascade |
| 0 | REACTOME_RAP1_SIGNALLING | Rap1 Signalling |
| 1 | REACTOME_RAS_ACTIVATION_UOPN_CA2_INFUX_THROUGH_NMDA_RECEPTOR | Ras Activation Uopn Ca2 Infux Through Nmda Receptor |
| 0 | REACTOME_RECRUITMENT_OF_MITOTIC_CENTROSOME_PROTEINS_AND_COMPLEXES | Recruitment Of Mitotic Centrosome Proteins And Complexes |
| 0 | REACTOME_RECRUITMENT_OF_NUMA_TO_MITOTIC_CENTROSOMES | Recruitment Of Numa To Mitotic Centrosomes |
| 0 | REACTOME_RECYCLING_OF_BILE_ACIDS_AND_SALTS | Recycling Of Bile Acids And Salts |
| 0 | REACTOME_RECYCLING_PATHWAY_OF_L1 | Recycling Pathway Of L1 |
| 0 | REACTOME_REDUCTION_OF_CYTOSOLIC_CA_LEVELS | Reduction Of Cytosolic Ca Levels |
| 0 | REACTOME_REGULATED_PROTEOLYSIS_OF_P75NTR | Regulated Proteolysis Of P75Ntr |
| 0 | REACTOME_REGULATION_OF_ACTIVATED_PAK-2P34_BY_PROTEASOME_MEDIATED_DEGRADATION | Regulation Of Activated Pak-2P34 By Proteasome Mediated Degradation |
| 0 | REACTOME_REGULATION_OF_AMPK_ACTIVITY_VIA_LKB1 | Regulation Of Ampk Activity Via Lkb1 |
| 0 | REACTOME_REGULATION_OF_APCC_ACTIVATORS_BETWEEN_G1S_AND_EARLY_ANAPHASE | Regulation Of Apcc Activators Between G1S And Early Anaphase |

| | | |
|---|---|--|
| 0 | REACTOME_REGULATION_OF_APOPTOSIS | Regulation Of Apoptosis |
| 0 | REACTOME_REGULATION_OF_BETA-CELL_DEVELOPMENT | Regulation Of Beta-Cell Development |
| 0 | REACTOME_REGULATION_OF_DNA_REPLICATION | Regulation Of Dna Replication |
| 0 | REACTOME_REGULATION_OF_GENE_EXPRESSION_IN_BETA_CELLS | Regulation Of Gene Expression In Beta Cells |
| 0 | REACTOME_REGULATION_OF_GLUKOKINASE_BY_GLUKOKINASE_REGULATORY_PROTEIN | Regulation Of Glucokinase By Glucokinase Regulatory Protein |
| 0 | REACTOME_REGULATION_OF_IFNA_SIGNALING | Regulation Of Ifna Signaling |
| 0 | REACTOME_REGULATION_OF_IFNG_SIGNALING | Regulation Of Ifng Signaling |
| 0 | REACTOME_REGULATION_OF_INSULIN_SECRETION | Regulation Of Insulin Secretion |
| 0 | REACTOME_REGULATION_OF_INSULIN_SECRETION_BY_ACETYLCHOLINE | Regulation Of Insulin Secretion By Acetylcholine |
| 0 | REACTOME_REGULATION_OF_INSULIN_SECRETION_BY_GLUCAGON-LIKE_PEPTIDE-1 | Regulation Of Insulin Secretion By Glucagon-Like Peptide-1 |
| 0 | REACTOME_REGULATION_OF_INSULIN-LIKE_GROWTH_FACTOR_IGF_ACTIVITY_BY_INSULIN-LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPs | Regulation Of Insulin-Like Growth Factor Igf Activity By Insulin-Like Growth Factor Binding Proteins Igfbps |
| 0 | REACTOME_REGULATION_OF_KIT_SIGNALING | Regulation Of Kit Signaling |
| 0 | REACTOME_REGULATION_OF_LIPID_METABOLISM_BY_PEROXISOME_PROLIFERATOR-ACTIVATED_RECEPTOR_ALPHA | Regulation Of Lipid Metabolism By Peroxisome Proliferator-Activated Receptor Alpha Pparalpha |
| 0 | REACTOME_REGULATION_OF_MITOTIC_CELL_CYCLE | Regulation Of Mitotic Cell Cycle |
| 0 | REACTOME_REGULATION_OF_MRNA_STABILITY_BY_PROTEINS_THAT_BIND_AU-RICH_ELEMENTS | Regulation Of Mrna Stability By Proteins That Bind Au-Rich Elements |
| 0 | REACTOME_REGULATION_OF_ORNITHINE_DECARBOXYLASE_ODC | Regulation Of Ornithine Decarboxylase Odc |
| 0 | REACTOME_REGULATION_OF_PYRUVATE_DEHYDROGENASE_PDH_COMPLEX | Regulation Of Pyruvate Dehydrogenase Pdh Complex |
| 0 | REACTOME_REGULATION_OF_SIGNALING_BY_CBL | Regulation Of Signaling By Cbl |
| 0 | REACTOME_REGULATION_OF_WATER_BALANCE_BY_RENAL_AQUAPORINS | Regulation Of Water Balance By Renal Aquaporins |
| 0 | REACTOME_REGULATORY_RNA_PATHWAYS | Regulatory Rna Pathways |
| 0 | REACTOME_REMOVAL_OF_DNA_PATCH_CONTAINING_ABASIC_RESIDUE | Removal Of Dna Patch Containing Abasic Residue |
| 0 | REACTOME_REMOVAL_OF_LICENSING_FACTORS_FROM_ORIGINS | Removal Of Licensing Factors From Origins |
| 0 | REACTOME_REMOVAL_OF_THE_FLAP_INTERMEDIATE | Removal Of The Flap Intermediate |
| 0 | REACTOME_REPAIR_SYNTHESIS_FOR_GAP-FILLING_BY_DNA_POLYMERASE_IN_TC-NER | Repair Synthesis For Gap-Filling By Dna Polymerase In Tc-Ner |
| 0 | REACTOME_REPAIR_SYNTHESIS_OF_PATCH_27-30_BASES_LONG_BY_DNA_POLYMERASE | Repair Synthesis Of Patch 27-30 Bases Long By Dna Polymerase |
| 0 | REACTOME_RESOLUTION_OF_ABASIC_SITES_AP_SITES | Resolution Of Abasic Sites Ap Sites |
| 0 | REACTOME_RESOLUTION_OF_AP_SITES_VIA_THE_MULTIPLE-NUCLEOTIDE_PATCH_REPLACEMENT_PATHWAY | Resolution Of Ap Sites Via The Multiple-Nucleotide Patch Replacement Pathway |
| 0 | REACTOME_RESOLUTION_OF_AP_SITES_VIA_THE_SINGLE-NUCLEOTIDE_REPLACEMENT_PATHWAY | Resolution Of Ap Sites Via The Single-Nucleotide Replacement Pathway |
| 0 | REACTOME_RESPIRATORY_ELECTRON_TRANSPORT | Respiratory Electron Transport |
| 0 | REACTOME_RESPIRATORY_ELECTRON_TRANSPORT_ATP_SYNTHESIS_BY_CHEMIOSMOTIC_COUPLING_AND_HEAT_PRODUCTION_BY_UNCOUPLING_PROTEINS | Respiratory Electron Transport Atp Synthesis By Chemiosmotic Coupling And Heat Production By Uncoupling Proteins |
| 0 | REACTOME_RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2 | Response To Elevated Platelet Cytosolic Ca2 |
| 1 | REACTOME_RETROGRADE_NEUROTROPHIN_SIGNALLING | Retrograde Neurotrophin Signalling |
| 0 | REACTOME_REV-MEDIATED_NUCLEAR_EXPORT_OF_HIV-1_RNA | Rev-Mediated Nuclear Export Of Hiv-1 Rna |
| 0 | REACTOME_RHO_GTPASE_CYCLE | Rho Gtpase Cycle |
| 0 | REACTOME_RIBOSOMAL_SCANNING_AND_START_CODON_RECOGNITION | Ribosomal Scanning And Start Codon Recognition |
| 0 | REACTOME_RIG-IMDA5_MEDIATED_INDUCTION_OF_IFN-ALPHABETA_PATHWAYS | Rig-Imda5 Mediated Induction Of Ifn-Alpha-beta Pathways |
| 0 | REACTOME_RNA_POL_II_CTD_PHOSPHORYLATION_AND_INTERACTION_WITH_CE | Rna Pol Ii Ctd Phosphorylation And Interaction With Ce |
| 0 | REACTOME_RNA_POLYMERASE_I_CHAIN_ELONGATION | Rna Polymerase I Chain Elongation |
| 0 | REACTOME_RNA_POLYMERASE_I_PROMOTER_CLEARANCE | Rna Polymerase I Promoter Clearance |
| 0 | REACTOME_RNA_POLYMERASE_I_PROMOTER_ESCAPE | Rna Polymerase I Promoter Escape |
| 0 | REACTOME_RNA_POLYMERASE_I_PROMOTER_OPENING | Rna Polymerase I Promoter Opening |
| 0 | REACTOME_RNA_POLYMERASE_I_RNA_POLYMERASE_III_AND_MITOCHONDRIAL_TRANSCRIPTION | Rna Polymerase I Rna Polymerase Iii And Mitochondrial Transcription |
| 0 | REACTOME_RNA_POLYMERASE_I_TRANSCRIPTION | Rna Polymerase I Transcription |
| 0 | REACTOME_RNA_POLYMERASE_I_TRANSCRIPTION_INITIATION | Rna Polymerase I Transcription Initiation |
| 0 | REACTOME_RNA_POLYMERASE_I_TRANSCRIPTION_TERMINATION | Rna Polymerase I Transcription Termination |
| 0 | REACTOME_RNA_POLYMERASE_II_HIV-1_PROMOTER_ESCAPE | Rna Polymerase Ii Hiv-1 Promoter Escape |
| 0 | REACTOME_RNA_POLYMERASE_II_PRE-TRANSCRIPTION_EVENTS | Rna Polymerase Ii Pre-Transcription Events |
| 0 | REACTOME_RNA_POLYMERASE_II_PROMOTER_ESCAPE | Rna Polymerase Ii Promoter Escape |
| 0 | REACTOME_RNA_POLYMERASE_II_TRANSCRIPTION | Rna Polymerase Ii Transcription |
| 0 | REACTOME_RNA_POLYMERASE_II_TRANSCRIPTION_ELONGATION | Rna Polymerase Ii Transcription Elongation |
| 0 | REACTOME_RNA_POLYMERASE_II_TRANSCRIPTION_INITIATION | Rna Polymerase Ii Transcription Initiation |
| 0 | REACTOME_RNA_POLYMERASE_II_TRANSCRIPTION_INITIATION_AND_PROMOTER_CLEARANCE | Rna Polymerase Ii Transcription Initiation And Promoter Clearance |
| 0 | REACTOME_RNA_POLYMERASE_II_TRANSCRIPTION_PRE-INITIATION_AND_PROMOTER_OPENING | Rna Polymerase Ii Transcription Pre-Initiation And Promoter Opening |
| 0 | REACTOME_RNA_POLYMERASE_II_TRANSCRIPTION_TERMINATION | Rna Polymerase Ii Transcription Termination |
| 0 | REACTOME_RNA_POLYMERASE_III_ABORTIVE_AND_RETRACTIVE_INITIATION | Rna Polymerase Iii Abortive And Retractive Initiation |
| 0 | REACTOME_RNA_POLYMERASE_III_CHAIN_ELONGATION | Rna Polymerase Iii Chain Elongation |
| 0 | REACTOME_RNA_POLYMERASE_III_TRANSCRIPTION | Rna Polymerase Iii Transcription |
| 0 | REACTOME_RNA_POLYMERASE_III_TRANSCRIPTION_INITIATION | Rna Polymerase Iii Transcription Initiation |
| 0 | REACTOME_RNA_POLYMERASE_III_TRANSCRIPTION_INITIATION_FROM_TYPE_1_PROMOTER | Rna Polymerase Iii Transcription Initiation From Type 1 Promoter |

| | | |
|---|--|---|
| 0 | REACTOME_RNA_POLYMERASE_III_TRANSCRIPTION_INITIATION_FROM_TYPE_2_PROMOTER | Rna Polymerase Iii Transcription Initiation From Type 2 Promoter |
| 0 | REACTOME_RNA_POLYMERASE_III_TRANSCRIPTION_INITIATION_FROM_TYPE_3_PROMOTER | Rna Polymerase Iii Transcription Initiation From Type 3 Promoter |
| 0 | REACTOME_RNA_POLYMERASE_III_TRANSCRIPTION_TERMINATION | Rna Polymerase Iii Transcription Termination |
| 0 | REACTOME_ROLE_OF_DCC_IN_REGULATING_APOPTOSIS | Role Of Dcc In Regulating Apoptosis |
| 0 | REACTOME_ROLE_OF_SECOND_MESSENGERS_IN_NETRIN-1_SIGNALING | Role Of Second Messengers In Netrin-1 Signaling |
| 0 | REACTOME_S_PHASE | S Phase |
| 0 | REACTOME_SCF-BETA-TRCP_MEDIATED_DEGRADATION_OF_EMI1 | Scf-Beta-Trcp Mediated Degradation Of Emi1 |
| 0 | REACTOME_SCFSKP2-MEDIATED_DEGRADATION_OF_P27P21 | Scfskp2-Mediated Degradation Of P27P21 |
| 1 | REACTOME_SEMA3A_PAK_DEPENDENT_AXON_REPULSION | Sema3A Pak Dependent Axon Repulsion |
| 1 | REACTOME_SEMA3A-PLEXIN_REPULSION_SIGNALING_BY_INHIBITING_INTEGRIN_ADHESION | Sema3A-Plexin Repulsion Signaling By Inhibiting Integrin Adhesion |
| 1 | REACTOME_SEMA4D_IN_SEMAPHORIN_SIGNALING | Sema4D In Semaphorin Signaling |
| 1 | REACTOME_SEMA4D_INDUCED_CELL_MIGRATION_AND_GROWTH-CONE_COLLAPSE | Sema4D Induced Cell Migration And Growth-Cone Collapse |
| 1 | REACTOME_SEMAPHORIN_INTERACTIONS | Semaphorin Interactions |
| 1 | REACTOME_SEROTONIN_NEUROTRANSMITTER_RELEASE_CYCLE | Serotonin Neurotransmitter Release Cycle |
| 1 | REACTOME_SEROTONIN_RECEPTORS | Serotonin Receptors |
| 0 | REACTOME_SHC-MEDIATED_CASCADE | Shc-Mediated Cascade |
| 0 | REACTOME_SHC-MEDIATED_SIGNALING | Shc-Mediated Signalling |
| 0 | REACTOME_SHC-RELATED_EVENTS | Shc-Related Events |
| 0 | REACTOME_SHC1_EVENTS_IN_EGFR_SIGNALING | Shc1 Events In Egfr Signaling |
| 0 | REACTOME_SHC1_EVENTS_IN_ERBB2_SIGNALING | Shc1 Events In Erbb2 Signaling |
| 0 | REACTOME_SHC1_EVENTS_IN_ERBB4_SIGNALING | Shc1 Events In Erbb4 Signaling |
| 0 | REACTOME_SIGNAL_AMPLIFICATION | Signal Amplification |
| 0 | REACTOME_SIGNAL_ATTENUATION | Signal Attenuation |
| 0 | REACTOME_SIGNAL_REGULATORY_PROTEIN_SIRP_FAMILY_INTERACTIONS | Signal Regulatory Protein Sirp Family Interactions |
| 0 | REACTOME_SIGNAL_TRANSDUCTION_BY_L1 | Signal Transduction By L1 |
| 0 | REACTOME_SIGNALING_BY_BMP | Signaling By Bmp |
| 0 | REACTOME_SIGNALING_BY_CONSTITUTIVELY_ACTIVE_EGFR | Signaling By Constitutively Active Egfr |
| 0 | REACTOME_SIGNALING_BY_EGFR | Signaling By Egfr |
| 0 | REACTOME_SIGNALING_BY_EGFR_IN_CANCER | Signaling By Egfr In Cancer |
| 0 | REACTOME_SIGNALING_BY_ERBB2 | Signaling By Erbb2 |
| 0 | REACTOME_SIGNALING_BY_ERBB4 | Signaling By Erbb4 |
| 0 | REACTOME_SIGNALING_BY_FGFR | Signaling By Fgfr |
| 0 | REACTOME_SIGNALING_BY_INSULIN_RECEPTOR | Signaling By Insulin Receptor |
| 0 | REACTOME_SIGNALING_BY_INTERLEUKINS | Signaling By Interleukins |
| 0 | REACTOME_SIGNALING_BY_NODAL | Signaling By Nodal |
| 0 | REACTOME_SIGNALING_BY_NOTCH | Signaling By Notch |
| 0 | REACTOME_SIGNALING_BY_PDGF | Signaling By Pdgf |
| 0 | REACTOME_SIGNALING_BY_RHO_GTPASES | Signaling By Rho Gtpases |
| 0 | REACTOME_SIGNALING_BY_ROBO_RECEPTOR | Signaling By Robo Receptor |
| 0 | REACTOME_SIGNALING_BY_SCF-KIT | Signaling By Scf-Kit |
| 0 | REACTOME_SIGNALING_BY_TGF_BETA | Signaling By Tgf Beta |
| 0 | REACTOME_SIGNALING_BY_VEGF | Signaling By Vegf |
| 0 | REACTOME_SIGNALING_BY_WNT | Signaling By Wnt |
| 1 | REACTOME_SIGNALLING_BY_NGF | Signalling By Ngf |
| 0 | REACTOME_SIGNALLING_TO_ERKS | Signalling To Erks |
| 0 | REACTOME_SIGNALLING_TO_P38_VIA_RIT_AND_RIN | Signalling To P38 Via Rit And Rin |
| 0 | REACTOME_SIGNALLING_TO_RAS | Signalling To Ras |
| 0 | REACTOME_SLC-MEDIATED_TRANSMEMBRANE_TRANSPORT | Slc-Mediated Transmembrane Transport |
| 0 | REACTOME_SMOOTH_MUSCLE_CONTRACTION | Smooth Muscle Contraction |
| 0 | REACTOME_SNRNP_ASSEMBLY | Snrnp Assembly |
| 0 | REACTOME_SOS-MEDIATED_SIGNALLING | Sos-Mediated Signalling |
| 0 | REACTOME_SPHINGOLIPID_DE_NOVO_BIOSYNTHESIS | Sphingolipid De Novo Biosynthesis |
| 0 | REACTOME_SPHINGOLIPID_METABOLISM | Sphingolipid Metabolism |
| 0 | REACTOME_SPRY_REGULATION_OF_FGF_SIGNALING | Spry Regulation Of Fgf Signaling |
| 0 | REACTOME_SRP-DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE | Srp-Dependent Cotranslational Protein Targeting To Membrane |
| 0 | REACTOME_STABILIZATION_OF_P53 | Stabilization Of P53 |
| 0 | REACTOME_STEROID_HORMONES | Steroid Hormones |
| 0 | REACTOME_STRIATED_MUSCLE_CONTRACTION | Striated Muscle Contraction |
| 0 | REACTOME_SULFUR_AMINO_ACID_METABOLISM | Sulfur Amino Acid Metabolism |

| | | |
|---|--|---|
| 0 | REACTOME_SWITCHING_OF_ORIGINS_TO_A_POST-REPLICATIVE_STATE | Switching Of Origins To A Post-Replicative State |
| 0 | REACTOME_SYNTHESIS_AND_INTERCONVERSION_OF_NUCLEOTIDE_DI-_AND_TRIPHOSPHATES | Synthesis And Interconversion Of Nucleotide Di- And Triphosphates |
| 0 | REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS | Synthesis Of Bile Acids And Bile Salts |
| 0 | REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS_VIA_7ALPHA-HYDROXYCHOLESTEROL | Synthesis Of Bile Acids And Bile Salts Via 7Alpha-Hydroxycholesterol |
| 0 | REACTOME_SYNTHESIS_OF_DNA | Synthesis Of Dna |
| 0 | REACTOME_SYNTHESIS_OF_GLYCOSYLPHOSPHATIDYLINOSITOL_GPI | Synthesis Of Glycosylphosphatidylinositol Gpi |
| 0 | REACTOME_SYNTHESIS_OF_SUBSTRATES_IN_N-GLYCAN_BIOSYTHESIS | Synthesis Of Substrates In N-Glycan Biosynthesis |
| 0 | REACTOME_SYNTHESIS_OF_VERY_LONG-CHAIN_FATTY_ACYL-COAS | Synthesis Of Very Long-Chain Fatty Acyl-Coas |
| 0 | REACTOME_SYNTHESIS_SECRETION_AND_DEACYLATION_OF_GHRELIN | Synthesis Secretion And Deacylation Of Ghrelin |
| 0 | REACTOME_SYNTHESIS_SECRETION_AND_INACTIVATION_OF_GLUCAGON-LIKE_PEPTIDE-1_GLP-1 | Synthesis Secretion And Inactivation Of Glucagon-Like Peptide-1 Glp-1 |
| 0 | REACTOME_SYNTHESIS_SECRETION_AND_INACTIVATION_OF_GLUCOSE-DEPENDENT_INSULINOTROPIC_POLYPE | Synthesis Secretion And Inactivation Of Glucose-Dependent Insulinotropic Polypeptide Gip |
| 0 | REACTOME_TAK1_ACTIVATES_NFKB_BY_PHOSPHORYLATION_AND_ACTIVATION_OF_IKKS_COMPLEX | Tak1 Activates Nfkb By Phosphorylation And Activation Of Ikks Complex |
| 1 | REACTOME_TANDEM_PORE_DOMAIN_POTASSIUM_CHANNELS | Tandem Pore Domain Potassium Channels |
| 0 | REACTOME_TAT-MEDIATED_ELONGATION_OF_THE_HIV-1_TRANSCRIPT | Tat-Mediated Elongation Of The Hiv-1 Transcript |
| 0 | REACTOME_TAT-MEDIATED_HIV-1_ELONGATION_ARREST_AND_RECOVERY | Tat-Mediated Hiv-1 Elongation Arrest And Recovery |
| 0 | REACTOME_TCR_SIGNALING | Tcr Signaling |
| 0 | REACTOME_TELOMERE_C-STRAND_LAGGING_STRAND_SYNTHESIS | Telomere C-Strand Lagging Strand Synthesis |
| 0 | REACTOME_TELOMERE_MAINTENANCE | Telomere Maintenance |
| 0 | REACTOME_TERMINATION_OF_O-GLYCAN_BIOSYNTHESIS | Termination Of O-Glycan Biosynthesis |
| 0 | REACTOME_TETRAHYDROBIOPTERIN_BH4_SYNTHESIS_RECYCLING_SALVAGE_AND_REGULATION | Tetrahydrobiopterin Bh4 Synthesis Recycling Salvage And Regulation |
| 0 | REACTOME_THE_CITRIC_ACID_TCA_CYCLE_AND_RESPIRATORY_ELECTRON_TRANSPORT | The Citric Acid Tca Cycle And Respiratory Electron Transport |
| 0 | REACTOME_THE_NLRP3_INFLAMMASOME | The Nlrp3 Inflammasome |
| 0 | REACTOME_THE_ROLE_OF_NEF_IN_HIV-1_REPLICATION_AND_DISEASE_PATHOGENESIS | The Role Of Nef In Hiv-1 Replication And Disease Pathogenesis |
| 0 | REACTOME_THROMBIN_SIGNALLING_THROUGH_PROTEINASE_ACTIVATED_RECEPTORS_PARS | Thrombin Signalling Through Proteinase Activated Receptors Pars |
| 0 | REACTOME_THROMBOXANE_SIGNALLING_THROUGH_TP_RECEPTOR | Thromboxane Signalling Through Tp Receptor |
| 0 | REACTOME_TIE2_SIGNALING | Tie2 Signaling |
| 0 | REACTOME_TIGHT_JUNCTION_INTERACTIONS | Tight Junction Interactions |
| 0 | REACTOME_TOLL_LIKE_RECEPTOR_10_TLR10_CASCADE | Toll Like Receptor 10 Tlr10 Cascade |
| 0 | REACTOME_TOLL_LIKE_RECEPTOR_2_TLR2_CASCADE | Toll Like Receptor 2 Tlr2 Cascade |
| 0 | REACTOME_TOLL_LIKE_RECEPTOR_3_TLR3_CASCADE | Toll Like Receptor 3 Tlr3 Cascade |
| 0 | REACTOME_TOLL_LIKE_RECEPTOR_4_TLR4_CASCADE | Toll Like Receptor 4 Tlr4 Cascade |
| 0 | REACTOME_TOLL_LIKE_RECEPTOR_5_TLR5_CASCADE | Toll Like Receptor 5 Tlr5 Cascade |
| 0 | REACTOME_TOLL_LIKE_RECEPTOR_78_TLR78_CASCADE | Toll Like Receptor 78 Tlr78 Cascade |
| 0 | REACTOME_TOLL_LIKE_RECEPTOR_9_TLR9_CASCADE | Toll Like Receptor 9 Tlr9 Cascade |
| 0 | REACTOME_TOLL_LIKE_RECEPTOR_TLR1TLR2_CASCADE | Toll Like Receptor Tlr1Tlr2 Cascade |
| 0 | REACTOME_TOLL_LIKE_RECEPTOR_TLR6TLR2_CASCADE | Toll Like Receptor Tlr6Tlr2 Cascade |
| 0 | REACTOME_TOLL_RECEPTOR_CASCADES | Toll Receptor Cascades |
| 0 | REACTOME_TRAF3-DEPENDENT_IRF_ACTIVATION_PATHWAY | Traf3-Dependent Irf Activation Pathway |
| 0 | REACTOME_TRAF6_MEDIATED_INDUCION_OF_NFKB_AND_MAP_KINASES_UPON_TLR78_OR_9_ACTIVATION | Traf6 Mediated Induction Of Nfkb And Map Kinases Upon Tlr78 Or 9 Activation |
| 0 | REACTOME_TRAF6_MEDIATED_INDUCION_OF_PROINFLAMMATORY_CYTOKINES | Traf6 Mediated Induction Of Proinflammatory Cytokines |
| 0 | REACTOME_TRAF6_MEDIATED_INDUCION_OF_TAK1_COMPLEX | Traf6 Mediated Induction Of Tak1 Complex |
| 0 | REACTOME_TRAF6_MEDIATED_IRF7_ACTIVATION | Traf6 Mediated Irf7 Activation |
| 0 | REACTOME_TRAF6_MEDIATED_NF-KB_ACTIVATION | Traf6 Mediated Nf-Kb Activation |
| 1 | REACTOME_TRAFFICKING_OF_AMPA_RECEPTORS | Trafficking Of Ampa Receptors |
| 1 | REACTOME_TRAFFICKING_OF_GLUR2-CONTAINING_AMPA_RECEPTORS | Trafficking Of Glur2-Containing Ampa Receptors |
| 0 | REACTOME_TRANS-GOLGI_NETWORK_VESICLE_BUDDING | Trans-Golgi Network Vesicle Budding |
| 0 | REACTOME_TRANSCRIPTION | Transcription |
| 0 | REACTOME_TRANSCRIPTION_OF_THE_HIV_GENOME | Transcription Of The Hiv Genome |
| 0 | REACTOME_TRANSCRIPTION-COUPLED_NER_TC-NER | Transcription-Coupled Ner Tc-Ner |
| 0 | REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION | Transcriptional Regulation Of White Adipocyte Differentiation |
| 0 | REACTOME_TRANSFERRIN_ENDOCYTOSIS_AND_RECYCLING | Transferrin Endocytosis And Recycling |
| 0 | REACTOME_TRANSLATION | Translation |
| 0 | REACTOME_TRANSLATION_INITIATION_COMPLEX_FORMATION | Translation Initiation Complex Formation |
| 0 | REACTOME_TRANSLOCATION_OF_ZAP-70_TO_IMMUNOLOGICAL_SYNAPSE | Translocation Of Zap-70 To Immunological Synapse |
| 0 | REACTOME_TRANSMEMBRANE_TRANSPORT_OF_SMALL_MOLECULES | Transmembrane Transport Of Small Molecules |
| 1 | REACTOME_TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES | Transmission Across Chemical Synapses |
| 0 | REACTOME_TRANSPORT_OF_GLUCOSE_AND_OTHER_SUGARS_BILE_SALTS_AND_ORGANIC_ACIDS_METAL_ION | Transport Of Glucose And Other Sugars Bile Salts And Organic Acids Metal Ions And Amine Compounds |
| 0 | REACTOME_TRANSPORT_OF_INORGANIC_CATIONSANIONS_AND_AMINO_ACIDSOLIGOPEPTIDES | Transport Of Inorganic Cationsanions And Amino Acidsoligopeptides |
| 0 | REACTOME_TRANSPORT_OF_MATURE_MRNA_DERIVED_FROM_AN_INTRON-CONTAINING_TRANSCRIPT | Transport Of Mature Mrna Derived From An Intron-Containing Transcript |

| | | |
|---|---|--|
| 0 | REACTOME_TRANSPORT_OF_MATURE_MRNA_DERIVED_FROM_AN_INTRONLESS_TRANSCRIPT | Transport Of Mature Mrna Derived From An Intronless Transcript |
| 0 | REACTOME_TRANSPORT_OF_MATURE_MRNAS_DERIVED_FROM_INTRONLESS_TRANSCRIPTS | Transport Of Mature Mrnas Derived From Intronless Transcripts |
| 0 | REACTOME_TRANSPORT_OF_MATURE_TRANSCRIPT_TO_CYTOPLASM | Transport Of Mature Transcript To Cytoplasm |
| 0 | REACTOME_TRANSPORT_OF_ORGANIC_ANIONS | Transport Of Organic Anions |
| 0 | REACTOME_TRANSPORT_OF_RIBONUCLEOPROTEINS_INTO_THE_HOST_NUCLEUS | Transport Of Ribonucleoproteins Into The Host Nucleus |
| 0 | REACTOME_TRANSPORT_OF_THE_SLBP_DEPENDANT_MATURE_MRNA | Transport Of The Slbp Dependant Mature Mrna |
| 0 | REACTOME_TRANSPORT_OF_THE_SLBP_INDEPENDENT_MATURE_MRNA | Transport Of The Slbp Independent Mature Mrna |
| 0 | REACTOME_TRANSPORT_OF_VITAMINS_NUCLEOSIDES_AND_RELATED_MOLECULES | Transport Of Vitamins Nucleosides And Related Molecules |
| 0 | REACTOME_TRANSPORT_TO_THE_GOLGI_AND_SUBSEQUENT_MODIFICATION | Transport To The Golgi And Subsequent Modification |
| 0 | REACTOME_TRIF_MEDIATED_TLR3_SIGNALING | Trif Mediated Tlr3 Signaling |
| 0 | REACTOME_TRIGLYCERIDE_BIOSYNTHESIS | Triglyceride Biosynthesis |
| 0 | REACTOME_TRNA_AMINOACYLATION | Trna Aminoacylation |
| 0 | REACTOME_TRYPTOPHAN_CATABOLISM | Tryptophan Catabolism |
| 0 | REACTOME_UBIQUITIN_MEDIATED_DEGRADATION_OF_PHOSPHORYLATED_CDC25A | Ubiquitin Mediated Degradation Of Phosphorylated Cdc25A |
| 0 | REACTOME_UBIQUITIN-DEPENDENT_DEGRADATION_OF_CYCLIN_D | Ubiquitin-Dependent Degradation Of Cyclin D |
| 0 | REACTOME_UBIQUITIN-DEPENDENT_DEGRADATION_OF_CYCLIN_D1 | Ubiquitin-Dependent Degradation Of Cyclin D1 |
| 1 | REACTOME_UNBLOCKING_OF_NMDA_RECEPTOR_GLUTAMATE_BINDING_AND_ACTIVATION | Unblocking Of Nmda Receptor Glutamate Binding And Activation |
| 0 | REACTOME_UNFOLDED_PROTEIN_RESPONSE | Unfolded Protein Response |
| 0 | REACTOME_UNWINDING_OF_DNA | Unwinding Of Dna |
| 0 | REACTOME_VEGF_LIGAND-RECEPTOR_INTERACTIONS | Vegf Ligand-Receptor Interactions |
| 0 | REACTOME_VIF-MEDIATED_DEGRADATION_OF_APOBEC3G | Vif-Mediated Degradation Of Apobec3G |
| 0 | REACTOME_VIRAL_DSRNATLR3TRIF_COMPLEX_ACTIVATES_RIP1 | Viral Dsrnatlr3Trif Complex Activates Rip1 |
| 0 | REACTOME_VIRAL_MESSENGER_RNA_SYNTHESIS | Viral Messenger Rna Synthesis |
| 0 | REACTOME_VIRAL_MRNA_TRANSLATION | Viral Mrna Translation |
| 0 | REACTOME_VITAMIN_B5_PANTOTHENATE_METABOLISM | Vitamin B5 Pantothenate Metabolism |
| 1 | REACTOME_VOLTAGE_GATED_POTASSIUM_CHANNELS | Voltage Gated Potassium Channels |
| 0 | REACTOME_VPR-MEDIATED_NUCLEAR_IMPORT_OF_PICS | Vpr-Mediated Nuclear Import Of Pics |
| 0 | REACTOME_VPU_MEDIATED_DEGRADATION_OF_CD4 | Vpu Mediated Degradation Of Cd4 |
| 0 | REACTOME_XENOBIOTICS | Xenobiotics |
| 0 | REACTOME_ZINC_INFLUX_INTO_CELLS_BY_THE_SLC39_GENE_FAMILY | Zinc Influx Into Cells By The Slc39 Gene Family |
| 0 | REACTOME_ZINC_TRANSPORTERS | Zinc Transporters |

| Related to neuronal function | Gene Set ID | Gene Set Name |
|---------------------------------|---|--|
| 0 | KEGG_ABC_TRANSPORTERS | Abc Transporters |
| 0 | KEGG_ACUTE_MYELOID_LEUKEMIA | Acute Myeloid Leukemia |
| 0 | KEGG_ADHERENS_JUNCTION | Adherens Junction |
| 0 | KEGG_ADIPOCYTOKINE_SIGNALING_PATHWAY | Adipocytokine Signaling Pathway |
| 0 | KEGG_ALANINE_ASPARTATE_AND_GLUTAMATE_METABOLISM | Alanine Aspartate And Glutamate Metabolism |
| 0 | KEGG_ALDOSTERONE_REGULATED_SODIUM_REABSORPTION | Aldosterone Regulated Sodium Reabsorption |
| 0 | KEGG_ALLOGRAFT_REJECTION | Allograft Rejection |
| 0 | KEGG_ALPHA_LINOLENIC_ACID_METABOLISM | Alpha Linolenic Acid Metabolism |
| 0 | KEGG_ALZHEIMERS_DISEASE | Alzheimers Disease |
| 0 | KEGG_AMINO_SUGAR_AND_NUCLEOTIDE_SUGAR_METABOLISM | Amino Sugar And Nucleotide Sugar Metabolism |
| 0 | KEGG_AMINOACYL_TRNA_BIOSYNTHESIS | Aminoacyl Trna Biosynthesis |
| 0 | KEGG_AMYOTROPHIC_LATERAL_SCLEROSIS_ALS | Amyotrophic Lateral Sclerosis Als |
| 0 | KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION | Antigen Processing And Presentation |
| 0 | KEGG_APOPTOSIS | Apoptosis |
| 0 | KEGG_ARACHIDONIC_ACID_METABOLISM | Arachidonic Acid Metabolism |
| 0 | KEGG_ARGININE_AND_PROLINE_METABOLISM | Arginine And Proline Metabolism |
| 0 | KEGG_ARRHYTHMOGENIC_RIGHT_VENTRICULAR_CARDIOMYOPATHY_ARVC | Arrhythmogenic Right Ventricular Cardiomyopathy Arvc |
| 0 | KEGG_ASCORBATE_AND_ALDARATE_METABOLISM | Ascorbate And Aldarate Metabolism |
| 0 | KEGG_ASTHMA | Asthma |
| 0 | KEGG_AUTOIMMUNE_THYROID_DISEASE | Autoimmune Thyroid Disease |
| 1 | KEGG_AXON_GUIDANCE | Axon Guidance |
| 0 | KEGG_B_CELL_RECEPTOR_SIGNALING_PATHWAY | B Cell Receptor Signaling Pathway |
| 0 | KEGG_BASAL_CELL_CARCINOMA | Basal Cell Carcinoma |
| 0 | KEGG_BASAL_TRANSCRIPTION_FACTORS | Basal Transcription Factors |
| 0 | KEGG_BASE_EXCISION_REPAIR | Base Excision Repair |
| 0 | KEGG_BETA_ALANINE_METABOLISM | Beta Alanine Metabolism |
| 0 | KEGG_BIOSYNTHESIS_OF_UNSATURATED_FATTY_ACIDS | Biosynthesis Of Unsaturated Fatty Acids |
| 0 | KEGG_BLADDER_CANCER | Bladder Cancer |
| 0 | KEGG_BUTANOATE_METABOLISM | Butanoate Metabolism |
| 1 | KEGG_CALCIIUM_SIGNALING_PATHWAY | Calcium Signaling Pathway |
| 0 | KEGG_CARDIAC_MUSCLE_CONTRACTION | Cardiac Muscle Contraction |
| 0 | KEGG_CELL_ADHESION_MOLECULES_CAMS | Cell Adhesion Molecules Cams |
| 0 | KEGG_CELL_CYCLE | Cell Cycle |
| 0 | KEGG_CHEMOKINE_SIGNALING_PATHWAY | Chemokine Signaling Pathway |

| | | |
|---|---|--|
| 0 | KEGG_CHRONIC_MYELOID_LEUKEMIA | Chronic Myeloid Leukemia |
| 1 | KEGG_CIRCADIAN_RHYTHM_MAMMAL | Circadian Rhythm Mammal |
| 0 | KEGG_CITRATE_CYCLE_TCA_CYCLE | Citrate Cycle Tca Cycle |
| 0 | KEGG_COLORECTAL_CANCER | Colorectal Cancer |
| 0 | KEGG_COMPLEMENT_AND_COAGULATION_CASCADES | Complement And Coagulation Cascades |
| 0 | KEGG_CYSTEINE_AND_METHIONINE_METABOLISM | Cysteine And Methionine Metabolism |
| 0 | KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION | Cytokine Cytokine Receptor Interaction |
| 0 | KEGG_CYTOSOLIC_DNA_SENSING_PATHWAY | Cytosolic Dna Sensing Pathway |
| 0 | KEGG_DILATED_CARDIOMYOPATHY | Dilated Cardiomyopathy |
| 0 | KEGG_DNA_REPLICATION | Dna Replication |
| 0 | KEGG_DORSO_VENTRAL_AXIS_FORMATION | Dorso Ventral Axis Formation |
| 0 | KEGG_DRUG_METABOLISM_CYTOCHROME_P450 | Drug Metabolism Cytochrome P450 |
| 0 | KEGG_DRUG_METABOLISM_OTHER_ENZYMES | Drug Metabolism Other Enzymes |
| 0 | KEGG_ECM_RECEPTOR_INTERACTION | Ecm Receptor Interaction |
| 0 | KEGG_ENDOCYTOSIS | Endocytosis |
| 0 | KEGG_ENDOMETRIAL_CANCER | Endometrial Cancer |
| 0 | KEGG_EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER_PYLORI_INFECTION | Epithelial Cell Signaling In Helicobacter Pylori Infection |
| 1 | KEGG_ERBB_SIGNALING_PATHWAY | ErbB Signaling Pathway |
| 0 | KEGG_ETHER_LIPID_METABOLISM | Ether Lipid Metabolism |
| 0 | KEGG_FATTY_ACID_METABOLISM | Fatty Acid Metabolism |
| 0 | KEGG_FC_EPSILON_RI_SIGNALING_PATHWAY | Fc Epsilon Ri Signaling Pathway |
| 0 | KEGG_FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS | Fc Gamma R Mediated Phagocytosis |
| 0 | KEGG_FOCAL_ADHESION | Focal Adhesion |
| 0 | KEGG_FOLATE_BIOSYNTHESIS | Folate Biosynthesis |
| 0 | KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM | Fructose And Mannose Metabolism |
| 0 | KEGG_GALACTOSE_METABOLISM | Galactose Metabolism |
| 0 | KEGG_GAP_JUNCTION | Gap Junction |
| 0 | KEGG_GLIOMA | Glioma |
| 0 | KEGG_GLUTATHIONE_METABOLISM | Glutathione Metabolism |
| 0 | KEGG_GLYCEROLIPID_METABOLISM | Glycerolipid Metabolism |
| 0 | KEGG_GLYCEROPHOSPHOLIPID_METABOLISM | Glycerophospholipid Metabolism |
| 0 | KEGG_GLYCINE_SERINE_AND_THREONINE_METABOLISM | Glycine Serine And Threonine Metabolism |
| 0 | KEGG_GLYCOLYSIS_GLUONEOGENESIS | Glycolysis Gluconeogenesis |
| 0 | KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_CHONDROITIN_SULFATE | Glycosaminoglycan Biosynthesis Chondroitin Sulfate |
| 0 | KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_HEPARAN_SULFATE | Glycosaminoglycan Biosynthesis Heparan Sulfate |
| 0 | KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_KERATAN_SULFATE | Glycosaminoglycan Biosynthesis Keratan Sulfate |

| | | |
|---|--|--|
| 0 | KEGG_GLYCOSAMINOGLYCAN_DEGRADATION | Glycosaminoglycan Degradation |
| 0 | KEGG_GLYCOPHINGOLIPID_BIOSYNTHESIS_GANGLIO_SERIES | Glycosphingolipid Biosynthesis Ganglio Series |
| 0 | KEGG_GLYCOPHINGOLIPID_BIOSYNTHESIS_GLOBO_SERIES | Glycosphingolipid Biosynthesis Globo Series |
| 0 | KEGG_GLYCOPHINGOLIPID_BIOSYNTHESIS_LACTO_AND_NEOLACTO_SERIES | Glycosphingolipid Biosynthesis Lacto And Neolacto Series |
| 0 | KEGG_GLYCOSYLPHOSPHATIDYLINOSITOL_GPI_ANCHOR_BIOSYNTHESIS | Glycosylphosphatidylinositol Gpi Anchor Biosynthesis |
| 0 | KEGG_GLYOXYLATE_AND_DICARBOXYLATE_METABOLISM | Glyoxylate And Dicarboxylate Metabolism |
| 1 | KEGG_GNRH_SIGNALING_PATHWAY | Gnrh Signaling Pathway |
| 0 | KEGG_GRAFT_VERSUS_HOST_DISEASE | Graft Versus Host Disease |
| 0 | KEGG_HEDGEHOG_SIGNALING_PATHWAY | Hedgehog Signaling Pathway |
| 0 | KEGG_HEMATOPOIETIC_CELL_LINEAGE | Hematopoietic Cell Lineage |
| 0 | KEGG_HISTIDINE_METABOLISM | Histidine Metabolism |
| 0 | KEGG_HOMOLOGOUS_RECOMBINATION | Homologous Recombination |
| 0 | KEGG_HUNTINGTONS_DISEASE | Huntingtons Disease |
| 0 | KEGG_HYPERTROPHIC_CARDIOMYOPATHY_HCM | Hypertrophic Cardiomyopathy Hcm |
| 0 | KEGG_INOSITOL_PHOSPHATE_METABOLISM | Inositol Phosphate Metabolism |
| 0 | KEGG_INSULIN_SIGNALING_PATHWAY | Insulin Signaling Pathway |
| 0 | KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PRODUCTION | Intestinal Immune Network For Iga Production |
| 0 | KEGG_JAK_STAT_SIGNALING_PATHWAY | Jak Stat Signaling Pathway |
| 0 | KEGG_LEISHMANIA_INFECTION | Leishmania Infection |
| 0 | KEGG_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION | Leukocyte Transendothelial Migration |
| 0 | KEGG_LINOLEIC_ACID_METABOLISM | Linoleic Acid Metabolism |
| 1 | KEGG_LONG_TERM_DEPRESSION | Long Term Depression |
| 1 | KEGG_LONG_TERM_POTENTIATION | Long Term Potentiation |
| 0 | KEGG_LYSINE_DEGRADATION | Lysine Degradation |
| 0 | KEGG_LYSOSOME | Lysosome |
| 0 | KEGG_MAPK_SIGNALING_PATHWAY | Mapk Signaling Pathway |
| 0 | KEGG_MATURITY_ONSET_DIABETES_OF_THE_YOUNG | Maturity Onset Diabetes Of The Young |
| 0 | KEGG_MELANOGENESIS | Melanogenesis |
| 0 | KEGG_MELANOMA | Melanoma |
| 0 | KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450 | Metabolism Of Xenobiotics By Cytochrome P450 |
| 0 | KEGG_MISMATCH_REPAIR | Mismatch Repair |
| 0 | KEGG_MTOR_SIGNALING_PATHWAY | Mtor Signaling Pathway |
| 0 | KEGG_N_GLYCAN_BIOSYNTHESIS | N Glycan Biosynthesis |
| 0 | KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY | Natural Killer Cell Mediated Cytotoxicity |
| 1 | KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION | Neuroactive Ligand Receptor Interaction |
| 1 | KEGG_NEUROTROPHIN_SIGNALING_PATHWAY | Neurotrophin Signaling Pathway |

| | | |
|---|---|--|
| 0 | KEGG_NICOTINATE_AND_NICOTINAMIDE_METABOLISM | Nicotinate And Nicotinamide Metabolism |
| 0 | KEGG_NITROGEN_METABOLISM | Nitrogen Metabolism |
| 0 | KEGG_NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY | Nod Like Receptor Signaling Pathway |
| 0 | KEGG_NON_HOMOLOGOUS_END_JOINING | Non Homologous End Joining |
| 0 | KEGG_NON_SMALL_CELL_LUNG_CANCER | Non Small Cell Lung Cancer |
| 0 | KEGG_NOTCH_SIGNALING_PATHWAY | Notch Signaling Pathway |
| 0 | KEGG_NUCLEOTIDE_EXCISION_REPAIR | Nucleotide Excision Repair |
| 0 | KEGG_O_GLYCAN_BIOSYNTHESIS | O Glycan Biosynthesis |
| 0 | KEGG_OLFACTORY_TRANSDUCTION | Olfactory Transduction |
| 0 | KEGG_ONE_CARBON_POOL_BY_FOLATE | One Carbon Pool By Folate |
| 0 | KEGG_OOCYTE_MEIOSIS | Oocyte Meiosis |
| 0 | KEGG_OTHER_GLYCAN_DEGRADATION | Other Glycan Degradation |
| 0 | KEGG_OXIDATIVE_PHOSPHORYLATION | Oxidative Phosphorylation |
| 0 | KEGG_P53_SIGNALING_PATHWAY | P53 Signaling Pathway |
| 0 | KEGG_PANCREATIC_CANCER | Pancreatic Cancer |
| 0 | KEGG_PANTOTHENATE_AND_COA_BIOSYNTHESIS | Pantothenate And Coa Biosynthesis |
| 0 | KEGG_PARKINSONS_DISEASE | Parkinsons Disease |
| 0 | KEGG_PATHOGENIC_ESCHERICHIA_COLI_INFECTION | Pathogenic Escherichia Coli Infection |
| 0 | KEGG_PATHWAYS_IN_CANCER | Pathways In Cancer |
| 0 | KEGG_PENTOSE_AND_GLUCURONATE_INTERCONVERSIONS | Pentose And Glucuronate Interconversions |
| 0 | KEGG_PENTOSE_PHOSPHATE_PATHWAY | Pentose Phosphate Pathway |
| 0 | KEGG_PEROXISOME | Peroxisome |
| 0 | KEGG_PHENYLALANINE_METABOLISM | Phenylalanine Metabolism |
| 1 | KEGG_PHOSPHATIDYLINOSITOL_SIGNALING_SYSTEM | Phosphatidylinositol Signaling System |
| 0 | KEGG_PORPHYRIN_AND_CHLOROPHYLL_METABOLISM | Porphyrin And Chlorophyll Metabolism |
| 0 | KEGG_PPAR_SIGNALING_PATHWAY | Ppar Signaling Pathway |
| 0 | KEGG_PRIMARY_BILE_ACID_BIOSYNTHESIS | Primary Bile Acid Biosynthesis |
| 0 | KEGG_PRIMARY_IMMUNODEFICIENCY | Primary Immunodeficiency |
| 0 | KEGG_PRION_DISEASES | Prion Diseases |
| 0 | KEGG_PROGESTERONE_MEDIATED_OOCYTE_MATURATION | Progesterone Mediated Oocyte Maturation |
| 0 | KEGG_PROPANOATE_METABOLISM | Propanoate Metabolism |
| 0 | KEGG_PROSTATE_CANCER | Prostate Cancer |
| 0 | KEGG_PROTEASOME | Proteasome |
| 0 | KEGG_PROTEIN_EXPORT | Protein Export |
| 0 | KEGG_PROXIMAL_TUBULE_BICARBONATE_RECLAMATION | Proximal Tubule Bicarbonate Reclamation |
| 0 | KEGG_PURINE_METABOLISM | Purine Metabolism |

| | | |
|---|---|--|
| 0 | KEGG_PYRIMIDINE_METABOLISM | Pyrimidine Metabolism |
| 0 | KEGG_PYRUVATE_METABOLISM | Pyruvate Metabolism |
| 0 | KEGG_REGULATION_OF_ACTIN_CYTOSKELETON | Regulation Of Actin Cytoskeleton |
| 0 | KEGG_REGULATION_OF_AUTOPHAGY | Regulation Of Autophagy |
| 0 | KEGG_RENAL_CELL_CARCINOMA | Renal Cell Carcinoma |
| 0 | KEGG_RENIN_ANGIOTENSIN_SYSTEM | Renin Angiotensin System |
| 0 | KEGG_RETINOL_METABOLISM | Retinol Metabolism |
| 0 | KEGG_RIBOFLAVIN_METABOLISM | Riboflavin Metabolism |
| 0 | KEGG_RIBOSOME | Ribosome |
| 0 | KEGG_RIG_I_LIKE_RECEPTOR_SIGNALING_PATHWAY | Rig I Like Receptor Signaling Pathway |
| 0 | KEGG_RNA_DEGRADATION | Rna Degradation |
| 0 | KEGG_RNA_POLYMERASE | Rna Polymerase |
| 0 | KEGG_SELENOAMINO_ACID_METABOLISM | Selenoamino Acid Metabolism |
| 0 | KEGG_SMALL_CELL_LUNG_CANCER | Small Cell Lung Cancer |
| 0 | KEGG_SNARE_INTERACTIONS_IN_VESICULAR_TRANSPORT | Snare Interactions In Vesicular Transport |
| 0 | KEGG_SPHINGOLIPID_METABOLISM | Sphingolipid Metabolism |
| 0 | KEGG_SPLICEOSOME | Spliceosome |
| 0 | KEGG_STARCH_AND_SUCROSE_METABOLISM | Starch And Sucrose Metabolism |
| 0 | KEGG_STEROID_BIOSYNTHESIS | Steroid Biosynthesis |
| 0 | KEGG_STEROID_HORMONE_BIOSYNTHESIS | Steroid Hormone Biosynthesis |
| 0 | KEGG_SULFUR_METABOLISM | Sulfur Metabolism |
| 0 | KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS | Systemic Lupus Erythematosus |
| 0 | KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY | T Cell Receptor Signaling Pathway |
| 0 | KEGG_TASTE_TRANSDUCTION | Taste Transduction |
| 0 | KEGG_TERPENOID_BACKBONE_BIOSYNTHESIS | Terpenoid Backbone Biosynthesis |
| 0 | KEGG_TGF_BETA_SIGNALING_PATHWAY | Tgf Beta Signaling Pathway |
| 0 | KEGG_THYROID_CANCER | Thyroid Cancer |
| 0 | KEGG_TIGHT_JUNCTION | Tight Junction |
| 0 | KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY | Toll Like Receptor Signaling Pathway |
| 0 | KEGG_TRYPTOPHAN_METABOLISM | Tryptophan Metabolism |
| 0 | KEGG_TYPE_I_DIABETES_MELLITUS | Type I Diabetes Mellitus |
| 0 | KEGG_TYPE_II_DIABETES_MELLITUS | Type Ii Diabetes Mellitus |
| 0 | KEGG_TYROSINE_METABOLISM | Tyrosine Metabolism |
| 0 | KEGG_UBIQUITIN_MEDIATED_PROTEOLYSIS | Ubiquitin Mediated Proteolysis |
| 0 | KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_BIOSYNTHESIS | Valine Leucine And Isoleucine Biosynthesis |
| 0 | KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION | Valine Leucine And Isoleucine Degradation |

| | | |
|---|---|--|
| 0 | KEGG_VASCULAR_SMOOTH_MUSCLE_CONTRACTION | Vascular Smooth Muscle Contraction |
| 0 | KEGG_VASOPRESSIN_REGULATED_WATER_REABSORPTION | Vasopressin Regulated Water Reabsorption |
| 0 | KEGG_VEGF_SIGNALING_PATHWAY | Vegf Signaling Pathway |
| 0 | KEGG_VIBRIO_CHOLERAЕ_INFECTION | Vibrio Cholerae Infection |
| 0 | KEGG_VIRAL_MYOCARDITIS | Viral Myocarditis |
| 0 | KEGG_WNT_SIGNALING_PATHWAY | Wnt Signaling Pathway |